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Abstract 
 
This state-of-the art review is based on the final report of a project carried out by the European Commission’s Joint 
Research Centre (JRC) for the European Chemicals Agency (ECHA). The aim of the project was to review the state of the 
science of non-standard methods that are available for assessing the toxicological and ecotoxicological properties of 
chemicals. Non-standard methods refer to alternatives to animal experiments, such as in vitro tests and computational 
models, as well as animal methods that are not covered by current regulatory guidelines.  
 
This report therefore reviews the current scientific status of non-standard methods for a range of human health and 
ecotoxicological endpoints, and provides a commentary on the mechanistic basis and regulatory applicability of these 
methods. For completeness, and to provide context, currently accepted (standard) methods are also summarised. In 
particular, the following human health endpoints are covered: a) skin irritation and corrosion; b) serious eye damage and 
eye irritation; c) skin sensitisation; d) acute systemic toxicity; e) repeat dose toxicity; f) genotoxicity and mutagenicity; g) 
carcinogenicity; h) reproductive toxicity (including effects on development and fertility); i) endocrine disruption relevant to 
human health; and j) toxicokinetics. In relation to ecotoxicological endpoints, the report focuses on non-standard methods 
for acute and chronic fish toxicity. While specific reference is made to the information needs of REACH, the Biocidal
Products Regulation and the Classification, Labelling and Packaging Regulation, this review is also expected to be 
informative in relation to the possible use of alternative and non-standard methods in other sectors, such as cosmetics 
and plant protection products. 
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 EXECUTIVE SUMMARY 
 
 
This state-of-the art review is based on the final report of a project carried out by the 
European Commission’s Joint Research Centre (JRC) for the European Chemicals 
Agency (ECHA) under the terms of a Service Level Agreement (SLA/ECHA-
JRC/2012-2) between ECHA and the JRC. The aim of the project was to review the 
state of the science of non-standard methods that are available for assessing the 
toxicological and ecotoxicological properties of chemicals. Non-standard methods refer 
to alternatives to animal experiments, such as in vitro tests and computational models, 
as well as animal methods that are not covered by current regulatory guidelines. 
 
ECHA needs to have up-to-date information on non-standard methods since the Agency 
is responsible for implementing different regulatory processes in which there is an 
obligation or an opportunity to use non-standard methods, depending on the context. 
These processes relate to the REACH Regulation, the Biocidal Products Regulation 
(BPR), as well as the Classification, Labelling and Packaging (CLP) Regulation. 
 
This report reviews the current scientific status of non-standard methods for a range of 
human health and ecotoxicological endpoints, and provides a commentary on the 
mechanistic basis and regulatory applicability of these methods. For completeness, and 
to provide context, currently accepted (standard) methods are also summarised. In 
particular, the following human health endpoints are covered: a) skin irritation and 
corrosion; b) serious eye damage and eye irritation; c) skin sensitisation; d) acute 
systemic toxicity; e) repeat dose toxicity; f) genotoxicity and mutagenicity; g) 
carcinogenicity; h) reproductive toxicity (including effects on development and 
fertility); i) endocrine disruption relevant to human health; and j) toxicokinetics. In 
relation to ecotoxicological endpoints, the report focuses on non-standard methods for 
acute and chronic fish toxicity.  
 
While this report makes specific reference to the information needs of REACH, the 
BPR, and the CLP Regulation, it is also expected to be informative in relation to the 
possible use of alternative and non-standard methods in other sectors, such as cosmetics 
and plant protection products.  
 
 
DISCLAIMER 
 
This report presents the findings and conclusions of the authors, but does not represent 
an official view of the JRC, the European Commission or the European Chemicals 
Agency. 
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1. Background to the report 
This state-of-the-art review is based on the final report of a project carried out by the 
European Commission’s Joint Research Centre (JRC) for the European Chemicals 
Agency (ECHA) under the terms of a Service Level Agreement (SLA/ECHA-
JRC/2012-2) between ECHA and the JRC. The aim of the project was to review the 
state of the science of non-standard methods that are available for assessing the 
toxicological and ecotoxicological properties of chemicals. Non-standard methods refer 
to alternatives to animal experiments, such as in vitro tests and computational models, 
as well as animal methods that are not covered by current regulatory guidelines. This 
project was one of several activities carried out within the frame of the collaboration 
agreement between the JRC's Institute for Health & Consumer Protection (IHCP) and 
ECHA. 
 
ECHA needs to have up-to-date information on non-standard methods since the Agency 
is responsible for implementing different regulatory processes in which there is an 
obligation or an opportunity to use non-standard methods, depending on the context. 
These processes relate to the REACH Regulation, the Biocidal Products Regulation 
(BPR), and well as the Classification and Labelling and Packaging (CLP) Regulation. 
 
The registration of chemicals under REACH (Regulation 1907/2006 on the 
Registration, Evaluation and Authorisation of Chemicals) is based on their production 
volume and their hazard properties (i.e. Substances of Very High Concern [SVHCs]), 
with the assessment of the inherent substance properties based on data provided by 
manufacturers or importers. The registrant is encouraged to provide data obtained with 
non-standard methods under the conditions described in Annex XI of the REACH legal 
text. When this is done it is necessary to demonstrate that the data provided are relevant, 
reliable, and that their use in the context of classification and risk assessment is 
acceptable. REACH registration dossiers may be examined by ECHA under the dossier 
evaluation processes.  
 
Under CLP (Regulation 1272/2008 on the Classification, Labelling and Packaging of 
substances and mixtures), hazard information on chemicals is assessed against the 
classification criteria in order to establish a harmonised classification which is legally 
binding within the EU, or to provide a self-classification for hazard classes or categories 
not falling under the harmonised classification procedure. Self-classifications are 
reported by manufacturers and importers to the CLP Inventory, hosted by ECHA, for all 
chemicals placed on the market or subject to REACH, however they are not legally 
binding. Under CLP, it is possible to use non-standard data as a basis for hazard 
assessment in a weight of evidence approach.  
 
The use of non-standard methods is also pertinent to hazard and risk assessments carried 
out under the BPR (Regulation (EU) 528/2012), which concerns the placing on the 
market and use of biocidal products. 
 
Furthermore, in the light of the Directive on the protection of animals used for scientific 
purposes (Directive 2010/63/EU), the use of non-standard methods not requiring the use 
of animals is encouraged in all sectors of EU Chemicals Policy. It is however 
fundamentally important to ensure that the use of non-standard data is appropriate for an 
adequate risk assessment or classification and does not reduce the protection of human 
health and the environment. 
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This report reviews the current scientific status of non-standard methods for a range of 
human health and ecotoxicological endpoints, and provides a commentary on the 
mechanistic basis and regulatory applicability of these methods. For completeness, and 
to provide context, currently accepted (standard) methods are also summarised. In 
particular, the following human health endpoints are covered: a) skin irritation and 
corrosion; b) serious eye damage and eye irritation; c) skin sensitisation; d) acute 
systemic toxicity; e) repeat dose toxicity; f) genotoxicity and mutagenicity; g) 
carcinogenicity; h) reproductive toxicity (including effects on development and 
fertility); i) endocrine disruption relevant to human health; and j) toxicokinetics. In 
relation to ecotoxicological endpoints, the report focuses on non-standard methods for 
acute and chronic fish toxicity.  
 
While this report makes specific reference to the information needs of REACH, the 
BPR, and the CLP Regulation, it is also expected to be informative in relation to the 
possible use of alternative and non-standard methods in other sectors, such as cosmetics 
and plant protection products.  
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2. Adverse Outcome Pathways and their role in assessing non-standard methods 
Andrew Worth, Sharon Munn, Maurice Whelan & Clemens Wittwehr 
 
2.1 The Adverse Outcome Pathway (AOP) concept 
Over the past decade, attempts to describe and predict the biological and toxicological 
effects of chemicals have increasingly taken mechanistic considerations into account. 
Among the many publications in the rapidly growing field of predictive toxicology, the 
report of the U.S. National Academy of Sciences and National Research Council (NRC) 
“Toxicity Testing in the 21st Century: A Vision and A Strategy” (NRC, 2007) has 
attracted considerable attention and triggered a debate about the need for a “paradigm 
shift” in hazard and risk assessment of chemicals (Collins et al, 2008; Andersen et al, 
2010; Ankley et al, 2010; Schultz, 2010; Hartung & Bride, 2011; Boekelheide & 
Andersen, 2010). The NRC report envisions a transformation of the current way of 
conducting toxicity testing from a system based on phenotypic responses in animals 
towards an approach that increasingly relies on an understanding of the molecular 
mechanisms of toxicant effects in human cells and tissues. The move towards a more 
mechanistically-based risk assessment process implies the use of in vitro tests based on 
high-throughput and high-content screening (HTS/HCS) assays in mammalian 
(preferably human) cell lines, cell cultures and/or tissue surrogates, combined with the 
application of a range of computational methods for data analysis and the modelling of 
molecular interactions between toxicant and molecular target, adverse effects and fate. 
 
Different terms are being used to capture variants of this general framework, including 
source-to-outcome pathway, toxicity pathway (TP), mode of action (MoA) and adverse 
outcome pathway (AOP). While these terms are not yet harmonised, they are all based 
on the assumption that a toxicant, after reaching and interacting with a biological target, 
initiates a cascade of events which may lead to an adverse outcome at the organism or 
population level. The general premise of the AOP approach is that a limited set of key 
measurable events are sufficient for describing biological pathways and predicting 
adverse outcomes at multiple levels of biological organisation (cell, tissue/organ, 
organism, population). For practical purposes in chemical hazard and risk assessment, 
this means that a basic understanding of the key molecular interactions and effects 
should be sufficient, and that ultimately it may be sufficient for decision making to 
predict the adverse outcome at organism and population level from early (“upstream”) 
key events. Table 2.1 provides definitions for some commonly used terms, and also 
includes working definitions for the purposes of this report. 
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Table 2.1. Definitions used in mechanistic frameworks for predicting and assessing toxicity 
 
Term Definition Reference 
Key Event Key events are events that are 
toxicologically relevant and necessary to 
the apical outcome and experimentally 
quantifiable. They include the Molecular 
Initiating Event and subsequent 
intermediate effects. 
Definition for the 
purpose of this report 
Molecular Initiating Event 
(MIE) 
The initial interaction of a chemical and a 
biological target which results in a cascade 
of events (perturbation of the biological 
system) and which may lead to adversity 
at a higher level of biological organisation. 
Definition for the 
purpose of this report 
Intermediate Effect An event in a pathway that occurs after 
(downstream of) the Molecular Initiating 
Event and is part of the cascade which 
may lead to adversity at a higher level of 
biological organisation. An intermediate 
effect is distinguished from a key event in 
that not all intermediate effects are 
necessarily key events. 
Definition for the 
purpose of this report 
Source-to-Outcome Pathway Cascade of measurable events starting 
from release of a chemical into the 
environment to an adverse outcome. 
Krewski et al, 2011 
Toxicity pathway (TP) A cellular response pathway that would 
result in an adverse health effect when 
sufficiently perturbed 
NRC, 2007 
Mode of Action (MoA) Sequence of events, starting with a 
Molecular Initiating Event, and leading to 
an adverse effect at the level of whole 
organism/individual. This term does not 
(usually) include consideration of 
exposure or effects at higher levels than 
the individual. 
EPA, 2005 
Mode of Action (MoA) A biologically plausible sequence of key 
events leading to an observed effect 
supported by robust experimental 
observations and mechanistic data. A 
mode of action describes key cytological 
and biochemical events – that is, those that 
are both measurable and necessary to the 
observed effect – in a logical framework.  
WHO, 2009 
Adverse Outcome Pathway 
(AOP) 
 
The sequence of events from the exposure 
of an individual or population to a 
chemical substance through a final adverse 
(toxic) effect at the individual level (for 
human health) or population level (for 
ecotoxicological endpoints). AOPs 
incorporate the toxicity pathway and mode 
of action for an adverse effect.  
OECD, 2013 
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2.2 Use of the AOP framework in assessing non-standard methods 
The AOP framework provides a means of organising and sharing knowledge on the 
mechanisms underlying chemical toxicity. It is a descriptive framework that can be used 
as the basis of predictive approaches, including chemical categories, mechanistically 
based QSARs, in vitro tests with toxicologically relevant read-outs, as well as integrated 
approaches (often referred to as Integrated Testing Strategies [ITS] or Integrated 
Approaches to Testing and Assessment [IATA]). A recently published OECD Guidance 
Document (OECD, 2013) provides guidance on which pieces of information are 
necessary to identify, document and justify an AOP in terms of its relevance and 
adequacy. A reporting template is also provided to improve consistency in the reporting 
of AOPs. 
 
In this report, we will use the elements of the AOP framework, as far as is possible in 
the light of incomplete knowledge and the absence of an agreed ontology of key events, 
to identify non-standard methods that are toxicologically relevant. In other words, these 
are non-standard methods that can be associated with key events in one or more AOPs. 
 
2.3 Development of an AOP Knowledge Base 
Progress made with the implementation of the AOP framework will generate data and 
knowledge describing the molecular initiating events (MIEs), Intermediate Effects (IEs) 
and Adverse Outcomes (AOs). In order to facilitate the collection and retrieval of this 
information in a coherent way, the JRC has instigated and is involved in a series of 
initiatives that will help generating a flexible yet standardised way of looking at AOP 
related data. 
 
Being committed to the standard data format paradigm of OHTs (OECD Harmonised 
Templates, a collection of data entry forms for 100+ endpoints describing a chemical), 
the JRC has developed an OHT (working title "OHT 201", assigned by OECD) which 
will, once adopted by OECD, allow capturing chemical-specific data on IEs, to be used 
for hazard assessment in all kinds of contexts. In addition, OHT 201 formatted study 
reports of effects can be used as real-life manifestations of Key Events playing roles in 
one ore more AOPs, i.e. not necessarily linked to one single Adverse Outcome (as is the 
case with the current OHTs). 
 
Consequently, Intermediate Effects reported using OHT 201 will be linked together to 
form AOPs. At the request of the OECD EAG MST (Extended Advisory Group on 
Molecular Screening and Toxicogenomics) and WHO IPCS (World Health 
Organisation International Programme on Chemical Safety), the JRC is implementing 
(together with US EPA) an AOP Knowledge Base (AOP-KB), which will consist of 
three elements: 
 
• AOP Wiki, a text-based tool implementing the OECD AOP guidance, to be used 
for capturing qualitative AOPs, being the first module to be exposed to the 
public; 
• AOP Effectopedia, a graphical tool for capturing quantitative AOPs (but 
synchronized with the qualitative AOP wiki data) and foreseen to depict 
mathematical AOP models; 
• AOP Intermediate Effects Database - a collection of IEs captured in the OHT 
201 format. 
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3. Skin corrosion and irritation 
Claudius Griesinger, Michael Schaeffer, Andrew Worth & Valérie Zuang 
 
3.1 Introduction 
Being the primary interface between the human body and the environment, the skin is 
readily exposed to chemicals. In the industrialised world, adverse skin effects are of 
major concern for occupational and consumer safety (Elsner, 1994; Wigger-Alberti & 
Elsner, 2000). Irritant Contact Dermatitis (ICD), resulting from acute or cumulative skin 
irritation is, after skeletomuscular diseases, the most common occupational disease. 
There is reliable evidence that ICD has, at least in the workplace, a greater incidence 
(Turner et al., 2007; Dickel et al., 2002) than Allergic Contact Dermatitis (ACD) 
resulting from skin sensitisation. Consequently, legislators and regulators attach high 
priority to the identification of chemicals that have skin corrosion or irritation potential 
so that adequate risk management measures can be chosen to protect workers and 
consumers. Despite the sophisticated barrier properties of skin, a wide range of 
chemicals that skin is acutely or repeatedly exposed to can lead to adverse effects in the 
skin tissue. This is reflected in the information requirements of the REACH Regulation, 
where data on skin irritation/corrosion is required for registrations at the lowest tonnage 
level of 1-10 tonnes per year. According to the severity and reversibility of effects one 
distinguishes skin corrosion (skin burns) from skin irritation. 
 
Skin corrosive substances damage the exposed skin area leading to necrosis (death) of 
the skin tissue beyond repair. As a consequence, the affected area can be regenerated 
only from the healthy skin surrounding the necrotic patch. For the purposes of chemical 
safety assessments, skin corrosion is defined on the basis of the traditional animal test 
(not on the basis of effects in humans): 'Dermal [skin] corrosion is the production of 
irreversible damage of the skin; namely visible necrosis through the epidermis and into 
the dermis, following the application of a test substance for up to four hours. Corrosive 
reactions are typified by ulcers, bleeding, bloody scabs, and, by the end of observation 
at 14 days, by discolouration due to blanching of the skin, complete areas of alopecia 
and scars'. (Citation from TG404; the same definition is reproduced in the EU CLP 
Regulation [EC 2008b] based on the United Nations UN Globally Harmonised System 
[UN GHS; UN 2013]). 
 
Skin irritation is due to a reversible local inflammatory reaction in the skin. In contrast 
to corrosion, it involves complex and yet not fully described interactions of the innate 
immune system of the affected tissue patch. The clinical term for skin irritation, as 
observed in humans, is Irritant Contact Dermatitis (ICD). The inflammatory response 
leads, as downstream effects, to the classical clinical symptoms of irritation: redness 
(rubor), warmth (calor), painful sensations (dolor) and also the swelling (oedema) of the 
affected tissue area. For the purposes of chemical safety assessments, skin irritation is 
defined on the basis of the traditional animal test (not on the basis of the effects in 
humans): 'Dermal [skin] irritation is the production of reversible damage of the skin 
following the application of a test substance for up to 4 hours.' (Citation from TG404; 
the same definition is reproduced in the EU CLP Regulation [EC 2008b] based on UN 
GHS [UN 2013]). 
 
While some (mainly intrinsically weak irritant) chemicals will only trigger an irritant 
response after repeated exposure of the same skin area (cumulative irritants) (Dahl 
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1988), other chemicals will even after a one-time exposure cause irritation (acute 
irritants). Chronic cumulative exposure to irritants can elicit dermatitis which may 
resemble Allergic Contact Dermatitis and lead to inappropriate treatment and/or 
preventive measures (Dahl 1988; Basketter et al., 2004b). Although cumulative 
irritation clinically is far more frequent than acute irritation, current regulatory 
requirements focus on the assessment of the acute irritation potential of chemicals (i.e. 
intrinsic hazard of causing skin irritation following acute exposure). Therefore, this 
report focuses on acute irritation.  
  
Information on skin irritation may be relevant for other health effects under certain 
circumstances. There is indication from human studies that the early inflammatory 
response of skin to sensitising and irritant substances is the same (Willis et al., 1986), 
and dermal inflammation is one of the key events involved in the skin sensitisation 
pathway (OECD, 2012). Thus, it is conceivable that substances that cause irritation 
without being sensitisers themselves may create an inflammatory environment 
supporting the skin sensitisation process caused by other chemicals. Therefore, 
consideration of the irritant potential of substances contained in mixtures (e.g. cosmetic 
products) that also contain substances with sensitising properties is important. 
 
3.2 The traditional animal test and its regulatory use 
Both skin corrosion and irritation have been traditionally assessed using rabbits as 
models. The traditional in vivo assay, the Draize test (Draize et al., 1944) has been in 
use for well over half a century. OECD Test Guideline (TG) 404 (OECD 2002) 
summarises the internationally recognized standard procedure for the testing of the 
dermal toxicity potential of substances in vivo, covering both corrosives and irritants. 
Several improvements with regard to its protocol and the conclusions drawn have been 
introduced over time (adoption as OECD TG in 1981 with revisions in 1992 and 2002, 
when a testing strategy supplement was added). Using the live animal, the effects of 
substances on patches of shaved skin that have been exposed for up to four hours are 
assessed and scored for (a) erythema (skin reddening) and eschar formation as well as 
(b) oedema (skin swelling). The scoring uses five steps, from 0 (no erythema / oedema) 
to four (maximum effect). Corrosion is differentiated from irritation by virtue of non-
reversibility of the effects and by the production of serious histopathological damage to 
the skin in case of corrosion (ulcers, bleeding, discolouration, blanching of skin, 
alopecia, scars) at the end of the observation period (14 days).  
 
The Draize method has the advantage of providing a simple readout of corrosive effects 
as well as the downstream effects of the inflammatory response induced by irritant 
xenobiotics (i.e. reddening, swelling etc). The inflammatory response ultimately leads to 
observable phenomena, two of which are assessed in the traditional animal test: 
localised skin swelling (edema - due to increased permeability of blood vessels to 
facilitate diapedesis/extravasation of immune cells into the interstitium) and redness 
(erythema - due to the increased diameter of blood vessels). Other reactions (e.g. C fibre 
activation, pain) are not easily accessible through such an observational method. 
 
Despite these advantages, the in vivo method also has methodological drawbacks, the 
most important ones relating to variability and relevance regarding the species of 
interest: (a) coloured substances are difficult to score due the visual inspection of the 
skin and skin redness being a readout; (b) being performed in a proxy model (the rabbit) 
the test may make incorrect predictions due to species differences (e.g. Philips et al. 
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1972; Basketter et al. 2004b, Jirova et al., 2010; Basketter et al., 2012); (c) probably due 
to the fact that the test relies on the subjective scoring of the two effects (instead of 
using an empirical measure of a parameter related to irritation) variability of the 
recorded responses is high (e.g. Weil & Scala, 1971; ECETOC, 1995); this variability 
may be exacerbated due to inter-individual (inter-animal) variability with regard to the 
severity of the responses. 
 
Data on skin irritation/corrosion effects are required by several pieces of legislation, all 
of which regulate use classes of chemicals that are likely to come into contact with skin: 
a) the REACH Regulation (EC 1907/2006); b) the Biocides Regulation (EC 528/2012); 
c) the Plant Protection Product Regulation (EC 1107/2009): and d) the Cosmetics 
Regulation (EC 1223/2009; in force since 11 July 2013, replacing Directive 
76/768/EEC). Such legislation foresees the development and use of alternatives to 
traditional animal testing. The REACH regulation and accompanying ECHA guidance, 
for example, specifies the criteria by which registrants may be able to meet the 
information requirement for an animal test for skin irritation by using results obtained 
from human experience and alternative approaches where these are available. It may 
also be possible to combine the use of such information in a weight of evidence 
approach.  
 
The CLP Regulation (Regulation on Classification, Labelling and Packaging of 
substances and mixtures: EC 1272/2008) does not itself stipulate any information 
requirements, but it lays down the rules for classification and labelling of skin corrosion 
and irritation that are applicable to REACH. The CLP Regulation implements the UN 
Globally Harmonised System (UN 2013) for C&L and repeals Directives 67/548/EEC 
("Dangerous Substances Directive") and 1999/45/EC ("Dangerous Preparations 
Directive") and provides the classification criteria as well as the categories and 
subcategories for skin corrosion and irritation. Currently the CLP Regulation foresees 
Categories 1A, 1B and 1C for corrosive substances and Category 2 for severe irritants. 
Category 3 (mild irritants) is not implemented in the EU. Although EU CLP describes 
the general Category 1 (section 3.2.2.6.1 and Table 3.2.1 therein), there is some 
inconsistency regarding the implementation of a general Category 1 as UN GHS 
originally foresaw its use for authorities not implementing subcategories ("applies to 
authorities not using sub categories", UN 2011). Recently the 5th revision of UN GHS 
has been published which allows the use of Category 1 also for countries that do 
implement subcategories (UN  2013). This change will likely be taken up in EU CLP.  
 
More details on these information requirements as well as the relevant categories as 
stipulated in the CLP Regulation are given below (see References with Notes). 
 
3.2.1 Variability of the Draize skin test  
A systematic analysis of variability of Draize test data was performed in 1971 (Weil and 
Scala, 1971): 10 substances were distributed to 24 laboratories and intra- and inter-
laboratory variability of the scoring was assessed. The study found moderate within 
laboratory reproducibility and low between laboratory reproducibility and concluded 
that some of the substantial variability observed may be due to (1) the subjective way of 
scoring effects and (2) variations between laboratories in performing the test. However, 
high variability is also evident in the ECETOC database of skin irritation chemicals. 
Since these data were are all produced following OECD test guideline 404 and under 
Good Laboratory Practice (GLP), variations due to between-laboratory deviations in the 
 10 
 
test protocols can be excluded with high certainty. Hence, the variability is most likely 
based on either a) the subjective scoring or b) the intrinsic variability of responses in 
animals or c) a combination of both factors. 
 
One of the reasons for employing only one irritant category (category 2) under UN GHS 
(category 3 is an optional category) is inter-animal variability: the UN GHS text 
explicitly acknowledges that “…animal responses in a test may be quite variable” in the 
context of explaining the rationale for one single irritant category (UN, 2013). 
 
Inter-animal (within test) and between test (laboratory) variability is also evident in the 
high quality dataset of the ECETOC skin irritation chemicals (ECETOC, 1995). Based 
on this dataset, Griesinger et al. (2010) show that the variability in the erythema and 
oedema scores can be observed across the entire range of Draize scores (from 0 to 4). 
These quality-assured data show high inter-animal variability, and it is not immediately 
evident how the traditional in vivo test can indeed be used for sub-categorisation beyond 
one irritant category. The variability in Draize skin scores is also analysed by Worth & 
Cronin (2001), who illustrate its impact on the maximum predictive performance that 
can be expected of any alternative method trying to reproduce such scores. 
 
The variability of the animal test places an upper limit on the expected performance of 
alternative test methods that were mainly developed, optimised, evaluated and validated 
in reference to Draize data (Worth & Cronin, 2001a). As the majority of alternative in 
vitro methods are based on human keratinocytes, they may potentially resemble more 
closely the human situation. Recent studies indicate that the alternative methods for skin 
irritation testing based on Reconstructed human Epidermis (RhE) are more accurate 
with regard to predicting effects in humans than the traditional animal test (Jirova et al., 
2012). ECVAM has taken this into account when defining the Performance Standards 
(ECVAM, 2009a) for OECD TG 439 (EU test method B.46), where some of the 
reference predictions are based on human data from the human patch test (Basketter et 
al., 2004b; Basketter et al., 2012). 
 
3.3 Mechanistic understanding of the endpoints 
3.3.1 Skin corrosion  
Mechanisms of skin corrosion concern mainly direct destruction of the skin tissue by 
chemicals, i.e. the erosion of the stratum corneum by many inorganic acids and bases 
and by strong organic acids with extreme pH: pH < 2 and > 11.5. Chemical classes that 
are taken up by skin and react with proteins, lipids and other biomolecules of skin tissue 
include quaternary ammonium ions, heterocyclic ammonium ions, sulphonium salts and 
acrylates. Cationic surfactants are readily taken up by skin and may bind to skin 
components and disrupt cellular plasma membranes thus leading to erosion of the tissue 
and subsequent necrosis. 
 
3.3.2 Skin irritation  
Skin irritation triggered by chemicals was originally assumed to be a simple process but 
is now considered a complex biological event with distinct pathophysiology and 
involving a complex reaction of the skin's innate immune system that is far from being 
fully understood and comprehensively described. Comprehensive reviews on the 
pathophysiology of skin irritation have been published (Basketter et al., 1997; Wells et 
al, 2004; Chew & Maibach, 2006; Kindt et al., 2006; Fluhr et al., 2008).  
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A putative Adverse Outcome Pathway (AOP) for irritation is being developed by the 
JRC (Griesinger, in preparation) based on the following key events leading to 
chemically-induced skin inflammation: dermal bioavailability and damage to the dermal 
barrier, metabolism, chemically-induced tissue trauma, release of inflammatory 
mediators, activation of the innate immune system). This AOP is elaborated in 
Appendix 1. 
 
Although dermal inflammation has been identified as a key event of the OECD's 
Adverse Outcome Pathway for skin sensitisation, this should not lead to the conclusion 
that dermal irritation is mechanistically fully understood. In particular, the complex 
interactions of inflammatory mediators with the skin tissue, and the role of axonal 
reflexes (neurogenic inflammation) in the pathogenesis/toxicogenesis of skin irritation, 
are not understood in detail. Recently, irritation has been classified into 10 types based 
on the morphological and clinical course of the inflammatory reaction (Sugibayashi et 
al., 2002) suggesting that distinct mechanisms or pathways may be involved. There are 
forms of irritation that lack the classical clinical signs of inflammation described by 
Rudolf Virchow (redness, swelling, heat, pain and dysfunction). Such purely sensory or 
"subjective" irritation is nevertheless an important entity in the full range of clinical 
irritation (Lammintausta et al., 1988). Mechanistic investigations of irritation have 
profited from advanced imaging methods allowing the optical investigation of inflamed 
tissue (Astner et al., 2006; Welzel et al., 2003). 
 
3.4 Status of alternative methods 
For evaluation of skin corrosion and irritation, several in vitro and ex vivo test methods 
are accepted in addition to the traditional in vivo test (Draize rabbit test). The methods 
are presented in more detail in the following two subsections. Table 3.1 provides an 
overview of currently accepted test methods, and also indicates those standardized 
testing methods that have recently (in 2013) been updated in view of adaptation to 
technical progress such as amendment of performance standards or inclusion of non-
validation data on predictive capacity. Briefly, these updates concerned OECD test 
guidelines TG 430 (addition of Performance Standards), TG 431 (extension of 
applicability domain to include also partial information on subcategorisation of 
Category 1 into 1A and a combination of Categories 1B and 1C) and TG 439 (inclusion 
of additional test method validated in reference to the TG's Performance Standards). 
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Table 3.1. EU test methods and OECD test guidelines for skin corrosion and irritation 
testing 
 
Generic description of test 
method 
Standardised description of test 
method in EU Test Method 
Regulation 
OECD Test guidelines (TGs) 
In vivo skin corrosion and irritation 
In vivo Draize rabbit test for skin 
corrosion/irritation testing 
B.4 
Acute toxicity: dermal 
irritation/corrosion 
TG 404 
Acute Dermal 
Irritation/Corrosion 
In vitro skin corrosion 
Transcutaneous electrical 
resistance test (TER) 
 
B.40 
In vitro skin corrosion: 
Transcutaneous electrical resistance 
test (TER) 
TG 430 
In vitro skin corrosion: 
Transcutaneous electrical 
resistance test (TER) 
> Updated in 2013 
In vitro skin corrosion using RhE- 
based human skin models: 
• EpiskinTM,  
• EpidermTM,  
• SkinEthicTM 
• EpiCSTM(EST-1000) 
B.40bis 
In vitro skin corrosion: human skin 
model test  
TG 431 
In vitro skin corrosion: human 
skin model test 
> Updated in 2013 
CORROSITEX® No EU test method available TG 435 
In Vitro Membrane Barrier Test 
Method for Skin Corrosion 
In vitro skin irritation 
In vitro skin irritation testing using 
RhE-based human skin models: 
• EpiskinTM,  
• EpidermTM SIT (EPI-200) 
• SkinEthicTM RHE  
• LabCyteTM EPI-MODEL24 
SIT 
B.46 
In Vitro Skin Irritation: Reconstructed 
Human Epidermis (RHE) Model Test. 
B.46 has not yet been updated to 
include the LabCyteTM test method. 
TG 439 
In Vitro Skin Irritation: 
Reconstructed Human 
Epidermis Test Method 
> Updated in 2013 
 
 
3.4.1 Standard non-animal test methods for corrosion  
Internationally accepted test methods for skin corrosion testing are, apart from the 
traditional animal test (TG404): 
• TG435: the CorrositexTM test method based on an artificial membrane barrier 
(hydrogenated collagen matrix) 
• TG430: the Transcutaneous Electrical Resistance (TER) test method based on excised 
skin 
• TG431: in vitro test methods based on Reconstructed human Epidermis (RhE) using 
normal human keratinocytes. 
 
Corrositex 
The Corrositex test method is a simple in chemico test method based on fact that 
corrosive substances either pass through or destroy the skin barrier (composed mainly of 
extracellular matrix and lipid membrane layers in the stratum corneum), penetrating into 
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the tissue where they lead to severe burns. The Corrositex method recapitulates the 
stratum corneum barrier of the skin using a hydrated collagen matrix supported by a 
filter membrane. Corrosive chemicals or mixtures pass through this biobarrier (by 
diffusion and/or destruction/erosion) and elicit a colour change in the underlying liquid 
"Chemical Detection System" (CDS), composed of water and pH indicator dyes. The 
assay has the limitation that many non-corrosive chemicals and mixtures and some 
corrosive chemicals and mixtures may not qualify for testing with this test method. For 
instance, aqueous substances with a pH range from 4.5 to 8.5 do typically not qualify 
for testing in the Corrositex assay. This excludes a lot of potential corrosives. The 
Corrositex method has undergone evaluation and validation by ECVAM (Fentem et al., 
1998; ECVAM 2000b) and NICEATM/ICCVAM (ICCVAM, 1999). While the 
Corrositex test method is accepted by OECD, it has not been included in the EU test 
methods regulation (EU, 2008a). The test method allows subcategorisation of corrosives 
(Category 1) into subcategories 1A, 1B, 1C, implemented by EU CLP and based on the 
UN GHS (UN, 2013), but, as explained above, its chemical applicability is limited. 
 
Transcutaneous Electrical Resistance (TER) 
The TER test method is based on the testing of chemicals on excised skin discs from 
rats to identify corrosives. The test method is based on the observation that corrosive 
substances impair the barrier function of skin by reacting with extracellular matrix 
molecules and destroying/eroding this matrix leading to a reduction of the electrical 
resistance across the skin. The test method was validated by ECVAM on the basis of 
about 60 chemicals of a wide range of chemical classes and physical states (Barratt et 
al., 1998; Fentem et al., 1998), including liquids (aqueous or non-aqueous), semi solids, 
solids (soluble or insoluble in water) and waxes. While mixtures were not included in 
the validation study, there is no obvious a priori reason to exclude them from the 
applicability domain of the test. TG430 provides more information on this issue and 
complicating factors (e.g. mixtures cover a wide spectrum of chemical categories and 
composition and there is considerable lack of availability of information on testing of 
mixtures) and points to a proposed strategy for testing mixtures developed during a 
recent workshop on regulatory applicability of skin corrosion/irritation test methods 
(Eskes et al., 2012). The test method does not allow the subcategorisation of corrosives 
(Category 1) into subcategories 1A, 1B, 1C implemented by EU CLP and based on the 
UN GHS (UN, 2013). 
 
Reconstructed human Epidermis models for skin corrosion testing (TG 431) 
RhE models use normal (e.g. non-transformed) human epidermal keratinocytes that, 
during culturing, form a multi-layered epidermis including a stratum corneum at the top, 
functioning as a barrier. These tissue-engineered models closely resemble human 
epidermis from a histological and biochemical point of view (e.g. lipid profile). The test 
method is based on the capacity of skin corrosives to destroy tissue and thus impair the 
viability of skin cells. Using a simple prediction model, the skin corrosion potential is 
predicted on the basis of cell viability measurements (using MTT/formazan) following 
exposure of the artificial epidermis and a post incubation period. At present the 
following RhE-based methods are accepted for skin corrosion testing: 
• EpiSkinTM 
• EpiDermTM SCT 
• SkinEthicTM RHE 
• epiCS® 
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Following prevalidation (Botham et al., 1995), the EpiSkin™ test method was validated 
by ECVAM in 1998 (Barratt et al., 1998; Fentem et al., 1998; ECVAM 1998). The 
EpiDerm™ test method underwent external validation in 2000 (Liebsch et al., 2000; 
ECVAM, 2000a). The epiCS® (Hoffmann et al., 2005) and SkinEthic™ (Kandarova et 
al, 2006; Tornier et al., 2010) test methods have been validated based on Performance 
Standards (ECVAM 2006; ECVAM 2009c).  
 
All test methods can be used to distinguish corrosive substances from substances not 
requiring classification (ECVAM 1998, 2000a, 2000b, 2006, 2009c). In addition, the 
EpiSkin was also found capable to distinguish the categories R35 (now Category 1) 
from R34 (a combination of Categories 2 and 3). Recently the test method developers of 
the EpiSkin™, EpiDerm™ and SkinEthic™ test methods have re-evaluated (under non-
validation conditions) the capacity of the test methods to subcategorise corrosives. More 
details are described in the "References with Notes" section. The applicability domain 
of these methods is as described for the TER and the same considerations regarding the 
testing of mixtures apply.  
 
3.4.2 Standard non-animal test methods for irritation  
Currently, all internationally accepted test methods for skin irritation testing (apart from 
the traditional animal test) are in vitro test methods based on the Reconstructed Human 
Epidermis (RhE) technology validated by ECVAM (TG439 / EU test method B.46). 
The test methods are shown in Table 3.2, which also outlines the type of validation 
study and provides the relevant references. All these test methods are proprietary, i.e. 
they need to be purchased from the test method developers: 
• EpiskinTM 
• EpidermTM SIT (EPI-200) 
• SkinEthicTM RHE 
• LabCyteTM EPI-MODEL24 SIT 
 
The EpiSkinTM and the original EpiDermTM test methods underwent full validation, 
while the updated version of the EpiDermTM test method as well as the SkinEthicTM 
and LabCyteTM test methods underwent validation on the basis of the Performance 
Standards defined by ECVAM (ECVAM 2007 and 2009; Griesinger et al., 2010) and 
annexed to TG 439. A further validation study on the epiCS® model (formerly known 
as EST-1000 and already accepted for skin corrosion assessment) is expected to be 
validated by 2014). Furthermore, an open-source RhE-based skin model ("OS-Rep") 
based on the reconstructed human epidermis model and protocol developed by Poumay 
et al., (2004) is currently being validated by industry and will be submitted to ECVAM 
for evaluation and potential ECVAM Scientific Advisory Committee (ESAC) review. 
All technical details for producing/reconstructing this model are freely available. 
 
All accepted RhE models use normal (e.g. non-transformed) human epidermal 
keratinocytes that, during culturing, form a multi-layered epidermis including a stratum 
corneum at the top, functioning as a barrier. These tissue-engineered models closely 
resemble human epidermis from a histological and biochemical point of view (e.g. lipid 
profile). Clearly however, the RhE systems lack vascularisations, i.e. have no blood 
vessels and, as they are not full thickness models, also the dermal innervation. Thus, 
they cannot recapitulate the endpoints assessed (through observation) in the animal test, 
which are due to the physiology of the endothelial (vascular) system in skin: erythema 
 15 
 
and oedema. The RhE methods mechanistically assess at present cell and tissue 
damage/trauma, the primary event in the skin inflammation cascade leading to dermal 
irritation. This is measured through viability of the cells in the tissue constructs (i.e. 
keratinocytes). There have been attempts to also use the release of inflammatory 
mediators as readouts for making predictions on the skin irritation potential of 
chemicals (e.g. Interleukin 1 alpha). However, so far the variability of these parameters 
was too high to be taken as a basis for routinely used standardised test systems 
(Griesinger & Zuang 2012, ECVAM, 2007a). 
 
All of the RhE test methods are accepted for predicting the presence (Category 2) and 
absence (no classification) of skin irritation potential based on the UN GHS system 
(UN, 2013) as implemented in the EU through the CLP Regulation (EU 2008b). 
However, none of the methods is able to predict the optional UN GHS Category 3 
("mild irritants). While this optional Category is not implemented in the EU (EU, 
2008b), it is used in other areas of the world (e.g. USA) and the extent to which data 
generated with TG439 methods can be used therefore depends on the regulatory 
context. In the EU, however, the TG439 test methods are considered full replacements 
to the animal test as they address the information requirements stipulated in relevant 
legislation (EU, 2008b). There are only very few restrictions known at present with 
regard to the chemical applicability domain of these methods. On the basis of 
physicochemical properties the test methods are applicable to: a) solids (water soluble 
and water insoluble); b) liquids (aqueous and non-aqueous); c) semi-solids; and d) 
waxes. 
 
The chemicals used for validation were all from the EU new chemicals database (Eskes 
et al., 2007, Spielmann et al., 2007), representing molecules of a complex and modern 
chemistry. This may create confidence that the test methods are applicable also to a 
wide range of (also complex) chemical structures. However, highly coloured chemicals 
may interfere with the colorimetric cell viability measurement of the test methods. 
Other restrictions are currently not known.  
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Table 3.2. In vitro test methods accepted by OECD and EU for skin irritation testing, all 
based on Reconstructed human Epidermis technology 
  
1. Validated test methods used for development of the Performance Standards  
Nr. Test method  Validation study type References 
1 EpiSkin™ Full prospective validation study (2005-2007). 
The test method components of this method 
were used to define the essential test method 
components of the original and updated 
ECVAM Performance Standards (PS) (ECVAM, 
2009a, b; ECVAM 2007). Moreover, the 
method's data relating to identification of 
non-classified vs classified substances formed 
the main basis for defining the specificity and 
sensitivity values of the original ECVAM PS. 
• Fentem et al., 2001 
• Portes et al., 2002 
• Zuang et al., 2002 
• Cotovio et al., 2005 
• Hoffmann, 2006 
• Spielmann et al., 2007 
• Cotovio et al., 2007 
• Eskes et al., 2007 
• ECVAM, 2007a 
• ECVAM, 2007b 
• ECVAM, 2008 
• ECVAM 2009 
• ECVAM 2009a 
• ECVAM 2009b 
• Griesinger et al., 2010 
Initially the test method underwent full 
prospective validation together with Nr. 1. 
from 2005-2007. The test method 
components of this method were used to 
define the essential test methods components 
of the original and updated ECVAM PS 
(ECVAM, 2009a, b; ECVAM 2007). 
• Fentem et al., 2001 
• Zuang et al., 2002 
• Kandarova et al., 2004 
• Kandarova et al., 2005 
• Hoffmann, 2006 
• Spielmann et al., 2007 
• Eskes et al., 2007 
• ECVAM 2007a 
• ECVAM 2007b 
• ECVAM 2009 
• ECVAM 2009a 
• ECVAM 2009b 
• Griesinger et al., 2010 
2 EpiDerm™ SIT 
(EPI-200) 
A modification of the EpiDerm ™ SIT (EPI-200) 
was validated using the original ECVAM PS 
(ECVAM 2007a) in 2008 
• ECVAM 2007a 
• ECVAM 2008 
• ECVAM 2009 
• Griesinger et al., 2010 
2. Methods validated on the basis of Performance Standards 
Nr. Test method 
name 
Validation study type References 
3 SkinEthic™ RHE  Validation study based on the original ECVAM 
Performance Standards (ECVAM 2009a) in 
2008. 
• ECVAM 2007 
• ECVAM 2008 
• ECVAM 2009 
• Griesinger et al., 2010 
4 LabCyte  
EPI-MODEL24 SIT 
Validation study (2011-2012) based on the 
Performance Standards (PS) of OECD TG 439 
which are based on the updated ECVAM PS 
(ECVAM 2009a, b). 
• ECVAM 2009a 
• ECVAM 2009b 
• Katoh et al., 2009 
• Katoh et al., 2011 
• OECD, 2011 
• OECD, 2011a 
• Kojima et al, 2012 
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3.4.3 Non-standard test methods (not yet validated / accepted as OECD TGs) 
Three test submissions of skin irritation test methods, all of which use simple 
reconstructed epidermis as the test system, were submitted to (EURL) ECVAM during 
2009-2012 (see Appendix 2). Two of these methods have already been evaluated by 
ECVAM with respect to their similarity to validated reference methods. Based on a 
comparison of the essential test method components and the protocol parameters with 
the ECVAM Performance Standards (ECVAM, 2009d), it was established that these 
two methods are sufficiently similar to qualify for PS-based validation. The third 
method is still in the development phase.  
 
One of the test methods is based on an "open source" concept. This test method was 
originally developed by Poumay et al. and has been published without any restrictions 
(Poumay et al., 2004). The "open source" concept would carry this further: all necessary 
information on both the production and maintenance of OS-Rep, i.e. the relevant 
Standard Operating Procedures (SOPs), will not be subject to any restrictions (e.g. 
patents or other intellectual property rights) as is the case with the current tissue models 
marketed by the various producers. The idea is that all interested users (either in 
academia, in research or contract-research organisations) will be able to reconstruct the 
RhE test system in their facilities and use the test system either in association with the 
relevant protocol for skin irritation testing (i.e. as skin irritation test method) or for other 
purposes (e.g. research and development). This approach is novel to an area of complex 
tissue-engineered test systems which, so far, are all manufactured and quality-controlled 
by the original test method producers who sell batch-controlled tissue kits with elements 
that are protected by intellectual property rights. The transferability of the reconstructed 
model, and the implementation of appropriate batch quality control procedures, need to 
be considered with care. 
 
3.4.4 Quantitative Structure-Activity Relationships 
Several QSAR modelling studies have attempted to model skin irritation or corrosion, 
focusing either on the prediction of tissue scores such as the primary irritation index 
(PII) or regulatory classifications. The status of literature-based models has changed 
little since the previous JRC reviews (Gallegos Saliner et al., 2006, 2008), with 
relatively few publications appearing since 2008 (e.g. Golla et al., 2009; Mombelli, 
2008). 
 
The simplest model for skin corrosion is based on pH measurements and takes the form 
of a simple decision rule: 
 
 If pH < 2 or pH > 11.5 then predict to be corrosive 
 
This model is included in the OECD testing strategy for skin irritation and corrosion 
(OECD, 2002). Measurements of pH can also be used as a predictor of skin irritation 
(Worth & Cronin, 2001b). For defined chemical classes, QSARs have been reported for 
discriminating between corrosives and non-corrosives (Barratt 1996a, 1996b), and 
between irritants and non-irritants (Smith et al, 2000a, 2000b). A few models for 
predicting PII have also been reported, mainly for specific chemical classes (Hayashi et 
al., 1999; Kodithala et al., 2002), although Golla et al. (2009) reported a QSAR for 
predicting the PII of diverse chemical classes.  
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Software tools with functionalities for predicting skin irritation potential include 
Toxtree, the OECD QSAR Toolbox, Derek Nexus, TOPKAT, HazardExpert, Molcode 
QSARModel, and Multi-CASE. A comparison of the predictive capacities of three 
commercial tools, Derek, HazardExpert and TOPKAT (Mombelli, 2008) concluded that 
TOPKAT had the best performance (in terms of highest sensitivity). The freely 
available Toxtree and the OECD Toolbox tools include the so-called BfR rulebase, 
developed by the German Federal Institute for Risk Assessment (BfR; Bundesinstitut 
für Risikobewertung), which applies a set of physicochemical rules to predict the 
absence of effects, along with a set of structural rules to predict the presence of effects.  
 
Evaluations of the predictive performance of the physicochemical (Rorije & Hulzebos, 
2005) and structural (Saliner et al., 2007) rules found a high negative predictivity (99% 
for non-corrosives; 97% for non-irritancy) of the physicochemical exclusion rules, and a 
high positive predictivity of the structural inclusion rules (95% for corrosives; and 68% 
for irritants). These evaluations were performed before the BfR rulebase was 
implemented in Toxtree and the OECD Toolbox, so it would be worthwhile to revisit 
the analysis, using the more modern tools and recently published data. Both rules would 
need to be fulfilled in order to predict that a substance is non-irritant, i.e. a substance 
should fulfil the exclusion rules, and not have any alert for the inclusion rules. A 
limitation of this system is that the BfR exclusion rules depend on physicochemical 
properties of the substance, such as surface tension or lipid solubility, for which there is 
no reliable calculation method either in the Toolbox or in Toxtree. Hence, to use this 
system with some confidence, it would be necessary to have the measured values of the 
relevant physicochemical properties, unlike for the above-mentioned commercial tools 
which can be applied using only a structure as an input. The alerts from the inclusion 
rules might potentially be used on their own for a positive prediction, since this would 
represent a conservative approach. 
  
The above-mentioned software tools can be used in a WoE approach or tiered testing 
strategy. As with all computational tools, the predictions needed to be carefully 
evaluated using information on the model characteristics. For classification and 
labelling, the BfR rulebase provides information that is closest to the regulatory goal, 
since the system was designed to predict former EU Risk Phrases for irritation (R38) 
and corrosion (R34, R35). 
 
3.5 Status of Integrated Testing Strategies 
There are two major integrated strategies available for the testing and evaluation of skin 
corrosion and skin irritation. Both make use of a wide range of information including 
from in vitro and in vivo test methods. In addition, a tiered approach for classification 
and labelling is described in UN GHS (UN, 2013). The EU CLP Regulation makes 
reference to this tiered approach (EU, 2008). 
 
3.5.1 Testing and Evaluation Strategy in OECD TG 404 
TG404 on the traditional Draize animal test contains a supplement which provides a 
"Testing and evaluation strategy for dermal irritation / corrosion". Importantly, unlike 
the body text of the TG, the supplement does not fall under the provisions of Mutual 
Acceptance of Data. This supplement was annexed to the TG in 2002 in relation to 
animal welfare concerns. This supplement outlines a possible "Testing and Evaluation 
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Strategy for Dermal Irritation/Corrosion", developed at an OECD workshop in 1996 
(OECD, 1996). This strategy has been evaluated in relation to its ability to classify skin 
corrosives (Worth et al., 2008) and irritants (Hoffmann et al., 2008). The strategy 
foresees a sequential approach based on the use of: 
  
(a) available information as well structural and physicochemical data;  
(b) validated and accepted in vitro / ex vivo tests for skin corrosion and irritation;  
(c) animal testing (i.e. traditional Draize rabbit test). 
 
The strategy contains eight steps that can be grouped according to the three above-
mentioned data sources: 
 
(a) Available information (human or animal data & structural and physicochemical 
information) 
1. Consideration of existing human or animal data with regard to skin corrosion / irritation. 
2. Structure-Activity Relationship (SAR) data with regard to skin corrosion / irritation. 
3. pH measurements: extreme pH (≤ 2 or ≥ 11.5) suggests corrosive properties  
4. systemic toxicity data via the dermal route (can also be considered before steps 2 and 3) 
(b) In vitro tests  
5. conducting validated and accepted in vitro or ex vivo test for skin corrosion (consider 
positives) 
6. conducting validated and accepted in vitro or ex vivo test for skin irritation (consider 
positives) 
(c) In vivo rabbit test 
7. conducting TG404 test using one animal to test for corrosive effects 
8. if not corrosive in step 7: perform testing using one or two animals to assess whether 
substance is corrosive or irritant or not. 
 
This strategy is not currently (October 2013) in line with the status of acceptance of 
alternative methods as it foresees only the use of positive results from in vitro methods 
for skin corrosion and irritation and suggests confirmatory testing for negative in vitro 
results in the animal test. However, in vitro methods, especially those based on 
Reconstructed human Epiderms (RhE) applicable to a wide range of chemicals, can be 
used to conclude both on the presence and absence of skin corrosion potential as well as 
on the presence and absence of skin irritation potential – at least in areas (such as the 
EU) not implementing optional Category 3 ("mild irritants") and not corrosive 
subcategories (1A, 1B, 1C). Currently, in the context of the OECD expert group on skin 
irritation/corrosion, there are efforts to update this testing strategy and provide sufficient 
guidance for its proper use. This activity is led by Germany. The resulting guidance 
document uses the Integrated Testing Strategy (ITS) developed for REACH (ECHA, 
2012). As a new element, a more consistent and explicit description of the performance 
characteristics of the individual elements of the ITS has been included, providing, for 
example, for each test method information on the predictive capacity, reliability, 
applicability and limitations. Initially the derivation of possible weighing factors 
attached to the various data sources was also considered but this was not followed up. 
This would have included the definition of a consistent data matrix of chemicals with 
credible reference data and an analysis of the relative contribution of each data source to 
the decision making using a semi-quantitative approach. The derived factors would have 
been used as weighing factors for the individual test methods when conducting a 
Weight of Evidence (WoE) analysis of chemicals. 
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3.5.2 Integrated Testing Strategy in REACH guidance 
The testing strategy recommended in REACH guidance (ECHA, 2012) is based on 
expert knowledge and judgement, and consists of three general steps: 
 
STEP (1) Gathering and evaluation of existing information, taking into account data on/from: 
  
• pH 
• physicochemical properties 
• human data 
• existing animal data from animal corrosion/irritation studies (including from chemical 
analogues) 
• dermal toxicity data 
• other studies (sensitisation and repeated exposure) 
• (Q)SAR 
• Read across or grouping 
• Validated In vitro corrosion test methods 
• Validated In vitro irritation test methods 
• Non validated in vitro assays 
 
STEP (2) Weight of Evidence integration of all information gathered in Step (1) 
 
STEP (3) New testing if the information integrated/evaluated in Step (2) is found insufficient to 
make a decision on classification and labelling (goal one of the human health hazard 
assessment under REACH, REACH Annex I): 
 
• skin corrosion in vitro data from an OECD adopted test method 
• skin irritation in vitro data from an OECD adopted test method 
• skin irritation in vitro data from a non-validated in vitro test 
• in vivo skin irritation data (TG404) 
 
3.5.3 United Nations tiered approach for classification and labelling 
The Globally Harmonised System for Classification and Labelling includes a "decision 
logic" for the classification and labelling of skin corrosion / irritation (UN, 2013). 
Formally, the decision logic is based on existing information only. The UN GHS 
decision logic is currently undergoing revision in the context of the 5th edition of UN 
GHS. The “tiered evaluation for skin corrosion and irritation” provides guidance on 
"how to organize existing information on a substance and to make a weight of evidence 
decision about hazard assessment and hazard classification (ideally without conducting 
new animal tests)" (UN, 2013). This tiered approach is referenced in the EU CLP 
Regulation (EU, 2008). 
 
3.6. Conclusions 
Skin corrosion and irritation are important health endpoints due to the readiness with 
which skin can be exposed to chemicals and as evidenced by the high incidence of 
Irritant Contact Dermatitis (ICD) compared with other health endpoints. Hazard 
information on these endpoints are required under REACH and the Biocidal Products 
Regulation, and can also be used in the implementation of the CLP Regulation. 
 
The mechanisms of skin corrosion are relatively simple and largely based on the 
chemical destruction / erosion of the skin tissue and subsequent irreversible necrosis of 
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the affected tissue. In contrast, the mechanisms of skin irritation are more complex. 
While the triggers of irritation can be assumed to be largely based on mechanisms 
inducing tissue trauma (e.g. reactive chemicals, chemicals interfering with the integrity 
of plasma membranes), the subsequent events involving the innate immune system and 
nerve endings of the skin leading to a local inflammatory reaction (the actual irritation 
response) are complex and not yet fully understood. Nevertheless, there is sufficient 
understanding of the key events underlying skin irritation to develop a putative AOP 
(Appendix 1). Furthermore, by modelling up-stream key events rather than mid-stream 
inflammatory events, in vitro methods have been developed that can predict skin 
irritation potential with great accuracy. QSAR models have been developed mainly for 
predicting the adverse outcome (skin corrosion or irritation) itself, rather than 
intermediate events. These approaches are applicable to specific chemical classes and 
can provide useful information in the context of integrated approaches. Further QSAR 
efforts should focus on the modelling of specific key events in the AOP by exploiting 
available datasets generated by standardised in vitro methods. 
 
When limitations/scope of the accepted in vitro methods are considered, these methods 
can be used to meet the information requirement of REACH Regulation, provided that 
the testing strategy specified above is followed. Guidance on this will be available from 
ECHA (http://echa.europa.eu/support/testing-methods-and-alternatives). Technically 
speaking, information from in vitro test methods needs to be submitted as part of a 
Weight of Evidence approach under REACH; the respective instructions are given in 
http://echa.europa.eu/documents/10162/13655/pg_report_in_vitro_data_en.pdf 
 
For both skin corrosion and irritation, a number of different testing and non-testing 
methods are available in addition to the standard animal test. In vitro methods have 
undergone full prospective validation or validation based on performance standards and 
are internationally recognized (OECD Test Guidelines) and accepted by EU regulatory 
authorities (EU test methods regulation) as standard test methods. Detailed Performance 
Standards are available for all in vitro methods (corrosion and irritation) and in 
particular for skin models based on Reconstructed human Epidermis (RhE). Moreover, 
testing strategies for skin corrosion and irritation have been published by regulatory 
bodies. These provide guidance on how to combine information on physicochemical 
properties and QSARs with information from in vitro methods, the in vivo test and, 
where available, existing human information to support decisions on classification and 
labelling.  
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Appendix to Chapter 3. Putative Adverse Outcome Pathway for Skin Irritation 
 
General considerations: 
 
• Skin irritation – in its clinical manifestation – is a result of inflammatory processes in 
the skin.  
• Inflammation is a physiological response of any tissue to injury and trauma.  
• Chemically-induced skin inflammation, as most inflammatory processes, is triggered by 
tissue trauma: impairment and damage of the various cell populations building up the 
affected tissue. It may however also involve more specific inflammatory activation of 
cells as well as neurogenic inflammatory pathways (i.e. activation of nerve endings in 
the dermal layers of the skin). This tissue trauma leads to an inflammatory reaction 
causing, as downstream effects, the classical inflammatory symptoms such as redness, 
swelling etc. Moreover, in case of "sensory"/"subjective" irritation, symptoms may be 
restricted to sensations of itching, stinging, burning and tingling without classical 
manifestations of irritation. 
• Due to the complex interaction of the various key events (e.g. dermal penetration, 
destruction of skin barrier, damage of skin cells etc.) there is the possibility that 
chemicals show additive effects when applied in combination (e.g. in mixtures). 
Additive effects in skin irritation have been shown for instance for SLS, biogenic 
amines, solvents and fruit acids (Fluhr et al, 2004; Fluhr et al., 2005a; Wigger-Alberti et 
al, 2002). 
 
Key events: 
 
Key event 1 - Dermal bioavailability, skin penetration and absorption 
It is self-evident that only chemicals that penetrate into the skin (epidermis and dermis) 
or are absorbed by the skin can trigger an inflammatory reaction in the skin tissue. The 
intrinsic physicochemical properties of chemicals (size, net charge, lipophilicity, 
partition coefficient (logP) etc.) are important determinants of their bioavailability. 
Moreover, the intrinsic skin condition is another important determinant for percutaneous 
absorption. This includes the integrity of the so-called "acid mantle" of the skin (the pH 
of skin ranges between 4.2 and 5.6) The acid mantle is based on a molecular film 
composed of triglycerides, phospholipids, esterified cholesterol released by holocrine 
sebaceous glands in the skin (Nikolaides, 1963). The skin pH appears to be a regulator 
of barrier function (Schmidt-Wendtner & Korting, 2006) by affecting epidermal 
permeability barrier homeostasis and stratum corneum cohesion/integrity (Hachem et 
al., 2003). The incomplete acid mantle in neonate skin is a key factor involved in diaper 
dermatitis (Atherton, 2001). Also in adults the acid mantle may vary due to endogenous 
(age, ethnicity, anatomical site, gender, other disorders) as well as exogenous factors 
(use of cosmetics, contact with specific chemicals (e.g. for occupational reasons), 
seasonal change). Other factors affecting dermal permeation/absorption include the 
thickness of the barrier (may vary depending on age, disease conditions and anatomical 
site), the lipid composition of the skin (Sato et al., 1991), as well as the density of hair 
follicles (permeation through the "shunt pathway"). Species differences regarding 
absorption rates of substances (Bartek et al., 1972) may be due, at least in part, to 
different levels of follicle density. Importantly, the presence of other substances in 
mixtures may change the bioavailability of a given substance. For instance, it has been 
shown that detergents and physical irritants work synergistically with respect to their 
effect on the impairment of the skin barrier, i.e. their combined effect is greater than the 
effect of both detergent and physical irritant applied on their own (Fluhr et al., 2005b, 
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2000c). The integrity of the dermal barrier (mainly maintained by the stratum corneum) 
is obviously of key importance for dermal irritation: an impaired stratum corneum 
renders the skin more permeable and irritants can more readily permeate into the living 
epidermal and eventual also the dermal layers increasing the susceptibility of such skin 
to irritation. The importance of a functioning barrier has been demonstrated in patients 
with atopic dermatitis (Cork et al., 2006): the irritant response to xenobiotics is 
increased in such patients and the strength of the irritant response correlates with the 
level of impairment of the stratum corneum (Al-Jaberi & Marks, 1984; Cowley & Farr, 
1992). On a molecular level, the importance of the stratum corneum in the minimising 
susceptibility to irritant dermatitis has been underlined by a mutation in filaggrin, a 
protein that plays an role in stratum corneum homeostasis (Dereure, 2007; Houben E, 
2007). Despite the importance of the stratum corneum, there are also irritants that do not 
or not to an significant extent disrupt the skin barrier (Fluhr et al., 2001; Snater et al., 
1995). There is a variety of molecular mechanisms by which irritants may disrupt the 
barrier function of the skin. Anionic surfactants (such as Sodium Lauryl Sulfate) 
damage structural protein integrity (e.g. of keratin, the major component of the stratum 
corneum). This exposes water-binding sites in the proteins leading to hyperhydration of 
the stratum corneum and disruption of lipid bilayers (Fartasch, 1997; Ponec & 
Kempenaar J, 1995). In contrast organic solvents (benzene, toluol, acetone etc.) destroy 
the integrity of the skin barrier by extracting lipids from the stratum corneum, rendering 
it more permeable to a variety of substances (Fartasch, 1997). 
 
Key event 2 - Metabolism 
Metabolic transformation of xenobiotics (i.e. their bioactivation) may play a role in 
many toxic adverse effects, including skin irritation. Skin has innate metabolic capacity 
especially in the epidermal layers (Zhang et al., 2009; Steinsträsser & Merkle, 1995; 
Schaefer & Filaquier, 1992; Kao et al., 1985) and it is conceivable that substances may 
be transformed to more reactive metabolites by skin tissue. This has for instance been 
considered in the context of transepidermal drug delivery (discussed in Griesinger & 
Zuang, 2012; reviews: Zhang et al., 2009; Steinsträsser & Merkle, 1995). 
 
Key event 3 - Tissue trauma triggered by chemical reactivity and other 
physicochemical interactions with molecular targets (biomolecules):  
Tissue trauma, i.e. the impairment of the physiological functioning of cells (e.g. 
keratinocytes) is a universal trigger for inflammatory processes, irrespective of the 
tissue. Inflammation is the body's response to tissue trauma resulting from physical and 
chemical stressors, including xenobiotic substances carried by pathogens. In case of 
chemically-induced irritation, chemicals that bind to proteins residing in the 
extracellular matrix or in cell plasma membranes, or that bind to other moieties of cell 
plasma membranes (e.g. sugars) may impair the viability of cells in the affected skin 
tissue. This may include reactions such as protein denaturation, change of protein 
folding, saponification of membrane lipids. Morphological changes as a consequence of 
tissue trauma clearly precede irritant responses in man (Willis et al, 1989). Oxidative 
stress may also play a role (Willis et al., 1998). Apart from these general mechanisms 
leading to inflammatory skin reactions, some chemicals may act through more specific 
mechanisms or lead to sensations of irritation (sensory irritation) through targeted 
mechanisms. Examples are lactic acid or capsaicin activating TRPV1 channels in nerve 
fibres (TRPV1 = transient receptor potential cation channel subfamily V member 1). 
Moreover, it is conceivable that sensory nerve fibres (in dermis and epidermis) form 
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part of a complex regulatory loop of the innate immune system of the skin. There is 
evidence that peptidergic nerve fibres are required for both the induction and effector 
stage of contact sensitivity in mice (Beresford et al., 2004). Due to the fact that both 
endpoints are based to a considerable extent on local inflammation, these findings may 
have significance also for skin irritation. 
 
Key event 4 - Release of inflammatory mediators by impaired cells  
In response to tissue injury or trauma by irritant chemicals (key event 3), a complex 
cascade of nonspecific events is initiated involving inflammatory mediators, i.e. 
chemokines and cytokines. In skin inflammation these include Interleukines (IL) (IL-1 
alpha, IL-5, IL-6, IL-8, IL-13, IL-33 as well as Tumor Necrosis Factor-alpha (TNF-
alpha) and Granulocyte-Marcrophage Colony-Stimulating Factor (GMCSF) (Stamatas 
et al., 2013). Release of inflammatory mediators may happen via the regular secretory 
pathway or through non-classical export routes (Prudovsky et al, 2003; Prudovsky et al, 
2008) including simple leakage of cytosolic inflammatory mediators from damaged skin 
cells into the interstitium (the intercellular space). The inflammatory mediators activate 
inflammatory pathways in the affected tissue (key event 5). There appears to be a 
relationship between the dose as well as the chemical nature of the irritant and the 
cytokine response evoked (Hoefakker et al., 1995; Spiekstra et al., 2005). One of the 
key players in dermal irritation appears to be Interleukin 1 alpha. Disruption of the 
plasma membrane barrier leads to the release of interleukin 1 alpha into the interstitium 
(Spiekstra et al., 2005; Wood et al., 1996; Mizutani et al., 1991). Interleukines in 
general appear to play a key role in the regulation of the expression and release of other 
cytokines and chemokines involved in inflammatory reactions. Primary signals involved 
in human dermal inflammation leading to irritation appear to be IL-1alpha and TNF-
alpha leading to the release of secondary chemokine signals including CCL20 and 
CXCL8 (Spiekstra et al., 2005). CCL20 and CXCL8 have pro-inflammatory effects by 
activating epidermal residential cells involved in irritation by attracting a variety of 
immune cells including immature dendritic cells. Another CCL, CCL21 has been shown 
to be unregulated in response to exposure to chemical and physical irritants (Eberhard et 
al., 2004). CCL21 attracts dendritic cells to the site of injury (Saeki, 1999). 
 
Key event 5 – Activation of the innate immune system and development of an 
inflammatory reaction of the skin tissue 
Inflammatory mediators have a wide variety of effects on the tissue: they increase the 
diameter and permeability of blood vessels, attract innate immune cells (e.g. mast cells) 
and migratory immune cells (neutrophils, monocytes, T-cells, B-cells) to the site of 
injury and trigger the migration of migratory immune cells through the endothelium 
(leukodiapedesis) into the tissue where they participate in antigen clearance and tissue 
repair/remodelling. Mast cells residing in the dermal layers may play a key role as 
receptors of inflammatory mediator signalling. Mast cells are most numerous in the 
vicinity of nerve fibres, blood vessels and skin appendages. Mast cell granules contain 
histamine, heparin and vasoactive agents that may be released upon stimulation of the 
cells and these mediators may contribute to irritant responses (Tharp, 1991; Wasserman, 
1990; Wasserman, 1983). In addition to these actions, inflammatory mediators may 
stimulate nerve endings leading to itching, stinging and burning sensations. Overall, the 
local inflammatory response leads to the classical clinical symptoms of skin irritation: 
redness (rubor), warmth (calor), painful sensations (dolor) and also the swelling 
(oedema) of the tissue area affected. Redness and warmth of the skin tissue are 
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consequences of increased blood flow of the inflamed area. The swelling of the skin is 
due to increased permeability of the endothelial cells forming the walls of blood vessels. 
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Chapter 3. Table of References with Notes 
 
Traditional animal test – OECD TG 
TG available from: http://www.oecd.org/env/testguidelines 
OECD (2002). Acute Dermal Irritation/Corrosion, 
OECD Guideline for the Testing of Chemicals No. 404, 
OECD 
This Test Guideline describes the in vivo test procedure in laboratory rabbits (healthy 
young adult albinos). The test substance is applied to a patch of skin on a dorsal area of 
the animal's trunk. The area should be freed of fur a day before the test. Test substances 
are applied to a small skin area (ca 6 cm2) for normally 4 hours. Two physiological 
responses to the local inflammatory reaction are observed at 60 minutes, 24 , 48 and 72 
hours after patch removal and up to 14 days. The reactions are erythema (skin reddening) 
and oedema (skin swelling). If these are reversible within 14 days, the substance is 
considered an irritant. If these are not reversible and/or if there other reactions (necrosis, 
bleeding etc.) the substance is considered corrosive.  
Accepted alternative test methods – OECD TGs and publications 
TG available from: http://www.oecd.org/env/testguidelines 
Skin corrosion 
OECD (2004). In Vitro Skin Corrosion: 
Transcutaneous Electrical Resistance (TER), OECD 
Guideline for the Testing of Chemicals No. 430, 
OECD, Paris.  
The test guideline is based on the rat transcutaneous electrical resistance (TER) test 
method for skin corrosion assessment. The method uses excised skin discs as a test 
system. Loss of electrical resistance following application of a test substance indicates 
that the substance impairs the proper barrier function (based on an integer stratum 
corneum) and is thus indicative of corrosive properties.  
 
Current update of TG 430 (to be adopted by OECD in 2013) The update concerns the 
definition and inclusion of Performance Standards (PS) as Annex 1 to the TG. These PS 
will support the ready assessment and validation of similar and modified TER-based test 
methods in accordance with the principles of Guidance Document No. 34. The list of 
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reference chemicals (RCs) suggested in the updated version of the TG is identical to the 
RCs suggested in TG431. 
OECD (2004). In Vitro Skin Corrosion: Human Skin 
Model Test, OECD Guideline for the Testing of 
Chemicals No. 431, OECD, Paris. 
The test guideline is based on Reconstructed human Epidermis (RhE) technology. The 
assay measures impairment of cell viability in the artificial skin construct as a readout of 
the damage caused by corrosives to skin. The RhE-based test methods for skin corrosion 
testing are accepted to distinguish corrosive substances (Category 1) from substances 
considered non-corrosive or non-classified (TG431; EU test method R40.bis). 
 
Current update of TG431 (to be adopted by OECD in 2013) 
The UN GH system foresees three further optional corrosive subcategories (1A, 1B, 1C) 
which are fully implemented in the EU through EU CLP but which are currently not 
predicted by the in vitro models. Notably, one of these RhE test methods, the EpiSkin, 
had originally been validated by ECVAM for subcategorisation of corrosives into R35 
and R34, according to the previous DSD system (ESAC statement 1998). These 
categories correspond currently to subcategories 1A (=R35) and a combination of 1B and 
1C (=R34). Information on subcategorisation is considered particularly important for the 
transport of chemicals: the three hazard subcategories directly correspond to UN 
packaging groups I to III. These differ substantially with regard to the restrictions 
imposed on the packaging and transport of substances (e.g. packaging size, dimension 
and quality of packaging material, means of transport etc.). Therefore, information on 
subcategorisation and hence packing groups would be useful additional information for 
chemicals producers and their downstream users in view of economising on packaging 
needs of chemicals that can be demonstrated to fall in packing groups II and III. 
 
To address this need, the OECD expert group on skin corrosion and irritation agreed that, 
on the background of the successful original validation of the EpiSkin (Fentem et al., 
1998) for partial subcategorisation (R35 and R34), the currently available suite of RhE 
test methods for corrosion testing should be further evaluated in view of their ability to 
subcategorise. One of the major driving forces was the availability of new control 
experiments, not available during original validation. These control experiments address 
possible false predictions associated mainly with chemicals (a) that directly reduce the 
viability dye used in the protocols (MTT) or (b) interfere with an accurate measurement 
of optical density of formazan, the MTT reduction product (e.g. colorants).  
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The projects provided the following results:  
• None of the methods was able to resolve all three subcategories. However the 
SkinEthic assay was able to reliably and accurately predict category 1A versus a 
combination of categories 1B and 1C versus non-classified substances. 
• The remaining test methods (EpiDerm and SkinEthic) showed a high rate of 
over-predictions of 1B/1C categories as 1A (ca 45% over-prediction rate). 
• While this is not a concern from a precautionary point of view, it is an 
unacceptably high rate of false positive predictions. ECVAM has therefore 
suggested considering 1A predictions from these test methods as unresolved 
Category 1 predictions. This has been taken up in the draft TG (up for adoption 
by WNT in 2013). Thus, these test methods are able to predict Category 1, a 
combination of categories 1B and 1C and non-classified substances. 
• A very useful outcome of this project was the definition of a suitable list of 
reference chemicals (n=30) which have been included in the updated 
Performance Standards of TG431 and also TG 430. 
 
It should be noted that this project was not a validation study, i.e. testing was performed 
only in the test developers' laboratories under non-blinded conditions and without using a 
consistent set of chemicals for all evaluated test methods. 
OECD (2006). In Vitro Membrane Barrier Test Method 
for Skin Corrosion, OECD Guideline for the Testing of 
Chemicals No. 435, OECD, Paris. 
The Corrositex method recapitulates the stratum corneum barrier of the skin using a 
matrix of hydrated collagen matrix in a supporting filter membrane. Corrosive chemicals 
or mixtures to pass through, by diffusion and/or destruction/erosion, this biobarrier and 
elicit a colour change in the underlying liquid "Chemical Detection System" (CDS), 
composed of water and pH indicator dyes. The assay has several limitations: many non-
corrosive chemicals and mixtures and some corrosive chemicals and mixtures may not 
qualify for testing. For instance, aqueous substances with a pH range from 4.5 to 8.5 do 
typically not qualify for testing in the Corrositex assay. This excludes a lot of potential 
corrosives. While the Corrositex test method is accepted by OECD, it has not been 
included into EU legislation (i.e. test method regulation). 
Skin irritation 
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OECD (2010). In Vitro Skin Irritation: Reconstructed 
Human Epidermis Test Method No. 439, OECD, Paris. 
The test guideline is based on Reconstructed human Epidermis (RhE) technology. The 
assay measures impairment of cell viability in the artificial skin construct as a readout of 
the cell damage and tissue trauma, the initial step in the inflammatory cascade leading to 
skin irritation. The test methods are accepted for predicting skin irritants (Category 2) 
versus non-classified substances. They are not able to predict the optional Category 3 of 
UN GHS (UN, 2013), not implemented in the EU (EU, 2008). 
 
Current update of TG 439 (to be adopted by OECD in 2013) 
Following a performance-based validation study of the Japanese LabCyte EPI-MODEL 
(manufactured by J-Tec, Ltd), the Japanese Centre for the Validation of Alternative 
Methods had requested an evaluation of this study by the OECD expert group. Following 
positive evaluation of the (amended) study by the OECD expert group, the Working 
Group of the National Coordinators of the Test Guidelines Programme (WNT) decided in 
2012 to include this assay in TG 439. On request of the OECD Test Guidelines 
Programme, ECVAM acted as lead organisation and prepared, in collaboration with 
JaCVAM, the necessary update of TG439, taking the opportunity to amend the test 
guideline also with regard to a) the clarity of presentation of the underlying validation 
evidence for each of the methods and b) an overview on the main communalities and 
differences of the various test methods' protocols included in TG 439. The latter should 
support test users with regard to selecting the test methods that meets their specific 
requirements. Such a comparison table adds moreover to the transparency of the test 
methods included in the TG and may become a standard element in Performance-Based 
Test Guidelines (PBTGs). The updated version is currently (July 2013) scheduled for 
adoption by OECD within 2013.  
Griesinger C, Barroso J, Zuang V, Cole T, Genschow E 
& Liebsch M (2010). Explanatory background 
document to the OECD Test Guideline on in vitro skin 
irritation testing. OECD Series on Testing and 
Assessment, No. 137, OECD, Paris. 
 
An updated version is made available from the EURL 
ECVAM webpage:  
"Explanatory Background Document to the OECD 
This background document compiles comprehensive information on the ECVAM 
validation study and other validation studies relating to the RhE test methods of TG439 
for skin irritation testing. It provides a summary of the scientific work leading the 
validated RhE methodology, the adaptations of the performance standards reference 
chemicals and accuracy values necessary as a consequence of the change from the former 
EU DSD-based classification system to the UN GHS-based EU CLP system. The 
document provides a detailed description (including structural formula) of the test 
chemicals used for validation. Finally, also the results from the preceding optimisation 
studies are presented.  
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Draft Test Guideline on in vitro Skin Irritation Testing. 
1. Performance of Test Methods under UN-GHS; 2. 
Update of Performance Standards; 3. Comprehensive 
Data Compilation pursuant to the Validation Process 
and the preceding Optimisation Studies." 
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-
ecvam/validation-regulatory-acceptance/topical-
toxicity/skin-irritation 
Traditional animal test – Scientific publications 
Draize JH, Woodard G & Calvery HO (1944). Methods 
for the study of irritation and toxicity of substances 
applied topically to the skin and mucous membranes. J. 
Pharmacol. and Exp. Therapeutics. 82, 377–390.  
The paper suggests the use of rabbits for testing irritation and toxicity (corrosion) of 
substances, applied to the skin and mucous membranes (including eyes) of the animals. 
Weil CS, Scala RA (1971). Study of intra- and 
interlaboratory variability in the results of rabbit eye 
and skin irritation tests. Toxicol Appl Pharmacol. 
Jun;19(2):276-360. 
This paper analyses the intra- and interlaboratory variability of Draize eye and skin 
irritation testing data on the basis of 10 substances distributed to 24 laboratories. The 
study finds within- and between laboratory variability. 
ECETOC (1995). Skin Irritation and Corrosion 
Reference Chemicals Data Bank. ECETOC technical 
report No. 66. Brussels, Belgium. 
This Reference Chemicals Data Bank provides animal testing data of high quality (i.e. 
performed under GLP). Analysis of the variability of these data shows high variability.  
An analysis is presented in Griesinger C et al., Explanatory background document to the 
OECD draft Test Guideline on in vitro skin irritation testing. OECD 2010. OECD Series 
on Testing and Assessment, No. 137, OECD, Paris. 
Phillips L 2nd, Steinberg M, Maibach HI, Akers WA 
(1972). A comparison of rabbit and human skin 
response to certain irritants. Toxicol Appl Pharmacol. 
21(3):369-82. 
An early comparative analysis of animal Draize irritation versus human data which finds 
differences in the irritant responses.  
Jírová D, Basketter D, Liebsch M, Bendová H, Kejlová 
K, Marriott M, Kandárová H (2010). Comparison of 
human skin irritation patch test data with in vitro skin 
irritation assays and animal data. Contact Dermatitis 
62(2):109-16. 
The paper presents an interesting comparison between (a) human skin irritation data with 
(b) in vivo irritation data and (c) data from in vitro RhE skin irritation tests (using 
EpiDerm and EpiSkin). Background to this analysis is the high variability of animal 
reference data and the issues with regard to relevance for the species of interest, the 
human. Using the 4-hour human patch test (HPT) the authors examined 16 chemicals 
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whose EU classification of skin irritancy is known to be borderline (i.e. at the border 
between Category 2 and No Category), or for which in vitro methods have been reporting 
conflicting results. Of the 16 chemicals classified as irritants in the rabbit, five substances 
were found to be irritant to human skin. Concordance of the rabbit test with the 4-hr HPT 
was only 56%, whereas concordance of human epidermis models with human data was 
76% (EpiDerm) and 70% (EpiSkin). The study confirms that the rabbit model is 
overpredicting (which from a precautionary point of view needn't be a worry), but which 
has drawbacks for industry. Furthermore, the study shows that in vitro methods based on 
human cells may have a higher relevance with respect to human effects when comparing 
the in vitro data with data from a human standardised irritation test (HPT).  
Basketter DA, York M, McFadden JP, Robinson MK 
(2004). Determination of skin irritation potential in the 
human 4-h patch test. Contact Dermatitis. 51(1):1-4.  
The paper presents a substantial database on the skin irritation potential of some 65 
substances tested in a standard human 4-h patch test. These provide a high quality dataset 
for the development, evaluation and validation of in vitro or in silico alternatives. This 
allows avoiding the optimisation of alternative methods against non-human reference data 
from the rabbit. 
Young JR, How MJ, Walker AP, Worth WMH (1988). 
Classification as Corrosive or Irritant to Skin of 
Preparations Containing Acidic or Alkaline Substance 
Without Testing on Animals. Toxicol. In Vitro 2, 19-
26. 
The paper suggest that materials that for substances with strong acidity or alkalinity, 
animal testing is not necessary. This was taken up in the testing strategy described in the 
supplement of TG 404. 
Accepted alternative test methods – Scientific publications 
Skin Corrosion 
Barratt MD, Brantom PG, Fentem JH, Gerner I, Walker 
AP, Worth AP (1998) The ECVAM international 
validation study for in vitro tests for skin corrosivity. 1. 
Selection and distribution of the test chemicals. 
Toxicol. In Vitro 12:471-482. 
 
Fentem JH, Archer GE, Balls M, Botham PA, Curren 
These papers describe the ECVAM validation study on skin corrosion assays, involving 
the following test methods TER (later TG430), Skin(2TM) ZK1350 test method, 
Corrositex (later TG435) and EpiSkin test methods (later TG431). While the paper by 
Barratt et al., focuses on the test selection of appropriate test substances, the publication 
by Fentem et al, provides the results of the validation study. 
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RD, Earl LK, Esdaile DJ, Holzhütter HG, Liebsch M. 
(1998) The ECVAM International Validation Study on 
In Vitro Tests for Skin Corrosivity. 2. Results and 
Evaluation by the Management Team. Toxicol In Vitro 
12(4):483-524. 
Kandárová H, Liebsch M, Spielmann H, Genschow E, 
Schmidt E, Traue D, Guest R, Whittingham A, Warren 
N, Gamer AO, Remmele M, Kaufmann T, Wittmer E, 
De Wever B, Rosdy M. (2006). Assessment of the 
human epidermis model SkinEthic RHE for in vitro 
skin corrosion testing of chemicals according to new 
OECD TG 431. Toxicol In Vitro 20(5):547-59. 
The paper summarises the SkinEthic validation study based on the TG431 Performance 
Standards for RhE based skin corrosion tests involving assessment of 12 reference 
chemicals.  
Tornier C, Roquet M, Fraissinette AB (2010).  
Adaptation of the validated SkinEthicTM 
Reconstructed Human Epidermis (RHE) skin corrosion 
test method to 0.5 cm2 tissue sample. Toxicol. In Vitro 
24, 1379-1385. 
The publication describes the adaptation of the SkinEthic validated method to a smaller 
tissue insert size and provides information on the performance of this slightly modified 
method. 
Hoffmann J, Heisler E, Karpinski S, Losse J, Thomas 
D, Siefken W, Ahr HJ, Vohr HW, Fuchs HW (2005). 
Epidermal-skin-test 1,000 (EST-1000) - a new 
reconstructed epidermis for in vitro skin corrosivity 
testing. Toxicol In Vitro 19(7):925-9.  
The paper describes the EST-1000 validation study based on the TG431 Performance 
Standards for RhE based skin corrosion tests involving assessment of 12 reference 
chemicals. From 2012 on, the EST-1000 model has been marketed under the trade name 
"EpiCS". The model's technical specifications have not changed. 
Skin Irritation 
Fentem JH, Briggs D, Chesné C, Elliot GR, Harbell 
JW, Heylings JR, Portes P, Roguet R, van de Sandt 
JJM and Botham P (2001). A prevalidation study on in 
vitro tests for acute skin irritation, Results and 
evaluation by the Management Team. Toxicol. in Vitro 
15, 57-93. 
The paper describes the ECVAM prevalidation study (1999-2000) on a selection of in 
vitro / ex vivo skin irritation tests. These were:  
 
• the EpiDerm assay, 
• the EPISKIN assay,  
• the PREDISKIN assay,  
• the non-perfused pig ear method,  
• the mouse skin integrity function test (SIFT). 
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Neither PREDISKIN nor the pig ear method performed sufficiently well to proceed to the 
final stage of the Prevalidation study. The SIFT assay needed further refinement work 
and did not proceed to the last stage. Only the two RhE-basd methods (EpiDerm and 
EpiSkin) successfully underwent all phases of the prevalidation study. However, none of 
the methods was found ready to enter into a formal validation study and improvement of 
the protocols and prediction models was recommended. 
Zuang V, Balls M, Botham PA, Coquette A, Corsini E, 
Curren RD, Elliot GR, Fentem JH, Heylings JR, 
Liebsch M, Medina J, Roguet R, van De Sandt JJM, 
Wiemann C and Worth A (2002). Follow-up to the 
ECVAM prevalidation study on in vitro tests for acute 
skin irritation, The European Centre for the Validation 
of Alternative Methods Skin Irritation Task Force 
report 2. ATLA 30, 109-129. 
The paper summarised the outcome of an ECVAM task force meeting on skin irritation 
during which the results of the Prevalidation study (Fentem et al., 2001) were discussed 
and during which decisions were taken with regard to the test methods that were found 
sufficiently well developed to enter formal validation. 
Kandárová H, Liebsch M, Genschow E, Gerner I, 
Traue D, Slawik B and Spielmann H (2004). 
Optimisation of the EpiDerm test protocol for the 
upcoming ECVAM validation study on in vitro skin 
irritation tests. ALTEX 21, 107–114. 
 
Kandárová H, Liebsch M, Gerner I, Schmidt E, 
Genschow E, Traue D and Spielmann H (2005). The 
EpiDerm test protocol for the upcoming ECVAM 
validation study on in vitro skin irritation tests – An 
assessment of the performance of the optimised test. 
ATLA 33, 351-367. 
These publications summarise the test method optimisation work of the EpiDerm model 
prior to its validation by ECVAM. 
Cotovio J, Grandidier MH, Portes P, Roguet R and 
Rubinsteen G (2005). The in vitro acute skin irritation 
of chemicals: optimisation of the EPISKIN prediction 
model within the framework of the ECVAM validation 
process. ATLA 33, 329-349. 
This publication summarises the test method optimisation work of the EpiSkin model 
prior to its validation by ECVAM. 
Spielmann H, Hoffmann S, Liebsch M, Botham P, This publication summarises the findings of the ECVAM validation study on the RhE test 
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Fentem JH, Eskes C, Roguet R, Cotovio J, Cole T, 
Worth A, Heylings J, Jones P, Robles C, Kandárová H, 
Gamer A, Remmele M, Curren R, Raabe H, Cockshott 
A, Gerner I, Zuang V (2007). The ECVAM 
international validation study on in vitro tests for acute 
skin irritation: report on the validity of the EPISKIN 
and EpiDerm assays and on the Skin Integrity Function 
Test. ATLA 35(6):559-601. 
methods for skin irritation testing (EpiDerm and EpiSkin). 
Eskes C, Cole T, Hoffmann S, Worth A, Cockshott A, 
Gerner I and Zuang V (2007). The ECVAM 
international validation study on in vitro tests for acute 
skin irritation: selection of test chemicals. ATLA 35, 
603-619. 
The paper provides a detailed summary of the test chemicals used (n=58) in the ECVAM 
skin irritation validation study and provides information on the chemical selection process 
using a set of pre-defined criteria.  
Katoh M and Hata K (2011). Refinement of LabCyte 
EPI-MODEL24 skin Irritation test method for 
adaptation to the requirements of OECD test guideline 
439. AATEX, 16, 111-122 
 
Katoh M, Hamajima F, Ogasawara T and Hata K 
(2009). Assessment of human epidermal model 
LabCyte EPI-MODEL for in vitro skin irritation testing 
according to European centre for the validation of 
alternative methods (ECVAM)-Validated Protocol. J 
Toxicol Sci, 34, 327-334 
 
Kojima H, Ando Y, Idehara K, Katoh M, Kosaka T, 
Miyaoka E, Shinoda S, Suzuki T, Yamaguchi Y, 
Yoshimura I, Yuasa A, Watanabe Y and Omori T 
(2012). Validation Study of the In Vitro Skin Irritation 
Test with the LabCyte EPI-MODEL24. ATLA 40, 33-
50. 
These papers summarise the optimisation and validation of the Japanese LabCyte model. 
The validation study was peer reviewed by OECD in 2011 and the test method adopted 
for TG439 in 2012. The updated TG439 is expected to be formally adopted by OECD in 
2013. 
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Regulatory requirements across sectors 
European Commission (2006). Regulation (EC) No 
1907/2006 of the European Parliament and the Council 
of 18 December 2006 concerning the Registration, 
Evaluation, Authorisation and Restriction of Chemicals 
(REACH), establishing a European Chemicals Agency, 
amending Directive 1999/45/EC and repealing Council 
Regulation (EEC) No 793/93 and Commission 
Regulation (EC) No 1488/94 as well as Council 
Directive 76/769/EEC and Commission Directives 
91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. 
Official Journal of the European Union L396: 1-849. 
REACH/Chemicals: Information requirements depend on the production volume of the 
chemical concerned. While Annex VII foresees only in vitro testing, Annex VIII foresees 
the traditional animal test. 
 
Annex VII stipulates the information requirements for substances manufactured or 
imported in the EU in quantities of one ton or more per year (lowest tonnage level); these 
include skin irritation and corrosion. The assessment of these effects should follow four 
consecutive steps: (1) assessment of available human and animal data; (2) assessment of 
acid or alkaline reserve; (3) in vitro study for skin corrosion; (4) in vitro study for skin 
irritation.  
 
Annex VIII stipulates the information requirements for substances manufactured or 
imported in the EU in quantities of 10 tonnes or more per year. It foresees the assessment 
of skin irritation using the in vivo test. 
 
Furthermore, with Annex XI, REACH allows adaptation of the standard testing regime 
outlined in Annexes VII to X and thus, in principle, allows the adaptation of the in vivo 
testing requirement set out in Annex VIII (Annex VI in any case foresees only in vitro 
testing) beyond the specific rules laid out in Column 2 of Annex VIII. Possible ways of 
adapting the standard regime are Annex XI 1.2 (weight of evidence) and Annex XI 1.4 (in 
vitro methods). 
European Commission (2008). Regulation (EC) No 
1272/2008 of the European Parliament and of the 
Council of 16 December 2008 on classification, 
labelling and packaging of substances and mixtures, 
amending and repealing Directives 67/548/EEC and 
1999/45/EC, and amending Regulation (EC) No 
1907/2006. Official Journal of the European Union 
L353: 1-1355. 
Classification, Labelling and Packaging: The CLP Regulation itself does not stipulate 
information requirements, but lays out the rules for Classification and Labelling. It 
complements in particular the REACH legislation: the aim of human health hazard 
assessment under REACH (Annex I, section 1.) is after all the determination of the 
classification and labelling of a substance in agreement with the relevant rules (formerly 
Directive 67/548/EEC, replaced by CLP Regulation. 
 
The EU CLP Regulation implements the UN Globally Harmonized System (UN GHS) 
for classification and labelling (C&L). The C&L categories used are based on visually 
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observable effects in rabbit skin following exposure (Draize skin corrosion and skin 
irritation test, EU test method B.4; OECD Test Guideline 404). 
 
Corrosive substances are labelled 'Category 1'. This category contains three further 
optional subcategories which correspond to the UN Packing Groups I, II and III for the 
transport of goods. The subcategories are implemented in the EU. They differ with regard 
to the exposure times required to elicit skin corrosion in the rabbit and are referred to as 
1A ("strong corrosives"), 1B ("moderate corrosives") and 1C ("mild corrosives"). 
 
Irritant substances are labelled 'Category 2'. While UN GHS allows furthermore the use 
of an additional "opt-in" category to classify mild irritants ('Category 3'), this optional 
category is not implemented in the EU and hence, C&L of skin irritants in the EU is 
follows a dichotomous categorisation: Category 2 versus non-classified. 
European Commission (2009a). Regulation (EC) No 
1107/2009 of the European Parliament and of the 
Council of 21 October 2009 concerning the placing of 
plant protection products on the market and repealing 
Council Directives 79/117/EEC and 91/414/EEC. 
Official Journal of the European Union L309: 1-47. 
Plant Protection Products (PPPs): The PPP Regulation requests information on skin 
irritation and corrosion (section 7.1.4; note that the title of the section refers only to 
irritation, while the text refers to both, irritation and corrosion). The Regulation stipulates 
that, before carrying out in vivo studies for corrosion/irritation of the PPP, a Weight of 
Evidence (WoE) analysis should be carried out. This strategy is similar to that outlined in 
the supplement to OECD TG 439: If the data evaluated by WoE is insufficient to reach 
conclusions on corrosion/irritation potential of the PPP, a testing strategy should be 
carried out using (a) a validate in vitro method for skin corrosion; (b) assessment of 
irritation using a validated in vitro test method (such as human reconstructed skin 
models); (c) an initial in vivo study using one animal and (d) confirmatory testing using 
one or two animals.  
Information on corrosion and irritation may also be derived from dermal toxicity studies 
(section 7.1.2), however such studies are required only on a case by case basis under the 
PPP Regulation. 
European Commission (2009b). Regulation (EC) No 
1223/2009 of the European Parliament and the Council 
of 30 November 2009 on cosmetic products. Official 
Journal of the European Union L342: 59-209. 
Cosmetics: The Cosmetics Regulation requests a characterisation of the "toxicological 
profile of substance contained in the cosmetic product for all relevant toxicological 
endpoints. A particular focus on local toxicity evaluation (skin and eye irritation…)" 
(Annex I, point 8 of Cosmetics Regulation). Clearly the evaluation of the corrosion and 
irritation potential of substances voluntarily and repeatedly applied to skin is obviously of 
great relevance. 
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European Union Regulation (2012). Regulation (EU) 
No 528/2012 of the European Parliament and of the 
Council of 22 May 2012 concerning the making 
available on the market and use of biocidal products. 
Official Journal of the European Union L 167: 1-116. 
Biocides: All biocidal products and active substances marketed in the UE independent of 
tonnage level. Information requirement for skin irritation and skin corrosion follows a 
strategic approach using in vitro methods for skin corrosion and irritation and, only in 
case of specific limitations of these in vitro methods, in vivo testing should be considered. 
(ECHA guidance on Biocides Regulation, section 8.1). 
Mechanistic understanding 
Elsner P (1994). Irritant dermatitis in the workplace. 
Dermatol Clin. 12(3):461-7 
The article reviews pathogenesis, epidemiology, diagnosis, and treatment of irritant 
dermatitis at the workplace. Irritant contact dermatitis is the most frequent occupational 
skin disease and results in considerable morbidity and economic losses. The importance 
of integrated preventive measures (that require robust knowledge about the irritancy 
potential of substances) are suggested which should be implemented by companies and 
employees to achieve optimal efficacy. 
Wigger-Alberti W, Elsner P (2000). Contact Dermatitis 
due to Irritation, p99-110. In Handbook of 
Occupational Dermatology. Berlin, Springer. 
The paper outlines the clinical relevance of Irritant Contact Dermatitis (ICD). Skin 
diseases are the second most frequent occupation disease (after musculoskeletal disorders, 
e.g. "back pain"). Most dermatotes (diseases of skin) are cases of contact dermatitis and 
ICD is more frequent than Allergic Contact Dermatitis (ACD) resulting from skin 
sensitisation. In contrast to ACD, ICD is defined as a result of primarily nonspecific 
damage (trauma) to the skin and hence does not represent a precise entity in clinical terms 
but a spectrum of disease patterns. The authors argue that the perception of ICD as more 
trivial than the more intellectually appealing problem of allergic sensitisation (ACD) is 
changing. The review stresses the eminent importance of reliable data on skin corrosion 
and irritation potential of substances. 
Willis CM, Stephens CJ, Wilkinson JD (1989). 
Epidermal damage induced by irritants in man: a light 
and electron microscopic study. J Invest Dermatol. 
93(5):695-9. 
This paper is one of the very few thorough contributions to the study of the pathogenesis 
of Irritant Contact Dermatitis by studying histophathological damages in human skin 
resulting from exposure to a series of structurally unrelated irritants (i.e. reflecting a 
diverse chemistry in view of determining possible differences in histophathology). 
Human volunteers were patch-tested with nonanoic acid, sodium lauryl sulphate, 
dithranol, benzalkonium chloride, croton oil, and propylene glycol, which produced 
generally mild to moderate responses. Biopsy specimens were excised 48 h after topial 
application of the irritants and examined by light and electron microscopy. Spongiosis 
and infiltration of predominantly mononuclear cells were observed in the epidermis. 
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Several irritants induced characteristic patterns of keratinocyte damage, others caused 
morphologic changes indicative of disturbances in keratinocyte metabolism and 
differentiation. The results suggest that there is a diversity and specificity in the 
histopathology of irritant contact dermatitis, reflecting the different ways in which 
chemicals may interact with components of the skin. However, tissue trauma resulting 
from severe impairment of cell viability appears a common consequence irrespective of 
the irritant. The authors have published four other papers on ultrastructural effects 
following irritant exposure in humans. These are not presented in greater detail, but listed 
below: 
 
Willis CM, Stephens CJ, Wilkinson JD (1991). Selective expression of immune-
associated surface antigens by keratinocytes in irritant contact dermatitis. J Invest 
Dermatol. 96(4):505-11. 
 
Willis CM, Stephens CJ, Wilkinson JD (1990). Differential effects of structurally 
unrelated chemical irritants on the density and morphology of epidermal CD1+ cells. J 
Invest Dermatol. 95(6):711-6. 
 
Willis CM, Stephens CJ, Wilkinson JD (1992). Differential effects of structurally 
unrelaed chemical irritants on the density of proliferating keratinocytes in 48 h patch test 
reactions. J Invest Dermatol. 99(4):449-53. 
 
Willis CM, Stephens CJ, Wilkinson JD (1993). Differential patterns of epidermal 
leukocyte infiltration in patch test reactions to structurally unrelated chemical irritants. J 
Invest Dermatol. 101(3):364-70. 
Willis CM, Reiche L, Wilkinson JD (1998). 
Immunocytochemical demonstration of reduced Cu,Zn-
superoxide dismutase levels following topical 
application of dithranol and sodium lauryl sulphate: an 
indication of the role of oxidative stress in acute irritant 
contact dermatitis. Eur J Dermatol. 8(1):8-12. 
This paper demonstrates the involvement of oxidative stress in the genesis of chemically 
induced skin inflammation / skin irritation leading to Irritant Contact Dermatitis (ICD). 
Willis CM, Young E, Brandon DR, Wilkinson JD 
(1986). Immunopathological and ultrastructural 
This paper compares the histopathological features of Allergic Contact Dermatitis (ACD) 
with those of Irritant Contact Dermatitis (ICD) in a group of 17 patients that each patient 
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findings in human allergic and irritant contact 
dermatitis. Br J Dermatol. 115(3):305-16. 
received simultaneous patch tests of a known allergen and a standardized irritant 
(benzalkonium chloride). Cellular changes occurring between 3 h and 7 days after patch 
test application were studied by light and electron microscopy and immunocytochemistry. 
Interestingly the paper did not find any differences between the induced ACD and the 
ICD, neither in the responding cell types nor the sequence of cellular events. In both cases 
infiltration mainly by T lymphocyte occurred (no polymorphonuclear leukocyte 
involvement). Apposition of Langerhans cells to lymphocytes in the epidermis was seen 
in both types of response. While there was considerable variability in the intensity of 
reaction to irritant and allergen occurred within individuals, no statistically significant 
difference between the intensity of the reactions to the irritant and the allergen was 
observed in the patient group tested. The paper demonstrates that the early inflammatory 
response mediated mainly by the innate immune system of the skin tissue is the same for 
ACD and ICD. 
Stamatas GN, Morello AP Mays DA (2013). Early 
Inflammatory Processes in the Skin. Curr Mol Med. 
Feb 27 
This review focuses on immunologic activity occurring in the absence of any visual 
inflammatory cues. The authors discuss the importance of subclinical inflammation in 
human skin and its relevance to innate immune surveillance under physiologic conditions. 
Fluhr JW, Darlenski R, Angelova-Fischer I, Tsankov 
N, Basketter D (2008) Skin irritation and sensitization: 
mechanisms and new approaches for risk assessment. 1. 
Skin irritation. Skin Pharmacol Physiol. 21(3):124-135. 
This review outlines advanced techniques for studying irritation as well as an overview of 
key inflammatory mediators involved in skin irritation. 
Status of non-standard methods / Status of new in-vitro based  standard methods 
Bouvier d'Yvoire M, Bremer S, Casati S, Ceridono M, 
Coecke S, Corvi R, Eskes C, Gribaldo L, Griesinger C, 
Knaut H, Linge JP, Roi A, Zuang V (2012). ECVAM 
and New Technologies for Toxicity Testing in New 
Technologies for Toxicity Testing, eds Balls M, 
Combes RD, Bhogal N. Adv Exp Med Biol. 745:154-
80.  
This book chapter contains a section on skin corrosion/irritation where new developments 
are presented in detail. 
Poumay Y, Dupont F, Marcoux S, Leclercq-Smekens 
M, Hérin M, Coquette A (2004). A simple 
This paper describes a method for reconstructing human epidermis in vitro. The method 
was developed by university and is devoid of any proprietary elements. The protocol of 
Poumay and co-authors has later been taken up by Henkel, Germany, who is developing 
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reconstructed human epidermis: preparation of the 
culture model and utilization in in vitro studies. Arch 
Dermatol Res. 296(5):203-11. 
it further in view of marketing this "open source" model for standardised use. 
Integrated Testing Strategies 
OECD (2004). Acute Dermal Irritation/Corrosion, 
OECD Guideline for the Testing of Chemicals No. 404, 
OECD 
The TG contains a supplement outlining a simple testing strategy. The supplement 
recommends that a weight-of-the-evidence analysis may be used to evaluate existing 
information regarding the skin irritation and corrosion of substances to determine whether 
additional studies, other than in vivo dermal studies, should be performed to help 
characterise such potential. Although this sequential testing strategy is not an integral part 
of Test Guideline 404, it expresses the recommended approach for the determination of 
skin irritation/corrosion characteristics. The strategy provides an approach for the 
evaluation of existing data on the skin irritation/corrosion properties of test substances 
and a tiered approach for the generation of relevant data on substances for which 
additional studies are needed, or for which no studies have been performed. It also 
recommends the performance of validated and accepted in vitro or ex vivo tests for skin 
corrosion/irritation under specific circumstances. 
ECHA (2012). Guidance on information requirements 
and chemical safety assessment. Chapter R.7a: 
Endpoint specific guidance. In "Guidance for the 
implementation of REACH". Version 2.0. November 
2012.: 
http://echa.europa.eu/documents/10162/13632/informat
ion_requirements_r7a_en.pdf  
This document provides guidance on information requirements including skin corrosion 
and irritation. It contains the testing strategy developed during the REACH 
implementation project.  
Hoffmann S, Saliner AG, Patlewicz G, Eskes C, Zuang 
V & Worth AP (2008). A feasibility study developing 
an integrated testing strategy assessing skin irritation 
potential of chemicals. Toxicology Letters 180: 9–20. 
 
This paper describes a feasibility study investigating how a combination of in silico, in 
vitro, and in vivo information could be applied in the assessment of skin irritation hazard. 
Therefore, a database of 100 existing and new chemicals was compiled. A number of 
strategies, both animal-free and inclusive of animal data were constructed and 
subsequently evaluated considering predictive capacities, severity of misclassifications 
and testing costs. Comparison of constructed ITS based on these assessment parameters 
identified best performing strategies for chemical classification. However, defining the in 
vivo test as the reference test limited the evaluation of the ITS inclusive of animal data. 
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This study demonstrated that ITS can be constructed, evaluated and compared in a 
systematic fashion. To promote ITS, further guidance on construction and multi-
parameter evaluation need to be developed. 
Worth AP, Fentem JH, Balls M, Botham PA, Curren D, 
Earl LK, Esdaile DJ & Liebsch M (1998). An 
Evaluation of the Proposed OECD Testing Strategy for 
Skin Corrosion. 709–720. 
 
The widespread concern over the severity of the Draize rabbit test for assessing skin 
irritation and corrosion led to the proposal of a stepwise testing strategy at an OECD 
workshop in January 1996. Subsequently, the proposed testing strategy was adopted, with 
minor modifications, by the OECD Advisory Group on Harmonization of Classification 
and Labelling. This article reports an evaluation of the proposed OECD testing strategy as 
it relates to the classification of skin corrosives. By using a set of 60 chemicals, an 
assessment was made of the effect of applying three steps in the strategy, taken both 
individually and in sequence. The results indicate that chemicals can be classified as 
corrosive (C) or non-corrosive (NC) with sufficient reliability by the sequential 
application of three alternative methods, i.e., structure-activity relationships (where 
available), pH measurements, and a single in vitro method (either the rat skin 
transcutaneous electrical resistance (TER) assay or the EPISKINTM assay). It is 
concluded that the proposed OECD strategy for skin corrosion can be simplified without 
compromising its predictivity. For example, it does not appear necessary to measure 
acid/alkali reserve (buffering capacity) in addition to pH for the classification of pure 
chemicals. 
QSARs and Expert Systems 
Barratt MD (1996a). Quantitative structure-activity 
relationships (QSARs) for skin corrosivity of organic 
acids, bases and phenols: Principal components and 
neural network analysis of extended datasets. 
Toxicology in Vitro 10: 85–94. 
Quantitative structure-activity relationships (QSARs) relating skin corrosivity data of 
organic acids, bases and phenols to their log(octanol/water partition coefficient), 
molecular volume, melting point and pK(a). have been extended to substantially larger 
datasets. In addition to principal components analysis, as used in earlier work, the 
datasets have also been analysed using neural networks. Plots of the first two principal 
components of the four independent variables, which broadly model skin permeability 
and cytotoxicity, for each of the extended datasets confirmed that the analysis was able to 
discriminate well between corrosive and non-corrosive chemicals. Neural networks using 
the same parameters as inputs, were trained to an output in the range 0.0 to 1.0, with non-
corrosive chemicals being assigned the value 0 and corrosive chemicals the value 1. As 
well as yielding classification predictions in agreement with those in the training sets, 
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predicted outputs in the 0 to 1 range gave a useful indication of the confidence of the 
predicted classification. These QSARs are useful (a) for the prediction of the skin 
corrosivity potentials of new or untested chemicals and (b) for determining the 
confidence of predictions in regions of 'biological uncertainty' which exist at the 
classification threshold between corrosive and non-corrosive chemicals. 
Barratt MD (1996b). Quantitative structure-activity 
relationships for skin irritation and corrosivity of 
neutral and electrophilic organic chemicals. Toxicology 
in Vitro 10: 247–256. 
Quantitative structure-activity relationships (QSARs) have been derived by relating skin 
irritation and corrosivity data of neutral and electrophilic organic chemicals to their 
log(octanol/water partition coefficient) (logP), molecular volume, dipole moment and 
1/molecular weight. Datasets were analysed using stepwise regression, discriminant and 
principal components analysis. Discriminant analysis between irritant and non-irritant 
neutral and electrophilic organic chemicals using the above parameters, which broadly 
model skin permeability (logP and molecular volume), 'reactivity' (dipole moment) and 
l/molecular weight to compensate for the fact that skin irritation/corrosivity testing is 
carried out using a fixed mass or volume of chemical, was found to discriminate well for 
only 73.1% of the dataset (67.3% cross-validated). The poor discrimination at the 
irritant/non-irritant classification boundary is attributed largely to biological variability. 
Stepwise regression analysis of the Primary Irritation Index (PII) for the same dataset 
showed a poor correlation (r(2) = 0.422; cross-validated r(2) = 0.201) with a positive 
dependence on logP and dipole moment and a negative dependence on molecular 
volume; l/molecular weight was not a significant variable. While this QSAR for PII has 
little value as a predictive model, mainly because of the large biological variability 
evident in PII values, it is useful in confirming the putative model for skin irritation. 
Discriminant analysis using logP, molecular volume and dipole moment, was able to 
discriminate reasonably well (92.9% well-classified; 92.9% cross-validated) between 
corrosive and non-corrosive electrophiles. A plot of the first two principal components of 
the same parameters showed a clear demarcation between corrosive and non-corrosive 
electrophiles. In contrast to the QSARs for skin irritation, increasing skin corrosivity was 
found to correlate with decreasing molecular volume, with increasing dipole moment, and 
with decreasing logP. The predominant parameter in determining the skin corrosivity of 
electrophilic organic chemicals appears to be the molar dose at which they are tested; this 
arises because skin corrosivity testing is conducted using a fixed mass or volume of 
chemical. A stepwise approach to the skin corrosivity/irritation classification of neutral 
and electrophilic organic chemicals is outlined. The derived QSARs should be useful for 
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the prediction of the skin corrosivity potential of new or untested electrophiles. (Non-
electrophilic neutral organic chemicals, as a category, do not generally appear to be 
corrosive.) Discrimination between some non-irritant and irritant neutral and electrophilic 
organic chemicals using these techniques is also possible. For a large number of 
chemicals whose irritation potentials lie in a fairly broad band around the irritant/non-
irritant classification boundary, no firm prediction of classification is possible. 
Gallegos Saliner A, Patlewicz G & Worth AP (2006). 
Review of Literature-Based Models for Skin and Eye 
Irritation and Corrosion. JRC Report EUR 22320 EN.  
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicol
ogy/doc/QSAR_Review_Irritation.pdf 
 
 
This report reviews the state-of-the-art of in silico and in vitro methods for assessing 
dermal and ocular irritation and corrosion. Following a general introduction, the current 
EU legislation for the classification and labelling of chemicals causing irritation and 
corrosivity is summarized. Then currently available non-animal approaches are reviewed. 
The main alternative approaches to assess acute local toxic effects are: a) in silico 
approaches, including SARs, QSARs and expert systems integrating multiple approaches; 
and b) in vitro test methods. In this review, emphasis is placed on literature-based 
(Q)SAR models for skin and eye irritation and corrosion as well as computer-based 
expert systems. 
Gallegos Saliner A, Patlewicz G & Worth AP (2008). A 
Review of (Q)SAR Models for Skin and Eye Irritation 
and Corrosion. QSAR & Combinatorial Science 27: 49-
59.  
 
This paper reviews the state-of-the-art of in silico methods for assessing dermal and 
ocular irritation and corrosion. It is based on an in-depth review performed by the 
European Chemicals Bureau of the European Commission: Joint Research Centre in 
support of the development of technical guidance for the implementation of the REACH 
legislation, and is one of a series of minireviews in this journal. The most widely used in 
silico approaches are classified into methods to assess (1) skin irritation, (2) skin 
corrosion and (3) eye irritation.In this review, emphasis is placed on literature-based 
(Q)SAR models. 
Gerner I, Schlegel K, Walker JD & Hulzebos E (2004). 
Use of Physicochemical Property Limits to Develop 
Rules for Identifying Chemical Substances with no 
Skin Irritation or Corrosion Potential. QSAR 
Combinatorial Science 23:726–733. 
This paper describes limit values for specific physicochemical properties that are 
appropriate for identifying chemical substances that have no skin irritation or corrosion 
potential. These physicochemical properties include melting point, molecular weight, 
octanol-water partition coefficient, surface tension, vapour pressure, aqueous solubility 
and lipid solubility. Based on analyses of 1833 chemicals, physicochemical properties for 
limits were defined to determine that when a chemical's physicochemical properties were 
either greater or less than these limits that these chemicals would have no skin irritation 
or corrosion potential. To facilitate classification and labeling, the application domains of 
these limits were constructed to correspond with the European Union's risk phrases for 
chemicals classified for skin irritation/corrosion, viz., R 34, R35 or R38. This is the 
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second paper of four companion papers. The first paper discussed mechanisms that can 
lead to significant skin irritation or corrosion after acute exposures to chemicals. The 
third paper described the application of structural alerts to identify chemical substances 
with skin irritation or corrosion potential. The fourth paper described the Skin Irritation 
Corrosion Rules Estimation Tool (SICRET), a tool that allows non-(Q)SAR experts to 
identify chemical substances with skin irritation or corrosion potential based on 
physicochemical property limits and structural alerts. 
Golla S, Madihally S, Robinson RL & Gasem KAM 
(2009). Quantitative structure-property relationships 
modeling of skin irritation. Toxicology in vitro: 
23:176–84.  
Interest in developing procedures for estimating skin irritation potential of chemicals has 
been increasing as a result of concerns regarding animal welfare and costs involved in 
experimental irritation studies. In response to these concerns, a number of expert systems 
and quantitative structure-activity relationship (QSAR) models have been proposed for 
predicting the skin irritation potential of compounds. However, these models require as 
input independent estimates of several physiochemical properties. Hence, to predict skin 
irritation potential using these models often requires additional models capable of 
estimating the physiochemical properties of diverse structures; a requirement that most 
literature QSARs fail to meet. In the work reported here, we developed a skin irritation 
QSPR model based on rabbit Draize test data for 186 compounds, which included 
chemicals from diverse molecular classes. The effectiveness of using a combination of 
traditional, functional group and structural descriptors has been studied. Our non-linear 
QSPR model is capable of predicting the skin irritation potential of chemical compounds 
with an R2 of 0.78. Further, the final set of descriptors used to model skin irritation was 
analyzed to elucidate the effects of molecular size, reactivity and skin penetration on skin 
irritation. 
Hayashi M et al. (1999). A quantitative structure-
activity relationship study of the skin irritation potential 
of phenols. Toxicology in Vitro 13: 915–922. 
QSARs for skin irritation potential were studied using twenty-four phenols. Based on the 
hypothesis that skin irritation is induced by reaction of phenols with macromols. present 
in epidermal and dermal levels of the skin, the following descriptors for QSAR were 
selected, the abs. hardness (N) calcd. from HOMO and LUMO energy levels for 
reactivity, and log P (octanol-water partition coeff.) for permeability. Using these 
descriptors, we fitted a regression function to the set of skin irritation scores obtained 
from an in vivo study, which allowed derivation of equations (r=0.85). The equations 
were verified with six additonal phenols, showing good correlations with the expected 
skin irritation scores. From the above findings, the equations can be considered useful for 
predicting the skin irritation potential of phenol compounds.  
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Hulzebos E, Walker JD, Gerner I & Schlegel K (2005). 
Use of structural alerts to develop rules for identifying 
chemical substances with skin irritation or skin 
corrosion potential. QSAR Combinatorial Science 
24:332–342. 
In this paper structural alerts for acute skin lesions were categorized as irritation or 
corrosion or a combination of corrosion/irritation alerts. Categorizing the alerts according 
to their mechanisms of skin irritation and corrosion and connecting them with 
physicochemical property limits characterizing their domain of applicability provides 
strategies to save test animals and costs. These alerts can be used for positive 
classification of chemicals causing skin irritation or skin corrosion according to EU and 
OECD guidelines. This paper is the third in the series of four papers describing practical, 
user-friendly and mechanism-based approaches for predicting when chemicals are likely 
to irritate or corrode the skin. In the first paper the mechanisms of skin irritation and 
corrosion were described. In the second paper the physicochemical property limit values 
for chemicals not causing skin irritation and corrosion were given. In the third paper, 
described here, structural alerts associated with chemicals causing skin irritation and 
corrosion were identified and characterized. In the fourth paper, the Skin Irritation 
Corrosion Rules Estimation Tool (SICRET) was described that allows users to classify 
chemicals as either not causing skin irritation and corrosion based on physicochemical 
property limit values or irritating or corrosive to the skin based on structural alerts. 
Kodithala, K., Hopfinger, A.J., Thompson, E.D. & 
Robinson, M.K. (2002). Prediction of skin irritation 
from organic chemicals using membrane-interaction 
QSAR analysis. Toxicological Sciences 66: 336–346. 
 
Membrane-interaction (MI) quantitative structure activity relationship (QSAR) analysis 
was carried out for a training set of 22 hydroxy organic compounds for which the Draize 
skin irritation scores, PII, had been determined. Significant MI-QSAR models were 
constructed in which skin irritation potency is predicted to increase with (1) increasing 
effective concentration of the compound available for uptake into phospholipid-rich 
regions of a cellular membrane, (2) increasing binding of the compound to the 
phospholipid-rich regions of a cellular membrane, and (3) the chemical reactivity of the 
compound as reflected by the highest occupied molecular orbital (HOMO) and/or lowest 
unoccupied molecular orbital (LUMO) of the molecule. Overall, the MI-QSAR models 
constructed for skin irritation are very similar, with respect to the types of descriptors, to 
those found for eye irritation. In turn, the skin irritation MI-QSAR models suggest a 
similar molecular mechanism of action to that postulated for eye irritation from MI-
QSAR analysis. Significant and predictive QSAR models cannot be constructed unless 
test compound-membrane interaction descriptors are computed and used to build the 
QSAR models. 
Mombelli E (2008). An evaluation of the predictive 
ability of the QSAR software packages, DEREK, 
According to the REACH chemicals legislation, formally adopted by the EU in 2006, 
Quantitative Structure-Activity Relationships (QSARs) can be used as alternatives to 
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HAZARDEXPERT and TOPKAT, to describe 
chemically-induced skin irritation. ATLA 36:15–24.  
animal testing, which itself poses specific ethical and economical concerns. A critical 
assessment of the performance of the QSAR models is therefore the first step toward the 
reliable use of such computational techniques. This article reports the performance of the 
skin irritation module of three commercially-available software packages: DEREK, 
HAZARDEXPERT and TOPKAT. Their performances were tested on the basis of data 
published in the literature, for 116 chemicals. The results of this study show that only 
TOPKAT was able to predict the irritative potential for the majority of chemicals, 
whereas DEREK and HAZARDEXPERT could correctly identify only a few irritant 
substances. 
Rorije, E. & Hulzebos, E. (2005). Evaluation of 
(Q)SARs for the prediction of Skin Irritation/Corrosion 
Potential. Physicochemical exclusion rules. Final report 
for ECB contract IHCP.B430206. Joint Research 
Centre, Ispra, Italy.  
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicol
ogy/doc/Evaluation_of_Eye_Irritation_QSARs.pdf 
 
In this work an evaluation of a set of QSAR rules for predicting the absence of skin 
irritation and/or corrosion is evaluated. The results show that the evaluated rule-base is 
highly useful for regulatory purposes, as almost all OECD principles on (Q)SARs are met 
and the good (external) predictivity could lead to waiving of skin irritation tests for at 
least 42.3% of EU new substance notifications. 
 
This evaluation includes 1) the compliance of the rule-base with the OECD principles on 
(Q)SARs, 2) the derivation of the (Q)SAR rules, 3) the external validation of these rules, 
including an assessment of the suitability of the dataset used for validation. The rule-base 
on irritation and corrosion developed by the BfR, the German Federal Institute for Risk 
Assessment, predicts non-irritation and non-corrosion using physico-chemical cut-off 
values, defining general rules applicable to all substances and separate rules for special 
chemical classes of substances. The distribution of the training set data over the domains 
of the physico-chemical parameters used in the rule-base is visualised and analysed. 
Recommendations are given for setting the cut-off values of the rules at a consequent 
“safe” level (not allowing for any exception to the rule in the training set) and for 
including a consistently calculated safety margin. Specific results of the analysis were: 
 
• The rule-base fulfils the OECD principles on (Q)SARs for the largest part 
• Most rules cover all irritatant/corrosive substances in the training set, however: 
• Some physico-chemical parameters have limited predictive value: 
- lipid solubility, as this is not a generally available parameter; 
- vapour pressure, as the experimental data used for derivation of the rules is not 
conclusive, and 
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- melting point, as the cut-off values for this parameter were not set at a “safe” 
level, making predictions based on melting point less reliable. 
 
An external validation of the set of rules using 201 new substances not present in the 
training set showed 99.3% correct predictions of non-corrosivity and 96.6% correct 
predictions of non-irritancy. These predictions would allow declassification as R34/R35 - 
Corrosive for 28.4% of the chemicals, and R38 - Irritant for 42.3% of the chemicals. 
These results would thus allow waiving of skin irritation tests for at least 42.3% of the 
EU new substance notifications. Four predictions were incorrect, however, for 3 of these 
reasons could be given why the set of rules failed (2 substances were misclassified based 
on melting point rules shown to be unreliable in our analysis), and/or how these incorrect 
predictions can be avoided in the future. The performance of the rules then increases to 
100% correct predictions of noncorrosivity and 98.8% correct predictions of non-
irritancy. 
 
It was concluded that by applying these rules in combination with the OECD guideline 
404 a large potential for saving animal lives, time and money can be realised. The rules 
are straightforward, easy to interpret, easily accessible and based on (measured) 
physicochemical data that is available for every substance that has to be notified in the 
EU. 
Saliner AG, Tsakovska I, Pavan M, Patlewicz G & 
Worth AP (2007). Evaluation of SARs for the 
prediction of skin irritation/corrosion potential: 
structural inclusion rules in the BfR decision support 
system. SAR and QSAR in Environmental Research 
18: 331–342. 
The German Federal Institute for Risk Assessment (BfR) has developed a Decision 
Support System (DSS) to assess certain hazardous properties of pure chemicals, including 
skin and eye irritation/corrosion. The BfR-DSS is a rule-based system that could be used 
for the regulatory classification of chemicals in the European Union. The system is based 
on the combined use of two predictive approaches: exclusion rules based on 
physicochemical cut-off values to identify chemicals that do not exhibit a certain hazard 
(e.g., skin irritation/corrosion), and inclusion rules based on structural alerts to identify 
chemicals that do show a particular toxic potential. The aim of the present study was to 
evaluate the structural inclusion rules implemented in the BfR-DSS for the prediction of 
skin irritation and corrosion. The following assessments were performed: (a) a 
confirmation of the structural rules by rederiving them from the original training set 
(1358 substances), and (b) an external validation by using a test set of 200 chemicals not 
used in the derivation of the rules. It was found as a result that the test data set did not 
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match the training set relative to the inclusion of structural alerts associated with skin 
irritation/corrosion, albeit some skin irritants were in the test set. 
Walker JD, Gerner I, Hulzebos E & Schlegel K (2004). 
(Q)SARs for Predicting Skin Irritation and Corrosion: 
Mechanisms, Transparency and Applicability of 
Predictions. QSAR Combinatorial Science 23: 721–
725. 
This paper describes previously-developed (Q)SARs for predicting skin irritation and 
corrosion, proposes mechanisms of skin irritation and corrosion, and discusses the 
transparency and applicability of predictions. This paper was written to set the tone for 
companion papers that describe three applications of skin irritation and corrosion 
(Q)SARs. The first companion paper describes physicochemical property limits that can 
be used to develop rules for identifying chemical substances with no skin irritation or 
corrosion potential. The second companion paper describes structural alerts that can be 
used to develop rules for identifying chemical substances with skin irritation or corrosion 
potential. The third companion paper describes the Skin Irritation Corrosion Rules 
Estimation Tool (SICRET), a user-friendly tool that allows non-(Q)SAR experts to 
identify chemical substances with skin irritation or corrosion potential based on 
physicochemical property limits and structural alerts. 
Walker JD, Gerner I, Hulzebos E & Schlegel K (2005). 
The Skin Irritation Corrosion Rules Estimation Tool 
(SICRET). QSAR Combinatorial Science 24: 378–384. 
This paper describes the Skin Irritation Corrosion Rules Estimation Tool (SICRET) that 
was developed to allow others to estimate whether their chemicals are likely to cause skin 
irritation or skin corrosion. SICRET uses physicochemical property limits to identify 
chemicals with no skin corrosion or skin irritation potential. If a chemical's 
physicochemical properties do not meet the prescribed limits to identify chemicals with 
no skin corrosion or skin irritation potential, then the chemical's structural alerts are used 
to identify chemicals with skin corrosion or skin irritation potential. If a chemical does 
not contain structural alerts that indicate it has skin corrosion or skin irritation potential, 
then in vitro skin corrosion or skin irritation testing is conducted. If the in vitro skin 
corrosion or skin irritation testing is positive, then the data are included in feedback loops 
for development of new structural alerts to identify chemicals with skin corrosion or skin 
irritation potential. If in vitro testing for skin corrosion or skin irritation is negative then 
the data are included in feedback loops for development of new physicochemical 
property limits to identify chemicals with no skin corrosion or skin irritation potential. 
The use of in vitro tests was proposed as a safety net to identify either new structural 
alerts for chemicals with skin corrosion or skin irritation potential or new 
physicochemical property limits for chemicals with no skin corrosion or skin irritation 
potential. In summary, SICRET is a tiered approach that uses physicochemical property 
limits, structural alerts and in-vitro tests to classify chemicals that cause skin irritation or 
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skin corrosion without further animal testing. 
Worth AP & Cronin MTD (2001). The use of pH 
measurements to predict the potential of chemicals to 
cause acute dermal and ocular toxicity. Toxicology 
169: 119-131. 
 
Regulatory guidelines for the assessment of acute dermal and ocular toxicity refer to the 
need to take the pH values of chemicals into consideration, since the acidic and basic 
properties of chemicals are known to play a role in the generation of acute dermal and 
ocular lesions. However, not all test guidelines provide an objective interpreting pH 
measurements in terms of acute skin or eye toxicity. The aim of this study was to develop 
classification models based on pH data for predicting the potential of chemicals to cause 
skin corrosion, skin irritation and eye irritation. The possible application of these models 
in the context of tiered testing strategies is discussed. 
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4. Serious eye damage and eye irritation 
Michael Schaeffer, João Barroso, Andrew Worth & Valérie Zuang 
 
4.1 The traditional animal test and its regulatory use 
Serious eye damage is the production of tissue damage in the eye, or serious physical 
decay of vision, following application of a test substance to the anterior surface of the 
eye, which is not fully reversible within 21 days of application. Eye irritation is the 
production of changes in the eye following the application of a test substance to the 
anterior surface of the eye, which are fully reversible within 21 days of application. 
Currently, serious eye damage/eye irritation potential is assessed in rabbits according to 
OECD Test Guideline 405 (OECD, 2012), also known as the Draize eye test. The 
effects are graded on the basis of in vivo responses in the conjunctiva, cornea and iris. 
For classification and labelling, mean scores for each rabbit are calculated for four 
endpoints (corneal opacity, iritis, conjunctival chemosis, conjunctival redness) 
following visual grading at 24, 48 and 72 hours after installation of the test chemical to 
the eye sack of three different animals. A Supplement to TG 405 also includes a 
stepwise testing strategy for the determination of the serious eye damage/eye irritation 
potential. This serves to reduce and refine animal testing, since all available information 
on serious eye damage/eye irritation is considered prior to in vivo testing. 
 
The assessment of serious eye damage/eye irritation is used for classification and 
labelling. The EU has implemented the United Nations Globally Harmonized System 
(UN, 2013) for the classification and labelling of hazardous chemicals with Directive 
1272/2008 (EU CLP; EC, 2008). The test chemical is classified as “Category 1” 
(serious eye damage/irreversible effects on the eye) when it has the potential to 
seriously damage the eye, including the production of corneal, iris or conjunctival 
lesions in at least one animal that are not expected to reverse or have not fully reversed 
within an observation period of normally 21 days and/or the induction of a mean corneal 
opacity ≥ 3 in at least 2 of 3 animals and/or the induction of a mean iritis > 1.5 in at 
least 2 of 3 animals. Chemicals that have the potential to induce reversible eye irritation 
should be classified as “Category 2”. UN GHS provides an option (not implemented in 
EU CLP) to distinguish "Category 2" test chemicals into two sub-categories: “Category 
2A” (irritant to eyes) when the eye irritant effects are not fully reversible within 7 days 
of observation; “Category 2B” (mildly irritant to eyes) when the eye irritant effects are 
fully reversible within 7 days of observation. Test chemicals that fall in none of the 
above categories do not require classification for serious eye damage/eye irritation (“No 
Category”). The UN scheme for the classification of serious eye damage/eye irritation 
based on the ocular tissue scores obtained in the Draize eye test is illustrated in Table 
4.1. 
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Table 4.1. GHS classification of eye irritation based on observations in the Draize eye test  
 
Location Ocular Lesions Grade 
No ulceration or opacity 0 
Scattered or diffuse areas of opacity; details of iris clearly visible 1 
Easily discernible translucent area; details of iris slightly obscured 2 
Nacrous area; no details of iris visible; size of pupil barely discernible 3 
Cornea 
Opacity: degree of 
density 
Opaque cornea; iris not discernible through the opacity 4 
Normal 0 
Markedly deepened rugae, congestion, swelling, moderate 
circumcorneal hyperaemia; or injection; iris reactive to light (a 
sluggish reaction is considered to be an effect) 
1 
Iris 
Hemorrhage, gross destruction, or no reaction to light 2 
Normal 0 
Some blood vessels hyperaemic (injected)  1 
Diffuse, crimson colour; individual vessels not easily discernible 2 
Conjunctiva 
Redness: refers to 
palpebral and 
bulbar 
conjunctivae; 
excluding cornea 
and iris 
Diffuse beefy red 3 
normal 0 
Some swelling above normal 1 
Obvious swelling, with partial eversion of lids 2 
Swelling, with lids about half closed 3 
Chemosis 
Swelling: refers to 
lids and/or nictating 
membranes 
Swelling, with lids more than half closed 4 
 
Decision Criteria 
(a) in at least one animal effects on the cornea, iris 
or conjunctiva that are not expected to reverse 
or have not fully reversed within an observation 
period of normally 21 days, including grade 4 
cornea lesions and other severe reactions (e.g., 
destruction of cornea, discoloration of the 
cornea by a dye substance, adhesion, pannus, 
interference with the function of the iris or other 
effects that impair sight) observed at any time 
during the test; and/or 
(b) in at least 2 of 3, 3 of 4, 3 of 5, or 4 of 6 tested 
animals, a positive response of: 
 (i) corneal opacity ≥ 3, and/or 
 (ii) irirtis > 1.5; 
 calculated as the mean scores following 
grading at 24, 48 and 72 hours after installation 
of the test chemical.  
(a) in at least 2 of 3, 3 of 4, 3 of 5, or 4 of 6 tested 
animals a positive response of: 
(i) corneal opacity ≥ 1; and /or 
(ii) iritis ≥ 1; and/or 
(iii) conjunctival redness ≥ 2; and/or 
(iv) conjunctival oedema (chemosis) ≥ 2 
Calculated as the mean scores following grading 
at 24, 48 and 72 hours after installation of the 
test chemical and which fully reverses within an 
observation period of normally 21 days. 
Category 1 
Serious eye damage/Irreversible effects on the 
eye 
Category 2a  
Eye irritation/Reversible effects on the eye 
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a UN GHS foresees a further categorisation of Category 2 into 2A (irritant to eyes) and 2B 
(mildly irritant to eyes) depending on the reversibility of the observed effects within 7 days after 
instillation. These optional categories are not implemented in the EU legislation. 
 
In a recent study by Adriaens et al. (2014), co-sponsored by the European Commission 
and Cosmetics Europe, statistical resampling of in vivo Draize eye test data on 2134 
chemicals demonstrated an overall probability of at least 11% that chemicals classified 
as UN GHS/EU CLP Category 1 by the Draize eye test could be equally identified as 
UN GHS/EU CLP Category 2 and of about 12% for UN GHS/EU CLP Category 2 
chemicals to be equally identified as UN GHS/EU CLP No Category simply due to the 
test method's inherent within-test variability. On the other hand, the over-classification 
error for No Cat and Cat 2 was negligible (< 1%), which strongly suggest the high over-
predictive power of the Draize eye test. Considering these results, it is probably not 
achievable to develop in vitro test methods with no false negatives. Thus, Adriaens et 
al. (2014) proposed that a false negative rate of up to 10% should be acceptable for an 
in vitro test method designed to identify chemicals not requiring classification for 
serious eye damage/eye irritation within UN GHS/EU CLP. Moreover, a critical 
revision of the UN GHS/EU CLP decision criteria for the classification of chemicals 
based on Draize eye test data was proposed based on the results of the analyses. In 
particular, it was proposed that i) the biological relevance of a threshold of 2 for 
classifying chemicals as Cat 2 based on conjunctival redness is reassessed considering 
that a significant proportion of No Category chemicals show mean conjunctival redness 
scores equal to or greater than 1 and that some conjunctival redness may even be 
present in non-treated animals; ii) conjunctival redness and/or conjunctival chemosis 
scores of less than 2 at day 21 are considered as fully reversed conjunctival effects and 
do not drive a Category 1 classification in the absence of any other Category 1 
triggering effects; iii) corneal opacity scores equal to 4 that fully reverse within 21 days 
do not trigger a Category 1 classification in the absence of any other Category 1 
triggering effects; iv) studies where a corneal opacity score equal to 4 is observed are 
only terminated before day 21, without investigating the reversibility of the effect and 
accepting a Category 1 classification, if such effects are observed in the majority of the 
animals tested, i.e., in 2 out of 3, 3 out of 4, 3 out of 5 or 4 out of 6 animals. Such 
revisions may be critical to facilitate the acceptance of alternative methods. 
 
The results of the study by Adriaens and colleagues (Adriaens et al., 2014) also indicate 
that the persistence and severity of corneal opacity play an equally important role in the 
classification of a chemical into UN GHS/EU CLP Category 1, whereas corneal opacity 
and conjunctival redness are the most important endpoints that determine the 
classification of UN GHS/EU CLP Category 2 eye irritants. 
 
 
4.2 Mechanistic understanding of the endpoint 
The cornea and the conjunctiva cover the anterior surface of the eye, with the cornea 
representing the most likely primary site of contact with chemicals. Four “mechanisms” 
of eye irritation were identified in an ECVAM workshop (Scott et al. 2010), as 
explained in Table 4.2.  
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Table 4.2. Main mechanisms of eye irritation  
 
Mechanism / key event Explanation 
  
1) Cell membrane lysis The breakdown of membrane integrity that might arise 
from exposure to membrane active chemicals (e.g. 
surfactants) 
2) Coagulation Precipitation and/or denaturation of macromolecules 
(proteins in particular), most likely caused by contact 
with acids, alkalis, or organic solvents 
3) Saponification Alkaline hydrolysis of lipids. The morphological 
impact may resemble those to membrane lysis and 
coagulation, but the effect may proceed with time 
through the tissue. 
4) Chemical reactivity  Chemicals reacting with cellular macromolecules such 
as essential proteins or nucleic acids, which may lead 
to lysis or coagulation. This group is of particular 
concern because of the lack of immediate response in 
the tissue and thus a delayed onset of the 
irritation/corrosion. Examples include peroxides, 
mustards and bleaches. 
5) Physical damage to the eye  
 
 
4.3 Status of alternative methods 
Many in vitro test methods have been developed and evaluated for serious eye 
damage/eye irritation testing, as reviewed elsewhere (Eskes et al., 2005; Adler et al., 
2010).  
 
Since the cornea is most likely to be the primary site of contact with chemicals, corneal 
tissue has served as the primary model in the development of alternative methods for 
serious eye damage/eye irritation testing. The alternative methods can be grouped 
according to the nature of the test system (organotypic methods based on isolated eyes 
or corneas, organotypic methods based on the chicken egg chorio-allantoic membrane, 
reconstructed human tissues, cell-based assays, and in chemico assays). Some 
alternative test methods have gained regulatory acceptance at the EU and/or OECD 
levels. The main methods and their regulatory status are summarised in Table 4.3. 
 
4.3.1 Organotypic (ex vivo) methods based on isolated eyes or corneas 
Ex vivo methods are based on the use of isolated whole eyes or corneas. The main 
examples include the Bovine Corneal Opacity & Permeability test method (BCOP; 
Gautheron et al., 1994; Gautheron, 1996), the Isolated Chicken Eye (ICE; Prinsen & 
Koeter, 1993; Prinsen 1994), and the Isolated Rabbit Eye (IRE; Burton et al., 1981; 
Earl, 1994) tests. Whilst BCOP, ICE and IRE do not consider conjunctival and iridal 
injuries, they address corneal effects, which are the major driver of classification in vivo 
when considering the UN GHS classification. A common limitation of these methods is 
that they do not allow the evaluation of reversibility of corneal lesions on their own. It 
has been proposed, based on rabbit eye studies, that an assessment of the initial depth of 
corneal injury may be used to identify some types of irreversible effects (Maurer et al., 
2002). However, further scientific knowledge is required to understand how irreversible 
effects not linked with initial high level injury occur. BCOP and ICE are accepted by 
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the OECD to identify chemicals inducing serious eye damage (Category 1) and 
chemicals not requiring classification for serious eye damage/eye irritation (No 
Category), but they cannot be used on their own to identify Category 2 eye irritants 
(OECD, 2013a and b). 
 
It is known that the under-predictions for Category 1 chemicals obtained with 
organotypic methods like BCOP and ICE, which were developed to detect immediate 
severe effects, are more likely for chemicals classified in vivo based only on persistence 
of effects than for those classified based on severity (ICCVAM, 2006; ICCVAM, 2007; 
ICCVAM, 2010; Adriaens et al., 2014). Two organotypic methods, the Ex-Vivo Eye 
Irritation Test (EVEIT) based on isolated rabbit corneas (Spöler et al., 2010; Frentz et 
al., 2008) and the Porcine Cornea Reversibility Assay (PorCORA) based on isolated 
porcine corneas (Piehl et al., 2010 and 2011), have been proposed to specifically 
address reversibility/persistence of effects, but neither has yet undergone a formal 
validation study. Both these methods are based on the direct monitoring of the recovery 
process in exposed excised corneas kept in culture over several days. The EVEIT uses 
optical coherence tomography (OCT) as a state-of-the-science, non-invasive technique 
to monitor the full-thickness recovery of the corneal tissue (epithelium and stroma). 
Methods like EVEIT and PorCORA may be needed for the correct identification of 
Category 1 chemicals and may significantly contribute in a testing strategy to the full 
replacement of the in vivo Draize eye test method. Histopathology may also be used in 
conjunction with BCOP and ICE to improve their prediction of chemicals inducing 
persistent effects without occurrence of initial high level injuries (classified in vivo 
based on persistence of effects) (Cazelle et al., 2014). However, histopathology remains 
a rather subjective endpoint that only gives single time-point information as compared 
to methods like EVEIT and PorCORA, which are able to monitor recovery as a function 
of time in the living tissue. Moreover, it has been reported that although histopathology 
could increase the sensitivity of the organotypic assays to identify Category 1 
chemicals, it may also lead to a decrease in their specificity (increase the number of 
chemicals over-classified as Category 1) (Schrage et al., 2011). 
 
4.3.2 Organotypic (chorio-allantoic membrane) methods  
Methods based on the chicken egg chorio-allantoic membrane include the Hens Egg 
Test on the Chorio-Allantoic Membrane (HET-CAM; Luepke 1985; de Silva et al., 
1992; Gilleron et al., 1996; Spielmann et al., 1996) and similar methods like the 
Chorioallantoic Membrane Vascularization Assay (CAMVA; Bagley et al., 1994). 
These methods have been proposed to provide information on conjunctival effects in 
vivo due to the similarity of the CAM to the conjunctiva. Both the HET-CAM and 
CAMVA have undergone multiple international validation studies (Bagley et al., 1992b; 
Spielmann et al., 1993; Brantom et al., 1997; Spielmann et al., 1996; Spielmann et al., 
1997; Ohno et al., 1999; Hagino et al., 1999; Bagley et al., 1999b). More recently, 
HET-CAM underwent formal validation by the Interagency Coordinating Committee on 
the Validation of Alternative Methods (ICCVAM) for the UN GHS classification 
system, but was not considered useful at that time to be used for regulatory purposes for 
the evaluation of serious eye damage/eye irritation potential of chemicals (ICCVAM, 
2007; ICCVAM, 2010). ICCVAM considered that the HET-CAM might be useful for 
identifying chemicals not requiring hazard classification and labelling for serious eye 
damage/eye irritation but did not recommend the test method due to lack of data in the 
mild/moderate irritancy range. ICCVAM recommended that additional data be collected 
on mild and moderate irritants to more adequately characterise the usefulness of HET-
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CAM. Following this recommendation, an international workshop on HET-CAM was 
held at the BfR in Berlin in October 2012 to help advance regulatory acceptance of the 
test method. 
 
4.3.3 Reconstructed human Tissue (RhT) assays 
Two Reconstructed human Tissue (RhT)-based test methods have recently undergone 
formal validation conducted by the European Union Reference Laboratory for 
Alternatives to Animal Testing (EURL ECVAM) and Cosmetics Europe - The Personal 
Care Association. These are the SkinEthic™ Human Corneal Epithelium (HCE) and the 
EpiOcular™ Eye Irritation Test (EIT), both of which use as test systems RhTs intended 
to model the properties of the human corneal epithelium. Recently, the results of a 
prevalidation study on the EpiOcular™ EIT (Pfannenbecker et al. 2013) and the 
SkinEthic™ HCE (Alépée et al. 2013) were published. The Eye Irritation Validation 
Study (EIVS), co-sponsored by EURL ECVAM and Cosmetics Europe, evaluated the 
validity (relevance and reliability) of these two RhT test methods to discriminate 
chemicals not requiring classification for serious eye damage/eye irritancy (No 
Category) from chemicals requiring classification and labelling (Category 1 and 
Category 2) according to the United Nations Globally Harmonized System of 
Classification and Labelling of Chemicals (UN GHS) and as implemented by the EU 
Classification, Labelling and Packaging regulation (EU CLP) (UN, 2013; EC, 2008).  
The test methods are not intended to differentiate between UN GHS/EU CLP Category 
1 (serious eye damage) and UN GHS/EU CLP Category 2 (eye irritation) and were 
therefore not evaluated in this respect. This differentiation will need to be addressed by 
another tier of a test strategy (Scott et al., 2010). Two protocols for each test method 
were evaluated in EIVS, namely the SkinEthic™ HCE Short-time Exposure (SE) and 
Long-time Exposure (LE) protocols and the EpiOcular™ EIT protocols for liquids and 
for solids. All protocols were found to be highly reproducible, but some refinements of 
the SkinEthic™ HCE SE and LE and of the EpiOcular™ EIT protocol for solid 
chemicals were deemed necessary to improve their predictive capacity. A revised 
EpiOcular™ EIT protocol for solid chemicals has undergone additional validation 
showing high reproducibility and predictive capacity. The SkinEthic™ HCE is currently 
undergoing external optimisation and validation outside the framework of EIVS. In the 
end of 2013, the European Commission submitted a project proposal to the OECD for 
the development of a new Test Guideline on the EpiOcular™ EIT. This project proposal 
was approved by the Working Group of the National Coordinators of the Test 
Guidelines Programme (WNT) during its April 2014 meeting and the Test Guideline is 
currently being drafted by the European Commission's Joint Research Centre. 
 
4.3.4 Cell-based assays 
The Fluorescein Leakage (FL) assay is the only cell-based test method that has so far 
gained regulatory acceptance at the OECD level (TG 460), following a retrospective 
validation study conducted by ECVAM. The FL can be used to identify water-soluble 
chemicals inducing serious eye damage (UN GHS/EU CLP Category 1). Four other 
cell-based assays that have been the focus of development and validation efforts are the 
Cytosensor Microphysiometer (CM), the Neutral Red Release (NRR), the Red Blood 
Cell (RBC), and the Short Time Exposure (STE) test methods. The CM, the NRR and 
the RBC also underwent an ECVAM-coordinated retrospective validation study. The 
CM was considered suitable by the Validation Management Group (VMG) and ESAC 
for identifying water miscible substances and mixtures inducing serious eye damage 
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(UN GHS/EU CLP Category 1) as well as water miscible surfactants and surfactant 
containing mixtures not requiring classification for serious eye damage/eye irritation 
(UN GHS/EU CLP No Category), and is currently under review by the OECD for 
adoption as a Test Guideline. The NRR test method was considered suitable for 
identifying water miscible chemicals not requiring classification for serious eye 
damage/eye irritation by the VMG, but the ESAC peer review panel (ECVAM, 2009) 
concluded that the available evidence was insufficient to recommend its acceptance for 
regulatory use. The same conclusion was reached by the VMG and ESAC on the RBC 
and the test method was therefore not recommended for regulatory use to predict the 
serious eye damage/eye irritation potential of chemicals. The STE test method 
underwent two validation studies, one coordinated by the Validation Committee of the 
Japanese Society for Alternative to Animal Experiments (JSAAE) (Sakaguchi et al., 
2011) and the other by the Japanese Center for the Validation of Alternative Methods 
(JaCVAM) (Kojima et al., 2013), and was peer reviewed by NICEATM/ICCVAM. It 
was found suitable to identify chemicals inducing serious eye damage (UN GHS/EU 
CLP Category 1) as well as surfactant solids and chemicals with a vapour pressure < 6 
kPa (not highly volatile) not requiring classification for serious eye damage/eye 
irritation (UN GHS/EU CLP No Category). The STE test method is currently under 
review by the OECD for adoption as a Test Guideline. 
  
4.3.5 In chemico assays 
In chemico assays are based on physicochemical effects observed in acellular systems. 
To assess the chemical reactivity of test chemicals, the Eye Peptide Reactivity Assay 
(EPRA) was proposed as a variant of the Direct Peptide Reactivity Assay (DPRA), 
developed to screen for skin sensitizers (Gerberick et al., 2004). It is based on the 
reactivity of a test chemical with Cysteine and Lysine containing heptapeptides. The 
EPRA has been used in a tiered test strategy together with the SkinEthic™ HCE test 
method as a means of choosing between two treatment procedures in the SkinEthic™ 
HCE test method (short exposure for reactive chemicals and long exposure for non-
reactive chemicals; Alépée et al., 2013). 
 
Another example is the Ocular Irritection® assay which predicts the ocular irritation 
potential of chemicals by measuring protein denaturation. This test method mimics the 
biochemical phenomena of corneal protein denaturation and disruption caused by 
irritant chemicals acting on the cornea. The chemical effects observed in the Ocular 
Irritection® assay are assumed to mimic the disruptive effects ocular irritants can have 
on the highly organised structure of corneal proteins and carbohydrates which result in 
corneal cloudiness/opacity in the in vivo Draize eye test. This assay underwent an 
external validation study and is being proposed to identify chemicals not requiring 
classification for serious eye damage/eye irritation (UN GHS No Category) and 
chemicals inducing serious eye damage (UN GHS Category 1) (Eskes et al., 2014). 
 
4.3.6 Quantitative Structure-Activity Relationships 
Various QSAR modelling studies have attempted to model eye irritation responses, 
focusing either on the prediction of weighted averages of the underlying tissue scores, 
such as  the MMAS (modified maximum average score; e.g. Abraham et al., 2003), or 
on classification models (e.g. Worth & Cronin, 1999). The status of literature-based 
models has changed little since the previous JRC reviews (Gallegos Saliner et al.; 2006, 
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2008), with relatively few new publications appearing since 2008 (e.g. Solimeo et al., 
2012). 
 
Software tools with functionalities for predicting eye irritation potential include 
Toxtree, the OECD QSAR Toolbox, Derek Nexus, TOPKAT, Molcode QSARModel, 
and Multi-CASE. The freely available Toxtree and the OECD Toolbox tools include the 
BfR rulebase which applies a set of physicochemical rules to predict the absence of 
effects, along with a set of structural rules to predicting the presence of effects. 
Evaluations by the JRC of the predictive performance of the physicochemical 
(Tsakovska et al., 2005) and structural (Tsakovska et al., 2007) rules found a high 
negative predictivity (87%) of the physicochemical exclusion rules, and a high positive 
predictivity of the structural inclusion rules (>80%, depending on the hazard class). 
These evaluations were performed before the BfR rulebase was implemented in Toxtree 
and the OECD Toolbox, so it would be worthwhile to revisit the analysis, using the 
modern tools and more recently published data. 
 
These software tools can be used in a WoE approach or tiered testing strategy. As with 
all computational tools, the predictions need to be carefully evaluated using information 
on the model characteristics. For classification and labelling, the BfR rulebase provides 
information that is closest to the regulatory goal, since the system was designed to 
predict the then EU Risk Phrases for irritation (R36, R41) and corrosion (R34, R35). 
 
4.4 Status of alternative testing strategies 
In the area of toxicological assessment for eye hazards, it is currently generally accepted 
that, in the foreseeable future, no single in vitro serious eye damage/eye irritation test 
method will be able to replace the in vivo Draize eye test to predict across the full range 
of ocular effects for different chemical classes. However, strategic combinations of 
several alternative methods (in vitro and in silico) may be able to replace the Draize eye 
test. Testing strategies for serious eye damage/eye irritation have been reviewed 
(Gallegos Saliner & Worth, 2007) or proposed (Grindon et al, 2008) elsewhere. More 
recently, a conceptual framework for tiered testing strategies was developed within an 
ECVAM workshop (Scott et al., 2010). The framework is based on alternative serious 
eye damage/eye irritation methods that vary in their capacity to detect either chemicals 
inducing serious eye damage (UN GHS/EU CLP Category 1) or chemicals not requiring 
classification for serious eye damage/eye irritation (UN GHS/EU CLP No Category). 
According to this framework, the entire range of irritancy may be resolved by arranging 
tests in a tiered strategy that may be operated from either end. If the test chemical is 
expected to be a moderate to severe eye irritant, the “Top-Down approach” is initiated, 
in which chemicals inducing serious eye damage are identified first. Conversely, if the 
test chemical is expected to be a non-irritant or mild irritant, the “Bottom-Up” approach 
is initiated, starting with the identification of non-irritants (Figure 4.1). The Top-
Down/Bottom-Up framework thus proposes a two-step procedure where validated 
methods are used to determine if a test chemical is not classified (UN GHS/EU CLP No 
Category) or if it induces serious eye damage (UN GHS/EU CLP category 1). If neither 
a No Category nor a Category 1 is assigned in this stepwise tiered testing, the 
framework proposes that either an in vivo test is conducted or a default UN GHS/EU 
CLP Category 2 classification is assigned (Figure 4.1). 
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Figure 4.1. Bottom-Up and Top-Down approaches for serious eye 
damage/eye irritation (after Scott et al., 2010) 
 
 
One of the problems associated with the two-tier Top-Down/Bottom-Up testing strategy 
is that a default UN GHS/EU CLP Category 2 classification after only testing in two test 
methods will generate a significant number of false negative (Category 1 
underclassified as Category 2) and false positive (No Category overclassified as 
Category 2) results. On the one hand, currently accepted methods for identifying UN 
GHS/EU CLP Category 1, like BCOP and ICE, underpredict 14-48% of the in vivo 
Category 1 chemicals, mostly those inducing persistent effects without occurrence of 
initial high level injuries (classified in vivo based only on persistence of effects). This 
shortcoming may be resolved by inclusion in the strategy of a method specifically 
addressing reversibility/persistence of effects based on the direct monitoring of the 
recovery process, like EVEIT or PorCORA (Figure 4.2). On the other hand, it is clear 
that due to the very high sensitivity required by regulatory authorities for accepting the 
use of in vitro test methods to identify chemicals not requiring hazard classification and 
labelling for serious eye damage/eye irritation (UN GHS/EU CLP No Category), their 
specificity will never go beyond 60-80% (the highest the specificity, the more limited 
the applicability). EpiOcular™ EIT, ICE and STE are the three test methods showing 
the best accuracy for identifying UN GHS/EU CLP No Category chemicals and their 
specificity is only 60-80% with already a few false negatives being obtained (sensitivity 
around 95%). In such a scenario, several methods capable of identifying UN GHS/EU 
CLP No Category chemicals with very high sensitivity will need to be combined to 
increase the overall specificity of the testing strategy to acceptable values (Figure 4.3). 
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Figure 4.2. Illustrated example of a Top-Down testing strategy for serious eye damage/eye 
irritation combining methods like EpiOcular™ EIT, BCOP, ICE, FL, STE, CM, HET-CAM, 
EVEIT and/or PorCORA. The order of the different methods in the strategy presented is only 
hypothetical and it will dependent on several aspects like the purpose of the testing, the 
complementarity of the different test methods, their limitations, their price, their rates of false 
positives and false negatives, and their mechanistic coverage. EpiOcular™ EIT, STE, CM, 
HET-CAM, EVEIT and PorCORA are still not covered by an OECD Test Guideline and 
therefore still need to gain regulatory acceptance. ICE image courtesy of Dr Menk Prinsen, 
TNO, The Netherlands; BCOP image courtesy of Institute for In Vitro Sciences, Inc., USA; 
EpiOcular™ image courtesy of MatTek Corporation, USA; EVEIT image courtesy of Dr 
Norbert Schrage, ACTO e.V. & Dr. Felix Spöler, IHT, RWTH Aachen University, Germany; 
PorCORA image courtesy of MB Research Laboratories, USA) 
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Figure 4.3. Illustrated example of a Bottom-Up testing strategy for serious eye damage/eye 
irritation combining methods like EpiOcular™ EIT, BCOP, ICE, FL, STE, CM, HET-CAM, 
EVEIT and/or PorCORA. The order of the different methods in the strategy presented is only 
hypothetical and it will dependent on several aspects like the purpose of the testing, the 
complementarity of the different test methods, their limitations, their price, their rates of false 
positives and false negatives, and their mechanistic coverage. EpiOcular™ EIT, STE, CM, 
HET-CAM, EVEIT and PorCORA are still not covered by an OECD Test Guideline and 
therefore still need to gain regulatory acceptance. ICE image courtesy of Dr Menk Prinsen, 
TNO, The Netherlands; BCOP image courtesy of Institute for In Vitro Sciences, Inc., USA; 
EpiOcular™ image courtesy of MatTek Corporation, USA 
 
 
Potential ways of combining in vitro tests methods in testing strategies based on the 
concept of the Bottom-up and Top-down approaches have been investigated by Kolle et 
al. (2011) and Hayashi et al. (2012). Kolle et al. (2011) combined EpiOcular™ EIT and 
BCOP in a two-tier Bottom-up/Top-Down test strategy and Hayashi et al. (2012) 
combined EpiOcular™ EIT, BCOP, STE and HET-CAM in a two-stage Bottom-Up 
tiered approach. From the data presented in these two publications, it can be seen that 
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the specificity for identifying UN GHS/EU CLP No Category chemicals will increase 
substantially (to close to 90%) by combining in a test strategy several methods able to 
identify this type of chemicals. This occurs as a result of multiple methods 
complementing each other by correctly identifying different sets of UN GHS/EU CLP 
No Category chemicals. Importantly, the increase in specificity of the test strategy as 
compared to the individual methods is not accompanied by a significant decrease in 
sensitivity due to the very high sensitivity already displayed by all of these methods on 
their own (> 90%). In the data published by Kolle et al. (2011), it can be seen that one 
UN GHS/EU CLP No Category chemical is overpredicted by EpiOcular™ EIT but 
correctly predicted by BCOP, while 10 other UN GHS No Category chemicals are 
overpredicted by BCOP but correctly predicted by EpiOcular™ EIT. Hayashi et al. 
published results obtained with BCOP, EpiOcular™ EIT, STE and HET-CAM on 26 
UN GHS/EU CLP No Category chemicals, 13 UN GHS/EU CLP Category 2 chemicals 
and 16 UN GHS/EU CLP Category 1 chemicals. Ten of the 26 UN GHS/EU CLP No 
Category chemicals were correctly identified by BCOP, 13 by EpiOcular™ EIT, 17 by 
STE, and 9 by HET-CAM, which gives individual false positive rates ranging from 35% 
to 65%. However, for 23 of these UN GHS/EU CLP No Category chemicals (88.5%) a 
correct prediction was obtained in at least one of these 4 methods. If one would start a 
Bottom-Up approach with EpiOcular™ EIT, 13 of the UN GHS/EU CLP No Category 
chemicals would be overpredicted as irritant (50% false positives) and no false 
negatives would be produced. Using BCOP in the next tier as a method able to identify 
both Category 1 and No Category, the latter with 100% sensitivity (no false negatives), 
two of the EpiOcular™ EIT false positives would be correctly identified by BCOP as 
UN GHS/EU CLP No Category without producing any false negatives. Fifteen of the 16 
UN GHS/EU CLP Category 1 chemicals would also be correctly identified by BCOP, 
with the one Category 1 that is missed being a chemical that is classified in vivo based 
only on persistence of effects. Finally, 7 of the 13 UN GHS/EU CLP Category 2 
chemicals would be overclassified as Category 1. If HET-CAM would then be used in a 
third tier to further identify UN GHS/EU CLP No Category chemicals it would 
correctly identified two other EpiOcular™ EIT false positives as No Category. HET-
CAM alone would underclassify 1 of the 29 classified chemicals (a Category 2A) as No 
Category, but in a test strategy, this chemical would have been already overclassified as 
Category 1 by BCOP. Finally, using STE as the final tier, a further 6 of the EpiOcular™ 
EIT false positives would be correctly identified as No Category, but in this case two 
false negatives would be produced, one Category 2A and one Category 2B. STE alone 
would actually underclassify 4 of the 29 classified chemicals (3 Category 2A and 1 
Category 2B) as No Category, but in a test strategy, two of these chemicals (2 Category 
2A) would have been already overclassified as Category 1 by BCOP. In conclusion, by 
combining multiple methods able to identify UN GHS No Category chemicals, the 
number of correctly identified UN GHS/EU CLP No Category chemicals would 
increase from 35-65% to 88.5%, and at the same time the accuracy for the identification 
of UN GHS/EU CLP Category 2 by default at the end of the strategy would be 
significantly improved. 
 
 
4.5 Conclusions 
Information on serious eye damage/eye irritation potential, traditionally obtained by the 
Draize rabbit eye test, is required for the purposes of REACH, the Biocidal Products 
Regulation and the CLP regulation. While it is generally accepted that no single 
alternative method for serious eye damage/eye irritation will be able to replace the in 
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vivo Draize eye test across the full range of irritation for different chemical classes, 
strategic combinations of several alternative test methods may be able to replace the 
Draize eye test. With more and more alternative tools becoming available, Integrated 
Approaches to Testing and Assessment (IATA), incorporating existing information, 
QSAR predictions, and new in vitro test results, should now be developed to provide a 
means for standardised and comprehensive decision making. 
 
Testing strategies such as the Top-Down/Bottom-Up approach provide a convenient 
framework for generating new in vitro test data when a decision on classification and 
labelling cannot be taken based on existing data and QSAR predictions. The framework 
is based on the combination of in vitro methods able to identify chemicals inducing 
serious eye damage (UN GHS/EU CLP Category 1) and/or chemicals not requiring 
classification for serious eye damage/eye irritation (UN GHS/EU CLP No Category). A 
number of OECD Test Guidelines based on in vitro test methods have already been 
adopted (TG 437, 438, 460), and three other draft Test Guidelines on CM, STE and 
EpiOcular™ EIT are under discussion at OECD level. All these Test Guidelines 
identify chemicals inducing serious eye damage (UN GHS/EU CLP Category 1) and/or 
chemicals not classified for serious eye damage/eye irritation in the framework of a 
Top-Down/Bottom-Up approach. In the absence of suitable methods for directly 
identifying eye irritants (UN GHS/EU CLP Category 2), the Top-Down/Bottom-Up 
approach may be used to indirectly identify such chemicals by an accurate exclusion of 
Category 1 and No Category. For this framework to work with acceptable accuracy, 
several methods addressing each of the two ends of the irritancy scale will however 
need to be combined. Although combinations of the existing assays within testing 
strategies such as described above are already encouraging, a full replacement of the in 
vivo Draize eye test has still not been achieved, mostly because of the lack of test 
methods able to identify Category 2 chemicals and to discriminate persistent from 
reversible effects. 
 
Further research efforts will need to focus on the development of mechanistically-based 
in vitro assays and, in particular, methods capable of detecting conjunctival effects 
(important in the classification of Category 2 eye irritants) as well as the persistence of 
effects (important in the classification of Category 1 chemicals) (Adriaens et al., 2014). 
In addition, it would be worthwhile to re-evaluate some of the QSAR tools with a view 
to applying them in an IATA for serious eye damage/eye irritation. 
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Table 4.3. Alternative methods for serious eye damage/eye irritation 
 
Method Test system Description Applicability Regulatory status 
Organotypic (Ex vivo isolated eyes) methods 
Bovine Corneal Opacity 
& Permeability (BCOP) 
Ex vivo bovine 
cornea, obtained 
as a by-product 
from abattoirs 
Based on normal physiological and biochemical 
function of the bovine cornea in vitro. The damage 
caused by the test chemical is assessed by quantitative 
measurements of changes in corneal opacity and 
permeability with an opacitometer and a visible light 
spectrophotometer. Permeability is quantified as the 
amount of fluorescein dye that passes across the full 
thickness of the cornea from the epithelial surface. 
Suitable for identifying 
UN GHS/EU CLP 
Category 1 (JRC, 2004; 
ECVAM, 2007) and UN 
GHS/EU CLP No 
Category chemicals. 
 
The false positive rate for 
alcohols and ketones and 
the false negative rates 
for solids have been 
noted as limitations for 
the identification of UN 
GHS/EU CLP Category 1 
(OECD, 2013a). 
OECD TG 437 (adopted 
in 09/2009 and updated 
in 07/2013). 
Isolated Chicken Eye 
test (ICE) 
Ex vivo whole 
chicken eye, 
obtained as a by-
product from 
abattoirs  
Damage by the test substance is assessed by 
determination of corneal swelling, opacity, and 
fluorescein retention, which is a subjective 
measurement of the degree of the fluorescein dye that 
is retained by epithelial cells in the cornea after the 
exposure to a test chemical. The extent of fluorescein 
retention is representative of damage to the corneal 
epithelium. While the latter two parameters involve a 
qualitative assessment, analysis of corneal swelling 
provides for a quantitative assessment. Each 
measurement is either converted into a quantitative 
score used to calculate an overall Irritation Index, or 
assigned a qualitative categorization that is used to 
Suitable for identifying 
UN GHS/EU CLP 
Category 1 (JRC, 2004; 
ECVAM, 2007) and UN 
GHS/EU CLP No 
Category chemicals. 
 
The false positive rate for 
alcohols and the false 
negative rates for solids 
and surfactants have been 
noted as limitations for 
the identification of UN 
OECD TG 438 (adopted 
in 09/2009 and updated 
in 07/2013). 
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Method Test system Description Applicability Regulatory status 
assign an in vitro classification. Either of these 
outcomes can then be used to predict the in vivo 
ocular hazard effects of a test chemical. 
GHS/EU CLP Category 1 
(OECD, 2013b). 
 
Isolated Rabbit Eye test 
(IRE) 
Ex vivo whole 
rabbit eye 
Determines the opacification of the cornea and the 
increase in corneal thickness (corneal swelling) after 
exposure to irritant substances. Whole eyeballs 
obtained by immediate dissection from humanely 
killed laboratory rabbits with healthy eyes are 
mounted and maintained in a vertical position in a so-
called superfusion chamber with controlled 
temperature and humidity.  
 
Primarily predicts corneal effects and does not provide 
information on the effects of chemicals on the 
conjunctiva of the eye or on the recovery of the cornea 
from damage (beyond a few hours), which might 
occur in the eye in vivo.  
Suitable for identifying 
UN GHS/EU CLP 
Category 1 (JRC, 2004).  
 
A draft TG on IRE has 
never been submitted to 
OECD. 
 
The ESAC, 2007 
released a statement "on 
the conclusions of the 
ICCVAM retrospective 
study on organotypic in 
vitro assays and 
recommended for the 
IRE test method, "that 
further work should be 
performed before a 
statement on [its] 
validity can be made" 
(ECVAM, 2007). 
However, ESAC 
emphasized that 
although not yet 
validated, positive 
outcomes from this test 
could be used as the 
basis for classifying and 
labelling chemicals as 
inducing serious eye 
damage (UN GHS/EU 
CLP Category 1) as 
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Method Test system Description Applicability Regulatory status 
previously stated by 
European authorities 
(EC, 2004).  
Organotypic (chorio-allantoic membrane ) methods  
 
Hen's Egg Test - 
Chorioallantoic 
Membrane (HET-CAM)  
CAM of a hen’s 
egg 
Permits the identification of irritant reactions which 
look similar to those occurring in the eye in the 
standard Draize rabbit eye test. In the HET-CAM 
assay, which is carried out with hen’s eggs at the ninth 
day of embryonic development when the nervous 
system has not yet developed, reactions to test 
chemicals specifically haemorrhage, lysis, coagulation 
and to some extend hyperaemia of the chorio-allantoic 
membrane (CAM) are monitored after placing the test 
sample directly onto the CAM. A visual evaluation of 
the above mentioned parameters over a 5-minute 
observation period takes place.  
Suitable for identifying at 
least UN GHS/EU CLP 
Category 1 (JRC, 2004). 
May also be suitable for 
identifying UN GHS/EU 
CLP No Category but 
more data are needed, 
especially for UN 
GHS/EU CLP Category 2 
chemicals, to confirm this 
usefulness. 
HET-CAM underwent 
formal validation by the 
Interagency 
Coordinating 
Committee on the 
Validation of 
Alternative Methods 
(ICCVAM) for the UN 
GHS classification 
system, but was not 
considered useful at that 
time to be used for 
regulatory purposes for 
the evaluation of the eye 
irritation potential of 
chemicals (ICCVAM, 
2006; ICCVAM, 2010). 
Its usefulness for 
identifying UN GHS/EU 
CLP No Category was 
not recommended by 
ICCVAM due to the 
lack of sufficient data 
for Category 2 
chemicals (ICCVAM, 
2010) 
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Method Test system Description Applicability Regulatory status 
Reconstructed Human Tissue Models 
EpiOcular™ Eye 
Irritation Test (EIT) 
EpiOcular™ 
Reconstructed 
human Tissue 
model 
This tissue construct is a non-keratinized multilayered 
and stratified (but not cornified) epithelium prepared 
from normal human-derived epidermal keratinocytes. 
It is intended to model properties of the corneal 
epithelium. The reconstructed tissue is prepared in 
inserts with a porous membrane (MTI-003) through 
which the nutrients pass to the cells. A cell suspension 
is seeded into the MTI-003 membrane in specialized 
medium. After a period of initial cell proliferation, the 
medium is removed from the top of the tissue so that 
the epithelial surface is in direct contact with the air. 
This allows the test chemical to be directly applied to 
the epithelial surface, mimicking exposure of the 
corneal epithelium in vivo/in situ. This topical 
exposure is essential for modelling the same kind of 
progressive injury expected in vivo, allowing 
moreover the application of both solid and liquid 
chemicals. In the EpiOcular™ EIT, liquids and solids 
are applied using different exposure and post-
exposure incubation times. 
 ESAC peer review will 
initiate Q4 2013 
SkinEthic™ Human 
Corneal Epithelium 
(HCE) 
SkinEthic™ HCE 
Reconstructed 
human Tissue 
model 
The tissue construct consists of immortalized human 
corneal epithelial cells seeded on a polycarbonate 
membrane at the air–liquid interface. The tissue 
construct obtained is a multilayered epithelium 
resembling the in vivo corneal epithelium. As in vivo, 
columnar basal cells are present, including Wing cells. 
The model is characterized by the presence of ultra-
structural features such as intermediate filaments, 
mature hemi-desmosomes and desmosomes that 
characterize the relevant epithelium in situ. Specific 
 Undergoing further 
optimisation 
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Method Test system Description Applicability Regulatory status 
cytokeratins 64kD (K.3) have also been described 
(Nguyen D.H. et al., 2003). 
Cell-based assays 
Cytosensor 
Microphysiometer (CM) 
Mouse L929 
fibroblasts 
Cytotoxicity and cell-function based in vitro assay that 
is performed on a sub-confluent monolayer of 
adherent mouse L929 fibroblasts cultured in a sensor 
chamber using a pH-meter to detect changes in 
acidity. Mechanistically, the CM test method is 
intended to model the cytotoxic action of an irritant 
chemical on the cell membranes of the cornea and 
conjunctival epithelium where the test chemical would 
reside in an in vivo exposure. The CM estimates the 
metabolic rate of a population of cells maintained in 
low volume flow-through chambers by measuring the 
rate of excretion of acid by-products and the resulting 
decrease in pH of the surrounding medium. The rate 
of change in pH per unit time becomes the metabolic 
rate of the population of cells. If a test chemical 
causes cytotoxicity to this population of cells it is 
assumed that the metabolic rate will fall. The CM may 
also address cell metabolism and recovery. 
Suitable for identifying 
UN GHS/EU CLP 
Category 1 water-
miscible chemicals 
(ECVAM, 2009) 
 
Suitable for identifying 
UN GHS/EU CLP No 
Category water-miscible 
surfactants and 
surfactant-containing 
mixtures (ECVAM, 
2009). 
 
Draft OECD TG 
(proposed 12/2012) 
Fluorescein Leakage 
(FL) 
Madin-Darby 
Canine Kidney 
(MDCK) cells 
Toxic effects after a short exposure time of the test 
substance are measured by an increase in permeability 
of sodium fluorescein dye through the epithelial 
monolayer of Madin-Darby Canine Kidney (MDCK) 
cells cultured on permeable inserts. The amount of 
fluorescein leakage that occurs is proportional to the 
chemical-induced damage to the tight junctions, 
desmosomal junctions and cell membranes, and can 
be used to estimate the ocular toxicity potential of a 
test substance 
Suitable for identifying 
UN GHS/EU CLP 
Category 1 water-
miscible chemicals 
(ECVAM, 2009) 
 
OECD TG 460 (adopted 
10/2012) 
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Method Test system Description Applicability Regulatory status 
Short Time Exposure 
(STE) 
Statens 
Seruminstitut 
Rabbit Cornea 
(SIRC) cells 
The STE test method is a cytotoxicity-based in vitro 
assay that is performed on a confluent monolayer of 
Statens Seruminstitut Rabbit Cornea (SIRC) cells, 
cultured on a 96-well polycarbonate microplate. The 
STE test method attempts to approximate the actual 
exposure in the human eye and evaluate cytotoxicity 
as an endpoint that measures the extent of damage to 
the SIRC cells following a five-minute exposure to a 
test chemical. In the STE test, cytotoxicity is 
quantitatively measured as the relative viability of 
SIRC cells. Cell viability is measured using an MTT 
assay (4). Decreased cell viability is predictive of 
adverse effects leading to corneal damage. 
Suitable for identifying 
UN GHS/EU CLP 
Category 1 chemicals as 
well as UN GHS/EU CLP 
No Category surfactant 
solids and chemicals with 
a vapour pressure < 6 kPa 
(not highly volatile) 
Draft OECD TG 
(proposed 11/2013) 
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Chapter 4. Table of References with Notes 
 
OECD TG and draft updates relevant for Eye Irritation 
OECD (2012). Test No. 405: Acute Eye Irritation/Corrosion, OECD 
Guidelines for the Testing of Chemicals, Section 4, OECD Publishing. 
doi: 10.1787/9789264070646-en 
This Test Guideline (adopted in 1981 and updated in 1987, 2002, and 2012) 
includes the recommendation that prior to undertaking the described in vivo test 
for acute eye irritation/corrosion, a weight-of-the-evidence analysis be performed 
on the existing relevant data. Where insufficient data are available, it is 
recommended that they be developed through application of sequential testing. 
The testing strategy includes the performance of validated and accepted in vitro 
tests and is provided as a Supplement to the Guideline. Testing in animals should 
only be conducted if determined to be necessary after consideration of available 
alternative methods, and use of those determined to be appropriate. At the time of 
drafting of this updated TG 405, there are instances where using this Test 
Guideline is still necessary or required by some regulatory authorities. 
 
The latest update (2012) mainly focused on the use of analgesics and anesthetics 
without impacting the basic concept and structure of the Test Guideline. The 
refinements described in this proposal will substantially reduce or avoid animal 
pain and distress in most testing situations where in vivo ocular safety testing is 
still necessary. 
OECD (2013). Test No. 437: Bovine Corneal Opacity and 
Permeability Test Method for Identifying i) Chemicals Inducing 
Serious Eye Damage and ii) Chemicals Not Requiring Classification 
for Eye Irritation or Serious Eye Damage, OECD Guidelines for the 
Testing of Chemicals, Section 4, OECD Publishing. 
doi: 10.1787/9789264076303-en 
 
The Bovine Corneal Opacity and Permeability test method (BCOP) is an in vitro 
test method that can be used to identify chemicals inducing serious eye damage 
(UN GHS/EU CLP Category 1) as well as chemicals not requiring classification 
for serious eye damage/eye irritation. The BCOP uses isolated corneas from the 
eyes of cattle slaughtered for commercial purposes, thus avoiding the use of 
laboratory animals. Each treatment group (test substance, negative/positive 
controls) consists of a minimum of three eyes where the cornea has been excised 
and mounted to a holder. Depending on the physical nature and chemical 
characteristics of the test substance, different methods can be used for its 
application since the critical factor is ensuring that the test substance adequately 
covers the epithelial surface. 
While it is not considered valid as a complete replacement for the in vivo rabbit 
eye test, the BCOP is recommended for use as part of a tiered-testing strategy for 
regulatory classification and labelling within a specific applicability domain. Test 
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chemicals (including substances and mixtures) can be classified/identified as UN 
GHS/EU CLP Category 1 or No Category without further testing in rabbits. 
 
An update of the TG 437 took place in 2013. The main differences between the 
original 2009 version and the 2013 updated version concern, but are not limited 
to: the use of the BCOP test method to identify chemicals not requiring 
classification according to UN GHS (paragraphs 2 and 7); clarifications on the 
applicability of the BCOP test method to the testing of alcohols, ketones and 
solids (paragraphs 6 and 7) and of substances and mixtures (paragraph 8); 
clarifications on how surfactant substances and surfactant-containing mixtures 
should be tested (paragraph 28); updates and clarifications regarding the positive 
controls (paragraphs 39 and 40); an update of the BCOP test method decision 
criteria (paragraph 47); an update of the study acceptance criteria (paragraph 48); 
an update to the test report elements (paragraph 49); an update of Annex 1 on 
definitions; the addition of Annex 2 for the predictive capacity of the BCOP test 
method under various classification systems; an update of Annex 3 on the list of 
proficiency chemicals; and an update of Annex 4 on the BCOP corneal holder 
(paragraph 1) and on the opacitometer (paragraphs 2 and 3). 
OECD (2013). Test No. 438: Isolated Chicken Eye Test Method for 
Identifying i) Chemicals Inducing Serious Eye Damage and ii) 
Chemicals Not Requiring Classification for Eye Irritation or Serious 
Eye Damage, OECD Guidelines for the Testing of Chemicals, Section 
4, OECD Publishing. 
doi: 10.1787/9789264076310-en 
The Isolated Chicken Eye (ICE) test method is an in vitro test method that can be 
used to identify chemicals inducing serious eye damage (UN GHS/EU CLP 
Category 1) as well as chemicals not requiring classification for serious eye 
damage/eye irritation. The ICE method uses eyes collected from chickens 
obtained from slaughterhouses where they are killed for human consumption, 
thus eliminating the need for laboratory animals. The eye is enucleated and 
mounted in an eye holder with the cornea positioned horizontally. The test 
chemical and negative/positive controls are applied to the cornea. Toxic effects to 
the cornea are measured by a qualitative assessment of opacity, a qualitative 
assessment of damage to epithelium based on fluorescein retention, a quantitative 
measurement of increased thickness (swelling), and a qualitative evaluation of 
macroscopic morphological damage to the surface. The endpoints are evaluated 
separately to generate an ICE class for each endpoint, which are then combined to 
generate an Irritancy Classification for each test substance. 
 
An update of the TG 438 took place in 2013. The main differences between the 
original 2009 version and the 2013 updated version concern, but are not limited 
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to: the use of the ICE test method to identify chemicals not requiring 
classification according to UN GHS Classification System, an update to the test 
report elements, an update of Annex 1 on definitions, and an update to Annex 2 
on the proficiency chemicals. 
OECD (2012). Test No. 460: Fluorescein Leakage Test Method for 
Identifying Ocular Corrosives and Severe Irritants, OECD Guidelines 
for the Testing of Chemicals, Section 4, OECD Publishing. 
doi: 10.1787/9789264185401-en 
This Test Guideline describes an in vitro assay that may be used for identifying 
water soluble ocular corrosives and severe irritants as defined by the UN Globally 
Harmonized System of Classification and Labelling, Category 1. The assay is 
performed in a well where a confluent monolayer of Madin-Darby Canine Kidney 
(MDCK) is used as a separation between two chambers. It uses a fluorescein dye 
as marker. The test substance has the potential to impair the junctions of the 
MDCK cells and thus to increase the monolayer's permeability. Consequently the 
fluorescein passes through the monolayer and the fluorescein leakage (FL) 
increases. The FL is calculated as a percentage of leakage relative to both a blank 
control and a maximum leakage control. The concentration of test substance that 
causes 20% FL (FL20, in mg/mL) is calculated and used in the prediction model 
for identification of ocular corrosive and severe irritants. The cut-off value of 
FL20 to identify water soluble chemicals as ocular corrosives/severe irritants is 
≤100mg/mL. The FL test method should be part of testing strategies in which.  
strategic combinations of several alternative test methods may be able to replace 
the in vivo eye test. The Top-Down approach (Scott et al. 2010) is designed to be 
used when, based on existing information, a chemical is expected to have high 
irritancy potential.  
The FL test method can identify substances within a limited applicability domain 
as ocular corrosives/severe irritants (UN GHS Category 1; EU CLP Category 1; 
U.S. EPA Category I) without any further testing. The same is assumed for 
mixtures although mixtures were not used in the validation. Therefore, the FL test 
method may be used to determine the eye irritancy/corrosivity of chemical 
following the sequential testing strategy of TG 405. 
In vitro test methods 
Pfannenbecker U, Bessou-Touya S, Faller C, et al. (2013): Cosmetics 
Europe multi-laboratory pre-validation of the EpiOcular™ 
reconstituted human tissue test method for the prediction of eye 
irritation. Toxicol In Vitro 27: 619-626. 
Cosmetics Europe, The Personal Care Association (known as Colipa before 
2012), conducted a program of technology transfer and within/between laboratory 
reproducibility of MatTek Corporation’s EpiOcular™ Eye Irritation Test (EIT) as 
one of the two human reconstructed tissue test methods. This this test method 
uses a single exposure period for each chemical and a prediction model based on 
a cut-off in relative survival [≤60% = irritant (I) (UN GHS/EU CLP Categories 2 
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and 1); >60% = no classification (UN GHS/EU CLP No Category)]. Two 
different protocols with different exposure times and post-treatment incubations 
are used for liquid and solid chemicals. Tissue viability is determined by 
tetrazolium dye (MTT) reduction. In the Cosmetics Europe study, combinations 
of 20 coded chemicals were tested in 7 laboratories. Standardized laboratory 
documentation was used by all laboratories. Twenty liquids (11 NC/9 I) plus 5 
solids (3 NC/2 I) were selected so that both exposure regimens could be assessed. 
Concurrent positive (methyl acetate) and negative (water) controls were tested in 
each trial. In all, 298 independent trials were performed and demonstrated 99.7% 
agreement in prediction (NC/I) across the laboratories. Coefficients of variation 
for the % survival for tissues from each treatment group across laboratories were 
generally low. This test method entered a formal ECVAM validation study in 
December 2008. 
Alépée N, Bessou-Touya S, Cotovio J, De Smedt A, De Wever B, 
Faller C, Jones P, Le Varlet B, Marrec-Fairley M, Pfannenbecker U, 
Tailhardat M, Van Goethem F & McNamee P (2013). Cosmetics 
Europe Multi-Laboratory Pre-Validation of the SkinEthic™ 
Reconstituted Human Corneal Epithelium Test Method for the 
Prediction of Eye Irritation. Toxicology in Vitro 27: 1476-1488.  
 
Cosmetics Europe, The Personal Care Association, known as Colipa before 2012, 
conducted a program of technology transfer and assessment of Within/Between 
Laboratory (WLV/BLV) reproducibility of the SkinEthic™ Reconstituted Human 
Corneal Epithelium (HCE) as one of two human reconstructed tissue eye 
irritation test methods. The SkinEthic™ HCE test method involves two exposure 
time treatment procedures – one for short time exposure (10 min – SE) and the 
other for long time exposure (60 min – LE) of tissues to test substance. This 
paper describes pre-validation studies of the SkinEthic™ HCE test method (SE 
and LE protocols) as well as the Eye Peptide Reactivity Assay (EPRA). In the SE 
WLV study, 30 substances were evaluated. A consistent outcome with respect to 
viability measurement across all runs was observed with all substances showing 
an SD of less than 18%. In the LE WLV study, 44 out of 45 substances were 
consistently classified. These data demonstrated a high level of reproducibility 
within laboratory for both the SE and LE treatment procedures. For the LE BLV, 
19 out of 20 substances were consistently classified between the three 
laboratories, again demonstrating a high level of reproducibility between 
laboratories. The results for EPRA WLV and BLV studies demonstrated that all 
substances analysed were categorised similarly and that the method is 
reproducible. The SkinEthic™ HCE test method entered a formal ECVAM 
validation study in 2010. 
Van Goethem F, Adriaens E, Alépée N, Straube F, De Wever B, 
Cappadoro M, Catoire S, Hansen E, Wolf A & Vanparys P (2006). 
This multicentre study aimed at evaluating the reliability (reproducibility) and 
relevance (predictivity) of a new commercially available human corneal epithelial 
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Prevalidation of a new in vitro reconstituted human cornea model to 
assess the eye irritating potential of chemicals. Toxicology in Vitro 20: 
1-17. 
(HCE) model (SkinEthic Laboratories, Nice, France) to assess acute ocular 
irritation. A prevalidation approach (protocol optimization, transfer and 
performance) was followed and at each of the four participating laboratories, 20 
coded reference chemicals, covering the whole range of irritancy, were tested. 
The compounds were applied topically to the HCE cultures and the level of 
cytotoxicity (tissue viability and histological analysis) was determined. Once a 
standardised protocol was established, a high level of reproducibility between the 
laboratories was observed. In order to assess the capability of the HCE model to 
discriminate between irritants (I) and non-irritants (NI), a classification prediction 
model (PM) was defined based on a viability cut-off value of 60%. The obtained 
in vitro classifications were compared with different in vivo classifications (e.g. 
Globally Harmonised System) which were calculated from individual rabbit data 
described in the ECETOC data bank. Although an overall concordance of 80% 
was obtained (sensitivity = 100% and specificity = 56%), the predictivity of the 
HCE model substantially increased when other sources of in vivo and in vitro data 
were taken into account. 
 
NB This reference is now dated, since formal validations studies have taken place 
since then (see main text). 
 
QSAR 
Solimeo R, Zhang J, Kim M, Sedykh A & Zhu H (2012). Predicting 
Chemical Ocular Toxicity Using a Combinatorial QSAR Approach. 
Chemical Research in Toxicology 25 (12): 2763-2769  
These authors have developed quantitative structure-activity relationship (QSAR) 
models for a set of small molecules with animal ocular toxicity data compiled by 
the National Toxicology Program Interagency Center for the Evaluation of 
Alternative Toxicological Methods. The data set was initially curated by 
removing duplicates, mixtures, and inorganics. The remaining 75 compounds 
were used to develop QSAR models. Both k nearest neighbor and random forest 
statistical approaches in combination with Dragon and Molecular Operating 
Environment descriptors were applied. Developed models were validated on an 
external set of 34 compounds collected from additional sources. The external 
correct classification rates (CCR) of all individual models were between 72 and 
87%. Furthermore, the consensus model, based on the prediction average of 
individual models, showed additional improvement (CCR = 0.93). The validated 
models could be used to screen external chemical libraries and prioritize 
chemicals for in vivo screening as potential ocular toxicants. 
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Gallegos Saliner A, Patlewicz G & Worth AP (2006). Review of 
Literature-Based Models for Skin and Eye Irritation and Corrosion. 
JRC Report EUR 22320 EN. Availabel from: 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/doc/QSAR
_Review_Irritation.pdf 
 
 
This report reviews the state-of-the-art of in silico and in vitro methods for 
assessing dermal and ocular irritation and corrosion. Following a general 
introduction, the current EU legislation for the classification and labelling of 
chemicals causing irritation and corrosivity is summarized. Then currently 
available non-animal approaches are reviewed. The main alternative 
approaches to assess acute local toxic effects are: a) in silico approaches, 
including SARs, QSARs and expert systems integrating multiple approaches; 
and b) in vitro test methods. In this review, emphasis is placed on literature-
based (Q)SAR models for skin and eye irritation and corrosion as well as 
computer-based expert systems. 
Gallegos Saliner A, Patlewicz G & Worth AP (2008). A Review of 
(Q)SAR Models for Skin and Eye Irritation and Corrosion. QSAR & 
Combinatorial Science 27: 49-59.  
 
This paper reviews the state-of-the-art of in silico methods for assessing dermal 
and ocular irritation and corrosion. It is based on an in-depth review performed 
by the European Chemicals Bureau of the European Commission: Joint Research 
Centre in support of the development of technical guidance for the 
implementation of the REACH legislation, and is one of a series of minireviews 
in this journal. The most widely used in silico approaches are classified into 
methods to assess (1) skin irritation, (2) skin corrosion and (3) eye irritation.In 
this review, emphasis is placed on literature-based (Q)SAR models. 
Tsakovska I, Netzeva T & Worth AP (2005). Evaluation of (Q)SARs 
for the prediction of Eye Irritation/Corrosion Potential - 
physicochemical exclusion rules. European Commission Report EUR 
21897 EN. European Commission-Joint Research Centre, Ispra, Italy. 
Available from: 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology 
 
A set of rules (rulebase) has been developed by the German 
Bundesinstitut für Risikobewertung (BfR) and incorporated into a Decision 
Support System (DSS), which is used within the BfR to support regulatory 
decisions. The rulebase is based on the combined use of two predictive 
approaches: a) physicochemical exclusion rules to identify chemicals with 
no skin irritation/corrosion or eye irritation/corrosion potential; and b) 
structural inclusion rules to identify chemicals with skin irritation/corrosion 
or eye irritation/corrosion potential.  
 
In this study, an evaluation was performed of the physicochemical 
rulebase (comprising 31 physicochemical exclusion rules) for predicting 
the absence of eye irritation/corrosion. In particular, the following aspects 
were addressed: a) an assessment of the derivation of the rules by using 
the rulebase training set of 1358 substances (343 irritants/corrosives and 
1015 non-irritants and non-corrosives); b) an external validation by using 
a test set of 199 chemicals (45 irritants/corrosives and 154 non-irritants 
and non-corrosives); c) an assessment of the suitability of the test set 
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used for validation; d) an assessment of the compliance of the rule-base 
with the OECD principles for the validation of (Q)SARs. According to the 
results of this study: a) the physicochemical exclusion rules for eye 
irritation/corrosion comply well with the OECD validation principles; b) 
predictions of no adverse effect (NOT R34/R35/R36/R41) can be made 
for 20 out of the 199 chemicals in the test set; c) 3 of the 45 
irritants/corrosives are falsely predicted as non-irritant or non corrosive; d) 
the probability of a negative prediction being correct (Negative Predictive 
Value) is 0.87; and e) approximately 10% of Draize rabbit eye tests could 
be avoided by relying on the predictions of no adverse effect. On the basis 
of the results, some recommendations were made regarding the 
improvement of the physicochemical exclusion rules for eye 
irritation/corrosion. 
Tsakovska I, Gallegos A, Netzeva T, Pavan M & Worth AP (2007). 
Evaluation of SARs for the prediction of eye irritation/corrosion 
potential – structural inclusion rules in the BfR decision support 
system. SAR and QSAR in Environmental Research 18, 221-235.  
 
The proposed REACH regulation within the European Union (EU) aims to 
minimise the number of laboratory animals used for human hazard and risk 
assessment while ensuring adequate protection of human health and the 
environment. One way to achieve this goal is to develop non-testing methods, 
such as (quantitative) structure–activity relationships ([Q]SARs), suitable for 
identifying toxicological hazard from chemical structure and physicochemical 
properties alone. A database containing data submitted within the EU New 
Chemicals Notification procedure was compiled by the German Bundesinstitut 
für Risikobewertung (BfR). On the basis of these data, the BfR built a decision 
support system (DSS) for the prediction of several toxicological endpoints. For 
the prediction of eye irritation and corrosion potential, the DSS contains 31 
physicochemical exclusion rules evaluated previously by the European Chemicals 
Bureau (ECB), and 27 inclusion rules that define structural alerts potentially 
responsible for eye irritation and/or corrosion. This work summarises the results 
of a study carried out by the ECB to assess the performance of the BfR structural 
rulebase. The assessment included: (a) evaluation of the structural alerts by using 
the training set of 1341 substances with experimental data for eye irritation and 
corrosion; and (b) external validation by using an independent test set of 199 
chemicals. The test set of 199 substances contained 154 (77%) non-labeled 
substances and 45 (23%) labeled as eye irritants/corrosives, subdivided as 
follows: (i) 10 R36 substances (5%); (ii) 28 R41 substances (14%); and (iii) 7 
substances (4%) labeled R34 or R35. Recommendations are made for the further 
  91 
development of the structural rules in order to increase the overall predictivity of 
the DSS.  
Abraham MH, Hassanisadi M, Jalali-Heravi M, Ghafourian T, Cain 
WS & Cometto-Muniz JE (2003). Draize rabbit eye test compatibility 
with eye irritation thresholds in humans: a quantitative structure-
activity relationship analysis. Toxicological Sciences 76(2):384-391. 
Draize rabbit eye test scores, as modified maximum average score (MMAS), for 
68 pure bulk liquids were adjusted by the liquid-saturated vapor pressure P. These 
68 adjusted scores, as log (MMAS/P), were shown to be completely equivalent to 
eye irritation thresholds (EIT), expressed as log (1/EIT), for 23 compounds in 
humans. Thus, for the first time the Draize eye test in rabbits for pure bulk liquids 
is shown to be perfectly compatible with eye irritation thresholds in humans. The 
total data set for 91 compounds was analyzed by the general solvation equation of 
Abraham. Values of log (MMAS/P) or log (1/EIT) could be fitted to a five-
parameter equation with R2 = 0.936, SD = 0.433, AD = 0.000, and AAD = 0.340 
over a range of 9.6 log units. When divided into a training set of 45 compounds, 
the corresponding equation could be used to predict the remaining 46 compounds 
in a test set with AD = -0.037 and AAD = 0.345 log units. Thus, the 91-
compound equation can now be used to predict further EIT values to around 0.4 
log units. It is suggested that the mechanism of action in the Draize test and in the 
human EIT involves passive transfer of the compound to a biophase that is quite 
polar, is a strong hydrogen bond base, a moderate hydrogen bond acid, and quite 
hydrophobic. The biophase does not resemble water or plasma, but resembles an 
organic solvent such as N-methylformamide. 
Testing Strategies 
Gallegos Saliner A & Worth AP (2007). Testing Strategies for the 
Prediction of Skin and Eye Irritation and Corrosion for Regulatory 
Purposes. JRC Report EUR 22881 EN. Available from: 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/ 
 
This report reviews the use of stepwise testing approaches for the prediction of 
skin and eye irritation and corrosion in a regulatory context. It is published as a 
companion report to the Review of Literature-Based Models for Skin and Eye 
Irritation and Corrosion, an ECB report which reviewed the state-of-the-art of in 
silico and in vitro dermal and ocular irritation and corrosion human health hazard 
endpoints. In the former review, the focus was placed on reviewing alternative in 
silico approaches to assess acute local toxic effects, such as QSARs, SARs, 
chemical categories, and read-across and analogue approaches. Special emphasis 
was placed on literature-based (Q)SAR models for skin and eye irritation and 
corrosion and expert systems. In the present review, the emphasis is on different 
schemes (testing strategies) that have been conceived for the integrated use of 
different approaches, including in silico, in vitro and in vivo methods. 
Grindon C, Combes R, Cronin MT, Roberts DW, Garrod JF (2008). 
An integrated decision-tree testing strategy for eye irritation with 
This paper presents some results of a joint research project, sponsored by Defra 
and conducted by FRAME and Liverpool John Moores University, on the status 
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respect to the requirements of the EU REACH legislation. ATLA 
6(1):81-92. 
of alternatives to animal testing with regard to the European Union REACH 
(Registration, Evaluation and Authorisation of Chemicals) system for the safety 
testing and risk assessment of chemicals. The project covered all the main 
toxicity endpoints associated with REACH. This paper focuses on the use of 
alternative (non-animal) methods (both in vitro and in silico) for eye irritation 
testing. The manuscript reviews numerous in vitro tests and their possible 
collation into test batteries, in silico models and a refined in vivo method (the low 
volume eye test), before combining the use of all these methods into an integrated 
testing strategy. The aim of this strategy is a reduction in the number animal tests 
which would need to be performed in the process of fulfilling the REACH system 
criteria; this would also lead to a lowering of the number of animals required in 
compliance with the REACH system requirements. 
Scott L, Eskes C, Hoffmann S, et al. (2010) A proposed eye irritation 
testing strategy to reduce and replace in vivo studies using Bottom-Up 
and Top-Down approaches. Toxicology in Vitro 24: 1-9. 
 
This report shows the outcome of an Expert Meeting convened by ECVAM in 
February 2005 to identify test strategies for eye irritation. In this workshop test 
developers/users were requested to nominate methods to be considered as 
“building blocks” to populate such testing strategies. Assays were evaluated and 
categorized based on their proposed applicability domains (e.g., categories of 
irritation severity, modes of action, chemical class, and physicochemical 
compatibility). The difficulty in predicting the middle category of irritancy (e.g. 
R36, GHS Categories 2A and 2B) was recognized. The testing scheme proposes 
using a Bottom–Up (begin with using test methods that can accurately identify 
non-irritants) or Top–Down (begin with using test methods that can accurately 
identify severe irritants) progression of in vitro tests (based on expected 
irritancy). Irrespective of the starting point, the approach would identify non-
irritants and severe irritants, leaving all others to the (mild/moderate) irritant GHS 
2/R36 categories. Since then, all in vitro test methods have been validated and 
were regulatory adopted within the top-down/bottom-up framework. 
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5. Skin sensitisation 
Silva Casati, Coralie Dumont & Andrew Worth 
 
5.1 The traditional animal test and its regulatory use 
Allergic contact dermatitis (ACD), the clinical manifestation of skin sensitisation, is the result 
of occupational, environmental or domestic exposure to sensitising chemicals and represents 
the most frequent manifestation of immunotoxicity in humans.  
 
Skin sensitisation is an immunological process which develops in two distinct phases. The 
first phase, induction, is initiated when a susceptible individual is exposed to a contact 
allergen in a sufficient amount to trigger the proliferation of memory T lymphocytes. During 
the second phase, elicitation, which occurs following a subsequent contact with the allergen, 
the expanded population of memory T lymphocytes reacts to the sensitising agent, leading to 
the allergic response with the clinical signs of ACD.  
 
The regulatory assessment of skin sensitisation has traditionally involved the use of animals. 
These include the classical methods based on guinea-pigs: the Magnusson Kligman Guinea 
Pig Maximisation Test (GPMT; OECD, 1992), an adjuvant-type test in which the allergic 
response is potentiated by intradermal injection of Freunds’ Complete Adjuvant (FCA), and 
the Buehler test (OECD, 1992), a non-adjuvant technique that involves topical induction 
treatment only. More recently, a murine test, the Local Lymph Node Assay (LLNA; OECD, 
2010a), has gained acceptance as an alternative to the guinea-pig tests, with the advantage of 
providing both refinement and reduction of animal usage and a more objective and 
quantitative endpoint.   
 
The mouse and guinea-pig methods differ with respect to the endpoints evaluated. The LLNA 
measures the responses provoked during the induction of sensitisation, and specifically the 
extent of proliferation of lymphocytes in regional lymph nodes draining the site of application 
of the test substance measured through quantification of radioactive label incorporation 
(Kimber & Basketter, 1992). Non-radioactive variations of the LLNA have also been 
developed (OECD, 2010b,c). The two guinea-pig tests measure elicitation reactions in the 
skin in previously sensitised animals. The GPMT is considered to be more sensitive than the 
Buehler assay. The LLNA generates dose-response information from which an EC3 value 
(concentration of substance needed to elicit a positive response at the threshold level) can be 
derived. The EC3 value can be used as an indicator of relative potency in risk assessment, or 
to classify chemicals on the basis of potency bands. 
 
Information on skin sensitisation (potential or potency) is required to support the human 
safety assessment of substances under several pieces of EU legislation. Information on 
sensitisation potential is needed for the hazard assessment of industrial chemicals (European 
Commission, 2006), biocides (European Union, 2012) plant protection products (European 
Commission, 2009a) and for classification and labelling (European Commission, 2008). For 
cosmetics, information on sensitisation potency is additionally required, and this must be 
obtained without recourse to animal testing, since testing and marketing bans are in force 
(European Commission, 2009b). 
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5.2 Mechanistic understanding of the endpoint 
The biological mechanisms underlying the induction and elicitation phases of skin 
sensitisation (Figures 5.1 and 5.2) are relatively well understood and extensively documented 
in the scientific literature (Vocanson et al., 2009; Basketter & Kimber, 2010).  
 
 
Figure 5.1. The induction phase of skin sensitisation (from OECD 2012a) 
 
 
Figure 5.2. The elicitation phase of skin sensitisation (from OECD 2012a) 
 
The key events in the skin sensitisation pathway include: 1) the ability of the substance to 
cross the stratum corneum of the skin and reach the viable epidermis (epidermal disposition or 
bioavailability); 2) the covalent binding of the substance (hapten) to skin proteins 
(haptenation); 3) the release of pro-inflammatory cytokines and the induction of cyto-
protective cellular pathways in keratinocytes (KC); 4) the activation and maturation of 
dendritic cells (DC), the skin’s immunocompetent cells, and their migration from skin to the 
regional lymph nodes; 5) the presentation by DCs of the haptenated protein to T cells (T-cell 
priming) and the clonal expansion of memory T cells (Adler et al., 2011).  While there is 
general agreement on these key events, a detailed understanding of the underling chemical 
and biological interactions remains incomplete. More recently, the existing knowledge has 
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been recast in form of an Adverse Outcome Pathway (AOP) by the OECD (OECD 2012a,b; 
Figure 5.3). 
 
 
 
Figure 5.3. Adverse Outcome Pathway for Skin Sensitisation (OECD, 2012a) 
 
The majority of skin sensitising substances share the common feature of being low molecular 
weight reactive chemicals that are not able to elicit an immune response on their own but need 
to bind to proteins to form a hapten-protein conjugate, which is recognised by the immune 
system. Reactivity towards skin proteins is considered to be the main Molecular Initiating 
Event (MIE) needed to trigger the cascade of subsequent events. While organic chemicals 
bind proteins through stable covalent bonds, metals can form coordination complexes.  
 
A proportion of the organic skin sensitisers are not directly reactive but need to be activated 
either by cutaneous enzymes (pro-haptens) or by abiotic transformation (pre-haptens) (e.g. by 
air oxidation) (Lepoittevin, 2006). There is little information on the role of human skin 
metabolism in the sensitisation pathway.  
 
5.3 Status of non-standard methods and Integrated Testing Strategies 
Our understanding of the chemistry and biology of skin sensitisation has favoured the 
development in recent years of alternative test methods designed to detect and measure the 
key events in the skin sensitisation pathway (Adler et al., 2011).  
 
Penetration through the stratum corneum to the viable epidermis is essential for a chemical to 
exert sensitisation activity. While there are no officially accepted models for epidermal 
disposition (Basketter et al., 2007), some physicochemical properties of the compound can be 
used to provide information about its potential to penetrate the skin. The molecular weight 
(MW), the octanol-water partition coefficient (logKOW or logP) and the ionisation state are 
considered to be useful physicochemical predictors (World Health Organization (WHO) 
2006; Roberts and Williams, 1982). LogKOW is commonly used in Quantitative Structure 
Activity Relationship (QSAR) models. A common shortcoming of available QSARs is that 
they do not account for solvent and formulation effects, and are typically based on the 
assumption of passive diffusion through a homogeneous compartment. In addition, 
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mathematically-based and more biologically faithful toxicokinetic models have been 
developed to simulate the skin penetration process (e.g. Dancik et al., 2013).  
 
The ability to detect pre-haptens and pro-haptens remains a challenge, since these sensitisers 
are not systematically detected by test methods that lack or have limited metabolic and 
oxidative capacity. However, expert systems such as TIMES-SS (Patlewicz et al., 2007; 
Roberts et al., 2007) and the OECD QSAR toolbox (http://www.qsartoolbox.org) provide a 
means of simulating abiotic and enzymatic reactions and incorporating this information into 
their predictions. 
 
The recognition that reactivity towards skin proteins is the main MIE in the skin sensitisation 
pathway has led to the development of in chemico methods (based on organic chemistry) to 
detect and quantify chemical reactivity. The majority of these methods monitor either the 
depletion of a nucleophile and/or the formation of an adduct between an electrophilic 
chemical and the nucleophile. The experimental nucleophile is an organic compound (such as 
nitrobenzenethiol) or a peptide like cysteine, lysine and glutathione (GSH) (Gerberick et al., 
2008).  Some of these assays have been adapted to provide information on reaction kinetics 
(Schultz et al., 2005; Böhme et al., 2009). These approaches are generally limited by the lack 
of metabolism and oxidation capacity, although a recent development of one of these assays 
incorporates an-enzyme mediated activation step for the identification of pro-haptens 
(Gerberick et al., 2009). The availability of in chemico data has enabled the development of 
QSARs for protein reactivity, as reviewed by Asturiol & Worth (2011). 
 
KCs are the predominant cells in the skin and play a role in the initiation of the immune 
response by releasing a wide range of pro-inflammatory mediators and growth factors 
(Griffiths et al., 2005). Measurement of intracellular interleukin-18 (IL-18) production in a 
human keratinocyte cell line following exposure to sensitisers has been proposed as a 
biomarker for the detection of skin sensitisers and for discriminating between skin and 
respiratory sensitisers (Galbiati et al., 2011). Studies in animals have shown that the 
antioxidant/electrophile response element ARE/EpRE-dependent pathway, which plays a 
central role in cellular defence against oxidative and electrophilic stress,  is relevant to the 
skin sensitisation process (Kim et al., 2008). Accordingly, endpoints associated with the 
activation of this pathway are used in several in vitro methods based on keratinocyte reporter 
cell lines (Emter et al., 2010; Bauch et al., 2012) or the 3-dimensional reconstituted human 
epidermis (RhE) (McKim et al., 2010).  
 
The next key event in the skin sensitisation pathway is the recognition and internalisation of 
the hapten-protein conjugate by immature DCs. During this process, DCs undergo a process 
of maturation in which they lose their antigen processing capacity and acquire the capability 
to present the allergen to naïve T lymphocytes. DC maturation is typically measured 
experimentally by assessing the expression of co-stimulatory and intercellular adhesion 
molecules (e.g. CD40, CD54, CD83, CD86) on the surface of DCs that are needed for the 
interaction with, and activation of T lymphocytes, or by quantifying cytokine secretion (e.g. 
Il-1β, IL-6, IL-8) (Casati et al., 2005). Several test methods based on the measurement of 
biomarkers for DC activation are available (Adler et al., 2011), including DCs derived from 
peripheral blood, cord blood or bone-marrow samples, as well as DC-like cell lines (e.g. THP-
1, U-937, MUTZ 3). Genomic and proteomic signatures in KC-based and DC-based assays 
have also been proposed as predictive markers for both skin sensitisation potential and 
potency assessment (Johansson et al., 2013; Lambrechts et al., 2010). 
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Following maturation, DCs migrate from the skin to regional lymph nodes, where they 
present the antigen to responsive T-lymphocytes. The activation and clonal expansion of 
naïve T-lymphocytes represent the last key event in the skin sensitisation pathway, and is the 
endpoint measured in the LLNA. The majority of T-cell based assays measure the in vitro 
proliferation of naïve T-cells (isolated from the peripheral blood mononuclear cells of healthy 
donors), following co-culture with sensitiser-treated DCs (Martin et al., 2010). Although these 
methods may represent the most specific tool for the identification of contact allergens, they 
involve rather complex DC-T cell co-culture procedures which have made it difficult to 
standardise the protocols. Therefore the availability of a robust test method based on in vitro 
T-cell proliferation will require further development.  
 
Most QSARs and expert systems have been developed to be directly predictive of the 
sensitisation response in animals, as reviewed elsewhere (Patlewicz & Worth, 2008; 
Chaudhry et al, 2010; Adler et al., 2011). Some of these approaches (e.g. Toxtree and Derek) 
are based on mechanistic/expert knowledge, whereas others are based on statistical 
correlations (e.g. CAESAR, TOPKAT, MulitCASE), or are best characterised as hybrid 
(based on both approaches, e.g, TIMES-SS). For the quantitative prediction of potency, 
mathematically-based (toxicokinetic and toxicodynamic) models (e.g. Maxwell & MacKay, 
2008) will be needed. These models require a considerable amount of experimental data for 
calibration.  
 
In order to replace animal testing in the assessment of skin sensitisation, a combination of 
different alternative methods addressing the key events in the skin sensitisation pathway will 
be needed. Test methods under formal validation by EURL ECVAM are being assessed for 
their reliability, with a view to their possible use within integrated assessment approaches. 
These methods include: 1) the Direct Peptide Reactivity Assay (DPRA) which addresses 
protein binding by monitoring the depletion of a nucleophile-containing synthetic peptide 
(Gerberick et al., 2007); 2) the KeratinoSens assay which measures the activity of the 
antioxidant/electrophile response element ARE/EpRE-dependent pathway in keratinocytes 
(Emter et al., 2010); and 3) the human Cell Line Activation Test (h-CLAT) which measures 
the induction of CD54 and CD86 protein markers on the surface of THP-1 cell lines 
(Sakaguchi et al., 2006; Ashikaga et al., 2010). These methods appear sufficiently 
reproducible to justify their inclusion in integrated approaches for hazard identification and 
classification. Their potential to contribute to the potency assessment of cosmetic ingredients 
is being evaluated by the Cosmetics Europe Skin Tolerance Task Force. 
 
Following an initial proposal for integrating information from alternative approaches by 
Jowsey et al. (2006), a number of different approaches for data integration have emerged.  
These range from sequential testing strategies (STS), in which the decision making follows a 
stepwise approach involving interim decision steps (Nukada et al., 2013; van der Veen et al., 
2014), weight-of-evidence based approaches (e.g. Natsch et al., 2009; Bauch et al., 2012) to 
mathematically based approaches such as Bayesian Networks, which encode probabilistic 
relationships among the input variables (Jaworska et al., 2011; 2013), and artificial neural 
networks  (Hirota et al., 2013). These approaches are all mechanistically-based, in the sense 
that they use predictor variables associated with Key Events in the established AOP, and they 
are all data-driven, in the sense that statistical methods are used to optimise the models. An 
advantage of the weight of evidence approach is its simplicity, whereas an advantage of the 
probabilistic approach is that it provides information on the interdependences of all variables 
and is optimised to reduce the overall uncertainty of prediction. 
  
  98
In addition, the use of mathematical models to represent the mechanisms underlying skin 
sensitisation induction is being explored (Maxwell & MacKay, 2008; Maxwell et al., 2014).  
 
EURL ECVAM (EURL ECVAM, 2013) has initiated the development of non-animal testing 
strategies for hazard identification and potency sub-categorisation according to the two 
subcategories 1A and 1B of the Globally Harmonised System of Classification and Labelling 
of Chemicals (GHS). This will contribute to a new OECD activity aimed at developing 
generic guidance on how to document and evaluate Integrated Approaches to Testing and 
Assessment (IATA) for skin sensitisation. EURL ECVAM is developing an IATA to meet the 
needs of REACH and CLP, with a view to reducing the need for animal testing in relation to 
the next registration deadline of 2018. 
 
5.4 Conclusions 
Information on skin sensitisation potential is required for hazard identification under REACH, 
the Biocides Directive, the Plant Protection Products Regulation, and can be used for 
classification and labelling under CLP. For cosmetics, additional information on sensitisation 
potency is required. 
 
The mechanisms underlying skin sensitisation are sufficiently well understood to enable the 
development of non-standard methods addressing the key events of the skin sensitisation 
pathway. In vitro methods designed to cover haptenation, keratinocyte responses and DC 
activation are well developed, while further development efforts are needed to make robust T-
cell proliferation assays available. Some of these methods are in an advanced status of formal 
validation by EURL ECVAM, and the development of corresponding OECD test guidelines 
has started. 
 
QSAR models designed to predict key events in the sensitisation pathway should be useful 
sources of information in IATA, whereas QSARs that are directly predictive of the 
sensitisation response may be useful for increasing confidence in Weight of Evidence (WoE) 
arguments. QSARs are available for predicting skin penetration and protein binding, as well 
as the adverse outcome in animals, but models for the intermediate events are lacking. 
Mathematically based (systems biology) models provide the most promising means of 
simulating the dynamics of skin sensitisation and predicting potency, but these approaches 
need to be further developed and implemented in user-friendly tools. 
 
Efforts are underway to develop integrated approaches for predicting skin sensitisation 
potential and potency based on the use of in silico, in chemico, and in vitro methods. AOP-
based IATA, which are motivated by an understanding of the underlying mechanistic 
pathways, will be particularly useful for regulatory purposes. With a view to promoting the 
international acceptance of these integrated approaches, the OECD will develop guidance on 
how to document and evaluate IATA in view of their intended applications. The development 
of a single IATA, suitable for all chemicals and regulatory applications, is unrealistic, but a 
systematic approach to the description and evaluation of IATA will help the user to make an 
appropriate choice.  
 
The extent and quality of the non-standard information needed in a regulatory assessment will 
depend on the regulatory purpose and the level of confidence required. In general, a greater 
burden of proof will be required to conclude on the absence of skin sensitisation potential 
than to conclude on its presence. 
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deoxyuridine (BrdU) content is used as an indicator of lymphocytes proliferation. 
Traditional animal tests – Scientific publications 
Kimber I & Basketter DA (1992). The murine local 
lymph node assay: a commentary on collaborative 
studies and new directions. Food and Chemical 
Toxicology 30(2): 165-169. 
This paper provides a historical background to the development of the murine LLNA. It 
reports performance of the LLNA in an interlaboratory trial designed to evaluate the 
utility of the method as an alternative to the guinea-pig methods. In addition the authors 
make some recommendations regarding the use and interpretation of the LLNA including 
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comparisons of the LLNA with guinea-pig methods. 
Mechanistic understanding 
Adler S, Basketter D, Creton S, et al. (2011). 
Alternative (non-animal) methods for cosmetics testing: 
current status and future prospects-2010. Archives of 
Toxicology 85(5): 367-485. 
This report provides an analysis made by a panel of experts of the status and prospects of 
alternative methods in five toxicological areas of concern in view of the full marketing 
ban entered into force in 2013 for cosmetics products and ingredients tested on animals in 
Europe. The report includes five chapters dealing with toxicokinetics, skin sensitisation, 
repeated dose toxicity, carcinogenicity and reproductive toxicity. 
Ashikaga T, Sakaguchi H, Sono S, Kosaka N, Ishikawa 
M, Nukada Y, Miyazawa M, Ito Y, Nishiyama N & 
Itagaki H (2010). A comparative evaluation of in vitro 
skin sensitisation tests: the human cell-line activation 
test (h-CLAT) versus the local lymph node assay 
(LLNA). Alternatives to Laboratory Animals 38(4): 
275-284. 
This paper describes a comparative evaluation of the h-CLAT in vitro test and the LLNA 
in order to confirm the predictive value of the h-CLAT for skin sensitisation activity. The 
study tested one hundred chemicals including non-sensitisers and sensitisers distributed in 
the four LLNA potency classes: weak, moderate, strong and extreme. The correlation of 
the h-CLAT results with the LLNA results was 84%. The use of the combination of 
CD86 and CD54 induction as positive indicator, improved the accuracy of the test. In 
conclusion, the h-CLAT is expected to be a useful cell-based in vitro method for 
predicting skin sensitisation potential 
Basketter DA & Kimber I (2010). Contact 
hypersensitivity: In: McQueen CA (ed) Comprehensive 
Toxicology, 2nd edition. Elsevier, Kidlington. Vol 5: 
397-411. 
This article provides a detailed review of the mechanistic aspects of skin sensitisation and 
contact hypersensitivity. 
Griffiths CEM, Dearman RJ, Cumberbatch M & 
Kimber I (2005). Cytokines and Langerhans cell 
mobilisation in mouse and man. Cytokine 32: 67-70. 
This review focuses on the mobilisation of epidermal Langerhans cells (LC), critical 
event during the development of cutaneous immune response. The authors highlight that 
regulation of mobilisation and migration of LC present similarities in man and mouse as 
shown by experimental studies. They concluded that, with respect to LC biology at least, 
the mouse provides a very valuable experimental surrogate for the human skin immune 
system. 
Kim H-J, Barajas B, Wang M & Nel AE (2008). Nrf2 
activation by sulforaphane restores the age-related 
decrease of TH1 immunity. Role of dendritic cells. 
Journal of Allergy and Clinical Immunology 121(5): 
1255-1261. 
This paper presents the results of an in vivo study in Nrf2-knockout mice demonstrating 
that the Nrf2 pathway, which regulates the transcriptional activation of more than 200 
antioxidant and protective genes, is a relevant pathway for contact allergy. 
Lepoittevin JP (2006). Metabolism versus chemical 
transformation or pro-versus prehaptens? Contact 
Dermatitis 54: 73-74. 
In this editorial, the author introduces the term of “prehapten” to define non-reactive 
sensitising molecules transformed into haptens by simple chemical transformation and 
without requirement of a specific enzymatic system.  
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Organisation for Economic Cooperation and 
Development (2012a). The Adverse Outcome Pathway 
for Skin Sensitisation Initiated by Covalent Binding to 
Proteins; Part 1: Scientific Evidence Series on Testing 
and Assessment No.168 
ENV/JM/MONO(2012)10/PART1.  Paris, France. 
Available from: http://www.oecd.org 
This OECD document describes the collective knowledge of the adverse outcome 
pathway (AOP) for skin sensitisation initiated by covalent binding to proteins. It also 
provides an overview of the scientific evidence supporting the AOP and of the 
experimental evidence supporting the key events in the AOP. 
Organisation for Economic Cooperation and 
Development (2012b). The Adverse Outcome Pathway 
for Skin Sensitisation Initiated by Covalent Binding to 
Proteins; Part 2: Use of the AOP to Develop Chemical 
Categories and Integrated Assessment and Testing 
Approaches  Series on Testing and Assessment No.168  
ENV/JM/MONO(2012)10/PART2. Paris, France. 
Available from: http://www.oecd.org 
This document focuses on how to use the AOP in the context of forming chemical 
categories. In addition, it addresses the efforts to build AOP-based Integrated Approaches 
to Testing and Assessment for skin sensitisation.  
Vocanson M, Hennino A, Rozieres A, Poyet G & 
Nicolas JF (2009). Effector and regulatory mechanisms 
in allergic contact dermatitis. Allergy 64: 1699-1714. 
This paper provides a detailed review of the mechanisms in allergic contact dermatitis 
(ACD).  
Status of non-standard methods  
Asturiol D & Worth A (2011). The use of chemical 
reactivity assays in toxicity prediction. JRC Scientific 
and Technical Reports.  Available from: 
http://publications.jrc.ec.europa.eu/repository/handle/1
11111111/22180 
 
In this report the authors illustrate the basis of the in chemico approach to toxicity 
prediction in the fields of skin sensitisation, aquatic toxicity and hepatotoxicity and 
review the studies that have developed the concept and its practical application since the 
1930s, with special attention paid to studies aimed at the development of Quantitative 
Structure-Activity Relationship (QSAR) models and read-across approaches. Authors 
conclude that in chemico approaches provide a promising means of toxicity prediction, 
especially in the context of integrated testing strategies based on the use of multiple non-
animal methods. 
Basketter DA, Casati S, Cronin MTD, Diembeck W, 
Gerberick GF, Hadgraft J, Kasting G, Marty JP, 
Nikolaidis E, Patlewicz E, Pease C, Roberts DW, 
Roggen E, Rovida C & van der Standt J (2007). Skin 
sensitisation and epidermal disposition: the relevance 
of epidermal disposition for sensitisation hazard 
This report describes the outcome of a workshop on skin sensitisation and epidermal 
disposition aimed to review the state-of-the-art of approaches available to measure the 
disposition of chemicals in skin compartments and to develop recommendations on how 
to use such information into non-animal testing strategies for skin sensitisation.  
The workshop participants acknowledged the importance of epidermal disposition 
information in the context of Integrated Testing Strategies for both hazard and potency 
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identification and risk assessment. Alternatives to 
Laboratory Animals 35(1): 137-154. 
prediction. However, they also acknowledged that the requirements for epidermal 
disposition data may differ depending on whether the need is for hazard identification or 
for risk assessment. 
Böhme A, Thaens D, Paschke A & Schüürmann G 
(2009). Kinetic glutathione chemoassay to quantify 
thiol reactivity of organic electrophiles--application to 
,β-unsaturated ketones, acrylates, and propiolates. 
Chemical Research in Toxicology 22(4): 742-750. 
This paper describes a new kinetic glutathione (GSH) chemoassay which employs a 
photometric method to quantify GSH loss enabling an efficient determination of second-
order rate constants, ƙGSH of the reaction between electrophilic substances and GSH. 
First results obtained with 15 ,β-unsaturated ketones and 11 ,β-unsaturated ketones 
demonstrate the capability of the kinetic GSH chemoassay to quantify electrophilic 
reactivity over a large value range and to serve as a respective ITS tool for the analysis 
and the prediction of the reactive toxicity of electrophiles. 
Casati S, Aeby P, Basketter DA, Cavani A, Gennari A, 
Gerberick GF, Griem P, Hartung T, Kimber I, 
Lepoittevin JP, Meade BJ, Pallardy M, Rougier N, 
Rousset F, Rubinstenn G, Sallusto F, Verheyen GR & 
Zuang V (2005). Dendritic cells as a tool for the 
predictive identification of skin sensitisation hazard. 
Alternatives to Laboratory Animals 33: 47-62. 
This report presents the outcome of a workshop aimed to review the state-of-the-art of the 
use of cultured dendritic cells for the identification of skin sensitisation hazard and to 
develop strategies for the eventual replacement of in vivo testing. The authors concluded 
that opportunities are available for exploring the potential of cultured DCs and cell lines 
of hematopoietic origin in order to provide the basis for in vitro skin sensitisation testing. 
General observations and recommendations are highlighted for further development, 
subsequent evaluation and validation and requirements for further research. Progress has 
been made in the area since the publication of this workshop report, standardised test 
methods based on the use of DC-like cell lines are now available.  
Chaudhry Q, Piclin N, Cotterill J, Pintore M, Price NR, 
Chrétien JR & Roncaglioni A (2010). Global QSAR 
models of skin sensitisers for regulatory purposes. 
Chemistry Central Journal 4(1):S5  
This paper reports the development of two global QSAR models. The construction of the 
models was based on a common dataset of 209 heterogeneous compounds using two 
computational techniques, particularly suited for data presented as classes of responses.  
Dancik Y, Miller MA, Jaworska J & Kasting GB 
(2013). Design and performance of a spreadsheet-based 
model for estimating bioavailability of chemicals from 
dermal exposure. Advanced Drug Delivery Reviews 
65: 221-236. 
This paper presents an in silico model of chemical penetration through the stratum 
corneum, viable epidermis and dermis formulated in term of an ExcelTM spread sheet. 
Model predictions are compared with representative in vitro skin permeation data 
obtained from the literature using as summary parameters total absorption (Qabs), 
maximum flux (Jmax) and skin permeability coefficient (kp). The results of this evaluation 
demonstrate the current state-of-the-art in prediction of transient skin absorption and 
highlight areas in which further elaborations are needed to obtain satisfactory predictions. 
EURL ECVAM (2013). EURL ECVAM strategy for 
replacement of animal testing for skin sensitisation 
hazard identification and classification. JRC scientific 
This document outlines the EURL ECVAM strategy for the skin sensitisation area. In 
order to achieve the highest impact on the 3Rs ECVAM will focus its efforts in the next 
five years on the development of non-animal testing strategies for hazard identification 
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and policy reports. Available from: 
http://publications.jrc.ec.europa.eu/repository/hand
le/111111111/27708 
and sub-categorisation according to sub-categories 1A and 1B of the Globally 
Harmonised System for Classification and Labelling of Chemicals (GHS). In addition 
EURL ECVAM will support the OECD in the development of generic guidance on how 
to document and evaluate Integrated Approaches to Testing and Assessment (IATA). 
Emter R, Ellis G & Natsch A (2010). Performance of a 
novel keratinocyte-based reporter cell line to screen 
skin sensitizers in vitro. Toxicology and Applied 
Pharmacology 245: 281-290. 
This study reports the assessment of the performance of a reporter cell line derived from 
keratinocytes stably transfected with a luciferase reporter gene under the control of a 
single copy of antioxidant response element (ARE)-element of the human AKR1C2 gene 
for assessing the skin sensitisation potential of substances.  
Galbiati V, Lucchi L, Mitjans M, Viviani B, Galli CL, 
Marinovitch M & Corsini E (2011). Further 
development of the NCTC 2544 IL-18 assay to identify 
in vitro contact allergens. Toxicology in Vitro 25: 724-
732. 
This paper describes the work undertaken to optimise a test method based on the 
quantification of IL-18 production in the human keratinocyte cell line NTC 2544 to 
discriminate contact sensitizer from irritants and low molecular weight respiratory 
allergens.  
Gerberick GF, Vassallo JD, Foertsch LM, Price BB, 
Chaney JG & Lepoittevin JP (2007). Quantification of 
chemical peptide reactivity for screening contact 
allergens: a classification tree model approach. 
Toxicological Sciences 97(2): 417-427. 
In this study, the authors tested the ability of 82 chemicals (including non-allergens and 
allergens of different potencies) to react with reduced glutathione or with two synthetic 
peptides, containing either cysteine or lysine, in order to determine whether and to what 
extent peptide reactivity correlates with skin sensitisation potential. The results showed 
that measurement of peptide reactivity has considerable potential utility as a screening 
approach for skin sensitisation testing, and thereby for reducing reliance on animal-based 
test methods. 
Gerberick F, Aleksic M, Basketter D, Casati S, 
Karlberg AT, Kern P, Kimber I, Lepoittevin JP, Natsch 
A, Ovigne JM, Rovida C, Sakaguchi H & Schultz T 
(2008). Chemical reactivity measurement and the 
predictive identification of skin sensitisers. Alternatives 
to Laboratory Animals 36: 215-242. 
This report presents the outcome of a workshop aimed to review the state-of-the-art of 
methods for the identification of skin sensitisers based on measurement of chemical 
reactivity including their limitations. Furthermore, consideration was given as to how 
such methods could contribute to integrated testing strategies for the replacement of in 
vivo testing. A number of recommendations were made in order to promote the progress 
of relevant and reliable methods towards prevalidation and validation. 
Gerberick GF, Troutman JA, Foertsch LM, Vassallo 
JD, Quijano M, Dobson RLM, Goebel C & Lepoittevin 
JP (2009). Investigation of peptide reactivity of pro-
hapten skin sensitizers using a peroxidase-peroxide 
oxidation system. Toxicological Sciences 112(1): 164-
174. 
This paper describes the use of an enzyme-mediated activation step (horseradish 
peroxidase and hydrogen peroxide) into an in chemico skin sensitisation assay (peptide 
reactivity) for assessing the skin sensitisation potential of pro-haptens. 
Johansson H, Albrecht A-S, Borrebaek CAK & This paper describes an assay for skin sensitisation hazard assessment which is based on a 
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Lindstedt M (2013). The Gard assay for assessment of 
chemical skin sensitizers. Toxicology in Vitro 27: 
1163-1169. 
genomic readout. A signature of 200 genes in the myeloid cell line MUTZ-3 is used to 
discriminate between sensitisers and non sensitisers The genes are reported to participate 
in signalling pathways that are involved with recognition of foreign substances. A number 
of these pathways, such as nuclear factor-erythroid-related factor 2 (NRF2) mediated 
oxidative response, aryl hydrocarbon receptor (AHR) signalling and Toll-like receptor 
(TLR) signalling, are known to lead to transcription of cytoprotective enzymes and DC 
maturation as a response to xenobiotic challenges.   
Lambrechts N, Vanheel H, Nelissen I, Witters H, van 
den Heuvel R, Van Tendeloo V, Schoeters G & 
Hooyberghs J (2010). Assessment of chemical skin-
sensitizing potency by an in vitro assay based on 
human dendritic cells. Toxicological Sciences 116(1): 
122-129. 
In the study described in this paper, authors tried to predict the potency (LLNA EC3 
values) of 15 skin sensitisers using  in vitro-generated gene expression data from CD34-
DC-based assay associated to the concentration of the compound that causes 20% (IC20) 
cell damage in CD34-DC. Applying a linear regression with both IC20 and expression 
changes of CREM and CCR2, a high linear correlation was established between the in 
vitro model and the LLNA values. 
Martin SF, Esser PR, Schmucker S, Dietz L, Naisbitt 
DJ, Park K, Vocanson M, Nicolas JF, Keller M, Pichler 
WJ, Peiser M, Luch A, Wanner R, Maggi E, Cavani A, 
Rustemeyer T, Richter A, Thierse HJ & Sallusto F 
(2010). T-cell recognition of chemicals, protein 
allergens and drugs: towards the development of in 
vitro assays. Cellular and Molecular Life Sciences 67: 
4171-4184. 
This review reports the outcome of an expert meeting aimed to review the status of 
development of T-cell-based in vitro assays as tools in immunotoxicology to identify 
hazardous chemicals and drugs.  
 
Maxwell G & MacKay C (2008). Application of a 
Systems Biology Approach to skin allergy risk 
assessment. Alternatives to Laboratory Animals 36: 
521-556. 
This paper describes an in silico model of the induction of skin sensitisation. This model 
was developed in order to characterise and quantify the contribution of each pathway to 
the overall biological process. Using a “systems biology” approach, a computer-based 
mathematical model was constructed. In this one, biological mechanisms underlying the 
induction phase of skin sensitisation are represented by non-linear ordinary differential 
equation and defined by using from over 500 published papers. By using this model, 
authors identified knowledge gaps for future investigation and key factors with major 
influence on the induction of skin sensitisation.  
McKim JM Jr, Keller DJ 3rd & Gorski JR (2010). A 
new in vitro method for identifying chemical sensitizers 
combining peptide binding with ARE/EpRE-mediated 
gene expression in human skin cells. Cutaneous and 
This study reports the development of a new in vitro screening assay using a human skin 
cell line (HaCat), chemical reactivity (measurement of glutathione depletion in a cell free 
matrix) and gene expression profiling for three signalling pathways (Keap1/Nrf 
2/ARE/EpRE, ARNT/AhR/XRE and Nrf1/MTF/MRE) known to be activated by 
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Ocular Toxicology 29(3): 171-192. sensitizing agents. The system was developed with 39 chemicals and 3 cationic metals 
and challenged with 58 additional compounds. With an accuracy of approximately 84%, a 
sensitivity of 81% and a specificity of 92%, authors concluded the method described 
demonstrates a valuable in vitro method to identify chemicals and metals that induce skin 
sensitisation.  
Patlewicz G, Dimitrov SD, Low LK, Kern PS, 
Dimitrova GD, Comber MIH, Aptula AO, Phillips RD, 
Niemela J, Madsen C, Wedebye EB, Roberts DW, 
Bailey PT & Mekenyan OG (2007). TIMES-SS – A 
promising tool for the assessment of skin sensitization 
hazard. A characterisation with respect to the OECD 
Validation Principles for (Q)SARs. Regulatory 
Toxicology and Pharmacology 48: 225–239. 
This study reports the results of an external evaluation of the TIMES-SS, a hybrid expert 
system encoding structure-toxicity and structure-skin metabolism relationships through a 
number of transformations. As part of this exercise data were generated for 40 chemicals 
in the LLNA and then compared with predictions made by TIMES-SS with an overall 
concordance of 83%. In addition the extent of adherence of the model to the five OECD 
principles for (Q)SAR validation was evaluated. The authors concluded that the model is 
a promising tool to aid in the evaluation of skin sensitisation hazard under legislative 
programs such as REACH. 
Patlewicz G, Aptula AO, Roberts DW & Uriarte E 
(2008). A Minireview of Available Skin Sensitization 
(Q)SARs/Expert Systems. QSAR & Combinatorial 
Science 27(1): 60-76. 
This minireview describes the state-of-the-art of available (Q)SARs/expert systems for 
skin sensitisation and evaluates their utility for potential regulatory use. 
Patlewicz G & Worth A (2008). Review of data 
sources, QSARs and Integrated Testing Strategies for 
skin sensitisation. JRC Scientific and Technical 
Reports. Available from:  
http://publications.jrc.ec.europa.eu/repository/handle/1
11111111/998 
This review reports information of skin sensitisation data and computational tools for the 
estimation of skin sensitisation potential. It presents an overview of what constitutes an 
Integrated Testing Strategy. Summaries of general models, models for specific chemical 
classes and mechanisms of action and expert system are provided.   
Roberts DW & Williams DL (1982). The derivation of 
quantitative correlations between skin sensitisation and 
physio-chemical parameters for alkylating agents, and 
their application to experimental data for sultones. 
Journal of Theorical Biology 99(4): 807-825. 
This paper describes a new mathematical model based on quantitive correlation between 
skin sensitisation and physio-chemical parameters for alkylating agents: the relative 
alkylating index RAI is intended to provide a relative measure of the extent of in vivo 
alkylation and is function of chemical reactivity, lipophilicity and dose administrated.  
Roberts DW, Patlewicz G, Dimitrov SD, Low LK, 
Aptula AO, Kern PS, Dimitrova GD, Comber MIH, 
Phillips RD, Niemelä J, Madsen C, Wedebye EB, 
Bailey PT & Mekenyan OG (2007). TIMES-SS--a 
mechanistic evaluation of an external validation study 
This paper describes the evaluation of LLNA results, generated in a study designed to 
perform an external evaluation of the Times Metabolism Simulator platform (TIMES-SS) 
for predicting skin sensitisation, with respect to reaction chemistry principles for 
sensitization. Testing on additional four chemicals was carried out to explore some of the 
specific reaction chemistry findings in more detail. Improvements for TIMES-SS, where 
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using reaction chemistry principles. Chemical Research 
in Toxicology 20(9):1321-1330. 
appropriate, were put forward together with proposals for further research work. 
Schultz TW, Yarbrough JW & Johnson EL (2005). 
Structure-activity relationships for reactivity of 
carbonyl-containing compounds with glutathione. SAR 
and QSAR in Environmental Research 16(4): 313-322. 
This paper describes the development of a spectrophotometric assay for determining the 
reactive to glutathione (GSH) and its use to determine GSH reactivity of 21 aliphatic 
derivatives of esters, ketones and aldehydes. To quantify the reactivity, the parameter 
chosen was the RC50 (concentration giving 50% depletion of GSH) calculated from 
concentration-response curves and which are algebraically related to the rate constant and 
independent of the experimental methodology.  Results were then used to evaluate a 
series of structure-activity relationship. 
Integrated Testing Strategies 
Bauch C, Kolle SN, Ramirez T, Eltze T, Fabian E, 
Mehling A, Teubner W, van Ravenzwaay B & 
Landsiedel R (2012). Putting the parts together: 
combining in vitro methods to test for skin sensitizing 
potential. Regulatory Toxicology and Pharmacology 
63: 489-504. 
In this paper the authors report the performance of  different in vitro (h-CLAT, LuSens 
assay, Keratinosens and mMUSST), in chemico (DPRA) and in silico (OECD QSAR 
toolbox) methods in predicting the skin sensitisation potential of a set of 54 test 
substances compared to human or LLNA data. 
The predictive performance of test methods’ combinations has also been explored and an 
in vitro testing scheme and a prediction model based on information on peptide reactivity, 
activation of Keap-1/Nrf2 signalling pathway and dendritic cell activation is proposed. 
For the set of 54 chemicals evaluated in the study the model offers an overall accuracy of 
94% (sensitivity 93% and specificity 95%) compared to human data and an overall 
accuracy of 83% (sensitivity 81% and specificity 88%) when compared to LLNA data. 
The authors conclude that the high accuracy of the proposed prediction model points to a 
possible future replacement of animal testing while maintaining the same degree of 
accuracy and prediction for human skin sensitisers. Future activities should focus on 
better defining the applicability domain of the test battery and explore its potential to 
deliver potency information. 
Goebel C, Aeby P, Ade N, et al. (2012). Guiding 
principles for the implementation of non-animal safety 
assessment approaches for cosmetics: Skin 
sensitisation, Regulatory Toxicology & Pharmacology 
63: 40-52. 
 
This paper reports the outcome of a workshop aimed to analyse to what extent skin 
sensitisation safety assessments for cosmetic ingredients can be made in absence of 
animal data. It was evaluated how and when non-animal test methods, predictions based 
on physico-chemical properties, threshold concepts and weight-of-evidence based hazard 
characterisation could be used to enable safety decisions. The goal was to propose 
guiding principles for the application and further development of non-animal safety 
assessment strategies. 
Hirota M, Kouzuki H, Ashikaga T, Sono S, Tsujita K, This paper describes the development the “iSENSver.1” model to predict LLNA 
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Sasa H & Aiba S (2013). Artificial neural network 
analysis of data from multiple in vitro assays for 
prediction of skin sensitization potency of chemicals. 
Toxicology In Vitro 27(4): 1233-1246. 
thresholds (i.e. EC3 values for LLNA-positive chemicals and maximum concentrations 
for LLNA-negative chemicals) of chemicals from in vitro test data, using the learning 
function of a non-linear artificial neural network (ANN). MAC value (SH test). The 
minimum EC150, EC200 (h-CLAT) and CV75 (cytotoxicity) were selected as descriptors 
for the input layer of the ANN-system. The ANN-predicted values were well correlated 
with reported LLNA thresholds. The authors concluded that the use of ANN appears be 
promising for predicting skin sensitisation potential of chemicals from in vitro test data. 
Jaworska J, Harol A, Kern PS & Gerberick F (2011). 
Integrating non-animal test information into an 
adaptive testing strategy – skin sensitization proof of 
concept phase. Alternative to Animal Experimentation 
28: 211-225. 
The paper describes the development of a Bayesian Network Integrated Testing Strategy 
(BN ITS) for skin sensitization hazard assessment and with the specific goal of estimating 
potency in the mouse LLNA.The BN ITS combines biological knowledge with 
heterogeneous experimental  in silico, in chemico, and in vitro data related to skin 
penetration, peptide reactivity, and dendritic cell activation. Prediction results are 
expressed in terms of probabilistic hypothesis about the potency of chemical as predicted 
by the LLNA. The BN ITS is proposed as a reduction strategy since chemicals with clear 
potency (i.e. with a high probability associated to the prediction) can be discriminated 
from chemicals for which more evidence is needed. In addition the BN ITS can be 
considered a testing guiding tool since it allows the possibility of evaluating the impact of 
generating additional data on the target information uncertainty reduction before testing is 
commenced.  
Jaworska J, Dancik Y, Kern P, Gerberick F & Natsch A 
(2013). Bayesian integrated testing strategy to assess 
skin sensitization potency: from theory to practice. 
Journal of Applied Toxicology. Journal of Applied 
Toxicology 33:1353-1364. 
This paper presents an updated Integrated Testing Strategy in the form of a Bayesian 
Network (BN ITS) developed to assess skin sensitisation potency expressed as LLNA 
potency classes. The parameters of the updated BN ITS were calculated from an extend 
data set of 124 chemicals. The improved BN ITS predicted correctly 95% and 86% of 
chemicals in a test set (n=21) for hazard and LLNA potency classes, respectively. 
Moreover, the BN ITS model can develop a hypothesis using subsets of data as small as 
one data point and can be queried on the value of adding additional tests before testing is 
commenced. 
Jowsey IR, Basketter DA, Westmoreland C & Kimber I 
(2006). A future approach to measuring relative skin 
sensitising potency: a proposal. Journal of Applied 
Toxicology 26: 341-350. 
In this paper, the authors propose a theoretical framework for the identification of skin 
sensitising chemicals and for relative potency prediction. 
The approach is based on the integration of five independent sources of information: 
structural alerts from SAR and/or expert systems, estimations of epidermal 
bioavailability, protein reactivity, impact on the phenotype and/or function of DC or DC-
like cells and ability to provoke T lymphocyte responses. Specific scoring criteria were 
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applied to facilitate both hazard identification and the deviation of a single measure of 
relative potency.  
Maxwell G, MacKay C, Cubberley R, Davies M, 
Gellatly N, Glavin S, Gouin T,Jacquoilleot S, Moore C, 
Pendlington R, Saib O, Sheffield D, Stark R & 
Summerfield V (2014). Applying the skin sensitisation 
adverse outcome pathway (AOP) to quantitative risk 
assessment. Toxicology In Vitro 28(1): 8-12. 
This article describes the development of two mathematical models (‘total haptenated 
protein’ model and ‘CD8+ T cell response’ model) that will be linked in order to provide 
predictions of the human CD8+ T cell response for a defined skin exposure to a 
sensitising chemical. Using these approaches, authors intended to quantify the correlation 
between the dose of sensitiser applied to the skin and the extent of the hapten-specific T 
cell response that would result. Moreover, using clinical dataset as benchmark points (e.g. 
human diagnostic patch test data) the authors claimed that this approach could represent a 
new paradigm for mechanistic toxicology. 
Mekenyan O, Patlewicz P, Dimitrova G, Kuseva C, 
Todorov M, Stoeva S, Kotov S & Donner EM (2010). 
Use of Genotoxicity Information in the Development of 
Integrated Testing Strategies (ITS) for Skin 
Sensitization. Chemical Research in Toxicology 23: 
1519-1540. 
In this study, the Tissue Metabolism Simulator (TIMES) hybrid expert system was used 
to compare underlying mechanisms of mutagenicity and skin sensitisation. The authors 
concluded that mutagenicity information, when used as part of an integrated testing 
strategy, can provide useful insights on skin sensitisation potential. 
Natsch A, Emter R & Ellis G (2009). Filling the 
concept with data: Integrating data from different in 
vitro and in silico assays on skin sensitizers to explore 
the battery approach for animal-free skin sensitization 
testing. Toxicological Sciences 107(1): 106-121. 
The aim of this paper is to fill for the first time and to use the widely cited “battery 
approach” proposal of Jowsey et al. 2006 with both novel and literature data compilation 
on 116 chemicals. The results were scaled into five classes to give an in vitro score and 
compared to the LLNA results also scaled. Then different ways of data integration were 
explored to rate the hazard of chemicals and to assess their potency. The optimized model 
developed gave an overall accuracy for predicting sensitizers of 87.9%, a sensitivity of 
85.7%, a specificity of 93.8% and showed a linear correlation between LLNA score and 
the in vitro score. However, as suggested by the relatively high variation in the in vitro 
score between chemicals belonging to the same sensitization potency class, the 
correlation need to be improved. 
Nukada Y, Miyazawa M, Kazutoshi S, Sakaguchi H & 
Nishiyama N (2013). Data integration of non-animal 
tests for the development of a test battery to predict the 
skin sensitizing potential and potency of chemicals. 
Toxicology in Vitro 27: 609-618. 
The authors used a dataset of 101 chemicals with LLNA, h-CLAT, DPRA and in silico 
prediction system for the development of a non-animal test battery to predict the skin 
sensitizing potential and potency of chemicals. The results of these studies were scored 
and compared to LLNA data. The sum of individual scores provided the accuracy of 85% 
and 71% for the potential and potency prediction. The second tiered system of h-CLAT 
and DPRA gave 86% and 73%, respectively. It showed a higher sensitivity (96%) 
compared with h-CLAT alone.  These data support that h-CLAT can be a part of a test 
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battery. Moreover, they demonstrate the utility of a tiered system when h-CLAT and 
DPRA are the first screening methods for skin sensitisation.  
Patlewicz P, Mekenyan O, Dimitrova G, Kuseva C, 
Todorov M, Kotov S, Stoeva S & Donner EM (2010). 
Can mutagenicity information be useful in an 
Integrated Testing Strategy (ITS) for skin sensitization? 
SAR and QSAR in Environmental Research 21(7-8): 
619-656. 
In this study, the authors tested the validity of a relationship between in vitro 
mutagenicity information and assessment of skin sensitisation potential using a dataset 
reported by Wolfreys and Basketter (Cutaneous and Ocular Toxicology 23 (2004):197-
205) and the Tissue Metabolism Simulator (TIMES). They concluded that mutagenicity 
information can play a significant role in evaluating sensitisation potential as part of an 
integrated testing strategy. Careful attention needs to be made to ensure that any 
information is interpreted in the appropriate context. 
Patlewicz G, Kuseva C, Kesova A, Popova I, Zhechev 
T, Pavlov T, Roberts DW & Mekenyan O (2014). 
Towards AOP application - Implementation of an 
integrated approach to testing and assessment (IATA) 
into a pipeline tool for skin sensitization. Regulatory 
Toxicology and Pharmacology 69(3): 529-545. 
This article describes the development of an Integrated Approach to Testing and 
Assessment (IATA) for skin sensitisation, implemented into a pipeline tool using OASIS 
technology. It focuses on existing information including non-testing approaches such as 
QSAR and read-across. Assessed with a set of 100 substances, the IATA based on in 
silico and in chemico profiling information showed a preliminary accuracy of 73.5%. 
Including information from other relevant endpoint coupled with a reaction chemistry 
mechanistic understanding, accuracy increased (87.6%). Authors concluded that this 
pipeline platform could be useful in the assessment of skin sensitisation potential. 
van der Veen JW, Rorije E, Emter R, Natsch A, van 
Loveren H & Ezendam J (2014). Evaluating the 
performance of integrated approaches for hazard 
identification of skin sensitizing chemicals. Regulatory 
Toxicology and Pharmacology 69(3): 371-379. 
This article focuses on the comparison between a tiered strategy (including QSAR, 
peptide binding, KeratinoSens/Gene Signature and h-CLAT) and a majority voting 
approach (peptide binding, gene signature or KeratinoSens and h-CLAT). The tiered 
strategy was able to correctly identify all the 41 chemicals tested. Comparing both 
methods, the tiered strategy required less experiments but it is more complex in term of 
different alternative methods required. Costs are similar for both strategies and both 
provide a mechanistic basis for skin sensitisation testing. 
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6. Acute systemic toxicity 
Pilar Prieto & Andrew Worth 
 
 
6.1 The traditional animal test and its regulatory use 
The term acute systemic toxicity comprises the general adverse effects that occur after a 
single or multiple exposure of an animal to a substance within 24 hours and during an 
observation period of at least 14 days. The substance may be administered orally, by 
inhalation or dermally. Currently, acute oral systemic toxicity is assessed in rats 
according to three refinement and reduction alternative methods (modifications of the 
classical LD50 test) described in OECD test guidelines (OECD, 2001a, b, c) and EU Test 
Methods (EC, 2008, EU, 2014). The endpoint measured in these standard assays is 
animal morbidity or death (TG423, EU Test Method B.1 tris, TG425) or evident toxicity 
(TG420, EU Test Method B.1 bis). Clinical signs and conditions associated with pain, 
suffering, and impending death, are described in detail in the OECD Guidance Document 
19 (OECD, 2000). Acute dermal systemic toxicity is assessed according to the classical 
dermal LD50 study (OECD, 1987) and acute inhalation toxicity according to the revised 
version of the classical LC50 study (OECD, 2009a, EU Test Method B.2) and the new 
Acute Toxic Class test guideline (OECD, 2009b, EU Test Method B.52) that allows to 
reduce considerably the number of animals used (6 to 9 animals instead of 40-80 with the 
revised TG 403). One of the main purposes of conducting the test is to categorise 
substances according to their potential hazards and the dose required to cause toxicity 
(i.e. classification and labelling). The use of lethality as an endpoint has long been 
criticised on animal welfare grounds, and the utility of the data generated by acute 
toxicity tests with regard to their ultimate purpose, namely to predict the human hazard 
potential of substances, has also been questioned (Creton et al., 2010; Seidle et al., 2010).  
 
Regulatory requirements for the test vary depending on the type of chemical under 
regulation and the region (Seidle et al., 2010). For cosmetics ingredients and products, 
acute toxicity testing on animals is prohibited in the EU (EC, 2009a), while the test is 
required for industrial chemicals (EC, 2006), biocides (EU, 2012) and plant protection 
products (EC, 2009b; EC, 2013). The pharmaceutical sector has discontinued the use of 
stand-alone acute toxicity studies (ICH, 2009), since it has been shown that they are not 
useful in supporting the first clinical trial in humans (Robinson et al., 2008) and do not 
provide additional value in supporting the management of overdose (Chapman et al., 
2010). In many circumstances, the relevant information can be obtained from other 
studies that are already part of drug development such as short-term or dose range finding 
studies (Robinson et al., 2008, ICH, 2009). 
 
6.2 Mechanistic understanding of the endpoint 
What is our current knowledge about human acute toxicity pathways? Is death induced by 
acute toxic substances the result of specific mechanisms of action involving specific 
molecular targets in certain tissues, or is it due to general cytotoxicity? What about 
sublethal effects? 
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A general conclusion from the Multicenter Evaluation of In Vitro Cytotoxicity (MEIC) 
programme was that the majority of chemicals are acutely toxic to humans by basal 
cytotoxicity, that is, by interfering with general cell functions common to all cells 
(Ekwall, 1999). Mechanisms common to many cell types leading to organ failure include, 
for example, disruption of membrane structure or function, inhibition of mitochondrial 
function, disturbance of protein turnover, and disruption of metabolism and energy 
production.  
 
In an ICCVAM/ECVAM/JaCVAM workshop on acute chemical safety testing (NIH, 
2009) approaches that could help to identify key toxicity pathways for acute oral toxicity 
were discussed. It was agreed that the mechanistic information could be used to develop 
more predictive in vitro test methods and to identify earlier and more humane endpoints 
during in vivo testing. However, a major gap at present is our understanding of all in vivo 
mechanisms of action of chemicals. In vivo omics evaluation was considered a relevant 
approach to assess mechanism of action and to identify biomarkers (Boekelheide and 
Schuppe-Koistinen, 2012). Recently, Liu et al (2013) have integrated the outcome of 
placental mRNA expression analysis and serological proteome profiling to develop 
biomarkers of preeclampsia, a pregnancy-related vascular disorder that is the leading 
cause of maternal morbidity and mortality. Moreover, the collection of as much data as 
possible from the animal study could help to understand modes of action. Information 
from diagnosis and treatment of human poisoning could also contribute to improve our 
understanding and rationale for developing in vitro methods for acute systemic toxicity 
testing. In this regard, the following key events were identified as important to better 
understand the toxicity of chemicals and to better treat human poisonings: general 
cellular function, neuronal transmission (central and peripheral), sodium/potassium 
ATPase function, xenobiotic and aerobic metabolism, cardiac conduction, oxidative 
stress, receptor activity and immune function (NIH, 2009; see section 6.0 of the report).  
 
While the identification of cellular pathways is relevant in understanding the key initial 
interactions (e.g. oxidative stress, loss of membrane function, specific interaction with a 
key receptor), this will not be enough to decipher the subsequent steps involved in acute 
systemic toxicity pathways. Test methods should allow measurements of integrated 
cellular responses (e.g. glutathione concentration, mitochondrial function, cytotoxicity, 
apoptosis, proliferation) or interaction with cellular targets (e.g. over-expression of 
transporters in cell lines, uptake rates into the cells). The assessment of the interactions 
between tissues is another challenge when using in vitro methods (e.g. an inflammatory 
response following toxicity in one organ or remote tissue target). Some recommendations 
of the workshop include the development of MoA-based test methods, the use of human 
cell-based systems, to study the interaction among the affected cellular pathways assessed 
in the developed human cell-models, and to develop tools for determining toxicokinetics 
both in vitro and in vivo. Prediction of in vivo acute toxicity from the activation of 
specific toxicity pathways requires the development of computational systems biology 
approaches, in which a pathway-based point of departure (e.g. significant upregulation of 
mRNA expression of a given gene or gene set) is translated into a corresponding apical 
point of departure (e.g. oral NOAEL) by physiologically-based biokinetic (PBBK) 
modelling. In applying this approach, it is first necessary to identify a toxicologically 
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relevant point of departure at the pathway level, for example, a key event (upstream of 
the apical effect) in an Adverse Outcome Pathway. 
 
Acute toxicity after oral, dermal or inhalation exposure requires that the substance 
becomes bioavailable at the target site, which means that biokinetic factors are also key 
determinants of toxicity (Adler et al., 2011; Coecke et al., 2013). In addition, if the 
damage involves interference with homeostatic signalling mechanisms, non-exposed 
tissues and vital organs can also be affected (Gennari et al., 2004). For example, 
respiratory depression leading to death may be due to depression of the central nervous 
system rather than a direct effect on the respiratory system.  
 
6.3 Status of non-standard methods and Integrated Testing Strategies 
Cytotoxicity assays have been developed and evaluated against in vivo oral LD50 data 
(correlative approaches) and the results of several international projects are published 
(Ekwall, 1999, NIH, 2006, Prieto et al., 2013a; Kinsner-Ovaskainen et al., 2013). The 
overall accuracy of the validated neutral red uptake (NRU) basal cytotoxicity test 
methods when predicting the acute oral toxicity classification categories of the United 
Nations Globally Harmonised System turned out to be low (~30%). Nevertheless, these 
methods have been proposed for use in weight-of-evidence approaches to determine the 
starting dose for acute oral toxicity testing in vivo (NIH, 2006, OECD, 2010). Schrage et 
al (2011) confirmed the low overall concordance of 35% and also reported that the 
prediction of the starting dose for the subsequent in vivo test was useful with regard to 
potential reduction in animal usage for 59% of the 203 substances tested. 
 
A range of Quantitative Structure-Activity Relationships (QSAR) models have been 
developed to predict acute systemic toxicity (LD50 values or classifications) via various 
routes, as reviewed by Lapenna et al (2010). Such models are generally statistically-based 
models, supported by little or no mechanistic rationale, but they may nevertheless be 
predictive for specific chemical classes. In a recent JRC study (Norlén et al, 2012), four 
QSAR models and the 3T3 NRU in vitro prediction model were applied to a dataset of 
180 chemicals. The results showed that the QSAR models have a predictive capacity 
(correlation with LD50 of 49-84%, depending on the model) equivalent to or greater than 
the 3T3 NRU in vitro test (correlation with LD50 of ~50%). Similar predictive 
performances have been obtained in the context of the Antares project 
(http://www.antares-life.eu/; E. Benfenati, personal communication), using a much larger 
dataset of 7420 compounds. In the JRC study, the five methods were also applied in 
combination, but this did not yield a significantly better predictive performance. It did 
however enable the classification of chemicals to be optimised for overall accuracy, 
sensitivity or specificity, according to the end-user’s requirements.  
 
Assuming that most industrial chemicals are not likely to be acutely toxic (Bulgheroni et 
al., 2009), the capacity of the 3T3 NRU cytotoxicity assay to specifically identify non-
classified chemicals on the basis of the 2000 mg/kg b.w. threshold introduced by the EU 
Classification, Labelling and Packaging (CLP) Regulation (EU CLP 2008) has been 
evaluated by EURL ECVAM (Prieto et al, 2013b). The results have shown that the test 
method has a high sensitivity (about 95%) and hence a low false negative rate (less than 
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5%), which means that substances found to be negative (non-classified) in this test would 
most likely not require classification for acute oral toxicity under the CLP Regulation. 
Conversely, the low specificity of the assay (about 42%) means that the test overpredicts 
many negatives as positives (false positive rate of 58%), which means that the test cannot 
be used on its own for the identification of substances requiring classification. When the 
2000 mg/kg threshold was applied to the data set from the NICEATM/ECVAM 
validation study (NIH, 2006) and from Schrage et al., (2011), which cover a wide range 
of chemical uses, a similar high sensitivity and low negative rate was obtained. In the 
light of these results, it is questionable whether many acutely toxic chemicals really act 
via a specific mechanism without also showing any cytotoxicity.  
 
Moreover, Bulgheroni and colleagues (2009) evaluated the possibility to identify non-
toxic substances (those with an LD50 > 2000 mg/kg) from 28-days repeated dose studies 
and set a NOAEL level threshold equal of higher than 200 mg/kg b.w. which allowed to 
correctly identify 63% (913/1436) of the non-toxic substances. Using this threshold, less 
than 1% of harmful compounds were misclassified as non-toxic. Due to the 37% of non-
toxic substances predicted as toxic (false positives) the ability to predict toxic substances 
with this approach is difficult. 
 
The EU FP6 ACuteTox project aimed to develop a non-animal testing strategy for 
predicting human acute oral toxicity by evaluating and combining cytotoxicity assays, 
organ-specific toxicity assays, and biokinetic/metabolism methods (Kinsner-Ovaskainen 
et al., 2013). The outcome of this research project reinforced previous results obtained 
with the 3T3 NRU assay, supporting its use within a tiered testing strategy to identify 
non-classified substances. The results showed that complementing the 3T3 NRU 
cytotoxicity assay with additional target organ specific in vitro assays did not 
significantly improve the classification of compounds in acute oral CLP toxicity 
categories 1-4. However, target organ specific in vitro assays were considered to provide 
added value by alerting for specific toxicity (e.g. neurotoxicity) and further reducing the 
number of under-predictions (Prieto et al., 2013a; Zurich et al., 2013). In general, the 
ACuteTox strategies had a tendency to over-predict toxicity, which was explained by 
their failure to capture in vivo biokinetics (i.e. restricted access to the target tissue, quick 
elimination or detoxification through metabolism). The importance of incorporating 
suitable kinetic parameters in testing strategies for acute oral toxicity is widely 
acknowledged (Adler et al., 2011; Coecke et al., 2012; Blaauboer et al., 2012). 
 
One of the efforts of the European Partnership for Alternative Approaches to Animal 
Testing (EPAA) in the area of acute systemic toxicity is to identify opportunities to avoid 
redundant testing (EPAA, 2010; 2012). The value of acute toxicity testing by more than 
one route has been evaluated in several publications (Indans et al., 1998; Thomas and 
Dewhurst 2007; Seidle et al., 2010; Creton et al., 2010; Seidle et al., 2011; Andrew and 
Wright-Williams, 2011; Moore et al., 2013). These analyses have shown that testing for 
acute dermal toxicity is redundant for substances not classified for acute oral toxicity, 
which casts doubt on the need for acute dermal toxicity as a default information 
requirement in safety assessment and CLP. The data requirements under the recently 
adopted Biocidal Products Regulation (European Union, 2012) state that testing via other 
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routes is only necessary when specified criteria are met. Moreover, the new data 
requirements for plant protection product active substances allow to waive the dermal 
route if scientifically justified e.g. where oral LD50 > 2000 mg/kg (European Comission, 
2013). A document containing the technical progress made in some areas has been 
recently prepared by an EPAA technical expert group with the ultimate goal to invite the 
European Commission to consider similar improvements in other pieces of EU legislation 
(e.g. REACH). The Competent Authorities for REACH and CLP (CARACAL) have 
discussed this proposal to modify REACH standard information requirements for acute 
toxicity and, at the July 2014 meeting, agreed to amend REACH Annex VIII (point 8.5.3) 
so that substances that have not shown oral acute toxicity up to a limit dose of 2000mg/kg 
body weight would not require dermal data. 
 
In addition, the experts of the EPAA project on acute toxicity are discussing ways of 
improving the current animal-based methods to support classification and labelling 
decisions in the agrochemical and chemical sectors. Among the opportunities considered, 
the replacement of lethality as an endpoint with appearance of clinical signs and the use 
of data from e.g. dose range finding studies, could contribute to reduce, refine and/or 
replace the current methods while maintaining human safety, as recognised during a 
workshop held in 2012 (EPAA, 2012). 
 
6.4 Conclusions 
Information on the acute systemic toxicity of chemicals is required for human health risk 
assessments under REACH and the Biocides Products Regulation, and can be used for 
classification and labelling under CLP. 
 
Non-standard methods and ITS for acute systemic toxicity should predict LD50 values or 
official acute toxicity categories, depending on the regulatory application. Ideally, they 
should eventually be predictive of acute toxicity to humans. 
 
Despite considerable research efforts over the past 20 years in the area of acute systemic 
toxicity, a complete mechanistic understanding of the key pathways is lacking, which is 
hampering the development of non-standard methods and AOP-based ITS. The ongoing 
EU FP7 SEURAT-1 research initiative, although focused on alternatives for repeat dose 
toxicity testing, is contributing to our understanding of toxicological modes of action, and 
could also provide innovative methodologies and tools for acute toxicity testing. The 
importance of biokinetic factors is well recognised, and yet there is still a need to further 
evaluate the usefulness of kinetic parameters in the context of ITS. The coupling of 
PBBK models with toxicodynamic models, as a means of predicting toxicologically 
relevant target tissue/organ doses in vivo, is currently being demonstrated in the EU FP7 
COSMOS project. However, such models are available for relatively few chemicals, and 
thus do not support routine safety assessments.  
 
Based on the current status of non-standard methods, it seems reasonable to use basal 
cytotoxicity methods, especially those that have been validated, for the identification of 
negatives (non-classified substances). Due to the limitations of these methods, results 
should always be used in combination with other information sources to build confidence 
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in the decision not to classify a substance for acute oral toxicity (EURL ECVAM, 2013). 
For the classification of acutely toxic substances, in vitro methods and QSARs may be 
suitable, but this would have to be evaluated on a case-by-case basis. To reduce animal 
testing for non-oral routes of exposure, extrapolation from in vivo oral toxicity to dermal 
toxicity is generally expected to be protective. However, the ability to extrapolate from 
the oral to the inhalational routes is less well established. 
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Traditional animal tests – OECD TGs and GD 
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(OECD). 1987. Guideline for Testing of Chemicals, 402, 
Acute Dermal toxicity. OECD Guidelines for the Testing of 
Chemicals, Section 4, OECD Publishing. doi: 
10.1787/9789264070585-en. 
Dermal route. This method is based on the classical LD50 test. 
Organisation for Economic Cooperation and Development 
(OECD). 2000. Guidance document on the recognition, 
assessment, and use of clinical signs as humane endpoints for 
experimental animals used in safety evaluation.  Series on 
Testing and Assessment N°19. Paris, France. Available from: 
http://www.oecd.org. 
The purpose of this Guidance Document is to apply the principles of the Three Rs to the use of 
animals in regulatory toxicity tests. It specifically addresses Refinement. The objective of the 
document is to provide useful guidance and criteria for determining when an animal is in a 
moribund condition, or expected to become moribund, or experiencing significant pain and 
distress, and should therefore be euthanised. The ultimate purpose of the application of humane 
endpoints to toxicology studies is to be able to accurately predict severe pain, severe distress, 
suffering, or impending death, before the animal experiences these effects. 
Organisation for Economic Cooperation and Development 
(OECD). 2001a. Guideline for Testing of Chemicals, 420, 
Acute Oral Toxicity – Fixed Dose Method. OECD Guidelines 
for the Testing of Chemicals, Section 4, OECD Publishing. 
doi: 10.1787/9789264070943-en. 
 
EU Test Method B.1 bis. Acute Oral Toxicity — Fixed Dose 
Procedure 
Oral route. This method is based on a stepwise approach. It does not use lethality as endpoint but 
evident signs of toxicity. It provides an estimated LD50 range. 
Organisation for Economic Cooperation and Development 
(OECD). 2001b. Guideline for Testing of Chemicals, 423, 
Acute Oral Toxicity – Acute Toxic Class Method. OECD 
Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264071001-en. 
 
EU Test Method B.1 tris. Acute Oral Toxicity — Acute Toxic 
Class Method 
Oral route. This method is based on a stepwise approach. It uses lethality as endpoint. It provides 
an estimated LD50 range. 
Organisation for Economic Cooperation and Development 
(OECD). 2001c. Guideline for Testing of Chemicals, 425, 
Acute Oral Toxicity – Up-and-Down Procedure. OECD 
Guidelines for the Testing of Chemicals, Section 4, OECD 
Oral route. This method is based on a stepwise approach. It uses lethality as endpoint. It provides 
LD50 point estimate with confidence intervals. 
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Organisation for Economic Cooperation and Development 
(OECD). 2009a. Guideline for Testing of Chemicals, 403, 
Acute Inhalation Toxicity. OECD Guidelines for the Testing of 
Chemicals, Section 4, OECD Publishing. doi: 
10.1787/9789264070608-en 
 
EU Test Method B.2 Acute Inhalation Toxicity 
Inhalation route. This revised Test Guideline describes the traditional LC50 protocol and a 
Concentration x Time (C x t) protocol. It can be used to estimate a median lethal concentration 
(LC50), non-lethal threshold concentration (LC01) and slope, and to identify possible sex 
susceptibility 
Organisation for Economic Cooperation and Development 
(OECD). 2009b. Guideline for Testing of Chemicals, 436, 
Acute Inhalation Toxicity – Acute Toxic Class Method. OECD 
Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264076037-en. 
 
EU Test Method B.52. Acute Inhalation Toxicity — Acute 
Toxic Class Method 
Inhalation route. The test method is based on a stepwise procedure, each step using 3 animals of 
each sex (the preferred species is rat). Animals are exposed in inhalation chambers to a pre-defined 
concentration for 4 hours. 
Organisation for Economic Cooperation and Development 
(OECD). 2010. Guidance Document No 129 on using 
Cytotoxicity Tests to Estimate Starting Doses for Acute Oral 
Systemic Toxicity Tests. Paris, France. Available from: 
http://www.oecd.org 
This guidance document describes methods to determine the in vitro basal cytotoxicity of test 
substances and to use these in vitro data to estimate the starting dose for the acute oral in vivo test. 
 
Regulatory requirements across sectors  
European Commission, 2006. Regulation (EC) No 1907/2006 
of the European Parliament and the Council of 18 December 
2006 concerning the Registration, Evaluation, Authorisation 
and Restriction of Chemicals (REACH), establishing a 
European Chemicals Agency, amending Directive 1999/45/EC 
and repealing Council Regulation (EEC) No 793/93 and 
Commission Regulation (EC) No 1488/94 as well as Council 
Directive 76/769/EEC and Commission Directives 
91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Official 
Journal of the European Union L396, 1-849. 
Chemicals: Information requirements depend on the production volume of the chemical concerned: 
• Annex VII (1-10 tpa): acute toxicity by the oral route. 
o The study/ies do(es) not generally need to be conducted if the substance is 
classified as corrosive to the skin or if a study on acute toxicity by the inhalation 
route is available. 
• Annex VIII-X (10->1000 tpa): In addition to the oral route, for substances other than 
gases, the information shall be provided for at least one other route. The choice for the 
second route will depend on the nature of the substance and the likely route of human 
exposure. If there is only one route of exposure, information for only that route need to be 
provided. 
o Testing by the inhalation route is appropriate if exposure of humans via inhalation 
is likely taking into account the vapour pressure of the substance and/or the 
possibility of exposure to aerosols, particles or droplets of an inhalable size. 
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o Testing by the dermal route is appropriate if: (1) inhalation of the substance is 
unlikely; and (2) skin contact in production and/or use is likely; and (3) the 
physicochemical and toxicological properties suggest potential for a significant 
rate of absorption through the skin. 
European Union, 2008. Council Regulation (EC) No 440/2008 
of 30 May 2008 laying down test methods pursuant to 
Regulation (EC) No 1907/2006 of the European Parliament 
and of the Council on the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) 
AND 
European Union, 2014. Commission Regulation (EU) No 
260/2014 of 24 January 2014 amending, for the purpose of its 
adaptation to technical progress, Regulation (EC) No 440/2008 
laying down test methods pursuant to Regulation (EC) No 
1907/2006 of the European Parliament and of the Council on 
the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH). Official Journal of the European Union 
L 81, 1-253 
The Regulation of May 2008 and its subsequent amendments, define tests testing of chemicals for 
the REACH Regulation. They are based on the OECD Guidelines for the Testing of Chemicals. 
 
The January 2014 adaptation contains, among others, nine methods for the determination of 
toxicity and other health effects including four inhalation toxicity test methods, which include an 
update of three methods and one new method to reduce the number of animals used and to improve 
assessment of effects, an update of the repeat dose 28-day oral toxicity test method to include 
parameters for assessment of endocrine activity, an update of the toxicokinetics test method 
relevant for the design and understanding of toxicological studies and an update of chronic, 
carcinogenicity and combined chronic and carcinogenicity test methods.  
European Commission, 2008. Regulation (EC) No 1272/2008 
of the European Parliament and of the Council of 16 December 
2008 on classification, labelling and packaging of substances 
and mixtures, amending and repealing Directives 67/548/EEC 
and 1999/45/EC, and amending Regulation (EC) No 
1907/2006. Official Journal of the European Union L353. 
EU CLP Regulation 
Substances can be allocated to one of four toxicity categories based on acute toxicity by the oral, 
dermal or inhalation route according to the numeric criteria. 
 
Robinson, S., Delongeas, J.L., Donald, E., Dreher, D., Festag, 
M., Kervyn, S., Lampo, A., Nahas, K., Nogues, V., Ockert, D., 
Quinn, K., Old, S., Pickersgill, N., Somers, K., Stark, C., Stei, 
P., Waterson, L., Chapman, K., 2008. A European 
pharmaceutical company initiative challenging the regulatory 
requirement for acute toxicity studies in pharmaceutical drug 
development. Regul. Toxicol. Pharmacol. 50, 345-352. 
This paper describes the results of an evidence-based review of acute toxicity studies undertaken 
by 13 European pharmaceutical companies and 3 research organisations, aimed to assess the value 
of the data generated. The two main objectives were to review how acute toxicity data were 
gathered and used across the pharmaceutical industry and to develop a strategy for challenging the 
guidelines on the requirement for acute toxicity where lethality is an endpoint. The ultimate 
objective was to assess the usefulness of acute toxicity in the drug development process and to 
provide recommendations for alternative strategies that use information derived from other studies. 
The group concluded that acute toxicity studies are not needed prior to first clinical trial in 
humans. As a direct result of this work, the requirement for acute toxicity data prior to first in man 
clinical trials has been removed from ICH M3 guidelines. 
European Commission, 2009a. Regulation (EC) No 1223/2009 Cosmetics: This Regulation establishes rules to be complied with by any cosmetic product made 
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of the European Parliament and the Council of 30 November 
2009 on cosmetic products. Official Journal of the European 
Union L342, 59-209. 
 
available on the market, in order to ensure the functioning of the internal market and a high level 
of protection of human health.  
Article 18 (Animal testing) 
European Commission, 2009b. Regulation (EC) No 1107/2009 
of the European Parliament and of the Council of 21 October 
2009 concerning the placing of plant protection products on 
the market and repealing Council Directives 79/117/EEC and 
91/414/EEC. Official Journal of the European Union L309, 1-
47. 
AND 
Commission Regulation, 2013. Regulation (EU) No 283/2013 
of 1 March 2013 setting out the data requirements for active 
substances, in accordance with Regulation (EC) No 1107/2009 
of the European Parliament and of the Council concerning the 
placing of plant protection products on the market 
Plant Protection Products: 
• The acute oral toxicity of the active substance shall always be reported.  
• The acute dermal toxicity of the active substance shall be reported unless waiving is 
scientifically justified (for example where oral LD50 is greater than 2000 mg/kg). Both 
local and systemic effects shall be investigated.  
• The acute inhalation toxicity of the active substance shall be reported where any of the 
following apply: 
o the active substance has a vapour pressure > 1 × 10 –2 Pa at 20 °C; 
o the active substance is a powder containing a significant proportion of particles of 
a diameter < 50 μm ( > 1 % on weight basis); 
o the active substance is included in products that are powders or are applied by 
spraying 
ICH, 2009. International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals 
for Human Use. Guidance on Nonclinical Safety Studies for 
the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals M3(R2). Recommended for 
Adoption at Step 4 of the ICH Process on June 11, 2009. 
Pharmaceuticals: Acute toxicity data prior to first in man clinical trials are not any longer 
required. When the acute toxicity information is available from any study, separate single-dose 
studies are not recommended. Studies providing acute toxicity information can be limited to the 
clinical route only and such data can be obtained from non-GLP studies if clinical administration is 
supported by appropriate GLP repeated-dose toxicity studies. Lethality should not be an intended 
endpoint in studies assessing acute toxicity. 
Chapman, K., Creton, S., Kupferschmidt, H., Bond, G.R., 
Wilks, M.F., Robinson, S., 2010. The value of acute toxicity 
studies to support the clinical management of overdose and 
poisoning: a cross-discipline consensus. Regul. Toxicol. 
Pharmacol. 58(3):354-9. 
This paper describes the outcome of a workshop aimed to explore whether data from acute toxicity 
studies are used by clinicians and Poison Centres to assess and treat human overdoses and 
poisoning. The key conclusions were the following:  
• Acute toxicity studies do not provide information to clinicians on how to treat poisoning and 
overdose patients for pharmaceutical and non-pharmaceutical chemicals. 
• Human data are of most value to Poison Centres in informing treatment of overdose and 
poisoning. 
• More useful animal toxicity data could be obtained from nonlethal studies that are already 
carried out as part of the product development process. 
• In sectors where acute toxicity may be the only systemic toxicity study performed, the value of 
such studies could be maximised by improving the design. 
• There is little differentiation in hazard statements and treatment advice between classification 
and labelling categories and therefore this is of no value in the specific management of 
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poisoning. 
The consensus formed at the workshop was that acute toxicity studies are not used for managing 
overdose of pharmaceuticals and are of little value to treat human poisoning from chemicals. This 
was the last remaining driver for acute toxicity studies for pharmaceuticals and it has been 
removed. 
European Union, 2012. Regulation (EU) No 528/2012 of the 
European Parliament and of the Council of 22 May 2012 
concerning the making available on the market and use of 
biocidal products. Official Journal of the European Union L 
167, 1-116. 
Biocides: Annex II, Data Requirement 8.7 (acute toxicity): in addition to the oral route testing via 
other routes is only necessary when specified criteria are met.  
for chemical Active Substances: ‘Before a new dermal acute toxicity study is carried out, an in 
vitro dermal penetration study (OECD 428) should be conducted to assess the likely magnitude 
and rate of dermal bioavailability’.  
 
Testing by the dermal route is necessary only if: ‘inhalation of the substance is unlikely; or skin 
contact in production and/or use is likely; and either the physicochemical and toxicological 
properties suggest potential for a significant rate of absorption through the skin; or the results of 
an in vitro dermal penetration study (OECD 428) demonstrate high dermal absorption and 
bioavailability’. 
Mechanistic understanding 
Ekwall B., 1999. Overview of the Final MEIC Results: II. The 
In Vitro--In Vivo Evaluation, Including the Selection of a 
Practical Battery of Cell Tests for Prediction of Acute Lethal 
Blood Concentrations in Humans. Toxicology In Vitro 13 (4-
5):665-73. 
This paper provides an overview of the results of the Multicenter Evaluation of In Vitro 
Cytotoxicity 7-year programme that was set up by the Scandinavian Society of Cell Toxicology 
with the main goal of evaluating the relevance of in vitro toxicity assays for human acute toxicity. 
Fifty chemicals were tested in 29 laboratories in 61 cytotoxicity assays. The basal cytotoxicity 
hypothesis claims that a) a majority of chemicals cause lethal toxicity in humans by interfering 
with functions common to all human cells, b) basal cytotoxicity can be tested in undifferentiated 
cell lines (preferably of human origin), c) only a fraction of the IC50 for cell lines will led to human 
lethality through functional interference with vital neurons in the brain, d) the basal cytotoxicity is 
a baseline minimal toxicity for all chemicals – thus, cell tests will not give false positive results. 
The correlative/mechanistic in vitro/in vivo evaluation of the results supported the four hypotheses. 
Gennari A, van den Berghe C, Casati S, Castell J, et al., 2004. 
Strategies to replace in vivo acute systemic toxicity testing. 
The report and recommendations of ECVAM Workshop 50. 
ECVAM Workshop 50. Altern Lab Anim. 2004 32(4):437-59. 
This report reviews the state-of-the-art of in vitro methods for estimating acute systemic toxicity 
and to develop research, development and validation strategies necessary for the replacement of in 
vivo testing with a focus on the oral route of exposure. The workshop participants developed a list 
of potential susceptible targets that are common to many cell types and that could serve as in vitro 
endpoints for acute toxicity. Kidney, liver, central nervous system, cardiovascular system, 
lung/respiratory system, blood and the gastrointestinal tract were identified as the main organ 
systems known to be susceptible to acute toxicity resulting in lethality. The susceptible function 
for each organ was also identified. An attempt was also made to identify the common 
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physiological processes and the assay systems for quantifying specific endpoints related to each of 
them. The main outcome of the workshop was to suggest the development of an integrated testing 
strategy based on the use of physicochemical properties, in vitro-in vivo data, computational 
methods, basal cytotoxicity assays and complementary assays for metabolisms, transport, kinetics 
and target organ toxicity. 
National Institutes of Health (NIH), 2009. The report on the 
ICCVAM-NICEATM/ECVAM/JaCVAM Scientific 
Workshop on Acute Chemical Safety Testing: Advancing In 
Vitro Approaches and Humane Endpoints for Systemic 
Toxicity Evaluations. Available from:  
http://iccvam.niehs.nih.gov/docs/acutetox_docs/Workshop-
Feb09/AcuteWkspRpt.pdf 
The development of alternative test methods and subsequent replacement of animals in acute oral 
toxicity testing calls for a better understanding of critical toxicity pathways. The scientific 
workshop on acute chemical safety testing contributed to this proof-of-concept by developing 
approaches to identify the key toxicity pathways for acute systemic toxicity. The participants 
discussed (a) the current understanding of key pathways for in vivo acute systemic toxicity and 
identified knowledge gaps, (b) the current acute systemic toxicity injury and toxicity assessment, 
(c) earlier humane endpoints for acute systemic toxicity, (d) the application of in vitro mode of 
action and mechanistic information to the development and validation of in vitro methods for 
assessing acute systemic toxicity, and (e) industry involvement in test method development, 
validation and use. The workshop suggested that the mechanistic information could be used to 
develop predictive in vitro alternative test methods and might also help to identify predictive 
biomarkers of systemic toxicity for use as earlier, more humane endpoints during in vivo tests, 
thereby reducing pain and distress. 
Boekelheide K & Schuppe-Koistinen I. 2012. 
SOT/EUROTOX debate: biomarkers from blood and urine will 
replace traditional histopathological evaluation to determine 
adverse responses. Toxicol Sci. 129(2): 249-55. 
The 2011 SOT/EUROTOX debate addressed the proposition that “Biomarkers From Blood and 
Urine will Replace Traditional Histopathological Evaluation to Determine Adverse Responses,” 
identifying and comparing the strengths and limitations of histopathology and serum and urine 
biomarkers. This article discusses the uses and the limitations of having a gold standard, how 
adverse responses are determined, the evolutionary (as opposed to revolutionary) process by which 
one technology is typically replaced by another, and the overall goal of developing biomarkers 
which can translate from preclinical safety assessment to clinical utility. The ultimate purpose is to 
help researchers and regulators understand the challenges they face in the development and 
integration of new and existing biomarkers to determine adverse responses.  
• Biomarkers have been used in clinical diagnosis and drug development for decades to measure 
physiological parameters such as blood pressure, heart rate, body temperature, and urine color, 
and clinical chemistry parameters such as enzymes in blood and urine, serum creatinine levels, 
and urinary glucose.  
• Advances in molecular biology and analytical technologies have enabled the discovery of 
novel biomarkers which include individual genes, transcripts, proteins, and endogenous 
metabolites (including lipids), and their associated patterns of expression. Other examples 
include the use of imaging patterns, electrical signals, and cell levels in body fluids to identify 
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potential concern.  
• Today, it is technically feasible to identify tissue-specific markers through the use of these –
omics technologies by integrating and correlating toxicology data. These changes in gene, 
protein, and metabolite expressions are consistent, sensitive, and early, and provide the 
molecular basis of drug-induced injuries. The genomic-derived candidate markers can then be 
localized to organs using in situ hybridization and immunohistochemistry for their proteins. 
The perturbations at the transcript level are mirrored on the protein level and subsequently 
secreted into body fluids where they can be measured. 
• The use of safety biomarkers is increasing the confidence of decision making in drug research 
and development; early-stage projects can be pulled from development more quickly, and late-
stage projects become less risky when translational safety biomarker data provide the clarity, 
the predictability, and the possibility to monitor drug-induced toxicity. New technologies and 
molecular approaches, including molecular profiling and molecular pathology as a complement 
to the classical toolbox, promise a future of further discoveries and improvements in the safety 
biomarker field. 
Liu LY, Yang T, Ji J, Wen Q, Morgan AA, Jin B, Chen G, 
Lyell DJ, Stevenson DK, Ling XB, Butte AJ., 2013. 
Integrating multiple 'omics' analyses identifies serological 
protein biomarkers for preeclampsia. BMC Med. 11(1): 236. 
The authors have employed a comprehensive unbiased multi-’omics’ approach, integrating results 
from microarray multiplex analysis and proteomic identification by two-dimensional gel analysis 
with the ultimate aim of discovering diagnostic biomarkers for preeclampsia (PE), a multifactorial 
disease for which it is likely unrealistic that a single biomarker could be used for diagnoses. They 
have used a novel concept: combining a transcriptomic approach in placenta tissue (closer to the 
focus of the pathophysiology) with a proteomic approach in serum (which is more appropriate for 
clinical use). In addition to the previously identified biomarkers, the authors found 3 up-regulated 
and 6 down-regulated biomakers in PE sera. Two optimal biomarker panels were developed for 
early and late onset PE assessment, respectively. The functional significance of these PE 
biomarkers and their associated pathways were also analysed, which may provide new insights 
into the pathogenesis of PE. 
Biokinetic considerations 
Adler, S., Basketter, D., Creton, S., et al., 2011. Alternative 
(non-animal) methods for cosmetics testing: current status and 
future prospects-2010. Arch. Toxicol. 85(5):367-485. 
This report provides an analysis made by a panel of experts of the status and prospects of 
alternative methods in five toxicological areas of concern in view of the full marketing ban 
foreseen for 2013 for cosmetics products and ingredients tested on animals in Europe. The report 
includes five chapters dealing with toxicokinetics, skin sensitisation, repeated dose toxicity, 
carcinogenicity and reproductive toxicity. 
Information on toxicokinetics is indispensable for the development and design of more efficient 
strategies, for in vitro-in vivo extrapolation, and for the identification of clearance and the role of 
metabolites. 
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Blaauboer, B.J., Boekelheide, K., Clewell, H.J., Daneshian, 
M., Dingemans, M.M., Goldberg, A.M., Heneweer, M., 
Jaworska, J., Kramer, N.I., Leist, M., Seibert, H., Testai, E., 
Vandebriel, R.J., Yager, J.D., Zurlo, J., 2012. The use of 
biomarkers of toxicity for integrating in vitro hazard estimates 
into risk assessment for humans. ALTEX 29(4):411-25. 
This report presents the results of a workshop aimed at better defining the use of in vitro-derived 
biomarkers of toxicity and determining the place these data can have in human risk assessment. As 
a result, a conceptual framework is presented for the incorporation of in vitro-derived toxicity data 
into the risk assessment process. The implementation of the proposed framework requires the 
collection and collation of data from existing literature and new in vitro test systems, as well as the 
categorization of biomarkers of toxicity and their relation to pathways-of-toxicity. Data selection 
and integration need to be also driven by their usefulness in a quantitative in vitro-in vivo 
extrapolation. 
Coecke, S., Pelkonen, O., Leite, S.B., Bernauer, U., Bessems, 
J.G., Bois, F.Y., Gundert-Remy, U., Loizou, G., Testai, E., 
Zaldívar, J.M., 2013. Toxicokinetics as a key to the integrated 
toxicity risk assessment based primarily on non-animal 
approaches. Toxicol. In Vitro 27(5):1570-7. 
This paper discusses the importance of toxicokinetics as a key element to integrate the results from 
in silico, in vitro and already available in vivo studies, in particular when non-animal testing 
approaches need to be implemented. Toxicokinetics is needed to estimate the range of target organ 
doses that can be expected from realistic human external exposure scenarios. This information is 
crucial for determining the dose/concentration range that should be used for in vitro testing. 
Toxicokinetics is necessary to convert the in vitro results, generated at tissue/cell or sub-cellular 
level, into dose response or potency information relating to the entire target organism, i.e. the 
human body (in vitro–in vivo extrapolation, IVIVE). 
In vitro NRU cytotoxicity assays 
National Institutes of Health (NIH), 2006. Background Review 
Document (BRD): Validation of Neutral Red Uptake Test 
Methods NIH /In Vitro Cytotoxicity Test Methods for 
Estimating Acute Oral Systemic Toxicity. Publication No. 07-
4518, November 2006. Available from: 
http://iccvam.niehs.nih.gov/methods/acutetox/inv_nru_brd.htm 
This report provides an overview of the in vitro cytotoxicity data generated during the 
NICEATM/ECVAM In Vitro Cytotoxicity Validation Study to predict rodent in vivo LD50 values 
and starting doses for acute oral systemic toxicity test methods. The in vitro tests evaluated used 
rodent (mouse fibroblast [3T3]) and human (normal human epidermal keratinocyte [NHK]) cells. 
The validation study had the following objectives: a) to further standardise and optimise the in 
vitro basal cytotoxicity protocols to maximize test reliability (intra- and inter-laboratory 
reproducibility); b) to assess the accuracy of the standardised in vitro cytotoxicity test methods for 
estimating rodent oral LD50 values across the five UN GHS categories of acute oral systemic 
toxicity, as well as unclassified toxicities; c) to estimate the reduction and refinement in animal use 
achievable from using the in vitro basal cytotoxicity test methods to identify starting doses for in 
vivo acute oral systemic toxicity tests; d) to develop databases containing high quality data from in 
vivo acute oral lethality and in vitro basal cytotoxicity tests that can be used to support the 
investigation of other in vitro test methods necessary to improve the prediction of in vivo acute oral 
lethality. 
 
An independent scientific review panel evaluated the validation status of the 3T3 and NHK basal 
cytotoxicity test methods for use as adjuncts to in vivo acute oral systemic toxicity tests for the 
purpose of determining starting doses and concluded that they should be considered for use in a 
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weight-of-evidence approach to determine starting doses for acute oral systemic toxicity test 
methods (i.e., the Up-and-Down Procedure and the Acute Toxic Class method) to reduce the use of 
animals required for these methods. The panel also concluded that these in vitro cytotoxicity test 
methods could not be used to determine the hazard classification of chemicals.  
Schrage, A., Hempel, K., Schulz, M., Kolle, S.N., van 
Ravenzwaay, B., Landsiedel, R., 2011. Refinement and 
Reduction of Acute Oral Toxicity Testing: A Critical Review 
of the Use of Cytotoxicity Data. Alt. Lab. Anim. 39:273-295. 
This paper shows an analysis aimed to estimate the value of the 3T3 NRU in vitro method for 
predicting the in vivo acute oral classification and for predicting the starting dose for the 
subsequent in vivo test. The authors also calculated the animal numbers required in each instance, 
in order to estimate possible reductions in animal use. Additionally, they tried to identify specific 
applicability domains, hoping to improve the predictivity of the cytotoxicity test.  
Two hundred and two substances (187 of which were BASF in-house substances) including a 
broad variety of chemicals, agrochemicals and formulations were tested. The overall capacity of 
the 3T3 NRU uptake to predict the EU-GHS acute oral toxicity categories was low (35%), while a 
good concordance of 74%, was obtained only for the weakly toxic substances (EU-GHS Cat. 4). 
The estimation of the starting dose by the cytotoxicity test was useful for 59% of the substances. 
However, the use of a standard starting dose of 300mg/kg b.w. by default would have been almost 
as useful (50%). In contrast, the prediction by an experienced toxicologist was correct for 95% of 
the substances. However, this was only performed for 40% of the substances, mainly those of no to 
low toxicity. The outcome supports the argument that 3T3 NRU cytotoxicity data cannot be used 
as stand alone to assess the acute oral toxicity of test substances. 
EURL ECVAM recommendation on the 3T3 Neutral Red 
Uptake (3T3 NRU) Cytotoxicity Assay for the Identification of 
Substances not Requiring Classification for Acute Oral 
Toxicity.  
Available from: http://ihcp.jrc.ec.europa.eu/our_labs/eurl-
ecvam/eurl-ecvam-recommendations 
 
The 3T3 NRU test method could prove a valuable component of a WoE or ITS approach for 
supporting hazard identification and safety assessment in agreement with the EU CLP Regulation 
and international regulatory schemes implementing the upper threshold of UN GHS Category 4 as 
the cut-off for non-classification of substances. In particular, data from the 3T3 NRU assay may 
constitute an information source within a WoE approach under the provisions of the REACH 
regulation (Annex XI, 1.2) potentially supporting conclusions on absence of acute oral toxicity of 
industrial chemicals. 
 
(1) Considering the results of the EURL ECVAM study and the data available from the 
previous NICEATM/EURL ECVAM validation study (NIH, 2006), the 3T3 NRU test method 
shows a high sensitivity (ca 95%) and, consequently, a low false negative rate (ca 5%) when 
employed in conjunction with a prediction model to distinguish potentially toxic versus non-toxic 
(i.e. classified versus non-classified) substances. Therefore, substances found to be negative in this 
test would most likely not require classification for acute oral toxicity based on a cut-off value of 
>2000 mg / kg b.w.. Concluding on likely non-classification however requires careful 
consideration of the limitations of the assay (see points 2 and 3). 
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(2) The 3T3 NRU test method is sensitive to hazardous chemicals acting through general 
mechanisms of toxicity common to most cell types, often referred to as 'basal cytotoxicity'. 
However, chemicals not exhibiting significant cytotoxicity but which act through mechanisms 
specific only to certain cell types and tissues (e.g. of the heart or central nervous system) may not 
be indicated as potentially acutely toxic by this method. Moreover, chemicals requiring metabolic 
activation to induce toxicity may also go undetected since the cell model lacks significant 
metabolic capacity. Care must be taken therefore in interpreting negative results derived from this 
assay, despite the low false negative rate demonstrated in the EURL ECVAM validation study. 
(3) Considering its limitations, results derived from the 3T3 NRU test method should be 
always used in combination with other information sources to build confidence in the decision not 
to classify a substance for acute oral toxicity. Possible complementary information sources include 
chemical analogues, physico-chemical properties, structural alerts, structure–activity relationships, 
and toxicokinetic data. The 3T3 NRU method would fit well therefore within a Weight of 
Evidence (WoE) approach or as a component of an Integrated Testing Strategy (ITS). 
(4) The 3T3 NRU test method appears to be particularly relevant for the assessment of 
industrial chemicals since they are not designed to act on specific biological targets and in general 
tend not to be acutely toxic. Moreover, industrial chemicals which do exhibit toxicity are likely to 
act through multiple non-specific mechanisms that affect most cell types (i.e. basal cytotoxicity). 
Following the provisions of the REACH Regulation (1907/2006/EU) and in particular its Annex 
XI, data from the 3T3 NRU test method could be used within a WoE approach to adapt the 
standard information requirements. 
(5) The 3T3 NRU test method has a high false positive rate therefore positive results cannot 
be readily used in a meaningful way. A likely reason is that the test method does not capture 
important biokinetic processes such as absorption, distribution, metabolism and excretion. Thus, 
certain chemicals, despite having cytotoxic potential, may not actually be acutely toxic via the oral 
route. 
(6) As this test method informs about basal cytotoxicity which is a key event in many 
prevalent toxicological modes-of-action associated with both acute and chronic health effects, and 
since the EURL ECVAM validation study has shown the method to be amenable to automation 
and High Throughput Screening (HTS), it may constitute a valuable and economical information 
source for hazard profiling of substances. 
(7) Respecting the provisions of Directive 2010/63/EU on the protection of animals used for 
scientific purposes, before embarking on animal experiments to identify acute oral toxicity the 3T3 
NRU test method should be considered as an initial screening tool together with complimentary 
information in order to possibly reduce or avoid animal testing. 
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Prieto, P., Curren, R., Gibson, R.M., Raabe, H., Tuomainen, 
A.M., Whelan, M., Kinsner-Ovaskainen, A., 2013b. 
Assessment of the predictive capacity of the 3T3 neutral red 
uptake cytotoxicity test method to identify substances not 
classified for acute oral toxicity (LD50 > 2000 mg/kg): results 
of an ECVAM validation study, Regulatory Toxicology and 
Pharmacology 65(3): 344-365. 
This paper describes the results of a validation study that was organised to assess if the 3T3 
Neutral Red Uptake cytotoxicity assay could identify substances not requiring classification as 
acute oral toxicants under the EU regulations. Fifty six coded industrial chemicals were tested. The 
assay exhibited high sensitivity (92-96%) but relatively low specificity (40-44%). The false 
negative rate was very low (ca 5%) and only three chemicals were under predicted. Assuming that 
most industrial chemicals are not likely to be acutely toxic, this test method could prove a valuable 
component of an integrated testing strategy, a read-across argument, or weight-of-evidence 
approach to identify non toxic chemicals (LD50 > 2000 mg/kg). However, it is likely to under 
predict chemicals not exhibiting significant cytotoxicity but which act through mechanisms 
specific to certain cell types and tissues (e.g. of the heart or central nervous system) not captured 
by the 3T3 test system, or which first require biotransformation in vivo. 
QSARs  
Lapenna S, Fuart-Gatnik M & Worth A (2010). Review of 
QSAR Models and Software Tools for predicting Acute and 
Chronic Systemic Toxicity. JRC Scientific and Technical 
Report. EUR 24639 EN. Available from: 
http://publications.jrc.ec.europa.eu/repository/ 
This JRC report provides a review of different computational estimation methods for predicting 
acute and chronic systemic toxicity. It provides an overview of Quantitative Structure-Activity 
Relationship (QSAR) models published in the literature, commonly used software tools, and 
available databases suitable for QSAR analysis. It also briefly explains the Threshold of 
Toxicological Concern (TTC) concept and how this is used in prioritising chemicals for further 
assessment and preliminary risk characterisation. 
Norlén H, Berggren E, Whelan M & Worth A (2013). An 
investigation into the use of computational and in vitro 
methods for acute systemic toxicity prediction. JRC Scientific 
and Technical Report. EUR 25473 EN. Available from: 
http://publications.jrc.ec.europa.eu/repository/ 
This report describes a JRC study on the abilities of five alternative approaches to predict acute 
oral toxicity. The authors investigated four QSAR models (ToxSuite, TOPKAT, TEST and 
ADMET Predictor) and one in vitro method (3T3 NRU). Based on a test set of in vitro and in vivo 
data for 180 compounds, they characterized the predictive performance of each method when used 
alone (both for LD50 prediction and acute toxicity classification into three categories), as well as 
multiple test combinations (batteries) and stepwise testing strategies (for acute toxicity 
classification into three categories). When used individually, the alternative methods showed an 
ability to predict LD50 with correlation coefficients in the range from 49% to 84%, and to classify 
into three toxicity groups with accuracies in the range from 41% to 72%. When the alternative 
methods were combined into batteries or testing strategies, the overall accuracy of prediction could 
reach 76%. The authors also illustrate how different combinations of methods can be used to 
optimize sensitivity or specificity. 
 
Testing strategies – Results from the EU FP6 Project ACuteTox aimed at the development of non-animal testing strategies for predicting human acute oral 
toxicity 
 
Kinsner-Ovaskainen, A., Prieto, P., Stanzel, S., Kopp- This paper describes the methods used for statistical evaluation of concentration-response data 
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Schneider, A. 2013. Selection of test methods to be included in 
a testing strategy to predict acute oral toxicity: an approach 
based on statistical analysis of data collected in phase 1 of the 
ACuteTox project. Toxicology In Vitro 27(4): 1377-1394 
collected for each of the endpoint assays used in the first phase of the ACuteTox project (assessing 
specific organ- and system-toxicity, such as haemato-, neuro-, nephro- and hepatotoxicity, as well 
as intestinal absorption, distribution and metabolism), and for the development of a testing strategy 
applicable for acute oral toxicity classification of chemicals based on the achieved results of the 
concentration-response analysis. The final list of in vitro test methods considered to be promising 
candidates for building blocks of the testing strategy is presented. 
Prieto, P., Kinsner-Ovaskainen, A., Stanzel, et al., 2013a. The 
value of selected in vitro and in silico methods to predict acute 
oral toxicity in a regulatory context: Results from the European 
Project ACuteTox. Toxicol In Vitro 27(4): 357-376. 
 
This paper describes the classification approaches studied in the ACuteTox project (single step 
procedures and two step tiered testing strategies) to evaluate the capacity of several competing 
non-animal testing strategies to correctly classify compounds into the four EU CLP acute oral 
toxicity categories and the non-classified. In summary, four in vitro testing strategies were 
proposed as best performing. In addition, a heuristic testing strategy is suggested that combines the 
prediction results gained from the 3T3 NRU cytotoxicity assay, with information on neurotoxicity 
alerts identified by the primary rat brain aggregates test method. Octanol–water partition 
coefficients and in silico prediction of intestinal absorption and blood–brain barrier passage were 
also considered. This approach allowed to reduce the number of chemicals wrongly predicted as 
non-classified (oral LD50 > 2000 mg/kg b.w.). 
Zurich MG, Stanzel S, Kopp-Schneider A, Prieto P, Honegger 
P., 2013. Evaluation of aggregating brain cell cultures for the 
detection of acute organ-specific toxicity. Toxicol. In Vitro, 
27(4): 1416–1424 
Primary aggregating brain cell cultures (AGGR) were examined for their capability to detect 
organ-specific toxicity apparently missed by using the 3T3 NRU in vitro cytotoxicity assay. The 
lowest observed effect concentration determined for each chemical (86 chemicals tested) was 
compared with the IC20 reported for the 3T3 NRU cytotoxicity assay. The results showed that the 
frequency of alerts increased with the level of toxicity observed in AGGR. The overall findings 
suggest that AGGR are suitable for the detection of organ-specific toxicity and that they could, in 
conjunction with the 3T3 NRU cytotoxicity assay, improve the predictive capacity of in vitro 
toxicity testing. 
Estimation of not-classified chemicals from repeat dose studies 
Bulgheroni, A., Kinsner-Ovaskainen, A., Hoffmann, S., 
Hartung, T., Prieto, P., 2009. Estimation of acute oral toxicity 
using the No Adverse Effect Level (NOAEL) from the 28-day 
repeated dose toxicity studies in rats. Regulatory Toxicology 
and Pharmacology 53: 16-19. 
 
This paper proposes an approach to identify non toxic compounds (oral LD50 > 2000 mg/kg) using 
information from 28 days repeated dose toxicity studies. The data used in this study were retrieved 
from the New Chemical Database (NCD). This database was accessed on 27th March 2008. Of 
7200 notifications since 1981, 4773 substances were found of which 4219 included oral toxicity 
data. The prevalence of the different oral acute toxicity classes was analysed within the new 
chemicals notified in the NCD and a high prevalence of non-toxic substances (87%) was found. It 
was possible to set a NOAEL threshold of ≥ 200 mg/kg that allowed the correct identification of 
63% of non-toxic compounds, while <1% of harmful compounds were misclassified as non-toxic. 
This approach could be useful under REACH and other chemical assessment programs where the 
28-day study is legally required. 
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Redundant testing – waiving possibilities 
Indans, I., Fry, T., Parsons, P., Evans, P., 1998. Classification 
and labelling of new industrial chemicals for acute toxicity, 
skin and eye irritation. Hum ExpToxicol 17: abstract 529. 
This report uses information from a base set of 438 notifications (1984-1997). On of the questions 
addressed was “how often does acute dermal toxicity contribute to overall classification?” The 
results showed that they contributed to for only about 1% of the chemicals tested. In only one 
instance the acute dermal study resulted in more severe classification than the oral study. 
Thomas, H.D., Dewhurst, I.C., 2007. What Does a Dermal 
Acute Toxicity Study Add to the Information on a Plant 
Protection Pesticide? Abstracts Toxicology 231: 114 – 115. 
The authors undertook an evaluation on the information on acute toxicity results and classification 
for 195 pesticides active substances evaluated within the EU since 1996 and 3111 formulated 
products approved by the Pesticides Safety Directorate (PSD). The results showed that 85% of the 
active substances and 92% of the formulated products merit no classification for dermal hazard. 
Only two active substances out of the 195 evaluated (1%) were more severely classified by dermal 
than oral route, one of which was also classified as ‘causes burns’. Only 9 out of 3111 products 
(0.3%) had a higher classification by dermal route than via other routes of exposure. It was 
concluded that the dermal acute toxicity study adds little if anything to the database on pesticide 
active substances. In all cases an equivalent indication of hazard, although often by a different 
route, was present. 
Creton, S., Dewhurst, I.C., Earl, L.K., Gehen, S.C., Guest, 
R.L., Hotchkiss, J.A., Indans, I., Woolhiser, M.R., Billington, 
R., 2010. Acute toxicity testing of chemicals – Opportunities 
to avoid redundant testing and use alternative approaches. 
Critical Reviews in Toxicology 40(1): 50-83. 
This paper reviews existing arguments for redundancy in acute toxicity testing of chemicals and 
chemical preparations, and the potential for use of alternative methodologies in the generation of 
acute toxicity data, giving consideration to the sometimes disparate regulatory approaches in place 
across various industry sectors. 
With regard to acute oral and dermal toxicity the authors reviewed 240 pesticide substances and 
demonstrated concordance of approaching 100% between substances not classified for acute 
toxicity by the oral or dermal routes; there was only one exception and this was a substance which 
demonstrated local corrosive effects in the dermal toxicity study. The authors also reviewed data 
for 438 industrial chemicals and report that only a single substance, whose identity was unknown, 
was classified for acute dermal toxicity but not for acute oral toxicity. 
EPAA, Annual Report 2010 The document gives an overview of EPAA main activites during 2010. With regard to acute 
systemic toxicity a summary is provided on a workshop involving regulators, academics, poison 
centre staff and industry representatives that was held in Brussels on 16 September 2010. The 
focus was on two areas stemming from the the paper “Cross-Sector Review of Drivers and 
Available 3Rs Approaches for Acute Systemic Toxicity Testing”, T. Seidle et al, in Toxicological 
Sciences: assessing 1) whether there are scientific drivers for acute toxicity testing and 2) whether 
the available concordance data set is adequate to support the deletion of the requirement for dermal 
testing from relevant legislation. Specific proposals were made for waivers that would deliver 
direct 3Rs benefits. The outcome of the workshop was communicated in a workshop report. 
Follow up steps included a wider consultation of the key recommendations with regulatory 
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stakeholders and considerations of how the removal of the dermal route as part of default testing 
can be implemented. 
Seidle, T., Robinson, S., Holmes, T., Creton, S., Prieto, P., 
Scheel, J., Chlebus, M., 2010. Cross-sector review of drivers 
and available 3Rs approaches for acute systemic toxicity 
testing. Toxicological Sciences 116(2): 382-396. 
Based on the experience made within the pharmaceutical industry with acute oral toxicity studies, 
this review aimed to identify, a) regulatory and scientific drivers for acute toxicity testing in other 
industrial sectors, b) activities aimed at replacing, reducing, or refining the use of animals, and c) 
to make recommendations for future work in the area of acute toxicity testing. The work was 
carried out by the EPAA task force established to examine scientific and regulatory drivers for 
such testing and to promote the use of 3Rs approaches. Reference is also made to the results of an 
EPAA survey that included questions on the scientific and regulatory objectives of the studies, 
routes of administration, preferred test guideline, parameters examined, dose limit, and regulatory 
experience. 
Andrew, D., Wright-Williams, S., 2011. Analysis of acute 
toxicity and irritation data submitted under the first REACH 
deadline. TSGE Poster presented at 2011 Autumn meeting of 
the British Toxicology Society. 
This analysis over 100 substances registered under the first REACH deadline demonstrated that all 
of the substances not classified for acute oral toxicity were also not classified for acute dermal 
toxicity. 
Two substances were found to have more severe classification for acute dermal than acute oral 
toxicity. Both of them were highly toxic and corrosive inorganic substances and, therefore, the 
authors concluded that the dermal toxicity of both of these substances is likely to be a combination 
of severe local corrosivity and systemic effects. 
Seidle, T., Prieto P, Bulgheroni A. 2011. Examining the 
Regulatory Value of Multi-route Mammalian Acute Systemic 
Toxicity Studies. Alternatives to Animal Experimentation 
28(2): 95-102. 
This paper describes the results of the analysis performed to assess oral-dermal and oral inhalation 
concordances among regulatory classifications for large data sets of chemicals (1569) and pesticide 
active ingredients (337) to determine the value of acute toxicity testing by more than one route. 
Overall the analysis provides further evidence that dermal acute systemic toxicity data almost 
never drive regulatory classification and labelling decisions in the chemicals, agrochemicals, or 
biocides sectors. With regard to industrial chemicals the oral-dermal classification concordance 
was 93.7% (1470/1569). The oral route lead to more toxic classification than the dermal route in 
6.2% (98/1569) of cases and the dermal route lead to more toxic classification for only one 
substance out of the 1569 evaluated (0.06%). In addition, 1469 out of 1569 substances were not 
classified for acute toxicity (93%) and in all these cases the oral and dermal routes lead to no 
classification (none of the substances which were not classified for acute oral toxicity were 
classified for acute dermal toxicity). It was recommended to conduct an in vitro dermal 
absorption/penetration study (OECD, 2004) before carrying out a new dermal acute toxicity study 
to assess the likely magnitude and rate of dermal bioavailability. The differences seen in acute 
toxic responses following oral and inhalation exposure need further investigation. 
EPAA Annual report 2012 The document gives an overview of EPAA main activites during 2012. With regard to acute 
systemic toxicity it provides a summary of the three Workstreams: 1) Reducing animal use in 
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dermal safety evaluation of substances, 2) How could C&L decisions in the agrochemical and 
chemical sectors be made if stand-alone acute toxicity testing were prohibited?, and 3) Minimising 
the requirements for inhalation testing. 
Moore, N.P., Andrew, D.J., Bjerke, D.L., Creton, S., Dreher, 
D., Holmes, T., Prieto, P., Seidle, T., Rowan, T.G., 2013. Can 
acute dermal systemic toxicity tests be replaced with oral tests? 
A comparison of route-specific systemic toxicity and hazard 
classifications under the Globally Harmonized System of 
Classification and Labelling of Chemicals (GHS). Regul. 
Toxicol. Pharmacol. 66(1): 30-37. 
In this paper acute systemic toxicity data (LD50 values) and hazard classifications derived in the rat 
following oral administration and dermal application have been analysed to examine whether or 
not orally-derived hazard classification or LD50 values can be used to determine dermal hazard 
classification (335 substances analysed). The challenges associated with comparing route-specific 
classifications are discussed. The comparison of oral and dermal classifications resulted in 17% 
concordance, with 7% of substances classified less severely and 76% more severely if oral 
classifications were applied directly to the dermal route. In contrast, applying the oral LD50 values 
within the dermal classification criteria to determine the dermal classification reduced the 
concordance to 15% and the relative ‘under-classification’ to 1%, but increased the relative ‘over-
classification’ to 84%. The authors concluded  that toxicity of chemicals is greater by the oral route 
than the dermal route and that oral acute systemic toxicity data can be used in place of equivalent 
dermal testing, with little or no concern for under-classification, by application of the dermal 
classification criteria. This approach does increase the potential for over-classification, which may 
be ameliorated by consideration of dermal penetration. Furthermore, testing a substance with an 
oral LD50 value of >2000 mg/kg by the dermal route will not add to its hazard characterisation and 
should be dissuaded. 
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7. Repeat dose systemic toxicity 
Pilar Prieto & Andrew Worth 
 
7.1 The traditional animal test and its regulatory use 
Repeat dose toxicity studies in animals are performed to characterise the toxicological profile 
of a test substance in mammalian species following daily administration of the substance to be 
tested for a defined period of time up to the whole lifespan of the animals (i.e. sub-acute, sub-
chronic and chronic exposures). There are different regulatory purposes, and the degree of 
uncertainty tolerated from the assessment varies accordingly; however the ultimate aim is to 
assess potential adverse effects on humans. These tests provide information on possible 
adverse effects on target organs, on dose-response relationships, and on the 
reversibility/irreversibility of the effects. In addition, they can be used to demonstrate delayed 
and accumulative effects. Information on a wide range of endpoints is provided, including 
histological changes in many organs and tissues, clinical signs, clinical chemistry and 
haematology. These in vivo tests generate the no-observed-adverse-effect level (NOAEL) or 
benchmark dose that is used as the point of departure in human risk assessment (ECHA, 
2012). The study types are described in several OECD test guidelines [OECD, 1981a,b, 1996, 
1998a,b,c, 2008, 2009a,b,c,d)] and EU Test methods (EC, 2008, EU, 2014) including 28 day 
oral, dermal and inhalation studies in rodents, 90 day oral, dermal and inhalation studies in 
rodents, 90 day oral study in non-rodents, and chronic toxicity studies in rodents (OECD TGs 
407-413, 452, EU test methods B.7 – B.9, B.26-B.30). The current revised OECD TG 407 
allows the identification of certain endocrine mediated effects, as well as chemicals with 
neurotoxic potential and those that interfere with thyroid physiology. It may also warn on 
immunological effects. Other studies include combined repeat dose toxicity study with the 
reproduction/developmental toxicity screening test (OECD TG 422) and the combined 
chronic toxicity/carcinogenicity studies (OECD TG 453, EU Test Method B.33). 
 
The regulatory hazard/risk assessment procedures for industrial chemicals (European 
Commission, 2006), agrochemicals (European Commission, 2009a; European Commission, 
2013), biocides (European Union, 2012), pharmaceuticals (EMA, 2010; ICH, 2010) and 
cosmetics (European Commision, 2009b; SCCS, 2012) require repeat dose toxicity testing to 
assess the potential risks of a substance. 
 
7.2 Mechanistic understanding of the endpoint 
The in vivo consequences of the repeat/chronic exposure to chemicals involve integrated 
processes at the molecular, cellular, organ and system levels. Overall, there is limited 
knowledge of the underlying mechanistic pathways and their interactions, despite several 
decades of research using in vitro and in vivo models. Many compounds are thought to induce 
their toxic effects by interfering with basic biochemical functions (e.g. interference with 
energy production, DNA function, receptor-mediated signalling pathways) or homeostatic 
mechanisms (e.g. perturbation of calcium homeostasis), resulting in functional impairments at 
the cell, tissue and organ levels. However, a quantitative description of these effects (dose-
response relationships) is generally lacking. 
 
Nevertheless, for some mechanisms of target organ systemic toxicity, a substantial body of 
knowledge already exists. For instance, due to its location and function in the organism, the 
liver is a sensitive target organ for several substances and considerable attention has been paid 
over the years to decipher the precise mechanisms underlying the induced adverse liver 
effects, such as necrosis, fibrosis, steatosis, phospholipidosis and cholestasis. Several recent 
review papers describe the molecular mechanisms of liver toxicity (Russmann et al., 2009; 
Gomez-Lechon et al., 2010). In addition to the liver, other common target organs and systems 
such as the kidney, lung, central and peripheral nervous systems, cardiovascular system, and 
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immune system have been also the subject of several mechanistic investigations over the 
years (Prieto et al., 2006; Adler et al., 2011; Basketter et al., 2012). 
 
Recently, in line with the mode of action/adverse outcome pathway (MoA/AOP) approach to 
toxicity prediction, work has started on the elucidation of the AOPs for some effects, such as 
fibrosis, steatosis and cholestasis (Landesmann et al., 2012; Vinken et al., 2013). The basic 
idea is that the knowledge of the underlying mechanisms simplified and represented in the 
form of AOPs, will enable the rational and flexible design of predictive systems. This 
approach is being explored by the SEURAT-1 consortium (SEURAT-1, 2011). A web-based 
platform (http://moa-kb.jrc.ec.europa.eu/) for sharing and developing AOPs is being 
developed by the JRC and EPA, in collaboration with the OECD and WHO IPCS. 
 
7.3 Status of non-standard methods and Integrated Testing Strategies 
7.3.1 In vitro methods 
The availability and status of alternative methods for repeat dose toxicity has recently been 
reviewed in the context of the Cosmetics Directive 2013 marketing ban deadline (Adler et al., 
2011). The expert group, convened by the JRC, concluded that although in vitro models are 
available for the most common target organs and systems such as the liver, kidney, lung, 
central nervous system, cardiovascular system and immune system (see Table 7.1 for 
summary of main approaches), none of them can be applied for quantitative risk assessment 
for repeat dose toxicity. However, for a limited number of target organs, in vitro models may 
be useful for mechanistic investigations and for hazard identification. In applying these 
models for hazard identification, it is important to understand whether chemically-induced 
perturbations observed in vitro (i.e. biochemical changes, up and down regulation of genes) 
are real biomarkers of toxicological effect, or simply adaptive responses (SEURAT-1, 2011; 
Blaauboer et al., 2012), and the potential differences between in vitro and in vivo responses. 
In this context, and following, a biomarker is defined a parameter that provides quantitative 
information that is mechanistically relevant to and predictive of an adverse effect 
(Boekelheide & Schuppe-Koistinen, 2012). 
 
7.3.2 Multi-parametric approach 
Several authors (Russmann et al., 2009; Gomez-Lechon et al., 2010) have advocated the use 
of in vitro multi-parametric screening assays covering a wide spectrum of (mechanistically-
based) key events, not only for mechanistic investigations but also for the prediction of 
systemic toxicities. These assays can include novel imaging technologies, which provide the 
possibility for continuous observation of critical cellular level events such as cell morphology, 
proliferation, migration, cell-cell interactions and colony formation. For example, multi-
parametric assays for mechanistic and predictive studies have recently been proposed for 
drug-induced liver toxicity (hepatotoxicity) (Tolosa et al., 2012) and for mitochondrial 
dysfunction (Porceddu et al., 2012), a major mechanism of drug-induced liver injury.  
 
7.3.3 Omics 
Another major area of research and development concerns the wide range of “omics” 
techniques, which provide a means of understanding mechanisms of action at the molecular 
level, such as chemically-induced gene expression (Heijne et al., 2005; Jennings et al, 2013; 
Wilmes et al., 2011). While these technologies hold considerable promise, further 
development is needed before they can be applied in quantitative risk assessment for repeat 
dose toxicity. Stable and reproducible long-term culture systems need to be developed, along 
with optimised protocols. One of the reported limitations of using well-established in vitro 
primary hepatocytes in toxicogenomics is in fact the significant discrepancy between test 
compound-induced gene expression alterations in the liver in vivo and in hepatocytes in vitro. 
In this regard, Schug et al. (2013) have recently shown that in vitro and in vivo discrepancies 
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in the chemically-induced expression of three metabolising genes can be explained by the 
rapid decrease of the orally administered chemical in vivo (i.e. short half-life) in contrast to 
the slow decrease of the concentrations of the chemical in the culture medium. These 
pharmacokinetic differences between the two systems clarified why the genes were still 
deregulated after 24 h exposure in vitro, but not in vivo. 
 
One of the challenges ahead is to study the interactions between genes, proteins and 
metabolites and to integrate the results. Some authors have already presented the benefits of 
an integrated in vitro omics approach in repeat dose toxicity assessment, combining 
transcriptomics, proteomics and metabolomics together with pharmacokinetics (e.g. Wilmes 
et al., 2013) and systems biology models (Hamon et al., 2014).  
 
7.3.4 In silico and QSAR models 
The availability of QSAR models for repeat dose toxicity endpoints is limited, as reviewed by 
Lapenna et al. (2010). Efforts have focussed on the use of molecular descriptors and 
statistically based modelling for the prediction of dose descriptors (e.g. prediction of the 
Lowest Observed Adverse Effect Level (LOAEL) or the Maximum Recommended 
Therapeutic Dose (MRTD) value), or of organ-related toxicities, including hepatotoxicity, 
nephrotoxicity, neurotoxicity and cardiotoxicity. For example, Myshkin et al. (2012) have 
developed models for hepatotoxicity and nephrotoxicity, as well as more precisely defined 
specific toxicity types for these  organs (e.g. liver necrosis, kidney necrosis). The models for 
hepatotoxicity and nephrotoxicity were less accurate than those developed for more specific 
toxicity types within an organ. A more recent trend, in line with the MoA/AOP concept, has 
been to develop or use models for certain key events along a known toxicity pathway, for 
example binding to the LXR receptor (Spreafico et al, 2010), to be potentially used as a 
building block in a future AOP. 
 
The most commonly used QSAR software tool for overall LOAEL prediction is probably 
TOPKAT (http://www.accelrys.com), which is a commercial product. Despite the lack of 
transparency in its predictions, several studies (e.g. Tilaoui et al, 2007) have claimed that 
TOPKAT gives reasonable predictions for a range of chemicals (including industrial 
chemicals). A more recently commercialised tool for LOAEL prediction is MolCode 
Toolboxes (http://molcode.com/). MRTD prediction can be carried out by using ADMET 
Predictor (http://www.simulations-plus.com/), MultiCase (http://www.multicase.com/) or the 
freely available software tool, Lazar (http://lazar.in-silico.de). 
 
7.3.5 Threshold of Toxicological Concern 
Another non-animal approach, which has gained increasing acceptance in the assessment of 
chemicals (especially non-intentionally added substances) in food (EFSA, 2012a) and 
cosmetics (SCHER/SCCS/SCENIHR, 2012), is based on the Threshold of Toxicological 
Concern (TTC) concept. The TTC concept is based on empirical evidence that for non-cancer 
effects, there are thresholds (exposure levels) below which toxicity does not occur, whereas 
for cancer effects, the likelihood of tumours is zero to very small at very low exposure levels. 
Thus, for chemicals of unknown toxicity, human exposure thresholds can be established 
below which there is a low probability of adverse effects on health. Accordingly, a range of 
human exposure thresholds (TTC values) have been developed for both cancer and non-
cancer endpoints, on the basis of data from extensive toxicological testing in animals. For 
non-cancer effects (repeat dose toxicities), the most commonly accepted TTC values were 
proposed by Munro et al (1996) and are related to structural classes by the Cramer 
classification scheme (Lapenna et al, 2011). Specifically, Cramer classes I, II and III, 
respectively relating to low, medium and high concern for oral systemic toxicity, were 
associated exposure thresholds of 1800, 540 and 90 μg/person/day, respectively. More 
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recently, in order to address all types of populations, it has been considered that the thresholds 
should be expressed in µg/kg body weight (bw) per day. Based on the (historical) assumption 
of a 60 kg adult, the corresponding thresholds for Cramer classes I, II and III are 30, 9, and 
1.5 μg/kg bw per day. 
 
7.3.6 Challenges of the non-animal approaches 
The difficulty in developing non-animal approaches for repeat dose toxicity is related to 
complexity of the underlying processes, which includes effects at different levels of biological 
organisation and time scales. In vitro methods have generally been developed to predict 
effects in specific target organs, without considering how the information generated can be 
used to predict the complex in vivo interactions between different cell types and tissue 
systems leading to toxicity.  
 
Part of the solution lies in the use of Physiologically Based Biokinetic (PBBK) models. These 
are mathematical models which describe the flow of substances between the interconnected 
compartments (organs and tissues) of the whole organism, and which generate dose and time-
dependent internal concentration profiles (e.g. internal concentrations at target organs), PBBK 
models rely on multiple input parameters, including substance-independent physiological 
parameters such as organ weights and blood flows, and substance-dependent parameters such 
as partitioning coefficients (e.g. blood-tissue partitioning) and metabolic fate (e.g. rate 
constants). PBBK models can be used to extrapolate biological effects between species, 
individuals, routes of exposure, and time scales (Coecke et al., 2013). They can also be used 
for in vitro to in vivo extrapolation. In this context, most studies have used the nominal 
(applied) in vitro concentration as the starting point for the extrapolation, but this can 
introduce inaccuracies due to the fate of the chemical in the in vitro system, such as binding to 
plastic, cell membranes and serum proteins, reducing bioavailability inside the cell (Broeders 
et al., 2013; Wilmes et al., 2013; Zaldivar et al., 2011). Therefore, recent efforts have 
focussed on modelling the in vitro system as well, and introducing a correction into the in 
vitro to in vivo extrapolation for the specific substance. An example is the virtual cell-based 
assay developed by the JRC (Zaldivar et al., 2011). A more complex solution is to integrate 
directly the dynamics of target tissue response, and use multi-scale modelling to translate the 
effects across multiple levels of biological organisation [from the cell to the whole body and 
timescales (Diaz et al, 2012)]. These developments are still at the research stage, and not yet 
ready for routine application in regulatory decision making. 
 
7.4 Integrated testing strategies 
Despite the limitations of individual alternative methods, it is widely considered that there are 
opportunities to avoid in vivo testing by optimal use of predictive methods such as QSARs, 
read-across, TTC and in vitro methods (Grindon et al., 2008; Adler et al., 2011). Several 
research initiatives around the world have taken up the challenge of combining and 
interpreting data on multiple targets generated by a variety of non-animal approaches. 
 
In the USA, multiple initiatives are underway, including the Tox21 programme 
(http://www.epa.gov/ncct/Tox21/), the ToxCast screening programme 
(http://www.epa.gov/ncct/toxcast/) and work led by the Hamner Institute for Chemical Safety 
Sciences (http://www.thehamner.org/institutes-centers/institute-for-chemical-safety-
sciences/). These initiatives are developing new assays to characterise major “toxicity 
pathways,” dose response models to quantify when perturbations in toxicity pathways result 
in adverse events in cells and tissues, and in vitro to in vivo extrapolation tools to predict the 
level and duration of exposure that is likely to result in adverse events in humans. 
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In Europe, the FP7 project Predict-IV (www.predict-iv.toxi.uni-wuerzburg.de/) aimed to 
combine in vitro biological effects (determined by transcriptomics, proteomics and 
metabolomics, and high content imaging) with pharmacokinetics and modelling (in vitro to in 
vivo extrapolation) in order to develop testing strategies based on mechanistic information 
that could improve pre-clinical safety testing of pharmaceuticals. The emphasis of SEURAT-
1 research strategy is on the identification and elucidation of MoA related to repeat dose 
systemic toxicity in humans and the development of experimental and computational models 
that capture the related key events and toxicity pathways (http://www.seurat-1.eu/; SEURAT-
1, 2012, 2013).  
 
7.5 Conclusions  
Information on the repeat dose effects of chemicals is required for human health hazard 
assessments under REACH and the Biocides Products Regulation, and can be used for 
classification and labelling under CLP. 
 
The development of reliable and useful non-animal approaches for repeat dose toxicity has 
been hampered by an incomplete understanding of the complex network of biological 
processes involved, as well as the technical challenge of simulating the most relevant 
processes in vitro or in silico. These processes include both the biokinetics of internal 
exposure in whole organisms and the dynamics of effects in target organs. Until recently, the 
need to explicitly account for in vivo biokinetics (by using PBBK models) has largely been 
ignored, with efforts focusing on the development of methods predicting effects in target 
organs. Due to the potentially large number of targets and mechanisms, it is however unlikely 
that any single in vitro test or QSAR model will be capable of making reliable predictions for 
all chemicals of interest.  
 
A wide range of in vitro models are available, but none generates reliable quantitative 
information suitable for use in hazard assessment. However, for a limited number of target 
organ toxicities, in vitro models may be useful for hazard identification and to obtain 
mechanistic information. The application of multi-parametric, high-throughput screening 
(HTS), high content imaging (HCI) and omics technologies to in vitro models is a broad and 
promising area of research, although at present, these approaches are not sufficiently well 
developed or practicable for routine use in quantitative hazard assessment. These approaches 
do however provide a powerful means of hypothesis building and informing the development 
of more targeted and simpler assays. For example, omics techniques can be used to explore 
the time-dependencies of differential gene expression, and to establish which genes and time 
point(s) are most relevant for predicting a given adverse outcome.  
 
A limited number of QSAR models are available. QSARs for LOAEL prediction are of 
questionable relevance, since they do not conform with the OECD validation principle of 
predicting a “defined endpoint”; there is no convincing mechanistic basis for the statistical 
association between a set of molecular descriptors and the potencies of lead effects arising in 
different organs. More credible QSARs, more in line with 21st Century thinking, need to be 
developed for the prediction of specific key events in AOPs, which provide a rational basis 
for integrating their predictions with experimental data generated by in vitro methods. 
 
In view of the limited availability of QSARs and PBBK models, the well-established 
chemical category/read-across approach is of key importance. Particularly interesting in this 
regard is the possibility of filling data gaps by using read-across based on both structural and 
biological descriptors, sometimes referred to as “chemical biological” read-across (CBRA; 
Low et al, 2013). In this context, any toxicologically relevant read-out (including functional 
parameters and omics measurements) from an in vitro system could be a useful biological 
descriptor. This topic merits further investigation. 
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PBBK models have been developed for a limited number of chemicals, and are increasingly 
being integrated with toxicological data from in vitro studies. However, further research is 
needed to expand the repertoire of such models and integrate them with relevant in vitro data 
to make quantitative predictions of toxicological effects by extrapolating from in vitro to in 
vivo points of departure. It will also be important to implement these models in user-friendly 
platforms to make them more accessible for routine use in risk assessment. 
 
In the assessment of industrial chemicals and biocides, the TTC approach could be used 
alongside QSAR in the assessment of degradates and metabolites for which experimental 
toxicity data are neither available nor explictly required. To explore this further, a good 
starting point would be the guidance developed by EFSA for the assessment of pesticide 
metabolites (EFSA 2012b). Within current research projects (e.g. the FP7 project COSMOS), 
efforts are underway to further develop the TTC approach. 
 
For quantitative risk assessment, an integrated approach based on an understanding of MoA 
and perturbation of biological pathways, as well as a better knowledge of in vitro and in vivo 
kinetics, and target organ/tissue dose-response relationships is needed (Adler et al.; 2011; 
SEURAT-1, 2011). A possible concern for regulatory implementation is that in moving 
towards a new toxicological paradigm will entail replacing a checklist of standard animal 
studies with a possibly more extensive checklist of more ad hoc in vitro and modelling 
studies. However, the vision and hope is that by employing the MoA/AOP framework, it 
should be possible to identify a limited number of key events that act as common “nodes” in 
multiple toxicity pathways, with the practical benefit that a limited set of (in vitro and in 
silico) models based on these key events will provide a sufficient toolkit for quantitative 
hazard assessment based entirely on non-animal approaches. A suite of AOPs relevant to 
repeat dose toxicity, including some of those from the above-mentioned research initiative, 
will be evaluated and published by the OECD. 
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Table 7.1. In vitro methods for common target organs in repeat dose toxicity 
 
In vitro tests available  
 
Part of mechanism covered Area(s) of application Status References 
Liver-derived in vitro systems: 
• Liver slices 
• Immortalised liver based cell lines 
• Primary hepatocytes (suspensions, 
monolayer cultures, sandwich cultures) 
• 3D tissue constructs 
• Bioartificial livers 
• Co-cultures of various cell types with 
hepatocytes 
• Stem cell models 
 
Cytotoxicity (including 
necrosis and apoptosis), 
cholestasis, steatosis, 
phospholipidosis, fibrosis 
Hazard identification 
 
R&D Adler et al., 2011 
Soldatow et al., 2013 
Kidney-derived in vitro systems: 
• Primary cell cultures 
• Renal cortical slices 
• Not transformed renal epithelial cell 
lines (from several species) 
• Human proximal tubule epithelial cell 
lines 
• 3D tissue constructs 
• Liver-kidney co-culture model in micro-
fluid chip 
• Human Proximal Tubule-on-a-chip 
• Renal epithelial like cells derived from 
stem cells 
Nephrotoxicity 
 
Hazard identification R&D Adler et al., 2011 
Choucha-Snouber et 
al., 2012  
DesRochers et al., 
2013 
Ginai et al., 2013 
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In vitro tests available  
 
Part of mechanism covered Area(s) of application Status References 
Cardiovascular system derived in vitro 
systems: 
• Murine and human embryonic stem cell-
derived cardiomyocytes 
• Primary cardiomyocytes from a variety 
of animal species 
• Cell lines 
• Engineered cardiac tissue 
 
Cytotoxicity, alterations in 
cardiac action potential, 
effects on ion channels 
(primarily hERG), arrhythmia 
Screening/hazard 
identification 
R&D 
 
hERG assays used in 
pharmaceutical 
development 
Adler et al., 2011 
Sukardi et al, 2011 
Abassi et al., 2012 
Central and peripheral nervous system 
derived in vitro systems: 
• Primary cultures 
• Re-aggregate cultures (or explant/slice 
culture) 
• Neuroblastoma and glioma cell lines 
• Human and rodent neural stem cell lines 
• Non-mammalian models (e.g. zebra fish, 
medaka or C. elegans) 
 
Neurophysiology testing 
Neural electrical 
communication 
Neurotransmission 
Enzymatic activity 
Cell morphology 
Cell differentiation 
General biochemistry 
Screening/prioritisation 
Hazard identification 
R&D Adler et al., 2011 
Sukardi et al, 2011 
Respiratory tract derived in vitro systems: 
• Primary cultures from human and rodent 
tissue 
• Lung slices 
• Cell lines mimicking different cell types 
of the respiratory tract 
• Co-cultures models (e.g. epithelial and 
dendritic cells or macrophages) 
• 3D in vitro human models 
Allergic asthma 
Cystic fibrosis 
Inflamation 
Remodeling 
Mucus secretion 
Ciliary clearance 
Active ion trasnport 
Irritation 
Adaptive imunity 
 
Hazard identification R&D Adler et al., 2011 
Sauer et al., 2013 
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In vitro tests available  
 
Part of mechanism covered Area(s) of application Status References 
Immune system derived in vitro systems: 
• Human whole blood 
• Human peripheral blood cells 
• Human, mouse and rat bone marrow 
progenitors such as granulocyte-
macrophage and  megakaryocyte 
progenitors 
• Haematopoietic stem cells 
Immunotoxicity 
Myelotoxicity 
Hazard identification R&D 
 
Scientifically 
validated for 
evaluating 
myelotoxicity 
(human and murine 
CFU-GM) 
Adler et al., 2011 
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Chapter 7. Table of References with Notes 
 
Traditional animal tests – OECD TGs/EU test methods 
OECD (1996), Test No. 422: Combined Repeated Dose Toxicity Study 
with the Reproduction/Developmental Toxicity Screening Test, OECD 
Guidelines for the Testing of Chemicals, Section 4, OECD Publishing. doi: 
10.1787/9789264070981-en 
 
This method is designed for use with the rat and oral administration is assumed. It 
provides information on the possible health hazards likely to arise from repeated 
exposure over a relatively limited period of time. The method comprises the basic 
repeated dose toxicity study that may be used for chemicals on which a 90-day 
study is not warranted (e.g. when the production volume does not exceed certain 
limits) or as a preliminary study to a long-term study. It further comprises a 
reproduction/developmental toxicity screening test and also places emphasis on 
neurological effects as a specific endpoint. 
OECD (1981a) Test No. 410: Repeated Dose Dermal Toxicity: 21/28-day 
Study. OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264070745-en 
 
EU test method B.9. Repeated dose (28 days) toxicity (dermal). 
This method provides information on possible health hazards likely to arise from 
repeated exposures by the dermal route over a period of 21 or 28 days. The test 
substance is applied daily to the skin. The adult rat, rabbit or guinea pig may be 
used. Both sexes should be used.  
OECD (1981b) Test No. 411: Subchronic Dermal Toxicity: 90-day Study. 
OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264070769-en 
 
EU test method B.28. Sub-chronic dermal toxicity study 90 day repeated 
dermal dose study using rodent species 
This method is based on the repeated application by the dermal route of the 
substance of interest during 90 days (several hours daily). It is intended for use 
with the adult rat, rabbit or guinea pig. Both sexes should be used.  
OECD (1998b) Test No. 409: Repeated Dose 90-Day Oral Toxicity Study 
in Non-Rodents. OECD Guidelines for the Testing of Chemicals, Section 4, 
OECD Publishing. doi: 10.1787/9789264070721-en. 
 
EU test method B.27. Sub-chronic oral toxicity test repeated dose 90-day 
oral toxicity study in non-rodents 
This method is based on the repeated oral administration of the substance during 
90 days (one dose level daily). It is intended primarily for use with non-rodent 
species (the dog and, in particular, the beagle is frequently used). Both sexes 
should be used.  
OECD (1998a) Test No. 408: Repeated Dose 90-Day Oral Toxicity Study 
in Rodents. OECD Guidelines for the Testing of Chemicals, Section 4, 
OECD Publishing. doi: 10.1787/9789264070707-en 
 
EU test method B.26. Sub-chronic oral toxicity test repeated dose 90 – day 
oral toxicity study in rodents 
This method is based on the repeated oral administration of the substance of 
interest over 90 days (one dose level daily). It is intended primarily for use with 
rodents (rat preferably). Both sexes should be used. 
OECD (2008) Test No. 407: Repeated Dose 28-day Oral Toxicity Study in 
Rodents. OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
This method is based on the repeated administration of the substance of interest 
via the oral route during 28 days (one dose level daily). It is intended primarily 
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Publishing. doi: 10.1787/9789264070684-en 
 
EU test method B.7. Repeated dose 28-day oral toxicity study in rodents 
for use with rodents (rat preferably) and both sexes should be used. This method 
is intended to investigate effects on a very broad variety of potential targets of 
toxicity, including effects on the nervous, immune and endocrine systems. 
Regarding these particular endpoints, it should identify chemicals with neurotoxic 
potential, which may warrant further in-depth investigation of this aspect, and 
chemicals that interfere with thyroid physiology. It may also provide data on 
chemicals that affect the male and/or female reproductive organs in young adult 
animals and may give an indication of immunological effects. 
OECD (2009c) Test No. 452: Chronic Toxicity Studies, OECD Guidelines 
for the Testing of Chemicals. Section 4, OECD Publishing. doi: 
10.1787/9789264071209-en 
 
EU test method B.30. Chronic toxicity studies 
The aim of this method is to characterise the profile of a substance in a 
mammalian species (primarily rodents) following prolonged and repeated 
exposure over 12 months. Frequency of exposure normally is daily, but may vary 
according to the route chosen (oral, dermal or inhalation) and should be adjusted 
according to the toxicokinetic profile of the test substance. Both sexes should be 
used.  
OECD (2009d) Test No. 453: Combined Chronic Toxicity/Carcinogenicity 
Studies. OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264071223-en 
 
EU test method B.33. Combined chronic toxicity/carcinogenicity studies 
The objective of a combined chronic toxicity/carcinogenicity study is to identify 
carcinogenic and the majority of chronic effects, and to determine dose-response 
relationships following prolonged and repeated exposure. The rat is typically 
used for this study and focuses on the oral route of administration. 
OECD (2009a) Test No. 412: Subacute Inhalation Toxicity: 28-Day Study. 
OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264070783-en 
 
EU test method B.8. Subacute inhalation toxicity: 28-day study 
This method aims to fully characterise the test substance toxicity by the 
inhalation route following repeated exposure during 28 days, and to provide data 
for quantitative inhalation risk assessments.  
OECD (2009b) Test No. 413: Subchronic Inhalation Toxicity: 90-day 
Study. OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264070806-en 
 
EU test method B. 29. Subchronic inhalation toxicity: 90-day study 
This method aims to fully characterise the test substance toxicity by the 
inhalation route following repeated exposure during 90 days, and to provide 
robust data for quantitative inhalation risk assessments. 
Regulatory requirements across sectors 
European Commission, 2006. Regulation (EC) No 1907/2006 of the 
European Parliament and the Council of 18 December 2006 concerning the 
Registration, Evaluation, Authorisation and Restriction of Chemicals 
(REACH), establishing a European Chemicals Agency, amending Directive 
1999/45/EC and repealing Council Regulation (EEC) No 793/93 and 
Commission Regulation (EC) No 1488/94 as well as Council Directive 
Chemicals: Information requirements depend on the production volume of the 
chemical concerned: 
• Annex VIII (10-100 tpa): Short-term repeated dose toxicity study (28 
days), one species, male and female, most appropriate route of 
administration, having regard to the likely route of human exposure. 
• Annex IX - X (100->1000 tpa): In addition to the 28-day repeated dose 
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76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 
93/105/EC and 2000/21/EC. Official Journal of the European Communities 
L396, 1-849. 
toxicity study, a sub-chronic toxicity study (90 days) should be carried 
out in rodents, male and female, by the most appropriate route of 
administration, having regard to the likely route of human exposure. 
European Commision, 2008. Council Regulation (EC) No 440/2008 of 30 
May 2008 laying down test methods pursuant to Regulation (EC) No 
1907/2006 of the European Parliament and of the Council on the 
Registration, Evaluation, Authorisation and Restriction of Chemicals 
(REACH) 
AND 
European Union, 2014. Commission Regulation (EU) No 260/2014 of 24 
January 2014 amending, for the purpose of its adaptation to technical 
progress, Regulation (EC) No 440/2008 laying down test methods pursuant 
to Regulation (EC) No 1907/2006 of the European Parliament and of the 
Council on the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH). Official Journal of the European Union L 81, 1-253 
The Regulation of May 2008 and its subsequent amendments, define tests testing 
of chemicals for the REACH Regulation. They are based on the OECD 
Guidelines for the Testing of Chemicals. 
The January 2014 adaptation contains, among others, nine methods for the 
determination of toxicity and other health effects including four inhalation 
toxicity test methods, which include an update of three methods and one new 
method to reduce the number of animals used and to improve assessment of 
effects, an update of the repeat dose 28-day oral toxicity test method to include 
parameters for assessment of endocrine activity, an update of the toxicokinetics 
test method relevant for the design and understanding of toxicological studies and 
an update of chronic, carcinogenicity and combined chronic and carcinogenicity 
test methods.  
European Commission, 2009a. Regulation (EC) No 1223/2009 of the 
European Parliament and the Council of 30 November 2009 on cosmetic 
products. Official Journal of the European Communities L342, 59-209. 
Cosmetics: This Regulation establishes rules to be complied with by any cosmetic 
product made available on the market, in order to ensure the functioning of the 
internal market and a high level of protection of human health.  
Article 18 (Animal testing) 
European Commission, 2009b. Regulation (EC) No 1107/2009 of the 
European Parliament and of the Council of 21 October 2009 concerning the 
placing of plant protection products on the market and repealing Council 
Directives 79/117/EEC and 91/414/EEC. Official Journal of the European 
Union L309, 1-47. 
AND 
European Commission, 2013. Regulation (EU) No 283/2013 of 1 March 
2013 setting out the data requirements for active substances, in accordance 
with Regulation (EC) No 1107/2009 of the European Parliament and of the 
Council concerning the placing of plant protection products on the market. 
Active substances: Where available, oral 28-day studies shall be reported. Oral 
90-day studies, usually the rat, and non-rodents (90-day toxicity study in dogs), 
shall always be reported. For human risk assessment additional dermal studies 
shall be considered on a case by case basis, unless the active substance is a severe 
irritant. For volatile active substances (vapour pressure >10 –2 Pascal) expert 
shall be required to decide whether the short term studies have to be performed 
by inhalation exposure. A long-term oral toxicity study of the active substance 
shall be conducted using rat as test species; where possible this study shall be 
combined with a long-term carcinogenicity study (two years). 
European Medicines Agency, 2010. Guideline on repeated dose toxicity. 
Committee for Human Medicinal Products. Reference number 
CPMP/SWP/1042/99 Rev 
This Guideline concerns the conduct of repeated dose toxicity studies of active 
substances intended for human use. It includes herbal medicinal products while 
for biotechnology-derived compounds, vaccines and anticancer medicinal 
products, specific guidance is available. In general, repeated dose toxicity studies 
shall be carried out in two species of mammals, one of which must be a non-
rodent. The dose regimen, duration and route of administration should be chosen 
based on the intended clinical use in humans. 
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ICH - International conference on harmonisation of technical requirements 
for registration of pharmaceuticals for human use, 2010. Guidance on 
nonclinical safety studies for the conduct of human clinical trials and 
marketing authorization for pharmaceuticals M3(R2). 
The purpose of this document is to recommend international standards for, and 
promote harmonisation of, the nonclinical safety studies recommended to support 
human clinical trials of a given scope and duration as well as marketing 
authorization for pharmaceuticals. The recommended duration of the repeated-
dose toxicity studies is usually related to the duration, therapeutic indication and 
scope of the proposed clinical trial. Repeated-dose toxicity studies in two species 
(one non-rodent) for a minimum duration of 2 weeks would generally support any 
clinical development trial up to 2 weeks in duration. Clinical trials of longer 
duration should be supported by repeated-dose toxicity studies of at least 
equivalent duration. Six month rodent and 9 month no-rodent studies generally 
support dosing for longer than 6 months in clinical trials.  
Safety pharmacology and pharmacodynamic (PD) studies are defined in ICH 
S7A. The core battery of safety pharmacology studies includes the assessment of 
effects on cardiovascular, central nervous and respiratory systems, and should 
generally be conducted before human exposure, in accordance with ICH S7A and 
S7B. When warranted, supplemental and follow-up safety pharmacology studies 
can be conducted during later clinical development. Consideration should be 
given to inclusion of any in vivo evaluations as additions to general toxicity 
studies, to the extent feasible, in order to reduce animal use. In addition, primary 
PD studies (in vivo and/or in vitro) are intended to investigate the mode of action 
and/or effects of a substance in relation to its desired therapeutic target. Such 
studies are generally conducted during the discovery phase of pharmaceutical 
development and as such, are not generally conducted in accordance with Good 
Laboratory Practice. These studies can contribute to dose selection for both 
nonclinical and clinical studies 
European Chemicals Agency, 2012. Guidance on information requirements 
and chemical safety assessment Chapter R.7a: Endpoint specific guidance.  
Available from: 
http://echa.europa.eu/documents/10162/13632/information_requirements_r
7a_en.pdf 
Chemicals: This document describes the information requirements under REACH 
with regard to substance properties, exposure, uses and risk management 
measures, and the chemical safety assessment. For repeated dose toxicity, all 
available information relevant for the endpoint needs to be evaluated and 
classification considered at each tonnage level. The standard information 
requirements on repeated dose toxicity are specified in REACH Annexes VII-X. 
European Union, 2012. Regulation (EU) No 528/2012 of the European 
Parliament and of the Council of 22 May 2012 concerning the making 
available on the market and use of biocidal products. Official Journal of the 
European Union L 167, 1-116. 
Biocides: In general, only one route of administration is necessary and the oral 
route is the preferred route. However, in some cases it may be necessary to 
evaluate more than one route of exposure. Short-term repeated dose toxicity study 
(28 days) and for the sub-chronic repeated dose toxicity study (90 days) the 
preferred species is rat. The duration of the long-term repeated dose toxicity is 
equal or higher to 12 months  
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Further repeat dose studies including testing on a second species (non-rodent), 
studies of longer duration or through a different route of administration shall be 
undertaken if certain conditions are met. 
SCCS: Scientific Committee on Consumer Safety (2012): The SCCS’s 
notes of guidance for the testing of cosmetic ingredients and their safety 
evaluation. Available from: 
http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs
_s_006.pdf. 
The 28-day and 90-day oral toxicity tests in rodents are the most commonly used 
repeated dose toxicity tests. Preferably studies of 90 days or more should be used 
in safety assessments. If studies of only 28 days duration are available, an 
additional uncertainty factor can be used in the calculation of the margin of 
safety. The inhalation route is only rarely used due to the complex study design, 
as well as to the lack of relevance of this route of repeated exposure for the 
majority of cosmetic products. In a number of cases, dermal repeated dose 
toxicity studies are present among the submitted data (e.g. UV-filter). 
Current status and opportunities for the development of alternative approaches for systemic toxicity testing 
Heijne, W.H., Kienhuis, S., van Ommen, B., Stierum, R.H., Groten, J.P., 
2005. Systems toxicology: applications of toxicogenomics, transcriptomics, 
proteomics and metabolomics in toxicology. Expert Rev Proteomics. 2(5), 
767-80. 
According to this review: 
• Toxicogenomics can facilitate the identification and characterisation of 
toxicity. 
• Toxicogenomics methods may reduce uncertainties by providing detailed 
insight into molecular mechanisms underlying the toxic endpoint. 
• Application of toxicogenomics to in vitro studies has the potential to 
reduce, refine and replace animal experiments. 
• Functional genomic methods will only be fully deployed when these 
methods are integrated with conventional techniques to allow an iterative 
process of hypothesis generation and confirmation. 
• Transcriptomics and metabolomics are sensitive and becoming 
increasingly reproducible, while proteomics methods may become so 
after further developments. 
• The current challenge is to study interactions between genes, proteins and 
metabolites, and to integrate the results of the different genomics 
methods using a systems toxicology concept. 
Prieto, P, Baird, A W, Blaauboer, B J, et al., 2006. The assessment of 
repeated dose toxicity in vitro: a proposed approach. The report and 
recommendations of ECVAM workshop 56.- ATLA, 34, 315-341. 
This report summarises the outcome of a workshop during which alternative 
approaches to in vivo repeated dose toxicity testing were discussed and evaluated 
by a selected panel of experts. Due to the problem of conducting toxicity testing 
with high doses for hazard assessment in vivo, there is a need to complement 
animal toxicity studies with a greater understanding of mechanisms and modes of 
action, to support a dose–response. The experts discussed a) how to improve in 
vitro systems in order to assess repeated dose toxicity, b) the selection of relevant 
endpoints for repeated dose toxicity testing, and c) novel biomarkers for 
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assessment of toxicity arising from the range of omics technologies. An approach 
to predict NOEL/NOAEL levels from in vitro methods was proposed and uses the 
most sensitive endpoints indicative of adverse effects for determination of the 
NOEC in vitro and biokinetic modelling. A summary of the in vitro models 
available for five of the most common targets for toxicity (liver, kidney, CNS, 
lung and haematopoietic system) was also provided. The in vitro systems and 
endpoints used need to be carefully selected for their in vivo relevance to general 
mechanisms, as well as to cell-type-specific mechanisms of toxicity or expression 
of toxic effects. 
Grindon, C., Combes, R., Cronin, M.T.D., Roberts, D.W., Garrod, J.F., 
2008. An Integrated Decision-tree Testing Strategy for Repeat Dose 
Toxicity with Respect to the Requirements of the EU REACH Legislation. 
ATLA 36, 93–101 
This paper focuses on the use of alternative (non-animal) methods (both in vitro 
and in silico) for repeat dose (sub-acute, sub-chronic and chronic) toxicity testing. 
It reviews the limited number of in silico and in vitro tests available for this 
endpoint, and outlines new technologies which could be used in the future, e.g. 
the use of biomarkers and the 'omics' technologies. An integrated testing strategy 
is proposed, which makes use of as much non-animal data as possible, before any 
essential in vivo studies are performed. Although none of the non-animal tests are 
currently undergoing validation, their results could help to reduce the number of 
animals required for testing for repeat dose toxicity. 
Adler, S., Basketter, D., Creton, S., et al., 2011. Alternative (non-animal) 
methods for cosmetics testing: current status and future prospects-2010. 
Arch. Toxicol. 85(5):367-485. 
This report analyses the status and prospects of alternative methods and provides 
a scientifically sound estimate of the time necessary to achieve full replacement 
of animal testing in five toxicological areas, i.e. toxicokinetics, repeated dose 
toxicity, carcinogenicity, skin sensitisation, and reproductive toxicity. For the 
systemic toxicological endpoint of repeated dose toxicity the time horizon for full 
replacement could not be estimated. In vitro models in relation to six of the most 
common targets for repeated dose toxicity (liver, kidney, central nervous system, 
lung, cardiovascular and haematopoietic system) are included. In silico tools such 
as (Q)SARs for predicting repeated dose toxicity are also discussed. It was 
concluded that alternative methods have been developed mainly with the aim of 
producing stand-alone methods predicting effects in specific target organs. 
However, for the purpose of quantitative risk assessment better and more 
scientific knowledge on exposure, toxicokinetics, dose response and mechanisms 
of toxicity are needed. Additional efforts are necessary to develop improved 
biokinetic models which would be able to correctly estimate the impact of the 
distribution over time and level of the repeated external exposure and resulting 
internal dose. Such models are also needed for extrapolating from in vitro to in 
vivo and for understanding of dose responses, so that the in vitro data can be 
applied for quantitative risk assessment. Optimal use of existing data by the 
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Threshold of Toxicological Concern concept, read-across and integrated testing 
strategies can provide an opportunity to avoid the need for in vivo testing for a 
range of substances and applications. 
Basketter, D.A., Clewell, H., Kimber, I., Rossi, A., Blaauboer, B., Burrier, 
R., Daneshian, M., Eskes, C., Goldberg, A., Hasiwa, N., Hoffmann, S., 
Jaworska, J., Knudsen, T.B., Landsiedel, R., Leist, M., Locke, P., Maxwell, 
G., McKim, J., McVey, E.A., Ouédraogo, G., Patlewicz, G., Pelkonen, O., 
Roggen, E., Rovida, C., Ruhdel, I., Schwarz, M., Schepky, A., Schoeters, 
G., Skinner, N., Trentz, K., Turner, M., Vanparys, P., Yager, J., Zurlo, J., 
Hartung, T. 2012. A roadmap for the development of alternative (non-
animal) methods for systemic toxicity testing - t4 report. ALTEX 29(1), 3-
91. 
This report proposes a roadmap for how to overcome the acknowledged scientific 
gaps for the full replacement of systemic toxicity testing using animals. 
Toxicokinetics, skin sensitization, repeated-dose toxicity, carcinogenicity, and 
reproductive toxicity testing were addressed. 
For repeated dose toxicity testing the following was recommended: 1) to gather 
all current data on a wide variety of compounds to improve the quality and speed 
of new test development and validation; 2) to refine and reduce the number of 
animals used today by implementing decision trees, tiered approaches and/or 
applying screening strategies. Existing animal data, data from in vitro tests and 
data from in silico systems, as well as human data (epidemiological and 
clinical/medical), can be integrated into these types of approaches; 3) to better 
understand the molecules and pathways involved in toxicological events 
(quantification of the alternation of normal signals both the duration or the 
magnitude of the response); 4) to choose appropriate endpoints for each test and 
test system; 5) to evaluate the actual toxic dose by considering the real free 
concentration and the stability of the compounds during the exposure in vitro; 6) 
to create a reference list of compounds with information on mechanisms of 
toxicity and potency readily available in order to speed the validation process for 
all new testing systems; 7) to be sure of the quality of data used to build in silico 
models. 
Blaauboer, B.J., Boekelheide, K., Clewell, H.J., Daneshian, M., 
Dingemans, M.M., Goldberg, A.M., Heneweer, M., Jaworska, J., Kramer, 
N.I., Leist, M., Seibert, H., Testai, E., Vandebriel, R.J., Yager, J.D., Zurlo, 
J., 2012. The use of biomarkers of toxicity for integrating in vitro hazard 
estimates into risk assessment for humans. ALTEX 29(4): 411-25. 
This report presents the results of a workshop aimed at better defining the use of 
in vitro-derived biomarkers of toxicity (BoT) and determining the place these 
data can have in human risk assessment. The selection of BoT takes into account 
that they need to distinguish adverse and adaptive changes in cells. One of the 
challenges today when interpreting in vitro data is indeed to distinguish between 
adversity and adaptation. A framework is presented that defines the place of in 
vitro systems in the context of data on exposure, structural and physico-chemical 
properties, and toxicodynamic and biokinetic modelling. The authors highlight 
the importance of collecting and integrating existing and new data. The selection 
of these data and their integration needs to be driven by their usefulness in a 
quantitative in vitro-in vivo extrapolation.  It is also important to categorise 
biomarkers of toxicity and their relation to pathways of toxicity. 
Boekelheide K & Schuppe-Koistinen I (2012). SOT/EUROTOX debate: This article discusses the uses and the limitations of having a gold standard, how 
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biomarkers from blood and urine will replace traditional histopathological 
evaluation to determine adverse responses. Toxicological Sciences 129: 
249–255. 
adverse responses are determined, the evolutionary (as opposed to revolutionary) 
process by which one technology is typically replaced by another, and the overall 
goal of developing biomarkers which can translate from preclinical safety 
assessment to clinical utility. The ultimate purpose of the discussion is to help 
researchers and regulators understand the challenges they face in the development 
and integration of new and existing biomarkers to determine adverse responses. 
QSARs 
Munro IC, Ford RA, Kennepohl E, Sprenger JG, 1996. Correlation of 
structural class with No-Observed-Effect Levels: A proposal for 
establishing a threshold of concern. Food Chem Toxicol 34: 829-867.  
This is the key reference providing the basis for relating TTC values to the 
Cramer Classes. The relationship between chemical structure and toxicity was 
explored through the compilation of a large reference database consisting of over 
600 chemical substances tested for a variety of endpoints resulting in over 2900 
no-observed-effect levels (NOELs). Each substance in the database was classified 
into one of three structural classes using a decision tree approach. The resulting 
cumulative distributions of NOELs for each of the structural classes differed 
significantly from one another, supporting the contention that chemical structure 
defines toxicity. The database was used to derive a threshold of acceptable human 
exposure for each of the structural classes that could be applied in the absence of 
specific toxicity data on a substance within one of the three structural classes. The 
human exposure thresholds provide guidance on the degree of testing and 
evaluation required for substances that lack toxicity data. 
Tilaoui L., Schilter B., Tran L.-A., Mazzatorta P., Grigorov M., 2007. 
Integrated Computational Methods for Prediction of the Lowest Observable 
Adverse Effect Level of Food-Borne Molecules. QSAR Comb. Sci., 26, 
102. 
The authors present an integrated system partly based on the commercially 
available software TOPKAT, which predicts chronic toxicity through provision 
of a computational estimation of Lowest Observed Adverse Effect Level 
(LOAEL) values. The provide evidence that the LOAEL is correlated with a 
specific class of molecular descriptors, known as 2D autocorrelation descriptors. 
The authors concluded that the system developed is helpful in supporting the 
prioritisation of issues in chemical food research, by establishing levels of safety 
concern in the absence of sufficient experimental toxicological data. 
Lapenna S, Fuart-Gatnik M & Worth A, 2010. Review of QSAR models 
and software tools for predicting acute and chronic systemic toxicity. JRC 
Scientific and Technical report EUR 24639 EN. Publications Office of the 
European Union. Luxembourg. Available from: 
http://publications.jrc.ec.europa.eu/repository/ 
This JRC report provides a review of different computational estimation methods 
for predicting acute and chronic systemic toxicity. It provides an overview of 
Quantitative Structure-Activity Relationship (QSAR) models published in the 
literature, commonly used software tools, and available databases suitable for 
QSAR analysis. It also briefly explains the Threshold of Toxicological Concern 
(TTC) concept and how this is used in prioritising chemicals for further 
assessment and preliminary risk characterisation. 
Spreafico M., Smiesko M., Peristera O., Rossato G., Vedani A., 2010. The authors describe the addition of a model for LXR to their commerical 
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Probing Small-Molecule Binding to the Liver-X Receptor: A Mixed-Model 
QSAR Study, Mol. Info. 29, 27. 
software, VirtualToxLab, a fully automated technology that allows for the 
identification of the endocrine-disrupting potential of drugs, chemicals and 
natural products. This protocol was applied to screen a series of 161 natural 
compounds probing their binding to the LXR. The results of the simulation were 
compared with experimental data (where available), suggesting that the LXR 
model can be applied to predict the binding affinity of existing or hypothetical 
compounds for screening purposes. The binding of 52 ligands towards the liver X 
receptors (LXRs) was identified through docking to the three-dimensional protein 
structure and quantified by multidimensional QSAR (mQSAR), an approach 
referred to as ‘mixed-model QSAR’. The model was validated by the prediction 
of 17 external compounds (oxysterols) present neither in the training nor in the 
test set.. 
Myshkin E., Brennan R., Khasanova T., Sitnik T., Serebriyskaya T., 
Litvinova E., Guryanov A., Nikolsky Y., Nikolskaya T., Bureeva S., 2012. 
Prediction of Organ Toxicity Endpoints by QSAR Modeling Based on 
Precise Chemical-Histopathology Annotations. Chem. Biol. Drug Des., 
80(3), 406. 
Under the guidance of the MetaTox consortium (Thomson Reuters, CA, USA), 
which comprised toxicologists from the pharmaceutical industry and government 
agencies, the authors created a comprehensive ontology of toxic pathologies for 
19 organs, classifying pathology terms by pathology type and functional organ 
substructure. By manual annotation of full-text research articles, the ontology was 
populated with chemical compounds causing specific histopathologies. Annotated 
compound-toxicity associations defined histologically from rat and mouse 
experiments were used to build QSAR models predicting subcategories of liver 
and kidney toxicity: liver necrosis, liver relative weight gain, liver lipid 
accumulation, nephron injury, kidney relative weight gain, and kidney necrosis. 
All models were validated using two independent test sets and demonstrated 
overall good performance: initial validation showed 0.80-0.96 sensitivity 
(correctly predicted toxic compounds) and 0.85-1.00 specificity (correctly 
predicted non-toxic compounds). Later validation against a test set of compounds 
newly added to the database in the 2 years following initial model generation 
showed 75-87% sensitivity and 60-78% specificity. General hepatotoxicity and 
nephrotoxicity models were less accurate, as expected for more complex 
endpoints. 
TTC 
Lapenna S, Worth A, 2011. Analysis of the Cramer classification scheme 
for oral systemic toxicity - implications for its implementation in Toxtree. 
JRC Scientific and Technical Report EUR 24898 EN. Publications Office 
of the European Union, Luxembourg. Available from: 
http://publications.jrc.ec.europa.eu/repository/ 
This JRC report analyses the application of the Threshold of Toxicological 
Concern (TTC) concept to non-cancer endpoints. The decision tree proposed by 
Cramer, Ford and Hall in 1978, commonly referred to as the Cramer scheme, is 
probably the most widely used approach for classifying and ranking chemicals 
according to their expected level of oral systemic toxicity. The decision tree 
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categorises chemicals, mainly on the basis of chemical structure and reactivity, 
into three classes indicating a high (Class III), medium (Class II) or low (Class I) 
level of concern. Each Cramer class is associated with a specified human 
exposure level, below which chemicals are considered to present a negligible risk 
to human health. In the absence of experimental hazard data, these exposure 
threshold (TTC) values have formed the basis of priority setting in the risk 
assessment process. To facilitate the application of the TTC approach, the 
original Cramer scheme, and an extended version, have been implemented in 
Toxtree, a freely available software tool for predicting toxicological effects and 
mechanisms of action. The report provides some suggestions for improving the 
Cramer scheme based on a review of the scientific literature, a survey of Toxtree 
users, and an analysis of lists of body and food components incorporated in 
Toxtree. 
EFSA, 2012a. Scientific Opinion on exploring options for providing advice 
about possible human health risks based on the concept of Threshold of 
Toxicological Concern (TTC). EFSA Journal 2012;10(7):2750. European 
Food Safety Authority. Available from:  
http://www.efsa.europa.eu/en/efsajournal/doc/2750.pdf 
EFSA’s Scientific Committee developed an opinion on the applicability of the 
threshold of toxicological concern (TTC) approach as a tool for providing 
scientific advice about possible human health risks from low level exposures of 
chemicals in food and feed. The Scientific Committee examined the published 
literature on the TTC approach, undertook its own analyses and commissioned an 
in silico investigation of the databases underpinning the TTC approach. The 
Scientific Committee concluded that the TTC approach can be recommended as a 
useful screening tool either for priority setting or for deciding whether exposure 
to a substance is so low that the probability of adverse health effects is low and 
that no further data are necessary. The following human exposure threshold 
values are sufficiently conservative to be used in EFSA’s work; 0.15 μg/person 
per day for substances with a structural alert for genotoxicity, 18 μg/person per 
day for organophosphate and carbamate substances with anti-cholinesterase 
activity, 90 μg/person per day for Cramer Class III and Cramer Class II 
substances, and 1800 μg/person per day for Cramer Class I substances, but for 
application to all groups in the population, these values should be expressed in 
terms of body weight, i.e. 0.0025, 0.3, 1.5 and 30 μg/kg body weight per day, 
respectively. Use of the TTC approach for infants under the age of 6 months, with 
immature metabolic and excretory systems, should be considered on a case-by-
case basis. The Committee defined a number of exclusion categories of 
substances for which the TTC approach would not be used. 
EFSA, 2012b. Scientific Opinion on evaluation of the toxicological 
relevance of pesticide metabolites for dietary risk assessment. EFSA 
Journal 2012;10(07):2799. European Food Safety Authority. Available 
EFSA’s Panel on Plant Protection Products and their Residues developed an 
opinion on approaches to evaluate the toxicological relevance of metabolites and 
degradates of pesticide active substances in dietary risk assessment. The opinion 
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from:  http://www.efsa.europa.eu/en/efsajournal/doc/2799.pdf identifies the threshold of toxicological concern (TTC) concept as an appropriate 
screening tool. The TTC values for genotoxic and toxic compounds were found 
to be sufficiently conservative for chronic exposure, as a result of a validation 
study with a group of pesticides belonging to different chemical classes. Three 
critical steps were identified in the application of a TTC scheme: 1) the estimate 
of the level of the metabolite, 2) the evaluation of genotoxicity alerts and 3) the 
detection of neurotoxic metabolites. Tentative TTC values for acute exposure 
were established by the PPR Panel by analysis of the lowest 5th percentiles of No 
Observed Adverse Effect Levels (NOAELs) used to establish the Acute 
Reference Doses (ARfD) for the EFSA pesticide data set. Assessment schemes 
for chronic and acute dietary risk assessment of pesticide metabolites, using the 
TTC approach and combined (Q)SAR and read across, are proposed. The opinion 
also proposes how the risk assessment of pesticide metabolites that are 
stereoisomers should be addressed due to isomer ratio changes reflected in the 
composition of metabolites. The approach is ready for use, but it is anticipated 
that on many occasions the outcome of the assessment scheme will be that further 
testing is needed to reach a firm conclusion on the toxicological relevance of the 
metabolite. However, the benefit of applying the approach is that it will allow 
prioritisation of metabolites for subsequent testing. 
SCHER/SCCS/SCENIHR, 2012. Opinion on the Use of the Threshold of 
Toxicological Concern (TTC) Approach for Human Safety Assessment of 
Chemical Substances with focus on Cosmetics and Consumer Products. 
Available from: 
http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs
_o_092.pdf 
 
This the European Commission’s non-food scientific committees' opinion on the 
use of the TTC approach for risk assessment of chemical substances in cosmetics 
and consumer products. They concluded that the TTC approach is interesting as 
an alternative to costly and time consuming toxicological testing. However, there 
are two conditions which must be met for TTC to be used as a substitute: 1) 
where there is little or no information on the toxicity of a chemical substance and 
2) where the human exposure is so low that adverse effects are very unlikely to 
happen. The opinion identifies classes of chemicals and toxic effects for which 
the TTC approach may be appropriate and those for which it may not. They also 
addressed the issue of data gaps and research efforts required to strengthen the 
TTC approach.  
Current initiatives to develop alternative approaches 
SEURAT-1 annual report, 2011. Towards the Replacement of in vivo 
repeated Dose Systemic Toxicity Testing. Volume 1. Available from: 
http://www.seurat-1.eu/media/download_gallery/SEURAT-
1_Annual%20Report_Vol%201_Sept2011_HR.pdf 
This publication is the first volume of a series of six Annual Reports that 
summarises the activities of a new Research Initiative in the field of repeated 
dose systemic toxicity, which started on 1 January 2011. The aim of the 
SEURAT-1 Research Initiative is the development of a concept and 
corresponding long-term research strategy for future research and development 
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work leading to pathway based human safety assessments in the field of repeat 
dose systemic toxicity testing of chemicals. This first Annual Report presents a 
comprehensive overview of the work in the different projects of the SEURAT-1 
Research Initiative. This is given in the context of recent developments in 
European legislation regarding regulation of chemicals to improve their safety 
assessment and related international activities. This Research Initiative is 
designed as a coordinated cluster of five research projects, supported by a ‘data 
handling and servicing project’ and a ‘coordination and support project’. Detailed 
project descriptions, reports about the kick-off meetings of each of the specific 
projects as well as of the SEURAT-1 Research Initiative as a whole are also 
included. The projects of this research initiative are the following: 
• SCR&Tox: Stem cell differentiation for providing human-based organ 
specific target cells to assay toxicity pathways in vitro. 
• HemiBio: Development of a hepatic microfluidic bioreactor mimicking 
the complex structure and function of the human liver. 
• DetetcIVE: Identification and investigation of human biomarkers in 
cellular models for repeated dose in vitro testing. 
• COSMOS: Delivery of an integrated suite of computational tools to 
predict the effects of long-term exposure to chemicals in humans based 
on in silico calculations. 
• NOTOX: Development of systems biological tools for organotypic 
human cell cultures suitable for long term toxicity testing and the 
identification and analysis of pathways of toxicological relevance. 
• ToxBank: Data management, cell and tissue banking, selection of 
reference compounds and chemical repository 
• COACH: Cluster level coordinating and support action 
SEURAT-1 annual report, 2012. Towards the Replacement of in vivo 
repeated Dose Systemic Toxicity Testing. Volume 2. Available from: 
http://www.seurat1.eu/media/download_gallery/SEURAT%201v2(BD).pdf 
This publication is the second volume of a series of six Annual Reports that 
summarises the activities of the SEURAT-1 Research Initiative in the field of 
repeated dose systemic toxicity. The core of this second Annual Report is formed 
by a comprehensive overview of the first results obtained in the different projects 
of the SEURAT-1 Research Initiative. This is given in the context of recent 
developments in European legislation regarding the regulation of chemicals to 
improve their safety assessment and related international activities. 
The SCR&Tox report focuses on the development of quality control standards 
that can be applied in routine pluripotent stem cell-based toxicity testing. 
• HeMiBio reports on the generation of the different bioreactor prototypes 
including the incorporation of high-resolution fluorescent markers into 
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pluripotent stem cells as well as the initial complement of 
electrochemical sensors. 
• DETECTIVE will deliver functional as well as ‘-omics’ biomarkers for 
different organs (liver, heart and kidney) and reports about first 
experiments to evaluate the most appropriate human cellular model 
system for each organ. 
• Data sets likely to be of use to the COSMOS project, suitable for the 
development of in silico models, have been identified. A non-cancer 
dataset about Thresholds for Toxicological Concern (TTC) for cosmetic 
ingredients has been compiled and the applicability of the TTC approach 
to cosmetic ingredients has been explored. Furthermore, a process based 
model able to simulate the dynamics of a chemical compound in cell-
based assays has been developed as a basis for in vitro – in vivo 
extrapolations. 
• NOTOX describes the establishment of a spheroid cultivation system and 
its successful application in several cell lines. First toxicity tests have 
been carried out and ‘-omics’ profiles as well as structural changes were 
monitored. Tools of integrative and predictive computational systems 
biology were applied to integrate information obtained from iterative 
cycles of model predictions and experimental validations by in vitro 
experiments, in order to eventually predict the possible toxicity of test 
compounds in vivo. 
• The ToxBank report focuses on the selection of standard reference 
compounds (‘gold compounds’) for toxicity testing and the development 
of a shared cross-cluster database to enable an integrated data analysis. 
• The COACH report provides information about the cross-cluster 
coordination, facilitating exchange activities between the projects, and 
dissemination of research activities at the cluster level. 
SEURAT-1, 2013. Towards the Replacement of in vivo repeated Dose 
Systemic Toxicity Testing. Volume 3. Available from: http://www.seurat-
1.eu/media/download_gallery/SEURAT%201-v3%28bd.pdf. 
This publication is the third volume of a series of six Annual Reports that 
summarise the activities of the SEURAT-1 Research Initiative. This third Annual 
Report, prepared by the coordination and support action project COACH, 
presents a comprehensive overview of research highlights from the different 
projects of the SEURAT-1 Research Initiative. This is given in the context of 
recent developments in European legislation regarding the regulation of 
chemicals to improve safety assessment and related international activities. 
Hepatotoxicity 
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Russmann, S., Kullak-Ublick, G.A., and Grattagliano, I. 2009. Current 
Concepts of Mechanisms in Drug-Induced Hepatotoxicity. Current 
Medicinal Chemistry 16, 3041-3053 
This review summarises current mechanistic concepts of Drug-induced liver 
injury (DILI) in a 3-step model that limits its principle mechanisms to three main 
ways of initial injury, i.e. direct cell stress, direct mitochondrial impairment, and 
specific immune reactions. Initial injury initiates further downstream events, i.e. 
direct and death receptor-mediated pathways leading to mitochondrial 
permeability transition, which then results in apoptotic or necrotic cell death. For 
all mechanisms, mitochondria play a central role in events leading to apoptotic 
versus necrotic cell death. 
Gómez-Lechón, M.J., Lahoz, A., Gombau, L., Castell, J.V., Donato M.T., 
2010. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr 
Pharm Des. 16(17), 1963-77. 
This paper describes the molecular mechanisms of hepatotoxicity. All of them 
have direct effects on organelles such as mitochondria, the endoplasmic 
reticulum, the cytoskeleton, microtubules, or the nucleus or indirect effects 
through the activation or inhibition of signalling kinases, enzymes, transcription 
factors and gene expression profiles. The resulting intracellular stress leads to 
death by either apoptosis or necrosis. The most important systems to study 
hepatotoxicity and metabolic activity in vitro are liver slices, isolated liver cells 
in suspension or in primary cultures including co-culture methods and special 3D 
techniques, various subcellular fractions and cell lines. These models can be used 
for cytotoxicity and genotoxicity screening and also to identify the mechanisms 
involved in drug-induced hepatotoxicity. The development of robust in vitro-
based multiparametric screening assays covering a wider spectrum of key effects 
will improve the predictive capacity for human hepatotoxicity. 
Landesmann B., Goumenou M., Munn S., Whelan M. 2012. Description of 
prototype modes-of-action related to repeated dose toxicity. JRC Scientific 
and Policy Report EUR 25631 EN. Publications Office of the European 
Union, Luxembourg. Available from: 
http://publications.jrc.ec.europa.eu/repository/ 
This report presents the definition and detailed documentation of chosen 
toxicological MoAs associated with repeated dose target organ toxicity as a first 
step in building a "prototype" safety assessment framework. In addition to 
providing a detailed description of the two chosen MoAs related to chronic liver 
toxicity, namely "MoA from Protein Alkylation to Liver Fibrosis" and "MoA 
from Liver X Receptor Activation to Liver Steatosis", the report also describes 
the working process leading to this result including the problems that have been 
encountered, such as scarcity of quantitative data and the difficulty in capturing 
and describing complex non-linear processes in a narrative manner. 
The exercise followed as far as possible relevant WHO-IPCS and OECD 
guidance and the results have been introduced into a Wiki-based forum that is 
being developed by the US EPA and the JRC. 
Porceddu, M., Buron, N., Roussel, C., Labbe, G., Fromenty, B., and 
Borgne-Sanchez, A., 2012. Prediction of Liver Injury Induced by 
Chemicals in Human With a Multiparametric Assay on Isolated Mouse 
In this study the authors aimed to improve early prediction of DILI in humans by 
investigating drug-induced mitochondrial dysfunction as this toxic effect is a 
major mechanism of DILI. They developed a high-throughput screening platform 
  171 
Liver Mitochondria. Toxicological Sciences 129(2), 332-345. using isolated mouse liver mitochondria. Their multiparametric assay was 
designed to detect the global mitochondrial membrane permeabilization 
(swelling), inner membrane permeabilization (transmembrane potential), outer 
membrane permeabilization (cytochrome c release), and alteration of 
mitochondrial respiration driven by succinate or malate/glutamate. This screening 
assay revealed high sensitivity for clinical outcome of DILI (94 or 92% 
depending on cutoff) and a high positive predictive value (89 or 82%). A highly 
significant relationship between drug-induced mitochondrial toxicity and DILI 
occurrence in patients was calculated (p < 0.001). Moreover, it allowed 
identifying several compounds for which mitochondrial toxicity had never been 
described before and even helped to clarify mechanisms with some drugs already 
known to be mitochondriotoxic. The authors conclude that investigation of drug-
induced loss of mitochondrial integrity and function with this multiparametric 
assay should be considered for integration into basic screening processes at an 
early stage to select drug candidates with lower risk of DILI in human. This assay 
is also a tool for assessing the mitochondrial toxicity profile and investigating the 
mechanism of action of new compounds and marketed compounds. 
Tolosa, L., Pinto, S., Donato, M.T., Lahoz, A., Castell, J.V., O’Connor, 
J.E., and Gómez-Lechón, M.J., 2012. Development of a Multiparametric 
Cell-based Protocol to Screen and Classify the Hepatotoxicity Potential of 
Drugs. Toxicological Sciences 127(1), 187-198. 
In this paper the authors aimed to develop a practical, reproducible, in vitro 
multi-parametric cell-based protocol to assess those drugs that are potentially 
hepatotoxic to humans and to suggest their mechanisms of action. They used 
HepG2 human cell line cultured in 96-well plates and exposed to 78 different 
compounds for 3 and 24 h at different concentrations. They measured parameters 
associated with nuclear morphology, plasma membrane integrity, mitochondrial 
function, intracellular calcium concentration, and oxidative stress, indicative of 
pre-lethal cytotoxic effects and representative of different mechanisms of 
toxicity. These parameters were measured at the single cell level with the high-
content screening (HCS) technology, which allows high-throughput screening. 
The strategy presented appears to identify early and late events in the hepatotoxic 
process and also suggests the mechanism(s) implicated in the toxicity of 
compounds to thereby classify them according to their degree of injury (no 
injury, low, moderate, and high injury). 
Vinken M, Landesmann B, Goumenou M, Vinken S, Shah I, Jaeschke H, 
Willett C, Whelan M, Rogiers V, (2013). Development of an adverse 
outcome pathway from drug-mediated bile salt export pump inhibition to 
cholestatic liver injury. Toxicol Sci. 136(1): 97-106.  
Colestahsis insults are among the most severe clinical manifestations of drug-
induced liver injury. In this article, an Adverse outcome pathway (AOP) 
framework is proposed for cholestasis triggered by drug-mediated inhibition of 
the bile salt export pump transporter protein. An in-depth survey of relevant 
scientific literature was carried out in order to identify intermediate steps and key 
events. The latter include bile accumulation, the induction of oxidative stress and 
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inflammation, and the activation of specific nuclear receptors. Collectively, these 
mechanisms drive both a deteriorative cellular response, which underlies directly 
caused cholestatic injury, and an adaptive cellular response, which is aimed at 
counteracting cholestatic insults. The postulated AOP, which was developed 
according to the Organisation for Economic Co-operation and Development 
(OECD) guidance, is expected to serve as the basis for the development of new in 
vitro tests and the characterization of novel biomarkers of drug-induced 
cholestasis. 
Cellular pathways 
Wilmes, A., Crean, D., Aydin, S., Pfaller, W., Jennings, P., Leonard, M.O., 
2011. Identification and dissection of the Nrf2 mediated oxidative stress 
pathway in human renal proximal tubule toxicity. Toxicology in Vitro 25, 
613-622. 
The authors have used whole genome DNA microarrays in an attempt to uncover 
molecular mechanisms of response to nephrotoxin exposure. For this purpose 
they treated human proximal tubular epithelial cells (HK-2 cell line) with three 
unrelated chronic nephrotoxins: the heavy metal and environmental pollutant 
cadmium, the contact herbicide diquat dibromide and the immunosuppressive 
calcineurin inhibitor cyclosporine. Using bioinformatic pathway analysis they 
identified the Nrf2 pathway as the most prominently altered pathway. 
Furthermore, they could demonstrate a Nrf2 dependent induction of HO-1 and 
NQO1 and that HO-1 is protective to cadmium toxicity. This study highlights the 
importance of HO-1 as a possible common biomarker for nephrotoxicity and as a 
mechanism of protection against nephrotoxic chemical damage. 
Jennings, P., Limonciel, A., Felice, L., Leonard, M.O. 2013. An overview 
of transcriptional regulation in response to toxicological insult. Arch. 
Toxicol. 87:49-72. 
This review summarises the major toxicologically relevant transcription factor-
governed molecular pathways. The authors focus on current knowledge of 
transcriptional responses to toxic exposure and describe how toxins can directly 
or indirectly produce distinct gene expression bio-signatures. They focus on the 
top-level response of transcription factor activation: 
• The cap ‘‘n’’ collar (CNC) subfamily of bZIP transcription factors, 
which is one of the best characterised responders to toxin exposure and is 
activated in response to oxidative or electrophilic stress. 
• The p53 pathway, which plays a pivotal role in differentiation and 
tumour suppression and has been extensively studied in many contexts 
including irradiation, carcinogenicity, ageing and toxicity. 
• The aryl hydrocarbon receptor which is a member of the bHLH/PAS 
family of transcription factors highly conserved through evolution and 
initially characterised as mediating the toxic effects of pollutants. 
• The nuclear receptor family which is the largest group of transcriptional 
regulators involved in xenobiotic sensing and toxicological response. 
  173 
• Immunomodulatory transcription factors: interference with normal 
immune regulatory signalling pathways is a primary cause of 
immunotoxicity observed with xenobiotic exposure. 
• Hypoxia-inducible factors: its activation orchestrates the transcriptional 
regulation of many processes including, erythropoiesis, glycolysis and 
angiogenesis. 
• The unfolded protein response which is mounted when ER stress is 
detected and serves primarily to return normal endoplasmic reticulum 
function. 
• Metal responsive transcription factor-1, which is primarily involved in 
directing gene expression in response to various heavy metals but can 
also respond to other cellular stresses such as hypoxia and oxidative 
chemical species. 
• Heat shock factors (HSF1-4) are considered major responders to 
proteotoxic stimuli including heat shock for which they were first 
discovered, and diverse environmental chemical and physiological 
stresses where protein mis-folding is the common factor. 
• Mitochondria is a major target for toxicant induced cellular injury, and 
alterations in the transcriptional regulation of components of this 
important organelle are clear indications of cellular stress. 
• Tissue-specific transcriptional regulation and in particular the authors 
discuss transcription factor control of renal epithelial cell differentiation 
and the response to toxicant-induced injury. 
 
The authors conclude that it is possible to gain important information regarding 
possible mechanisms of toxicity from analysing the likely transcriptional 
regulators responsible for the pattern of gene expression. This can now be 
achieved through the use of pathway analysis software. 
Wilmes, A., Limonciel, A., Aschauer, L., Moenks, K., Bielow, C., Leonard, 
M.O., Hamon, J., Carpi, D., Ruzek, S., Handler, A., Schmal, O., Herrgen, 
K., Bellwon, P., Burek, C., Truisi, G.L., Hewitt, P., Di Consiglio, E., 
Testai, E., Blaauboer, B.J., Guillou, C., Huber, C.G., Lukas, A., Walter, P., 
Mueller, S.O., Bois, F.Y., Dekant, W., Jennings, P., 2013. Application of 
integrated transcriptomic, proteomic and metabolomic profiling for the 
delineation of mechanisms of drug induced cell stress. J Proteomics 79, 
180-194. 
This paper investigates the added benefit of integrating transcriptomics, 
proteomics and metabolomics together with pharmacokinetics for application in 
drug safety, utilising cultured human renal epithelial cells treated with therapeutic 
and supratherapeutic concentrations of the nephrotoxin Cyclosporine A in repeat 
dose regimes (14 days). The results clearly showed that cells are simultaneously 
experiencing mitochondrial perturbations, oxidative- and ER-stress only at the 
high CsA concentration. 
However, CyP-B secretion was maximum already at the low CsA concentration. 
This study demonstrates that in vitro cell culture systems coupled with 
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pharmacokinetics and high content omic approaches can give extremely detailed 
and quantitative insights into both the pharmacological and toxicological effects 
of compounds. 
Hamon J, Jennings P, Bois FY, (2014). Systems biology modeling of omics 
data: effect of cyclosporine a on the Nrf2 pathway in human renal cells. 
BMC Syst Biol. 8(1): 76. doi:10.1186/1752-0509-8-76. 
One of the challenges of quantitative modeling of toxicity pathways is to 
integrate omics data with systems biology models for parametric inference and 
model checking. In this article the authors present a quantitative calibration of a 
differential equation model of the nuclear factor (erythroid-derived 2)-like 2 
pathway (Nrf2) pathway with a subset of the omics data previously published by 
Wilmes et al. (2013). In that publication Wilmes and colleagues showed that 
cyclosporine A (CsA) strongly activates Nrf2 in renal proximal tubular epithelial 
cells (RPTECs) exposed in vitro.  
Modeling was done into two steps: (i) Modeling the in vitro pharmacokinetics 
(PK) of CsA (exchange between cells, medium and vial walls) with a minimal 
distribution model. (ii) Modeling the effects of CsA on omics markers at the 
cellular level with a coupled PKsystems biology model. Posterior statistical 
distributions of the model parameter values were obtained by Markov chain 
Monte Carlo sampling in a Bayesian framework. The authors concluded that the 
model proposed can be used to analyze and predict cellular response to oxidative 
stress, provided sufficient data to set its parameters to cell-specific values. Omics 
data can be used to that effect in a Bayesian statistical framework which retains 
prior information about the likely parameter values. 
Biokinetic considerations 
Zaldivar Comenges J.M.,Menecozzi, M., Macko, P., Rodriguez, R., 
Bouhifd, M., and Baraibar Fentanes, J., 2011. A Biology-Based 
DynamicApproach for the Modelling of Toxicity in Cell Assays: PartII: 
Models for Cell Population Growth and Toxicity. JRC Scientific and 
Technical Report EUR 24898 EN. Publications Office of the European 
Union, Luxembourg. Available from: 
http://publications.jrc.ec.europa.eu/repository/ 
This paper provides a mathematical approach for extrapolating from in vitro 
concentrations to in vivo dose. To do this extrapolation it is necessary to be able 
to calculate and compare the free concentrations in both systems  
Concerning the in vitro side, the authors has previously developed and 
implemented, based on HTS (High Throughput Screening) laboratory data, a 
compound fate model using the partitioning approach. The developed fate model 
was able to predict the role of serum in toxicity assays as well as provide 
estimation on the partitioning of a certain compound between the headspace, 
plastic wall and the medium (attached to serum, free dissolved and attached to the 
cells). However, the partitioning approach assumes that the equilibrium is fast in 
comparison with the duration of the experiments, which could not be the case for 
the partitioning to the cells. For this reason, a DEB (Dynamic Energy Budget) 
stage-based toxicity model was developed and experimentally verified in this 
work. The results show that this approach offers the possibility of extrapolating 
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the values obtained to calculate in vivo human toxicology thresholds using a 
PBTK modelling approach. 
Coecke, S., Pelkonen, O., Leite, S.B., Bernauer, U., Bessems, J.G., Bois, 
F.Y., Gundert-Remy, U., Loizou, G., Testai, E., Zaldívar, J.M., 2013. 
Toxicokinetics as a key to the integrated toxicity risk assessment based 
primarily on non-animal approaches. Toxicol. In Vitro 27(5): 1570-7..  
This review summarises the current situation regarding toxicokinetics and it 
develops further some critical areas, such as crucial requirements of in vitro 
kinetics and conditions for the total replacement of animal toxicity tests. A set of 
recommendations are also provided. The conclusions from the authors are as 
follows: 
- For a proper in vitro–in vivo extrapolation of toxic responses, it is imperative to 
understand in vitro kinetics in in vitro toxicity testing systems. 
- Without the toxicokinetic information it remains questionable whether 
toxicodynamic effects observed at specific in vitro concentration ranges have any 
relevance for human exposure condition. 
- These contributions are a key for a further development of animal-free testing 
for systemic toxicity. 
- Full integration of kinetic expertise into design and execution of toxicity testing 
and risk assessment is essential, however, when risk assessment uses only in vitro 
data, it is indispensable to link toxicokinetic with toxicodynamic effect models 
based on in vitro tests. 
- For several kinetic parameters needed to parameterise PBTK models, non-
animal methods are available for chemicals at various levels of development. 
However, the authors concluded that alternative methods are lacking completely 
for predicting renal and biliary excretion, as well as absorption in the lung. 
Diaz Ochoa JG, Bucher J, Péry AR, Zaldivar Comenges JM, Niklas J, 
Mauch K. 2012. A multi-scale modeling framework for individualized, 
spatiotemporal prediction of drug effects and toxicological risk. Frontiers in 
Pharmacology 3, 204. 
This paper describes a multi-scale modelling approach for spatiotemporal 
prediction of the distribution of substances and resulting hepatotoxicity by 
combining cellular models, a 2D liver model, and whole body model. As a case 
study, the authors focused on predicting human hepatotoxicity upon treatment 
with acetaminophen based on in vitro toxicity data and potential inter-individual 
variability in gene expression and enzyme activities. By aggregating mechanistic, 
genome-based in silico cells to a novel 2D liver model and eventually to a whole 
body model, they predicted pharmacokinetic properties, metabolism, and the 
onset of hepatotoxicity in an in silico patient. Depending on the concentration of 
acetaminophen in the liver and the accumulation of toxic metabolites, cell 
integrity in the liver as a function of space and time as well as changes in the 
elimination rate of substances were estimated. They showed that the variations in 
elimination rates also influence the distribution of acetaminophen and its 
metabolites in the whole body. The integrated model also predicted variations in 
drug toxicity depending on alterations of metabolic enzyme activities. Variations 
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in enzyme activity, in turn, reflect genetic characteristics or diseases of 
individuals. 
Broeders, J.J.W., Blaauboer, B.J., Hermens, J.L.M., 2013. In vitro 
biokinetics of chlorpromazine and the influence of different dose metrics on 
effect concentrations for cytotoxicity in Balb/c 3T3, Caco-2 and HepaRG 
cell cultures. Toxicology in Vitro 27, 1057–1064. 
In this paper, the cytotoxicity (measured by Alamar Blue) and biokinetics of the 
antipsychotic chlorpromazine were studied in in vitro assays using different cell 
types (Balb/c 3T3, Caco-2 and HepaRG cells) and exposure conditions. Different 
dose metrics (the nominal, measured total and measured free chloropromazine  
medium concentrations) were assessed to express the sensitivity to 
chlorpromazine. Based on the results the authors had the following observations: 
(i) the concentration in the medium may decrease over time simply due 
to uptake into the cells, (ii) the decrease in medium concentration will be higher 
in an in vitro test with a higher cell density, (iii) the decrease in medium 
concentration over time will be lower at dose levels where cytotoxicity occurs, 
and (iv) conclusions about differences in sensitivity between cell systems based 
on nominal or even measured total concentrations often do not represent the 
differences in intrinsic sensitivity, and therefore they concluded that the freely 
dissolved concentration is a more appropriate dose metric than total concentration 
in the medium in comparing the sensitivity of the tested cell systems. The ranking 
in sensitivity was dependent on the dose metric used. 
Schug, M., Stöber, R., Heise, T., Mielke, H., Gundert-Remy, U., Godoy, P., 
Reif, R., Blaszkewicz, M., Ellinger-Ziegelbauer, H., Ahr, H.J., Selinski, S., 
Günther, G., Marchan, R., Blaszkewicz, M., Sachinidis, A., Nüssler, A., 
Oberemm, A., Hengstler, J.G., 2013. Pharmacokinetics explain in vivo/in 
vitro discrepancies of carcinogen-induced gene expression alterations in rat 
liver and cultivated hepatocytes. Arch. Toxicol. 87, 337-345. 
In this study the authors aimed to elucidate the reason why the non-genotoxic rat 
liver carcinogen methapyrilene alters the expression of the metabolizing genes 
SULT1A1 and ABAT, as well as the DNA damage response gene GADD34 in 
vitro, but not in vivo. There are two major limitations when using cultivated 
primary hepatocytes in toxicogenomics. Firstly, hepatocytes undergo massive 
gene expression alterations, particularly during the first 24h in culture. Therefore, 
gene expression alterations induced by test compounds have to be analyzed 
against a ‘‘noisy’’ background. Secondly, huge discrepancies between test 
compound-induced gene expression alterations in the liver in vivo and in 
hepatocytes in vitro have been reported. If the in vitro rat primary hepatocytes 
really induce false-positive results, further investment into its development as a 
tool for toxicogenomics for the in vivo situation is not justified. However, the 
data of this study demonstrate that the putative discrepancy has a 
pharmacokinetic explanation. The relatively short half-life of 2.8 h implies a 
rapid decrease in orally administered methapyrilene in vivo below concentrations 
that can cause gene expression alterations. RNAlevels are altered 1, 6 and 12 h 
after methapyrilene administration, but return to control levels after 24 and 72 h. 
In contrast, methapyrilene concentrations in the culturemediumsupernatant of 
primary rat hepatocyte cultures decreased slowly. This explains why GADD34, 
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ABAT and SULT1A1 were still deregulated after 24 h exposure in vitro, but not 
in vivo. The different pharmacokinetics in the 6-well dish compared to the in vivo 
situation is an interesting example to demonstrate the need for so-called in vitro 
biokinetic studies, in particular, if effects are to be monitored over a time period 
of several days. The authors conclude that the different pharmacokinetics of 
methapyrilene HCl in vivo and in vitro sufficiently explains the previously 
reported discrepancy. 
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8. Genotoxicity and mutagenicity 
 
Raffaella Corvi, Federica Madia & Andrew Worth 
 
 
8.1 The traditional in vitro and in vivo tests and their regulatory use 
Genetic alterations in somatic and germ cells are associated with serious health effects, which in 
principle may occur even at low exposure levels. Mutations in somatic cells may cause cancer if 
mutations occur in proto-oncogenes, tumour suppressor genes and/or DNA damage response 
genes, and are responsible for a variety of genetic diseases (Erickson, 2010). Accumulation of 
DNA damage in somatic cells has also been proposed to play a role in degenerative conditions 
such as accelerated aging, immune dysfunction, cardiovascular and neurodegenerative diseases 
(Hoeijmakers, 2009; Slatter & Gennery, 2010; De Flora & Izzotti, 2007; Frank, 2010). Mutations 
in germ cells can lead to spontaneous abortions, infertility or heritable damage to the offspring 
and possibly to the subsequent generations.  
 
Currently, the assessment of genotoxic hazard to humans follows a stepwise approach, beginning 
with a basic battery of in vitro tests followed in some cases by in vivo testing. Regulatory 
requirements, in particular for in vivo testing, vary depending on the type of chemical under 
regulation and the region. For cosmetics, in vivo testing is prohibited in the EU (EC No 
1223/2009; SCCS, 2012), while for industrial chemicals and biocidal products a positive outcome 
in one or more of the in vitro genotoxicity tests requires confirmation by appropriate follow-up in 
vivo testing (EC no. 1907/2006; EC no. 528/2012)). In these cases, if a substance is clearly 
negative in the in vitro battery it is considered as having no genotoxic hazard, thus no further in 
vivo study is needed. Regulatory requirements for pharmaceuticals, veterinary drugs and plant 
protection products foresee that the in vitro testing battery (irrespective of the outcome) is always 
followed by in vivo testing (ICH, 2011; VICH, 2012; EC No 1107/2009 and 283/284-2013).  
 
The standard in vitro test battery comprises the bacterial reverse mutation assay (OECD TG 471), 
the in vitro mammalian chromosomal aberration test (OECD TG 473), and the in vitro 
mammalian cell gene mutation test (OECD TG 476), and the in vitro mammalian cell 
micronucleus test (OECD TG 487). 
 
In vivo tests comprise the mammalian erythrocyte micronucleus test (OECD TG 474), the 
mammalian bone marrow chromosomal aberration test (OECD TG 475), the rodent dominant 
lethal assay (OECD TG 478), the mammalian spermatogonial chromosome aberration test 
(OECD TG 483), the mouse heritable translocation assay (OECD TG 485), the unscheduled 
DNA synthesis (UDS) test with mammalian liver cells in vivo (OECD TG 486), the transgenic 
rodent somatic and germ cell gene mutation assay (OECD TG 488) and the in vivo mammalian 
alkaline comet assay (draft OECD TG).  
 
The standard genotoxicity tests are summarised in Table 8.1. 
 
8.2 Mechanistic understanding of the endpoint 
Genotoxicity testing include both the measurement of direct, irreversible damage to the DNA 
("mutagenicity"), that is transmissible to the next cell generation, as well as the measurements of 
early, potentially reversible effects on the DNA or on mechanisms involved in the preservation of 
the integrity of the genome ("genotoxicity"). The definitions of the terms "mutagenicity" and 
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"genotoxicity" are taken from the REACH "Guidance on information requirements and chemical 
safety assessment" (ECHA, 2012). 
 
Mutagenicity refers to the induction of permanent transmissible changes in the amount or 
structure of the genetic material of cells or organisms. These changes may involve a single or 
block of base pairs, single gene or gene segment, a block of genes or chromosomes. The term 
clastogenicity is used for agents giving rise to structural chromosome aberrations. A clastogen 
can cause breaks in chromosomes that result in the loss or rearrangements of chromosome 
segments. Aneugenicity refers to the effects of agents that give rise to a change (gain or loss) in 
chromosome number. 
 
Genotoxicity is a broader term and refers to processes, which alter the structure, information 
content or segregation of DNA and are not necessarily associated with mutagenicity. Thus, tests 
for genotoxicity include tests which provide an indication of induced damage to DNA (but not 
direct evidence of mutation), as well as tests for mutagenicity. 
 
The detection of changes or damage directly to the DNA without measuring the adverse 
consequences of the genetic damage is generally performed with indicator tests. For example, 
some covalent DNA adducts do not change the coding properties of the DNA. Other damage 
such as that measured by the comet assay may be accurately repaired or inevitably leads to cell 
death, which does not pose a genotoxic hazard to the organism. Indicator tests may provide a 
measure of (target tissue) exposure or information on the mode of action (e.g. by indicating DNA 
interaction).  
 
For an adequate evaluation of the genotoxic potential of a chemical substance, different endpoints 
(i.e. induction of gene mutation, structural and numerical chromosome alterations) have to be 
assessed, as each of these events has been implicated in carcinogenesis and heritable diseases but 
an adequate coverage of all endpoints can only be obtained by the use of multiple test systems 
(i.e. a testing battery), as no individual test system currently covers all endpoints.  
 
Even though a number of well-established in vitro methods are available and officially accepted 
for genotoxic hazard assessment (Table 8.1), new methods and strategies continue to be 
developed.  This is because the existing in vitro methods, while having a high sensitivity (and 
thus low false negative rate), have a relatively low specificity and thus high rate of false 
(“misleading”) positive results, which typically leads to follow-up testing in vivo for the 
confirmation of these results (Kirkland et al., 2005).  During a workshop organised by ECVAM 
(2006, Ispra, Italy) the high rate of unexpected positive results in in vitro mammalian cell 
genotoxicity tests was addressed (Kirkland et al., 2007). It was recommended that better guidance 
on the likely mechanisms resulting in positive results not relevant for humans, and how to obtain 
evidence for these mechanisms was needed. Among the identified reasons for misleading 
positives are high cytotoxicity, high passage number, deficient p53 status, deficient DNA repair. 
The workshop recommendations paved the way for several international collaborative initiatives 
aiming to improve the existing genotoxicity in vitro tests and to identify and evaluate new cell 
systems with appropriate sensitivity but improved specificity.  
 
Several options are currently being explored to improve the overall assessment of genotoxicity: 
improvement of the existing standard tests, development of new tests, and development of 
integrated testing strategies (ITS) with emphasis on reducing the need for animal testing.  
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8.3 Improvement of standard tests 
The first option is partly addressed by the current revision of the OECD TGs for genotoxicity and 
development of an Introduction document to the OECD guidelines on genetic toxicology testing 
and a Guidance document on the selection and application of assays, in support of the 
Genotoxicity Test Guidelines (in preparation). The revision is taking into account the knowledge 
acquired during the last decades of testing and the results from recent collaborative studies (Parry 
et al., 2010; Kirkland and Fowler, 2010; Fowler et al., 2012a, 2012b), including 
recommendations on testing at reduced maximum concentration, careful choice of the cell lines 
and measure of cytotoxicity. The revised TGs are expected to enhance the quality of the data 
produced and consequently avoid in some cases the need for in vivo confirmation of the results. 
 
8.4 Development of new in vitro tests 
A number of new test methods are being developed and validated with the aim of improving the 
specificity of in vitro tests while maintaining an appropriate sensitivity. For the development of 
new test systems, an ECVAM workshop concluded that cell systems of human origin which are 
p53 and DNA repair proficient, and have defined phase 1 and phase 2 metabolism, offer the best 
option to reduce unexpected positive or negative results in the future (Kirkland et al, 2007).  
 
The micronucleus test and the comet assay in 3D human reconstructed skin models offer the 
potential for a more physiologically relevant approach for dermal exposure and metabolism (Hu 
et al., 2010). It is anticipated that these reconstructed skin models could improve the predictive 
value of a genotoxicity assessment compared with existing in vitro tests and, therefore, could be 
used as a follow-up test in case of positive results from the standard in vitro genotoxicity testing 
battery (Maurici et al., 2005; Pfuhler et al., 2010; Kirsch-Volders et al., 2011). Several 3D skin 
models are commercially available and are suitable for conducting such tests, provided that 
sufficient cell proliferation is available. A micronucleus test protocol using the EpiDermTM model 
(MatTek Corporation, Ashland, MA, USA) has been developed and evaluated with a variety of 
chemicals across three laboratories (Curren et al., 2006; Mun et al., 2009; Hu et al. 2010). An on-
going multi-laboratory prevalidation study coordinated by Cosmetics Europe aims at establishing 
the reliability of the method (Aardema et al., 2010) and at increasing the domain of chemicals 
tested for predictive capacity.  The comet assay in reconstructed skin models is a rapid and 
sensitive method to evaluate primary DNA damage and it could be used as a follow-up test for 
chemicals that cause gene mutation in the in vitro standard tests. Indeed, the International 
Workshop on Genotoxicity Testing (2009) suggested the in vitro comet assay in the 3D skin 
model as a valuable support to genotoxicity identification as i) it is, differently than the 
micronucleus test, independent of cell proliferation and ii) it covers a broader spectrum of DNA 
damage. Similarly to the micronucleus test, a protocol using the EpiDermTM model has been 
developed and evaluated across different laboratories (Reus et al., 2013). An on-going 
collaborative study between Cosmetics Europe and a German Consortium funded by BmBF 
regards also the evaluation of the comet assay in epidermis full thickness: a reconstructed skin 
model with a fully developed in vivo-like basement membrane (Epiderm-FTTM). Ultimately, it 
will be important to demonstrate whether these tests have an equivalent sensitivity and a better 
specificity compared to the standard in vitro genotoxicity mammalian cell tests. 
 
Another promising system that has been proposed as a follow-up for in vitro positives is the hen's 
egg test for micronucleus induction (HET-MN; Wolf et al., 2008). The HET-MN combines the 
use of the commonly accepted genetic endpoint “formation of micronuclei” with the well-
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characterized model of the incubated hen's egg, which enables metabolic activation, elimination 
and excretion of xenobiotics, including those that are mutagens or pro-mutagens. Studies on 
metabolism indicate that certain important phase I and II enzymes are active and, therefore, the 
detection of liver mutagens is possible. A German Consortium ring trial prevalidation study is 
on-going and a first report has been published on the reproducibility and robustness of the HET-
MN for the prediction of genotoxicity (Greywe et al., 2012).  
 
The in vitro cell transformation assays (CTA) are not genotoxicity assays, but they have been 
established in order to predict carcinogenicity (DiPaolo et al., 1969; Isfort et al., 1996; Matthews 
et al., 1993; LeBoeuf et al., 1999; SLA on carcinogenicity). The CTAs measure the 
transformation of cells and have the potential to detect both genotoxic and non-genotoxic 
carcinogens. The assays could be used as a follow-up assay for confirmation of in vitro positive 
results from genotoxicity assays as part of a weight of evidence assessment. Furthermore, data 
generated by the CTA can be useful for the genotoxicity assessment of chemical classes that are 
not reliably predicted by traditional in vitro genotoxicity tests (e.g. aromatic amines) (EFSA, 
2011; Vanparys et al., 2012; EURL ECVAM, 2012). An OECD TG on CTA in Syrian hamster 
embryonic stem cells is being drafted (draft OECD TG on SHE CTA). Further information on 
CTA for the assessment of transforming potential is given in the carcinogenicity chapter. 
 
Toxicogenomics can be used to identify global gene expression changes associated with a 
toxicological outcome, including carcinogenicity and genotoxicity. In the context of genotoxicity 
testing, its primary use is envisaged to be in providing information on mode of action and such 
information can be useful supporting evidence (Doktorova et al., 2012). The application of 
toxicogenomics to predict mode of action has been recently reviewed in depth (Ellinger-
Ziegelbauer et al., 2009; Waters et al., 2010). Although the published in vitro and in vivo data set 
show appreciable variability, common features emerge with respect to molecular pathways. For 
instance, the DNA damage-responsive p53 pathway is extensively activated both by DNA 
reactive genotoxins in vitro and genotoxic carcinogens in vivo (Doktorova et al., 2013; Jennings 
et al., 2013). Conversely, in vitro DNA non-reactive genotoxins and in vivo non-genotoxic 
carcinogens mostly induce genes associated with oxidative stress, signalling and cell cycle 
progression. These data represent a first proof of concept that the gene expression profiles reflect 
the underlying mechanism of action. However, additional studies should be performed to enlarge 
the number of chemicals tested, to fill the gaps in dose-response and time-course relationships 
and in the case of in vivo toxicogenomics to analyse different routes of exposure and organ 
systems (most studies so far have used rat liver) and other species. At the moment, these tests 
should be used to generate supportive mechanistic information to improve the genotoxicity 
assessment, rather than for routine testing.  
 
In the last few years several attempts have been made to develop and validate the induction of 
stress pathways/proteins as endpoints in genotoxicity assays by using high throughput screening 
approaches. The choice of the pathways was mostly based on microarray experiments with 
genotoxic substances. The GreenScreen HC assay, which uses a p53-competent TK6 
lymphoblastoid cell line genetically modified to incorporate a fusion cassette containing the 
genotoxic stress-inducible GADD45alfa gene sequence including promoter region with the GFP 
gene as reporter (GADD45a-EGFP reporter plasmid pEPGD532) (Hastwell et al., 2006), has 
been widely characterised and its sensitivity and specificity confirmed in independent studies 
(Hastwell et al., 2009; Jagger et al., 2009; Birrel et al., 2010). This assay was further adapted to 
test chemicals that require metabolic activation (Billinton et al., 2010; Hughes et al., 2012). HTS 
luciferase reporter assays based on four different stress pathways (RAD51, Cystatin A p53 and 
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Nrf2) in the HepG2 cell line have also been developed and shown to be useful for screening in 
early phases of drug development with the potential to reduce the attrition rate due to 
genotoxicity in the developmental phase of drug development (Westernik et al., 2010). On the 
basis of currently available information, these assays represent suitable in vitro screening 
methods for the ability to detect DNA damage induced by a broad spectrum of genotoxic insults.  
 
8.5 In silico models 
A number of in silico tools (QSAR models and expert systems) for genotoxicity are available, 
including freely available software in the public domain. These tools have been extensively 
characterised in the scientific literature (Serafimova et al 2010; Worth et al, 2010). In general, 
available QSAR models are based on DNA reactivity and predict Ames mutagenicity with high 
sensitivity. As with in vitro tests, this is generally accompanied with a high percentage of false 
positive predictions. Public domain tools include CAESAR (http://www.vega-qsar.eu/) and Lazar 
(Helma, 2006). 
 
Expert systems are ruled-based, with the rules being derived by expert knowledge and/or 
statistical induction. These systems typically aggregate data from multiple sources, and may 
therefore provide a “high level” assessment of genotoxic potential rather than reproduce specific 
and standardised test methods. Public domain tools include rulebases in Toxtree (Benigni et al., 
2008) and profilers in the OECD QSAR Toolbox (OECD, 2010d). The QSAR Toolbox can be 
used to group chemicals for read-across, an approach which may also be used to identify non-
genotoxic chemicals (Worth et al., 2012). Relatively few in silico tools are available for the 
prediction of in vivo genotoxic potential, and further efforts are needed to develop and evaluate 
these methods. 
 
8.6 Development of integrated testing strategies 
It is important to consider all available, relevant knowledge on the substance which may have an 
impact upon the selection of tests and/or may indicate that more or fewer genotoxicity tests are 
needed on the substance than defined by the standard information requirements. This existing 
information, which may include other toxicity data, physico-chemical and biokinetics properties, 
confounding factors, as well as mechanistic data, may be helpful for the interpretation of in vitro 
genotoxicity test results (Dearfield et al., 2011).  Additional in vitro tests may also be considered 
as part of follow-up testing for in vitro positive genotoxic results to generate supplementary 
information regarding mechanism (or mode) of action and to clarify the relevance of the positive 
results for humans. In this regard, in vitro tests which detect primary DNA damage (defined as 
indicator tests) or tests that measure gene expression may be considered particularly useful. At 
the moment the results of these non-standard methods are to be considered to add weight of 
evidence for improved genotoxicity risk assessments in humans (Lynch et al., 2011). 
 
Recently, the EFSA Scientific Committee and the UK Committee on Mutagenicity of Chemicals 
in Food, Consumers Products, and the Environment (COM) recommended that the set of tests 
used in the in vitro battery be as small as scientifically justifiable in order to reduce the number of 
misleading positives (EFSA, 2011; COM, 2011). Based on a recent data analysis (Kirkland et al., 
2011), a two tests initial step of testing has been proposed which includes the bacterial reverse 
mutation assay (OECD TG 471) and the in vitro micronucleus assay (OECD TG 487). As the in 
vitro micronucleus assay detects two of the endpoints (i.e. structural and numerical chromosome 
aberration), the proposed two-test battery covers all three endpoints to be assessed in the standard 
testing battery. 
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With the objective of reducing the use of experimental animals, the choice of the in vivo follow-
up test is critical and needs to cover the same endpoint as the one which showed positive results 
in vitro (Kirkland & Speit, 2008). As a default only one in vivo test should be performed initially. 
A second in vivo test should only be considered if the first in vivo test is negative, and does not 
cover all in vitro positive genotoxic endpoints (Dearfield et al., 2011). New in vivo tests have 
recently been developed in order 1) to be able to evaluate genotoxicity in almost all tissues, and 
2) to measure endpoints other than chromosome damage. However, with an increased number of 
in vivo tests available, there is a risk that more animals could be used in the future for the 
assessment of genotoxicity. Therefore, selection of the appropriate follow-up test is particularly 
important in view of the adoption of new in vivo genotoxicity OECD TGs (OECD TG 488 and 
draft OECD TG on comet assay).  
 
Several opportunities for reduction exist both at single test level (e.g. 1 sex versus 2 sexes, 
smaller animal groups) and ITS level (Pfuhler et al., 2009; EFSA, 2011). The integration of 
different endpoints into a single study (Pfuhler et al., 2009; Bowen et al., 2011) or the  
incorporation of in vivo genotoxicity endpoints into a short-term repeated dose toxicity test (28 
days) (Rothfuss et al., 2010, 2011; EFSA, 2011), if such a test is going to be performed anyhow, 
should always be considered. Most of the currently accepted in vivo tests are amenable to such 
integration. An integration of genotoxicity endpoints offers the possibility for an improved 
interpretation of genotoxicity findings since such data will be evaluated in conjunction with 
routine toxicological information obtained in the repeated dose toxicity study, such as 
haematology, clinical chemistry, histopathology and exposure data (Pfuhler et al., 2009). For 
substances that are somatic genotoxicants in vivo, the potential to affect germ cells should also be 
investigated.  It is reasonable to conclude that the substance can cause heritable genetic damage, 
provided that it has the ability to reach the gonads as its probably to interect with the DNA would 
be very high. Then no further testing should be performed and the substance can be considered a 
germ cell mutagen. 
 
8.7 Conclusions 
Several in vitro tests are available and officially accepted for the assessment of genotoxicity. 
However, despite the high sensitivity of these methods, the high percentage of false positives 
(low specificity) is problematic, and in most regulatory frameworks (including REACH) this 
triggers follow-up in vivo testing (Adler et al., 2011). 
 
A number of in silico (QSAR) tools are also available for predicting genotoxicity, and in 
particular in vitro mutagenicity. These tools can be used in a weight of evidence approach to add 
confidence to in vitro test results. 
 
A range of initiatives are aiming at the development of a new generation of in vitro tests, but 
none is yet sufficiently well developed and standardised for routine application in regulatory 
testing. In certain cases though, the results from these tests may be useful to provide 
supplementary data in a weight of evidence approach. 
 
The most promising near-term opportunities for applying the 3Rs in genotoxicity assessment will 
be through the improvement of standard tests and the development of integrated testing strategies 
with emphasis on reduction alternatives (EURL ECVAM, 2013). 
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Table 8.1. Standard genotoxicity test methods and endpoints 
 
Test  method Genotoxic endpoints EU method / OECD guideline 
   
In vitro test methods   
Bacterial reverse mutation test - Ames Mutagenicity: gene mutations EU B.12/13 OECD 471 
In vitro mammalian cell gene mutation test – 
HPRT, TK and XPRT tests  
Mutagenicity: gene mutations and 
structural chromosome aberrations (only 
in the TK test)  
EU B.17 
OECD 476* 
In vitro mammalian chromosome aberration 
test 
Mutagenicity: structural  chromosome 
aberrations 
EU B.10 
OECD 473** 
In vitro micronucleus test Mutagenicity: structural and numerical chromosome aberrations 
EU B.49 
OECD 487 ** 
In vivo test methods   
In vivo mammalian bone marrow 
chromosome aberration test 
Mutagenicity: structural chromosome 
aberrations 
EU B.11 
OECD 475** 
In vivo mammalian erythrocyte micronucleus 
test 
Mutagenicity: structural and numerical 
chromosome aberrations 
EU B.12 
OECD 474** 
Unscheduled DNA synthesis (UDS) test in 
mammalian liver cells in vivo Genotoxicity: DNA repair 
EU B.39 
OECD 486 
In vivo mammalian Comet assay Genotoxicity: DNA strand breaks EU (none) Draft OECD** 
Transgenic rodent somatic and germ cell gene 
mutation assay Mutagenicity: gene mutations 
EU (none) 
OECD 488 
Mouse heritable translocation assay Germ cell mutagenicity: structural and numerical chromosome aberrations 
EU B.25 
OECD 485 
Mammalian spermatogonial chromosome 
aberration test 
Germ cell mutagenicity: structural 
chromosome aberrations 
EU B.23 
OECD 483 
Rodent dominant lethal test Germ cell mutagenicity: structural and numerical chromosome aberrations 
EU B.22 
OECD 478 
* Two distinct guidelines are in preparation: one for hprt locus mutations detection and a second for tk locus. 
** Draft updated Test Guidelines approved. 
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Chapter 8. Table of References with Notes 
 
Traditional in vitro and in vivo tests – OECD TGs  
OECD (1997), Test No. 471: Bacterial Reverse Mutation 
Test, OECD Guidelines for the Testing of Chemicals, Section 
4, OECD Publishing. doi: 10.1787/9789264071247-en 
The bacterial reverse mutation test uses amino-acid requiring at least five strains of Salmonella 
typhimurium and Escherichia coli to detect point mutations by base substitutions or frame shifts. 
The principle of this bacterial reverse mutation test is that it detects mutations which, revert 
mutations present in the test strains and restore the functional capability of the bacteria to synthesize 
an essential amino acid.  
 
*OECD (1997), Test No. 473: In vitro Mammalian 
Chromosome Aberration Test, OECD Guidelines for the 
Testing of Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071261-en 
 
The purpose of the in vitro chromosome aberration test is to identify agents that cause structural 
chromosome aberrations in cultured mammalian somatic cells.  
OECD (1997),Test No. 476: In vitro Mammalian Cell Gene 
Mutation Test, OECD Guidelines for the Testing of 
Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071322-en 
The in vitro mammalian cell gene mutation test can be used to detect gene mutations induced by 
chemical substances. In the cell lines the most commonly-used genetic endpoints measure mutation 
at thymidine kinase (TK) and hypoxanthine-guanine phosphoribosyl transferase (HPRT), and a 
transgene of xanthineguanine phosphoribosyl transferase (XPRT). The TK, HPRT and XPRT 
mutation tests detect different spectra of genetic events.   
Two separate OECD TGs are being drafted: a) concerning TK mutation; b) concerning 
HRPT/XPRT mutation tests. 
 
*OECD (2010), Test No. 487: In Vitro Mammalian Cell 
Micronucleus Test, OECD Guidelines for the Testing of 
Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264091016-en 
 
The in vitro micronucleus test is used for the detection of micronuclei in the cytoplasm of interphase 
cells. The assay detects the activity of clastogenic and aneugenic test substances in cells that have 
undergone cell division during or after exposure to the test substance. 
 
*OECD (1997), Test No. 474: Mammalian Erythrocyte 
Micronucleus Test, OECD Guidelines for the Testing of 
Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071285-en 
The in vivo micronucleus test is used for the detection of micronuclei in the cytoplasm of interphase 
cells. The assay detects the activity of clastogenic and aneugenic test substances in cells that have 
undergone cell division during or after exposure to the test substance. 
The test is used for the detection of micronuclei induced in erythroblasts, by analysis of erythrocytes 
as sampled in bone marrow and/or peripheral blood cells of animals, usually rodents (mice or rats).  
 
*OECD (1997), Test No. 475: Mammalian Bone Marrow The mammalian in vivo chromosome aberration test is used for the detection of structural 
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Chromosome Aberration Test, OECD Guidelines for the 
Testing of Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071308-en 
 
chromosome aberrations induced by test compounds in bone marrow cells of animals, usually 
rodents (rats, mice and Chinese hamsters).  
OECD (1984), Test No. 478: Genetic Toxicology: Rodent 
Dominant Lethal Test, OECD Guidelines for the Testing of 
Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071360-en 
Dominant lethal (DL) effects cause embryonic or foetal death. Induction of a dominant lethal event 
after exposure to a test substance indicates that the substance has affected germinal tissue of the test 
species. Dominant lethals are generally accepted to be the result of chromosomal aberrations 
(structural and/or numerical anomalies), but gene mutations and toxic effects cannot be excluded.  
 
OECD (1997), Test No. 483: Mammalian Spermatogonial 
Chromosome Aberration Test, OECD Guidelines for the 
Testing of Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071469-en 
 
This test measures chromosome events in spermatogonial germ cells and is, therefore, expected to 
be predictive of induction of inheritable mutations in germ cells.  
 
OECD (1986), Test No. 485: Genetic toxicology, Mouse 
Heritable Translocation Assay, OECD Guidelines for the 
Testing of Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071506-en 
 
The mouse heritable translocation test detects structural and numerical chromosome changes in 
mammalian germ cells as recovered in first generation progeny.  
 
OECD (1997), Test No. 486: Unscheduled DNA Synthesis 
(UDS) Test with Mammalian Liver Cells in vivo, OECD 
Guidelines for the Testing of Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264071520-en 
The purpose of the unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo is to 
identify substances that induce DNA repair after excision and removal of a stretch of DNA 
containing a region of damage induced by chemical substances (solid or liquid) or physical agents in 
the liver.  
 
OECD (2011), Test No. 488: Transgenic Rodent Somatic and 
Germ Cell Gene Mutation Assays, OECD Guidelines for the 
Testing of Chemicals, Section 4,  
OECD Publishing. doi: 10.1787/9789264122819-en 
This in vivo assay detects chemicals that induce gene mutations. In this assay, transgenic rats or 
mice that contain multiple copies of chromosomally integrated plasmid or phage shuttle vectors are 
used. The transgenes contain reporter genes for the detection of various types of mutations induced 
by test substances. 
 
OECD (2013) DRAFT TG Publication: In vivo mammalian 
Alkline Comet Assay.  
http://www.oecd.org/env/ehs/testing/OECD_draft 
TG_Comet_December2013.pdf 
 
Rodent in vivo Comet assays are especially relevant to assessing DNA-damaging potential of 
chemicals for regulatory purposes. 
 
OECD (2013) DRAFT TG Publication: In Vitro In vitro cell transformation refers to the induction of phenotypic alterations in cultured cells that are 
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Carcinogenicity: Syrian Hamster Embryo (SHE) Cell 
Transformation Assay. 
http://www.oecd.org/env/ehs/testing/CTA TG_Feb2013.pdf 
characteristic of tumorigenic cells. This Test Guideline (TG) provides an in vitro procedure of the 
cell transformation assay in Syrian Hamster Embryonic stem cells (SHE), which may be used for 
hazard identification of chemical carcinogens. 
 
Regulatory requirements across sectors 
ICH (2011) S2(R1) Guidance on genotoxicity testing and 
data interpretation for pharmaceuticals intended for human 
use . Approval by the Steering Committee of S2(R1) under 
Step 4 and recommendation for adoption to the three ICH 
regulatory bodies (9 November 2011) 
 
Pharmaceuticals:  
Chapter 2. The standard test battery for genotoxicity: Description of the Two Options for the 
Standard Battery. 
The following two options for the standard battery are considered equally suitable: 
Option 1 
i. A test for gene mutation in bacteria. 
ii. A cytogenetic test for chromosomal damage (the in vitro metaphase chromosome aberration 
test or in vitro micronucleus test), or an in vitro mouse lymphoma Tk gene mutation 
assay. 
iii. An in vivo test for genotoxicity, generally a test for chromosomal damage using rodent 
hematopoietic cells, either for micronuclei or for chromosomal aberrations in metaphase 
cells. 
Option 2 
i. A test for gene mutation in bacteria. 
ii. An in vivo assessment of genotoxicity with two different tissues, usually an assay for 
micronuclei using rodent hematopoietic cells and a second in vivo assay. Typically this 
would be a DNA strand breakage assay in liver, unless otherwise justified.  
 
VICH (2012) GL23(R) (Safety) Genotoxicity Studies to 
evaluate the safety of residues of veterinary drugs in human 
food: Genotoxicity Testing. October 2012 Revision at Step 
9For consultation at Step 4, (Chapters 2-3), pp 1-7 (under 
revision). 
Veterinary Drugs:  
A battery of three tests is recommended for use as a screen of veterinary drugs for genotoxicity: 
• A test for gene mutation in bacteria. 
• A cytogenetic test for chromosomal damage (the in vitro metaphase chromosome aberration 
test or in vitro micronucleus test), or an in vitro mouse lymphoma tk gene mutation assay. 
• An in vivo test for chromosomal effects using rodent haematopoietic cells. 
Modifications can be applied and modified protocols should be used where it is evident that 
standard conditions will give a false negative result. 
 
European Commission, 2006. Regulation (EC) No 1907/2006 
of the European Parliament and the Council of 18 December 
Chemicals:  
Information requirements depend on the production volume of the chemical concerned: 
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2006 concerning the Registration, Evaluation, Authorisation 
and Restriction of Chemicals (REACH), establishing a 
European Chemicals Agency, amending Directive 
1999/45/EC and repealing Council Regulation (EEC) No 
793/93 and Commission Regulation (EC) No 1488/94 as well 
as Council Directive 76/769/EEC and Commission Directives 
91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. 
Official Journal of the European Communities L396, 1-849. 
• Annex VII (1-10 tpa):  
In vitro gene mutation study in bacteria. Further mutagenicity studies shall be considered in 
case of a positive result. 
 
• Annex VIII (10-100 tpa)  
1) In vitro cytogenicity study in mammalian cells or in vitro micronucleus study.  The study 
does not usually need to be conducted – if adequate data from an in vivo cytogenicity test 
are available or – the substance is known to be carcinogenic category 1 or 2 or mutagenic 
category 1, 2 or 3 (referring to GHS category 1A, 1B and 2, respectively).  
2) In vitro gene mutation study in mammalian cells, if a negative result in Annex VII and 
Annex VIII. The study does not usually need to be conducted if adequate data from a 
reliable in vivo mammalian gene mutation test are available. Appropriate in vivo 
mutagenicity studies shall be considered in case of a positive result in any of the 
genotoxicity studies in Annex VII or VIII.  
 
• Annex IX (100-1000 tpa)  
If there is a positive result in any of the in vitro genotoxicity studies in Annex VII or VIII 
and there are no results available from an in vivo study already, an appropriate in vivo 
somatic cell genotoxicity study shall be proposed by the registrant. If there is a positive 
result from an in vivo somatic cell study available, the potential for germ cell mutagenicity 
should be considered on the basis of all available data, including toxicokinetic evidence. If 
no clear conclusions about germ cell mutagenicity can be made, additional investigations 
shall be considered. 
 
• Annex X (1000-more tpa) 
If there is a positive result in any of the in vitro genotoxicity studies in Annexes VII or VIII, 
a second in vivo somatic cell test may be necessary, depending on the quality and relevance 
of all the available data. If there is a positive result from an in vivo somatic cell study 
available, the potential for germ cell mutagenicity should be considered on the basis of all 
available data, including toxicokinetic evidence. If no clear conclusions about germ cell 
mutagenicity can be made, additional investigations shall be considered.  
 
European Commission (2009a). Regulation (EC) No 
1223/2009 of the European Parliament and the Council of 30 
November 2009 on cosmetic products. Official Journal of the 
Cosmetics:  
On July 11, 2013, the Regulation no. 1223/2009 fully replaced the “Cosmetics Directive” 
76/68/EEC and following Amendments (Directive 93/35/EEC, Directive 2003/15/EC. This 
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European Communities L342, 59-209. 
 
And 
 
SCCS (2012) SCCS'S Notes of Guidance for the testing of 
cosmetics substances and their safety evaluation, 8th 
Revision, SCCS/1501/12 
Regulation establishes rules to be complied with by any cosmetic product made available on the 
market, in order to ensure the functioning of the internal market and a high level of protection of 
human health.  
The Regulation also prohibits the placing on the European Union market of [Chapter V, Article 18, 
Animal testing]:  
• Products where the final formulation has been the subject of animal testing;  
• Products containing ingredients or combinations of ingredients which have been the subject 
of animal testing.  
 
Based on the recent SCCS's Notes of Guidance (SCCS/1501/12), which is currently under revision, 
three assays, for the basic level testing of cosmetic substances are recommended:1. Tests for gene 
mutation: 
i)  Bacterial Reverse Mutation Test  
ii) In Vitro Mammalian Cell Gene Mutation Test  
 
2. Tests for clastogenicity and aneugenicity 
i)  In Vitro Micronucleus Test  OR 
ii) In vitro Mammalian Chromosome Aberration Test 
 
• In cases where negative results are seen in the conducted tests, a mutagenic potential is 
excluded.  
• Likewise, in cases where a positive result is seen in one of the tests, the compound has to be 
considered as a (in vitro/intrinsic) mutagen.  
 
 
European Commission (2009b). Regulation (EC) No 
1107/2009 of the European Parliament and of the Council of 
21 October 2009 concerning the placing of plant protection 
products on the market and repealing Council Directives 
79/117/EEC and 91/414/EEC. Official Journal of the 
European Union L309, 1-47. 
And 
 
Commission Regulation (EU), 2013, No 283/2013 of 
1 March 2013 setting out the data requirements for active 
Plant Protection Products: 
This Regulation establishes rules to be complied with by any plant protection product made 
available on the market. 
 
An active substance, safener or synergist shall only be approved if, on the basis of assessment of 
higher tier genotoxicity testing carried out in accordance with the data requirements for the active 
substances, safeners or synergists and other available data and information, including a review of the 
scientific literature, reviewed by the Authority, it is not or has not to be classified, in accordance 
with the provisions of Regulation (EC) No 1272/2008, as mutagen category 1A or 1B. 
New and revised genotoxicity testing requirements are reported in detail in Paragraph 5.4 (EU No. 
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substances, in accordance with Regulation (EC) 
No 1107/2009 of the European Parliament and of the Council 
concerning the placing of plant protection products on the 
market.  
 
Commission Regulation (EU), 2013, No 284/2013 of 1 
March 2013 setting out the data requirements for plant 
protection products, in accordance with Regulation (EC) No 
1107/2009 of the European Parliament and of the Council 
concerning the placing of plant protection products on the 
market (Text with EEA relevance) 
 
 
283/2013) 
European Union Regulation (2012). Regulation (EU) No 
528/2012 of the European Parliament and of the Council of 
22 May 2012 concerning the making available on the market 
and use of biocidal products. Official Journal of the European 
Union L 167, 1-116. 
Biocides: Annex II (par. 8.5-8.6), Data Requirement  
Mutagenicity 
The assessment of this endpoint shall comprise the following consecutive steps: — an assessment of 
the available in vivo genotoxicity data — an in vitro test for gene mutations in bacteria, an in vitro 
cytogenicity test in mammalian cells and an in vitro gene mutation test in mammalian cells are 
required — appropriate in vivo genotoxicity studies shall be considered in case of a positive result in 
any of the in vitro genotoxicity studies. 
 
In vivo genotoxicity study  
The assessment of this endpoint shall comprise the following consecutive steps: — If there is a 
positive result in any of the in vitro genotoxicity studies and there are no results available from an in 
vivo study already, an appropriate in vivo somatic cell genotoxicity study shall be 
proposed/conducted by the applicant — If either of the in vitro gene mutation tests is positive, an in 
vivo test to investigate unscheduled DNA synthesis shall be conducted — A second in vivo somatic 
cell test may be necessary, depending on the results, quality and relevance of all the available data 
— If there is a positive result from an in vivo somatic cell study available, the potential for germ cell 
mutagenicity should be considered on the basis of all available data, including toxicokinetic 
evidence to demonstrate that the substance reached the tested organ. If no clear conclusions about 
germ cell mutagenicity can be made, additional investigations shall be considered. 
Additional data set 
The study/ies do(es) not generally need to be conducted if: — the results are negative for the three in 
vitro tests and if no metabolites of concern are formed in mammals or — valid in vivo micronucleus 
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data is generated within a repeat dose study and the in vivo micronucleus test is the appropriate test 
to be conducted to address this information requirement — the substance is known to be 
carcinogenic category 1A or 1B or mutagenic category 1A, 1B or 2. 
 
European Commission (2008). Regulation (EC) No 
1272/2008 of the European Parliament and of the Council of 
16 December 2008 on classification, labelling and packaging 
of substances and mixtures, amending and repealing 
Directives 67/548/EEC and 1999/45/EC, and amending 
Regulation (EC) No 1907/2006. Official Journal of the 
European Union L353. 
 
UN (2013) Globally Harmonized System of Classification 
and Labelling of Chemicals (GHS), 5th revised edition. 
United Nations, New York and Geneva, 2013 
http://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs
/ghs_rev05/English/ST-SG-AC10-30-Rev5e.pdf. 
 
[Chapter 3.5, fig. 3.5.1]. 
 
EU CLP Regulation 
Par.     3.5.1 Definitions and general conditions: 'mutagenic, mutagen; genotoxic, genotoxicity' 
Par.     3.5.2 Classification criteria for substances 
Table. 3.5.1 Hazard categories for germ cell mutagens: 'Category 1A and 1B and Category 2'  -CLP 
and Globally harmonized System (GHS) classification 
 
Guidance Documents and Reviews on Genotoxicity 
ECHA (2012). Guidance on information requirements and 
chemical safety assessment Chapter R.7a: Endpoint specific 
Guidance Version 2.0 November 2012, R.7.7. Mutagenicity 
and Carcinogenicity.  
http://echa.europa.eu/documents/10162/13632/information_r
equirements_r7a_en.pdf 
 
This document describes the information requirements under REACH with regard to substance 
properties, exposure, uses and risk management measures, and the chemical safety assessment. In 
this chapter, specific guidance on meeting the information requirements set out in Annexes VI to XI 
to the REACH Regulation is provided.  
EFSA (2011). Scientific Opinion of the Scientific Committee 
on genotoxicity testing strategies applicable to food and feed 
safety assessment. EFSA Journal 2011; 9 (9): 2379 (69pp) 
The Scientific Committee reviewed the current state-of-the-science on genotoxicity testing and 
provided a commentary and recommendations on genotoxicity testing strategies. A step-wise 
approach is recommended for the generation and evaluation of data on genotoxic potential, 
beginning with a basic battery of in vitro tests, comprising a bacterial reverse mutation assay and an 
in vitro micronucleus assay. In the event of negative in vitro results, it can be concluded that the 
substance has no genotoxic potential. In case of inconclusive, contradictory or equivocal results, it 
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may be appropriate to conduct further testing in vitro. In case of positive in vitro results, review of 
the available relevant data on the test substance and, where necessary, an appropriate in vivo study 
to assess whether the genotoxic potential observed in vitro is expressed in vivo is recommended. The 
approach to in vivo testing should be also step-wise. The combination of assessing different 
endpoints in different tissues in the same animal in vivo should also be considered. 
 
COM (2011). Guidance on a Strategy for Testing of 
Chemicals for Mutagenicity. Committee on Mutagenicity of 
Chemicals in Food, Consumer Products and the Environment 
(COM). Department of Health, London.  
http://www.iacom.org.uk/guidstate/documents/COMGuidanc
eFINAL2.pdf 
 
The COM guidance provides a strategy for testing chemical substances where no genotoxicity data 
are available. 
Stage 0: Preliminary considerations prior to testing. Analysis of Physico-chemical and Toxicological 
Properties; (Q)SAR models for prediction of mutagenic activity; Screening tools i.e. in silico 
approach. 
Stage 1: In vitro genotoxicity testing. The strategy includes using appropriate tests to gain an insight 
into the nature of the genotoxic effects of a test substance and also to avoid misleading positive 
results. It comprises a two-test core system (namely an Ames test and in vitro micronucleus test, 
MNvit) with the objective of assessing mutagenic potential by investigating three different end 
points (gene mutation, structural chromosomal damage and changes in chromosome number). 
 
Stage 2: In vivo genotoxicity testing.  The in vivo genotoxicity testing strategy has to be designed on 
a case-by case basis and can be used to address aspects of in vivo mutagenicity. 
 
EURL ECVAM (2013). EURL ECVAM strategy to avoid 
and reduce animal use in genotoxicity testing. 
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-
strategy-papers 
 
 
Although several in vitro tests are available at different stages of development and acceptance, they 
cannot at present be considered to fully replace animal tests needed to evaluate the safety of 
substances. Based on an analysis of regulatory requirements for this endpoint within different pieces 
of EU legislation, EURL ECVAM proposes a pragmatic approach to improve the traditional 
genotoxicity testing paradigm that offers solutions in both the short- and medium-term and that 
draws on the considerable experience of 40 years of regulatory toxicology testing in this area. EURL 
ECVAM considers that efforts should be directed towards the overall improvement of the current 
testing strategy for better hazard and risk assessment approaches, which either avoids or minimises 
the use of animals, whilst satisfying regulatory information requirements, irrespective of regulatory 
context. Several opportunities for the improvement of the testing strategy have been identified 
which aim to i) enhance the performance of the in vitro testing battery so that fewer in vivo follow-
up tests are necessary and ii) guide more intelligent in vivo follow-up testing to reduce unnecessary 
use of animals. The implementation of this strategic plan will rely on the cooperation of EURL 
ECVAM with other existing initiatives and the coordinated contribution from various stakeholders. 
 
Maurici D, Aardema M, Corvi R, Kleber M, Krul C, Laurent This report provided an objective state of play of the status of alternative methods/strategies and the 
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C., Loprieno N, Pasanen M, Pfuhler S, Phillips B, Sabbioni 
E, Sanner T & Vanparys P (2005). Genotoxicty and 
mutagenicity. Alternatives to Laboratory Animals 33 Suppl 
1: 117-130  
prospects for their validation and regulatory acceptance so that they could be used for replacing 
animal tests in the safety assessment of cosmetic products as required by the EU Cosmetics 
Directive. Regarding the endpoint genotoxicity/mutagenicity, the experts were of the opinion that a 
total replacement of animal testing was not feasible in the short-term and this would depend, besides 
the development of in vitro tests on skin models, also on the progress in the fields of toxicokinetics 
and toxicogenomics. 
 
Adler S, Basketter D, Creton S, et al. (2011). Alternative 
(non-animal) methods for cosmetics testing: current status 
and future prospects-2010. Archives of Toxicology 85 (5): 
367-485. 
In regards of the 7th amendment to the EU Cosmetics Directive to prohibit  animal-tested cosmetics 
on the market starting 2013, the European Commission invited stakeholder bodies (industry, 
nongovernmental organisations, EU Member States, and the Commission’s Scientific Committee on 
Consumer Safety) to identify scientific experts to review the state of art of alternative methods in 
five toxicological areas, for which the Directive foresees that the 2013 deadline could be further 
extended in case alternative and validated methods would not be available in time i.e. toxicokinetics, 
repeated dose toxicity, carcinogenicity, skin sensitisation, and reproductive toxicity.  
In summary, the experts confirmed that it will take at least another 7–9 years for the replacement of 
the current in vivo animal tests used for the safety assessment of cosmetic ingredients for skin 
sensitisation. However, the experts were also of the opinion that alternative methods may be able to 
give hazard information, i.e. to differentiate between sensitizers and non-sensitizers, ahead of 2017.  
 
For toxicokinetics, the timeframe was 5–7 years to develop the models still lacking to predict lung 
absorption and renal/biliary excretion, and even longer to integrate the methods to fully replace the 
animal toxicokinetic models. For the systemic toxicological endpoints of repeated dose toxicity, 
carcinogenicity and reproductive toxicity, the time horizon for full replacement could not be 
estimated 
Misleading positives and follow up of in vitro positives 
Kirkland D, Aardema M, Henderson L & Müller L (2005). 
Evaluation of the ability of a battery of three in vitro 
genotoxicity tests to discriminate rodent carcinogens and 
non-carcinogens I. Sensitivity, specificity and relative 
predictivity. Mutation Research 584: 1-256. 
This paper evaluated how the current standard in vitro genotoxicity tests – Ames test, MLA and a 
test for clastogenicity (in vitro micronucleus or chromosomal aberration test) – performed in their 
ability to discriminate rodent carcinogens and non carcinogens.  The work deals separately with the 
performance indicators (sensitivity and specificity) of the individual tests and various combinations 
of two or three tests, and proposes reasons why some rodent carcinogens are not detected in this 
battery. While the sensitivity of the three test combination was high, its specificity was extremely 
low, highlights the importance of understanding the mechanism by which genotoxicity may be 
induced and using weight of evidence approaches to assess the carcinogenic risk from a positive 
genotoxicity signal. It also highlights deficiencies in the current prediction from and understanding 
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of such in vitro results for the in vivo situation.  
Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R. 
Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, 
Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, 
Meunier J-R, Müller L, Nohynek, G, Parry J, Parry E, 
Thybaud V, Tice R, van Benthem J, Vanparys P & White P 
(2007). How to reduce false positive results when 
undertaking in vitro genotoxicity testing and thus avoid 
unnecessary follow-up animal tests: Report of an ECVAM 
Workshop. Mutation Research  628: 31-55. 
 
A workshop organised by ECVAM in 2006 on "How to reduce the false positive results when 
undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests" 
addressed (i) whether it is possible to choose existing cell systems which give lower rates of false 
positive results, (ii) whether modifications of existing protocols and cell systems may result in lower 
false positive results, (iii) the performance of new test systems showing promise of improved 
specificity and definition of needs for the development of new tests. The recommendations of this 
workshop paved the way for many international research initiatives. 
Dearfield KL, Thybaud V, Cimino MC, Custer L, Czich A, 
Harvey JS, Hester S, Kim JH, Kirkland D, Levy DD, Lorge 
E, Moore MM, Ouédraogo-Arras G, Schuler M, Suter W, 
Sweder K, Tarlo K, van Benthem J, van Goethem F & Witt 
KL (2011). Follow-up actions from positive results of in vitro 
genetic toxicity testing. Environmental Molecular 
Mutagenicity  52 (3): 177-204. 
The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) 
Project Committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity 
(IVGT) Testing developed a decision process flow chart to be applied in case of clear positive 
results in vitro; providing for a variety of different possibilities and allowing flexibility in choosing 
follow-up action(s), depending on the results obtained in the initial battery of assays and available 
information.  
The Review Subgroup: 
• Reinforced the concept of weighing the totality of the evidence.  
• Highlighted the importance of properly analyzing the existing data, and considering 
potential confounding factors (e.g., possible interactions with the test systems, presence of 
impurities, irrelevant metabolism), and chemical modes of action when analyzing and 
interpreting positive results in the in vitro genotoxicity assays and determining appropriate 
follow-up testing.  
• Examined the characteristics, strengths, and limitations of each of the existing in vitro and 
in vivo genotoxicity assays to determine their usefulness in any follow-up testing. 
 
Lynch AM, Sasaki JC, Elespuru R, Jacobson-Kram D, 
Thybaud V, De Boeck M, Aardema MJ, Aubrecht J, Benz 
RD, Dertinger SD, Douglas GR, White PA, Escobar PA, 
Fornace A Jr, Honma M, Naven RT, Rusling JF, Schiestl RH, 
Walmsley RM, Yamamura E, van Benthem J & Kim JH 
(2011). New and emerging technologies for genetic toxicity 
testing. Environmental Molecular Mutagenicity 52 (3): 205-
The Health and Environmental Sciences Institute (HESI) Project Committee on the Relevance and 
Follow-up of Positive Results in In Vitro Genetic Toxicity (IVGT) convened a workshop in 
Washington, DC in May 2008 to discuss mature, maturing, and emerging technologies in genetic 
toxicology. This article collates the abstracts of the New and Emerging Technologies Workshop 
together with some additional technologies subsequently considered. 
 
In particular, consideration was given with regard to follow-up testing of positive results in the 
standard IVGT tests (i.e., Salmonella Ames test, chromosome aberration assay, and mouse 
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23. 
 
lymphoma assay) to add weight of evidence and/or provide mechanism of action for improved 
genetic toxicity risk assessments in humans.  
 
In silico methods 
Serafimova R, Fuart Gatnik M & Worth A (2010). Review of 
QSAR models and software tools for predicting genotoxicity 
and carcinogenicity. JRC report EUR 24427 EN: 
http://ihcp.jrc.ec.europa.eu/our_labs/computational_toxicolog
y/publications/ 
The authors reviewed QSARs for genotoxicity and carcinogenicity, taking into accounts both 
models available in software tools and models that are published in the literature. They focused also 
on the potential applicability of diverse models to pesticides as well as to other types of regulated 
chemicals and pharmaceuticals. 
Worth A, Lapenna S, Lo Piparo E, Mostrag-Szlichtyng A & 
Serafimova R (2010). The applicability of software tools for 
genotoxicity and carcinogenicity prediction: case studies 
relevant to the assessment of pesticides. JRC report EUR 
24640 EN. Available from:  
http://publications.jrc.ec.europa.eu/repository 
This report presents research results obtained in the framework of a project on the Applicability of 
Quantitative Structure-Activity Relationship (QSAR) analysis in the evaluation of the toxicological 
relevance of metabolites and degradates of pesticide active substances. 
Helma C (2006). Lazy structure-activity relationships (lazar) 
for the prediction of rodent carcinogenicity and Salmonella 
mutagenicity. Molecular Diversity 10:147-158. 
 
The author reports on the Lazar (lazy learning method) where compounds are selected at the time of 
processing a query compound. The method allows models to be updated as new data become 
available and includes models for mutagenicity and rodent carcinogenicity. 
OECD (2010d) OECD Principles for the validation, for 
regulatory purposes, of (quantitative) structure activity 
relationship models 
http://www.oecd.org/dataoecd/33/37/37849783.pdf 
 
The document describes the principles to facilitate the consideration of a (Q)SAR model for 
regulatory purposes. 
Benigni R, Bossa C, Jeliazkova N, Netzeva N & Worth A 
(2008). The Benigni /Bossa rulebase for mutagenicity and 
carcinogenicity –a module of Toxtree. JRC Report, EUR 
23241 EN – 2008. 
http://publications.jrc.ec.europa.eu/repository 
This paper describes novel hazard estimation software called Toxtree, capable of making structure-
based predictions for a number of toxicological endpoints, developed at the JRC. One of the 
modules developed as an extension to Toxtree is aimed at the prediction of carcinogenicity and 
mutagenicity. The main tool is a list of Structural Alerts (SA) for carcinogenicity. 
 
Worth A, Lapenna S & Serafimova R (2012). QSAR and 
metabolic simulation tools in the assessment of genotoxicity. 
Chapter 6 in: Computational Toxicology, Volume II. 
Methods in Molecular Biology, Volume 930. B Reisfeld & 
AN Mayeno (Eds). Humana Press, New York. pp 125-162. 
In this book chapter, a range of computational tools for applying QSAR and grouping/read-across 
methods are described, and their integrated use in the computational assessment of genotoxicity is 
illustrated through the application of selected tools to two case-study compounds—2-amino-9H-
pyrido[2,3-b]indole (AaC) and 2-aminoacetophenone (2-AAP). The first case study compound 
(AaC) is an environment pollutant and a food contaminant that can be formed during the cooking of 
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 protein-rich food. The second case study compound (2-AAP) is a naturally occurring compound in 
certain foods and also proposed for use as a flavoring agent. The overall aim is to describe and 
illustrate a possible way of combining different information sources and software tools for 
genotoxicity and metabolism prediction by means of a simple stepwise approach. The chapter is 
aimed at researchers and assessors who have a basic knowledge of computational toxicology and 
some familiarity with the practical use of computational tools. The emphasis is on how to evaluate 
the data generated by multiple tools, rather than the practical use of any specific tool. 
 
In vitro genotoxicity tests in 3D human reconstructed skin models 
Pfuhler S, Kirst A, Aardema M, Banduhn N, Goebel C, Araki 
D, Costabel-Farkas M,   Dufour E, Fautz R, Harvey J, Hewitt 
NJ, Hibatallah J, Carmichael P, Macfarlane M, Reisinger K, 
Rowland J, Schellauf F, Schepky A & Scheel J (2010). A 
tiered approach to the use of alternatives to animal testing for 
the safety assessment of cosmetics: Genotoxicity. A COLIPA 
analysis. Regulatory Toxicology Pharmacology 57:315-324. 
 
This article describes common approaches of cosmetic companies, with recommendations for 
evaluating in vitro genotoxins using non-animal approaches. A weight of evidence approach was 
employed to set up a decision-tree for the integration of alternative methods into tiered testing 
strategies. 
Hu T, Khambatta ZS, Hayden PJ, Bolmarcich J, Binder RL, 
Robinson MK, Carr GJ. Tiesman JP, Jarrold BB, Osborne R, 
Reichling TD, Nemeth ST & Aardema MJ (2010). 
Xenobiotic metabolism gene expression in the EpiDerm™ in 
vitro 3D human epidermis model compared to human skin. 
Toxicol in Vitro 24: 1450-1463. 
This paper presents the characterization of the metabolizing capacity of in vitro human skin models. 
A comparison of the expression of 139 genes encoding xenobiotic metabolizing enzymes in the 
EpiDerm™ model and human skin is reported. In microarray analysis, the expression of 87% of the 
genes was consistent between the EpiDerm™ model and human skin indicating the presence of 
similar metabolic pathways suggesting commonality in function. Analysis of EpiDerm™ models 
constructed from four donors showed highly comparable expression of xenobiotic metabolizing 
genes demonstrating reproducibility of the model. Overall, the expression of Phase II enzymes 
appeared to be more pronounced in human skin and the EpiDerm™ model than that of Phase I 
enzymes, consistent with the role of skin in detoxification of xenobiotics. Though the basal 
expression of CYPs in particular was low in EpiDerm™, significant induction of CYP1A1/1B1 
activity was observed following treatment with 3-methylcholanthrene. These results indicate that the 
xenobiotic metabolizing capacity of the EpiDerm™ model appears to be representative of human 
skin.  
 
Curren RD, Mun GC, Gibson DP & Aardema MJ (2006). 
Development of a method for assessing micronucleus 
induction in a 3D human skin model EpiDermTM. Mutation 
The paper describes the development of a micronucleus assay that uses EpiDerm engineered human 
reconstructed skin(MatTek Corp., Ashland, MA). Methods for isolating single cells from the 3D 
skin model and for processing the cells for microscopic analysis of micronuclei (MN) were also 
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Research  607: 192-204. described. 
 
Mun GC, Aardema MJ, Hu T, Barnett B, Kaluzhny Y, 
Karetsky V, Dahl EL & Curren RD (2009). Further 
development of the EpiDerm 3D reconstructed human skin 
micronucleus (RSMN) assay. Mutation research 673: 92-99. 
The authors developed an in vitro micronucleus assay using a three-dimensional human 
reconstructed skin model (EpiDerm™), and in this paper presented the refinements applied to the 
model. They assessed its ability to predict genotoxicity of a battery of chemicals that were 
previously classified as genotoxins or non-genotoxins based on in vivo rodent skin tests.  
 
Aardema MJ, Barnett B, Khambatta ZS, Reisinger K, 
Ouedrago-Arras G, Faquet B,  Ginestet A, Mun GC, Dahl, 
EL, Hewitt NJ, Corvi R & Curren RC (2010). International 
pre-validation studies of the EpiDerm TM 3D human 
reconstructed skin micronucleus (RSMN) assay: 
Transferability and reproducibility. Mutation Research 701: 
123-131. 
This inter-laboratory study aims at establishing the reliability of the EpiDerm TM 3D human 
reconstructed skin micronucleus (RSMN) assay and at increasing the domain of chemicals tested for 
predictive capacity. 
Reus AA, Reisinger K, Downs TR, Carr G, Zeller A, Corvi 
R, Krul CAM & Pfuhler S (2013).  Comet Assay in 
reconstructed 3D human epidermal skin models – 
investigation of intra- and inter-laboratory reproducibility 
with coded chemicals. Mutagenesis. 28 (6): 709-20. 
This paper describes the development and optimisation of a comet assay protocol in a 3D human 
EpiDermTM skin model, as well as intra- and inter-laboratory reproducibility results from the testing 
of five compounds. A high % tail DNA value of untreated controls was observed. Despite this, valid 
experiments showed an acceptable reproducibility within and across the laboratories. The work 
presented will provide a starting point for further investigation on the predictive capacity of comet 
assays in reconstructed skin models. 
 
Hen's egg test for micronucleus induction (HET-MN) 
Wolf T, Niehaus-Rolf C, Banduhn N, Eschrich D, Scheel J & 
Luepke NP (2008). The hen's egg test for micronucleus 
induction (HET-MN): novel analyses with a series of well-
characterized substances support the further evaluation of the 
test system. Mutation Research 650: 150-164. 
The hen's egg test for micronucleus induction (HET-MN) combines the use of the commonly 
accepted genetic endpoint "formation of micronuclei" with the well-characterized and complex 
model of the incubated hen's egg, which enables metabolic activation, elimination and excretion of 
xenobiotics - including those that are mutagens or promutagens. The authors present results of 
experiments involving genotoxic and non-genotoxic model substances. The comparison of these 
data with previously published data, showed a lack of false negatives or false positives, thus 
demonstrating a predictivity of genotoxic effects with the above assay. 
 
Cell transformation assay (CTA) 
DiPaolo JA, Donovan P, Nelson R (1969) Quantitative studies 
of in vitro transformation by chemical carcinogens. Journal of 
the National Cancer Institute 42: 867-874. 
The authors report that chemical carcinogens can induce malignant transformation in mammalian 
cell systems. However, the precise molecular and cellular alterations that result in transformation 
have not been identified. 
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Isfort RJ, Kerckaert GA & LeBoeuf RA (1996). Comparison 
of the standard and reduced pH Syrian hamster embryo (SHE) 
cell in vitro transformation assays in predicting the 
carcinogenic potential of chemicals. Mutation Research 356: 
11-63. 
The article is a comprehensive review of the Syrian Hamster Embryo (SHE) cell transformation 
literature; it was performed in order to catalogue the chemical/physical entities which have been 
evaluated for in vitro cell transformation potential. Both reduced pH (pH 6.7) and standard pH (pH 
7.1-7.3) SHE cell testing protocols were considered. The authors suggest that the SHE cell 
transformation assay is predictive for rodent carcinogenicity under either reduced or standard pH 
conditions; with the assay displaying better performance in prediction capability under reduced pH 
conditions. 
 
Matthews EJ, Spalding JW & Tennant RW (1993). 
Transformation of BALB/c-3T3 cells: V. Transformation 
responses of 168 chemicals compared with mutagenicity in 
Salmonella and carcinogenicity in rodent bioassays. 
Environmental Health Perspectives 101 Suppl 2: 347-482. 
This report describes the activities of 168 chemicals tested in a standard transformation assay using 
A-31-1-13 BALB/c-3T3 cells. 
Data analyses revealed that the transformation assay and rodent bioassay had a concordance of 
71%; sensitivity for carcinogens of 80.0%; specificity for detecting non carcinogens of 60%.  
 
In contrast, Salmonella mutagenicity assays and rodent bioassays had a concordance of 63%, a 
sensitivity of 58%, and a specificity of 69%. The transformation assay complemented the 
Salmonella mutagenesis assay in the identification of non-mutagenic carcinogens; thus, the two 
assays had a combined 83% sensitivity for all carcinogens and a specificity of 75% for non-
mutagenic non carcinogens. 
 
LeBoeuf RA, Kerckaert KA, Aardema MJ & Isfort RJ (1999). 
Use of Syrian hamster embryo and BALB/c 3T3 cell 
transformation for assessing the carcinogenic potential of 
chemicals. IARC Science Publications 146: 409-25.  
CTAs have been shown to involve a multistage process that closely models key stages of 
carcinogenesis. 
EURL ECVAM (2012) recommendation concerning the cell 
transformation assays using Syrian hamster embryo cells 
(SHE) and the BALB/c 3T3 mouse fibroblast cell line for in 
vitro carcinogenicity testing. Annex I: ESAC opinion on the 
ESAC peer review of an ECVAM-coordinated prevalidation 
study concerning three protocols of the cell transformation 
assay (CTA) for in vitro carcinogenicity testing. 
http://ihcp.jrc.ec.europa.eu/our_activities/alt-animal-testing 
 
ECVAM recommendation report on the three CTA protocol variants: (a) The SHE CTA performed 
at pH 6.7 (SHE pH 6.7 CTA); (b) the SHE CTA performed at pH 7.0 (SHE pH 7.0 CTA); and (c) 
the BALB/c 3T3 CTA. ECVAM coordinated an international study that was designed to address 
issues of CTA protocols standardisation, transferability and reproducibility in three protocol 
variants for the SHE CTA (at pH 6.7 and pH 7.0) and the BALB/c 3T3 assay. The study of the 
three test methods was peer reviewed by the ESAC that issued a peer review report and an ESAC 
opinion. Based on the available documents (study reports, ESAC opinion, OECD DRP), EURL 
ECVAM recommended that an OECD TG be developed for the SHE CTA and that further 
investigations were needed to confirm the performance of the BALB/c 3T3 CTA.   Moreover, the 
recommendation stated that in conjunction with other available data, the CTAs have the potential 
of partial replacement or reduction when used in a weight of evidence approach for hazard 
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identification and risk assessment.  
 
Vanparys P, Corvi R, Aardema MJ, Gribaldo L, Hayashi M, 
Hoffmann S & Schechtman L (2012). Application of in vitro 
cell transformation assays in regulatory toxicology for 
pharmaceuticals, chemical, food products and cosmetics. 
Mutation Research 744 (1): 111-116. 
The extensive review on CTAs by the OECD (2007) and the proven standardisation, intra- and 
inter-laboratory reproducibility of the SHE CTAs justify broader use of these methods to assess 
carcinogenic potential of chemicals. The manuscript describes possible applications of the CTA in 
relation to different industrial sectors, e.g. food additives, chemicals, cosmetics, pharmaceuticals, 
etc. 
 
Toxicogenomics-based Tests 
Ellinger-Ziegelbauer H Aubrecht J, Kleinjans JC & Ahr HJ 
(2009). Application of toxicogenomics to study mechanisms of 
genotoxicity and carcinogenicity. Toxicology Letters 186: 36-
44.  
The paper underlies the importance of developing novel scientific approaches bridging 
genotoxicity and carcinogenicity testing via understanding underlying mechanisms for facilitating 
cancer risk assessment. The authors consider extremely promising the toxicogenomics approaches 
as these have the potential of providing generic insight in molecular pathway responses.  The 
report reviews recent progress in the development and application of toxicogenomics to the 
derivation of genomic biomarkers associated with mechanisms of genotoxicity and carcinogenesis.  
 
Doktorova TY, Pauwels M, Vinken M, Vanhaecke T & 
Rogiers V (2012).  Opportunities for an alternative integrating 
testing strategy for carcinogen hazard assessment? Critical 
Reviews in Toxicology 42 (2): 91-106.  
In this review paper the major advantages and pitfalls of the existing alternative methodologies to 
the carcinogenicity bioassay are discussed.   Based on the available scientific data in the public 
domain, the authors propose a "feasible integrated testing strategy" which incorporates some 
promising new alternatives (toxicogenomics-, transcriptomics-based tests and CTAs), providing at 
the same time information on the mechanism of action and the toxic nature of the compounds 
tested. 
 
Doktorova TY, Yildirimman R, Vinken M, Vilardell M, 
Vanhaecke T, Gmuender H, Bort R, Brolen G, Holmgren G, Li 
R, Chesne C, van Delft J, Kleinjans J, Castell J, Bjorquist P, 
Herwig R & Rogiers V (2013). Transcriptomic responses 
generated by hepatocarcinogens in a battery of liver-based in 
vitro models. Carcinogenesis 34(6):1393-402. 
In the present study the transcriptomics responses following exposure to genotoxic and non-
genotoxic hepatocarcinogens and non-carcinogens in five liver-based in vitro models, namely 
conventional and epigenetically stabilized cultures of primary rat hepatocytes, the human 
hepatoma-derived cell lines HepaRG and HepG2 and human embryonic stem cell-derived 
hepatocyte-like cells, are examined. 
Jennings P, Limonciel A, Felice L & Leonard MO (2013). An 
overview of transcriptional regulation in response to 
toxicological insult. Archives of Toxicology 87: 49–72. 
This review aims to consolidate and summarise the major toxicologically relevant transcription 
factor-governed molecular pathways.  The authors focus on the importance of toxicogenomic data 
sets and information on regulation of stress pathways at the transcriptome level, in order to 
appreciate the diversity and complexity of biological responses to xenobiotics. 
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Waters MD, Jackson M & Lea I (2010). Characterizing and 
predicting carcinogenicity and mode of action using 
conventional and toxicogenomics methods. Mutation Research 
705: 184-200.  
The authors report that the evidence accumulated to date suggests that gene expression profiles 
reflect underlying modes or mechanisms of action, such that they will be useful in the prediction of 
chemical carcinogenicity, especially in conjunction with conventional short-term tests for gene 
mutation, chromosomal aberration and aneuploidy. 
Screening approaches 
Hastwell PW, Chai LL, Roberts KJ, Webster TW, Harvey JS, 
Rees RW & Walmsley RM (2006). High-specificity and high-
sensitivity genotoxicity assessment in a human cell line: 
validation of the GreenScreen HC GADD45a-GFP 
genotoxicity assay. Mutation Research 607:160-175. 
In light of the relatively high specificity of the Salmonella mutagenicity assay (Ames test) 
counteracting the low specificity of the established mammalian cell assays, which leads to 
difficulties in the interpretation of the biological relevance of results, the authors introduce a new 
high-throughput assay that links the regulation of the human GADD45a gene to the production of 
Green Fluorescent Protein (GFP). The test is proposed both as a valuable and amenable tool in the 
selection of candidate compounds for further development, or in product development areas where 
the use of animals is to be discontinued. As a microplate assay, the authors also propose the 
application of the test in early screening for genotoxic liability, as the qualities of high throughput 
and low compound use. 
 
Hastwell PW, Webster TW, Tate M, Billinton N, Lynch AM, 
Harvey JS, Rees RW & Walmsley RM  (2009). Analysis of 75 
marketed pharmaceuticals using the GADD45a-GFP 
‘GreenScreen HC’ genotoxicity assay. Mutagenesis 24: 455-
463. 
In this study, a collection of 75 marketed pharmaceuticals were tested in the GADD45a-GFP 
(GreenScreen HC) reporter assay which, detects genotoxic damage in the human lymphoblastoid 
TK6 cell line, giving positive results for all classes of genotoxins, including mutagens, aneugens 
and clastogens.  
Jagger C, Tate M, Cahill PA, Hughes C, Knight AW, Billinton 
N & Walmsley RM (2009). Assessment of the genotoxicity of 
S9-generated metabolites using the GreenScreen HC 
GADD45a-GFP assay. Mutagenesis 24: 35-50. 
The paper describes the method development, the derivation of decision thresholds for the 
identification of genotoxins using the method, and presents data from a 56-compound validation 
study of the method. The results illustrate that the method permitted the detection of the majority 
of pro-genotoxins tested and, importantly, the high specificity of the GADD45a-GFP assay was 
maintained. 
 
Birrell L, Cahill P, Hughes C, Tate M & Walmsley RM 
(2010). GADD45a-GFP GreenScreen HC assay results for the 
ECVAM recommended lists of genotoxic and non-genotoxic 
chemicals for assessment of new genotoxicity tests. Mutation 
Research  695: 87-95. 
Three categories of test chemicals comprising a total of 62 compounds were chosen based on the 
ECVAM recommended list of chemicals and analysed using the GreenScreen HC assay. The 
outcome results were in line with those from other studies with the GreenScreen HC assay 
confirming its high specificity.  
 
Billinton N, Bruce S, Hansen JR, Hastwell PW, Jagger C, 
McComb C, Klug ML, Pant K, Rabinowitz A, Rees R, Tate M, 
A new protocol has recently been developed for the GreenScreen HC GADD45a-GFP 
genotoxicity reporter assay, enabling the incorporation of an S9 metabolic activation system into 
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Vinggaard AM & Walmsley RM (2010). A pre-validation 
transferability study of the GreenScreen HC GADD45a-GFP 
assay with a metabolic activation system (S9). Mutation  
Research 700: 44-50. 
the assay. The outcome of the study was a refined protocol that was found to be highly transferable 
and reproducible between laboratories. 
Hughes C, Rabinowitz A, Tate M, Birrell L, Allsup J, Billinton 
N & Walmsley RM (2012). Development of a high-throughput 
Gaussia luciferase Reporter Assay for the Activation of the 
GADD45a Gene by Mutagens, Promutagens, Clastogens, and 
Aneugens. Journal of Biomolecular Screening 17:1302-1316. 
This article describes the development and validation of an alternative assay ("BlueScreen HC"), 
in which expression is linked to Gaussia luciferase (GLuc) expression, yielding a luminescent 
reporter, the preferred optical output in high-throughput screening. The new GLuc assay was as 
effective as the GFP (GreenScreen) assay in producing positive results for all classes of genotoxic 
carcinogen and negative results for all nongenotoxins tested. 
 
Westerink WM, Stevenson JC, Horbach GJ & Schoonen WG 
(2010). The development of RAD51C, Cystatin A, p53 and 
Nrf2 luciferase-reporter assays in metabolically competent 
HepG2 cells for the assessment of mechanism-based 
genotoxicity and of oxidative stress in the early research phase 
of drug development. Mutation Research 696: 21-40.  
Four different mechanism-based high-throughput luciferase-reporter assays were developed in 
human HepG2 cells. The promoter regions of RAD51C and Cystatin A, as well as the responsive 
element of the p53 protein, were selected for the generation of the genotoxicity reporter assays. 
Moreover, a luciferase-based reporter assay was generated that measures the activation of the Nrf2 
oxidative stress pathway. Validation with respect to the ECVAM compound list resulted in an 
overall sensitivity of the HepG2 genotoxicity reporter assays for genotoxicity of 85%. The use of 
these assays in combination with the previously validated Vitotox and RadarScreen assays has 
been shown to be valuable to reducing the attrition rate due to genotoxicity in the developmental 
phase of drug development. 
Testing Strategies 
Jaworska J, Gabbert S & Aldenberg T (2010). Towards 
optimization of chemical testing under REACH: a Bayesian 
network approach to Integrated Testing Strategies. Regulatory 
Toxicology & Pharmacology 57:157-167. 
This paper presents conceptual requirements for ITS development and optimization. First, ITS 
development should be based on probabilistic methods in order to quantify and update various 
uncertainties across testing stages. Second, reasoning should reflect a set of logic rules for 
consistently combining probabilities of related events. Third, inference should be hypothesis-
driven and should reflect causal relationships in order to coherently guide decision-making across 
testing stages. To meet these requirements, an information-theoretic approach to ITS development, 
the "ITS inference framework", which can be made operational by using Bayesian networks.  
 
Kirkland D, Reeve L, Gatehouse D & Vanparys P (2011). A 
core in vitro genotoxicity battery comprising the Ames test 
plus the in vitro micronucleus test is sufficient to detect rodent 
carcinogens and in vivo genotoxins. Mutation Research 721: 
27-73. 
The paper presents an analysis of an existing database of rodent carcinogens and a new database of 
in vivo genotoxins in terms of the in vitro genotoxicity tests needed to detect their in vivo activity. 
The outcome of the analysis shows that there is no convincing evidence that any genotoxic rodent 
carcinogens or in vivo genotoxins would remain undetected in an in vitro two test battery 
consisting of Ames + MNvit. 
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Kirkland D & Speit G (2008). Evaluation of the ability of a 
battery of three in vitro genotoxicity tests to discriminate 
rodent carcinogens and non-carcinogens III. Appropriate 
follow-up testing in vivo. Mutation Research 654: 114-132. 
The paper focuses on the discussion regarding the most appropriate follow-up testing in vivo when 
positive results are obtained in vitro but the in vivo micronucleus (MN) test (traditionally the most 
widely-used test) is negative. With the increased evaluation and use of other in vivo assays, e.g. for 
transgenic mutations (TG) and DNA damage (Comet assay) the authors considered extremely 
important to investigate their usefulness.  The work examined the published in vivo UDS, TG and 
Comet-assay results for 67 carcinogens that were negative or equivocal in the micronucleus test. 
The data obtained suggested that Comet and TG assays should play a more prominent role in 
regulatory testing strategies than the UDS test. 
 
Parry JM, Parry E, Phrakonkham P & Corvi R (2010). 
Analysis of published data for top concentration considerations 
in mammalian cell genotoxicity testing. Mutagenesis 25(6): 
531-8. 
The authors established a database of 384 chemicals classified as rodent carcinogens and reported 
Ames test results and the test concentrations that produced positive results in the mouse lymphoma 
assay (MLA), in vitro chromosome aberration (CA) assay and in vitro micronucleus test. This, in 
order to assess the impact that the reduction of testing concentrations would have on the outcome 
of in vitro genotoxicity testing. 62.5% produced positive results in the MLA, of which 20.3% 
required testing between 1 and 10 mM. A total of 58.0% produced positive results in in vitro CA 
assays, of which 25.0% required testing between 1 and 10 mM. If the testing concentration limit 
for mammalian cell assays was reduced to 1 mM, 24 (6.25%) potential carcinogens would not be 
detected in any part of the standard in vitro genotoxicity test battery (Ames test, MLA and in vitro 
CA assay). Further evaluation and/or retest of these compounds suggested that the current 10 mM 
top concentration can be reduced without any loss of sensitivity in detecting rodent carcinogens. 
 
Kirkland D & Fowler P (2010). Further analysis of Ames-
negative rodent carcinogens that are only genotoxic in 
mammalian cells in vitro at concentrations exceeding 1 mM, 
including retesting of compounds of concern. Mutagenesis 25 
(6): 539-53. 
In this article, the authors further evaluate the analysis performed by Parry and co-workers (Parry 
et al., 2010), regarding data for top concentration considerations in mammalian cell genotoxicity 
testing. The analysis focused on the 24 carcinogens which showed negative results in the Ames 
test and were positive in mammalian cells tests, instead, at concentrations between 1-10 mM. A 
more detailed evaluation of the studies performed and protocols used, many of them very old, 
prompted the authors to conclude that the 10 mM upper limit in mammalian cell tests could be 
lowered without any loss of sensitivity in detecting genotoxic rodent carcinogens. A new limit of 1 
mM or 500 μg/ml was proposed. 
 
Fowler P, Smith K, Young J, Jeffrey L, Kirkland D, Pfuhler S 
& Carmichael P (2012a). Reduction of misleading ("false") 
positive results in mammalian cell genotoxicity assays. I. 
Choice of cell type. Mutation Research 742 (1-2):11-25.  
 
Fowler and co-workers have compared several rodent cell lines (V79, CHL, CHO) with p53-
competent human peripheral blood lymphocytes (HuLy), TK6 lymphoblastoid cells, and the 
human liver cell line HepG2, since p53-deficiency in many of the rodent cell lines has been 
considered a key factor in the poor testing predictivity. The authors evaluated in vitro 
micronucleus (MN) induction following treatment with 19 compounds that were accepted as 
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 producing misleading or "false" positive results in in vitro mammalian cell assays. The rodent cell 
lines (V79, CHO and CHL) resulted consistently more susceptible to cytotoxicity and MN 
induction than p53-competent cells, and were therefore more susceptible to giving misleading 
positive results. The authors suggested that a reduction in the frequency of misleading positive 
results could be achieved by careful selection of the mammalian cell type for genotoxicity testing. 
 
Fowler P, Smith R, Smith K, Young J, Jeffrey L, Kirkland D, 
Pfuhler S & Carmichael P (2012b). Reduction of misleading 
("false") positive results in mammalian cell genotoxicity 
assays. II. Importance of accurate toxicity measurement. 
Mutation Research 747(1):104-17. 
In line with the outcomes of the analysis mentioned in the above paper (Fowler et al., 2012a); the 
authors investigated the impact of different toxicity measures, commonly used in vitro cytogenetic 
assays, on the occurrence of misleading positive results. The data showed that estimating toxicity 
by relative cell count (RCC) or replication index (RI) consistently underestimated the toxicity 
observed by other measures (Relative Population Doubling, RPD, or Relative Increase in Cell 
Count, RICC). RCC and RI were more likely to lead to selection of concentrations for 
micronucleus scoring that were highly cytotoxic and thus could potentially lead to artefacts of 
toxicity being scored (elevated levels of apoptosis and necrosis), generating misleading positive 
results.  The authors suggested that a further reduction in the frequency of misleading positive 
results in in vitro cytogenetic assays could be achieved (with 19 chemicals clearly giving 
misleading results) by avoiding the use of toxicity measures that underestimate the level of toxicity 
induced. 
 
Pfuhler S, Kirkland D. Kasper P, Hayashi M, Vanparys P, 
Carmichael P, Dertinger S, Eastmond D, Elhajouji A, Krul C, 
Rothfuss A, Schoening G, Smith A, Speit G, Thomas C, van 
Benthem J & Corvi R (2009). Reduction of use of animals in 
regulatory genotoxicity testing: Identification and 
implementation opportunities-Report from an ECVAM 
workshop. Mutation Research 680: 31-42. 
 
Report on the European Centre for the Validation of Alternative Methods (ECVAM) Workshop 
held in Ranco, Italy from 24 to 25 June 2008.  The objectives of the workshop were to discuss how 
to reduce the number of animals in standard genotoxicity tests, whether the application of smarter 
test strategies can lead to lower animal numbers, and how the possibilities for reduction can be 
promoted and implemented. 
Bowen DE, Whitwell JW, Lillford L, Henderson D, Kidd D, 
Mc Garry S, Pearce G, Beevers C & Kirkland DJ (2011). 
Evaluation of a multi-endpoint assay in rats, combining the 
bone-marrow micronucleus test, the Comet assay and the 
flow-cytometric peripheral blood micronucleus test. Mutation 
Research   722 (1): 7-19.  
Presented here are the results of an evaluation trial in which the bone-marrow and peripheral blood 
(via MicroFlow(®) flow cytometry) micronucleus tests (looking at potential chromosome 
breakage and whole chromosome loss) in developing erythrocytes or young reticulocytes were 
combined with the Comet assay (measuring DNA strand-breakage), in stomach, liver and blood 
lymphocytes. This within the scope of revised draft ICH guidelines (Draft ICH S2) to establish a 
combined multi-end point in vivo assay to alleviate the need for multiple in vivo assays, thereby 
reducing time, cost and use of animals. 
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Rothfuss A, O’Donovan M, De Boeck M, Brault D, Czich A, 
Custer L, Hamada S, Plappert-Helbig U, Hayashi M, Howe J, 
Kraynak A, van der Leede B, Nakajima M, Priestley C, 
Thybaud V, Saigo K, Sawant S, Shi J, Storer R, Struwe M, 
Vock E & Galloway S (2010). Collaborative study on 15 
compounds in the rat liver Comet Assay integrated into 2- and 
4-week repeat-dose studies. Mutation Research 702: 40-69. 
A collaborative trial was conducted to evaluate the possibility of integrating the rat-liver Comet 
assay into repeat-dose toxicity studies.  Fourteen laboratories from Europe, Japan and the USA 
tested fifteen chemicals. Laboratories provided liver Comet assay data obtained at the end of the 
long-term (2- or 4-week) studies together with an evaluation of liver histology. Most of the test 
compounds were also investigated in the liver Comet assay after short-term (1–3 daily) 
administration to compare the sensitivity of the two study designs. MN analyses were also 
conducted in bone marrow or peripheral blood for most of the compounds to determine whether 
the liver Comet assay could complement the MN assay for the detection of genotoxins after long-
term treatment. 
 
Rothfuss A, Honma M, Czich A, Aardema MJ, Burlinson B, 
Galloway, Hamada S, Kirkland D, Heflich RH, Howe J, 
Nakajima M, O’Donovan M, Plappert-Helbig U, Priestley C, 
Recio L, Schuler M, Uno Y & Martus HJ (2011). Improvement 
of in vivo genotoxicity assessment: Combination of acute tests 
and integration into standard toxicity testing. Mutation 
Research 723: 108–120. 
 
An IWGT working group reviewed current requirements for in vivo genotoxicity testing of 
different chemical product classes and identified opportunities for combination and integration of 
genotoxicity endpoints for each class. They considered: (1) combination of acute micronucleus 
(MN) and Comet assays into a single study, (2) integration of MN assays into repeated-dose 
toxicity (RDT) studies, (3) integration of Comet assays into RDT studies, and (4) requirements for 
the top dose when integrating genotoxicity measurements into RDT studies. Whereas the working 
group overall considered the presented data were adequate to conclude that the 
combination/integration of MNT and Comet is scientifically justified for both acute and RDT 
studies, it was noted that most recommendations made were based on limited data and may need to 
be refined in the future. 
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9. Carcinogenicity 
Federica Madia, Raffaella Corvi & Andrew Worth 
 
9.1 The traditional in vivo tests and their regulatory use 
Substances are defined as carcinogenic if after inhalation, ingestion, dermal application or 
injection they induce (malignant) tumours, increase their incidence or malignancy, or shorten 
the time of tumour occurrence. It is generally accepted that carcinogenesis is a multi-
hit/multi-step process from the transition of normal cells into cancer cells via a sequence of 
stages and complex biological interactions, strongly influenced by factors such as genetics, 
age, diet, environment, hormonal balance, etc.  
 
The induction of cancer involves genetic alterations which can be induced directly or 
indirectly. Therefore, carcinogens have conventionally been divided into two categories 
according to their presumed mode of action: genotoxic carcinogens and non-genotoxic 
carcinogens. Genotoxic carcinogens have the ability to interact with DNA and/or the cellular 
apparatus (such as e.g. the spindle apparatus and topoisomerase enzymes) and thereby affect 
the integrity of the genome, whereas non-genotoxic carcinogens exert their carcinogenic 
effects through other mechanisms that do not involve direct alterations to the DNA (Loeb & 
Harris, 2008; Adler, et al., 2011; Benigni, 2012).  
 
Based on the above principles and before embarking into carcinogenicity studies, the 
genotoxic hazard of all type of substances is usually assessed (see chapter on Genotoxicity 
and Mutagenicity).  The two-year cancer bioassay in rodents is widely regarded as the 'Gold 
standard' to evaluate cancer hazard and potency, although it is generally known that this test 
has its limitations to predict human cancer risk (Gottmann et al., 2001; Knight et al., 2005, 
2006; Alden et al., 2011). Carcinogenicity assessment requires the conduct of either a 
carcinogenicity bioassay (OECD TG 451, EC B.32) or a combined chronic 
toxicity/carcinogenicity test (OECD TG 453, EC B.33). These studies take several years to 
run (the in-life portion alone lasts 24 months) and are very costly (one million Euro/chemical, 
approximately). In addition, repeat-dose toxicity studies, as well as other in vitro and in vivo 
studies can be used to better understand the human relevance of findings in rodents (e.g. 
related to toxicokinetic properties or species-specific effects) or the mechanism and associated 
dose-response for a chemical (OECD,2012a; Luijten et al., 2012).  
 
At present, carcinogenicity testing, under REACH “can be proposed by the Registrant or may 
be required by ECHA” for chemicals at high level tonnage of production (≥ 1000t/y), which 
show widespread dispersive use or frequent or long-term human exposure and are classified 
as mutagens category 3 (GHS category 2), or there is evidence of hyperplasia and/or 
preneoplastic lesions from repeated dose toxicity studies (EC no. 1907/2006). However, 
REACH also requires that carcinogenic substances at all tonnage levels be identified as 
substances of high concern, taking into account information from all available relevant 
sources (non-human and human non-testing and testing data), which can inform hazard 
identification, underlying modes of action, or carcinogenic potency. The Biocidal Products 
legislation (EU no. 528/2012) requires carcinogenicity studies, unless substances are 
classified as mutagens category 1A and 1B or based on other specific justifications. A 
combined carcinogenicity study and long-term repeat-dose toxicity in the rat, possibly 
through the oral route plus a carcinogenicity study in a second rodent species, the mouse, are 
usually performed. For Plant Protection Products (PPRs) (EU nos. 1107/2009b and 283/284-
2013) or Veterinary Drugs (VICH, 2005), tests for carcinogenicity are always required in two 
different species. Pharmaceuticals are also tested for carcinogenic potential, although several 
restrictions regarding the class of compound, duration of treatment (at least 6 months), dose or 
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target population may apply (ICH S1A, 1995; S1B, 2009; S1C, 2008; S1, 2012). For cosmetic 
ingredients and products no in vivo test is permitted from March 2013 (EC no. 1223/2009; 
SCCS, 1501/2012).  
 
9.2 Mechanistic understanding of the endpoint 
For an adequate evaluation of the genotoxic potential of a compound, different endpoints (i.e. 
induction of gene mutation, structural and numerical chromosome alterations) have to be 
assessed, as each of these events has been implicated in carcinogenesis and heritable diseases. 
A number of well-established and regulatory accepted in vitro tests are in place however, the 
low level of specificity often leads to misleading results that need to be clarified by in vivo 
genotoxicity tests (Kirkland et al., 2005; Maurici et al., 2005; Kirkland et al., 2007; Fowler et 
al, 2012a,b; refer also to chapter on genotoxicity and mutagenicity). 
 
Although it is generally accepted that major carcinogenic risk is related to genotoxic 
compounds, the potential risk related to non-genotoxic compounds must also be evaluated. 
Several non-genotoxic substances may also cause tumours by affecting regulation of gene 
expression and genomic stability through epigenetic mechanisms, such as alternative states of 
gene expression, complex hyper- or hypo-methylation of DNA, histone modifications, 
inducing changes in protein folding and nucleosomal remodelling, RNA interference (Lo and 
Sukumar, 2008; Sadikovic et al., 2008). Also sustained cell proliferation and inhibition of 
gap-junction intercellular communication are possible non-genotoxic mechanisms. Although 
some of the major mechanisms behind non-genotoxic carcinogenicity are known, multiple 
mechanisms of action and the underlying cellular and molecular events are not completely 
understood.  
 
Typically modes of action of non-genotoxic substances are related to carcinogenesis phases of 
promotion and progression but participation into initiation phase is also proposed (Hattis et 
al., 2009). The induction of tissue-specific toxicity (cytotoxicity) resulting in inflammation 
and regenerative hyperplasia, for instance, is one of the well-known mechanisms (Loeb & 
Harris, 2008). Induction of immunosuppression by chemicals is regarded as another 
significant non-genotoxic mechanism of cancer (Hernández et al., 2009). Oxidative stress in 
cells also results in non-genotoxic carcinogenesis as it is shown that cancer cells commonly 
have increased levels of reactive oxygen species (ROS) and that ROS can induce cell 
malignant transformation (López-Lázaro, 2010: Klaunig et al., 2010). Oxidative stress has 
been suggested to have some involvement in the mode of carcinogenic activity of peroxisome 
proliferators in rodent livers (Doull et al., 1999, Hernández et al., 2009). Many non-genotoxic 
carcinogens act via binding to receptors such as aryl hydrocarbon, nuclear and peroxisome-
proliferator receptors (Hattis et al., 2009), thus affecting cell proliferation, apoptosis and 
intercellular communication. Other cellular targets are tyrosine kinase (TK), ion channel-
coupled and G-protein-coupled receptors (Silva Lima & Van der Laan, 2000). Many 
endocrine active substances act by binding to receptors such as the oestrogen, progesterone, 
aryl hydrocarbon and thyroid hormone receptors, thereby inducing cell proliferation in their 
target organs (Silva Lima & Van der Laan, 2000; Zhang & Ho, 2011; Labrecque et al., 2012; 
ECHA, 2012).  
 
Since the mechanisms by which non-genotoxic carcinogens cause tumours are often related to 
species-specific disturbances in the normal physiological control of cellular proliferation, 
survival and differentiation (Widschwendter & Jones, 2002, Baylin & Ohm, 2006, Esteller, 
2007), the observed effects are not necessarily predictive for humans (Shanks et al., 2009). In 
this context, the International Programme on Chemical Safety (IPCS) of the World Health 
Organisation (WHO) has been leading a project to harmonize approaches to the assessment of 
risk from exposure to chemicals, including chemical carcinogenesis and a Unified Human 
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Cancer Relevance Framework (IPCS HRF) has been produced. This is based on the concept 
that for a given tumour produced by a given compound in the experimental animal it may be 
possible to postulate a specific mode of action (MOA), the relevance of which at animal level 
can be clearly defined with a description of the key events (measurable parameters) that are 
along the causal path. The establishment of the specific animal MOA together with the 
analysis of dose-response and temporal relationships, along with analyses of the strength, 
consistency and specificity of key events, tumour responses, and biological plausibility and 
coherence, dynamic and kinetic factors allows a thorough qualitative and quantitative 
comparison between experimental animals and humans. By using this analytical approach, the 
human relevance of MOAs in the animal model can be determined, resulting in a transparent 
evaluation of human cancer risk (IPCS, 2007). 
 
9.3 Status of non-standard methods and Integrated Approaches 
Research into alternative predictive models for carcinogenicity has focused on medium-term 
carcinogenic in vivo models (e.g. in vivo transgenic models), short-term in vitro and in vivo 
biological assays, as well as computational models. 
 
At present, the challenge is to develop alternative test methods for both genotoxic and non-
genotoxic carcinogenicity. The complexity of the carcinogenicity process renders it difficult 
especially when developing in vitro alternative test models able to mimic the whole process 
and when considering non-genotoxic carcinogens. This challenge is also heightened because 
of the number of potential target organs. Some key events of the carcinogenesis process can 
be investigated in vitro. However, it is expected that an integrated approach involving 
multiple in vitro models will be needed, but a better understanding of the entire process is also 
required before this will be possible (Benfenati et al., 2009; Adler et al., 2011; Paules et al., 
2011). Scientific research is on-going to try to achieve this goal. In this regard, it is worth 
noting the effort shown by IARC to highlight the potential role of epigenetic phenomena in 
cancer etiology and to drive the attention of scientific and regulatory communities towards the 
incorporation of epigenetic mechanisms into carcinogen identification and evaluation (Herceg 
et al., 2013). 
 
9.3.1 In vitro methods 
Mammalian cell culture systems may be used to detect phenotypic changes in vitro induced 
by chemical substances associated with malignant transformation in vivo (DiPaolo et al., 
1969; Isfort et al., 1996; Matthews et al., 1993). The cell transformation assays (CTAs) have 
been shown to closely model some key stages of the in vivo carcinogenesis process (LeBoeuf 
et al., 1999) and to date they represent the only standardised in vitro tests that have the 
potential to detect both genotoxic and non-genotoxic carcinogens. Moreover, the CTA is 
faster and more cost efficient than the in vivo rodent carcinogenicity assay, providing a useful 
approach for screening of chemicals with respect to their carcinogenic potential. Although the 
use of CTA is not currently an explicit regulatory requirement, its application is mentioned in 
a number of guidance documents (SCCS, 1501/2012; Jacobson-Kram & Jacobs, 2005; 
ECHA, 2012; Pfuhler et al., 2010; EFSA, 2011; ICH 2009). In these guidance documents 
CTAs are considered to be used as screening methods or to provide additional useful 
information to more routinely employed tests for assessing carcinogenic potential or to 
(Vanparys et al., 2012). 
 
A study with SHE (pH 6.7 and 7.0) and BALB/c 3T3 cells was coordinated by ECVAM to 
address issues of standardisation of the protocols, transferability and reproducibility 
(Vanparys et al., 2010; Corvi et al., 2012). The study outcome in combination with the 
extensive database on CTA performances previously summarized in the OECD Detailed 
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Review Paper no. 31 (OECD, 2007; EURL ECVAM, 2012), supported the development of an 
OECD TG on CTA in SHE cells (Draft OECD TG, 2013).  
 
An EURL ECVAM recommendation has been published on on another CTA based on the 
Bhas42 cell line, which offers a relatively higher throughput than other CTA variants (Poth et 
al., 2007; Sakai et al., 2011; EURL ECVAM, 2013). EURL ECVAM recommended that 
CTAs should not be used as stand-alone tests, but may provide useful information about 
possible genotoxic and non-genotoxic carcinogenicity potential for use in conjunction with 
other data to generate supporting information for hazard identification that can eventually 
contribute to the risk assessment.  
 
The assay may thus be used for these purposes in the context of a weight of evidence 
approach. Depending on the extent of other information available from non-testing and testing 
approaches, it is conceivable that information on the presence or lack of transforming 
potential of chemicals generated with the CTA may be sufficient for decision-making to 
confirm or refute a suspicion of carcinogenicity, and may thus in specific cases allow waiving 
the use of the rodent bioassay. Based on available data related to sensitivity and specificity, 
both positive and negative results may be relevant in the context of carcinogenicity 
evaluation. For example, depending on other information available, in some cases a positive 
CTA result can add confidence that a substance has the potential to be carcinogenic, while in 
some other situations a negative result could hint towards an absence of effect. In other cases, 
the CTA may provide testing data that still require confirmatory testing (EURL ECVAM, 
2012).  Further work should focus on the development of conceptual frameworks to define 
optimal combinations of CTA data with complementary information sets to address 
carcinogenicity assessment specific to different sectorial needs. 
 
CTAs are currently used for clarification of in vitro positive results from genotoxicity assays 
to be used in the weight of evidence assessment. Data generated by CTAs can be useful where 
genotoxicity data for a certain substance class have limited predictive capacity (e.g. aromatic 
amines), for investigation of compounds with structural alerts for carcinogenicity or to 
demonstrate differences or similarities across a chemical category. Also the tumour-
promoting activity of chemicals can be investigated by the CTAs (Vanparys et al., 2012). 
Moreover, it has been suggested that the CTA assay can be used in defining possible 
thresholds (e.g. DNELs/DMELs) for transforming activity (Jacquet et al., 2012; Vanparys et 
al., 2012). Recently, some tiered testing approaches which include the use of the CTAs have 
been proposed (Benigni et al., 2013; Doktorova et al., 2012).  
 
Different research methods, including in vitro methods using several cell types, are available 
to study a number of potential non-genotoxic mechanisms. For example, tests are available to 
measure oxidative stress (Klaunig et al., 2010) or to measure the inhibition of gap junction 
intercellular communication (GJIC) (Klaunig & Shi, 2009), both of which have been 
associated with a number of non-genotoxic carcinogens. However, these methods cannot 
currently be used to reliably predict carcinogenic potential rather they are focused on better 
understanding the mechanism for effects elicited by a compound.  
 
9.3.2 Toxicogenomics 
In vitro toxicogenomics approaches using in vitro systems have shown to reach 80-90% 
accuracy (Tsujimura et al., 2006; Li et al., 2007; Le Fevre et al., 2007; Ellinger-Ziegelbauer et 
al., 2009; Guyton et al., 2009; Mathijs et al., 2010; Waters et al., 2010; Doktorova, 2012; 
Jennings et al., 2013) for predicting in vivo toxicity in rodents although the number of 
chemicals is still limited and may not represent the full spectrum of toxins. Further in vitro 
tests were evaluated in the frame of the EU-funded project carcinoGENOMICS which aimed 
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at developing toxicogenomics- in vitro tests to detect potential genotoxicants and carcinogens 
in liver, lung and kidney target organs using different types of cells (carcinoGENOMICS 
Project website: http://www.carcinogenomics.eu/index.php?id=100; Doktorova 2013). 
Interestingly, the application of toxicogenomics to in vitro CTA assay resulted in a gene 
signature predictive of carcinogenic potential (Rohrbeck et al., 2010; Ao et al., 2010), which 
can be regarded as providing more confidence on the regulatory relevance of CTA test results. 
 
Most in vivo toxicogenomics studies on assessment of carcinogenicity, focus, but do not limit, 
on short-term rat studies and non-genotoxic hepatocarcinogenicity and were shown to predict 
80-90% rodent carcinogenicity which is in the same range of accuracy as for in vitro 
toxicogenomics data (Ellinger-Ziegelbauer et al., 2008; Nie et al., 2006; Fielden et al., 2007; 
Stemmer et al., 2007; Nioi et al., 2008; Uehara et al., 2008; Jonker et al., 2009; Vinken et al., 
2012). They result instrumental for screening purpose or for better elucidation of modes of 
action (MOA), in particular in areas where the rodent bioassay is always required. The in vivo 
toxicogenomics assays can be helpful for hazard assessment and by that they may lead to a 
substantial reduction in the number of bioassays and the number of animals in the remaining 
in vivo tests. Indeed, the number of animals required for toxicogenomics-based assays is at 
least 10-fold-smaller and the exposure periods are 26-fold-shorter (max 4 weeks instead of 2 
years) than for the standard rodent bioassay (Guo et al., 2006; MAQC Consortium, 2006). 
 
Although significant technical progress has been made in the last decade, the limitations of 
toxicogenomics-based tests are many, including: quantitative risk assessment is in its infancy; 
limited public accessibility of raw data; poor knowledge of the function of many genes in the 
prediction sets; lack of uniformity in study design (e.g. rodent species and strain, dose setting 
criteria, time points, repeats) and bio-informatics analyses; requirement of expensive 
equipment and specialized staff. Moreover, formal validation of these methods is lacking at 
present and their regulatory acceptability is being discussed.  
 
9.3.3 In vivo testing 
Short-term tests with transgenic mouse models (p53+/-, rasH2, Tg.AC, Xpa-/- and Xpa-/-
p53+/) are possible alternatives for the classical 2-year cancer bioassay (Tennant et al., 1995 
and 1999; Ashby, 2001). The rationale for using transgenic mice in regulatory carcinogenicity 
testing is that transgenic mouse models may be more sensitive predictors of carcinogenic risk 
to humans. Indeed these transgenic mouse models have a reduced tumour latency period (6-9 
months) to chemically-induced tumours (Marx, 2003). Although not a complete replacement 
of the rodent 2-year cancer bioassay, transgenic mouse models can be considered as 
refinement methods and may result in a significant reduction in the use of experimental 
animals (20-25 animals/sex/treatment group) (ILSI/HESI ACT 2001; Eastin, 1998; Bucher, 
1998; Pritchard, 2003; de Vries et al., 2004). While these animal model systems have been 
shown to be promising for the detection of carcinogens, their sensitivity and specificity 
remains to be determined. Due to a relative lack of validation, these assays are generally not 
yet accepted as a full replacement for the rodent 2-year bioassay, but data from these models 
may be used in a weight-of-evidence analysis of chemical carcinogenicity. It should however 
be noted that the evaluation study carried out by ILSI/HESI (ILSI/HESI Act, 2001) and a 
consortium of academic, governmental and industrial laboratories, led to the initial acceptance 
by pharmaceutical regulatory agencies of three primary models: p53+/-, Tg.AC and rasH2 
model. The use of such models has been endorsed for the assessment of pharmaceuticals in 
lieu of a second species full carcinogenicity bioassay in mice (ICH S1B, 2009).  
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9.3.4 QSAR models 
To date, hundreds of qualitative structure-activity relationship (SAR) and quantitative 
structure-activity relationship (QSAR) model have been published in the literature for 
predicting genotoxicity and carcinogenicity (Benfenati et al. 2009; Serafimova et al. 2010). 
These methods have proven successful at predicting genotoxic potential, and are arguably as 
reliable and informative as the gene mutation test in bacteria. On the other hand, QSARs 
capable of detecting non-genotoxic carcinogenic potential are still at an early stage of 
development and only a few are available (Benigni & Bossa, 2008; Toropov et al., 2009). A 
number of structural alerts and characteristics of several types of non-genotoxic carcinogens 
have been summarised (Woo et al., 1995; Woo & Lai, 2003; Ferrari & Gini, 2010).  
 
Software tools in the public domain include CAESAR, Toxtree, OncoLogic and LAZAR. The 
models included in Toxtree (Benigni et al., 2008) and the OECD Toolbox are rule-based. 
Commercial models include MultiCase, TOPKAT, HazardExpert, Derek and ToxSuite. Derek 
and HazardExpert can be used in combination with programs Meteor and MetabolExpert to 
predict the genotoxicity and carcinogenicity potential of metabolites as well as parent 
compounds.  
 
QSAR models for carcinogenic potency prediction are less accurate. This is expected given 
the complexity of the carcinogenicity endpoint, and the fact that models do not explicitly 
include ADME (absorption, distribution, metabolism excretion) properties, which could be 
critical steps in the carcinogenic process. While QSARs cannot be used as stand-alone 
alternatives to traditional tests, the combined use of several models can provide useful support 
to the overall evaluation of carcinogenicity (Cronin et al., 2003; Eriksson et al., 2003; 
Contrera et al., 2007; Jaworska and Nikolova-Jeliazkova, 2007; Benigni and Bossa, 2008; 
Fjodorova et al., 2010; Wu et al., 2010; Benigni, 2012; ECHA, 2010a,b; OECD, 2010d).  
 
In addition, the use of categories, read-across and/or TTC approaches can be useful in filling 
data gaps and adding confidence to the predictions generated by QSARs (Van Leeuwen et al., 
2009). Furthermore, additional confidence can be provided by the combination of multiple 
QSARs and in vitro tests (e.g. Peer Consultation on Health Canada Draft Weight of Evidence 
Framework for Genotoxic Carcinogenicity 2005). 
 
9.3.5 Application of the Threshold of Toxicological Concern approach to cancer endpoints 
The Threshold of Toxicological Concern (TTC) is a scientifically-based risk assessment 
approach to establish acceptable exposure limits when sufficient chemical-specific 
toxicological information is lacking (US FDA, 1995). To apply the TTC approach, a reliable 
measure or estimate of the exposure level is required. TTC is a useful approach for 
prioritising the further assessment of trace contaminants and chemicals associated with very 
low consumer exposures (see chapter on repeated dose toxicity). It is used, or has been 
proposed for use, in various sectors, including pharmaceuticals, chemicals in food, and 
chemicals in consumer products (Munro et al., 1996; Blackburn et al., 2005; Kroes et al., 
2007; Safford RJ, 2008; Carthew et al., 2009; Felter et al., 2009; JEFCA, 1996-1997; EFSA, 
2004; EMEA, 2006 and 2008; SCCP, 2008). Bercu et al. (2010) have suggested the use of 
TTC in combination with QSAR tools to establish safe levels for genotoxic impurities (GTIs) 
in drug substances. 
 
9.3.6 Extrapolating from other animal studies 
The role of genotoxicity testing can be both qualitative (hazard assessment) and quantitative 
(risk assessment). A linear relationship has been reported between the lowest effective dose 
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(LED) for in vivo genotoxicity and the carcinogen dose descriptor T25 (the chronic daily 
dose, which gives 25% of the animals tumours at a specific tissue site) (Sanner and Dybing, 
2005). Indeed, the LED was suggested after further evaluation, as useful in a semi-
quantitative method for risk assessment of mutagens without a long-term carcinogenicity 
study. The above results have been further supported by investigations on the applicability of 
in vivo and more recently in vitro genotoxicity tests to estimate cancer potency using the 
benchmark dose approach (Hernandez et al., 2011; Hernandez et al., 2013). 
 
In light of the 3Rs Principle, the human pharmaceutical industry is currently exploring the 
possibility to predict carcinogenicity on the basis of available data (“Putting Animal Welfare 
Principles and 3Rs into Action” - European Pharmaceutical Industry 2011 Report), without 
necessarily requiring a 2-year bioassay. Rat chronic toxicology studies are good predictors of 
negative outcome in two-year rat carcinogenicity studies. The results derived from 182 
compounds across 242 rat chronic toxicology studies and 182 two-year rat carcinogenicity 
studies conducted by 13 pharmaceutical companies over several years were reviewed (Sistare 
et al, 2011). The predictivity on an organ-by-organ basis is poor, but the overall negative 
predictivity is very good on a whole animal basis. Therefore, in the absence of chronic 
toxicity, preneoplasia, genotoxicity or hormonal perturbation signals, there is no added value 
from conducting a 2-year bioassay study. The potential preneoplastic histopathologic effects 
seen in chronic (six months) rat toxicology studies may be predictive of tumour outcome in 2-
year bioassays. This is an interesting approach applicable to the pharmaceuticals sector 
however it is not directly relevant for REACH, since it would not require carcinogenicity 
testing under the above conditions. It is nevertheless worth investigating whether information 
related to other systemic toxicity endpoints can be extrapolated to provide information on 
carcinogenic potential, and potentially waive cancer bioassays. Similarly, for cosmetic 
ingredients in the past safety assessment for non-genotoxic chemicals has been based on 
identification of a NO(A)EL from repeat-dose (mainly 90 day) toxicity studies which along 
with appropriate conservative safety factors, has been used to perform a risk assessment for 
these chemicals, including the risk for carcinogenicity.  
 
9.4 Conclusions 
The major challenge for non-standard methods in carcinogenicity assessment is the 
identification and characterisation of non-genotoxic carcinogens. The proportion of non-
genotoxic versus genotoxic carcinogens in the environment is likely to increase in the future, 
since the scientific knowledge on DNA reactivity allows industrial chemists to design 
compounds without overly reactive moieties. In contrast to genotoxic carcinogens, for those 
chemicals shown to lack genotoxicity potential, it is generally assumed that there is a 
threshold and that the carcinogenic risk can be assessed based on data from repeated dose 
toxicity studies. Prior to the formation of tumours (generally seen only after long-term 
exposures), non-genotoxic carcinogens cause changes in normal physiological function and 
these adverse effects can be determined in a repeat-dose toxicity study. For those chemicals 
the protection of human health against the pre-cancerous lesion will also protect against 
cancer which is a secondary effect. It is noted though, that some of these non-genotoxic 
carcinogens, when not classified for any other property and not identified as such in repeated 
dose toxicity studies, will go unidentified. While hyperplasia and pre-neoplastic lesions can 
be observed in a repeated dose toxicity study (e.g. in a sub-chronic study), other effects such 
as altered gene expression, DNA-methylation or inhibition of gap-functional communication 
are not monitored, as such, in repeated dose toxicity studies. In order to fully exploit the in 
vivo experiment, the integration of such additional multiparametric analyses into standard in 
vivo assays should be considered. 
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Efforts are needed to develop a strategy for evaluating hazard by combining information 
across different systemic toxicity endpoints, rather than considering them individually. This 
integrated approach is expected to result in a set of options for waiving redundant testing, 
which are motivated by a mechanistic understanding of the toxicological effects and their 
inter-relationships. 
 
To avoid animal-specific and biased results, an in vitro testing battery based on human cell or 
tissue models with relevant biomarkers is seen as the most optimal way to replace animal tests 
in non-genotoxic carcinogenic assessment. It is expected that there will be significant 
synergies between work to develop replacement tests for repeat-dose toxicity studies with 
tests to predict non-genotoxic carcinogens and quantitative thresholds of response. Despite the 
fact that some mechanisms behind non-genotoxic carcinogenicity are known, multiple 
unknown mechanisms of action and the insufficient knowledge of the cellular and molecular 
events have not yet allowed for the imminent implementation of a battery of in vitro tests that 
could predict and/or explain their carcinogenic potential in humans. Moreover, those in vitro 
tests that could have a role in a testing strategy, which covers non-genotoxic endpoints, have 
not been sufficiently standardised and validated. 
 
Although some short-term in vitro tests (e.g. CTA, toxicogenomics-based tests) are available 
beyond the standard in vitro genotoxicity tests to support conclusions on cancer hazard 
identification, the in vitro short-term tests are not sufficient to fully replace the animal tests 
needed to perform risk assessment for carcinogenicity. However, for some chemical classes 
the available non-animal methods might be sufficient to rule out carcinogenic potential in a 
weight of evidence approach. On the other hand, for clear genotoxic chemicals, a possibility is 
to rely on clear positive genotoxic results and label the chemical as a possible carcinogen, as 
the default presumption would be that a genotoxic mechanism for carcinogenicity is likely.  
 
Although there is still a considerable need to develop reliable QSARs (and other theoretical 
models) for carcinogenicity prediction, existing models could be useful, but not as stand-alone 
approaches. Instead, QSARs can be applied, for example in the context of the TTC approach, 
to prioritise further testing, and they can be used for hazard identification in the context of 
weight-of-evidence approaches, along with in vitro data, grouping and read-across. 
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Chapter 9. Table of References with Notes 
 
Traditional in vivo tests  
OECD (2009), Test No. 451: Carcinogenicity Studies, OECD 
Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. doi: 10.1787/9789264071186-en 
The objective of a long-term carcinogenicity study is to observe test animals for a major portion of 
their life span for the development of neoplastic lesions during or after exposure to various doses of 
a test substance by an appropriate route of administration.  
 
This Test Guideline is intended primarily for use with rats and mice, and for oral administration. 
Both sexes should be used. Each dose group and concurrent control group should contain at least 50 
animals of each sex. At least three dose levels and a concurrent control should be used. Animals are 
dosed with the test substance daily (oral, dermal or inhalation administration) and the mode of 
exposure should be adjusted according to the toxicokinetic profile of the test substance. The 
duration of the study will normally be 24 months for rodents. For specific strains of mice, duration 
of 18 months may be more appropriate. Termination of the study should be considered when the 
number of survivors in the lower dose groups or the control group falls below 25 per cent. The 
results of these studies include: measurements (weighing, food consumption), and, at least, daily and 
detailed observations, as well as gross necropsy and histopathology. 
 
OECD (2009), Test No. 452: Chronic Toxicity Studies, 
OECD Guidelines for the Testing of Chemicals, Section 4, 
OECD Publishing. doi: 10.1787/9789264071209-en 
The objective of these chronic toxicity studies is to characterize the profile of a substance in a 
mammalian species (primarily rodents) following prolonged and repeated exposure.  
The Test Guideline focuses on rodents and oral administration. Both sexes should be used. For 
rodents, at least 20 animals per sex per group should normally be used at each dose level, while for 
non-rodents a minimum of 4 per sex per group is recommended. At least three dose levels should be 
used in addition to the concurrent control group. Frequency of exposure normally is daily, but may 
vary according to the route chosen (oral, dermal or inhalation) and should be adjusted according to 
the toxicokinetic profile of the test substance. The duration of the exposure period should be 12 
months. The study report should include: measurements (weighing) and regular detailed 
observations (haematological examination, urinalysis, clinical chemistry), as well as necropsy 
procedures and histopathology. 
 
OECD (2009), Test No. 453: Combined Chronic 
Toxicity/Carcinogenicity Studies, OECD Guidelines for the 
Testing of Chemicals, Section 4, OECD Publishing. 
doi: 10.1787/9789264071223-en 
The objective of a combined chronic toxicity/carcinogenicity study is to identify carcinogenic and 
the majority of chronic effects, and to determine dose-response relationships following prolonged 
and repeated exposure.  
The rat is typically used for this study. For rodents, each dose group and concurrent control group 
intended for the carcinogenicity phase of the study should contain at least 50 animals of each sex, 
while for the chronic toxicity phase of the study should contain at least 10 animals of each sex.  At 
least three dose levels should be used, in addition to the concurrent control group for both the 
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chronic toxicity phase and the carcinogenicity phase of the study. The three main routes of 
administration are oral, dermal, and inhalation. The Test Guideline focuses on the oral route of 
administration. 
The period of dosing and duration of the study is normally 12 months for the chronic phase, and 24 
months for the carcinogenicity phase. The study report should include:  measurements (weighing) 
and regular detailed observations (haematological examination, urinalysis, clinical chemistry), as 
well as necropsy procedures and histopathology. All these observations permit the detection of 
neoplastic effects and a determination of carcinogenic potential as well as the general toxicity.  
 
New in vivo and in vitro tests – Draft OECD TGs 
OECD (2013) DRAFT TG Publication: In vitro 
Carcinogenicity: Syrian Hamster Embryo (SHE) Cell 
Transformation Assay. October 2012 
http://www.oecd.org/env/ehs/testing/Draft%2017%20Octobe
r%202012.pdf 
In vitro cell transformation refers to the induction of phenotypic alterations in cultured cells that are 
characteristic of tumorigenic cells. This Test Guideline (TG) provides an in vitro procedure of the 
cell transformation assay in Syrian Hamster Embryonic stem cells (SHE), which may be used for 
hazard identification of chemical carcinogens. 
 
OECD (2013) DRAFT TG Publication: In vivo mammalian 
Alkaline Comet Assay.  
http://www.oecd.org/env/ehs/testing/OECD_draft%20TG_Co
met_December2013.pdf 
 
Rodent in vivo Comet assays are especially relevant to assessing DNA-damaging potential of 
chemicals for regulatory purposes. 
 
EURL ECVAM (2012) Recommendation concerning the cell 
transformation assays using Syrian hamster embryo cells 
(SHE) and the BALB/c 3T3 mouse fibroblast cell line for in 
vitro carcinogenicity testing. Annex I: ESAC opinion on the 
ESAC peer review of an ECVAM-coordinated prevalidation 
study concerning three protocols of the cell transformation 
assay (CTA) for in vitro carcinogenicity testing. 
http://ihcp.jrc.ec.europa.eu/our_activities/alt-animal-testing 
 
EURL ECVAM recommendation report on the three CTA protocol variants: (a) The SHE CTA 
performed at pH 6.7 (SHE pH 6.7 CTA); (b) the SHE CTA performed at pH 7.0 (SHE pH 7.0 
CTA); and (c) the BALB/c 3T3 CTA. 
ECVAM coordinated an international study that was designed to address issues of CTA protocols 
standardisation, transferability and reproducibility in three protocol variants for the SHE CTA (at 
pH 6.7 and pH 7.0) and the BALB/c 3T3 assay. The study of the three test methods was peer 
reviewed by the ESAC that issued a peer review report and an ESAC opinion. Based on the 
available documents (study reports, ESAC opinion, OECD DRP), EURL ECVAM recommended 
that an OECD TG be developed for the SHE CTA and that further investigations were needed to 
confirm the performance of the BALB/c 3T3 CTA.  
Moreover, the recommendation stated that in conjunction with other available data, the CTAs have 
the potential of partial replacement or reduction when used in a weight of evidence approach for 
hazard identification and risk assessment.  
 
EURL ECVAM (2013) Recommendation on the Cell 
Transformation Assay based on the Bhas 42 cell line 
CTA in Bhas 42 cell line that offers a relatively higher through-put than other CTA variants. 
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http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-
recommendations/eurl-ecvam-recommendation-on-the-cell-
transformation-assay-based-on-the-bhas-42-cell-line 
 
Regulatory Requirements for Carcinogens across Sectors 
European Commission, 2008. Regulation (EC) No 1272/2008 
of the European Parliament and of the Council of 16 
December 2008 on classification, labelling and packaging of 
substances and mixtures, amending and repealing Directives 
67/548/EEC and 1999/45/EC, and amending Regulation (EC) 
No 1907/2006. Official Journal of the European Union L353. 
Carcinogenicity (Section 3.6) 
 
CATEGORY 1 Known or presumed human carcinogens 
A substance is classified in Category 1 for carcinogenicity on the basis of epidemiological and/or 
animal data. A substance may be further distinguished as: 
Category 1A, known to have carcinogenic potential for humans, classification is largely 
based on human evidence, or 
Category 1B, presumed to have carcinogenic potential for humans, classification is largely 
based on animal evidence. 
The classification in Category 1A and 1B is based on strength of evidence together with additional 
considerations. Such evidence may be derived from: 
• human studies that establish a causal relationship between human exposure to a substance 
and the development of cancer (known human carcinogen); or 
• animal experiments for which there is sufficient evidence to demonstrate animal 
carcinogenicity (presumed human carcinogen). 
In addition, on a case-by-case basis, scientific judgment may warrant a decision of presumed human 
carcinogenicity derived from studies showing limited evidence of carcinogenicity in humans 
together with limited evidence of carcinogenicity in experimental animals 
 
CATEGORY 2 Suspected human carcinogens 
The placing of a substance in Category 2 is done on the basis of evidence obtained from human 
and/or animal studies, but which is not sufficiently convincing to place the substance in Category 
1A or 1B, based on strength of evidence together with additional considerations.  
Such evidence may be derived either from limited evidence of carcinogenicity in human studies or 
from limited evidence of carcinogenicity in animal studies. 
 
GHS (2013) UN (2013) Globally Harmonized System of 
Classification and Labelling of Chemicals (GHS), 5th revised 
edition. United Nations, New York and Geneva, 2013 
http://www.unece.org/fileadmin/DAM/trans/danger/publi/ghs
/ghs_rev05/English/ST-SG-AC10-30-Rev5e.pdf. 
Carcinogenicity (Chapter 3.6) 
3.6.1 Definitions 
The term carcinogen denotes a substance or a mixture which induces cancer or increases its 
incidence. Substances and mixture which have induced benign and malignant tumours in well 
performed experimental studies on animal are considered also to be presumed or suspected human 
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 carcinogens unless there is strong evidence that the mechanism of tumour formation is not relevant 
for humans.(…) 
 
3.6.2 Classification criteria for substances 
CATEGORY 1 Known or presumed human carcinogens 
Category 1A: Known to have carcinogenic potential for humans; the placing of a substance is 
largely based on human evidence 
Category 1B: Presumed to have carcinogenic potential for humans; the placing of a substance 
is largely based on animal evidence. 
 
CATEGORY 2 Suspected human carcinogens 
Based on evidence obtained from human and/or animal but not sufficiently convincing to place a 
substance in Category 1. 
 
IARC (2006) IARC Monographs on the Evaluation of 
Carcinogenic Risks to Humans. WHO, International Agency 
for Research on Cancer, volumes 1-107 
Evaluation and Rational (Preamble, par. 6) 
 
Group     1           Carcinogenic to humans  
Group   2A          Probably carcinogenic to humans 
Group   2B          Possibly carcinogenic to humans 
Group     3           Not classifiable as to its carcinogenicity to humans  
Group     4           Probably not carcinogenic to humans 
 
ICH Guideline (1995) S1A  
ICH harmonized Tripartite Guideline, Guideline on the Need 
for Carcinogenicity Studies of Pharmaceuticals, S1A, Current 
Step version 4, November 1995. 
 
ICH Guideline (2009) S1B  
Guideline on carcinogenicity testing of pharmaceuticals.  
http://www.ema.europa.eu/docs/en_GB/document_library/Sc
ientific_guideline/2009/09/WC500002735.pdf. 
 
ICH Guideline (2008) S1C(R2) 
Dose selection for carcinogenicity Studies of 
Pharmaceuticals, S1C (R2), Current Step version 4, 11 March 
2008. 
ICH Guideline (2009) M3 (R2)  
Pharmaceuticals:  
(S1A)  
The guideline sets the factors in need to be considered for carcinogenicity testing: exposure time, 
cause of concern, genotoxicity, indication and patient population, route of exposure, extent of 
systemic exposure, endogenous peptides, and analogues (Paragraphs 4.1 to 4.7). 
 
Carcinogenicity studies should be performed for any pharmaceutical whose expected clinical use is 
continuous for at least 6 months.  
Also for pharmaceuticals used frequently in an intermittent manner in the treatment of chronic or 
recurrent conditions the studies are generally needed. 
Studies are also recommended: 
-for some drugs if there is concern about their carcinogenic potential, derived from previous 
carcinogenicity studies or other toxicity tests or QSARs predictions. 
-for pharmaceuticals applied topically, unless a proof of poor systemic exposure is shown. 
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Guidance on Nonclinical Safety Studies for the Conduct of 
Human Clinical Trials and Marketing Authorization for 
Pharmaceuticals. June 2009. 
 
Concept Paper (2012) 
S1: Rodent Carcinogenicity Studies for Human 
Pharmaceuticals, Dated and endorsed by the Steering 
Committee on 14 November 2012 
 
ICH Guideline S1 (2012) 
Regulatory notice on changes to core guideline on rodent 
carcinogenicity testing of pharmaceuticals. 
EMA/CHMP/ ICH/752486/2012 December 2012. 
 
Unequivocally genotoxic compounds, instead, need not to be subjected to long-term carcinogenicity 
studies. The detection of early tumorigenic effects may be necessary if the drug is intended for 
chronic treatment (up to one year). 
 
Endogenous peptides or proteins and their analogues, produced by chemical synthesis, by 
extraction/purification from animal/human source or biotechnological methods may require special 
considerations.  
Not generally needed but, conduct of long-term carcinogenicity studies in rodent species are 
required for: 1) products where there are significant differences in biological effects with the natural 
counterparts; 2) for products where modifications lead to significant changes in structure; 3)for 
products resulting in humans in a significant increase over the existing local or systemic 
concentration. 
 
(S1B)  
The guideline embraces all the pharmaceutical agents that need carcinogenicity testing (S1A) apart 
from biotechnology-derived pharmaceuticals which are considered in a specific guideline (S6).  
Experimental approaches as from Paragraph 4.2: 
The basic scheme is: 
-One long-term rodent carcinogenicity study, generally rat, plus 
-One other study which provides additional information such as: 
      a) short or medium-term in vivo rodent test systems, either or 
      b) long-term study in a second rodent species (mouse generally) 
 
Mechanistic studies are considered for the interpretation of the results (i.e. tumor findings) from 
carcinogenicity studies: the above include cellular changes and biochemical measurements. 
 
Additional genotoxicity studies are also considered; they might be invoked for compounds negative 
in the standard test battery but showing effects in carcinogenicity studies via non-clear epigenetic 
mechanisms. 
 
S1C (R2)  
This document addresses the criteria for the selection of the high dose to be used in carcinogenicity 
studies on new therapeutic agents to harmonise current practices and improve the design of studies.  
In this second revision, the pharmacokinetic endpoint of 25 is declared to be applicable also for 
pharmaceuticals with positive genotoxicity signals. This change has implications on "Refinement" 
(one of the 3R's) in enhancing the welfare, i.e., reducing the pain or discomfort of the animals at the 
maximally tolerated dose (MTD). 
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M3 (R2)  
To recommend international standards for, and promote harmonisation of, the nonclinical safety 
studies to support human clinical trials of a given scope and duration, and for the marketing 
authorization of drug products 
 
Concept Paper 
A change to the current S1 harmonised Guidelines on rodent carcinogenicity testing is proposed to 
introduce a more comprehensive and integrated approach to addressing the risk of human 
carcinogenicity of pharmaceuticals, clarify and update, without compromising safety, the criteria for 
deciding whether the conduct of a two-year rodent carcinogenicity study of a given pharmaceutical 
would add value to this risk assessment. In November 2012, the SC endorsed the revision of both 
the S1 Concept Paper and Business Plan to provide clarification concerning how the prospective 
data gathering period should be integrated in the normal ICH Step process. The revised S1 Concept 
Paper and Business Plan describe the S1 strategy which consists of a draft "Regulatory Notice for 
Public Input" which would be issued by each ICH regulatory health authority to solicit comments 
from the public to the proposal, the procedure, and the specific weight-of-evidence criteria. A final 
“Regulatory Notice" is planned to be published in June 2014 and will mark the beginning of the 
prospective data (CADs: Carcinogenicity Assessment Documents) collection period. After 
collecting and incorporating results from the prospective analyses, a Step 2 document is planned to 
be published in November 2016, and a Step 4 document finalised in November 2017. 
 
VICH GL28 (SAFETY: CARCINOGENICITY) (2005) 
Studies to evaluate the safety of residues of veterinary drugs 
in human food: Carcinogenicity Testing. February 2005For 
implementation at Step 7 – Final (Chapter 2.) 
 
Veterinary Drugs:  
This guideline sets out a data-driven decision pathway to determine the need to conduct 
carcinogenicity studies. It also provides guidance on the conduct of carcinogenicity studies. 
 
The decision to undertake carcinogenicity testing should take into consideration: 
1) the results of genotoxicity tests,  
2) structure-activity relationships,  
3) findings from systemic toxicity tests that may be relevant to neoplasia in longer term 
studies. It should also take into consideration any known species specificity of the 
mechanism of toxicity.  
 
Any differences in metabolism between the test species, target animal species, and human beings 
should be taken into consideration. 
 
Genotoxic and non-genotoxic carcinogens: 
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Clearly negative results for genotoxicity will usually be taken as sufficient evidence of a lack of 
carcinogenic potential via a genotoxic mechanism. 
 
Non-genotoxic compounds do not need to be routinely tested for carcinogenicity. Such tests may 
however be required if, for example: 
1) the compound is a member of a chemical class known to be animal or human carcinogens,  
2) available systemic toxicity studies with the compound identify potentially preneoplastic 
lesions or findings indicative of neoplasia, or  
3) systemic toxicity studies indicate that the compound may be associated with effects known 
to be linked with epigenetic mechanisms of carcinogenicity that are relevant to humans. 
 
In vivo testing 
 OECD TGs: 451 and 453.  
Carcinogenicity bioassays consisting of a two-year rat study and an 18-month mouse study are 
generally required. With appropriate scientific justification, carcinogenicity studies may be carried 
out in one rodent species, preferably the rat. A positive response in either test species will be 
considered indicative of carcinogenic potential. 
 
European Commission, 2006. Regulation (EC) No 1907/2006 
of the European Parliament and the Council of 18 December 
2006 concerning the Registration, Evaluation, Authorisation 
and Restriction of Chemicals (REACH), establishing a 
European Chemicals Agency, amending Directive 
1999/45/EC and repealing Council Regulation (EEC) No 
793/93 and Commission Regulation (EC) No 1488/94 as well 
as Council Directive 76/769/EEC and Commission Directives 
91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. 
Official Journal of the European Communities L396, 1-849. 
 
And 
 
ECHA (2012) Guidance on information requirements and 
chemical safety assessment Chapter R.7a: Endpoint specific 
Guidance Version 2.0 November 2012,  R7.7. Mutagenicity 
and Carcinogenicity. 
Chemicals:  
Proposals for conducting a carcinogenicity test should be made with regard to the potential risk to 
human health and with consideration of the actual or intended production and/or use pattern. 
 
REACH only specifies a carcinogenicity test for substances at the Annex X tonnage level 
(≥1000 t/y).  
 
Annex X (1000 tpa-more) par. 8.9.1 
A carcinogenicity study may be proposed by the registrant or may be required by the Agency in 
accordance with Articles 40 or 41 if: 
• the substance has a widespread dispersive use or there is evidence of frequent or 
long-term human exposure; and 
• the substance is classified as mutagen category 3 or there is evidence from the 
repeated dose study (ies) that the substance is able to induce hyperplasia and/or pre-
neoplastic lesions. 
 
If the substance is classified as mutagen category 1 or 2, the default presumption would be that a 
genotoxic mechanism for carcinogenicity is likely. In these cases, a carcinogenicity test will 
normally not be required. 
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However, REACH also requires that carcinogenic substances at all tonnage levels be identified as 
substances of high concern, taking into account information from all available relevant sources. 
 
At the tonnage levels below 1000 t/y, the main concern is for those chemicals that are genotoxic. 
Chemicals may cause cancer secondary to other forms of toxicity, but protection of human health 
against the underlying toxicity (e.g., as identified from a repeat-dose toxicity study) will also protect 
against cancer that is secondary to that toxicity. It is noted, though, that some of these non-genotoxic 
carcinogens, when not classified for any other property and not identified as such in (limited) 
repeated dose toxicity studies will go unidentified; this also regards the risks associated with human 
exposures. 
 
Testing strategy for carcinogenicity 
 
As for other endpoints, the following three steps apply for the assessment of carcinogenicity (i.e. the 
hazard, underlying mode of action, and potency) for substances at each of the tonnage levels 
specified in Annexes VII to X of REACH. 
 
i. Gather and assess all available test and non-test data from read-across/proper chemical 
category and suitable predictive models. Examine the Weight of Evidence that relates to 
carcinogenicity. 
ii. Consider whether the standard information requirements are met. 
iii. Ensure that the information requirements of Annexes VII and VIII are met; make 
proposals to conform to Annexes IX and X. 
 
European Commission, 2009a. Regulation (EC) No 
1223/2009 of the European Parliament and the Council of 30 
November 2009 on cosmetic products. Official Journal of the 
European Communities L342, 59-209. 
 
And 
 
SCCS'S Notes of Guidance for the testing of cosmetics 
substances and their safety evaluation, 8th Revision, 
SCCS/1501/12 (par 3-4.8). 
Cosmetics:  
Before the testing/marketing ban of the 7th Amendment of the Cosmetics Directive [2003/15/EC] on 
cosmetic ingredients, the most commonly performed carcinogenicity tests were: 
i. the Carcinogenicity test [EC B.32, OECD 451] or  
ii. the combined chronic toxicity / carcinogenicity test [EC B.33, OECD 453]. 
 
Under this testing and marketing ban, in vivo testing to investigate the carcinogenic potential of 
substances is no longer possible.  
 
Unfortunately, at present no validated methods to study carcinogenicity are available. 
 
The in vitro Cell Transformation Assay (CTA) is at a late stage of development.  
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Without the 2-year bioassay, it is very difficult if not impossible to conclude on the carcinogenicity 
of substances. As far as genotoxic compounds are concerned, in vitro mutagenicity tests are quite 
well developed. Due to the relation between mutations and cancer, these genotoxicity tests can be 
seen as a pre-screen for cancer. A positive result in one of the genotoxicity tests may be indicative 
enough to consider a compound as putatively carcinogenic. In combination with the CTA, this 
indication may even be stronger.  However, as carcinogenicity is a multi-hit/multi step process, it 
can (for the time being) not be mimicked by in vitro tests. Today, any reliable, justified conclusion 
on the carcinogenicity of a substance needs in vivo tests. 
 
The situation is different for the non-genotoxic carcinogens.  
 
Before the animal testing and marketing ban, non-genotoxic carcinogens were detected by the (sub) 
chronic repeated dose studies, including the carcinogenicity test. Alternatives for these in vivo tests 
to detect non-genotoxic carcinogens, however, are not available with the exception of the CTA. 
Therefore, currently, in vivo rodent studies are essential to detect non-genotoxic substances. 
An extensive review of the actual status of in vitro carcinogenicity testing can be found in a JRC 
report [Adler et al. 2011]. 
 
European Commission, 2009b. Regulation (EC) No 
1107/2009 of the European Parliament and of the Council of 
21 October 2009 concerning the placing of plant protection 
products on the market and repealing Council Directives 
79/117/EEC and 91/414/EEC. Official Journal of the 
European Union L309, 1-47. 
 
Commission Regulation (EU), 2013, No 283/2013 of 
1 March 2013 setting out the data requirements for active 
substances, in accordance with Regulation (EC) 
No 1107/2009 of the European Parliament and of the Council 
concerning the placing of plant protection products on the 
market.  
 
Commission Regulation (EU), 2013, No 284/2013 of 1 
March 2013 setting out the data requirements for plant 
protection products, in accordance with Regulation (EC) No 
1107/2009 of the European Parliament and of the Council 
Plant Protection Products: 
Long-term toxicity and carcinogenicity 
The results of the long-term studies conducted and reported, taken together with other relevant data 
and information on the active substance, shall be sufficient to permit the identification of effects, 
following repeated exposure to the active substance, and in particular shall be sufficient to: 
 
i. identify adverse effects resulting from long-term exposure to the active substance, 
ii. identify target organs, where relevant, 
iii. establish the dose-response relationship, 
iv. establish the NOAEL and, if necessary, other appropriate reference points. 
 
Correspondingly, the results of the carcinogenicity studies taken together with other relevant data 
and information on the active substance, shall be sufficient to permit the evaluation of hazards for 
humans, following repeated exposure to the active substance, and in particular shall be sufficient: 
 
(a) to identify carcinogenic effects resulting from long-term exposure to the active substance; 
(b) to establish the species, sex, and organ specificity of tumours induced; 
(c) to establish the dose-response relationship; 
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concerning the placing of plant protection products on the 
market (Text with EEA relevance) 
 
 
(d) where possible, to identify the maximum dose eliciting no carcinogenic effect; 
(e) where possible, to determine the mode of action and human relevance of any identified 
carcinogenic response. 
 
Circumstances in which required 
 
The long-term toxicity and carcinogenicity of all active substances shall be determined. If in 
exceptional circumstances it is claimed that such testing is unnecessary, that claim shall be fully 
justified.  
 
Test conditions 
 
A long-term oral toxicity study and a long-term carcinogenicity study (two years) of the active 
substance shall be conducted using rat as test species; where possible these studies shall be 
combined. 
A second carcinogenicity study of the active substance shall be conducted using mouse as test 
species, unless it can be scientifically justified that this is not necessary. In such cases, scientifically 
validated alternative carcinogenicity models may be used instead of a second carcinogenicity study. 
If comparative metabolism data indicate that either rat or mouse is an inappropriate model for 
human cancer risk assessment, an alternative species shall be considered. Experimental data, 
including the elucidation of the possible mode of action involved and relevance to humans, shall be 
provided where the mode of action for carcinogenicity is considered to be non-genotoxic. 
 
Where submitted, historical control data shall be from the same species and strain, maintained under 
similar conditions in the same laboratory and shall be from contemporaneous studies. Additional 
historical control data from other laboratories may be reported separately as supplementary 
information. 
 
European Union Regulation, 2012. Regulation (EU) No 
528/2012 of the European Parliament and of the Council of 
22 May 2012 concerning the making available on the market 
and use of biocidal products. Official Journal of the European 
Union L 167, 1-116. 
Biocides:  
Annex II, Data Requirement  
 
8.11 Carcinogenicity study  
• A carcinogenicity study does not need to be conducted if: the substance is classified as 
mutagen category 1A or 1B. The default presumption would be that a genotoxic mechanism 
for carcinogenicity is likely. In these cases, a carcinogenicity test will normally not be 
required. 
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8.11.1. Combined carcinogenicity study and long-term repeated dose toxicity  
• Rat, oral route of administration is the preferred route. If an alternative route is proposed a 
justification must be provided. 
 
• For evaluation of consumer safety of active substances that may end up in food or feed, it is 
necessary to conduct toxicity studies by the oral route 
 
8.11.2 Carcinogenicity testing in a second species 
• A second carcinogenicity study should normally be conducted using the mouse as test 
species. 
• For evaluation of consumer safety of active substances that may end up in food or feed, it is 
necessary to conduct toxicity studies by the oral route 
 
Guidance Documents, Opinions and Reviews on Carcinogenicity testing 
US EPA (2005) Guidelines for Carcinogen Risk Assessment 
US EPA EPA/630/P-03/001F, March 2005 
 
This is a revision and replacement of the U.S. Environmental Protection Agency’s (EPA’s, or the 
Agency’s) Guidelines for Carcinogen Risk Assessment, published in 51 FR 33992, September 24, 
1986 (U.S. EPA, 1986a) and the 1999 interim final guidelines (U.S. EPA, 1999a; see U.S. EPA 
2001b). The documents provide guidance for developing and using risk assessments. They also 
provide basic information to the public about the EPA Agency's risk assessment methods. 
OECD Guidance Document (2012a), no. 116 On the conduct 
and Design of Chronic Toxicity and Carcinogenicity Studies, 
Support test Guidelines 451, 452 AND 453 2ND EDITION, 
ENV/JM/MONO (2011) 47; 13-Apr-2012 
This guidance provides additional information on the conduct of studies performed using TG 451, 
452 and TG 453. Its objective is to assist users of the TGs to select the most appropriate 
methodology to assess the chronic toxicity and carcinogenicity of a test chemical so that particular 
data requirements can be met while reducing animal usage if possible/appropriate.  
 
OECD (2010d) OECD principles for the validation, for 
regulatory purposes, of (quantitative) structure-activity 
relationship models. 
http://www.oecd.org/dataoecd/33/37/37849783.pdf 
The document describes the principles to facilitate the consideration of a (Q)SAR model for 
regulatory purposes. 
SCCS'S (2012) Notes of Guidance for the testing of 
cosmetics substances and their safety evaluation, 8th 
Revision, SCCS/1501/12. 
This document contains recommendations for the testing of cosmetics, in light of the full bun of in 
vivo experiments (March 13, 2013). 
ECHA (2011), Guidance on information requirements and 
chemical safety assessment Part B: Hazard assessment. 
Version 2.1 December 2011. 
 
This document contains guidance on REACH explaining the REACH obligations and how to fulfil 
them: this part refers to the Hazard Assessment. 
ECHA Guidance (2012). Guidance on information This document contains guidance on REACH explaining the REACH obligations and how to fulfil 
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requirements and chemical safety assessment Chapter R.7a: 
Endpoint specific Guidance Version 2.0 November 2012, 
R7.7. Mutagenicity and Carcinogenicity. 
them: this part refers to the Endpoints of Mutagenicity and Carcinogenicity. 
SCCP (2008). Opinion on the Use of the Threshold of 
Toxicological Concern (TTC) Approach for Human Safety 
Assessment of Chemical Substances with focus on Cosmetics 
and Consumer Products SCCP/1171/08 
(SCCS/SCHER/SCENIHR adopted on June 8, 2012). 
The SCCP (now SCCS)/SCHER/SCHENIHR (SCs) evaluated potential applications of the 
Threshold of Toxicological Concern (TTC) approach for human health risk assessment of chemical 
substances. The opinion focused on the potential applications of the TTC concept for cosmetics and 
other consumer products in relation to the mandates of the three SCs. The application of TTC in 
other areas, such as food, pharmaceuticals or EU chemical legislation (REACH) was not assessed, 
although such applications were described for completeness. 
 
EMEA (2006) European Medicines Evaluation Agency. 
Committee for Medicinal Products for Human Use (CHMP). 
Guideline on the limits of genotoxic impurities. 
CPMP/SWP/5199/02. London, 28 June 2006. 
EMEA/CHMP/QWP/ 251344/2006. 
http://www.emea.europa.eu/ pdfs/human/swp/519902en.pdf 
 
This Guideline describes a general framework and practical approaches, mainly establishment of 
TTC, on how to deal with genotoxic impurities in new active substances.  
EMEA (2008) Committee for Medicinal Products for Human 
Use (CHMP). Questions & Answers on the CHMP Guideline 
on the limits of Genotoxic Impurities. Rev 1. London, 26 
June 2008. Doc.Ref. EMEA/CHMP/SWP/431994/2007 
 
The aim of this question-and-answer document was to provide clarification and harmonisation of the 
'Guideline on the limits of genotoxic impurities' (EMEA/CHMP/QWP/251344/2006), published in 
2006. When and how applying TTC or QSAR approaches. 
ECHA (2010a) Practical guide on how to report (Q)SARs.  
http://echa.europa.eu/doc/publications/practical_guides/pg_re
port_qsars.pdf,  ECHA-10-B-10-EN 
 
This practical guide provides an overview of important aspects when predicting properties of 
substances using (Q)SAR models as defined in the REACH Regulation. 
ECHA (2010b) Practical guide on how to report categories 
and read-across. ECHA-10-B-11-EN 
http://echa.europa.eu/doc/publications/practical_guides/pg_re
port_readacross_categ.pdf 
 
This practical guide provides an overview of important practical aspects on how to develop and 
report in IUCLID 5 read-across and/or a chemical category approach for substances to be registered 
under the REACH Regulation. 
JECFA (1996) A procedure for the safety evaluation of 
flavouring agents. WHO Food Additive Series 35. Annex 5. 
World Health Organization, Geneva 
 
TTC approach application for the safety evaluation of flavouring agents. The objective of this paper 
was to provide a procedure that can be used by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) for the safety evaluation of flavouring substances. 
JECFA (1997) Safety evaluation of certain food additives and 
contaminants. Forty-ninth Report of the Joint FAO/WHO 
Six groups of flavouring agents were evaluated using the Procedure for the Safety Evaluation of 
Flavouring Agents, taking into account their metabolism. 
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Expert Committee on Food Additives. WHO Food Additive 
Series 40. World Health Organization, Geneva 
EFSA (2004) European Food Safety Authority. Scientific 
Panel on Food Additives, Flavourings, Processing Aids and 
Materials in Contact with Food. Opinion on Flavouring 
Group FGE.03 Acetals of branched- and straight-chain 
aliphatic saturated primary alcohols and branched- and 
straight-chain saturated aldehydes, and an orthoester of 
formic acid, from chemical groups 1 and 2. Opinion 
expressed on 7 October 2004. EFSA J. 107, 1-59. 
The Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food was 
asked to evaluate 42 flavouring substances in the Flavouring Group Evaluation FGE.03.  
Peer Consultation on Health Canada Draft Weight of 
Evidence Framework for Genotoxic Carcinogenicity (2005) 
http://www.tera.org/peer/comhaz/HC%20QSAR%20Peer%2
0Consultation%20Overview.pdf 
Evaluation of the available methods for the prediction of carcinogenic potential. 
Adler, S., Basketter, D., Creton, S., et al., (2011) Alternative 
(non-animal) methods for cosmetics testing: current status 
and future prospects-2010. ArchIves of Toxicology 85 (5): 
367-485. 
In regard of the 7th Amendment to the EU Cosmetics Directive to prohibit  animal-tested cosmetics 
on the market starting 2013, the European Commission invited stakeholder bodies (industry, 
nongovernmental organisations, EU Member States, and the Commission’s Scientific Committee on 
Consumer Safety) to identify scientific experts in five toxicological areas, i.e. toxicokinetics, 
repeated dose toxicity, carcinogenicity, skin sensitisation, and reproductive toxicity for which the 
Directive foresees that the 2013 deadline could be further extended in case alternative and validated 
methods would not be available in time.  
 
The experts evidenced impediments for a full replacement of animal testing, on due time, relating 
the carcinogenicity toxicological area. 
 
The carcinogenic potential of a chemical substance is far to be fully determined and/or mimicked by 
the use of non-animal testing because of the complexity of the carcinogenesis process, the multi-
stages type of its evolution and complex biological interactions. The 'Gold Standard' for cancer 
hazard evaluation is the 2-year cancer assay in rodents however, the animal testing ban under the 7th 
Amendment to the Cosmetics Directive will have a strong impact on the ability to conduct quality 
risk assessment for carcinogenic potential. The authors underlined that the impact is due not only to 
the ban of the cancer assay but mainly to the ban of in vivo genotoxicity testing, any repeated dose 
toxicity testing and others such as in vivo toxicokinetics studies and in vivo mechanistic assays. 
 
Beyond the availability of standard in vitro genotoxicity tests and several in vitro short-term tests 
(many of which at different stages of regulatory validation process), no sufficient in vitro test do 
exist to full replacement of animal testing. Moreover, the available tests are focused on hazard 
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evaluation and do not support a full safety assessment. 
 
Gottmann E, Kramer S, Pfahringer B & Helma C (2001). 
Data quality in predictive toxicology: reproducibility of 
rodent carcinogenicity experiments. Environmental Health 
Perspectives 109 (5): 509-14. 
 
In this study, 121 replicate rodent carcinogenicity assays from National Cancer Institute/National 
Toxicology Program and literature and the Carcinogenic Potency Database (CPDB) were compared 
in order to estimate the reliability of these experiments. A concordance of 57% between the overall 
rodent carcinogenicity classifications from both sources was found. The results indicate that rodent 
carcinogenicity assays were much less reproducible than previously expected. 
 
Knight A, Jonker MJ & Bruning J (2005). Which drugs cause 
cancer? British Medical Journal USA 5: 477-478. 
The authors highlighted the extremely low human carcinogenicity predictivity of in vivo 
experiments. The burden of cancer disease in United States is way too high despite the billions 
dollars spent in Research and millions of laboratory animals sacrificed, since the 'War against 
Cancer' was launched in the early '70s. The problem with in vivo tests is not the lack of sensitivity 
but rather the lack of human specificity. The adoption of alternatives is recommended such as 
QSAR models, enhanced in vitro assays and cDNA microarrays, the potential of which is to yield 
superior human specificity results. 
 
Knight A, Bailey J & Balcombe J (2006). Animal 
carcinogenicity studies: Implications for the REACH system. 
Alternatives to Lab Animals 34, Suppl. 1: 139-147. 
Based on a survey of the US Environmental Protection Agency's (EPAs) toxic chemicals database 
revealing that, for a majority of the chemicals of greatest public health concern (58.1%), animal 
carcinogenicity data are inadequate to support classifications of probable human carcinogen or non-
carcinogen, and show several significantly differences with IARC assessments of identical 
chemicals, the authors propose the replacement of animal carcinogenicity bioassays with a tiered 
combination of non-animal assays.  
The alternative strategy is expected to yield a weight-of-evidence characterisation of carcinogenic 
risk with superior human predictivity. Additional advantages include substantial savings of 
financial, human and animal resources, and potentially greater insights into mechanisms of 
carcinogenicity. 
 
Alden CL, Lynn A, Bourdeau A, Morton D, Sistare FD, 
Kadambi VJ & Silverman L (2011). A critical review of the 
effectiveness of rodent pharmaceutical carcinogenesis testing 
in predicting for human risk. Veterinary Pathology 48 (3): 
772-84. 
 
Reviewing the status of carcinogenicity testing in the pharmaceutical sector, the authors proposed 
the appropriate use of acute, subchronic, chronic, and special toxicology tests to identify the major 
associated cancer risk factors, specifically, hormonal modulation, immunosuppression, genetic 
toxicity, and chronic toxicity. They pointed at the existence of significant opportunities already 
available for improving the effectiveness and efficiency of the current cancer risk assessment 
paradigm. 
 
Luijten, M, Muller JJA, Hernández LG, van der Ven LTM & 
van Benthem J (2012). Prediction of carcinogenic potential of 
substances using repeated dose toxicity data. RIVM Report 
The group, through an extensive literature review, proposes as an alternative approach to determine 
the carcinogenic features of substances the use of data from sub-chronic repeated dose toxicity 
studies. This approach could lead to a substantial reduction in the number of carcinogenicity studies 
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performed without compromising human safety.  
Paules RS, Aubrecht J, Corvi R, Garthoff B & Kleinjans JC 
(2011). Moving Forward in Human Cancer Risk Assessment. 
Environmental Health Perspectives 119:439-443. 
 
The review focuses on the state-of-the-art in developing alternative testing strategies for 
carcinogenicity, emphasising on potential contributions from omics technologies.  
 
 
Maurici D, Aardema M, Corvi R, Kleber M, Krul C, Laurent 
C., Loprieno N, Pasanen M, Pfuhler S, Phillips B, Sabbioni 
E, Sanner T & Vanparys P (2005). Genotoxicity and 
mutagenicity. Alternatives to Lab Animals 33 Suppl 1: 117-
130.  
 
The aim of this report was to provide an objective state of play of the current status of alternative 
methods/strategies and the prospects for their validation and regulatory acceptance so that they 
could be used for replacing animal tests in the safety assessment of cosmetic products as required by 
the EU Cosmetics Directive. Regarding the endpoint genotoxicity/mutagenicity, the experts were of 
the opinion that a total replacement of animal testing was not feasible in the short-term and this 
would depend, besides the development of in vitro tests on skin models, also on the progress in the 
fields of toxicokinetics and toxicogenomics. 
 
Benigni R. (2012). Alternatives to the carcinogenicity 
bioassay for toxicity prediction: are we there yet? Expert 
Opinion Drug Metabolism & Toxicology 8 (4): 407-17. 
 
The expert in this review summarizes the theories on the early steps of carcinogenesis and reports 
about alternative detection methods for carcinogens based on genetic toxicology, structure--activity 
relationships and cell transformation assays. 
 
Benfenati E, Benigni R, DeMarini DM, Helma C, Kirkland 
D, Martin TM, Mazzatorta P, Ouédraogo-Arras G, Richard 
AM, Schilter B, Schoonen WGEJ, Snyder RD & Yang C 
(2009). Predictive models for carcinogenicity and 
mutagenicity: frameworks, state-of-the-art, and 
perspectives. Journal of Environmental Science and Health 
Part C Environmental Carcinogenesis & Ecotoxicology 
Reviews 27 (2): 57-90.  
 
The authors reports on the advances of new technologies and emerging methodologies, software 
tools, QSAR models and in silico methods for predicting genotoxicity and carcinogenicity. The use 
of these methodologies, particularly high-throughput assays and data mining in combination with in 
silico methods, is encouraged for industry and regulators assistance and ultimately for public health 
protection. 
Herceg Z, Lambert M-P, van Veldhoven K, Demtriou C, 
Vineis P, Smith MT, Straif K & Wild CP (2013). Towards 
incorporating epigenetic meachanisms into carcinogen 
identification and evaluation. Carcinogenesis 
doi:10.193/carcin/btg212. 1-13. 
The authors, taking into account the remarkable progress in the field of epigenetics, summarize the 
current status of incorporation of epigenetic mechanisms into carcinogen evaluation by the IARC. 
Mechanistic Understanding of Carcinogenesis: 
 Genotoxic and non-genotoxic driven mechanisms 
Fowler P, Smith K, Young J, Jeffrey L, Kirkland D, Pfuhler S 
& Carmichael P (2012). Reduction of misleading ("false") 
positive results in mammalian cell genotoxicity assays. I. 
As part of an European Cosmetics Industry Association initiative for improvement of in vitro 
mammalian cell assays, Fowler and co-workers have compared several rodent cell lines (V79, CHL, 
CHO) with p53-competent human peripheral blood lymphocytes (HuLy), TK6 human 
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Choice of cell type. Mutation Research 742 (1-2): 11-25.  lymphoblastoid cells, and the human liver cell line, HepG2 since, p53-deficiency in many of the 
rodent cell lines has been considered a key factor in the poor testing predictivity. The authors have 
compared in vitro micronucleus (MN) induction following treatment with 19 compounds that were 
accepted as producing misleading or "false" positive results in in vitro mammalian cell assays. 
The rodent cell lines (V79, CHO and CHL) resulted consistently more susceptible to cytotoxicity 
and MN induction than p53-competent cells, and were therefore more susceptible to giving 
misleading positive results.  
The authors suggested that a reduction in the frequency of misleading positive results could be 
achieved by careful selection of the mammalian cell type for genotoxicity testing. 
 
Fowler P, Smith R, Smith K, Young J, Jeffrey L, Kirkland D, 
Pfuhler S & Carmichael P (2012). Reduction of misleading 
("false") positive results in mammalian cell genotoxicity 
assays. II. Importance of accurate toxicity measurement. 
Mutation Research 747 (1): 104-17. 
 
In line with the outcomes of the analysis mentioned in the above paper (Fowler et al., 2012a); the 
authors investigated the impact of different toxicity measures, commonly used in vitro cytogenetic 
assays, on the occurrence of misleading positive results. The data showed that estimating toxicity by 
relative cell count (RCC) or replication index (RI) consistently underestimated the toxicity observed 
by other measures (Relative Population Doubling, RPD, or Relative Increase in Cell Count, RICC). 
RCC and RI were more likely to lead to selection of concentrations for micronucleus scoring that 
were highly cytotoxic and thus could potentially lead to artefacts of toxicity being scored (elevated 
levels of apoptosis and necrosis), generating misleading positive results.  
The authors suggested that a further reduction in the frequency of misleading positive results in in 
vitro cytogenetic assays could be achieved (with 19 chemicals clearly giving misleading results) by 
avoiding the use of toxicity measures that underestimate the level of toxicity induced. 
 
Kirkland D, Aardema M, Henderson L & Müller L (2005). 
Evaluation of the ability of a battery of three in vitro 
genotoxicity tests to discriminate rodent carcinogens and 
non-carcinogens I. Sensitivity, specificity and relative 
predictivity. Mutation Research 584: 1-256. 
 
This paper evaluated how the currently popular in vitro genotoxicity tests – Ames test, MLA and a 
test for clastogenicity (in vitro micronucleus or chromosomal aberration test) – performed in their 
ability to discriminate rodent carcinogens and non carcinogens.  
The work deals separately with the performance indicators (sensitivity first, then specificity) of the 
individual tests and various combinations of two or three tests, and proposes reasons why some 
rodent carcinogens are not detected in this battery.  
It also proposes a new method to look at the balance of rising sensitivity accompanied by falling 
specificity to help choose the best individual or combinations of tests.  
 
Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R. 
Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, 
Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, 
Meunier J-R, Müller L, Nohynek, G, Parry J, Parry E, 
Thybaud V, Tice R, van Benthem J, Vanparys P & White P 
(2007). How to reduce false positive results when 
A workshop organised by ECVAM in 2006 on "How to reduce the false positive results when 
undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests" 
addressed (i) whether it is possible to choose existing cell systems which give lower rates of false 
positive results, (ii) whether modifications of existing protocols and cell systems may result in lower 
false positive results, (iii) the performance of new test systems showing promise of improved 
specificity and definition of needs for the development of new tests. 
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undertaking in vitro genotoxicity testing and thus avoid 
unnecessary follow-up animal tests: Report of an ECVAM 
Workshop. Mutation Research 628: 31-55. 
 
Widschwendter M & Jones PA (2002). DNA methylation and 
breast carcinogenesis. Oncogene 21: 5462-5482. 
 
Knowledge about breast carcinogenesis has accumulated during the last decades but has barely been 
translated into strategies for early detection or prevention of this common disease. Changes in DNA 
methylation have been recognized as one of the most common molecular alterations in human 
neoplasia and hypermethylation of gene-promoter regions is being revealed as one of the most 
frequent mechanisms of loss of gene function. The heritability of methylation states and the 
secondary nature of the decision to attract or exclude methylation support the idea that DNA 
methylation is adapted for a specific cellular memory. There are six novel capabilities a cell has to 
acquire to become a cancer cell: limitless replicative potential, self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death, sustained angiogenesis 
and tissue invasion and metastasis. This review highlights how DNA-methylation contributes to 
these features and offers suggestions about how these changes could be prevented, reverted or used 
as a 'tag' for early detection of breast cancer or, preferably, for detection of premalignant changes. 
 
Baylin SB & Ohm JE (2006). Epigenetic gene silencing in 
cancer – a mechanism for early oncogenic pathway addition? 
Nature Reviews Cancer 6: 107-116. 
 
This review focuses on epigenetic changes, i.e. chromatin alterations and DNA methylation which 
associate with all stages of tumour formation and progression.  
DNA methylation particularly occurs at promoter regions of genes that regulate important cell 
functions. Recent evidence indicates that epigenetic changes might 'addict' cancer cells to altered 
signal-transduction pathways during the early stages of tumour development. Dependence on these 
pathways for cell proliferation or survival allows them to acquire genetic mutations in the same 
pathways, providing the cell with selective advantages that promote tumour progression. The 
authors highlight the relevance of strategies to reverse epigenetic gene silencing in cancer 
prevention and therapy. 
 
Esteller M (2007). Cancer epigenomics: DNA methylomes 
and histone-modification maps. Nature Reviews Genetics 8: 
286-298. 
 
The author reviews several studies exploring the mosaic patterns of DNA methylation and histone 
modification in cancer cells on a 'gene-by-gene basis': many of those reporting the role of CpG-
island-promoter hypermethylation in the transcriptional silencing of tumour-suppressor genes. 
However, the author promotes the 'genome-wide approach' to provide both biological insight and 
new avenues for translational research.  
 
Shanks N, Greek R & Greek J (2009). Are animal models 
predictive for humans? Philosophy, Ethics & Humanities in 
Medicine 4: 1-20. 
 
The focus of this essay is the scientific term predict and whether there is credible evidence that 
animal models, especially in toxicology and pathophysiology, can be used to predict human 
outcomes. Indeed, Shanks and co-workers state that animal models fall far short of being able to 
predict human responses to drugs and other chemicals. 
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Hattis D, Chu M, Rahmioglu N, Goble R, Verma, P, Hartman 
K & Kozlak M (2009). A preliminary operational 
classification system for nonmutagenic modes of action for 
carcinogenesis. Critical Reviews in Toxicology 39 (2): 97-
138. 
 
The article proposes a system of categories for non-mutagenic modes of action for carcinogenesis. 
The classification is of modes of action rather than individual carcinogens, because the same 
compound can affect carcinogenesis in more than one way. Basically, the authors categorize modes 
of action as: (1) co-initiation; (2) promotion; (3) progression and (4) multiphase.  
Agents that act at relatively early stages in the process are expected to manifest greater relative 
susceptibility in early life, whereas agents that act via later stage modes will tend to show greater 
susceptibility for exposures later in life. 
 
Loeb LA & Harris CC. (2008). Advances in chemical 
carcinogenesis: a historical review and prospective. Cancer 
Research 68 (17): 6863-72. 
 
This is an historical review and prospective on the advances in chemical carcinogenesis. The review 
starts from the first notes on chromatin changes by Theodor Boveri in 1914, and covers the step 
stones in molecular and cell biology research: the DNA discovery (1944), the DNA structure 
elucidation (1953), DNA sequencing and PCR method introduction (1977,1987) and many other key 
observations and experiments. 
Hernández LG, van Steeg H, Luijten M & van Benthem J 
(2009). Mechanisms of non-genotoxic carcinogens and 
importance of a weight of evidence approach. Mutation 
Research 682: 94-109. 
. 
In order to better understand the mechanisms of known human non-genotoxic carcinogens and to 
illustrate the importance of a weight of evidence approach when evaluating their carcinogenic 
potential, the authors (1) evaluated the proportion of non-genotoxic carcinogens among known, 
probable and possible human carcinogens classified by the IARC, (2) estimated the risk of exposure 
of human non-genotoxic carcinogens through margin of exposure (MOE) evaluation, and (3) 
discussed potential alternative methods for their detection.  
 
The analysis demonstrated that human non-genotoxic carcinogens were present in 12% of IARC's 
Groups 1, 2A and 2B carcinogens and that a potential hazard was associated with 27% of them. The 
authors suggested that for all genotoxic chemicals, the mode of action is investigated for hazard and 
risk evaluation. Further, if negative genotoxic compounds have putative non-genotoxic modes of 
action, appropriate risk measures should be implemented. 
 
López-Lázaro M (2010). A new view of carcinogenesis and 
an alternative approach to cancer therapy. Molecular 
Medicine 16 (3-4): 144-153. 
 
This article reviews the evidence that tumour cells, in addition to acquiring a complex array of 
genetic changes, develop an alteration in the metabolism of oxygen. Although both changes play an 
essential role in carcinogenesis, the altered oxygen metabolism of cancer cells is not subject to the 
high genetic variability of tumours and may therefore be a more reliable target for cancer therapy. 
The author highlights the relevance of oxygen metabolism manipulation, as a novel approach, for 
the development of therapies that selectively target tumour cells. 
 
Klaunig JE, Kamendulis LM & Hocevar BA (2010). 
Oxidative stress and oxidative damage in carcinogenesis. 
Toxicologic Pathology 38 (1): 96-109. 
Chemical and physical agents including those that induce reactive oxygen species (ROS) can induce 
and/or modulate the multistep process of carcinogenesis.  
Based on the identification that oxidative damage to cellular macromolecules can arise through 
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 overproduction of ROS and faulty antioxidant and/or DNA repair mechanisms and ROS can 
stimulate signal transduction pathways and lead to activation of key transcription factors such as 
Nrf2 and NF-κB, the authors discuss the aspects of ROS biology in the context of their relationship 
to carcinogenesis. They also considered the recent evidence demonstrating an association between a 
number of single nucleotide polymorphisms (SNPs) in oxidative DNA repair genes and antioxidant 
genes with human cancer susceptibility.  
 
Doull J, Cattley R, Elcombe C, Lake BG, Swenberg J, 
Wilkinson C, Williams G & van Gemert M (1999). A cancer 
risk assessment of di(2-ethylhexyl) phthalate: application of 
the new U.S. EPA risk assessment guidelines. Regulatory 
Toxicology & Pharmacology 29 (3): 327-357. 
The authors used new toxicology data and a considerable amount of new mechanistic evidence to 
reconsider the cancer classification of DEHP under EPA's proposed new cancer risk assessment 
guidelines.  
 
The total weight-of-evidence clearly indicates that DEHP is not genotoxic. In vivoIn vivo 
administration of DEHP to rats and mice results in peroxisome proliferation in the liver, and there is 
strong evidence and scientific consensus that, in rodents, peroxisome proliferation is directly 
associated with the onset of liver cancer. Recent studies of DEHP clearly indicate a nonlinear dose-
response curve that strongly suggests the existence of a dose threshold below which tumours in 
rodents are not induced. Thus, the hepatocarcinogenic effects of DEHP in rodents result directly 
from the receptor-mediated, threshold-based mechanism of peroxisome proliferation, a well-
understood process associated uniquely with rodents. Since humans are quite refractory to 
peroxisomal proliferation, even following exposure to potent proliferators such as hypolipidemic 
drugs, the authors concluded that the hepatocarcinogenic response of rodents to DEHP is not 
relevant to human cancer risk at any anticipated exposure level. DEHP should be classified an 
unlikely human carcinogen with a margin of exposure (MOE) approach to risk assessment.  
 
Silva Lima B & Van der Laan JW (2000). Mechanisms of 
nongenotoxic carcinogenesis and assessment of the human 
hazard. Regulatory Toxicology & Pharmacology 32 (2): 135-
43. 
 
The purpose of this paper is to describe some mechanisms for nongenotoxic tumorigenicity and to 
indicate which type of testing should be done to substantiate why in those cases such a mechanism 
is not relevant to humans.  The increasing attention being given to epigenetic carcinogenesis points 
at the need for a thorough evaluation during the toxicological program for safety assessment, 
enabling adequate assessment of the human hazard posed by such compounds. The authors suggest 
that data to support the nongenotoxic carcinogenesis may be obtained by collecting specific 
information from current safety assessment programs or from future, separate studies. 
 
Zhang X & Ho SM (2011). Epigenetics meets endocrinology. 
Journal of Molecular Endocrinology February 1, 46 R11-
R32. 
 
A review on the relationship between epigenetic mechanisms and endocrine phenotypes. 
Specifically, the authors review the regulation by epigenetics of the three levels of hormone action 
(synthesis and release, circulating and target tissue levels, and target-organ responsiveness) and the 
epigenetic action of endocrine disruptors. 
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Labrecque MP, Takhar MK, Hollingshead BD, Prefontaine 
GG, Perdew GH & Beischlag TV (2012). Distinct roles for 
aryl hydrocarbon receptor nuclear translocator and ah 
receptor in estrogen-mediated signalling in human cancer cell 
lines. PLoS One 7 (1): e29545. 
The activated AHR/ARNT complex (AHRC) regulates the expression of target genes upon exposure 
to environmental contaminants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Importantly, 
evidence has shown that TCDD represses estrogen receptor (ER) target gene activation through the 
AHRC. 
The paper reports data indicating that AHR and ARNT act independently from each other at non-
dioxin response element sites. The authors obtained experimental evidence demonstrating a dioxin-
dependent repressor function for AHR and a dioxin-independent co-activator/co-repressor function 
for ARNT in estrogen signalling. The results provide with further insight into the mechanisms of 
transcription factor crosstalk and putative therapeutic targets in estrogen-positive cancers. 
 
Lo PK & Sukumar S (2008). Epigenomics and breast cancer. 
Pharmacogenomics 9 (12): 1879-902. 
 
The authors review known roles of the epigenetic machinery in the development and recurrence of 
breast cancer. Furthermore, they highlight the significance of epigenetic alterations as predictive 
biomarkers and as new targets of anticancer therapy. 
 
Sadikovic B, Al-Romaih K, Squire JA & Zielenska M 
(2008). Cause and consequences of genetic and epigenetic 
alterations in human cancer. Current Genomics 9: 394-408. 
 
While there has been considerable progress in understanding the impact of genetic and epigenetic 
mechanisms in tumourigenesis, there has been little consideration of the importance of the interplay 
between these two processes.  
In this review Sadikovic and co-workers summarized current understanding of the role of genetic 
and epigenetic alterations in human cancer. Furthermore, the authors considered the associated 
interactions of genetic and epigenetic processes in tumour onset and progression. They also 
provided a model of tumourigenesis to address the combined impact of both epigenetic and genetic 
alterations in cancer cells. 
 
WHO, 2007 IPCS, Harmonization Project Document No. 4 
Part 1: IPCS Framework for analysing the relevance of a 
cancer mode of action for humans and case-studies.  
http://www.who.int/ipcs/methods/harmonization/areas/cancer
_mode.pdf 
This document presented a unified IPCS Human Relevance Framework for use of mode of action 
information in risk assessment for regulatory and other purposes, and it provided initial guidance for 
this task. 
Non-standard methods and Integrated Approaches 
QSARs models for Carcinogenicity Prediction 
Woo YT, Lai DY, Argus MF & Arcos JC (1995). 
Development of structure–activity relationship rules for 
predicting carcinogenic potential of chemicals. Toxicology 
Letters 79: 219-228. 
 
The authors describe the overall structure of the expert system, Oncologic, in the assessment of 
potential carcinogenic hazard of new chemicals discuss the scientific bases and principles of SAR 
analysis of chemical carcinogens used in the development of SAR knowledge rules, and delineate 
the major factors/rules useful for assessing the carcinogenic potential of fibers, polymers, 
metals/metalloids and several major classes of organic chemicals.  
An integrative approach using available short-term predictive tests and non-cancer toxicological 
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data to supplement SAR analysis has also been described. 
 
Cronin MT, Jaworska JS, Walker JD, Comber MH, Watts 
CD & Worth AP. (2003). Use of QSARs in International 
Decision-Making Frameworks to Predict Health Effects of 
Chemical Substances Environmental Health Perspectives 111 
(10): 1391-1401. 
 
The authors reviewed the international regulatory use of QSARs to predict the health effects of 
chemical substances. Specifically, they described the recommendations of QSARs across several 
regulatory agencies to prioritize chemicals for testing and to fill data gaps in risk assessment data 
sets. 
Woo YT & Lai DY (2003). Mechanisms of action of 
chemical carcinogens, and their role in Structure-Activity 
Relationships (SAR) analysis and risk assessment. In: 
Quantitative Structure-Activity Relationship (QSAR) Models 
of Mutagens and Carcinogens (R Benigni, ed). Boca Raton: 
CRC Press: 41-80. 
 
This paper summarizes most of the available QSAR methods for the prediction of carcinogenicity. 
Benigni R & Bossa C (2008). Predictivity of QSAR. Journal 
of Chemical Information & Modeling 48: 971-980. 
 
 
The authors assessed the efficiency, potential and reliance of a range of QSAR methods for the 
prediction of mutagenicity and carcinogenicity. 
 
Contrera JF, Kruhlak NL, Matthews EJ & Benz RD (2007). 
Comparison of MC4PC and MDL-QSAR rodent 
carcinogenicity predictions and the enhancement of 
predictive performance by combining QSAR models. 
Regulatory Toxicology & Pharmacology 49:172-182. 
 
The aim of the study was to investigate on the interpretation and prediction of QSAR models by 
comparing the results of two software programs, MC4PC and MDL-QSAR, using the same 2-year 
rodent carcinogenicity training data set.  
The presented methodology was suggested to be particularly useful with endpoints such as rodent 
carcinogenicity. 
Jaworska J & Nikolova-Jeliazkova N (2007). How can 
structural similarity analysis help in category formation? 
SAR and QSAR in Environmental Research 18: 195-207. 
 
In this study the authors aimed to discuss the feasibility to apply computational structural similarity 
methods to augment formation of a category (filling safety data gaps).  
Benigni R, Bossa C, Jeliazkova N, Netzeva N & Worth A 
(2008). The Benigni /Bossa rulebase for mutagenicity and 
carcinogenicity –a module of Toxtree. JRC Report, EUR 
23241 EN – 2008. 
 
This paper describes novel hazard estimation software called Toxtree, capable of making structure-
based predictions for a number of toxicological endpoints, developed at the JRC. One of the 
modules developed as an extension to Toxtree is aimed at the prediction of carcinogenicity and 
mutagenicity. The main tool is a list of Structural Alerts (SA) for carcinogenicity. 
Toropov AA, Toropova AP & Benfenati E (2009). Additive 
SMILES-based carcinogenicity models: probabilistic 
principles in the search for robust predictions. International 
The present study was aimed to estimate the ability of the SMILES-based optimal descriptors to be a 
tool for QSAR analysis of carcinogenicity of non-congeneric chemicals. 
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Journal of Molecular Science 10: 3106-3127. 
 
Van Leeuwen K, Schultz TW, Henry T, Diderich B & Veith 
GD (2009). Using chemical categories to fill data gaps in 
hazard assessment. SAR QSAR Environmental Research 20: 
207-220. 
 
The authors of this paper, provided a summary of the growing use by regulatory agencies of the 
chemical categories approach, which groups chemicals based on their similar toxicological 
behaviour and fills in the data gaps in animal test data such as genotoxicity and aquatic toxicity.  
 
Ferrari T & Gini G (2010). An open source multistep model 
to predict mutagenicity from statistical analysis and relevant 
structural alerts. Chemistry Central Journal 4 (Suppl 1), S2 
 
 
The authors developed a cascade model validated on a large public set of molecular structures and 
their associated Salmonella mutagenicity outcome, for the prediction of mutagenicity. The data 
obtained approached the 85% reproducibility of the experimental mutagenicity Ames test and were 
reported on CEASAR website. 
 
Fjodorova N, Vracko M, Novic M, Roncaglioni A & 
Benfenati E (2010). New public QSAR model for 
carcinogenicity. Chemistry Central Journal 4 Suppl 1:S3 
 
The authors reviewed all the available QSAR models concluding that currently they cannot replace 
the human expert opinion and conventional methods. However, the combination of several methods 
is suggested to provide useful support to the overall evaluation of carcinogenicity. In the paper 
models for classification of carcinogenic compounds using MDL and Dragon descriptors were also 
developed.  
 
Serafimova R, Fuart Gatnik M & Worth A (2010). Review of 
QSAR models and software tools for predicting genotoxicity 
and carcinogenicity. EUR 24427 EN. 
http://publications.jrc.ec.europa.eu/repository 
 
The authors reviewed QSARs for genotoxicity and carcinogenicity, taking into accounts both 
models available in software tools and models that are published in the literature. They focused also 
on the potential applicability of diverse models to pesticides as well as to other types of regulated 
chemicals and pharmaceuticals. 
 
Wu S, Blackburn K, Amburgey J, Jaworska J & Federle T 
(2010). A framework for using structural, reactivity, 
metabolic and physicochemical similarity to evaluate the 
suitability of analogs for SAR-based toxicological 
assessments. Regulatory Toxicology & Pharmacology 56: 
67-81. 
 
Wu et al. (2010) published a framework for using similarity based on chemical structure, reactivity, 
and metabolic and physicochemical properties to specifically evaluate the suitability of analogues 
for use in read-across toxicological assessments. 
Threshold of Toxicological Concern 
U.S. FDA (1995) Department of Health and Human Services. 
Food Additives; Threshold of Regulation for Substances 
Used in Food-Contact Articles 21 CFR Parts 5, 25, 170, 171, 
and 174 
 
Rules and Regulations on the consideration of a substance as a Food Addictive and its use. 
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Munro IC, Ford RA, Kennepohl E & Sprenger JG (1996). 
Correlation of structural class with no-observed effect levels: 
a proposal for establishing a threshold of concern. Food & 
Chemical Toxicology 34: 829-867. 
 
Munro and co-workers explored the relationship between chemical structure and toxicity through 
the compilation of a large reference database consisting of over 600 chemical substances tested for a 
variety of endpoints. The study resulted in approximately 3000 no-observed-effect levels (NOELs).  
The authors built a database that was used to derive a threshold of acceptable human exposure for 
each of the structural classes that could be applied in the absence of specific toxicity data on a 
substance within one of the three structural classes.  
 
Blackburn K, Stickney JA, Carlson-Lynch HL, McGinnis 
PA, Chappell L & Felter SP (2005). Application of the 
threshold of toxicological concern approach to ingredients in 
personal and household care products. Regulatory 
Toxicology & Pharmacology 43: 249-259. 
 
The authors evaluated the applicability of the TTC database to ingredients used in consumer 
products based on a comparison of the diversity of chemical structures with those in the original 
TTC database and to confirm that the range of NOELs for these ingredients was consistent with the 
range of NOELs in the original database.  The obtained results overlapped with the product 
ingredient structures and the NOELs for the ingredient chemicals were similar to the original 
dataset. Blackburn et al. supported the use of the TTC for ingredients in consumer products. 
 
Kroes R, Renwick AG, Feron V, Galli CL, Gibney M, Greim 
H, Guy RH, Lhuguenot JC & Van de Sandt JJM (2007). 
Application of the threshold of toxicological concern (TTC) 
to the safety evaluation of cosmetic ingredients. Food & 
Chemical Toxicology 45: 2533-2562. 
 
This paper was aimed to apply the TTC methodology used for packaging migrants and flavouring 
agents to cosmetic ingredients and impurities. The analysis took into account the different types of 
exposure (oral vs. topical) with default conservative adjustment factors. The TTC approach was 
suggested to provide a useful additional tool for the safety evaluation of cosmetic ingredients and 
impurities of known chemical structure in the absence of chemical-specific toxicology data. 
 
Safford RJ (2008). The dermal sensitization threshold - A 
TTC approach for allergic contact dermatitis. Regulatory 
Toxicology & Pharmacology 51: 195-200. 
 
In this paper, Safford presents the outcomes of a probabilistic analysis of available sensitisation 
data, using data sets from ELINCS and a distribution for sensitisation potency from Local Lymph 
Node Assay data, in a similar way of TTCs. He established a Dermal Sensitisation Threshold (DST) 
was established below which it is suggested there is no appreciable risk of sensitisation, even for an 
untested ingredient. The author concludes that the use of DST would preclude the need for 
sensitisation testing of ingredients where dermal exposure is sufficiently low. 
 
Carthew P, Clapp C & Gutsell S (2009). Exposure based 
waiving: the application of the toxicological threshold of 
concern (TTC) to inhalation exposure for aerosol ingredients 
in consumer products. Food Chemical Toxicology 47: 1287-
1295. 
In light of the concept of developing 'intelligent testing strategies' for REACH, the authors of this 
paper reviewed the inhalation toxicology studies available in the public domain to establish a 
database for inhalation toxicology and derive thresholds of toxicological concern (TTC) for effects 
in the respiratory tract. The authors propose that detailed exposure evaluation combined with 
potential QSAR for toxicity and TTCs for inhalation exposure could be used to waive [exposure 
based waiving (EBW) approach] undertaking inhalation toxicology studies under REACH. 
 
Felter SP, Lane RW, Latulippe ME, Llewellyn GC, Olin SS, 
Scimeca JA & Trautman TD (2009). Refining the threshold 
of toxicological concern (TTC) for risk prioritization of trace 
Felter and co-workers proposed the threshold of toxicological concern (TTC) methodology as a 
scientifically transparent approach for putting low-level exposures in the context of potential risk.  
Starting from the TTC literature the authors addressed to key two areas: genotoxicity data and time 
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chemicals in food. Food and Chemical Toxicology 47: 2236-
2245. 
 
of exposure.  
SCCP (2008), Opinion on the Use of the Threshold of 
Toxicological Concern (TTC) Approach for Human Safety 
Assessment of Chemical Substances with focus on Cosmetics 
and Consumer Products SCCP/1171/08 
(SCCS/SCHER/SCENIHR adopted on June 8, 2012). 
The SCCP (now SCCS)/SCHER/SCHENIHR (SCs) evaluated potential applications of the 
Threshold of Toxicological Concern (TTC) approach for human health risk assessment of chemical 
substances. The opinion focused on the potential applications of the TTC concept for cosmetics and 
other consumer products in relation to the mandates of the three SCs. The application of TTC in 
other areas, such as food, pharmaceuticals or EU chemical legislation (REACH) was not assessed, 
although such applications were described for completeness. 
 
Bercu JP, Morton SM, Deahl JT, Gombar VK, Callis CM & 
van Lier RB (2010). In silico approaches to predicting cancer 
potency for risk assessment of genotoxic impurities in drug 
substances. Regulatory Toxicology & Pharmacology 57: 300-
306. 
 
The authors proposed the use of TTC in combination with QSAR tools to establish safe levels for 
genotoxic impurities (GTIs) in drug substances. Indeed, the aim of the study was to use in silico 
tools to predict the cancer potency (TD(50)) of a compound based on its structure. Structure activity 
relationship (SAR) models were developed from the carcinogenicity potency database using 
MultiCASE and VISDOM softwares. The approach for non-potent compounds was considered 
useful to establish safe levels greater than the TTC for GTIs in a drug substance. 
 
LED for in vivo Genotoxicity to estimate Cancer Potency 
Sanner T & Dybing E (2005). Comparison of carcinogenic 
and in vivo genotoxic potency estimates. Basic Clinical 
Pharmacology & Toxicology 96: 131-139. 
 
The finding of a linear relationship between the lowest effective dose (LED) for in vivo genotoxicity 
and the carcinogen dose descriptor T25 is of importance. It was found for 34 carcinogens studied 
which covered a potency range of 10,000, that the median of the ratio LED/T25 was equal to 1.05 
and that for 90% of the substances the numerical value of LED was similar to the numerical value of 
T25 within a factor of less than 5–10. The results suggest that if further evaluated, LED for in vivo 
genotoxicity may be used in a semi-quantitative method for risk assessment of mutagens without a 
long-term study. 
 
Hernández LG, Slob W, van Steeg H & van Benthem J 
(2011). Can carcinogenic potency be predicted from in vivo 
genotoxicity data?: a meta-analysis of historical data. 
Environmental & Molecular Mutagenenesis 52 (7): 518-28. 
 
A preliminary investigation on the applicability of in vivo genotoxicity tests to estimate cancer 
potency looked promising. Positive correlations between in vivo genotoxicity (micronucleus test and 
transgenic rodent mutation test) and carcinogenic potency were found. Dose-response analyses 
using sophisticated dose-response software such as PROAST (RIVM) or the BMDS (USEPA) were 
used. The results suggest that in vivo genotoxicity tests may be used to estimate carcinogenic 
potency. 
 
Hernández LG, van Benthem J & Johnson GE (2013). A 
mode-of-action approach for the identification of genotoxic 
carcinogens. PLoS One May 13; 8 (5): e64532. 
 
In this study the authors performed the cytokinesis-block micronucleus assay and 
immunofluorescence mitotic machinery visualisation in human lymphoblastoid (AHH-1) and 
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Chinese Hamster fibroblast (V79) cell lines after treatment with the aneugen 17-β-oestradiol (E₂). 
Results were compared to previously published data on bisphenol-A (BPA) and Rotenone data. Two 
concentration-response approaches (the threshold-[Td] and benchmark-dose [BMD] approaches) 
were applied to derive a point of departure (POD) for in vitro MN induction. Ranking comparisons 
of the PODs from the in vitro MN and the carcinogenicity studies demonstrated a link between these 
two endpoints for BPA, E₂ and Rotenone. The analysis was extended to include additional 
aneugens, clastogens and mutagens and further concentration and dose-response correlations were 
observed between PODs from the in vitro MN and carcinogenicity. The approach looked promising 
and the authors suggested it could be extended to other genotoxic carcinogens. The MOA and 
quantitative information from the in vitro MN studies could be used in a quantitative manner to 
further inform cancer risk assessment. 
 
Cell Transformation Assay (CTA) 
DiPaolo JA, Donovan P & Nelson R (1969). Quantitative 
studies of in vitro transformation by chemical carcinogens. 
Journal of the Nationa Cancer Institute 42: 867-874. 
The authors report that chemical carcinogens can induce malignant transformation in mammalian 
cell systems. However, the precise molecular and cellular alterations that result in transformation 
have not been identified. 
 
Isfort RJ, Kerckaert GA & LeBoeuf RA (1996). Comparison 
of the standard and reduced pH Syrian hamster embryo 
(SHE) cell in vitro transformation assays in predicting the 
carcinogenic potential of chemicals. Mutatation Research 
356: 11-63. 
 
The article is a comprehensive review of the Syrian Hamster Embryo (SHE) cell transformation 
literature; it was performed in order to catalogue the chemical/physical entities which have been 
evaluated for in vitro cell transformation potential. Both reduced pH (pH 6.7) and standard pH (pH 
7.1-7.3) SHE cell testing protocols were considered. The authors suggest that the SHE cell 
transformation assay is predictive for rodent carcinogenicity under either reduced or standard pH 
conditions; with the assay displaying better performance in prediction capability under reduced pH 
conditions. 
 
Matthews EJ, Spalding JW & Tennant RW (1993). 
Transformation of BALB/c-3T3 cells: V. Transformation 
responses of 168 chemicals compared with mutagenicity in 
Salmonella and carcinogenicity in rodent bioassays. 
This report describes the activities of 168 chemicals tested in a standard transformation assay using 
A-31-1-13 BALB/c-3T3 cells. 
Data analyses revealed that the transformation assay and rodent bioassay had a concordance of 71%; 
sensitivity for carcinogens of 80.0%; specificity for detecting non carcinogens of 60%.  
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In contrast, Salmonella mutagenicity assays and rodent bioassays had a concordance of 63%, a 
sensitivity of 58%, and a specificity of 69%. The transformation assay complemented the 
Salmonella mutagenesis assay in the identification of nonmutagenic carcinogens; thus, the two 
assays had a combined 83% sensitivity for all carcinogens and a specificity of 75% for non-
mutagenic non carcinogens. 
 
LeBoeuf RA, Kerckaert KA, Aardema MJ & Isfort RJ 
(1999). Use of Syrian hamster embryo and BALB/c 3T3 cell 
transformation for assessing the carcinogenic potential of 
chemicals. IARC Science Publications 146: 409-25.  
 
CTAs have been shown to involve a multistage process that closely models key stages of 
carcinogenesis. 
Jacobson-Kram D & Jacobs A (2005). Use of genotoxicity 
data to support clinical trials or positive genotox findings on 
a candidate pharmaceutical or impurity ... now what? 
International Journal of Toxicology. 24 (3): 129-34. 
 
In situations where a genetic toxicology assay showed a positive result, some review divisions have 
asked sponsors to perform a Syrian hamster embryo (SHE) cell transformation assay or a p53 
carcinogenicity study prior to allowing repeat-dose clinical trials to proceed. This paper discusses 
alternatives to SHE cell and p53 assays when faced with a positive result in a genetic toxicology 
assay. In addition, the authors discuss factors to consider when setting limits for genotoxic 
impurities in drug substances and products. 
 
Poth A, Heppenheimer A & Bohnenberger S. (2007). Bhas42 
cell transformation assay as a predictor of carcinogenicity. 
ALTEX. 14: 519-521. 
 
Biomarkers associated with human cancer have been studied as a means of obtaining a more 
objective measure of cell transformation in the Bhas 42 assay. The authors observed in transformed 
Bhas 42 cells a significant increase of expression and activity of cholinesterase and alkaline 
phosphatase, respectively, compared to non-transformed cells. Very high activity and intensity were 
found in Type III foci compared with Type II. 
 
Ao L, Liu JY, Liu WB, Gao LH, Hu R, Fang ZJ, Zhen ZX, 
Huang MH, Yang MS & Cao J (2010). Comparison of gene 
expression profiles in BALB/c 3T3 transformed foci exposed 
to tumor promoting agents. Toxicology in Vitro 24: 430-438. 
 
The authors of this study used cDNA microarrays to analyse gene expression profiles and discern 
chemical-associated profiles induced by a variety of tumour promoting agents in transformed 
BALB/c 3T3 cells. The cDNA microarray was based on 1796 mouse genes. The expression of genes 
associated to specific pathways was detected. Indeed, genes involved in oxidative stress response or 
cell proliferation were up-regulated. The application of gene expression profile analysis was 
suggested to be extremely useful in providing insights into the etiology of different chemicals. 
 
Pfuhler S, Kirst A, Aardema M, Banduhn N, Goebel C, Araki 
D, Costabel-Farkas M, Dufour E, Fautz R, Harvey J, Hewitt 
NJ, Hibatallah J, Carmichael P, Macfarlane M, Reisinger K, 
Rowland J, Schellauf F, Schepky A & Scheel J (2010). A 
tiered approach to the use of alternatives to animal testing for 
the safety assessment of cosmetics: Genotoxicity. A COLIPA 
This article described common approaches of cosmetic companies, with recommendations for 
evaluating in vitro genotoxins using non-animal approaches. A weight of evidence approach was 
employed to set up a decision-tree for the integration of alternative methods into tiered testing 
strategies. 
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analysis. Regulatory Toxicology & Pharmacology 57: 315-
324. 
 
Vanparys Ph, Corvi R, Aardema M, Gribaldo L, Hayashi M, 
Hoffmann S & Schechtman L (2010). ECVAM prevalidation 
of three cell transformation assays. ALTEX 27: 267-270. 
 
A prevalidation study on the cell transformation assays in SHE cells at pH 6.7, SHE cells at pH 7.0 
and Balb/c 3T3 cell line was coordinated by ECVAM focussing on issues of standardisation of 
protocols, within-laboratory reproducibility, test method transferability and between-laboratory 
reproducibility. The Validation Management Team concluded that standardised protocols are now 
available that should be the basis for future use. The SHE pH 6.7, and the SHE pH 7.0 protocols and 
the assays system themselves are transferable between laboratories, and are reproducible within- and 
between-laboratories. For the Balb/c 3T3 method, some clarifications and modifications to the 
protocol were needed to obtain reproducible results. Overall, three methods have shown to be 
valuable to detect rodent carcinogens. 
 
Sakai A, Sasaki K, Hayashi K, Muramatsu D, Arai S, Endou 
N, Kuroda S, Albrecht P, Bohnenberger S, Kunkelmann T, 
Asakura M, Hirose H, Ishii N, Mizuhashi F, Kasamoto S, 
Nagai M, Pant K, Bruce SW, Sly JE, Yamazaki S, Umeda M 
& Tanaka N (2011). An international validation study of a 
Bhas 42 cell transformation assay for the prediction of 
chemical carcinogenicity. Mutation Research 725: 57-77.  
 
An international study was carried out to validate the Bhas 42 cell transformation assay in which six 
laboratories from three countries participated. The Bhas 42 cell transformation assay is a sensitive 
short-term system for predicting chemical carcinogenicity. Bhas 42 cells were established from 
BALB/c 3T3 cells by the transfection of v-Ha-ras gene and postulated to have acquired an initiated 
state in the two-stage carcinogenesis theory. The Bhas 42 cell transformation assay is capable of 
detecting both tumour-initiating and tumour-promoting activities of chemical carcinogens. Here, the 
results obtained are reported. The authors demonstrated that the Bhas 42 cell transformation assay is 
transferable and reproducible between laboratories and applicable to the prediction of chemical 
carcinogenicity. 
 
Jacquet N, Maire MA, Landkocz Y, & Vasseur P (2012). 
Carcinogenic potency of perfluorooctane sulfonate (PFOS) 
on Syrian hamster embryo (SHE) cells. Archives of 
Toxicology 86 (2): 305-14. 
The authors assessed carcinogenic potential of Perfluorooctane sulfonate (PFOS) by studying 
morphological transformation in Syrian hamster embryo (SHE) cells. Genotoxicity of PFOS and 
expression of PPARs genes in SHE cells were also measured. The results indicated that PFOS 
behave as a non-genotoxic carcinogen and impacted PPARs genes. Interestingly, its cell 
transforming potential paralleled an increased expression of ppar-β/δ. 
 
Vanparys P, Corvi R, Aardema MJ, Gribaldo L, Hayashi M, 
Hoffmann S & Schechtman L (2012). Application of in vitro 
cell transformation assays in regulatory toxicology for 
pharmaceuticals, chemical, food products and cosmetics. 
Mutation Research 744 (1): 111-116. 
 
The extensive review on CTAs by the OECD (2007) and the proven standardisation, intra- and inter-
laboratory reproducibility of the SHE CTAs justifies broader use of these methods to assess 
carcinogenic potential of chemicals. The manuscript describes possible applications of the CTA in 
relation to different industrial sectors, e.g. food additives, chemicals, cosmetics, pharmaceuticals, 
etc. 
 
Corvi R, Aardema MJ, Gribaldo L, Hayashi M, Hoffmann S, 
Schechtman L & Vanparys P. (2012). ECVAM prevalidation 
A prevalidation study of the in vitro cell transformation assays (CTAs) using the BALB/c 3T3 cell 
line, SHE cells at pH 6.7, and SHE cells at pH 7.0 was coordinated by the European Centre for the 
    256 
study on in vitro cell transformation assays: general outline 
and conclusions of the study. Mutation Research 744 (1): 12-
9. 
 
Validation of Alternative Methods (ECVAM) and focused on issues of standardisation of protocols, 
test method transferability and within- and between-laboratory reproducibility. The paper reports the 
results of the ECVAM study demonstrating that for the BALB/c 3T3 method, some modifications to 
the protocol were needed to obtain reproducible results between laboratories, while the SHE pH 6.7 
and the SHE pH 7.0 protocols are transferable between laboratories, and results are reproducible 
within- and between-laboratories.  
 
The authors recommend that the BALB/c 3T3 and SHE protocols as instituted in this prevalidation 
study should be used in future applications of these respective transformation assays. They also 
recommend the development of an OECD test guideline for the SHE CTAs, based on the protocol 
published in this issue to support the harmonised use and regulatory application of the methods. The 
development of an OECD test guideline for the BALB/c 3T3 CTA should likewise be further 
pursued upon the availability of additional supportive data and improvement of the statistical 
analysis. 
 
Benigni R, Bossa C & Tcheremenskaia O (2013). In vitro cell 
transformation assays for an integrated, alternative 
assessment of carcinogenicity: a data-based analysis. 
Mutagenesis 28 (1): 107-16. 
Based on the evidence that the 2-year bioassay can fail to detect all genotoxic carcinogens and it 
cannot detect nongenotoxic carcinogens, the authors report on an integrated strategy consisting of 
the in vitro Ames and SHE cells transformation assays, combined with QSARs, as a valid 
alternative to the present pre-screening strategies. The analysis has furthered by (i) including results 
of CTAs on inorganics, together with and the Bhas42 assay and (ii) considering new structural alerts 
for nongenotoxic carcinogenicity. The author suggest the strategy as an efficient tool to identify 
both genotoxic and nongenotoxic carcinogens. 
 
OECD, (2007) no. 31 Detailed Review Paper on cell 
transformation assays for detection of chemical carcinogens, 
no. 31 ENV/JM/MONO (2007)18. 
 
This document focuses on the three main in vitro CTAs, the SHE, the BALB/c 3T3 and the 
C3H10T1/2 assays. The SHE assay uses karyotypically normal cells and is believed to detect early 
steps of carcinogenesis. The other two assays are based on immortalized aneuploid cell lines which 
measure later stages of carcinogenesis. The DRP is a comprehensive collection of available data 
reported in the literature for three CTAs which are reported alongside genotoxicity test data using 
mammalian and non-mammalian cell systems. The performances of the CTAs in predicting 
carcinogenic potential are analysed in terms of classification as rodent and/or human carcinogens. 
Based on their performances, the OECD recommended that the CTAs using the SHE cells and the 
BALB/c 3T3 cell line be developed into OECD Test Guidelines. 
 
EURL ECVAM (2012) Recommendation concerning the cell 
transformation assays using Syrian hamster embryo cells 
(SHE) and the BALB/c 3T3 mouse fibroblast cell line for in 
vitro carcinogenicity testing. Annex I: ESAC opinion on the 
EURL ECVAM recommendation report on the three CTA protocol variants: (a) The SHE CTA 
performed at pH 6.7 (SHE pH 6.7 CTA); (b) the SHE CTA performed at pH 7.0 (SHE pH 7.0 
CTA); and (c) the BALB/c 3T3 CTA. 
ECVAM coordinated an international study that was designed to address issues of CTA protocols 
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ESAC peer review of an ECVAM-coordinated prevalidation 
study concerning three protocols of the cell transformation 
assay (CTA) for in vitro carcinogenicity testing. 
http://ihcp.jrc.ec.europa.eu/our_activities/alt-animal-testing 
 
standardisation, transferability and reproducibility in three protocol variants for the SHE CTA (at 
pH 6.7 and pH 7.0) and the BALB/c 3T3 assay. The study of the three test methods was peer 
reviewed by the ESAC that issued a peer review report and an ESAC opinion. Based on the 
available documents (study reports, ESAC opinion, OECD DRP), EURL ECVAM recommended 
that an OECD TG be developed for the SHE CTA and that further investigations were needed to 
confirm the performance of the BALB/c 3T3 CTA.  
Moreover, the recommendation stated that in conjunction with other available data, the CTAs have 
the potential of partial replacement or reduction when used in a weight of evidence approach for 
hazard identification and risk assessment.  
 
EFSA ( 2011). Scientific Opinion of the Scientific 
Committee on genotoxicity testing strategies applicable to 
food and feed safety assessment. EFSA Journal 2011; 9 (9): 
2379 (69pp) 
The Scientific Committee reviewed the current state-of-the-science on genotoxicity testing and 
provided a commentary and recommendations on genotoxicity testing strategies. A step-wise 
approach is recommended for the generation and evaluation of data on genotoxic potential, 
beginning with a basic battery of in vitro tests, comprising a bacterial reverse mutation assay and an 
in vitro micronucleus assay. It is suggested to consider whether specific features of the test 
substance might require substitution of one or more of the recommended in vitro tests by other in 
vitro or in vivo tests in the basic battery. In the event of negative in vitro results, it can be concluded 
that the substance has no genotoxic potential. In case of inconclusive, contradictory or equivocal 
results, it may be appropriate to conduct further testing in vitro. In case of positive in vitro results, 
review of the available relevant data on the test substance and, where necessary, an appropriate in 
vivo study to assess whether the genotoxic potential observed in vitro is expressed in vivo is 
recommended. The approach to in vivo testing should be also step-wise. The combination of 
assessing different endpoints in different tissues in the same animal in vivo should also be 
considered. 
 
Oxidative Stress and GJIC Communication Measurements 
Klaunig JE & Shi Y (2009). Assessment of gap junctional 
intercellular communication. Current Protocols in 
Toxicology. Chapter 2:Unit 2.17. 
 
Taking into account the key role of gap-junctions aberrations in the development of several human 
diseases such as cancer, cardiac arrhythmia, Charcot-Marie-tooth disease, and visceroatrial 
heterotaxia syndrome, Klaunig and Shi describe methods for measuring gap junctional intercellular 
communication using primary mouse hepatocytes as a model. The authors focus on functional 
evaluation based on dye coupling.  
 
Klaunig JE, Kamendulis LM & Hocevar BA (2010). 
Oxidative stress and oxidative damage in carcinogenesis. 
Toxicologic Pathology 38 (1): 96-109. 
 
Chemical and physical agents including those that induce reactive oxygen species (ROS) can induce 
and/or modulate the multistep process of carcinogenesis.  
Based on the identification that oxidative damage to cellular macromolecules can arise through 
overproduction of ROS and faulty antioxidant and/or DNA repair mechanisms and ROS can 
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stimulate signal transduction pathways and lead to activation of key transcription factors such as 
Nrf2 and NF-kappaB, the authors discuss the aspects of ROS biology in the context of their 
relationship to carcinogenesis. They also considered the recent evidence demonstrating an 
association between a number of single nucleotide polymorphisms (SNPs) in oxidative DNA repair 
genes and antioxidant genes with human cancer susceptibility. 
 
Toxicogenomics-based tests and The carcinoGENOMICS Project 
Tsujimura K, Asamoto M, Suzuki S, Hokaiwado N, Ogawa 
K & Shirai T (2006). Prediction of carcinogenic potential by 
a toxicogenomic approach using rat hepatoma cells. Cancer 
Science 97: 1002-1010. 
 
The authors conducted gene expression profiling of cultured rat hepatoma cells (MH1C1) exposed 
to carcinogenic chemicals with the aim of providing a basis for rapid and reliable prediction of 
carcinogenicity using microarray technology.  
Cells were treated with chemicals for three days at a non-toxic dose an the analysis of gene 
expression profile with an in-house microarray allowed a set of genes to be identified differentiating 
hepatocarcinogens from non-carcinogens, and all carcinogens from non-carcinogens, by statistical 
methods. The authors sought promising outcomes from these short-term bioassay systems for 
carcinogenicity. 
 
Guo L, Lobenhofer EK, Wang C, Shippy R, Harris SC, 
Zhang L, Mei N, Chen T, Herman D, Goodsaid FM, Hurban 
P, Philips KL, Qu J. Deng X. Sun YA. Tong W, Dragon WT 
& Shi L (2006). Rat toxicogenomic study reveals analytical 
consistency across microarray platforms. Nature 
Biotechnology 24: 1162-1169. 
 
In the context of the MicroArray Quality Control (MAQC) project, the authors validated and 
extended the obtained data. Toxicogenomics data sets were built using 36 RNA samples from rats 
treated with three chemicals (aristolochic acid, riddelliine and comfrey) and each sample was 
hybridized to four microarray platforms. The real-world toxicogenomic data set reported here 
showed high concordance in intersite and cross-platform comparisons.  
Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh 
L, Bittner A, Nelson J, Carmen A, Wan J & Lord PG (2006). 
Predictive toxicogenomics approaches reveal underlying 
molecular mechanisms of nongenotoxic carcinogenicity. 
Molecular Carcinogenesis 45: 914-933. 
 
Nie and co-workers built a large gene expression database using cDNA microarrays and liver 
samples treated with over one hundred paradigm compounds; data were obtained from male rats 
treated for 24 hrs. The aim of the study was to determine gene expression signatures for 
nongenotoxic carcinogens (NGTCs).  
The obtained gene expression profiles accurately predicted NGTC potential of compounds and 
resulted amenable for other toxicity signatures. 
 
Li HH, Aubrecht J & Fornace AJ Jr (2007). Toxicogenomics: 
overview and potential applications for the study of non-
covalent DNA interacting chemicals. Mutation Research 623: 
98-108. 
 
In this review the authors focus their attention onto the characterization of stress agents including 
non-covalent DNA interacting chemicals based on gene expression profiling, through the use of 
functional genomics approaches, highlighting both pro and cons of these methodologies. 
 
Le Fevre AC, Boitier E, Marchandeau JP, Sarasin A & 
Thybaud V (2007). Characterization of DNA reactive and 
In this study, human lymphoblastoid TK6 cells were exposed to several anticancer drugs for 4-h and 
examined them immediately or after a 20-h recovery period. Cytotoxicity (cell cycle), genotoxicity 
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non-DNA reactive anticancer drugs by gene expression 
profiling. Mutation Research 619: 16-29. 
 
(micronucleus), and gene expression profiles (human Affymetrix U133A GeneChips-22K) were 
evaluated. 
28 marker genes mainly involved in signal transduction and cell cycle pathways were detected, 
which were suggested to be useful as a predictive model to classify genotoxins according to their 
direct or indirect interaction with DNA. 
 
Stemmer K, Ellinger Ziegelbauer H, Ahr HJ & Dietrich DR 
(2007). Carcinogen-specific gene expression profiles in 
short-term treated Eker and wild-type rats indicative of 
pathways involved in renal tumorigenesis. Cancer Research 
67: 4052-4068. 
 
In this study, Eker rats, heterozygous for a dominant germ line mutation in the tuberous sclerosis 2 
(Tsc2) tumour suppressor gene, were used as a model to study renal carcinogenesis. Eker and 
corresponding wild-type rats were exposed to genotoxic aristolochic acid (AA) or non-genotoxic 
ochratoxin A (OTA) to elucidate early carcinogen-specific gene expression changes and to test 
whether Eker rats were more sensitive to carcinogen-induced changes in gene expression. 
 
Fielden MR, Brennan R & Gollub J (2007). A gene 
expression biomarker provides early prediction and 
mechanistic assessment of hepatic tumor induction by 
nongenotoxic chemicals. Toxicological Sciences 99: 90-10. 
 
Fielden and co-workers developed a multigene biomarker (signature) to predict the likelihood of 
non-genotoxic chemicals to induce liver tumours in long-term studies. The authors used hepatic 
gene expression profiles from rats 5-days-treated with several non-genotoxic hepatocarcinogens and 
non hepatocarcinogens (100). The authors found this method very accurate and able to facilitate the 
identification of mode of actions. Indeed, the signature was suggested to be helpful for the early 
assessment of cancer risk. 
 
Nioi P, Pardo ID, Sherratt PJ & Snyder RD (2008). 
Prediction of non-genotoxic carcinogenesis in rats using 
changes in gene expression following acute dosing. Chemico-
Biological Interactions 172: 206-215. 
 
In this study the authors investigated whether early changes in gene expression may be developed as 
markers for cancer.  
Gene expression profiles, from animals treated with either non-genotoxic carcinogens or non-
carcinogens, were analysed by qPCR. The data obtained suggested that acute changes in gene 
expression might be helpful to identify biomarkers for non-genotoxic carcinogenesis. 
 
Uehara T, Hirode M, Ono A, Kiyosawa N, Omura K, 
Shimizu T, Mizukawa Y, Miyagishima T, Nagao T & 
Urushidani T (2008). A toxicogenomics approach for early 
assessment of potential non-genotoxic hepatocarcinogenicity 
of chemicals in rats. Toxicology 250: 15-26. 
 
In this study, the possibility of applying a toxicogenomics approach by using comprehensive gene 
expression data in rat liver treated with various compounds was explored. 
 
Ellinger-Ziegelbauer H, Gmuender H, Bandenburg A & Ahr 
HJ (2008). Prediction of a carcinogenic potential of rat 
hepatocarcinogens using toxicogenomics analysis of short-
term in vivo studies. Mutation Research 637: 23-39. 
 
The authors evaluated the carcinogenic potential of several different chemicals (genotoxic and non-
genotoxic carcinogens and hepatocarcinogens and from non-carcinogens) using gene expression 
profile from livers of 14-days-treated rats. The data obtained were considered accurate enough to 
proof the feasibility of this method as classifier of carcinogens in short-term studies. 
 
Guyton KZ, Kyle AD. Aubrecht J, Cogliano VJ, Eastmond In light of the difficulties at discriminating between genotoxic and non-genotoxic carcinogens and 
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DA, Jackson M, Keshava N, Sandy MS, Sonawane B, Zhang 
L, Waters MD & Smith MT (2009). Improving prediction of 
chemical carcinogenicity by considering multiple 
mechanisms and applying toxicogenomic approaches. 
Mutation Research 681: 230-240. 
 
the at identifying the cancer dose-response relationship at low doses, Guyton et al report on new 
bioanalytical approaches (e.g., transcriptomics, proteomics, and metabolomics) which could be 
applied in human, animal and in vitro studies and could better characterize a wider array of hazard 
traits. Thus, to improving the ability to predict the potential carcinogenicity of chemicals.  
 
Ellinger-Ziegelbauer H, Aubrecht J, Kleinjans JC & Ahr HJ 
(2009). Application of toxicogenomics to study mechanisms 
of genotoxicity and carcinogenicity. Toxicology Letters 186: 
36-44. 
 
 
The paper underlies the importance of developing novel scientific approaches bridging genotoxicity 
and carcinogenicity testing via understanding underlying mechanisms for facilitating cancer risk 
assessment. The authors consider extremely promising the toxicogenomics approaches as these have 
the potential of providing generic insight in molecular pathway responses. The goal of the report is 
to review recent progress in the development and application of toxicogenomics to the derivation of 
genomic biomarkers associated with mechanisms of genotoxicity and carcinogenesis.  
 
Jonker MJ, Bruning O, van Iterson M, Schaap MM, van der 
Hoeven TV, Vrieling H, Beems RB, de Vries A, van Steeg H, 
Breit TM & Luijten M (2009). Finding transcriptomics 
biomarkers for in vivo identification of (non-)genotoxic 
carcinogens using wild-type and Xpa/p53 mutant mouse 
models. Carcinogenesis 30: 1805-1812. 
 
In this study the authors treated both wild-type and DNA repair-deficient Xpa(-/-)/p53(+/-) 
(Xpa/p53) mice up to 14 days to compounds of three distinct classes: genotoxic carcinogens 
(GTXC), non-genotoxic carcinogens (NGTXC) and non-carcinogens. Subsequently, extensive 
transcriptomics analyses were performed on several tissues, and transcriptomics data were screened 
for potential biomarkers using advanced statistical learning techniques. Jonker and collaborators 
obtained highly confident results and demonstrated a proof-of-principle for the identification and 
use of transcriptomics biomarkers for GTXC or NGTXC, for short-term studies. 
 
Mathijs K, Brauers KJ, Jennen DGJ, Lizarraga D, Kleinjans 
JCS & van Delft JHM (2010). Gene expression profiling in 
primary mouse hepatocytes discriminates true from false-
positive genotoxic compounds. Mutagenesis 25: 561-568. 
 
Considering the high rate of false-positive for predicting in vivo genotoxicity and carcinogenicity 
obtained from standard in vitro tests (Ames, CAvit MNvit), Mathijs and collaborators investigated 
the potential of gene expression profiling in metabolically competent primary mouse hepatocytes to 
discriminating true genotoxic (GTX) compounds from false-positive genotoxic (FP-GTX) 
compounds.  
 
Doktorova TY, Pauwels M, Vinken M, Vanhaecke T & 
Rogiers V (2012) Opportunities for an alternative integrating 
testing strategy for carcinogen hazard assessment? Critical 
Reviews in Toxicology 42 (2): 91-106.  
In this review paper, the major advantages and pitfalls of the existing alternative methodologies to 
the carcinogenicity bioassay are discussed.  
Based on the available scientific data in the public domain, the authors propose a "feasible 
integrated testing strategy" which incorporates some promising alternatives (toxicogenomics-, 
transcriptomics-based tests and CTAs), providing at the same time information on the mechanism of 
action and the toxic nature of the compounds tested. 
 
Doktorova TY, Yildirimman R, Vinken M, Vilardell M, 
Vanhaecke T, Gmuender H, Bort R, Brolen G, Holmgren G, 
Li R, Chesne C, van Delft J, Kleinjans J, Castell J, Bjorquist 
In the present study, the transcriptomics responses following exposure to genotoxic and non-
genotoxic hepatocarcinogens and non-carcinogens in five liver-based in vitro models, namely 
conventional and epigenetically stabilized cultures of primary rat hepatocytes, the human hepatoma-
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P, Herwig R, & Rogiers V (2013). Transcriptomic responses 
generated by hepatocarcinogens in a battery of liver-based in 
vitro models. Carcinogenesis 34: 1393-1402. 
 
derived cell lines HepaRG and HepG2 and human embryonic stem cell-derived hepatocyte-like 
cells, are examined. 
Jennings P, Limonciel A, Felice L & Leonard MO (2013). 
An overview of transcriptional regulation in response to 
toxicological insult. Archives of Toxicology 87: 49–72. 
 
This review aims to consolidate and summarise the major toxicologically relevant transcription 
factor-governed molecular pathways.  
The authors focus on the importance of toxicogenomic data sets and information on regulation of 
stress pathways at the transcriptome level, in order to appreciate the diversity and complexity of 
biological responses to xenobiotics. 
 
Waters MD, Jackson M & Lea I (2010). Characterizing and 
Predicting Carcinogenicity and Mode of Action Using 
Conventional and Toxicogenomics Methods. Mutation 
Research 705: 184-200.  
 
The authors report that the evidence accumulated to date suggests that gene expression profiles 
reflect underlying modes or mechanisms of action, such that they will be useful in the prediction of 
chemical carcinogenicity, especially in conjunction with conventional short-term tests for gene 
mutation, chromosomal aberration and aneuploidy. 
Rohrbeck A, Salinas G, Maaser K, Linge J, Salovaara S, 
Corvi R & Borlak J (2010). Toxicogenomics applied to in 
vitro carcinogenicity testing with Balb/c 3T3 cells revealed a 
gene signature predictive of chemical carcinogens. 
Toxicological Sciences 118: 31-41. 
 
The authors reported the application of advanced genomics to a cellular transformation assay to 
identify toxicity pathways and gene signatures predictive for carcinogenicity.  
During the study, the genome-wide gene expression analysis and quantitative real time polymerase 
chain reaction (qRT-PCR) were applied to untransformed and transformed mouse fibroblast Balb/c 
3T3 cells that were exposed to either 2, 4-diaminotoluene, benzo(a)pyrene, 2-acetylaminoflourene, 
or 3-methycholanthrene at IC20 conditions for 24 and 120 h, respectively.  
Prediction of carcinogenicity potential of the three substances was significant and the testing 
strategy was able to identify commonly regulated carcinogenic pathways and a gene signature that 
predicted the risk for carcinogenicity. 
 
Vinken M, Vanhaecke T & Rogiers V (2012). Primary 
hepatocyte cultures as in vitro tools for toxicity testing: quo 
vadis? Toxicology in Vitro 26: 541-544. 
 
The authors discuss on the mechanisms underlying hepatocyte dedifferentiation, which in turn can 
affect primary hepatocytes cultivation for in vitro toxicity testing. Recent insights into this 
mechanism have been suggested to be useful for the development of new long-term hepatic in vitro 
methods, especially in the light of the stringent European legislative modifications. 
 
Transgenic mouse models 
Tennant RW, French JE & Spalding JW (1995). Identifying 
chemical carcinogens and assessing potential risk in short-
term bioassays using transgenic mouse models. 
Environmental Health Perspectives 103: 942-950. 
 
Tenant et al reported on the advantages of transgenic mouse models for the carcinogenicity testing. 
In particular, the authors showed that mutagenic carcinogens could be identified with increased 
sensitivity and specificity using hemizygous p53 mice in which one allele of the p53 gene has been 
inactivated. The TG.AC transgenic model, carrying a v-Ha-ras construct, responded to a number of 
mutagenic and nonmutagenic carcinogens and tumour promoters, but not to non carcinogens, as 
well.  
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A decision-tree approach for testing chemicals was also presented. 
 
Tennant RW, Stasiewicz S, Mennear J, French JE & Spalding 
JW (1999). Genetically altered mouse models for identifying 
carcinogens. IARC Scientific Publications 146: 123-150. 
 
Modifications to the mouse genome can induce increased sensitivity to tumour incidence and 
formation. The possibility to identify carcinogens through transgenic mouse models relies on these 
modifications. 
Eastin WC, Haseman JK, Mahler JF & Bucher JR (1998). 
The National Toxicology program evaluation of genetically 
altered mice as predictive models for identifying carcinogens. 
Toxicologic Pathology 26: 461-473. 
 
The authors report on the evaluation, performed by the National Toxicology Program, of two mouse 
models potentialities, the Tg.AC (carrier of an activated mouse H-ras oncogene) and the p53+/- 
(heterozygous for the wild-type tumor suppressor gene Trp53) as a substitute for the 2-year rodent 
assays. 
 
Bucher JR (1998). Update on National Toxicology Program 
(NTP) assays with genetically altered or “transgenic” mice. 
Environmental Health Perspectives 106: 619-621. 
Brief review on the advance of transgenic mouse models research and development, based on the 
evaluation of several lines of genetically modified mice, performed by the National Toxicology 
Program. 
 
Ashby J (2001). Expectations for transgenic rodent cancer 
bioassay models. Toxicologic Pathology 29 Suppl, 177-182. 
 
In this paper, Ashby discussed about his analysis on the transgenic mouse models: advances in 
development, validation and potential to standard rodent bioassay replacement.  
The author focused on the phases in need of being improved for a more critical evaluation of new 
models. It was suggested further discussion of 5 key areas from test methodology to chemicals 
databases analysis, carcinogenesis process study to regulations and legislations update. 
 
Marx J (2003). Building Better Mouse Models for Studying 
Cancer. Science 299: 1972-1975. 
The article highlights the advances on new strains of transgenic mice research: in particular, mice 
baring tumours that more closely mimic human cancers, for use in both basic cancer studies and 
drug screening. 
 
Pritchard JB, French JE, Davis BJ & Haseman JK (2003). 
The role of transgenic mouse models in carcinogen 
identification. Environmental Health Perspectives 111: 444-
454. 
 
The paper examined existing data on the use of transgenic mouse models for identification of human 
carcinogens. The authors on the three most extensively studied of these mice, Trp53+/-, Tg/AC, and 
RasH2, and compare their performance with the traditional 2-year rodent bioassay. Data on 99 
chemicals were evaluated. A variety of potential testing strategies ranging from individual 
transgenic models to combinations of these three models with each other and with traditional rodent 
assays was evaluated using IARC carcinogens database. Transgenic models, for their performance, 
were suggested for regulatory acceptance and use in human cancer risk assessment, after further 
validation and standardization. 
 
De Vries A, van Steeg H & Opperhuizen A (2004). 
Transgenic mice as alternatives in carcinogenicity testing: 
current status. RIVM report 340700001 
Transgenic mouse models showed a high specificity given that all non-carcinogens tested gave 
negative results in all 5 transgenic models, providing evidence against “oversensitivity” concerns 
associated with such models. 
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ILSI HESI ACT (2001) ILSI HESI Alternatives to 
carcinogenicity testing Workshop. Toxicologic Pathology 29 
supplement: 1-351, Annex I. 
The ILSI Alternative Methods for Carcinogenicity Testing (ACT) Workshop (held November 1–3, 
2000 in Leesburg, Virginia, USA) featured two poster sessions to stimulate further discussion 
around the development, evaluation and application of alternative models for carcinogenicity 
assessment. In the Appendix I collected all the presented data. 
 
Testing strategy Improvements in the Pharmaceuticals Sector 
'Putting Animal Welfare Principles and 3Rs into Action' - 
European Pharmaceutical Industry 2011 Report. 
http://www.efpia.eu/documents/14/61/Putting-animal-
welfare-principles-and-3Rs-into-action-European-
Pharmaceutical-Industry-2011-Report 
 
The EFPIA (European Federation of Pharmaceutical Industries and Associations, reports on the 
state of the art on regulations, requirements, development, testing strategy, research and 
implementation of European Directives in the Pharmaceuticals Sector, in light of 3Rs principle. 
 
Sistare FD, Morton D, Alden C, Christensen J, Keller D, 
Jonghe SD, et al., (2011). An analysis of pharmaceutical 
experience with decades of rat carcinogenicity testing: 
support for a proposal to modify current regulatory 
guidelines. Toxicologic Pathology 39 (4): 716-44. 
 
Toxicology experts from the Pharmaceuticals Industry revised the carcinogenic potential of 182 
marked and not marked products, demonstrating that the rat 2-years assay was not adding any 
valuable result or information to the cancer risk hazard of compounds which bear no clear 
histopathologic sign of rat tumour, any hormonal perturbation or positivity for genotoxicity. 
The authors advocate an update of regulatory requirements and guidelines for carcinogenicity 
studies. 
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10. Reproductive toxicity – effects on fertility and developmental toxicity 
Alexandra Rolaki, Malgorzata Nepelska, Susanne Bremer, Rabea Graepel, Anna Price & Andrew 
Worth 
 
10.1 Introduction 
Normal human reproduction and development depends on the timely execution of a wide range of 
processes including the formation, transport and release of gametes, fertilization, implantation, 
gestation, and, ultimately, the development of offspring that is eventually capable of successfully 
repeating the entire process. A comprehensive description of the reproductive functions and 
reproductive cycle can be found in text books on reproduction biology and/or reproductive 
toxicology (e.g. Gupta, 2011; Strauss & Barbieri, 2013). 
 
In this document, the following definitions are taken from the Classification, Labelling and 
Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) “reproductive toxicity” includes 
adverse effects on sexual function and fertility in adult males and females, as well as developmental 
toxicity in the offspring; b) “effects on fertility” includes adverse effects on sexual function and 
fertility; and c) “developmental toxicity” includes adverse effects on development of the offspring. 
 
 
 
 
Figure 10.1. The main elements of the continuum of developmental stages and reproduction. 
Functional aspects such as libido, copulation, erection, ejaculation, oestrus cycle, pregnancy, labour 
and lactation are not included. 
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10.2 The traditional animal tests and their regulatory use 
Various animal methods for testing effects on fertility and developmental toxicity are available and 
standardised as OECD Test Guidelines (see Table of References with Notes).  
 
Under REACH, information on reproductive toxicity is required for chemicals with an annual 
production/importation volume of 10 metric tonnes or more. The standard information requirements 
are cumulative; requirements at higher tonnage levels add to the information requirements at lower 
tonnage levels. Standard information requirements include a screening study on reproduction 
toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study 
(OECD 414) on a first species at Annex IX (100-1000 t.p.a), a two-generation reproductive toxicity 
study (OECD 416) and, if not conducted already at Annex IX, a prenatal developmental toxicity 
study on a second species at Annex X (≥ 1000 t.p.a.). Taken together, at Annex X level, 
information on reproduction toxicity could be available from a screening reproductive toxicity 
study, prenatal developmental toxicity studies on two species, two-generation reproductive toxicity 
study, as well as from repeated dose toxicity studies. In the REACH, there is an obligation to carry 
out vertebrate testing only as a last resort and to consider all other options before performing or 
requiring testing, as described by Articles 13(1) and 25(1) in the REACH legal text.  
 
Under the Biocidal Products Regulation (BPR), which entered into force on 1 September 2013 
(replacing the Biocidal Products Directive, 98/8/EEC), information is also required on reproductive  
toxicity for active substances  as part of core data set and additional data set (EU 2012, ECHA 
2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first 
species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 
443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative 
approach to the multi-generation study. The need of a further prenatal developmental toxicity study 
on second species (part of additional data set) may be decided based on the results of the first test 
and all available information.   
 
The CLP regulation is based on the United Nations (UN) Globally Harmonized System (GHS) for 
classification and labelling. Also many other UN Member Countries are implementing (or will 
implement) GHS, having thus a comparable classification system as in the EU. 
 
The classification of a substance as toxic for reproduction may have important implications, such as 
the need to obtain authorisation for marketing of the substance. According to the CLP regulation, 
substances may be classified either into category 1A, 1B, or 2. Category 1 comprises substances 
that are known to be toxic for reproduction, based on evidence in humans (Category 1A) or 
presumed to be human reproductive toxicants, based on evidence from animal experiments 
(Category 1B). Substances that are suspected to be human reproductive or developmental toxicants, 
but for which the evidence is not sufficiently convincing to place the substance in Category 1, are 
assigned to Category 2. 
 
The designation of a substance as toxic for reproduction follows criteria that do not consider the 
dose level of the substance at which reproductive toxicity occur, as long as excessive generalized 
toxicity does not occur. The classification and labelling system is based on the intrinsic properties 
of the substance and gives indication about the hazards without consideration of exposure or the 
effective dose level and therefore, does not provide information on the actual risk of the chemical.  
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10.3 Mechanistic understanding of the endpoints 
Normal human fertility and development are regulated throughout the entire life-cycle by a finely 
tuned system of coordinated signals that direct the activity of multiple interdependent target cells. 
This complex signalling process involves a vast number of steroid hormones, growth factors and 
other molecules, each of which is programmed to be delivered to its target tissue in an appropriate 
amount and in a pre-defined time window. A mechanistic understanding of effects on fertility and 
developmental toxicity therefore needs to account for how chemicals disrupt normal physiological 
pathways, and how these perturbations translate into effects at higher levels of biological 
organisation and across multiple time scales. Adverse outcomes at the organism level include 
dysmorphogenesis, growth retardation, lethality, functional and behavioural alterations, and 
impaired fertility. These adverse effects are not necessarily based on cell growth and death, but 
rather on more subtle changes, for example on differentiation and intercellular/intracellular 
signalling pathways. 
 
Given the complexity of processes in reproduction, it is not surprising that our knowledge of the 
underlying mechanisms and their perturbations is incomplete. A great deal of fundamental 
knowledge is being generated in biology and genetics, but this is still a long way from being applied 
in toxicology. 
 
10.4 Status of alternative methods 
Given the diversity of physiological processes associated with the mammalian reproductive cycle, 
and the complexity of the underlying regulatory networks, it is not possible to model chemical 
effects on the whole cycle with a single or limited number of non-animal approaches.  
 
The approach taken so far has been to break down the reproductive cycle into its main biological 
components, some of which are then studied individually with a view to improving mechanistic 
understanding and developing mechanistically-based in vitro tests. Indeed, a substantial amount of 
research has been conducted to develop non-animal approaches, and in particular in vitro tests. 
These efforts have been reviewed in detail elsewhere (Worth & Balls, 2002; Adler et al., 2011) and 
in a special issue of Reproductive Toxicology summarizing key results of the ReProTect project 
(Piersma et al., 2010). The relationship between the main in vitro tests developed, and the part of 
the reproductive cycle they are intended to mimic, is given in Table 10.1. 
 
For some reproductive tissues and for some aspects of the reproductive cycle in vitro systems exist, 
but these have been used mainly for mechanistic research and have not been optimized for toxicity 
testing. Most of them consist of primary cultures or organ cultures.  
 
Culture systems of pre-implantation embryos are well established because of interest in in vitro 
fertilization techniques and reproductive cloning, but little attention has been paid to these as 
toxicology models.  
 
Stem cells provide a promising means of assessing chemical effects on stem cell differentiation into 
cells of the three germ layers as well as on their further differentiation and maturation into 
functional cells such as neurons or heart cells. In addition, stem cells possess the capacity to 
differentiate into any other cell type, which is valuable in the development of tissue-specific 
toxicity assays.  
 
In the case of developmental neurotoxicity (DNT), a range of in vitro models exists that allow to 
study neurodevelopmental specific processes in a quantitative manner and could be included into a 
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testing strategy for initial screening and prioritisation of chemicals with concern for developmental 
neurotoxicity. As for development from the early embryonic period through adulthood, no models 
are available.  
 
Despite the impressive number of in vitro methods that have been developed (Adler et al., 2011; 
Moschallski et al., 2011), most of them are not yet used in the regulatory assessment of 
reproductive toxicity. Many of the currently available assays have been developed for elucidating 
possible mechanisms of action, so they are not directly predictive of any specific adverse effects on 
reproduction. In addition, most of the assays do not consider the various aspects of absorption, 
distribution, metabolism and excretion (ADME), which need to be taken into account in 
determining the in vivo toxicological profile of a chemical. Another challenge consists in 
distinguishing general toxicity from reproductive toxicity, especially organ specific developmental 
effects, (even by means of whole embryo assays; see below). Furthermore, the influence of the 
maternal organism (maternal toxicity) on developmental toxicity cannot be directly captured by in 
vitro assays. The status of the main in vitro methods for reproducutive toxicity testing is given in 
Table 10.2. In spite of the difficulties in developing non-animal approaches for reproductive 
toxicity, more approaches for developmental toxicity and the endocrine system are available and 
closer to regulatory applicability as supporting information than methods assessing effects on 
fertility.  
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Table 10.1. Relationship of available in vitro test methods to steps in the reproductive cycle  
 
 
Step in reproductive cycle In Vitro Test Method 
Embryogenesis / Foetogenesis Embryonic Stem Cell Test (EST) 
Embryogenesis / Foetogenesis The micromass test (MM) 
Embryogenesis / Foetogenesis The rodent whole embryo culture test (WEC) 
Embryogenesis / Foetogenesis The zebrafish embryo teratogenicity assay 
Embryogenesis / Foetogenesis Frog embryo teratogenesis assay xenopus 
(FETAX) 
Embryogenesis / Foetogenesis The chicken embryotoxicity screening test 
(CHEST) 
Transport of substances through the 
placenta  
Placental perfusion assay 
Placental development / Blastocyst 
implantation  
Trophoblast cell assay 
Production and  release of gametes Leydig Cell Assay 
Production and  release of gametes Sertoli 3-D cell system 
Production and  release of gametes / 
mutagenic effects 
Comet and ReProComet Assay 
Production and release of gametes Computer Assisted Sperm Analysis (CASA) 
Production and  release of gametes Follicle culture bioassay (FBA) 
Oocyte Maturation In vitro bovine oocyte maturation assay (bIVM) 
Blastocyst implantation Mouse Peri-Implantation Assay (MEPA) 
Fertilization / Blastocyst 
implantation  
In vitro bovine fertilization assay (bIVF) 
 
 
10.4.1 In vitro methods for fertility 
Some in vitro methods have been designed to investigate the cytotoxic effects of chemicals on the 
main components of the male and female reproductive organs and systems without functional 
fertility and reproductive performance. The status of the main in vitro methods is presented in Table 
10.2. 
 
In the male gonads, the three critical cell types sensitive to chemical exposure are: germ cells, 
Leydig and Sertoli cells. Given the importance of the quality and quantity of spermatozoa in male 
reproductive capability, the measurement of sperm parameters is one of the essential endpoints in 
assessing reproductive toxicity. Male reproductive toxicity is mainly assessed in vitro by Computer 
Assisted Sperm Analysis (CASA), the Leydig cell assay, the Sertoli cell assay and the ReProComet 
assay (Cordelli et al., 2007; La et al., 2010; Schleh & Leoni 2013). 
 
In the female gonads, the essential functional and morphological unit is the follicle of the ovary. 
Each follicle consists of three basic cell types: theca and granulosa cells and the oocyte. A number 
of different in vitro assays have been developed to assess female reproductive toxicity, including 
the follicle culture bioassay (FBA), the bovine oocyte maturation assay (bIVM), the bovine 
fertilisation test (bIVF), and the mouse peri-implantation assay (MEPA) (Anon 2010; Lemeire et 
al., 2007; Lazzari et al., 2008; Luciano et al., 2010; Van Merris et al., 2007). 
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10.4.2 In vitro methods for developmental toxicity 
In vitro methods for developmental toxicity testing are more numerous, and in general closer to 
regulatory applicability, than in vitro methods for assessing effects on fertility. The status of the 
main methods is given in Table 10.2. 
 
The main in vitro methods for assessing placental transfer are the placental perfusion assay (Myren 
et al., 2007; Mose et al., 2008; Myllynen et al., 2009) and the trophoblast cell assay (Morck et al., 
2010). The latter uses the immortalized BeWo trophoblastic cell line of human origin, while the 
former is an ex vivo placental perfusion. The placenta differs more than any other organ between 
species (Leiser & Kaufmann, 1994). This is the primary reason to develop models utilizing human 
tissue to study placental functions and to assess the placental transfer of compounds and their 
effects on placental formation and pregnancy. It should be noted however that the placental 
perfusion assay is relatively low throughput and difficult to perform. 
 
Exposure to chemicals during development can affect nervous system development (as well as 
other systems) and cause transient or irreversible morphological and functional changes at doses 
much lower than those affecting adult brain function (Claudio et al., 2000; Tilson, 2000; Eriksson, 
1997). A particular challenge in developmental neurotoxicity (DNT) testing is that outcome of 
exposure to potentially neurotoxic chemicals depends not only on dose and duration of exposure but 
also on the developmental stage at the time of exposure. Presently there are many in vitro test 
methods that allow evaluation of the effects on key neurodevelopmental processes including 
neuronal progenitor cell proliferation, migration, differentiation into neurons and glia, neuronal 
outgrowth, myelination, synaptogenesis and network formation (Hogberg et al., 2009; Fritsche et 
al., 2011; Bal-Price et al., 2012). However, human in vitro models that have been developed for 
DNT testing are highly recommended as the most relevant for prediction of human toxicity. 
Currently, it is possible to investigate toxicity induced by chemicals on key neurodevelopmental 
processes using human neuronal in vitro systems derived from progenitor- or human stem cells 
(embryonic, adult or induced pluripotent stem cells). They have been studied intensively over the 
past decade because they are primary, of human origin, and expandable although not immortalized 
(Buzanska et al., 2009). These human in vitro models allow to study most of the DNT processes 
including human neural progenitor cells commitment, proliferation, migration, differentiation, 
neurite outgrowth, synaptogenesis and network formation (Bal-Price et al., 2012; Fritsche et al., 
2011).  
 
The effects of chemicals on these DNT-specific processes can be studied in vitro in a quantitative 
manner to characterise the concentration-response relationship (Radio et al., 2008; Bal-Price et al., 
2012; Balmer et al., 2012; Zimmer et al., 2012). 
 
It is postulated that the developmental effects of pre- and/or post-natal exposure may be linked not 
only to behavioural changes of children (e.g. autism, attention deficit disorder, mental retardation) 
(Grandjean and Landrigan, 2006,) but also to adult cognitive and mental disorders such as 
Parkinsons (Fox et al., 2012). Therefore, due to the complexity of relationship between exposure 
and toxicity, DNT is also an area representing considerable challenge for predictive toxicology. 
DNT often manifests itself in behavioural and other disturbances that are hard to model in vitro 
(Van Thriel et al., 2012) but may be studied to some extent using non-mammalian models such as 
zebrafish (Padilla et al., 2011). 
 
10.4.3 Non-mammalian models for developmental toxicity  
In recent years, there has been growing interest in the use of non-mammalian organisms, and in 
particular zebrafish embryos, as a test system for developmental toxicity, since zebrafish embryo 
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development is very similar to embryogenesis in higher vertebrates including humans (Weigt et al., 
2011; De Esch et al., 2012). Additionally, the zebrafish embryo possesses a set of convenient 
features including its small size, the rapid embryo development (major organs developed by 120 
hours post-fertilization [hpf]), transparency of the embryo, large number of eggs available, full 
DNA sequence available, and an extensive supporting data- and literature- base (Yang et al., 2009).  
An important attribute of the zebrafish embryo, from a regulatory point of view, is the fact that its 
development up to the independently feeding larval forms does not require permission by 
responsible authorities (according to the EU directive 2010/63/EU on the protection of animals used 
for scientific purposes). However, Directive 2010/63/EU only sets the minimum requirements, and 
the individual EU Member States may set stricter requirements (see also Chapter 13). The exact 
onset of the independently feeding zebrafish is a matter of debate but it is clearly recommended that 
from 120 hours post fertilisation it requires permission to be used as a laboratory animal (Strahle et 
al., 2012). The zebrafish assay has been recommended as a screening tool for the prioritization of 
chemicals (Crofton et al., 2011).  
 
10.4.4 ECVAM-validated in vitro tests for developmental toxicity 
Three in vitro methods for embryotoxicity testing have been endorsed by the ECVAM Scientific 
Advisory Committee (ESAC) as scientifically validated (ECVAM, 2002): the mouse Embryonic 
Stem cell test (EST), the Micromass assay (MM), and the whole embryo culture (WEC). The EST 
and WEC were considered valid for distinguishing between non, weak/moderate and strong 
embryotoxicants, whereas the MM was considered valid for identifying strongly embryotoxic 
chemicals.  
 
Of these three methods, the EST is the only method that does not entail the killing of animals for 
the tissue used in the assays. Although the test was formally validated additional investigations are 
needed to further define the relevance of the EST in the regulatory context. To date, the EST has 
not been accepted by the regulatory community, partly because of the unacceptably high false 
positive and negative prediction rates, and partly because of the need to improve the definition of 
the applicability domain, defined as the chemical classes and/or ranges of test method endpoints for 
which the model makes reliable predictions (Marx-Stoelting et al., 2009; Spielmann et al., 2006). 
An interesting development by researchers at Wageningen University is to combine the use of the 
EST with Physiologically Based Biokinetic (PBBK) modelling in order to derive quantitative points 
of departure in vitro, which are then extrapolated to in vivo points of departure for use in risk 
assessment (A. Punt, personal communication). 
 
While these methods cannot on their own replace animal testing, they could be potentially used as 
supporting elements in weight of evidence or read-across approaches reducing animal use. It has 
been suggested that the value of these methods could be increased by incorporating molecular-
based markers through the application of proteomic and toxicogenomic approaches (Piersma, 2006; 
van Dartel et al, 2010). The ESNATS project (see below) is exploring this possibility. 
 
10.4.5 QSAR models for developmental toxicity 
There have been a limited number of efforts aimed at developing Quantitative Structure-Activity 
Relationships (QSARs) for developmental toxicity, as reviewed elsewhere (Piparo & Worth, 2010; 
Cronin & Worth, 2008). Software tools based on QSARs include CAESAR, Derek, HazardExpert, 
MultiCASE, Leadscope, PASS and TOPKAT. Apart from the inherent difficulty of relating 
chemical structure to complex endpoints related to the reproductive cycle, modelling efforts have 
been limited by a lack of high quality datasets that can be used to train the models. In the case of 
developmental toxicity, two potentially useful databases in the public domain are the US EPA’s 
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ToxRef Database (http://www.epa.gov/NCCT/toxrefdb) and the International Life Science Institute 
(ILSI) developmental toxicity database (http://www.ilsi.org/Lists/Activities/AllItems.aspx). 
 
The only freely available software model for developmental toxicity is the CAESAR model 
(Cassano et al., 2010; http://www.caesar-project.eu), which is part of the VEGA suite. The same 
model is included in the US EPA’s The Toxicity Estimation Software Tool (T.E.S.T; 
http://www.epa.gov/nrmrl/std/qsar/qsar.html). This model was built on a data set of 292 compounds 
(Arena et al., 2004) by using a random forest modelling approach and with reference to the US 
FDA classification system which has five categories: category A means negative human studies; 
category B means negative animal studies and no human studies, or positive animal studies and 
negative human studies; category C means positive animal studies and no human studies, or no 
studies at all; category D means positive human studies; and category X means animal or human 
studies show abnormalities and/or evidence of foetal risk. To build the model, a compound was 
considered non-developmentally toxic if it had been classified under the FDA scheme in categories 
A or B, and was considered developmentally toxic if it had been classified to the categories C, D, or 
X. The usefulness of this model for the purposes of REACH and CLP has not been evaluated. 
 
In a study carried out by the JRC for EFSA (Worth et al., 2011), the predictive abilities of six 
models (Derek, CAESAR, TOPKAT, Leadscope, HazardExpert, and PASS) were evaluated against 
a dataset of 76 pesticides, an extended dataset of 135 chemicals including the 76 pesticides and 69 
additional chemicals, and a dataset of 366 pesticides from the US EPA’s ToxRef database. None of 
the models, and no two-model battery of models, was found useful in predicting the absence of 
developmental toxicity, since the negative predictivities were less than 50%. However, some QSAR 
tools, such as Derek, HazardExpert and PASS, might be useful for the identification of potential 
developmental toxicants, due to their high positive predictivities of 81-96%. A possible approach, 
demonstrated in the JRC report, is to use a stepwise assessment strategy in which QSARs are used 
in a first step to identify positives, followed by the use of read-across in a second step to identify 
negatives. The feasibility of this approach would depend on the availability of reliable data for 
analogues of the chemical of interest. 
 
With a view to developing structure-based prediction models, there have been recent efforts to 
better understand the relationship between chemical (sub)structures and toxicity pathways 
associated with reproductive toxicity. For example, based on a detailed review of 716 chemicals, 
Wu et al. (2013) have identified 25 structural groups including 5 groups assocaited with specific 
receptor-mediated interactions, and 20 more general chemical groups. The underlying structural 
alerts were arranged into a decision tree. Each step in the decision tree leads to another step or a 
final prediction (yes/no for reproductive toxicity effects). The decision tree is proposed for use in 
priority setting and in informing weight-of-evidence assessments. 
 
Another recent approach, which also provides a means of developing QSARs and grouping 
chemicals for read-across, is to use chemotypes as chemical descriptors. These are essentially 
structural alerts (SAs), but in contrast to traditional SAs, they encode information on atom-specific 
and whole-molecule physicochemical properties, providing a great capacity to identify reactivity 
and toxicity-informed chemical features. Preliminary studies have demonstrated the usefulness of 
chemotypes in predicting developmental toxicity potential (cleft lip and palate formation), as 
illustrated in a poster presentation at the 2013 SOT conference (Yang et al., 2013). Chemotypes 
have been identified for molecular initiating events in various signalling pathways whose disruption 
can lead to such developmental effects, including the hedgehog, glucocorticoid, RXR-α, Wnt, SHH, 
folate, AhR and sterol biosynthesis pathways (C. Yang, personal communication). A software tool, 
the Chemotyper, is freely available from Altamira (http://www.altamira-llc.com), for the screening 
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of datasets against a predefined set of 686 chemotypes (including chemotypes for developmental 
toxicity and other adverse outcomes).  
 
10.4.6 Pathway-based approaches and systems biology (mathematical models)  
Various mammalian and non-mammalian organisms are being explored for their usefulness as 
screening systems based on the perturbation of gene regulatory pathways by reproductive, and in 
particular developmental, toxicants. 
 
Pathway-based endpoints observed in mammalian cells can provide a means of establishing points 
of departure and enabling in vitro to in vivo extrapolation (Anderson et al., 2005). For example, 
using in vitro data on aromatase activity and mRNA levels in rat granulosa cells, Quignot and Bois 
developed a mathematical (systems biology) model that simulates the synthesis and secretion of 
steroid hormones in the rat ovary and the effects on these processes of endocrine active chemicals 
(Quignot & Bois, 2013). 
 
The use of pathway-based endpoints in non-mammalian cells is based on the fact that well-defined 
and conserved pathways involved in development are conserved across species and found in model 
organisms such as C. elegans (Goussen et al, 2013), Drosophila (Uysal et al., 2013), the zebrafish 
embryo (Perkins et al, 2013), and the sea urchin (Davidson et al., 2002; Ben-Tabou de-Leon & 
Davidson, 2007). For example, the retinol metabolism pathway is highly conserved across 
vertebrates, and perturbations to this pathway have been causally linked to developmental effects 
(skeletal deformities) in both zebrafish embryos and mammals (Laue et al, 2011). On this basis, 
Perkins et al (2013) proposed a pathway-based point-of-departure for these effects based on 
transcriptomic changes in the zebrafish embryo. They showed, for example, that the pathway based 
lowest observed effect level (LOEL) (2.8μΜ) for flusilazole-induced developmental effects in 
zebrafish embryo was ten-fold lower than the LOEL based on apical effects (>28μΜ). Key events 
(upstream of the apical effect) have been widely used as conservative points of departure (Hill et al, 
1998). 
 
10.4.7 Adverse Outcome Pathways for developmental toxicity 
The adverse outcome pathway (AOP) approach is also being explored as a basis for describing and 
predicting developmental toxicity. Examples include an AOP for paraoxon-induced effects on 
zebrafish embryogenesis (paraoxon is a reference compound for AChE inhibition) (Yozzo et al., 
2013), and an AOP linking the disruption of embryonic vascular development (for example by 
thalidomide, oestrogens, endothelins, dioxin, retinoids, cigarette smoke, and metals) to 
developmental toxicity (Knudsen & Kleinstreuer, 2011). 
 
10.4.8 Virtual embryo to model developmental toxicity 
Morphogenesis is a complex tissue phenomenon consisting of multiple processes that are controlled 
by the genome and affected by the environment (including chemicals and maternal-foetal 
interactions). The successful modelling of chemically-induced dismorphogenesis needs to describe 
multiple cell states (proliferation, differentiation, death, motility, shape, adhesivity) as well as 
spatiotemporal heterogeneities in cell viability and metabolic demands. Furthermore, a successful 
model needs to predict the cellular responses to genetic (programmed) and environmental signals, 
and the emergent morphogenetic properties associated with collective cellular behaviour. This 
represents a considerable scientific and technical challenge. 
 
The US EPA’s Virtual Embryo (v-Embryo™) research project (http://epa.gov/ncct/v-
Embryo/index.html) is applying the techniques of computational systems biology to explore the 
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feasibility of developing a mathematical model that is able to accurately predict the potential for 
environmental chemicals to affect the embryo. The initial focus of v-Embryo™ is to simulate early 
eye, vascular and limb development (Knudsen et al, 2011). The modelling is supported by data-
generating experiments using stem cells and zebrafish. 
 
10.4.9 EU research projects for reproductive toxicity 
Through its framework programme (FP) for research and development, the European Commission 
has invested substantially in developing alternative methods to animal testing for reproductive 
toxicity. In particular, three main projects have been funded.  
 
The FP6 FunGenES (Functional Genomics in Engineered ES cells) (2004-2007) project contributed 
to characterisation of the molecular mechanisms underlying differentiation of embryonic stem cells 
to somatic cells, which constitutes the basis for further use of these cells for toxicity testing.  While 
this was a toxicology project not directly focused on developmental toxicity, it developed an 
understanding of embryonic stem cell self-renewal, differentiation and lineage commitment to 
different organ-specific cells, including the identification of target genes for therapeutic 
intervention. In addition, new cellular and molecular tools were developed to characterise gene 
function in tissue-specific cell populations (functional genomics), along with new embryonic stem 
cell-based approaches to screening of small candidate molecules for therapeutic applications in 
human diseases. 
 
The FP6 ReProTect project (2004-2009) consisted of a consortium of 32 EU organizations with the 
aim of developing and optimising in vitro test methods in the area of reproductive toxicology 
(http://www.reprotect.eu). The project made advances on 15 in vitro tests that target adverse effects 
on mammalian female and male fertility and reflect various toxicological mechanisms such as 
effects on Leydig and Sertoli cells, folliculogenesis, germ cell maturation, sperm cell motility, 
steroidogenesis, the endocrine system, fertilisation, and on the pre-implantation embryo. The 
project aimed to define better the applicability domain of the validated embryonic stem cell test by 
testing additional substances.. Proteome analyses performed on mouse and human embryonic stem 
cells treated with selected chemicals during neuronal and cardiac differentiation were conducted in 
order to select biomarkers with a higher predictivity. In parallel, an integration of a metabolic 
system into the embryonic stem cell test (EST) was put forward. A special issue of Reproductive 
Toxicology summarises key results of the ReProTect project (Piersma et al., 2010). 
 
The development/optimisation of each test was performed according to the ECVAM modular 
approach and the INVITTOX protocols of the assays were made available. Besides, an independent 
statistical evaluation of the raw data has evaluated the reproducibility of the developed tests. The 
EST is now being challenged by testing newly selected compounds and using the previously 
developed standard operating procedures and new read-out technologies. 
 
An ECVAM/ReProTect workshop was organised in 2008 to discuss the status and future of the 
various derivatives of the EST assay, in order to identify how much flexibility can be introduced to 
the in vitro tests based on embryonic stem cells and their applicability for regulatory decision 
making. The outcome of the workshop was published in 2009 (Marx-Stoelting et al., 2009), in 
which conclusions and recommendations were made concerning the need to add a metabolic system 
to the EST, and the possibility to add new endpoints, including additional cell differentiation 
endpoints (in non-cardiac tissues), and new molecular markers (using omics and reporter gene 
assays) for toxic effects on embryonic development. 
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The FP7 ESNATS (Embryonic Stem cell-based Novel Alternative Testing Strategies) project 
(2007-2013) is developing a battery of toxicity tests based on embryonic stem cells (ESCs), in 
particular human ESC (hESCs), with a view to accelerating drug development and reducing related 
R&D costs (http://www.esnats.eu). ESNATS has established in vitro systems that recapitulate 
different critical periods of human early neuronal development. 
 
The FP7 ChemScreen (Chemical substance in vitro/in silico screening system to predict human- 
and ecotoxicological effects) project (2010-2013) aims  to generate a simple, rapid screening 
system for reproductive toxic chemicals, capable of being performed within the timeframe of the 
REACH implementation (http://www.chemscreen.eu). Unlike other EU-funded projects, 
ChemScreen places more emphasis to the development and integrated use of in silico and in vitro 
methods as a means of identifying potential reproductive toxicants. A High Throughput Screening 
(HTS) panel comprises in vitro assays expressing reporter genes associated with a wide range of 
signalling pathways potentially involved in reproductive toxicity. In addition to these HTS methods, 
assays are being established in more complex, differentiated cells such as murine ES cells by 
introducing reporter systems for signalling pathways controlling key differentiation pathways in 
embryonic development (Wnt/, SHH-, TGFβ-,  Delta/Notch-, and the RTK-signalling pathway). 
Furthermore, PBBK models are being developed to translate in vitro concentrations to in vivo dose 
levels. 
 
10.5 Conclusions  
Information on reproductive toxicity is required for the purposes of REACH, the Biocidal Products 
Regulation, Plant Protection Products Regulation and the CLP regulation. Since the assessment of 
these endpoints requires a considerable number of animals and testing costs are high, it is a priority 
area for the development of alternative methods. However, it is also one of the most challenging 
from both scientific and technical points of view.  
 
Currently available in vitro models cover only a small part of the reproductive cycle, with many 
steps not being covered at all. These in vitro tests range from cell-based models, including primary 
cultures and stem cells, to organ cultures, and whole embryo cultures. Recent work has also 
highlighted the value of non-mammalian species as model organisms, and in particular zebrafish 
embryos. 
 
A few QSAR models have been developed for endpoints related to developmental toxicity, but 
these do not provide information that is directly applicable in regulatory decision making. The 
recent use of chemotypes in developing mechanistic QSARs should prove useful in the screening of 
chemical inventories for specific positive effects (such as the potential for cleft palate formation). 
 
In conclusion, currently available in vitro tests and QSAR models may be useful for screening 
chemical inventories and identifying positives (priority setting). In addition, they may be useful 
elements for supporting chemical grouping and read-across, and weight-of-evidence assessments. 
However, these latter applications need to be evaluated on a case-by-case basis.  
 
The challenge in replacing animal tests for the effects on fertility and developmental toxicity is that 
many possible organs and physiological processes can be affected, and knowledge of the underlying 
regulatory networks and the possible impacts of their perturbation is limited. However, increasing 
the body of knowledge about key events of the reproductive cycle leading to adverse effects is 
expected to provide a basis for understanding the multiple disruption mechanisms and their 
interactions, and for translating this knowledge into test systems at least for some parts of the 
  275
reproductive cycle. In reproductive toxicity it is challenging to capture in a test system even the 
most relevant separate and interrelated endpoints. 
 
The current approach of developing in vitro tests to mimic some key elements  of the reproductive 
cycle has led to the development of many potentially useful “building blocks”, but these have still a 
number of limitations. For example, the lack of metabolic competence in many in vitro systems 
needs to be compensated by addition of metabolizing systems. Other limitations reflect the absence 
of whole animal physiology and cannot be captured by individual test methods, but rather by an 
integrated approach. For example, for the purposes of risk assessment, a range of biokinetic 
(ADME) parameters (in addition to metabolism) need to be measured or computed, and integrated 
by means of PBBK models. This may allow toxicologically relevant points of departure to be 
derived from in vitro concentration-response curves to be extrapolated from in vitro to in vivo.  
 
Integrated approaches testing and assessment will need to integrate both in vitro (in particular cell-
based assays) and computational tools (in particular QSARs and PBBK models). Based on the 
current state of the art, it is not anticipated that such testing strategies will completely replace the 
need to assess reproductive toxicity in vivo. However, they could provide a means to reduce animal 
testing. 
 
Finally, the premise that it is sufficient to mimic key parts of the reproductive cycle can be 
questioned. In other words, the toxic effects of chemicals on reproduction are more than the sum of 
multiple cellular effects. 
 
In the longer-term, the increased use of mechanistically-based in in vitro tests, for example cell-
based assays expressing signalling pathways associated with reproductive processes, along with the 
development of systems biology-based mathematical models to perform in vitro to in vivo 
extrapolations, may provide   reliable means supporting risk assessment and classification and 
labelling. 
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Table 10.2. Alternative methods for reproductive toxicity testing   
 
Method Test system Description Applicability Status 
Embryonic stem cell test 
(EST) 
Embryonic stem 
cell line 
Based on the assumption that chemicals with 
embryotoxic potential block the spontaneous 
development of embryonic stem cells into beating 
cardiac muscle cells within the first 10 days of 
embryonic development.  
 
Endpoints: 
• cell differentiation 
• cell viability 
• cell proliferation 
Suitable for screening the 
potential embryotoxic 
effects of substances, 
classifying them into 
three major classes:  
• non-embryotoxic;  
• weakly embryotoxic; 
and  
• strongly embryotoxic. 
 
ESAC statement 
(ECVAM, 2002) 
Micromass test (MM) Limb bud cells 
and/or neuronal 
cells 
The cells are isolated from the limb or the cephalic 
tissues of mid-organogenesis embryos. The viability 
and differentiation after exposure to test chemicals is 
analysed.  
 
Endpoints: 
• cell differentiation 
• cell viability 
• cell number 
• cell growth 
Suitable for screening the 
potential embryotoxic 
effects of substances, 
classifying them into 
three major classes: 
• non-embryotoxic;  
• weakly embryotoxic; 
and  
• strongly embryotoxic 
Additionally, the method 
is suggested for the 
monitoring of 
development within a 
period and/or within 
defined organ system. 
ESAC statement 
(ECVAM, 2002) 
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Method Test system Description Applicability Status 
Rodent post-
implantation whole 
embryo culture (WEC) 
Rat embryos Rat embryos are cultured during organogenesis in 
vitro and treated with test chemicals.  
 
Endpoints: 
• Embryo Morphology 
• Embryo Functionalities 
• Embryo Growth 
• Cell viability 
Suitable for identifying 
strongly embryotoxic or 
compounds causing 
malformations during the 
organogenesis in a 
complete mammalian 
embryo (an intact embryo 
is exposed in vitro, 
allowing the study of 
malformations). 
ESAC statement 
(ECVAM, 2002) 
Zebrafish embryo 
teratogenicity assay 
Fertilised 
zebrafish (Danio 
rerio) eggs 
The method uses the fertilised fish eggs that are 
exposed to different concentrations of a test substance. 
At different time points, the exposed developing fish 
embryos are observed and scored for lethal, 
embryotoxic and/or teratogenic effects.  
 
Endpoints: 
• lethality 
• malformations  
• growth retardation 
The method is used as a 
screening tool for potency 
to induce malformations, 
but also as a means of 
investigating specific 
mechanisms related to the 
induced malformations 
with certain substances. 
Optimisation  
Frog embryo 
teratogenesis assay 
xenopus (FETAX) 
Whole frog 
(Xenopus 
laevis) embryo 
FETAX is a whole embryo screening assay, based on 
frog Xenopus laevis, to identify substances (assessed 
at different time points) that may pose a 
developmental hazard in humans.  
 
Endpoints: 
• lethality 
• growth  
• retardation  
• malformations  
 
FETAX encompasses 
organogenesis and does 
not include later events of 
development. 
Optimisation 
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Method Test system Description Applicability Status 
Chicken embryotoxicity 
screening test (CHEST) 
Chicken 
embryo 
The chicken embryotoxicity screening test determines 
the toxic dose range in very early administration time 
(24 h) and the teratogenic dose range and covers late 
effects on the embryo development (days 2, 3 and 4). 
Endpoints: 
• mortality,  
• malformations,  
• embryo development,  
• blood vessel development  
• blood vessel coloration. 
Routine embryotoxicity 
screening and 
mechanistic studies 
Optimisation 
Placental perfusion assay Human placenta  Human ex vivo placental perfusion which is set up 30 
min. following the birth. To assess the transfer of 
substances from the maternal to the foetal side of the 
syncytiotrophoblast and to investigate molecular 
mechanisms of genotoxic compounds.  
Endpoints: 
• Transplacental transfer rate of compounds  
It serves to investigate the 
risks of foetal exposure to 
chemical compounds 
during pregnancy 
Optimisation  
Trophoblast cell assay BeWo human 
trophoblast cell 
line 
An assay that uses BeWo human trophoblast cell line, 
which have preserved many of the trophoblastic 
properties. It is considered as an appropriate in vitro 
system to investigate placenta transport. 
Endpoints: 
• Transplacental transfer rate of compounds  
 
It evaluates the placental 
transport of compounds 
during implantation and 
pregnancy.   
R&D 
Leydig Cell Assay Leydig cell line 
BLT1-L17 
The Leydig cell line BLT1-L17 has been developed to 
assess the disturbance of the endocrine system due to 
effects of chemicals. 
Endpoints: 
• Viability 
Toxicity assessment 
during spermatozoa 
development, with 
possible implications on 
fertility. 
R&D 
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Method Test system Description Applicability Status 
• Growth 
• Testosterone production 
 
 
Sertoli 3-D cell system Combination of 
sertoli and germ 
cells 
In vitro 3-D test model that replicates the composition, 
organization and functions of in vivo rat blood-testis 
barrier. The assay uses a combination of sertoli and 
germ cells.  
Endpoints: 
• Viability 
• Growth 
• Inhibin B production 
Hazard identification that 
might lead to fertility 
impairments 
R&D 
 
Comet and ReProComet 
Assay 
Sperm cells The sperm cells are incubated with the test compound 
for 2 hours followed by flow cytometric analysis. 
Endpoints: 
• Viability 
• Morphology  
• DNA fractions 
For the detection of 
chemically induced DNA 
damage in bull sperm 
with possible 
implications on male 
fertility 
 
Optimisation 
 
Computer Assisted 
Sperm Analysis (CASA) 
Spermatozoa 
 
Automated method to visualize and and evaluate 
consecutive images of viable sperms to obtain precise 
and valid information on the kinematics of individual 
sperms. 
 
Endpoints: 
• Spermatozoa viability, motility, velocity, 
motion, morphology 
• Metabolic effects 
Monitor effects of 
chemicals on 
spermatozoa with 
possible implications on 
fertility 
Optimisation 
Follicle culture bioassay 
(FBA) 
Mouse pre-antral 
follicles 
Mechanically isolated mouse pre-antral follicles are 
cultured in vitro until the pre-ovulatory phase 
followed by in vitro ovulation and maturation of the 
Evaluation of chemicals 
during folliculogenesis, 
steroidogenesis and 
Optimisation 
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Method Test system Description Applicability Status 
oocyte. During the growth period the follicle is 
exposed to chemicals in an acute or chronic manner.  
Endpoints: 
 
Follicle: 
• Viability 
• Steroid production 
• Differentiation 
Oocyte: 
• Spindle analysis 
• Growth 
• Nuclear maturation 
oogenesis 
In vitro bovine oocyte 
maturation assay (bIVM) 
Bovine 
cumulus/oocytes 
complexes 
Monitors the potential adverse effects of chemicals to 
the maturation process of bovine oocytes. The assay is 
focused on nuclear configuration changes within the 
oocyte. 
Endpoints: 
Successful achievement of the maturation stage of 
meiosis up to metaphase II 
To identify chemicals 
which impair the 
completion of the 
maturation process of a 
mammalian oocyte.  
Optimisation 
Mouse Peri-Implantation 
Assay (MEPA) 
Mouse zygotes In vitro cultures of mouse zygotes are used and the 
embryo development is observed daily in order to 
identify any deviations of the timely regulated pre-
implantation embryo. 
Endpoints: 
• Morphology 
• Viability 
• Blastocyst rate (number of blastocysts 
produced) 
• Hatching capacity 
In vitro bioassay that 
allows studying the effect 
of compounds on the 
development of the pre-
implantation embryo. 
 
Optimisation   
In vitro bovine Bovine Monitors the effects of chemicals on the formation of Toxicity assessment Optimisation 
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Method Test system Description Applicability Status 
fertilization assay (bIVF) cumulus/oocytes 
complexes and 
cryopreserved 
bovine sperm.  
male and female pronuclei after the penetration of 
sperm in the oocyte. Oocyte and sperm are exposed to 
test chemicals.  
Endpoints: 
•  Presence of the sperm head into the oocyte 
•  Presence of two well-formed pronuclei, two 
polar bodies and the sperm tail. 
 
during oocyte fertilization 
process, with possible 
implications on fertility 
  287 
 
Chapter 10. Table of References with Notes 
EU legislation 
REACH Regulation (EC No 1907/2006) Studies on reproductive and developmental toxicity are required from Annex VIII 
onwards, i.e. for all substances marketed or manufactured in quantities above 10 
t/a. From Annex VIII through X, the standard information requirements are 
cumulative; requirements at higher tonnage levels add to the information 
requirements at lower tonnage levels. Standard information requirements include 
a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII, a 
prenatal developmental toxicity study (EU TM B.31 on first species at Annex IX, 
a two-generation reproductive toxicity study (EU TM B.35) and prenatal 
developmental toxicity study on an second species at Annex X (if not conducted 
already at Annex IX). Taken together, at Annex X level, information on 
reproduction toxicity could be available from a screening reproductive toxicity 
study, prenatal developmental toxicity studies on two species, two-generation 
reproductive toxicity study, as well as from repeated dose toxicity studies. 
Regulation concerning the marketing and use of biocidal products (EU 
No 528/2012) 
A biocidal product shall not be authorised for use by the general public where it is 
classified as toxic for reproduction category 1 or 2 (Directive 1999/45/EC); toxic 
for reproduction category 1A or 1B under Regulation (EC) No 1272/2008; or it 
has developmental neurotoxic or immunotoxic effects. 
 
From the legislation "8.10. Reproductive toxicity … For evaluation of consumer 
safety of active substances that may end up in food or feed, it is necessary to 
conduct toxicity studies by the oral route. 
 
If a substance is known to have an adverse effect on fertility, meeting the criteria 
for classification as Reproductive toxicity Cat 1A or 1B: May damage fertility 
(H360F), and the available data are adequate to support a robust risk assessment, 
then no further testing for fertility will be necessary. However, testing for 
developmental toxicity must be considered if a substance is known to cause 
developmental toxicity, meeting the criteria for classification as Reproductive 
toxicity Cat 1A or 1B: May damage the unborn child (H360D), and the available 
data are adequate to support a robust risk assessment, then no further testing for 
developmental toxicity will be necessary. However, testing for effects on fertility 
must be considered. 
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8.10.1. Pre-natal developmental toxicity study, preferred species is rabbit; oral 
route of administration is the preferred route. The study shall be initially 
performed on one species.  
 
8.10.2. Two-generation reproductive toxicity study, rat, oral route of 
administration is the preferred route. If another reproductive toxicity test is used 
justification shall be provided. The extended one-generation reproductive toxicity 
study adopted at OECD level shall be considered as an alternative approach to the 
multi-generation study. 
 
8.10.3. Further pre-natal developmental toxicity study. A decision on the need to 
perform additional studies on a second species or mechanistic studies should be 
based on the outcome of the first test (8.10.1) and all other relevant available data 
(in particular rodent reproductive toxicity studies). Preferred species is rat, oral 
route of administration  
 
For repeated dose toxicity and reproductive toxicity the dose-response 
relationship shall be assessed for each active substance or substance of concern 
and, where possible, a NOAEL identified. If it is not possible to identify a 
NOAEL, the lowest-observed-adverse-effect level (LOAEL) shall be identified. 
Where appropriate, other dose-effect descriptors may be used as reference 
values." 
Regulation on Plant Protection Products (EC No 1107/2009) An active substance, safener or synergist shall only be approved if, on the basis of 
assessment of reproductive toxicity testing carried out in accordance with the data 
requirements for the active substances, safeners or synergists and other available 
data and information, including a review of the scientific literature, reviewed by 
EFSA, it is not or has not to be classified, in accordance with the provisions of 
Regulation (EC) No 1272/2008, as toxic for reproduction category 1A or 1B, 
unless the exposure of humans to that active substance, safener or synergist in a 
plant protection product, under realistic proposed conditions of use, is negligible, 
that is, the product is used in closed systems or in other conditions excluding 
contact with humans and where residues of the active substance, safener or 
synergist concerned on food and feed do not exceed the default value set in 
accordance with point (b) of Article 18(1) of Regulation (EC) No 396/2005. 
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From the Comission Regulation (EU) No 283/2013 of 1 March 2013 setting out 
the data requirements for active substances, in accordance with Regulation (EC) 
No 1107/2009:  
 
"5.6 Reproductive Toxicity: 
Possible effects on reproductive physiology and the development of progeny shall 
be investigated and reported concerning the following aspects: 
• Impairment of male and female reproductive functions or capacities […] 
• Harmful effects on the progeny, for example any effect interfering with 
normal development both before and after birth. […] 
Effects accentuated over generations shall be reported. 
The active substance and its relevant metabolites shall be measured in milk as a 
second tier investigation where relevant effects are observed in the offspring or 
are expected. […] 
 
Potential neurotoxic, immunotoxic effects and effects potentially related to 
changes in the hormonal system shall be carefully addressed and reported. 
 
Investigations shall take account of all available and relevant data, including the 
results of general toxicity studies if relevant parameters […] are included, as well 
as knowledge concerning structural analogues to the active substance.  
 
While the standard reference point for treatment responses shall be concurrent 
control data, historical control data may be helpful in the interpretation of 
particular reproductive studies. […] 
 
5.6.1 Generational studies 
[…] A reproductive toxicity study in rats over at least two generations shall be 
reported.  
The OECD extended one-generation reproductive toxicity study may be 
considered as an alternative […] 
Where necessary for a better interpretation of the effects on reproduction and as 
far as this information is not yet available, supplementary studies may be required 
to provide information on the affected gender and the possible mechanisms. 
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5.6.2. Developmental toxicity studies 
[…] Developmental toxicity studies shall always be carried out. 
Developmental toxicity shall be determined for rat and rabbit by the oral route; 
the rat study shall not be conducted if developmental toxicity has been adequately 
assessed as part of and extended one-generation reproductive toxicity study. 
Additional routes may be useful in human risk assessment. […] 
 
When indicated by observations in other studies or the mode of action of the test 
substance, supplementary studies or information may be required to provide 
information on the postnatal manifestation of effects such as developmental 
neurotoxicity." 
Cosmetics: Directive 76/768/EEC and Regulation (EC) No 1223/2009  Introduction of the directive resulted in an instant ban on the animal testing of 
finished consumer products, which in March 2009, was extended to a ban on the 
animal testing of cosmetic ingredients, irrespective of the availability of 
alternative methods. Since March 2013, a marketing ban has been in place to 
reinforce this prohibition. 
Regulation (EC) No 1272/2008 on Classification, Labelling and 
Packaging 
Aligns previous EU legislation on classification, packaging and labelling 
(Dangerous Substance Directive 67/548/EEC) of chemicals with the GHS 
(Globally Harmonized System of Classification and Labelling of Chemicals). In 
addition to the differences in the hazard statements that now begin with “H” 
instead of the old “R” phrases, a very important revolution is in place: submitters 
are now fully responsible for the classification and assessment of the chemical 
substances that they either manufacture or import into the EU. CLP still contains 
in its Annex I a full list of chemicals with mandatory harmonized classification, 
but it is explicitly required that whenever a new hazard is known, it must be 
immediately communicated to downstream users and consumers. 
US legislation 
Guidelines for Developmental Toxicity Risk Assessment. 
 
http://epa.gov/ncct/v-
Embryo/files/EPA_Guidelines_Developmental_Toxicity.pdf?p_downl
oad_id=4560 
 
The U.S. Environmental Protection Agency (EPA) is today issuing final amended 
guidelines for assessing the risks for developmental toxicity from exposure to 
environmental agents. As background information for this guidance, this notice 
describes the scientific basis for concern about exposure to agents that cause 
developmental toxicity, outlines the general process for assessing potential risk to 
humans because of environmental contaminants, summarizes the history of these 
guidelines, and addresses public and Science Advisory Board comments on the 
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1989 “Proposed Amendments to the Guidelines for the Health Assessment of 
Suspect Developmental Toxicants” [54 FR 9386-9403]. These guidelines, which 
have been renamed “Guidelines for Developmental Toxicity Risk Assessment” 
(hereafter “Guidelines”), outline principles and methods for evaluating data from 
animal and human studies, exposure data, and other information to characterize 
risk to human development, growth, survival, and function because of exposure 
prior to conception, prenatally, or to infants and children. These Guidelines 
amend and replace EPA’s 1986 “Guidelines for the Health Assessment of Suspect 
Developmental Toxicants” [51 FR 34028-34040] by adding new guidance on the 
relationship between maternal and developmental toxicity, characterization of the 
health-related database for developmental toxicity risk assessment, use of the 
reference dose or reference concentration for developmental toxicity (RfDDT or 
RfCDT), and use of the benchmark dose approach. 
In addition, the Guidelines were reorganized to combine hazard identification and 
dose-response evaluation since these are usually done together in assessing risk 
for human health effects other than cancer. 
Guidelines for Reproductive Toxicity Risk Assessment 
Published on October 31, 1996, Federal Register 61(212): 56274-
56322 
http://www.epa.gov/raf/publications/pdfs/REPRO51.PDF 
 
(This document replaces the proposed guidelines for Female 
Reproductive Risk and Proposed guideline for Male Reproductive 
Risk, both dated June 30, 1988.) 
"The U.S. Environmental Protection Agency (EPA) published a document 
entitled Guidelines for Reproductive Toxicity Risk Assessment (hereafter 
"Guidelines”). These Guidelines were developed as part of an interoffice 
guidelines development program by a Technical Panel of the Risk Assessment 
Forum. They were proposed initially in 1988 as separate guidelines for the female 
and male reproductive systems. Subsequently, based upon the public comments 
and Science Advisory Board (SAB) recommendations, changes made included 
combining those two guidelines, integrating the hazard identification and dose-
response sections, assuming as a default that an agent for which sufficient data 
were available on only one sex may also affect reproductive function in the other 
sex, expansion of the section on interpretation of female endpoints, and 
consideration of the benchmark dose approach for quantitative risk assessment. 
These Guidelines were made available again for public comment and SAB review 
in 1994. This notice describes the scientific basis for concern about exposure to 
agents that cause reproductive toxicity, outlines the general process for assessing 
potential risk to humans from exposure to environmental agents, and addresses 
Science Advisory Board and public comments on the 1994 Proposed Guidelines 
for Reproductive Toxicity Risk Assessment. Subsequent reviews have included the 
Agency’s Risk Assessment Forum and interagency comment by members of 
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subcommittees of the Committee on the Environment and Natural Resources of 
the Office of Science and Technology Policy."  
OECD TGs 
OECD TG 414: prenatal development toxicity study for the testing of 
chemicals (OECD 2001) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
Studies the effects of prenatal exposure on the pregnant animal and on the 
developing organism; this may include assessment of maternal effects as well as 
death, structural abnormalities, or altered growth in the foetus. 
Period considered: from preimplantation to the day before birth. 
– Endpoints: litter composition (e.g. resorptions, live, dead foetuses), 
embryonic development, foetal growth, morphological variations and 
malformations. Functional deficits are not considered. 
Species: rodent (preferably rat) and non-rodent (preferably rabbit). 
 
Standard information requirement for substance under REACH, active substances 
under Biocide Products Regulations and Regulation on Plant Protection Products.  
OECD TG 415: one-generation reproduction toxicity study (OECD 
1983) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
OECD TG 415 is designed to provide general information concerning the effects 
of a test substance on male and female reproductive performance. Studies the 
effects on male and female reproductive performance, such as gonadal function, 
oestrous cycle, mating behaviour, conception, parturition, lactation and weaning. 
It may also provide preliminary information about developmental toxic effects, 
such as neonatal morbidity, mortality, behaviour and teratogenesis and to serve as 
a guide for subsequent tests. 
Period considered: continuously over one generation. 
Endpoints: growth, development and viability; pregnancy length and birth 
outcome; histopathology of sex organs and target organs; and fertility. 
Preferred species: rat or mouse 
OECD TG 416: two-generation reproduction toxicity (OECD 2001) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
Studies the effects of a substance on the integrity and performance of the male 
and female reproductive systems, and on the growth and development of the 
offspring, including gonadal function, the oestrus cycle, mating behaviour, 
conception, gestation, parturition, lactation, and weaning, and the growth and 
development of the offspring. It may provide information on neonatal morbidity, 
mortality, and preliminary data on prenatal and postnatal developmental toxicity. 
Period considered: continuously over two or several generations. 
Endpoints: growth, development and viability; pregnancy length and birth 
outcome; histopathology of sex organs and target organs; fertility; and oestrus 
cyclicity and sperm quality. 
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Preferred species: the rat. 
Standard information requirement for substances under REACH, active 
substances under Biocide Products Regulation, and Regulation on Plant 
Protection Products.  
OECD TG 421: reproduction/developmental toxicity screening test 
(OECD 1995) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
OECD TG 421 can be used to provide initial information on possible effects on 
reproduction and/or development. This test does not provide complete 
information on all aspects of reproduction and development. Generates 
preliminary information concerning the effects of a substance on male and female 
reproductive performance such as gonadal function, mating behaviour, 
conception, development of the conceptus and parturition. It is not an alternative 
to, nor does it replace the Test Guidelines 414, 415 and 416. Positive results are 
useful for initial hazard assessment and contribute to decisions with respect to the 
necessity and timing of additional testing. 
Period: from 2 weeks prior to mating until day 4 postnatally. 
Endpoints: fertility; pregnancy length and birth outcome; histopathology of sex 
organs and target organs; foetal and pup growth and survival until day 3. 
Preferred species: the rat. 
Standard information requirement under the REACH regulation. 
OECD TG 422: combined repeated dose toxicity study with the 
reproduction/developmental toxicity screening test (OECD 1996) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
OECD TG 422 provides information on the possible health hazards likely to arise 
from repeated exposure over a relatively limited period of time. It also can be 
used to provide initial information on possible effects on male and female 
reproductive performance. This test does not provide complete information on all 
aspects of reproduction and development. Apart from gonadal function, mating 
behaviour, conception, development of the conceptus and parturition, the 
Guideline also places emphasis on neurological effects. 
Useful as part of the initial screening of chemicals for which little or no 
toxicological information is available and can serve as an alternative to 
conducting two separate tests for repeated dose toxicity (TG 407) and 
reproduction/developmental toxicity (TG 421), respectively. It can also be used as 
a dose range finding study for more extensive reproduction/developmental 
studies, or when otherwise considered relevant. It will not provide evidence for 
definite claims of no reproduction/developmental effects. 
Period: from 2 weeks prior to mating until day 4 postnatally. 
Endpoints: fertility; pregnancy length and birth outcome; histopathology of sex 
organs and target organs and brain; foetal and pup growth and survival until day 
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3. 
Preferred species: the rat. 
Alternative to standard requirement for 28 day repeated dose toxicity study and 
OECD TG 421 under the REACH regulation. 
OECD test guideline 426: developmental neurotoxicity study (OECD 
2007) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
Study the potential functional and morphological effects on the developing 
nervous system of the offspring of repeated exposure to a substance during in 
utero and early postnatal development. It can be conducted as a separate study, 
incorporated into a reproductive toxicity and/or adult neurotoxicity study (e.g. TG 
415, 416, 424), or added onto a prenatal developmental toxicity study (e.g. TG 
414). 
Period: during pregnancy and lactation.  
Endpoints: pregnancy length and birth outcome; physical and functional 
maturation; behavioural changes due to CNS and PNS effects; and brain weights 
and neuropathology. 
Preferred species: the rat. 
It is only regulatory required for the evaluation of agrochemicals and as an 
additional data set in Biocide Products Regulation. . 
OECD test guideline 440: uterotrophic bioassay in rodents: a short-
term screening test for oestrogenic properties (OECD 2007) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
This in vivo test in immature or ovariectomised animals evaluates the ability of a 
chemical to elicit biological endocrine disruption activities consistent with 
agonists or antagonists of natural oestrogens (e.g. 17b-estradiol). It is based on 
the increase in uterine weight or uterotrophic response. The uterus responds to 
oestrogens with an increase in weight due to water imbibition, followed by a 
weight gain due to tissue growth. 
Endpoint: uterotrophic response to oestrogens. 
Preferred species: rat (or mature mice). 
OECD test guideline 441: Hershberger bioassay in rats: a short-term 
screening assay for (anti-) androgenic properties (OECD 2009) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
This in vivo test in non-intact animals evaluates the ability of a chemical to elicit 
biological endocrine disruption activities consistent with androgen agonists, 
antagonists or 5 α-reductase inhibitors.  
Endpoints: changes in weight of five androgen-dependent tissues in the castrate-
peripubertal male rat 
Preferred species: the rat. 
OECD test guideline 443: extended one-generation reproductive 
toxicity study (OECD 2011) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
This study has a flexible modular study design with cohorts for 
reproductive/developmental toxicity (Cohorts 1A and 1B), developmental 
neurotoxicity (Cohorts 2A and 2B), and developmental immunotoxicity (Cohort 
3). Cohort 1B may be extended to include mating of the F1 animals and 
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 production of F2 generation. The study focuses on effects on F1 animals and it is 
optimised to assess effects related to certain endocrine modes of action.  
 Shall be considered as an alternative approach to multi-generation study in 
Biocide Products Regulation. 
OECD test guideline 455: the stably transfected human oestrogen 
receptor-a transcriptional activation assay for detection of oestrogenic 
agonist-activity of chemicals (OECD 2009c) 
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-
testing-of-chemicals-section-4-health-effects_20745788 
 
This in vitro assay evaluates the transcriptional activation mediated by the hERa 
of oestrogen responsive genes, a process considered to be one of the key 
mechanisms of possible endocrine disruption related health hazards. The assay 
provides mechanistic information and can be used for screening and prioritisation 
purposes of oestrogenic compounds. 
Endpoint: induction of hERa-mediated transactivation of luciferase gene 
expression. 
Test system: the hERa-HeLa-9903 cell line derived from a human cervical 
tumour and stably transfected. 
It is only used in some cases for cosmetic testing. 
Mechanistic understanding 
Perkins EJ, Ankley GT, Crofton KM, Garcia-Reyero N, Lalone CA, 
Johnson MS, Tietge JE & Villeneuve DL (2013). Current perspectives 
on the use of alternative species in human health and ecological hazard 
assessments. Environmental Health Perspectives 121: 1002–1010 
The authors reviewed and compared data spanning from high throughput in vitro 
assays to fish reproductive tests for seven chemicals and further investigated 
whether human-focused assays can be predictive of chemical hazards in the 
environment. By using several examples, the authors demonstrate that pathway-
based analysis of chemical effects provides new opportunities to use alternative 
models (non-mammalian species, in vitro tests) to support decision making while 
reducing animal use and associated costs. The authors postulate that, using a 
pathway-based hazard assessment approach, data from multiple species and non-
animal alternative models are equally valuable for both ecological and human 
health hazard assessment. Likewise, the paper describes how alternative models 
can be predictive of effects of human health concern (e.g., endocrine disruption) 
and link chemicals to toxicity pathways, or modes of action, in both mammals 
and ecological species. Finally, the way how dose-dependent effects in alternative 
models can be translated using a pathway-based measure to chemical hazard 
levels that are similar to those generated using mammalian species in chronic 
tests is documented. By these examples the authors highlight the scientifically 
credible foundation that supports the predictive application and/or extrapolation 
of pathway-based toxicological data across species. 
Van Dartel, D. a M., & Piersma, A. H. (2011). The embryonic stem 
cell test combined with toxicogenomics as an alternative testing model 
In the present review, the progress made with regard to the prediction of 
developmental toxicity using the EST combined with transcriptomics is 
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for the assessment of developmental toxicity. Reproductive toxicology, 
32(2), 235–44.  
presented. Furthermore, the developments of additional aspects required for 
further optimization of the EST, including kinetics, the use of human embryonic 
stem cells (ESC) and computational toxicology are discussed. Finally, the current 
and future use of the EST model for prediction of developmental toxicity in 
testing strategies and in regulatory toxicity evaluations is discussed. 
Yozzo, K. L., McGee, S. P., & Volz, D. C. (2013). Adverse outcome 
pathways during zebrafish embryogenesis: a case study with paraoxon. 
Aquatic toxicology , 126, 346–54. 
The objective of this study was to develop an adverse outcome pathway (AOP) 
that provided quantitative linkages across levels of biological organization during 
zebrafish embryogenesis. Using a well-studied reference chemical, this study 
highlights the potential challenges in developing quantitative AOPs to support 
chemical screening and prioritization strategies.  
De Esch, C., Slieker, R., Wolterbeek, A., Woutersen, R., & de Groot 
D. (2012). Zebrafish as a potential model for developmental 
neurotoxicity testing: A mini review. Neurotoxicology and Teratology, 
34: 545-553. 
The zebrafish is a powerful toxicity model; biochemical assays can be combined 
with observations at a structural and functional level within one individual. This 
mini review summarises the potency of zebrafish as a model for developmental 
neurotoxicity screening, and its possibilities to investigate working mechanisms 
of toxicants. The use of zebrafish in toxicity research can ultimately lead to the 
refinement or reduction of animal use. 
In vitro test methods 
Louisse, J., Verwei, M., Woutersen A. R., Blaauboer J. B., Rietjens 
MCM. I. (2012). Toward in vitro biomarkers for developmental 
toxicity and their extrapolation to the in vivo situation. Expert Opin 
Drug Metab Toxicol, 8(1), 11-27 
 
The present review gives an overview of alternative assays, as described in the 
literature, for in vivo developmental toxicity, including the effects (readouts) 
assessed in these assays. The authors discuss how these data may be used to 
obtain relevant biomarkers for in vivo developmental toxicity, and how in vitro 
effect data can be translated to the in vivo situation using physiologically based 
kinetic (PBK) modelling.  
 
Relevance of readouts in in vitro developmental toxicity assays as predictive 
biomarkers for in vivo developmental toxicity should be evaluated by comparing 
the obtained in vitro effect concentrations with in vivo internal concentrations at 
dose levels causing developmental toxicity. Extrapolation of the in vitro effect 
concentrations to in vivo dose levels using PBK modelling (i.e., reverse 
dosimetry) is promising in its use to derive points of departure for risk 
assessment, enabling the use of in vitro toxicity data in the safety assessment of 
compounds. 
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Adler, S., Basketter, D., Creton, S., Pelkonen, O., Van Benthem, J., 
Zuang, V., et al. (2011). Alternative (non-animal) methods for 
cosmetics testing: current status and future prospects-2010. Archives of 
Toxicology 85: 367–485.  
This report provides the findings of a panel of scientific experts tasked with 
assessing the availability of alternative methods to animal testing in view of the 
full marketing ban for cosmetic products and ingredients tested on animals in 
Europe. 
Theunissen, Peter T, Robinson, J. F., Pennings, J. L. a, De Jong, E., 
Claessen, S. M. H., Kleinjans, J. C. S., & Piersma, A. H. (2012). 
Transcriptomic concentration-response evaluation of valproic acid, 
cyproconazole, and hexaconazole in the neural embryonic stem cell 
test (ESTn). Toxicological sciences: an official journal of the Society 
of Toxicology 125: 430–438.  
 
The concentration-dependent effects of three known (neuro) developmental 
toxicants, two triazoles, cyproconazole (CYP) and hexaconazole (HEX), and the 
anticonvulsant valproic acid (VPA) were investigated using a transcriptomic 
approach. Compound effects on gene expression during neural differentiation and 
corresponding regulated gene ontology (GO) terms were identified after 24 h of 
exposure in relation to morphological changes on day 11 of culture. 
Concentration-dependent responses on individual gene expression and on 
biological processes were determined for each compound, providing information 
on mechanism and concentration-response characteristics. All compounds caused 
enrichment of the embryonic development process. CYP and VPA but not HEX 
significantly enriched the neuron development process. Furthermore, specific 
responses for triazole compounds and VPA were observed within the GO-term 
sterol metabolic process. The incorporation of transcriptomics in the ESTn was 
shown to enable detection of effects, which precede morphological changes and 
provide a more sensitive measure of concentration-dependent effects as compared 
with classical morphological assessments. Furthermore, mechanistic insight can 
be instrumental in the extrapolation of effects in the ESTn to human hazard 
assessment. 
Zhang, C., Cao, J., Kenyon, J. R., Panzica-kelly, J. M., Gong, L., & 
Augustine-rauch, K. (2012). Development of a Streamlined Rat Whole 
Embryo Culture Assay for Classifying Teratogenic Potential of 
Pharmaceutical Compounds, 127(2), 535–546.  
 
In this paper a novel rat whole embryo culture (rWEC) teratogenicity assay 
applying a simplified experimental design and statistical prediction model is 
presented. The described assay holds promise for reduced animal requirements 
and increased throughput with low prediction error rate for classifying teratogenic 
potential of compounds. A total of 70 compounds (38 teratogens and 32 non-
teratogens) were evaluated, and the prediction model was generated from a 
dataset of 59 compounds. The rWEC assay requires only one test concentration 
and three structural endpoints, which are used in a recursive partition model for 
classifying teratogenic liability. The model fitting concordance between the WEC 
assay and in vivo outcome was 83%. The predictivity for future compounds was 
evaluated by using two statistical methods. The overall estimate for prediction 
concordance is 74% (SD 5.2%). There is no statistically significant difference (p 
value > 0.50) in the predictivity between this model and the model supporting 
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ECVAM validated WEC assay with predictivity of 80% (SD 10.6%). Overall, the 
streamlined WEC assay is estimated to reduce animal use and operational costs 
by more than 50% and it substantially improves results turnaround with no loss of 
predictivity. 
Uysal, H., Semerdoken, S., Colak, D. A., & Ayar, A. (2013). The 
hazardous effects of the three natural food dyes on developmental 
stages and longevity of Drosophila melanogaster. Toxicology and 
Industrial Health. Epub ahead of print, 1 March 2013. doi: 
10.1177/0748233713480206. 
 
 
In this study, the toxic effects of three different natural food dyes (carmine, 
turmeric and annatto) on 72 ± 4 h larvae of Drosophila melanogaster were 
investigated. For this purpose, four different application doses were chosen by 
means of preliminary studies. It was determined that larval mortality increased 
with increasing concentration in the application groups and the toxicity order was 
carmine > turmeric > annatto. Moreover, it was observed that the survival rate 
was highest in the control with 98% and lowest in maximal used dose of carmine 
with 16%. In addition, the average lifespan of the adult individuals obtained from 
third instar larvae was also studied. According to the obtained results, when both 
the developmental period from larvae into adults and the lifespan of the 
developing adults were compared with the control group, the food dyes were 
found to be toxic and the toxicity order of carmine > turmeric > annatto was 
identified. 
Goussen, B., Parisot, F., Beaudouin, R., Dutilleul, M., Buisset-
Goussen, A., Péry, A. R. R., & Bonzom, J.-M. (2013). Consequences 
of a multi-generation exposure to uranium on Caenorhabditis elegans 
life parameters and sensitivity. Ecotoxicology (London, England).  
In this paper a 16-generation study was performed to assess the uranium exposure 
effects of two populations of the ubiquitous nematode Caenorhabditis elegans. 
Several generations were selected to assess growth, reproduction, survival, and 
dose-responses relationships, through exposure to a range of concentrations with 
all endpoints measured daily. The experiment showed an adaptation of 
individuals to experimental conditions (increase of maximal length and decrease 
of fecundity) for both populations. Moreover an increase of adverse effects 
(reduction of growth and fertility) as a function of uranium concentration was 
observed. The group also reported the emergence of population differentiation for 
reproduction traits. In contrast, no differentiation was observed on growth traits. 
These results confirm the importance of assessing environmental risk related to 
pollutant through multi-generational studies. 
Zimmer, B., Lee, G., Balmer, N. V, Meganathan, K., Sachinidis, A., 
Studer, L., & Leist, M. (2012). Evaluation of developmental toxicants 
and signaling pathways in a functional test based on the migration of 
human neural crest cells. Environmental health perspectives, 120(8), 
1116–22.  
 
This paper describes a robust and widely applicable human-relevant neural crest 
(NC) function assay that would allow for sensitive screening of environmental 
toxicants and defining toxicity pathways. The NC cells from human embryonic 
stem cells were generated, and a migration assay of NC cells (MINC assay) for 
testing environmental toxicants was established. Methylmercury, valproic acid, 
and lead-acetate affected the migration of NC cells more potently than migration 
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of other cell types. The MINC assay correctly identified the NC toxicants 
triadimefon and triadimenol. Additionally, it showed different sensitivities to 
various organic and inorganic mercury compounds. Using the MINC assay and 
applying classic pharmacologic inhibitors and large-scale microarray gene 
expression profiling, the authors found several signaling pathways that are 
relevant for the migration of NC cells. The MINC assay faithfully models human 
NC cell migration, and it reveals impairment of this function by developmental 
toxicants with good sensitivity and specificity. 
Li, H., Van Ravenzwaay, B., Rietjens, I. M. C. M., & Louisse, J. 
(2013). Assessment of an in vitro transport model using BeWo b30 
cells to predict placental transfer of compounds. Archives of 
toxicology. Archives of Toxicology 87(9):1661-1669. 
The human ex vivo placental perfusion model has regularly been used to study the 
transplacental transport of compounds. However, this method is laborious and 
dependent on the presence of fresh human placenta, hampering its use for the 
assessment of large numbers of compounds. An in vitro model for the placental 
barrier using BeWo b30 cells may provide an alternative to the ex vivo system. 
The present study aims to assess whether such an in vitro model could be used to 
reliably predict placental transfer. To this end, BeWo b30 cells, derived from a 
human choriocarcinoma, were grown on transwell insert to form a cell layer, 
separating an apical maternal compartment from a basolateral fetal compartment. 
For a set of nine selected model compounds, including the reference 
compound antipyrine, the transport velocity from the apical to the basolateral 
compartment was determined. Relative transport rates obtained were compared 
with the transfer indices (a measure for the transport relative to antipyrine) of 
these compounds obtained in ex vivo placental perfusion studies as reported in the 
literature. The relative transport rates in the in vitro BeWo model were in good 
correlation (R2 = 0.95) with the transfer indices reported for the ex vivo model. 
This indicates that the BeWo model could be a valuable in vitro model for 
prediction of placental transfer of compounds. 
Myllynen P., Immonen E., Kummu M., Vahakangas K. (2009) 
Developmental expression of drug metabolizing enzymes and 
transporter proteins in human placenta and fetal tissues. Expert Opin 
Drug Metab Toxicol. 5,1483–1499 
  
Over the decades several ex vivo and in vitro models which utilize delivered 
human placenta have been developed to study various placental functions. The 
use of models originating from human placenta to study transplacental transfer 
and related mechanisms is an attractive option because human placenta is 
relatively easily available for experimental studies. After delivery, placenta has 
served its purpose and is usually disposed of. The purpose of this review is to 
give an overview of the use of human placental models for the studies on human 
placental transfer and related mechanisms such as transporter functions and 
xenobiotic metabolism. Human placental perfusion, the most commonly used 
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continuous cell lines, primary cells and tissue culture, as well as subcellular 
fractions are briefly introduced and their major advantages and disadvantages are 
discussed. 
Gustafson, AL, Stedman DB, Ball J, Hillegass JM, Flood A, Zhang 
CX, Panzica-Kelly J, Cao J, Coburn A, Enright BP, Tornesi MB, 
Hetheridge M & Augustine-Rauch KA (2012). Inter-Laboratory 
Assessment of a Harmonized Zebrafish Developmental Toxicology 
Assay – Progress Report on Phase I. Reproductive Toxicology 33: 
155-164. 
This report provides a progress update of a consortium effort to develop a 
harmonized zebrafish developmental toxicity assay. Twenty non-proprietary 
compounds (10 animal teratogens and 10 animal non-teratogens) were evaluated 
blinded in 4 laboratories. Zebrafish embryos from pond-derived and cultivated 
strain wild types were exposed to the test compounds for 5 days and subsequently 
evaluated for lethality and morphological changes. Each of the testing 
laboratories achieved similar overall concordance to the animal data (60–70%). 
Subsequent optimization procedures to improve the overall concordance focused 
on compound formulation and test concentration adjustments, chorion permeation 
and number of replicates. These optimized procedures were integrated into a 
revised protocol and all compounds were retested in one lab using embryos from 
pond-derived zebrafish and achieved 85% total concordance. To further assess 
assay performance, a study of additional compounds is currently in progress at 
two laboratories using embryos from pond-derived and cultivated-strain wild type 
zebrafish. 
Selderslaghs IWT, Blust R & Witters H (2012). Feasibility study of 
the zebrafish assay as an alternative method to screen for 
developmental toxicity and embryotoxicity using a training set of 27 
compounds. Reproductive Toxicology 33:142-154. 
The zebrafish embryo/larva was studied as an alternative for animal testing for 
developmental toxicity and embryotoxicity and a training set of 27 compounds 
was evaluated with a standardized protocol. The classification of compounds in 
the zebrafish embryo/larva assay, based on a prediction model using a TI 
(teratogenic index) cut-off value of 2, was compared to available animal and 
human data. When comparing the classification of compounds in the zebrafish 
embryo/larva assay to available animal classification, a sensitivity of 72% and 
specificity of 100% were obtained. The predictive values obtained in comparison 
to a limited set of human data were 50, 60% respectively for teratogens, non-
teratogens. 
Overall, it was demonstrated that the zebrafish embryo/larva assay, may be used 
as a screening tool for prioritization of compounds and could contribute to 
reduction of animal experiments in the field of developmental toxicology. 
In silico models 
Arena VC, Sussman NB, Mazumdar S, Yu S & Macina OT (2004). 
The utility of Structure-activity relationship (SAR) models for 
prediction and covariate selection in developmental toxicity: 
Structure-activity relationship (SAR) models can be used to predict the biological 
activity of potential developmental toxicants whose adverse effects include death, 
structural abnormalities, altered growth and functional deficiencies in the 
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comparative analysis of logistic regression and decision tree models.  
SAR and QSAR in Environmental Research 15: 1-18. 
 
 
developing organism. Physicochemical descriptors of spatial, electronic and 
lipophilic properties were used to derive SAR models by two modelling 
approaches, logistic regression and Classification and Regression Tree (CART), 
using a new developmental database of 293 chemicals (FDA/TERIS). Both single 
models and ensembles of models (termed bagging) were derived to predict 
toxicity. Assessment of the empirical distributions of the prediction measures was 
performed by repeated random partitioning of the data set. Results showed that 
both the decision tree and logistic regression derived developmental SAR models 
exhibited modest prediction accuracy. Bagging tended to enhance the prediction 
accuracy and reduced the variability of prediction measures compared to the 
single model for CART-based models but not consistently for logistic-based 
models. Prediction accuracy of single logistic-based models was higher than 
single CART-based models but bagged CART-based models were more 
predictive. Descriptor selection in SAR for the understanding of the 
developmental mechanism was highly dependent on the modelling approach. 
Although prediction accuracy was similar in the two modelling approaches, there 
was inconsistency in the model descriptors. 
Sussman, N. B., Arena, V. C., Yu, S., Mazumdar, S., and Thampatty, 
B. P. 2003. Decision Tree SAR Models for Developmental Toxicity 
Based on an FDA/TERIS Database. SAR and QSAR in Environmental 
Research 14 (2):83-96. 
Structure-activity relationships (SARs) are models that could be used to 
efficiently predict the biological activity of potential developmental toxicants. 
However, at this time, no adequate SAR models of developmental toxicity are 
available for risk assessment. In the present study, a new developmental database 
was compiled by combining toxicity information from the Teratogen Information 
System (TERIS) and the Food and Drug Administration (FDA) guidelines. The 
authors implemented a decision tree modelling procedure, using Classification 
and Regression Tree (CART) software and a model ensemble approach termed 
bagging. The authors then assessed the empirical distributions of the prediction 
accuracy measures of the single and ensemble-based models, achieved by 
repeating our modelling experiment many times by repeated random partitioning 
of the working database. The decision tree developmental SAR models exhibited 
modest prediction accuracy. Bagging tended to enhance the accuracy of 
prediction. Also, the model ensemble approach reduced the variability of 
prediction measures compared to the single model approach.  
Novic M & Vracko M (2010). QSAR Models for Reproductive 
Toxicity and Endocrine Disruption Activity. Molecules 2010, 15.   
This review describes some QSAR modelling approaches for reproductive 
toxicity. In the first example the authors describe the CAESAR model for 
prediction of reproductive toxicity; the second example shows a classification 
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model for endocrine disruption potential based on counter propagation artificial 
neural networks; the third  example shows a modelling of relative binding affinity 
to rat oestrogen receptor, and the fourth one shows a receptor dependent 
modelling experiment. 
Lo Piparo E & Worth A (2010). Review of QSAR Models and 
Software Tools for predicting Developmental and Reproductive 
Toxicity. JRC report EUR 24522 EN. Publications Office of the 
European Union. Available from: 
http://publications.jrc.ec.europa.eu/repository 
  
This JRC report provides a state-of-the-art review of available computational 
models for developmental and reproductive toxicity, including Quantitative 
Structure-Activity Relationship (QSARs) and related estimation methods such as 
decision tree approaches and expert systems. At present, there are relatively few 
models for reproductive toxicity endpoints (development and fertility), and those 
available have limited applicability domains. This situation is partly due to the 
biological complexity of the endpoint, which covers many incompletely 
understood mechanisms of action, and partly due to the paucity and heterogeneity 
of high quality data suitable for model development. In contrast, there is an 
extensive and growing range of software and literature models for predicting 
endocrine-related activities, in particular models for oestrogen and androgen 
activity. There is a considerable need to further develop and characterise in silico 
models for reproductive toxicity, and to explore their applicability in a regulatory 
setting. 
Cassano A, Manganaro A, Martin T, Young D, Piclin N, Pintore M, 
Bigoni D, Benfenati E (2010). CAESAR models for developmental 
toxicity. Chemistry Central Journal 4, Suppl 1:S4. 
 
 
The REACH legislation requires assessment of a large number of chemicals in 
the European market for several endpoints. Developmental toxicity is one of the 
most difficult endpoints to assess, on account of the complexity, length and costs 
of experiments. Following the encouragement of QSAR (in silico) methods 
provided in REACH itself, the CAESAR project has developed several models. 
 
Two QSAR models for developmental toxicity have been developed, using 
different statistical/mathematical methods. Both models performed well. The first 
makes a classification based on a random forest algorithm, while the second is 
based on an adaptive fuzzy partition algorithm. The first model has been 
implemented and inserted into the CAESAR on-line application, which is java-
based software that allows everyone to freely use the model.  
 
The CAESAR QSAR models have been developed with the aim to minimize 
false negatives in order to make them more usable for REACH. The CAESAR 
on-line application ensures that both industry and regulators can easily access and 
use the developmental toxicity model (as well as the models for the other four 
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endpoints). 
Cronin MTD & Worth AP (2008). (Q)SARs for Predicting Effects 
Relating to Reproductive Toxicity. QSAR & Combinatorial Science 
27: 91-100. 
This paper reviews the current status of structure-based methods for predicting 
adverse reproductive effects in mammals. The methods described include 
QSARs, expert systems and the less formalised approaches of read-across and 
chemical categories. There are a number of problems with applying QSARs to 
reproductive toxicology notably the complexity, subtlety and sometimes ill-
defined nature of the endpoint and lack of data available for modelling. A small 
number of QSARs have been developed for individual classes of compounds on 
well-defined effects. These are supplemented by expert systems approaches (e.g. 
DEREK for Windows, TOPKAT, MultiCASE, PASS, OECD QSAR Application 
Toolbox) for a variety of endpoints associated with reproductive toxicology. By 
far the largest, and best developed, group of models are those for receptor binding 
effects related to endocrine disruption, in particular to the oestrogen receptor and, 
to a lesser extent, the androgen receptor. Strategies to improve predictive 
capabilities for reproductive toxicology are also suggested.  
Worth A, Fuart-Gatnik M, Lapenna S & Serafimova R (2011). 
Applicability of QSAR analysis in the evaluation of developmental 
and neurotoxicity effects for the assessment of the toxicological 
relevance of metabolites and degradates of pesticide active substances 
for dietary risk assessment. Report produced for EFSA. Available 
from: http://www.efsa.europa.eu/en/supporting/pub/169e.htm 
This is the final report of a project carried out by the European Commission’s 
Joint Research and sponsored by the European Food Safety Authority with the 
overall aim of evaluating the potential applicability of computational methods for 
predicting adverse developmental and neurotoxic effects in the dietary risk 
assessment of pesticides.  
While the toxicological profile of the parent active substance is fully 
characterised through the experimental studies required by EU legislation, only 
very limited toxicological data are usually available for their metabolites and 
degradates. For reasons of efficiency and animal welfare, computational methods 
based on structure-activity analysis and read-across are being investigated for 
their applicability in assessing the toxicological relevance of metabolites and 
degradates of pesticide active substances. The ability to reliably predict the 
presence and absence of short-term effects of concern, and in particular 
developmental toxicity and neurotoxicity, would have a positive impact on the 
way pesticide risk assessments are currently carried out by reducing the need for 
toxicity testing on metabolites and degradates as well as the need to conduct 
short-term exposure assessments.  
In this study, the ability of selected Quantitative Structure-Activity Relationship 
(QSAR) tools to predict developmental and neurotoxicity was analysed, and a 
stepwise approach based on the use of QSAR analysis and read-across was 
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proposed as a possible way of supporting, alongside other non-testing approaches 
such as the Threshold of Toxicological Concern (TTC) approach, the assessment 
of pesticide metabolites and degradates in terms of their toxicological relevance. 
In this stepwise approach, QSAR tools are used in a preliminary step to identify 
toxic chemicals, while read-across is applied, in cases where a chemical is 
predicted by QSAR to be non-toxic, as a means of distinguishing between true 
and false negatives. This approach is shown to improve the overall ability to 
distinguish between toxic and non-toxic chemicals compared with the use of 
individual tools. 
Martin MT, Knudsen TB, Reif DM, Houck KA, Judson RS, Kavlock 
RJ, Dix DJ (2011). Predictive model of rat reproductive toxicity from 
ToxCast high throughput screening. Biol Reprod. 85(2):327-339.  
 
 
The U.S. Environmental Protection Agency's ToxCast research program uses 
high throughput screening (HTS) for profiling bioactivity and predicting the 
toxicity of large numbers of chemicals. ToxCast Phase I tested 309 well-
characterized chemicals in more than 500 assays for a wide range of molecular 
targets and cellular responses. Of the 309 environmental chemicals in Phase I, 
256 were linked to high-quality rat multigeneration reproductive toxicity studies 
in the relational Toxicity Reference Database. Reproductive toxicants were 
defined here as having achieved a reproductive lowest-observed-adverse-effect 
level of less than 500 mg/kg/day. Eighty-six chemicals were identified as 
reproductive toxicants in the rat, and 68 of those had sufficient in vitro bioactivity 
to model. Each assay was assessed for univariate association with the identified 
reproductive toxicants. Significantly associated assays were linked to gene sets 
and used for the subsequent predictive modelling. Using linear discriminant 
analysis and fivefold cross-validation, a robust and stable predictive model was 
produced capable of identifying rodent reproductive toxicants with 77% ± 2% 
and 74% ± 5% (mean ± SEM) training and test cross-validation balanced 
accuracies, respectively. With a 21-chemical external validation set, the model 
was 76% accurate, further indicating the model's potential for prioritizing the 
many thousands of environmental chemicals with little to no hazard information. 
The biological features of the model include steroidal and nonsteroidal nuclear 
receptors, cytochrome P450 enzyme inhibition, G protein-coupled receptors, and 
cell signalling pathway readouts-mechanistic information suggesting additional 
targeted, integrated testing strategies and potential applications of in vitro HTS to 
risk assessment. 
Knudsen TB, Kleinstreuer NC (2011). Disruption of embryonic 
vascular development in predictive toxicology. Birth Defects Res C 
Toxicity testing in the 21st century is moving toward using high-throughput 
screening assays to rapidly test thousands of chemicals against hundreds of 
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Embryo Today 93(4):312-323. 
 
molecular targets and biological pathways, and to provide mechanistic 
information on chemical effects in human cells and small model organisms. First-
generation predictive models for prenatal developmental toxicity have revealed a 
complex web of biological processes with many connections to vasculogenesis 
and angiogenesis. This review examines disruption of embryonic vascular 
development as a potential adverse outcome pathway leading to developmental 
toxicity. The authors briefly review embryonic vascular development and 
important signals for vascular development (local growth factors and cytokines 
such as vascular endothelial growth factor-A and TGF-beta, components in the 
plasminogen activator system, and chemotactic chemokines). Genetic studies 
have shown that perturbing these signals can lead to varying degrees of adverse 
consequences, ranging from congenital angiodysplasia to foetal malformations 
and embryolethality. The molecular targets and cellular behaviours required for 
vascular development, stabilization and remodeling are amenable to in vitro 
evaluation. Evidence for chemical disruption of these processes is available for 
thalidomide, estrogens, endothelins, dioxin, retinoids, cigarette smoke, and metals 
among other compounds. Although not all compounds with developmental 
toxicity show an in vitro vascular bioactivity signature, many 'putative vascular 
disruptor compounds' invoke adverse developmental consequences. As such, an 
adverse outcome pathway perspective of embryonic vascular development can 
help identify useful information for assessing adverse outcomes relevant to risk 
assessment and efficient use of resources for validation. 
Martin MT, Knudsen TB, Judson RS, Kavlock RJ, Dix DJ (2012). 
Economic benefits of using adaptive predictive models of reproductive 
toxicity in the context of a tiered testing program. Syst Biol Reprod 
Med. 58(1): 3-9. 
 
 
A predictive model of reproductive toxicity, as observed in rat multigeneration 
reproductive (MGR) studies, was previously developed using high throughput 
screening (HTS) data from 36 in vitro assays mapped to 8 genes or gene-sets 
from Phase I of USEPA ToxCast research program, the proof-of-concept phase in 
which 309 toxicologically well characterized chemicals were tested in over 500 
HTS assays. The model predicted the effects on male and female reproductive 
function with a balanced accuracy of 80%. In a theoretical examination of the 
potential impact of the model, two case studies were derived representing 
different tiered testing scenarios to: 1) screen-out chemicals with low predicted 
probability of effect; and 2) screen-in chemicals with a high probability of 
causing adverse reproductive effects. 'Testing cost efficiency' was defined as the 
total cost divided by the number of positive chemicals expected in the definitive 
guideline toxicity study. This would approach $2.11 M under the current practice. 
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Under case study 1, 22% of the chemicals were screened-out due to low predicted 
probability of adverse reproductive effect and a misclassification rate of 12%, 
yielding a test cost efficiency of $1.87 M. Under case study 2, 13% of chemicals 
were screened-in yielding a testing cost efficiency of $1.13 M per test-positive 
chemical. Applying the model would also double the total number of positives 
identified. It should be noted that the intention of the case studies is not to 
provide a definitive mechanism for screening-in or screening-out chemicals or 
account for the indirect costs of misclassification. The case studies demonstrate 
the customizability of the model as a tool in chemical testing decision-making. 
The predictive model of reproductive toxicity will continue to evolve as new 
assays become available to fill recognized biological gaps and will be combined 
with other predictive models, particularly models of developmental toxicity, to 
form an initial tier to an overarching integrated testing strategy. 
Testing Strategies 
Grindon C, Combes R, Cronin MT, Roberts DW, Garrod JF (2008). 
An integrated decision-tree testing strategy for developmental and 
reproductive toxicity with respect to the requirements of the EU 
REACH legislation. ATLA 36 (1):123–138 
 
This paper presents some results of a joint research project, sponsored by Defra 
and conducted by FRAME and Liverpool John Moores University, on the status 
of alternatives to animal testing with regard to the European Union REACH 
system for the safety testing and risk assessment of chemicals. The project 
covered all the main toxicity endpoints associated with REACH. 
 
This paper focuses on the prospects for the use of alternative methods (both in 
vitro and in silico) in reproductive toxicity testing (both fertility and 
development). It considers many tests based on primary cells and cell lines, and 
the available expert systems and QSARs for developmental and reproductive 
toxicity, and also covers tests for endocrine disruption. Ways in which reduction 
and refinement measures can be used are also discussed by the authors. Decision-
tree style integrated testing strategies are also proposed for developmental and 
reproductive toxicity and for endocrine disruption, followed by a number of 
recommendations for the future facilitation of reproductive toxicity testing, with 
respect to human risk assessment. 
Robinson, J. F., & Piersma, A. H. (2013). Toxicogenomic approaches 
in developmental toxicology testing. Methods in molecular biology, 
947, 451–73. 
This review presents the basic framework of conducting toxicogenomic 
investigations in the field of developmental toxicology, providing examples of 
biological and technical factors that may influence response and interpretation. 
Furthermore, current diverse applications of toxicogenomic-based approaches in 
developmental toxicity testing, including exposure-response characterization 
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(dose and duration), chemical classification studies, and cross-model comparisons 
study designs are analysed. The intention of this review is to guide scientists 
through the challenging and complex structure of conducting toxicogenomic 
analyses, while considering the many applications of using toxicogenomics in 
study designs and the future of these types of "omics" approaches in 
developmental toxicology. The emergence of toxicogenomic applications 
provides new tools to characterize and potentially predict potency of causing 
malformations. However, due to the vast number of experimental and statistical 
procedural steps, toxicogenomic studies are challenging. 
Theunissen, P T, Schulpen, S. H. W., Van Dartel, D. A. M., Hermsen, 
S. A. B., Van Schooten, F. J., & Piersma, A. H. (2010). An 
abbreviated protocol for multilineage neural differentiation of murine 
embryonic stem cells and its perturbation by methyl mercury. 
Reproductive Toxicology 29(4), 383–92. 
This paper presents a test system for assessing neurodevelopmental toxicity using 
differentiating embryonic stem cells. The authors claim to have advanced 
previously established methods by merging, modifying and abbreviating the 
original 20-day protocol into a more efficient 13-day neural differentiation 
protocol. Using morphological observation, immunocytochemistry, gene 
expression and flow cytometry, it was shown that predominantly multiple 
lineages of neuroectodermal cells were formed in their protocol and to a lower 
extent, endodermal and mesodermal differentiated cell types. This abbreviated 
protocol has the potential to be used as an advanced screening method using 
morphology in combination with selected differentiation markers aimed at 
predicting neurodevelopmental toxicity. Finally, using the modified protocol 
differential sensitivity to a model developmental neurotoxicant, methyl mercury, 
was shown. 
Rovida, C., Longo, F., & Rabbit, R. R. (2011). t 4 Report * How are 
Reproductive Toxicity and Developmental Toxicity Addressed in 
REACH Dossiers? Altex 28: 273–294. 
 
In the present paper, data from 400 submitted dossiers were analyzed to check for 
compliance with REACH Regulations and published guidelines. The dossiers 
were randomly selected among full phase-in registered substances and the study 
focuses only on reproductive toxicity. 
Krug AK, Balmer N V, Matt F, Schönenberger F, Merhof D & Leist 
M (2013). Evaluation of a human neurite growth assay as specific 
screen for developmental neurotoxicants. Archives of Toxicology 87: 
2215-2231. 
 
In this paper certain assay features were evaluated that can affect test specificity 
and some general procedures are suggested on how positive hits in complex 
biological assays may be defined. Organ-specific in vitro toxicity assays are often 
highly sensitive, but they lack specificity. Differentiating human LUHMES cells 
were used as a potential model for developmental neurotoxicity testing. Forty 
candidate toxicants were screened, and several hits were obtained and confirmed. 
Although the cells had a definitive neuronal phenotype, the use of a general cell 
death endpoint in these cultures did not allow specific identification of 
neurotoxicants. As an alternative approach, neurite growth was measured as an 
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organ-specific functional endpoint. It was found that neurite extension of 
developing LUHMES was specifically inhibited by diverse compounds and these 
compounds reduced neurite growth at concentrations that did not compromise cell 
viability, and neurite growth was affected more potently than the integrity of 
developed neurites of mature neurons. A ratio of the EC50 values of neurite 
growth inhibition and cell death of >4 provided a robust classifier for compounds 
associated with a developmental neurotoxic hazard. The assay also identified 
compounds that accelerated neurite growth, such as the rho kinase pathway 
modifiers blebbistatin or thiazovivin. In summary, it was suggested that assays 
using functional endpoints (neurite growth) can specifically identify and 
characterize (developmental) neurotoxicants. 
Robinson, J. F., Verhoef, A., Pennings, J. L. a, Pronk, T. E., & 
Piersma, A. H. (2012). A comparison of gene expression responses in 
rat whole embryo culture and in vivo: time-dependent retinoic acid-
induced teratogenic response. Toxicological Sciences 126(1), 242–54. 
In this paper, the effects of the model teratogen, all-trans retinoic acid (RA) in 
WEC and embryos in vivo were investigated. The transcriptomic approach was 
applied to monitor the effects of RA on gene expression in RA exposed and 
nonexposed rat embryos derived using WEC or in vivo. In addition, 
morphological changes of the embryos were studied.  Across six time points the 
strong similarities in RA response at the gene and functional level were observed. 
The differences between models in the timing of RA-induced effects on genes 
related to embryonic development and RA metabolism were observed. The 
observations on the gene expression level were associated with specific 
differential morphological outcomes. This study supports the usefulness of the 
WEC to examine compound-induced molecular responses relative to in vivo 
embryos.  
Schenk, B., Weimer, M., Bremer, S., Van der Burg, B., Cortvrindt, R., 
Freyberger, A., … Schwarz, M. (2010). The ReProTect Feasibility 
Study, a novel comprehensive in vitro approach to detect reproductive 
toxicants. Reproductive toxicology 30(1), 200–18. 
ReProTect is a project within the 6th European Framework Program which has 
developed alternative methods aimed to reduce or replace animal experimentation 
in the field of reproductive toxicology. In its final year, a ring trial, named the 
“Feasibility Study”, was conducted, in which 10 blinded chemicals with 
toxicologically well-documented profiles were analyzed by employing a test 
battery of 14 in vitro assays. EC50 (half maximal effective concentration) or 
equivalent endpoints were determined and the test compounds were ranked 
relative to chemicals previously assayed in the tests of the battery. This 
comparative analysis together with a weight of evidence approach allowed a 
robust prediction of adverse effects on fertility and embryonic development of the 
10 test chemicals in vivo. In summary, the vast majority of the predictions made 
based on the in vitro results turned out to be correct when compared to the whole 
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animal data. The procedure used here, a nearest neighbour analysis coupled with 
a weight of evidence approach, may guide future activities in the field of 
alternative toxicity testing. 
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11. Endocrine disruption relevant to human health and wildlife populations 
Malgorzata Nepelska, Julien Burton, Marina Goumenou, Sharon Munn & Andrew Worth 
 
11.1 What are endocrine disrupters and why are they of concern? 
According to the World Health Organization (WHO), an “endocrine disrupter” is defined as 
“…an exogenous substance or mixture that alters function(s) of the endocrine system and 
consequently causes adverse health effects in an intact organism, or its progeny, or 
(sub)populations”, whereas a “potential endocrine disrupter” is “… an exogenous substance 
or mixture that possesses properties that might be expected to lead to endocrine disruption in 
an intact organism, or its progeny, or (sub)populations.” (WHO/IPCS, 2002) 
 
Endocrine disruptors are of societal concern because of their adverse effects on humans, 
wildlife and the environment (EEA, 2012). For example, endocrine-related adverse human 
health effects include certain cancers, as well as effects on fertility and development (UNEP 
WHO, 2013).  
 
The endocrine system can be considered to encompass all of the hormone-producing tissues 
that release hormones into the blood, which transports the hormones to target tissues where 
they elicit their physiological effects. The major functions of hormones are to regulate various 
functions including energy metabolism (i.e. energy storage, production, and utilisation); 
growth and development; and function of the immune and reproductive system.  
 
In classical endocrinology, the endocrine system comprises multiple axes consisting of 
different organs and hormones with distinct regulatory functions, the three main axes being 
the hypothalamus-pituitary-gonad (HPG), the hypothalamic-pituitary-adrenal (HPA), and the 
hypothalamic-pituitary-thyroid (HPT) axes. However, as noted by Kortenkamp et al. (2012), 
scientific advances in in our understanding of receptor signalling and molecular biology are 
continuously blurring the borders between the nervous system, immune system and endocrine 
system, which has the important implication that our understanding of the endocrine system 
and endocrine signalling “can therefore span from the classical definition of the endocrine 
system to one that encompasses any type of receptor-mediated signalling.”   
 
This finely tuned system may be susceptible to perturbation by exogenous substances, 
Endocrine Active Substances (EAS), which may in some circumstances result in adverse 
effects, including effects on foetal development and disruption of homeostasis in the adult 
organism.  The Endocrine Society proposes in a position statement from 2012 (Zoeller et al, 
2012) that “the dose makes the poison”, since screening and testing for EDs and estimating 
potency require insight derived from principles of endocrinology according to which 
(endogenous) hormones: 
 
1. coordinate the development and function of tissues in a highly integrated manner 
2. act via receptors  
a. receptors are tissue specific, most sensitive to the hormones at the low end of 
the dose response curve, and amplify the response;  
b. affinity for receptors is distinct from overall in vivo potency; 
c. response is dependent on hormone concentration, receptor affinity, receptor 
abundance and co-regulatory proteins; 
d. binding to different receptors may occur as dose increases (receptor cross-talk), 
resulting in different responses from those seen at low doses; 
3. act at very low concentrations, in the ppt-ppb range; 
4. often result in non-monotonic dose responses due to multiple mechanisms and 
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5. produce effects that are life stage dependent, with a greater potential for permanent 
effects occurring following activity during development  
 
Since hormones generally act at low doses and may activate their receptors in a non-linear 
fashion, there is concern that those EAS acting similarly to hormones may, initiate relevant 
effects depending on affinity to receptors also in a non-linear fashion, and some, depending 
on potency, may do so at very low concentrations. Most dose-response relationships follow 
the classical sigmoidal pattern, but the dose-relationship can also be more complex, including 
non-monotonic dose-response relationships (NMDR) (Vandenberg et al. 2012). NMDRs can 
be defined as a dose-response which changes direction from ascending to descending or vice 
versa and can occur at any part of the dose axis, producing, for example, U-shaped (with 
maximal responses observed at low and high doses) or inverted U-shaped (with maximal 
responses observed at intermediate doses) curves. Although, NMDRs are not specific to ED-
related endpoints, if hormones generally act with NMDRs, it is considered not unlikely that 
EAS that mimic hormones may also exhibit NMDR behaviour. One of the concerns related to 
current assessment methodology is that the occurrence of NMDR at doses below those tested 
in standardised assays cannot be ruled out a priori, and thus there is uncertainty whether a 
safety threshold derived from a classical (sigmoidal) dose-response relationship is sufficiently 
protective (Zoeller et al., 2012). This uncertainty is compounded by the fact that the 
traditional animal tests might not include the most sensitive endocrine-relevant endpoints. 
According to EFSA's Scientific Committee (EFSA, 2013) the debate is evolving in the 
scientific community as to the existence and/or relevance of low-dose effects and NMDRs in 
(eco)toxicology in relation to endocrine disruption or other endpoints/modes of action, but 
still lacks consensus. More work needs to be conducted to agree the definitions of the 
respective terms, and in practical terms to consider whether or how it could impact upon risk 
assessment (i.e. assessment of dose response relationships for adverse effects) and testing 
strategies. 
 
Another challenge related to the assessment of endocrine disruption is that the sensitivity of 
an organism to the action of hormones (and possibly EAS as well) varies throughout life, with 
increased sensitivity during critical periods of development. There are important differences 
in the maturity and functionality of the endocrine system between the pre- and post-natal life, 
including the lack of fully developed endocrine axes during foetal development. In addition, 
puberty, pregnancy and menopause are adult life stages which may be particularly sensitive to 
endocrine disruption. In this context a relevant issue is the possibility of delayed effects (delay 
between the exposure and the appearance of the adverse effect). For example, exposure to 
EAS in foetal life may lead to adverse effects during adulthood. Consequently, another 
concern related to current assessment methodology is that current tests are not capable of 
detecting the adverse effects of EAS that are triggered during sensitive windows of 
development and which may not be apparent until a later life stage.  
 
11.2 Regulatory implications for the identification of endocrine disruptors 
Already in the 90s, the Community Strategy for Endocrine Disruptors (EC, 1999) aimed at 
creating a list of substances requiring priority evaluation (“ED priority list”) for their role in 
endocrine disruption and to identify substances which could already be addressed under 
existing legislation, as well as addressing gaps in knowledge and specific cases of consumer 
use for special consideration. A candidate list of 553 chemicals was published in 2000, 
together with a series of actions proposed to further evaluate the role of these substances in 
endocrine disruption. This list of chemicals and associated toxicity data are being 
incorporated into a web-based database, the Endocrine Active Substances Information System 
(EASIS), developed by the JRC (Castello & Worth, 2011). The stated long-term goal of the 
Community Strategy was “to control substances having harmful effects on humans, wildlife 
and/or the environment”.  
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The need to identify EDs and to assess the risks they pose is reflected in various pieces of EU 
legislation, with a range of consequences in terms of risk management and the marketing of 
chemicals and their products (Table 11.1). To support the implementation of these pieces of 
EU legislation, efforts are ongoing to establish criteria and guidance for the identification and 
risk assessment of EDs. The key scientific considerations for identifying and characterising 
EDs have recently been proposed by the European Commission’s Endocrine Disrupters 
Expert Advisory Group (ED EAG; Munn & Goumenou, 2013)1 and by the EFSA Scientific 
Committee (EFSA, 2013). According to the ED EAG, for a substance to be identified as an 
ED, it must “demonstrate an adverse effect for which there is convincing evidence of a 
biologically plausible causal link to an endocrine disrupting mode of action of which the 
disruption is not a secondary consequence of other non-endocrine-mediated systemic 
toxicity.” For the characterisation of EDs, the ED EAG agreed that other factors should be 
considered, including potency, severity, (ir)reversibility, and lead toxicity/critical effect.  
 
11.3 Mechanistic understanding of endocrine disruption 
The assessment of endocrine disruption poses a scientific and technological challenge since 
there are many different mechanisms of endocrine-mediated toxicity, and many EAS are 
associated with multiple mechanisms, due to the “promiscuity” of ligand-receptor binding, 
and “cross-talk“ between hormone receptor pathways. Furthermore, EAS with similar 
mechanisms may work together in additive, synergistic or permissive mode to produce 
combined effects. These combination effects can occur at doses where each chemical 
individually is without detectable effects (Kortenkamp, 2007). 
 
While our mechanistic understanding of EAS action is still incomplete, different mechanisms 
can in principle be distinguished according to their Molecular Initiating Events (MIEs), i.e. 
the first chemico-biological interaction that results in a perturbation of a biological pathway. 
 
Receptor-mediated mechanisms are based on the ability of chemicals to act directly as ligands 
for hormone receptors, like oestrogen, androgen, and thyroid receptors. Nuclear hormone 
receptors are a class of proteins that act together with other proteins to regulate the expression 
of specific genes (Gronemeyer et al., 2004). These receptors are designed to bind small, 
lipophilic molecules (i.e. the native endogenous ligands such as steroid hormones) but such 
characteristics may be shared by other exogenous substances, including environmental 
contaminants.  
 
Other mechanisms of disruption are based on interference with the synthesis, release, 
transport and metabolism of hormones. For example, the molecular targets of EAS include the 
cytochrome P450 enzymes in the steroid biosynthesis pathway (Sanderson, 2006). In addition, 
there is also growing evidence for the involvement of epigenetic mechanisms and their trans-
generational consequences (Hung et al. 2010; Zhang & Ho 2010; Manikkam et al., 2013), 
although the implications of such mechanisms for human health are still poorly understood. 
 
11.4 Status of methodology, including non-standard methods 
A wide range of in silico models, in vitro and in vivo methods have been or are being 
developed to support the assessment of EDs, as reviewed in various reports (Lo Piparo & 
                                                 
1 The Endocrine Disrupters Expert Advisory Group (ED EAG) was established in November 2011 as a sub-
group of the ad hoc group of Commission Services, EU Agencies and Member States for the Community 
Strategy on Endocrine Disrupters. The main role of the ED EAG has been to provide detailed reflections on 
scientific issues relevant to endocrine disrupting substances, not specific to any regulatory framework, including 
advice/orientation on scientific criteria for the identification of endocrine disrupting substances. 
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Worth, 2010; EFSA, 2013) and by the OECD (OECD 2012a; OECD 2012b). However, no 
single model or assay is likely to provide all the information needed to label a substance as an 
ED, since information on both the mode of action and the adverse effect will be required, if 
recommendations from the EFSA and the ED EAG are followed (EFSA, 2013; Munn & 
Goumenou, 2013).  
 
The OECD Conceptual Framework (CF) for the testing and assessment of endocrine 
disrupters provides a structured guide to the standardised test methods available or proposed 
as OECD Test Guidelines (OECD, 2012a). According to OECD CF (Table 11.2), information 
on endocrine activity can be obtained from existing information, read-across, and in silico 
tools (collectively referred to as Level 1), as well as in vitro (Level 2) and in vivo (Level 3) 
screening assays providing mechanistic information. Since a prerequisite for an EAS to be 
regarded as an ED is likely to be the identification of an endocrine-mediated adverse effect, in 
vivo test methods based on apical endpoints to demonstrate the adverse pathological or 
functional effect in the intact organism are also included (Levels 4 and 5). It should be noted 
that the OECD CF is not intended to be a testing strategy, but rather a list of potentially useful 
methods and data sources. Most of the level 2, 3 and 4 endocrine specific methods in the 
OECD CF are not explicitly required for the assessment of chemicals under REACH, PPPR 
or the BPR. For assessment of effects on wildlife populations this also applies to the methods 
indicated under level 5. 
 
Level 1 of the OECD CF consists of all available information, including physicochemical 
properties, data from standardised and non-standardised tests, epidemiological and field 
studies, and in silico predictions.   
 
Given the wide variety of mechanisms by which EDs can act, it is unrealistic to capture all 
endocrine disrupting activity in a single in silico model. These models have therefore focused 
on the prediction of endocrine-related adverse outcomes (such as reproductive and 
developmental toxicity) or on the binding and subsequent activation or inactivation of 
receptors associated with these adverse outcomes (Lo Piparo & Worth, 2010; Cronin & 
Worth, 2008). The most popular target for modelling has been the Oestrogen Receptor (ER), 
with methods including both ligand-based and receptor-based modelling (Tsakovska et al., 
2011). Taking advantage of the numerous available 3D structures of the ER receptor (several 
high resolution structures of the α, β, and dimer forms co-crystalized with various ligands), 
docking simulations and 3D QSAR methods like CoMFA (Comparative Molecular Field 
Analysis) have been used. These methods simulate key MIEs associated with endocrine 
disruption. An alternative modelling approach has been to apply machine learning algorithms 
(e.g. linear regression, decision trees, nearest neighbours, neural networks, support vector 
machines) to molecular descriptors (Novic & Vracko, 2010). These statistical methods, based 
exclusively on the ligand properties, offer potentially useful classifiers, but are often lacking 
mechanistic interpretability. To a lesser extent, the androgen receptor and thyroid receptor 
have also been modelled. A promising and more recent development has been to combine 
automated docking simulations with QSAR (Vedani et al., 2012). The advantages and 
limitations of the main types of in silico methods are given in Table 11.3. 
 
Level 2 of the CF currently consists of in vitro methods for detecting estrogenic, androgenic 
and steroidogenic activity, whereas in vitro test guidelines based on thyroid activity are 
currently lacking. Examples of recently developed in vitro test guidelines include:  
a) OECD TG 455, a performance based test guideline for estrogenic (agonist) activity via 
ER transactivation;  
b) OECD TG 456, a human adenocarcinoma cell line (H295R) for effects on 
steroidogenesis; and  
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c) OECD TG 457, an ER transactivation assay based on a human ovarian 
adenocarcinoma cell line (BG1Luc4E2) to identify both estrogenic and anti-estrogenic 
activity. Other methods are undergoing validation by EURL ECVAM, including the 
MELN assay for ER agonism/antagonism (study in progress) and several assays for 
AR agonism/antagonism (study in planning phase). The advantages and limitations of 
the main types of in vitro test are given in Table 11.4. 
 
Level 3 consists of in vivo screening assays that provide insight into chemical interactions 
with single selected endocrine mechanism(s) / signalling pathways.  
 
Levels 4 and 5 consist of assays that assess in vivo adverse apical outcomes including 
endocrine-relevant endpoints. These assays provide insight into chemical interactions with 
multiple endocrine signalling pathways or endpoints. However, effects can be sensitive to 
more than one mechanism and may be due to non-endocrine mechanisms.  
 
Level 5 consists of whole-organism assays that are designed to provide more comprehensive 
data on adverse effects on endocrine-relevant endpoints over more extensive parts of the life 
cycle of the organism than level 4. 
 
There are many additional activities ongoing contributing to the development of 
methodologies for the assessment of endocrine disrupters, a number of which are being 
conducted under the auspices of OECD. Notably, the OECD Detailed Review Paper on “the 
State of the Science on novel in vitro and in vivo screening and testing methods and endpoints 
for evaluating endocrine disruptors” (OECD, 2012b) provides an evaluation of further 
endocrine pathways and targets for disruption, along with assays that show promise in 
evaluating the target in a screening and testing programme, in order to consider such assays 
for validation to complement the existing OECD Test Guidelines. In particular, an OECD 
Expert Group is currently focusing on the elucidation of pathways linked to disruption of 
thyroid hormone and the hypothalamic-pituitary-thyroid (HPT) axis, identifying the most 
promising assays capable of probing various modes of action to which could brought forward 
for validation. 
 
One of the critical missing components in the translation of in vitro data to the in vivo 
situation is knowledge of absorption, distribution, metabolism and excretion (ADME) in the 
intact organism. Consequently knowledge of the metabolic fate of the parent compound and 
delivery of the active moiety to the relevant tissue has also to be developed before it will be 
possible to accurately predict endocrine disruption in vivo (Jacobs et al., 2013). In relation to 
metabolism, the characterising of cells used in such assays for metabolic capacity and 
consideration of introducing additional metabolising systems into current in vitro assays is 
also being taken up within the OECD. 
 
11.5 Adverse Outcome Pathways (AOPs) 
Adverse Outcome Pathways is a concept in which existing knowledge concerning the linkage 
between a direct molecular initiating event and an adverse outcome is portrayed at a level of 
biological organisation relevant to risk assessment. Once an adverse outcome pathway (AOP) 
has been elucidated for one chemical whereby the series of events from MIE through a series 
of key events to an adverse outcome has been identified for one chemical or group of 
chemicals it may become possible to associate other chemicals to the group not only on the 
basis of structure but also in relation to shared modes of action. 
 
Although not specific to endocrine disrupters, it can be envisaged that once the linkages 
between upstream key events which can be measured in vitro can be quantitatively linked to 
the likelihood of an adverse effect occurring in vivo such evidence could be used in hazard 
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identification of EDs as well as providing points of departure for risk assessment. The 
development of AOPs for a number of adverse outcomes via endocrine modes of action is 
currently in progress at OECD. Examples include the AOPs linking Aromatase Inhibition, 
Androgen Receptor Agonism, Oestrogen Receptor Antagonism, and Steroidogenesis 
Inhibition, to Impaired Reproduction in Small Repeat-Spawning Fish Species. Further 
information is available from the OECD (http://www.oecd.org/env/ehs/testing/adverse-
outcome-pathways-molecular-screening-and-toxicogenomics.htm). 
  
One of the critical missing components in the translation of in vitro data to the in vivo 
situation is knowledge of absorption, distribution, metabolism and excretion (ADME) in the 
intact organism. Consequently knowledge of activation or deactivation of the parent 
compound and delivery of the active moiety to the relevant tissue has also to be developed 
before it will be possible to accurately predict endocrine disruption in vivo (OECD 2008; 
Jacobs et al, 2013). In relation to metabolism, the characterising of cells used in in vitro 
assays for metabolic capacity and consideration of introducing exogenous metabolising 
systems into current in vitro assays is also being actively pursued at OECD level. In addition 
an OECD Expert Group is currently focusing on the elucidation of pathways linked to 
disruption of thyroid hormone and the hypothalamic-pituitary-thyroid (HPT) axis, identifying 
the most promising assays capable of probing various modes of action which could be 
brought forward for validation. The OECD Detailed Review Paper No.178 (OECD, 2012b) 
describes a number of other endocrine-related pathways and available assays to measure 
modulation of such pathways which may be suitable for further development and validation, 
and some member countries are already proposing projects to develop assays for other 
endocrine pathways beyond estrogen, androgen, and thyroid-related pathways. 
 
11.6 Conclusions 
The policy need to identify EDs within REACH and the Biocidal Products Regulation (as 
well as a number of other chemical control-related pieces of legislation including the Plant 
Protection Products Regualtion) drives the need to develop assays that can identify not only 
the toxicity of a chemical but also the mode of action leading to toxicity. In order to proceed 
with risk assessment quantitative information on dose-response relationships will also be 
required.  
 
According to the opinion of the ED EAG, also supported by EFSA's Scientific Committee, the 
elements for identification of an endocrine disrupter are demonstration of an adverse effect for 
which there is convincing evidence of a biologically plausible link to an endocrine disrupting 
mode of action and for which disruption is not a secondary consequence of other non-
endocrine mediated systemic toxicity. The assays and tools specified in levels 1 to 5 of the 
OECD CF for the testing and assessment of endocrine disrupters provides a suite of assays 
that allows the identification of an adverse effect in the apical in vivo studies and the 
indication of some specific endocrine modes of action via disruption of oestrogen or androgen 
signalling, inhibition of steroidogenesis and some in vivo biomarkers of endocrine disruption. 
At the moment these mechanistic assays are foreseen to be used either in a screening and 
prioritisation context to identify potential endocrine disrupters, which can be followed with 
appropriate in vivo testing to identify plausibly linked adverse effects, or to investigate 
adverse effects already identified in in vivo studies that are suspected of being caused by an 
endocrine disrupting mode of action. Further work is needed to establish integrated 
assessment strategies not reliant on animal testing to meet the regulatory definition of an ED 
Therefore, it is currently unlikely that in vivo testing could be avoided in most cases apart 
from where strong arguments for read-across could be justified. 
 
A wide range of activities are in progress which can contribute towards the goal of developing 
alternative non-animal approaches for use in the identification of endocrine disrupters, but 
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considerable work is still required to optimise individual methods and combine them in a 
manner that could adequately model the complexity of endocrine disruption. Since knowledge 
of the underlying mechanisms of ED action is still incomplete, and the battery of suitable in 
silico models and in vitro tests inadequate, it is not possible to determine, with a high degree 
of certainty, whether a substance is an ED without performing appropriate in vivo studies. 
Furthermore, even currently available in vivo assays might result in an underestimation of the 
full extent of the risks associated with EDs, due to factors such as the sensitivity of the animal 
model in relation to humans, the possible lack of inclusion of the most sensitive endpoints 
during the most sensitive life stages in current in vivo assays and particularly the possibility of 
missing delayed and potentially serious effects. 
 
The OECD CF provides a useful way of categorising different (animal and non-animal) 
models according to the type of information they provide. Furthermore, the AOP approach 
provides a useful means of organising knowledge on the mechanistic pathways of endocrine 
disruption, thereby forming a rational basis for developing integrated assessment approaches 
and building weight-of-evidence arguments. For example, computational and in vitro models 
that provide information on ligand-receptor interactions could be used to establish the 
likelihood of ED-related MIEs. This information could then be combined with predictions of 
downstream events, including the final adverse outcome (AO). If the AOP is well established, 
evidence for a “plausible causal link” between the MIE and the AO will already be available; 
conversely, if the AOP is tentative, further information (either from the literature or generated 
by ad hoc studies) would be needed to support the conclusion that a substance is an ED.  
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Table 11.1. The treatment of EDs in REACH, PPPR, BPR and the cosmetic products regulation 
 
 
Legislation ED-related provisions 
REACH Regulation (EC No 
1907/2006), Art. 57(f)  
Stipulates that substances subject to authorisation may include 
…those having endocrine disrupting properties …for which 
there is scientific evidence of  probable serious effects to 
human health or the environment which give rise to an 
equivalent level of concern as Carcinogens, Mutagens and 
Reproductive and Developmental Toxicants (CMR) or 
Persistent, Bioaccumulative and Toxic (PBTs) or very Persistent 
and very Bioaccumulative (vPvBs) substances and which are 
identified on a case by case basis in accordance with Article 59 
(a review of the authorisation procedure with regard to endocrine 
disruptors is required by 1 June 2013 (cf. Article 138(7)2). 
Regulation (528/2012) on 
Biocidal Product (BPR) 
 
indicates that active substances shall not be approved if they are 
considered as having endocrine-disrupting properties that may 
cause adverse effects in humans or which are identified in 
accordance with Article 57(f) and 59(1) of REACH as having 
endocrine disrupting properties. No later than 13 December 2013 
the Commission shall adopt …. scientific criteria for the 
determination of endocrine disrupting properties3 
Pending the adoption of these criteria, substances that are or 
have to be classified, in accordance with the provisions of 
Regulation (EC) No 1272/2008, as  
• carcinogenic category 2 and toxic for reproduction 
category 2, shall be considered to have endocrine 
disrupting properties.  
• toxic for reproduction category 2 and which have toxic 
effects on the endocrine organs, may be considered to 
have such endocrine disrupting properties.  
 
                                                 
2 As of 4 April 2014 review not completed 
3 As of 4 April 2014 criteria not yet adopted 
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Legislation ED-related provisions 
Regulation on Plant Protection 
Products (EC No 1107/2009) 
(PPPR) 
stipulates that an active substance, safener or synergist shall only 
be approved if, …it is not considered to have endocrine 
disrupting properties that may cause adverse effects in humans 
or non-target organisms, unless the exposure is …negligible. 
Furthermore, the Commission is mandated to present a draft of 
the measures concerning specific scientific criteria for the 
determination of endocrine disrupting properties by 13 
December 20134.  
Pending the adoption of these criteria, substances that are or 
have to be classified, in accordance with the provisions of 
Regulation (EC) No 1272/2008, as  
• carcinogenic category 2 and toxic for reproduction 
category 2, shall be considered to have endocrine 
disrupting properties.  
• toxic for reproduction category 2 and which have toxic 
effects on the endocrine organs, may be considered to 
have such endocrine disrupting properties.  
 
 
Cosmetic Products Regulation 
(EC No 1223/2009), Article 15 
(4). 
 
states that as soon as Community or internationally agreed 
criteria for identifying substances with endocrine disrupting 
properties are available, or at the latest on 11 January 2015, the 
Commission shall review this Regulation with regard to 
substances with endocrine-disrupting properties. 
 
 
 
                                                 
4 As of 4 April 2014 criteria not yet proposed by COM 
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Table 11.2. OECD Revised Conceptual Framework for Testing and Assessment of Endocrine 
Disrupters 
 
OECD Conceptual 
Framework 
Mammalian and non-mammalian toxicology 
  
Level 1. Existing information 
and non-test information 
• Physical & chemical properties, e.g., MW reactivity, 
volatility, biodegradability 
• All available (eco)toxicological data from standardized or 
non-standardized tests 
• Read across, chemical categories, QSARs and other in silico 
predictions, and ADME model predictions 
Level 2. In vitro assays 
providing data about selected 
endocrine mechanism(s) / 
pathways(s) (Mammalian and 
non mammalian methods) 
• Estrogen or androgen receptor binding affinity 
• Estrogen receptor transactivation (OECD TG 455) 
• Androgen or thyroid transactivation (If/when TGs are 
available) 
• Steroidogenesis in vitro (OECD TG 456) 
• MCF-7 cell proliferation assays (ER antagonist) 
• Other assays as appropriate 
 
 
 Mammalian Toxicology Non-mammalian Toxicology 
Level 3. In vivo assays 
providing data about selected 
endocrine mechanism(s) / 
pathway(s)1 
• Uterotrophic assay (OECD 
TG 440) 
• Hershberger assay (OECD TG 
441) 
• Xenopus embryo thyroid 
signalling assay 
(When/if TG is available) 
• Amphibian metamorphosis 
assay (OECD TG 231) 
• Fish reproductive screening 
assay (OECD TG 229) 
• Fish screening assay 
(OECD TG 230) 
• Androgenized female 
stickleback screen (GD 140) 
 
Level 4. In vivo assays 
providing data on adverse 
effects on endocrine relevant 
endpoints2 
• Repeated dose 28-day study 
(OECD TG 407) 
• Repeated dose 90-day study 
(OECD TG 408) 
• 1-generation reproduction 
toxicity study (OECD TG 415) 
• Male pubertal assay (GD 
150)3 
• Female pubertal assay (GD 
150)3 
• Intact adult male endocrine 
screening assay (GD 150) 
 
• Prenatal developmental 
toxicity study (OECD TG 414) 
• Chronic toxicity and 
carcinogenicity studies (OECD 
TG 451-453) 
• Reproductive screening test 
(OECD TG 421 if enhanced) 
• Combined 28-
day/reproductive screening 
assay (OECD TG 422 if 
enhanced) 
• Fish sexual development 
test (Draft OECD TG 234) 
• Fish reproduction Partial 
Lifecycle Test (when/If TG 
is Available) 
• Larval amphibian growth & 
development assay (when 
TG is available) 
• Avian reproduction assay 
(OECD TG 206) 
• Mollusc partial lifecycle 
assays (when TG is 
available)4 
• Chironomid toxicity test 
(TG 218-219)4 
• Daphnia reproduction test 
(with male induction) 
(OECD TG 211)4 
 
• Earthworm reproduction 
test (OECD TG 
222)4 
• Enchytraeid reproduction 
test (OECD TG 
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OECD Conceptual 
Framework 
Mammalian and non-mammalian toxicology 
• Developmental neurotoxicity 
(OECD TG 426) 
220)4 
• Sediment water 
lumbriculus toxicity test 
using spiked sediment 
(OECD TG 225)4 
• Predatory mite 
reproduction test in soil 
(OECD TG 226)4 
• Collembolan reproduction 
test in soil 
(OECD TG 232)4 
 
Level 5. In vivo assays 
providing more comprehensive 
data on adverse effects on 
endocrine relevant endpoints 
over more extensive parts of the 
life cycle of the organism2 
• Extended one-generation 
reproductive toxicity study 
(OECD TG 443)5 
• 2-Generation reproduction 
toxicity study (OECD TG 416 
most recent update) 
• Fish lifecycle toxicity test 
(FLCTT) (when 
TG is available) 
• Medaka multigeneration 
test (MMGT) 
(when TG is available) 
• Avian 2 generation 
reproductive toxicity 
assay (when TG is available) 
• Mysid lifecycle toxicity test 
(when TG is 
available)4 
• Copepod reproduction and 
development test 
(when TG is available)4 
• Sediment water chironomid 
life cycle 
toxicity test (OECD TG 
233)4 
• Mollusc full lifecycle 
assays (when TG is 
available)4 
• Daphnia multigeneration 
assay (if TG is 
available)4 
 
 
Footnotes 
1) Some assays may also provide some evidence of adverse effects. 
2) Effects can be sensitive to more than one mechanism and may be due to non-ED mechanisms. 
3) Depending on the guideline/protocol used, the fact that a substance may interact with a hormone system in 
these assays does not necessarily mean that when the substance is used it will cause adverse effects in humans or 
ecological systems. 
4) At present, the available invertebrate assays solely involve apical endpoints which are able to respond to some 
endocrine disrupters and some non- EDs. Those in Level 4 are partial lifecycle tests, while those in Level 5 are 
full- or multiple lifecycle tests. 
5) The new EOGRT study (OECD TG 443) is preferable for detecting endocrine disruption because it provides 
an evaluation of a number of endocrine endpoints in the juvenile and adult F1, which are not included in the 2-
generation study (OECD TG 416) adopted in 2001 
 
Notes to the OECD Revised Conceptual Framework 
Note 1: Entering at all levels and exiting at all levels is possible and depends upon the nature of existing 
information and needs for testing and assessment. 
Note 2: The assessment of each chemical should be made on a case by case basis, taking into account all 
available information. 
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Note 3: The framework should not be considered as all inclusive at the present time. At levels 2, 3, 4 and 5 it 
includes assays that are either available or for which validation is under way. With respect to the latter, these are 
provisionally included. 
 
  
Table 11.3. Advantages and limitations of in silico methods for endocrine disruptors 
 
Type of Method Advantages Limitations 
QSAR and machine learning • High accuracy statistical 
modelling. 
• Defined applicability domain. 
• Some machine learning 
methods and molecular 
descriptors lack mechanistic 
interpretation. 
• Choice of multiple parameters 
(algorithm, descriptors, …) 
Docking • Simulation of the 
ligand/protein complex. 
• In depth mechanistic 
interpretation. 
• Need for receptor 
crystallographic structure. 
• Non-automated procedure may 
be time consuming. 
Structural alerts • Simple and quick evaluation 
of toxicity 
• Generalisation may be 
debatable (lots of exceptions) 
 
 
Table 11.4. Advantages and limitations of in vitro tests for endocrine disruptors  
 
Type of Method Advantages 
 
Limitations 
Transactivation reporter assay • provide quantitative & functional 
information 
• commercially available for many 
receptors 
• reporter assays could serve as a 
screening assay to discern a 
potential anchoring molecular 
event that would trigger 
assessment along the relevant 
adverse outcome pathway 
• known performance capabilities, 
OECD TG 455 ER transactivation 
assay describes several assays  
• overall recommended for 
interaction with nuclear receptors 
• some disrupting chemicals 
may interact with different 
nuclear receptors and 
would be missed if only 
one receptor or DNA array 
is employed, hence initial 
screening assays need to 
cover multiple targets 
within the axes of the 
endocrine system.  
 
Receptor-binding assays • Species-specific membrane 
binding experiments in 
conjunction with e.g. ER binding 
or transactivation reporter assays 
(e.g., OECD TG 455) would 
provide a complete molecular
assessment of chemical-receptor 
interactions that may serve as the 
initiating event in the e.g. estrogen 
adverse outcome pathway 
• improved sensitivity achieved by 
including  also co-activators 
 
Receptor binding alone does 
not provide information  on 
activation or inactivation of 
the receptor 
DNA/protein binding assays • capacity to detect chemicals that 
are "not direct receptor ligands" 
 
Cell-based microarrays • capture changes in gene 
expression for massive numbers of 
genes and enable the simultaneous 
analyses of components along the 
signalling pathway, and its 
• cost and time intensive 
(assays require the 
construction of the arrays, 
many are commercially 
available, but are relatively 
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Type of Method Advantages 
 
Limitations 
product 
• fingerprint of the analysed 
compound 
• overall potential ability to assess 
chemical impact on multiple 
endocrine signalling pathways 
simultaneously however  the 
approach may not be sufficiently 
developed for routine, validated 
use at this time 
expensive) 
• analyses of the mass of 
data is complex 
• often lack of 
reproducibility  
• significant variability in 
gene responses attributed 
to cell type, agonist, 
arbitrary selection of 
threshold response levels, 
and lack of intra-
experiment  replication 
General cell based assays • cell based assays are relatively 
simple to perform, time and cost 
effective, and cell propagation 
methods standardized and able to 
accommodate high throughput and 
can identify endocrine toxicants 
that interact directly with hormone 
receptors 
• in vitro systems offer good 
reproducibility because effects are 
measured using the same cellular 
background, however, inter-
laboratory collaborations are 
necessary for standardization and 
validation 
• the lower biological complexity of 
in vitro systems compared to the 
situation in vivo makes the data 
interpretation more 
straightforward 
• in vitro methods provide the 
information about molecular 
initiating events  
 
• additional complexities 
within relevant cell-types 
by assaying the normal 
function of the    cells as 
related to the endocrine 
signalling pathway under 
investigation 
• some assays  require the 
isolation of primary cells 
from animals, and thus are 
not strictly non-animal 
methods 
• species extrapolation 
problems (mouse models 
may not be always 
relevant for humans) 
• many established cell lines 
available (including 
human-derived) but may 
not behave as normal 
primary cells and thus 
relevance to in vivo 
situation still unclear 
• in vitro studies in cell 
systems are predominantly 
limited to assessment of 
parent compound 
examined as e.g. receptor 
transactivation only 
reflects primary ligand 
binding unless cells are 
“metabolically” active 
• the interactions 
demonstrated between 
HPA, HPG, and HPT axes, 
and the immune system, 
indicate that generally in 
vitro assays cannot be 
considered definitive for 
screening of chemicals for 
potential endocrine 
disruption since they do 
not capture these 
interactions 
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hypothesis’’) for chemicals with endocrine activity (endocrine disrupting chemicals or EDCs). 
This workshop consisted of lectures to present the current state of the science of EDC action and 
also the risk assessment process. These lectures were followed by breakout sessions to integrate 
scientists from various backgrounds to discuss in an open and unbiased manner the data supporting 
the ‘‘low dose hypothesis’’. While no consensus was reached the robust discussions were helpful 
to inform both basic scientists and risk assessors on all the issues.  
Borgert, C. J. Baker, S. P., Matthews, J.C. 2013. Potency 
matters: Thresholds govern endocrine activity. Reg. Toxicol. 
Pharmac. 67: 83 - 88 
This brief review highlights how the fundamental principles governing 
hormonal effects – affinity, efficacy, potency, and mass action – dictate the existence of thresholds 
and why these principles also define the potential that exogenous chemicals might have to interfere 
with normal endocrine functioning. According to the authors vital signalling functions of the 
endocrine system require it to continuously discriminate the biological information conveyed by 
potent endogenous hormones from a more concentrated background of structurally similar, 
endogenous molecules with low hormonal potential. This obligatory ability to discriminate 
important hormonal signals from background noise can be used to define thresholds for induction 
of hormonal effects, without which normal physiological functions would be impossible. From 
such 
EFSA Scientific Colloquium Summary Report, 14-15 June 
2012. Low dose response in toxicology and risk assessment.  
The low-dose effect and non-monotonicity hypotheses challenge key concepts in toxicology and 
risk assessment, and also the possibility to predict the effects of a chemical at low levels of 
  
 
330 
http://www.efsa.europa.eu/en/supporting/doc/353e.pdf 
 
exposure from its effects at higher levels of exposure. This colloquium aimed to exchange views 
on the topics of low-dose effects and NMDRC and how these phenomena should 
Rhomberg, L.R. & Goodman, J.E., 2012. Low-dose effects and 
non-monotonic dose-responses of endocrine disrupting 
substances: has the case been made. Reg. Toxicol. Pharmacol. 
64: 130-133 
The paper is a commentary critiquing Vandenberg et al. 2012 (see below) The authors state that te 
Vandenberg analysis framework lacks the scientific rigor necessary for an objective evaluation of 
the extent to which a body of scientific evidence does, or does not, support the NMDR hypothesis. 
In their view, the case for widespread non-monotonicity leading to undetected toxicity at low 
doses has not been made, and indeed cannot be made, simply through assembling selected cases 
that are presumed to represent causal effects 
Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs 
DR, Jr., Lee DH, Shioda T, Soto AM, vom Saal FS, Welshons 
WV, Zoeller RT and Myers JP, 2012. Hormones and 
endocrine-disrupting chemicals: low-dose effects and 
nonmonotonic dose responses. Endocrine Reviews 33: 378-
455 
In this paper two major concepts in EDC studies are discussed: low dose and non-monotonicity. 
The mechanistic data for low-dose effects and use of a weight-of-evidence approach to analyse 
examples from the EDC literature are reviewed. The authors illustrate that non-monotonic 
responses and low-dose effects are remarkably common in studies of natural hormones and EDCs. 
This paper concludes that when non-monotonic dose-response curves occur, the effects of low 
doses cannot be predicted by the effects observed at high doses. Thus, fundamental changes in 
chemical testing and safety determination are needed to protect human health. 
In vitro methods 
Nielsen FK, Hansen CH, Fey J A, Hansen M, Jacobsen NW, 
Halling-Sørensen B, et al (2012). H295R cells as a model for 
steroidogenic disruption: a broader perspective using 
simultaneous chemical analysis of 7 key steroid hormones. 
Toxicology in Vitro 26: 343-350 
 
In this paper the effects of three model endocrine disruptors, prochloraz, ketoconazole and 
genistein on steroidogenesis were tested in the adrenocortical H295R cell line. It was demonstrated 
that mechanistic differentiation was possible for these compounds in one assay by applying 
chemical analysis to the H295R assay. In general, the applied analytical method, analyzing 7 
hormones simultaneously, enables the identification of important steps and differentiation of 
modes of action for the EDs investigated and the present findings correlate well with previous 
reports. The authors propose combining the present method with other techniques such as PCR 
and/or microarray to provide information on genes, enzymes and receptors involved in 
steroidogenesis and further aid to understand the mechanism by which EDs exert their effects on 
steroidogenesis. This could provide a better understanding of effects observed in vivo and 
mechanistic information or differentiation of modes of action. 
Murk, A. J., Rijntjes, E., Blaauboer, B. J., Clewell, R., Crofton, 
K. M., Dingemans, M. M. L.Gutleb, A. C. (2013). Mechanism-
based testing strategy using in vitro approaches for 
identification of thyroid hormone disrupting chemicals. 
Toxicology in Vitro 27: 1320–1346.  
In this paper authors described and recommended a battery of test methods able to classify 
chemicals as of less or high concern for further hazard and risk assessment for TH disruption 
(THD). In addition, research gaps and needs were identified to optimize and validate the targeted 
THD in vitro test battery for a mechanism-based strategy for a decision to opt out or to proceed 
with further testing for THD. 
Rotroff, D., Dix, D., Houck, K., Knudsen, T., MT, M., 
McLaurin, K. W., … Judson, R. (2013). Using in vitro high 
throughput screening assays to identify potential endocrine-
This review analyses the briefly the history of the research and regulation in area of endocrine 
disruptors and proposes a new testing battery for high throughput screening for the endocrine 
disruptive potential of chemicals. The study uses U.S. EPA ToxCast HTS assays for estrogen, 
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disrupting chemicals. Environmental Health Perspectives 121: 
7–14. 
 
androgen, steroidogenic, and thyroid-disrupting mechanisms to classify compounds and compare 
ToxCast results to in vitro and in vivo data from Endocrine Disruptor Screening Program (EDSP) 
T1S assays. The authors implemented an iterative model that optimized the ability of endocrine-
related HTS assays to predict components of EDSP T1S and related results. The analysis shown 
that ToxCast estrogen receptor and androgen receptor assays predicted the results of relevant 
EDSP T1S assays with balanced accuracies and as well as  Uterotrophic and Hershberger. Models 
for steroidogenic and thyroid-related effects could not be developed with the currently published 
ToxCast data. Overall, the results suggested that current ToxCast assays can accurately identify 
chemicals with potential to interact with the estrogenic and androgenic pathways, and therefore 
help prioritize chemicals for EDSP T1S assays. 
In silico methods 
Benfenati E, Roncaglioni A, Boriani E, Porcelli C, Spreafico 
M and Lo Piparo E, 2005. Validation of selected, non-
commercial (Q)SAR models for Estrogen Receptor and 
Androgen Receptor binding. Final report of JRC contract 
CCR.IHCP.C430414.X0. 96 pp. Available from: 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/inf
ormation-sources/qsar-document-
area/Final_report_Mario_Negri.pdf 
 
A detailed literature review was conducted in order to identify all interesting publications related 
to ER and AR endpoints including bibliographic search, search through EC projects and the World 
Wide Web.  
Specific key points were collected, identifying suitable sources of data for testing that can serve as 
the basis for a new proposal for a high-quality QSAR. 
A rational scheme for applying the scores to each model was stated and its application permitted to 
identify most promising models at the top-level scores. 
Different kinds of model (regression and classification, SAR and QSAR models) have been 
analysed more in detail and when possible they were externally validated with data found in 
literature. Several ways for assessing the applicability domain have been evaluated depending on 
the available information. 
Currently available qualitative models (SAR and classification models) gave better results. 
Finally, based on the studies conducted during the project a rationale for developing a new high 
quality (Q)SAR is suggested for the future. 
Lo Piparo E & Worth A (2010). Review of QSAR Models and 
Software Tools for Predicting Developmental and 
Reproductive Toxicity. JRC Scientific and Technical Report 
EUR 24522 EN  Available from: 
http://publications.jrc.ec.europa.eu/repository 
 
This JRC report provides a state-of-the-art review of available computational models for 
developmental and reproductive toxicity, including Quantitative Structure-Activity Relationship 
(QSARs) and related estimation methods such as decision tree approaches and expert systems. At 
the time of the publication, there were relatively few models for developmental and reproductive 
toxicity endpoints, and those available had limited applicability domains. This situation is partly 
due to the biological complexity of the endpoint, which covers many incompletely understood 
mechanisms of action, and partly due to the paucity and heterogeneity of high quality data suitable 
for model development. In contrast, there is an extensive and growing range of software and 
literature models for predicting endocrine-related activities, in particular models for oestrogen and 
androgen activity. There is a considerable need to further develop and characterise in silico models 
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for developmental and reproductive toxicity, and to explore their applicability in a regulatory 
setting. 
OECD (2009b). Series on Testing and Assessment: No 111: 
Report of the Expert Consultation to Evaluate an Estrogen 
Receptor Binding Affinity Model for Hazard Identification. 
ENV/JM/MONO(2009)33, 119 pp. 
This document is a report of an expert consultation held on 17 February 2009 with the aim to  
evaluate a QSAR approach for estimating estrogen receptor binding affinity for chemicals in 
defined regulatory inventories developed by the United States Environmental Protection Agency. 
The expert consultation was held based on the key recommendation from the OECD Workshop on 
Structural Alerts for the OECD (Q)SAR Application Toolbox held in May 2008 to develop 
structural alerts for identifying estrogen receptor binders for inclusion in the Toolbox during phase 
2 development which started in November 2008. 
Johnson, C. M., Achary, M., & Suri, R. P. (2013). An 
interaction model for estimating in vitro estrogenic and 
androgenic activity of chemical mixtures. Environmental 
Science & Technology 47: 4661-4669.  
 
In this paper an alternate index, aRP, which enables the quantification of an antagonistic 
interaction from analytically derived concentrations of chemical constituents within a mixture that 
act upon the same molecular target is described. The index is calculated by measuring the degree 
to which the test compound modulates the activity of a standard hormone as a function of mixture 
proportions. The aRP was shown to be valid for additive mixtures. It theoretically estimates the 
product of the relative potential and the interaction index inverse for non-additive mixtures. The 
aRP values were computed for agonists and antagonists of both the estrogen and androgen 
receptors by using yeast-based methods (YES and YAS). The resulting aRP estimates were then 
validated using higher order mixtures of agonists and antagonists. The use of aRP led to improved 
predictions compared to estimates based on the toxicity equivalent factor (TEF) approach. The 
aRP model yielded estimates that were statistically indistinguishable (α = 0.01) from the measured 
responses in 75% of the 32 mixtures tested. By the same criteria, the TEF approach successfully 
predicted 34% of the mixtures. Both the aRP and TEF approach correlated well with the observed 
responses (Pearson R = 0.98 and 0.84, respectively); however, the TEF estimates produced higher 
percent errors, particularly in mixtures with higher proportions of antagonists. It is suggested that 
the use of the aRP index allows for a better approximation of the net activity captured by the 
bioassays through the use of chemically derived concentrations.  
 
Testing and assessment strategies  
Davis M, Boekelheide K, Boverhof DR, Eichenbaum G, 
Hartung T, Holsapple MP, Watkins PB (2013). The new 
revolution in toxicology: the good, the bad, and the ugly. 
Annals of the New York Academy of Sciences 1278: 11–24. 
http://onlinelibrary.wiley.com/doi/10.1111/nyas.12086/abstract
;jsessionid=908D828E061387ACD8A0D582AAC66151.d02t0
1 
This paper summarises the discussions held during the conference entitled “The New Revolution 
in Toxicology: The Good, Bad and Ugly” in 2011 hosted at the New York Academy of Sciences. 
The conference was focused on assessing the implementation of the vision presented in the report 
"Toxicity Testing in the 21st Century: A Vision and a Strategy", published by the United States 
National Academy of Sciences in 2007. The authors proposed the use some of the high-throughput 
assays from ToxCast to prioritize endocrine disruptor screening (EDSP21 program) as being the 
most advanced example ready for regulatory use. The article reviewed the achievements and the 
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relevance of these achievements to safety assessment of new chemical entities intended for 
pharmaceutical use. 
Kolle SN et al. (2012). A testing strategy for the identification 
of mammalian, systemic endocrine disruptors with particular 
focus on steroids. Regulatory Toxicology and Pharmacology: 
63:259-278. 
  
In this paper authors present an alternative testing paradigm for detection of endocrine modes of 
action that replace and reduce animal testing through refinement. The yeast-based receptor- 
mediated transcriptional activation YES/YAS assays were used to asses receptor mediated 
endocrine effects and effects on steroid hormone biosynthesis were assessed using the human cell 
line H295R in the steroidogenesis assay. The testing strategy was based on complementation of 
the in vitro assays with a single in vivo repeated dose study in which plasma samples are analyzed 
for their metabolome profile in addition to classical parameters such as histopathology. The 
authors claim that the combination of these methods does not only contribute to refinement and 
reduction of animal testing, but also has significantly increased the efficient allocation of resources 
and allows for a sound assessment of the endocrine disruption potential of compounds. Thus, this 
proposal constitutes a potentially attractive alternative to EPA’s Endocrine Disruptor Screening 
Program to identify mammalian, systemic endocrine modes of action. Data on 14 reference 
substances for which the in vitro YES/YAS and steroidogenesis assays and the in vivo 
metabolome analysis were performed to assess their putative endocrine modes of action are 
presented. 
Databases  
Ding D, Xu L, Fang H, Hong H, Perkins R, Harris S & Tong 
W (2010). The EDKB: an established knowledge base for 
endocrine disrupting chemicals. BMC Bioinformatics, 11 
Suppl 6(Suppl 6), S5. 
This project was initiated in the mid 1990’s by the FDA as a resource for the study of EDs. The 
EDKB database, a component of the project, contains data across multiple assay types for 
chemicals across a broad structural diversity. The database contains 1,284 binding assays, reporter-
gene assays, cell-proliferation assays, and in-vivo assays. It is cross-linked to other publicly 
available and related databases including TOXNET, Cactus, ChemIDplus, ChemACX, Chem 
Finder, and NCI DTP. 
Shen J, Xu L, Fang H, Richard AM, Bray JD, Judson RS, & 
Hong H (2013). EADB: An Estrogenic Activity Database for 
Assessing Potential Endocrine Activity. Toxicological 
Sciences: 135(2), 277–91. 
An Estrogenic Activity Database for Assessing Potential Endocrine Activity. EADB assembles a 
comprehensive set of estrogenic activity data from a variety of data sources and is a component of 
the enhanced Endocrine Disruptors Knowledge Base (EDKB). Searching can be carried out on 
structure (substructure search, super structure search, similarity search, full search, R-group 
search, and exclusion search) or on data, including numerical data (various estrogenic activity 
data) and text data (assay descriptions and literature references), as well as logical combinations of 
multiple searching operations.  
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12. Toxicokinetics 
Varvara Gouliarmou, Sandra Coecke, Alicia Paini & Andrew Worth 
 
12.1 In vivo sources of toxicokinetic information and regulatory guidelines 
Toxicokinetics is the description of the penetration of a chemical into the body and its 
subsequent fate following exposure, which can for example be oral, dermal or through 
inhalation. Simply stated, toxicokinetics (TK) can be defined as what the body does to the 
chemical, as opposed to toxicodynamics (TD), which can be defined as what the chemical 
does to the body. 
Traditionally, TK studies are performed in rats, according to OECD Test Guideline 417, by 
employing a minimum of four animals of each sex for each dose tested when no data are 
available. The measurement endpoints are the absorption rate, tissue distribution, metabolism 
and excretion of the chemical and its metabolites, together with TK parameters 
(bioavailability, Area under the curve [AUC], maximal plasma concentration [Cmax], time to 
reach Cmax [Tmax], clearance, half time). In the case of dermal exposure, in vivo studies are 
conducted according to the TG 427 and in vitro studies according to TG 428. EFSA has 
published a dermal absorption guidance document regarding the critical aspects related to the 
setting of dermal absorption values to be used in risk assessments of chemical plant protection 
products. EMA has published a guidance document (CPMP/ICH/384/95) regarding the TK 
assessment of pharmaceutical products intended for use in humans (Rowland, 2006). 
The microdosing technique is another source of in vivo TK information (bioavailability and 
even metabolite identification) where human volunteers are used. In this technique, the TK of 
a drug is studied through the administration of doses lower than 1% of pharmacological active 
dose and up to a maximum of 100 μg. These doses are unlikely to produce whole-body 
effects, but are high enough to allow the cellular response to be studied. However, prior to 
microdosing, study of the likely risk of the chemical should be provided. This is achieved by a 
mixture of in vitro and animal (usually rat) data and in accordance to requirements laid down 
the latest ICH M3 (R2) guideline, which is now universally accepted (EMA, 2009).   
The study of TK in mammals is a requirement for active ingredients in plant protection 
products (Regulation (EC) No 1107/2009) and in biocidal products (Regulation (EU) No 
528/2012). In the REACH regulation, the conduct of new TK studies is not obligatory. 
However, Annex I (Section 1.0.2) requires the TK profile to be considered in the human 
health hazard assessment, and Annexes VIII-X require consideration of TK data if they are 
available.  
 
12.2 Toxicokinetic processes - ADME 
The four components of TK are Absorption, Distribution, Metabolism and Excretion, referred 
to collectively as ADME. The interplay between these processes defines the penetration and 
the fate of a compound in the body (Coecke et al., 2013). 
Absorption is how a compound penetrates into the body. It is the process by which a 
compound passages from outer lining membranes such as the gut epithelium, the skin or the 
lung epithelium reaching subsequently the fluids and tissues/organs of the body. Compounds 
can be absorbed 1) passively through the cell membrane (transcellular route) or via the 
junctions between the cells (paracellular route) or 2) actively through carrier-mediation via an 
active or facilitated diffusion (Sarmento et al., 2012). Additional, more than 400 types of 
efflux and influx transporters, localized in tissues and various cellular membranes of the 
human body, are functional and play a crucial role in absorption and disposition (Kathleen et 
al., 2010). The preferred pathway for absorption or transport of a specific compound depends 
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on its physicochemical characteristics and the biological features of the membrane (Sarmento 
et al., 2012). 
Distribution is the dispersion of a compound throughout fluids and tissues/organs of the body. 
This process describes how the compound is allocated to specific body compartments. After 
absorption, the distribution of a compound (and its metabolites) inside the body is governed 
by three main factors: 1) its partitioning between plasma fluid and plasma proteins; 2) its 
partitioning between blood and specific tissues; and 3) the ability of the substance to cross 
internal physiological interfaces, the so-called barriers (e.g. blood-brain barrier, blood-
placenta barrier, blood-testis barrier) (Adler et al., 2011). 
Metabolism (or biotransformation) is how the body chemically modifies a compound and it is 
the principal elimination route for most compounds. A vast number of xenobiotic 
metabolizing enzymes exist in human body (Klaassen, 2011). A toxic compound can be 
detoxified or a nontoxic compound may be transformed to toxic metabolite by 
biotransformation. Metabolism occurs in many tissues with liver being the most important 
organ, but also the kidneys, intestines, lungs, brain, nasal epithelium and skin can be involved 
(Asha & Vidyavathi, 2010). Generally, hepatic metabolism involves a phase I reaction where 
non polar molecules are converted into a polar compound and phase II conjugation where 
suitable moieties are added to the compound (Li, 2005). 
Excretion is how the body irreversibly removes a chemical and its metabolites. Excretion 
occurs via kidneys (renal excretion), exhalation and less commonly via hepatobiliary system. 
Renal excretion is the results of three different mechanisms and they all include the interplay 
of both passive movement of the chemical and the participation of a number of active 
transporters. This process is mainly important for hydrophilic compounds. Exhalation is the 
primary excretion route for more volatile compounds. This process is mainly controlled by the 
affinity of compound between the blood and the air. Finally, biliary excretion is first preceded 
with the entry of the substance to the hepatocyte and its possible biotransformation by the 
phase I and/or phase II enzymes, with for some substances ultimately excreted into the bile 
(Adler et al., 2011).  
 
12.3 Uses of toxicokinetic information 
In the regulatory assessment of chemicals, TK information is useful in the design and 
interpretation of experimental studies, including animal experiments and non-animal testing 
strategies. A range of further possible applications is given in Table 12.1. In principle, all of 
these use cases could be addressed by using a suitable selection of non-standard methods. 
Some chemical-specific case studies illustrating how TK information can be used to improve 
experimental design and the final risk assessment are given by Bessems & Geraets (2013). 
No ADME process occurs in isolation, instead complex interactions between the four 
processes results in a time dependent concentration of the compound in the systemic 
circulation or at a target site. In the vitro methods described below, cells and tissues are 
exposed to a fixed concentration. In contrast, in the body, cells and internal barriers are 
exposed to a time-dependent concentration profile of both parent compounds and formed 
metabolites as a result of the interplay of ADME processes. TK has been identified as a key 
element to integrate the results from in silico, in vitro and already available in vivo toxicity 
studies.  
TK is needed to estimate the range of target organ doses that can be expected from realistic 
external exposure scenarios. This information is crucial for determining the dose range that 
should be used for in vitro testing. Vice versa, TK is necessary to convert the in vitro results, 
generated at tissue/cell or sub-cellular level, into dose response or potency information 
relating to the entire target organism, i.e. the human body (in vitro – in vivo extrapolation).  
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Physiologically based toxicokinetic modelling (PBTK) is currently regarded as the most 
adequate approach to simulate human TK. The fact that PBTK models are mechanism-based 
and therefore allows them to be ‘generic’ to a certain extent (various extrapolations possible) 
has been critical for their success so far. The need for high-quality in vitro and in silico TK 
data as input for PBTK models to predict human dose-response curves is currently a 
bottleneck for integrative risk assessment. The full replacement of current animal 
toxicokinetics tests by PBTK modelling, based on in silico and in vitro data, will take many 
years of increased efforts. 
TK information is crucial in read-across and grouping of chemicals. Verification that similar 
TK properties apply to the members of a suggested group/category of chemicals is considered 
to be one the steps in building a case of a plausible read-across case under the REACH 
Regulation. This is acknowledged in Annex XI, 1.5 according to which similarities among the 
group members may be based e.g. on “the common precursors and/or the likelihood of 
common break-down products via physical and biological processes, which result in 
structurally similar chemicals”.  
Under REACH there is a possibility to waive/adapt certain information requirements. The 
sub-chronic study can be waived, if “the substance is unreactive, insoluble and not inhalable 
and there is no evidence of absorption and no evidence of toxicity in a 28-day ‘limit test’, 
particularly if such a pattern is coupled with limited human exposure.” (REACH Regulation 
Annex IX, 8.6.2. Column 2). Furthermore, pre-natal developmental toxicity and two 
generation reproductive toxicity test can be waived, if  “the substance is of low toxicological 
activity (no evidence of toxicity seen in any of the tests available), it can be proven from 
toxicokinetic data that no systemic absorption occurs via relevant routes of exposure 
(e.g. plasma/blood concentrations below detection limit using a sensitive method and 
absence of the substance and of metabolites of the substance in urine, bile or exhaled air) 
and there is no or no significant human” (Annex IX, 8.7. Column 2). Obviously, generation of 
toxicokinetic data is a prerequisite, before these alternative approaches can be used.      
It is noteworthy that since there is no in vivo information requirement under REACH 
Regulation, the choice of scientifically valid in vitro methods does not need to be justified, 
when in vitro TK data is generated for specific regulatory purposes, for example those 
summarised above. 
 
12.4 Non-standard methods for ADME 
A large and rapidly growing body of scientific literature refers to the development of non-
standard methods (in vitro and in silico) for describing and predicting ADME processes (see 
Table of References with Notes for recent reviews). These include a variety of in vitro 
methods, the most widely used of which are presented in Table 12.2 together with the 
measured parameters that can be used as input data for PBTK models.   
 
12.4.1 In vitro methods for absorption through external barriers 
For the prediction of in vivo absorption, in vitro permeability studies are performed. 
Permeability methods include two diffusional compartments that are separated by cell lines or 
primary cells or tissues of human/animal origin, or by artificial/biological membranes. The 
choice of the barrier between the two compartments depends on the exposure route, while the 
ability of the model to predict chemical's absorption depends on how closely it mimics the 
characteristics of the in vivo situation. Cell lines are often employed as a barrier and their 
ability to form tight junctions is critical for the performance of the in vitro assay. Various cell 
lines like Caco-2, TC-7, HT29-MTX and IEC-18 have been employed to predict intestinal 
absorption (Grès et al., 1998; Behrens et al., 2001; Versantvoorta et al., 2002). Caco-2 cell 
line is the foremost used and well characterized and it has been widely used to generate drug 
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absorption data for regulatory purposes. Caco-2 is a very good model to mimic passive 
transport through barriers and it is believed that transporter proteins are functional on its 
membranes.  A disadvantage of Caco-2 model stems from the wide variation with passage 
number and differing results obtained across different laboratories (Zucco et al., 2005; Prieto 
et al., 2010; reviewed in Nigsch F et al., 2007). The parallel artificial membrane permeability 
assay (PAMPA) is also a frequently used system to assess intestinal permeability (Kansy et 
al., 1998). PAMPA model only deals with exclusive passive diffusion, while some intestinal 
cell lines attempt to capture some aspects of active transport across the intestinal barrier 
(Nigsch F et al., 2007). Absorption through the respiratory tract can be predicted using the 
respective cell lines or primary cell cultures. Concerning the human bronchial epithelia cell 
lines, Calu-3 (Zhu, 2010) and 16HBE14o- (Forbes et al., 2003) cell monolayers have been 
used as models for airway epithelium due to their morphological characteristics, barrier 
properties and expression of drug transport systems that exist in vivo (Zhu, 2010). Regarding 
the alveolar region, A549 cell lines have been employed either as monolayers (Wang & 
Zhang, 2004) or in co-culture with blood monocyte-derivered macrophages and dendritic cells 
(Lehmann et al., 2011). There are also commercially available 3D systems based on human 
derived tracheal/bronchial epithelia cells (Chemuturi et al., 2005). For nasal permeation 
studies, monolayers obtained with primary cultures of human epithelial cells have been 
extensively used (Kissel & Werner, 1998; Agu et al., 2002; Agu et al., 2011; Sarmento et al., 
2012). Additionally, cell lines such as RPMI 2650 (human), BT (bovine) and NAS 2BL (rat) 
have been employed in nasal drug development (Dimova et al., 2005), while recently co-
cultures composed by a collagen matrix with embedded human nasal fibroblasts covered by a 
RPMI 2650 were developed (Wengst & Reichl, 2010). Skin absorption can be predicted by 
employing reconstructed skin models that simulate human skin (Godin & Touitou, 2007). 
Various cultured human skin equivalents such as living skin equivalent models (LSEs) and 
the full thickness skin models have been used to measure percutaneous absorption, with some 
of them having also metabolic competence (Jäckh C et al., 2011). Commercially available in 
vitro human 3D skin models like Episkin, EpiDerm and Skin Ethic, employ epidermal cells 
(Netzlaff et al., 2005), the skin-PAMPA model uses an artificial membrane based on 
phospholipids, cholesterol or porcine polar dissolved in a solvent (Sinkó et al., 2012), these 
commercial models have been the most developed and used. The 3D reconstructed human 
skin models are able to mimic human skin to a large extent compared to the classical cell 
monolayers. Also real skin tissues have been implemented as membrane in ex vivo tests. 
According to the OECD 428 guideline excised skin can be used in in vitro methods, with 
human skin being the most acceptable followed by animal skin. Although rodent have been 
extensively used in in vivo experiments (OECD 417) it is well documented that absorption 
through rodent skin is greater than through human skin due to the potential for compounds to 
obtain rapid passage down the hair follicle and the relative thickness of the stratum corneum 
(Williams, 2006). However, pig ear skin is a more relevant animal tissue for ex vivo studies 
due to its more structural equivalence to human skin (Godin & Touitou, 2007). 
 
12.4.2 In vitro methods for distribution 
The prediction of a chemical's distribution within the body requires measurements of the free 
(unbound) compound fraction in blood, the distribution coefficients and permeability through 
internal physiological interfaces. Partitioning methods to determine free fractions and 
distribution coefficients were reviewed by Heringa and Hermens (Heringa & Hermens, 2003). 
The ultracentrifugation method employs powerful centrifugation (e.g. 250,000 g) and long 
centrifugation times (e.g. 16 hours) to separate the free from the bound form of the 
compound. The aim is to precipitate the binding matrix and then to measure the free 
compound concentration in the supernatant. In ultrafiltration method the phase separation 
between the bound and the free form is achieved by filtration using a special size-excluding 
filter. Filtration is performed either by applying pressure or by centrifugation and the free 
concentration is measured in the filtrate. Rapid equilibrium dialysis (RED) method employs a 
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device consisting of two compartments separated by a membrane. The one compartment 
contains the sample and the other compartment a buffer solution. Only the free form of the 
compound can cross the membrane. When equilibrium between the two compartments is 
established, the freely dissolved concentration of the two compartments is the same. The 
concentration of the compound in the matrix free compartment is measured and equals with 
the free concentration. Solid Phase Microextraction (SPME) is a method that requires no 
phase separation step and thus more precise since the phase separation can shift the 
equilibrium between the free and the bound form. SPME employs a small amount of a 
polymer as a third partitioning phase. The polymer is immobilized on a solid support (usually 
a fibre) and then is brought in equilibrium with the sample that contains both the free and the 
bound form. Only a minor mass of the free form of the compound can be absorbed/adsorbed 
by the polymer and it is consequently extracted from the polymer and quantified. The head 
space sampling method is useful to determine the free concentration of volatile compounds. 
The sample is placed inside a closed vial and is then equilibrated with the headspace. The 
measured concentration of the compound in the headspace is proportional to its free 
concentration in the sample. Usually the sampling of the head space is performed by inserting 
and equilibrating a SPME fibre, in this case the method is called head space SPME.  
 
The distribution process is also influenced by the passage through internal barriers such as 
blood-brain barrier, blood-testis barrier and placenta. The blood-brain barrier is one of the 
most important internal interfaces within the human body. Various in vitro methods have been 
developed during the last decades aiming to determine the permeability of chemicals through 
internal barriers. Naim and Cucullo have recently reviewed blood-brain barrier technologies 
(Naik & Cucullo, 2012). It seems that the in vitro cell based models are the most commonly 
used, since they can be established with any type of cell source (human, animal or cell line 
derivative) including endothelial cells and freshly isolated astrocytes. The primary bovine 
brain endothelial cells are employed and they are probably the most suitable in vitro model 
(Culot M et al., 2008; Gumbleton & Audus, 2001). Due to their limited availability and the 
difficulty to established and maintain primary cultures Garberg et al tried to identify an 
alternative cell system by comparing different cell lines (Garberg et al., 2005). They observed 
that higher correlations with in vivo studies were seen when only passively transported 
compounds were included in the analysis of the in vitro results. However no linear correlation 
between in vivo and in vitro permeability was found for any of the in vitro models when the 
whole set of tested compounds, reflecting different transport mechanism and different degrees 
of permeability, was taken into account. 
    
12.4.3 In vitro methods for metabolism 
In vitro assessment of metabolism is achieved using tissue preparations, whole cells, primary 
cell lines or cell extracts. In these systems the enzyme conditions can be optimized and 
controlled in order to measure catalytic processes, such as phase I and phase II 
biotransformation, to isolate bioactivation from detoxification (Lipscomb & Poet, 2008) and 
to enable inter/intra species comparison (Walker SA et al., 2006). Metabolism occurs to the 
higher extend in the liver although other organs/tissues (lungs, small intestine and skin) are 
contributing to the overall metabolisms. Primary cultures of human hepatocytes are a very 
relevant in vitro liver metabolism system (Billings et al., 1977) and are considered for many 
applications as the human metabolic competent in vitro standard. However, obtaining freshly 
isolated hepatocytes from human donors has practical difficulties. As a result cryopreserved 
human hepatocytes have become a viable alternative since they can maintain more than 90% 
of fresh hepatocyte activity for at least a year after preparation (Richert et al., 2010; 
McGinnity et al., 2004,). Metabolic competent system, such as human cryopreserved 
hepatocytes and the HepaRG cell line, have shown good data on metabolic clearance, 
cytochrome P450 (CYP) induction and metabolite identification (Gerin et al., 2013; Jouin et 
al., 2006).  
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The HepaRG cell line is an important in vitro tool and a good alternative to human 
hepatocytes. This cell line originates from the liver of a human female donor and it exhibits a 
long-term stability of biotransformation functions (Andersson et al., 2012). However, since 
HepaRG cells are delivered from a single donor, they do not represent the whole spectrum of 
inter-individual variances in the human liver as compared to human hepatocytes. HepaRG 
have been shown to provide reliable prediction and characterization of CYP induction by drug 
compounds in humans as well as correct plasma membrane transporter polarization 
(Andersson et al., 2012). In view of these properties, HepaRG cells are suitable for use in 
two-dimensional (2D) and three-dimensional (3D) models, such as liver bioreactors (Leite et 
al., 2012) which enable studies of disposition and toxicity involving uptake, metabolism and 
efflux mechanisms over an extended period of time, since the expression of CYP enzymes is 
maintained in the differentiated HepaRG cells for at least 4 weeks (Jossé R et al., 2008).  
 
During recent years, attempts have focused on producing metabolically active hepatocytes 
from human embryonic stem (ES) cells and hepatic stem cells, with several reports describing 
the development and optimization of various differentiation protocols. However, the 
applicability of the human ES cell-derived hepatocyte-like cells as a reliable tool to predict 
metabolism is under question since studies have shown that the key CYP3A4 isoform is 
present at 1000-fold lower amounts in differentiated ES cells than in human primary 
hepatocytes (Wobus et al., 2011). Recent progress has also been made in generating 
hepatocyte-like cells from human induced pluripotent stem (PS) cells. A direct comparison of 
differentiated ES cells and induced PS cells with human primary hepatocytes has shown that 
the liver specific functions (glycogen synthesis, urea production, albumin secretion and CYP 
activity) of the stem-cell derived cells were present but much lower compared to human 
hepatocytes (Song et al 2009).  At present it is not clear to what degree stem cell-derived 
hepatocytes need to resemble primary hepatocytes to ensure a reliable metabolically 
competent system and critical issues must be resolved before large numbers of metabolic 
competent hepatocytes can be generated from such cell lines and used for ADME testing 
(Pelkonen et al., 2013).   
 
Subcellular fractions, like microsomal protein (MSP), cytosol and S9 fractions have been used 
for decades in studies of xenobiotic metabolism. An advantage of these preparations is that 
they are relative stable over time and their metabolic activity is often initiated by the addition 
of substrate or cofactor, which practically means that the incubation time is easily controlled 
(Lipscomb & Poet, 2008). A disadvantage is that these preparations maintain neither the 
balance of phase I to phase II enzymes nor the ratio of cytosolic versus membrane bound 
enzymes (Lipscomb & Poet, 2008). Furthermore, they lack a cellular membrane barrier and 
maintain higher levels of metabolizing enzyme activity than hepatocytes (Alqahtani et al., 
2013). Tissue slices have been employed in in vitro methods on the assumption that they 
provide a more biologically relevant system; however they do not come without limitations. 
One limitation is that the slice preparation damages an important cell proportion and can 
make them metabolically incompetent. Also the slow diffusion of the compound within the 
tissue may lead to underestimation of the metabolic rates (Lipscomb & Poet, 2008). 
  
12.4.4 In vitro methods for elimination 
In vitro renal excretion tools for humans have not been developed, but this process can be 
indirectly determined using physiologically parameters. The renal excretion rate can be 
indirectly predicted by the combination of the glomerular filtration rate (GRF) and the free 
fraction of the compound in the blood, while excretion via exhalation can be predicted using 
blood:air distribution coefficients (Bessems et al., 2014). Cryopreseved hepatocytes cultured 
in a sandwich configuration allow for the development of intact bile canaliculi and the ability 
to measure hepatic uptake and biliary clearance (Bi Y-a et al., 2006). 
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12.4.5 In silico modelling 
In silico modelling covers a wide range of approaches, and these have been extensively 
applied to the prediction of ADME properties, as reviewed by Mostrag-Szlichtyng & Worth 
(2010). The main approaches include simple rules-of-thumb based on structural alerts and 
physicochemical properties (e.g. the Lipinksi rule-of-five), QSAR models, expert systems for 
simulating metabolism, models of receptor-mediated interactions (e.g. cytochromes), and 
physiologically based toxicokinetic (PBTK) models. 
A range of QSAR software tools include the capacity for predicting key ADME properties, 
such as human intestinal absorption, oral bioavailability, skin penetration, blood/brain barrier 
permeability, plasma protein binding, and metabolic clearance. Many of these models have 
been developed by using data sets skewed towards drugs. These models are easy to apply, but 
their applicability to non-pharmaceutical chemicals is not clear. 
Several expert systems for simulating metabolic pathways are also available, mainly in the 
commercial domain. These models generally provide qualitative information on possible 
metabolic pathways (with a tendency to overgenerate metabolites), but are not yet capable of 
predicting rates of metabolite formation. 
PBTK models are mechanistically-based mathematical models that integrate physicochemical 
and biological data in order to simulate the dose and time-dependent concentration profiles of 
a chemical through the systems of the body. Different compartments in the model correspond 
to different organs. The transfer between compartments is described by ordinary differential 
equations and these are connected with hypothetical blood flows mimicking the blood 
circulation in the body. Organ sizes, blood flow rates and tissue-plasma distribution 
coefficients are used to construct the model, which is based on mass balance assumptions. 
The differential equations are solved numerically with mathematical software packages. There 
is no universally suitable model - the complexity of the model can be tailored to the needs of 
the study. For instance, for the simple screening of chemicals it may be sufficient to take into 
account only passive processes between a limited number of compartments (e.g. Tonnelier et 
al, 2012). PBTK models also provide a means of extrapolating between doses and species, 
and of accounting for inter-individual variation. Compared with other in silico approaches, 
these models are relatively data-hungry and need to be carefully optimised. Although in the 
past, these models required specialised expertise to develop and apply, intense efforts are 
undertaken to strive for public available models that can be used for routine regulatory 
applications and thus simplified approaches are proposed (Bessems et al., 2014). 
 
12.4.6 Body-on-chip methods 
During recent years the development of microfabrication technology and its combination with 
cell culture techniques led to the emergence of microfluid devices that attempt to reproduce 
the multi-organ interactions. A microfluid device is fabricated with multiple chambers. Each 
chamber represents a different organ and all are connected with fluid conduits representing 
the blood flow; this new technology is called "body-on-a-chip" and provides the possibility to 
build up physical systems that mimics PBTK models (Sung et al., 2010). The concept behind 
the development of microfluid devices is promising; however these devices still pose some 
limitations (Kim et al., 2007) and many issues need to be addressed before they can be 
standardized. For instance, it is documented that the biochemical properties of cells differ in 
macro and microcultures, thus proper cell culture protocols suitable for these miniaturized 
platforms should be developed and employed (Su et al., 2013).      
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12.5 Conclusions 
TK information provides a useful supporting role in the regulatory assessment of chemicals, 
and does not necessarily need to be generated by traditional animal methods. There are 
multiple applications of TK methods, ranging from the relatively simple (e.g. supporting read-
across of toxicity data between analogues) to the complex (e.g. enabling animal-free risk 
assessments). To support these applications, a wide and diverse range of non-standard TK 
methods have been developed, including both in vitro and in silico tools, and mathematical 
modelling can be used to integrate multiple TK properties to simulate the dose and time-
dependent disposition of a chemical in the body. The relevance of TK properties is self-
evident, but the usefulness of individual TK methods can only be judged in the context of the 
intended application. In this respect, there is a need to develop further guidance on the use of 
TK information, and to develop standards for comparing the characteristics of new methods 
with more established ones.  
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Table 12.1. Applications of toxicokinetic methods  
 
 
Use Case  Examples 
  
1) Filling data gaps by extrapolating 
between species, exposure routes, and 
exposure durations. 
1) In developmental toxicity testing, rodent data are 
available. Is there a need for non-rodent data? 
 
2) How can I extrapolate from oral repeat dose toxicity 
data to assess the effects of exposure via the dermal route? 
   
3) How can I extrapolate from a subchronic (90d) repeat-
dose toxicity study to a long-term study? 
2) Optimal design of in vitro experiments 
for in vitro-in vivo extrapolation and 
reverse dosimetry. Animal-free risk 
assessment. 
For a given exposure scenario (e.g. dietary exposure) how 
do I design an in vitro toxicity study suitable for assessing 
repeat-dose toxicity?  
3) Optimal design of animal studies, 
where necessary 
If confirmatory testing in vivo is deemed necessary for the 
assessment of genotoxicity, how can I design an animal 
study for optimal information gain? 
4) Waiving or triggering of experimental 
studies based on bioavailability and 
distribution properties 
How to avoid unnecessary testing, and how to determine 
when testing is needed, based on predictions of 
bioavailability and distribution (e.g. distribution to germ 
cells in genotoxicity assessment, distribution to the CNS 
in neurotoxicity assessment)? 
5) Substantiating read-across arguments I have a 90-day NOEL for chemical X, and need to assess 
the subchronic effects of an analogue, chemical Y. Can I 
read-across with confidence, based on both structural and 
toxicokinetic similarity? 
6) Extrapolation from high to low doses 
taking into account non-monotonicity 
How to characterise the low-dose effects of endocrine-
active substances? 
7) Modelling the effects of chemical 
mixtures, taking into account TK and TD 
interactions 
How can I account for synergistic/antagonistic effects due 
to cross-talk in regulatory pathways, or effects on 
cytochrome P450 induction/inhibition? 
 
How can I account for synergistic/antagonistic effects due 
to interactions on absorption and distribution properties? 
8) Use of TK information to adjust 
default safety factors in risk assessment 
When can I reduce the default assessment factor, and 
when is a higher factor warranted?  
9) Assessment of human bioaccumulation 
potential as a property of high concern 
Ranking of environmental pollutants based on their 
expected bioaccumulation in humans 
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Table 12.2. Measured parameters and most commonly used in vitro systems for ADME†  
 
Footnotes. Papp: apparent barrier permeability or penetration coefficient/constant, Kb,a: inhalation blood:air distribution coefficient (volatiles), Kt,b: 
tissue:blood partition coefficient, fu: unbound or free fraction of the compound, Km: Michaelis Menten constant, Vmax: maximum metabolic rate, CLint: intrinsic 
clearance GFR: glomerular filtration rate, † adapted from (Bessems et al.) 
Process Measured Endpoint Measured Parameter (unit) In vitro method  
Absorption 〉 Permeation of 
external barriers Oral          Papp (cm⋅ h
-1) 
 
Dermal      Ps, app (cm⋅ h-1) 
 
Inhalatory 
                Papp(cm⋅ h-1) 
                 Kb,a (dimensionless) 
Caco-2, PAMPA 
 
skin-PAMPA, OECD TG 428 
 
 
 
Human airway epithelium models, alveolar barrier models, cell lines (e.g. 
Calu-3) 
Head space model, head space SPME 
Kt,b (dimensionless) Ultracentrifugation, ultrafiltration, rapid equilibrium dialysis (RED), solid 
phase microextraction (SPME) 
Papp (cm⋅ h-1) BBB model, cell line barrier model, co-cultures barrier model, organ culture 
barrier model, placenta barrier 
Distribution 〉 Permeation of internal 
barriers 
fu (dimensionless) Ultracentrifugation, rapid equilibrium dialysis (RED), solid phase 
microextraction  (SPME) 
Km (mmol⋅ mL-1) 
Vmax (mmol⋅ h-1) 
Metabolism 
 
 
 
〉 Intrinsic or hepatic 
clearance 
〉 Identification of 
metabolites 
CLint (mL⋅ h-1) 
Liver: microsomal incubation, hepatocyte suspension incubation, plated 
hepatocyte incubation, HepaRG, subcellular incubations (S9, microsomal 
protein, cytosol)  
Intestine: Microsomes, cytosol 
Lung: Microsomes, cytosol,  enterocytes, whole organ culture 
fu (dimensionless) 
Ultracentrifugation, rapid equilibrium dialysis (RED), solid phase 
microextraction  (SPME) 
Kb,a (dimensionless) 
Head space model  
Excretion 〉 Irreversible removal 
(clearance) from 
circulating blood 
GFR (mL/min) 
Human physiology  
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European Medicines Agency (EMA). Concept paper on the need for 
revision of the position on the replacement of animal studies by in vitro 
models. Reference number: EMA/CHMP/SWP/169839/2011, available 
from: http://www.ema.europa.eu 
The proposed Guideline will replace the Position on Replacement of Animal 
Studies by in vitro Methods (CPMP/SWP/728/95). 
 
European Medicines Agency (EMA). Replacement of animal studies by 
in vitro models. Reference number: EMA/CPMP/SWP/728/95, 
available from  http://www.ema.europa.eu 
Position adapted by the Committee for Proprietary Medicinal Products (CPMP). 
The paper addresses the feasibility of replacing in vivo animal studies by in vitro 
investigations in the preclinical development of medical products.  
European Medicines Agency (EMA). ICH: S 3 A: Toxicokinetics: A 
guidance for assessing systemic exposure in toxicology studies - Step 5. 
Reference number: CPMP/ICH/384/95, available from 
http://www.ema.europa.eu 
This Note for Guidance concerns toxicokinetics only with respect to the 
development of pharmaceutical products intended for use in human subjects. 
In this context, toxicokinetics is defined as the generation of pharmacokinetic data, 
either as an integral component in the conduct of non-clinical toxicity studies or in 
specially designed supportive studies, in order to assess systemic exposure. These 
data may be used in the interpretation of toxicology findings and their relevance to 
clinical safety issues. 
 
The Note for Guidance has been developed in order to provide an understanding of 
the meaning and application of toxicokinetics and to provide guidance on 
developing test strategies in toxicokinetics. The guidance highlights the need to 
integrate pharmacokineticsinto toxicity testing, which should aid in the 
interpretation of the toxicology findings and  
promote rational study design development. 
European Food Safety Authority (EFSA). Guidance on Dermal 
Absorption. EFSA Journal 2012;10(4):2665 [30 pp.]. 
doi:10.2903/j.efsa.2012.2665. Available from: 
http://www.efsa.europa.eu 
 
 
 
 
Significant aspects of the new EFSA guidance include:  
• Revised (lower) dermal absorption default values of 75% or 25%;  
• Defined criteria for many aspects of dermal absorption, intended to 
improve consistency of interpretation e.g. for extrapolating data between 
products and on approaches to the use of tape stripping data;  
• Support for dermal absorption values based on in vitro data alone.” 
• The agreement at the Standing Committee (May 2012) was that the new 
guidance will apply to all applications received after 30th November 2012. 
European Food Safety Authority (EFSA). Guidance for submission for TK studies are a prerequisite and should be conducted using the international 
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food additive evaluations. EFSA Journal 2012; 10(7):2760 [60 pp.]. 
doi:10.2903/j.efsa.2012.2760. Available from:  
http://www.efsa.europa.eu 
 
agreed guidelines 
Organisation for Economic Cooperation and Development (OECD). 
2010. Guideline for Testing of Chemicals, 417, Toxicokinetics. 
Available from: http://www.oecd.org 
 
 
 
 
 
This Test Guideline describes in vivo studies that provide information on mass 
balance, absorption, bioavailability, tissue distribution, metabolism, excretion, and 
basic toxicokinetic parameters [e.g. AUC], as well as supplemental approaches that 
may provide useful information on toxicokinetics. Information from toxicokinetic 
studies helps to relate concentration or dose to the observed toxicity and to 
understand its mechanism of toxicity. The test substance ("unlabelled" or 
"radiolabelled" forms) is normally administered by an oral route, but other routes 
of administration may be applicable. Single dose administration of the substance 
(preferably a minimum of two dose levels) may be adequate, but repeated dose 
may be needed in some circumstances. Toxicokinetic studies should preferably be 
carried out in the same species as that used in other toxicological studies performed 
with the substance (normally the rat, a minimum of 4 animals of one sex for each 
dose). Initial estimation of absorption can be achieved by mass balance 
determination, but further investigations such as intravenous (IV) administration 
and biliary excretion studies might be necessary. Bioavailability can be determined 
from plasma/blood kinetics of oral and IV groups. The percent of the total dose in 
tissues should at a minimum be measured at the termination of experiment,but 
additional time points may also be needed. Metabolites present at 5 % or greater of 
the administered dose should be identified. The rate and extent of excretion of the 
administered dose should be determined by measuring the percent recovered dose 
from urine, faeces and expired air. 
Regulatory test guidelines and guidance documents 
Organisation for Economic Cooperation and Development (OECD). 
2010. Guideline for Testing of Chemicals, 428, Skin absorption In vitro 
method. Available from: http://www.oecd.org 
This Test method has been designed to provide information on absorption of a test 
substance, (ideally radiolabelled), applied to the surface of a skin sample 
separating the two chambers (a donor chamber and a receptor chamber) of a 
diffusion cell. Static and flow-through diffusion cells are both acceptable. 
  
Skin from human or animal sources can be used. Although viable skin is preferred, 
non-viable skin can also be used. The skin has been shown to have the capability to 
metabolise some chemicals during percutaneous absorption. In this case, 
metabolites of the test chemical may be analysed by appropriate methods. 
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Normally more than one concentration of the test substance is used in typical 
formulations, spanning the realistic range of potential human exposures. The 
application should mimic human exposure, normally 1-5 mg/cm2 of skin for a 
solid and up to 10 µl/cm2 for liquids. The temperature must be constant because it 
affects the passive diffusion of chemicals. The absorption of a test substance 
during a given time period (normally 24h) is measured by analysis of the receptor 
fluid and the distribution of the test substance chemical in the test system and the 
absorption profile with time should be presented. 
Organisation for Economic Cooperation and Development (OECD). 
2010. Guideline for Testing of Chemicals, 427, Skin absorption In vivo 
method. Available from: http://www.oecd.org 
 
The in vivo percutaneous absorption study set out in this Test Guideline provides 
the linkage necessary to extrapolate from oral studies when making safety 
assessments following dermal exposure. The in vivo method, described in this 
guideline, allows the determination of the penetration of the test substance through 
the skin into the systemic compartment. 
  
The test substance, preferably radiolabelled, is applied, for a fixed period of time, 
to the clipped skin of animals at one or more appropriate dose levels in the form of 
a representative in-use preparation. The rat is the most commonly used species. At 
least four animals of one sex should be used for each test preparation and each 
scheduled termination time. A known amount of the test preparation is evenly 
applied to the site. This amount should normally mimic potential human exposure, 
typically 1-5 mg/cm² for a solid or up to 10 µl/cm² for liquids. A relevant exposure 
period (typically 6 or 24 hours) should be used, based on the expected human 
exposure duration. The animals should be observed for signs of toxicity/abnormal 
reactions at intervals for the entire duration of the study. This study includes: daily 
measurements (excreta), regular detailed observations, as well as sacrifice at the 
scheduled time and blood collected for analysis. 
World Health Organization (WHO). 2010. Characterization and 
application of physiologically based pharmacokinetic models in risk 
assessment. Available from: 
http://www.who.int/ipcs/methods/harmonization/areas/pbpk_models.pdf 
 
 
A guidance document on "Principles of Characterizing and Applying PBPK 
Models in Risk Assessment". 
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13. Aquatic (fish) toxicity  
Marlies Halder, Aude Kienzler & Andrew Worth 
 
13.1 Introduction 
Aquatic toxicity refers to the effects of a compound to organisms living in the water 
compartment and is usually determined by testing on organisms representing the three trophic 
levels, i.e. plants (algae), invertebrates (crustaceans as Daphnia spp.) and vertebrates (fish). 
This chapter focuses on standard and non-standard approaches for assessing fish toxicity 
(excluding bioaccumulation and endocrine disruptors). The two toxicological endpoints using 
fish are: a) acute fish toxicity (short-term exposure to determine the concentration that is 
lethal to 50% of the fish, LC50); and b) chronic fish toxicity (long-term exposure covering 
the life-cycle of the fish, to identify sublethal effects and determine the No Observed Effect 
Concentration [NOEC], the Lowest Observed Effect Concentration [LOEC], or effective 
concentration [ECx]). 
 
13.2 The traditional animal tests and their regulatory use 
The OECD Test Guidelines (TGs) / EU test methods for aquatic toxicity involve the use of 
fish at various life stages. For short-term toxicity, juvenile or adult fish are used, whereas 
long-term toxicity testing also covers early life stages: fertilised egg – embryo – (hatch) – 
sac-fry or larva (sac = yolk) – juvenile – adult. The duration of these developmental steps 
depends on the species used and the water temperature. Table 13.1 gives an overview on the 
OECD TGs and Table 13.2 summarises the regulatory requirements in the EU. 
 
13.2.1 Acute (short-term) fish toxicity 
The fish acute toxicity test (OECD TG 203) (OECD, 1992) is carried out with juvenile or 
adult fish. It is a short-term exposure test (96 h) and determines the concentration that is 
lethal to 50% of the fish (LC50). Other relevant endpoints, consistent with OECD TG 203, 
can include the LC0 and LC100 (0% mortality and 100% mortality). Groups of seven to 10 
fish are exposed via static, semi-static, or flow-through systems to at least five concentrations 
of the test substance, a water control and, if needed, a solvent control. The mortality is 
recorded on a daily basis for each concentration and used for the LC50 calculation. In 
addition, any sublethal effects observed should be reported. Analytical confirmation of the 
exposure concentrations is recommended. OECD TG 203 also allows to carry out a limit test 
at a single concentration (= 100 mg/L) with seven to 10 fish in the treatment group and seven 
to 10 fish in the control / solvent group. If no mortality occurs, LC50 is reported as 
>100mg/L. If mortality occurs, the full test needs to be conducted.  
 
Rufli and Springer (2011) demonstrated by retrospective analysis of acute fish toxicity tests 
that the number of fish / concentration could be reduced to six without loss of statistical 
power. In the interest of animal welfare, Rufli (2012) recommend that moribund (a state close 
to death involving severe suffering) fish be removed from tests and humanely killed. 
However, before introducing this modification into OECD TG 203, further analysis is 
necessary, since introducing “moribund stage” may lower LC50 values. This is the basis of a 
project in the OECD Test Guidelines programme. 
 
Depending on the regulatory framework and geographic region, the fish species to be used 
varies, or the tests have to be carried out on cold and/or warm water species. The following 
are the most commonly used OECD species: zebrafish (Danio rerio), fathead minnow 
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(Pimephales promelas), medaka (Oryzias latipes), bluegill sunfish (Lepomis macrochirus), 
and rainbow trout (Oncorhynchus mykiss). In addition, the common carp (Cyprinus carpio) 
and guppy (Poecilia reticulate) are recommended species.  
 
Another short-term fish toxicity test is described in OECD TG 204 (OECD, 1984), the fish 
prolonged toxicity test – 14 days study, which is carried out with juvenile or adult fish. In 
addition to lethal effects, sublethal effects are recorded and used for NOEC determination. 
Since this test is rarely conducted and OECD TG 203 includes the provision to extend the 
exposure beyond 96 h if necessary, e.g. in case of slow onset of mortality, the OECD Fish 
Toxicity Testing Framework report (OECD, 2012a) recommended deletion of this guideline. 
This recommendation was followed up by the OECD in late 2012 and the deletion of the 
guideline will come into force in April 2014.  
 
Requirements for acute fish toxicity testing vary depending on the type of regulation and the 
geographic region (OECD, 2012a). In Europe, acute fish toxicity data are required for (Table 
13.2):  
a) industrial chemicals (>10 t/year; EC, 2006); 
b) biocides; use of the threshold approach (see below) is recommended (EU, 2012a); 
c) plant protection products; for the active substance, data from rainbow trout and one 
warm water species; and for formulations, if fish is the most sensitive species for the 
active substance (EC, 2009a); from 2014, the threshold approach (see below) is 
recommended and only data from rainbow trout are required (EU, 2013a; 2013b) 
d) veterinary pharmaceuticals (EMA, 2004), and  
e) others (e.g. feed; EC, 2008; EFSA, 2008).  
 
Aquatic toxicity is not an endpoint in the cosmetics regulation, however, environmental 
concerns of cosmetics ingredients and products are considered through REACH (EC, 2009b).  
 
Annex VIII of the REACH regulation (EC, 2006) states that a study for short-term aquatic 
toxicity does not need to be conducted if “there are mitigating factors indicating that aquatic 
toxicity is unlikely to occur, for instance if the substance is highly insoluble in water or the 
substance is unlikely to cross biological membranes.” Moreover, “applicants are invited to 
consider aquatic long-term aquatic toxicity testing.” Long-term toxicity testing should be 
considered at this tonnage level in two cases: a) "if the chemical safety assessment according 
to Annex I indicates the need to investigate further the effects on aquatic organisms" (i.e. if 
PEC/PNEC >1 and for chemicals with log Kow >3 [or BCF >100] and a PEC >1/100th of the 
water solubility) and b) “if the substance is poorly water soluble.”  
 
13.2.2 Chronic (long-term) fish toxicity 
Chronic / long-term fish toxicity tests cover several life stages of fish depending on the 
OECD TG chosen.  
 
The most commonly used test to establish chronic fish toxicity is OECD TG 210, the fish 
early life-stage (FELS) test. The initial guideline of 1992 was reviewed and recently 
approved (OECD, 2013a). OECD TG 210 aims to determine lethal and sublethal effects of a 
chemical on early life stages of fish (embryos, larvae, juvenile fish). The endpoints are 
hatching success, abnormal appearance, abnormal behaviour, survival / mortality, and the 
weight and length of the fish at the end of the test. By comparison to the values of control 
fish, the LOEC, NOEC and/or ECx are determined for each endpoint. The test starts with 
fertilised eggs and continues until the control fish are freely feeding. In general, at least 5 
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concentrations with at least 80 eggs per concentration divided in four replicates are used as 
well as a control group and a solvent control group if needed. OECD TG 210 recommends 
four freshwater species (zebrafish, fathead minnow, medaka, rainbow trout) and a saltwater 
species (sheephead minnow). The revised OECD TG 210 allows the use of a limit test, or an 
extended limit test, with fewer than five concentrations (to be justified) (OECD, 2013a). 
 
OECD TG 212, Fish, Short-term Toxicity Tests on Embryo and Sac-fry Stages (OECD, 
1998), is less frequently carried out and covers embryo and sac-fry stages. Exposure starts 
with fertilised eggs and should be terminated before the yolk-sac is completely absorbed or 
before mortality due to starvation begins. It assesses effects of a chemical on hatching, 
abnormal appearance, abnormal behaviour, survival / mortality (at the embryo and sac-fry 
stages and overall), and the weight and length at the end of the test. The NOEC and LOEC 
are determined for the endpoints observed. The duration of the test varies depending on the 
species, e.g. for zebrafish 8-10 days are given in OECD TG 212. There is a major animal 
welfare concern associated with this guideline, which has also been referred to as the fish 
“starvation” assay, since there is no supply of food to the hatched embryos. The duration of 
the life stages given in the guideline is outdated and it is well-known that zebrafish embryos 
start feeding around 48 h after hatch and will starve without external food supply. The OECD 
Fish Toxicity Testing Framework report (OECD, 2012a) recommends the deletion of OECD 
TG 212 due to these animal welfare concerns as well as scientific concerns (low sensitivity, 
larval and juvenile life stages are not covered, and effects of highly lipophilic substances or 
specific modes of action might not be detected). 
 
OECD TG 215, Fish, Juvenile Growth Test (OECD, 2000), is a chronic exposure test that 
assesses the effects of a chemical on the growth of juvenile fish for 28 days. At least five 
concentrations should be tested. The guideline does not state the number of fish per 
concentration / control but states that it should be based on statistical power analysis. The 
endpoints evaluated are weight, length, mortality, abnormal appearance, abnormal behaviour 
and NOEC and LOEC are determined for each effect. Recommended species are rainbow 
trout, zebrafish, and medaka. OECD TG 215 is rarely used since it only covers toxicity to 
juvenile fish. 
 
Some regulatory frameworks recommend the use of OECD TG 212 and OECD TG 215, if it 
is not possible to carry out an OECD TG 210. 
 
Requirements for fish long-term toxicity tests vary depending on the type of regulation and 
the geographic region (OECD, 2012a). In the EU, fish chronic toxicity data may be required 
for (Table 13.2):  
 
a) industrial chemicals (>100 t/year; EC, 2006); 
a) biocides; as part of the additional dataset, chronic fish toxicity testing may be required 
using OECD TG 210, 212, 215 or fish full life cycle test (OECD TG under 
development) (EU, 2012a),  
b) plant protection products; OECD TG 204 or OECD TG 215 over 28 days, LC50 <0.1 
mg/L triggers OECD TG 210 or fish life cycle test (EC, 2009a); from 2014, revised 
data requirements coming into force require OECD TG 210 or fish full life cycle test 
(EU, 2013a; EU 2013b),  
c) veterinary pharmaceuticals; if risk quotient PEC/PNEC >1 for fish, OECD TG 210 
fish early life stage test to be carried out (EMA, 2004),  
d) human pharmaceuticals; base set requirement, OECD TG 210 (EMA, 2006)  
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e) and others (e.g. feed, EC, 2008; EFSA, 2008).  
 
For industrial chemicals produced at >100 t/year, Annex IX of the REACH regulation (EC, 
2006) states that “Long-term toxicity testing shall be proposed by the registrant if the 
chemical safety assessment according to Annex I indicates the need to investigate further the 
effects on aquatic organisms.” A risk from the Chemical Safety Assessment (Annex I) is 
indicated if PEC/PNEC >1 and for chemicals with log Kow >3 (or BCF >100) and a PEC 
>1/100th of the water solubility. 
 
13.3 Standard methods to replace, reduce, or refine the use of fish 
The Threshold Approach for Acute Fish Toxicity Testing (OECD GD 126; OECD, 2010) is a 
tiered testing strategy which has the potential to significantly reduce the number of fish used 
for acute aquatic toxicity testing. It is based on the fact that the LC50/EC50 value of the most 
sensitive of the three test species (fish, algae and invertebrates) is commonly used for hazard 
and risk assessment and that fish is often not the most sensitive test species.  
 
This concept was first described for pharmaceuticals as a “threshold/step-down” approach by 
Hutchinson et al. (2003) and further developed for chemicals by the JRC (Jeram et al., 2005) 
as a threshold approach taking into consideration the requirements of the limit test as 
described in OECD TG 203 (Hoeger et al., 2006; ECVAM, 2006).   
 
When fish acute toxicity data need to be generated, the fish limit test as described in OECD 
TG 203 (see above) should be carried out at a single concentration, the threshold 
concentration (TC), which corresponds to the lowest LC50/EC50 derived from reliable acute 
invertebrate (e.g. Daphnia, OECD TG 202) and algae (e.g. OECD TG 201) data. If no fish 
mortality is observed, it demonstrates that that the fish is not the most sensitive test species. 
No further testing is required and the TC value can be used as LC50 fish (LC50 fish is greater 
than TC with 99% confidence). If mortality occurs, a full LC50 test should be conducted. The 
Threshold Approach is recommended for acute fish toxicity testing in the biocides regulation 
(EU, 2012a), the REACH guidance on information requirements and chemical safety 
assessment (Chapter R.7b: Endpoint specific guidance; ECHA, 2012) and the OECD Fish 
Toxicity Testing Framework (OECD, 2012a). Based on a retrospective analysis of acute 
toxicity data, Creton et al. (2014) propose the use of the threshold approach for plant 
protection products (formulations). In fact, the recently published Commission Regulations 
on data requirements for active substances (2013/283/EU) and plant protection products 
(2013/284/EU) recommend the use of the threshold approach (EU, 2013a; EU 2013b). 
 
At the 25th WNT (Working Group of the National Coordinators of the Test Guidelines 
Programme, April 2013) of the OECD, the new OECD TG 236, Fish embryo acute toxicity 
(FET) test (OECD, 2013b), was adopted and is available on the OECD website (OECD, 
2013b). It is a short-term test (96 h) that determines the lethal effects of a compound on 
zebrafish embryos. Newly fertilised zebrafish eggs (20/concentration, water control, positive 
control, solvent control) are exposed to at least five concentrations of the test compound and 
incubated for 96 h at 26±1 °C with an appropriate light cycle (14 h light and 10 h dark). 
Lethal effects to the embryo (such as coagulation, absence of somite formation, non-
detachment of the tail, and absence of heartbeat) are recorded on a daily basis and used for 
the calculation of the LC50. The percentage of embryos for which at least one of the lethal 
observations is positive at 48 h and 96 h is plotted against tested concentrations and used for 
the LC50 calculations.  
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OECD TG 236 addresses the concerns expressed over years regarding the metabolic capacity 
of fish embryos and the possible barrier function of the chorion (fish egg envelope). Recent 
studies show that zebrafish embryos have metabolic capacity (Weigt et al., 2011; Weigt et al., 
2012; Kubota et al., 2011; Incardona et al., 2011), although it is not clear whether it is in the 
same range as that of juvenile or adult fish. OECD TG 236 recommends conducting the test 
with the toxic metabolites or other biotransformation products if they are believed to be more 
toxic than the parent compound and use this information when concluding on the toxicity of 
the compound. 
  
In some cases, OECD TG 236 may not be the most appropriate test, since the overall toxic 
effects of a compound may not become fully evident, due to their reduced bioavailability in 
the test system. For example, compounds with a molecular weight ≥3kDa or a very bulky 
molecular structure might not pass the chorion in sufficient quantities to cause lethal effects. 
In fact, two polymers had been included in the OECD validation study of the zebrafish 
embryo acute toxicity test to challenge the barrier function of the chorion (OECD, 2012b). 
Neither caused consistent toxicity before hatch but toxicity significantly increased after hatch. 
Other compounds might cause delayed hatch and thus reduce post-hatch exposure. In these 
cases, other toxicity tests should be chosen.  
 
The OECD TG 236 does not state whether the fish embryo acute toxicity test can be used as 
an alternative to the OECD TG 203; however, several recently published papers indicate that 
the LC50 values derived with the fish embryo acute toxicity test correlate well with those 
derived with juvenile or adult fish (Lammer et al., 2009; Knöbel et al., 2012; Belanger et al., 
2013). It should be noted that at present (February 2014) the suitability of OECD TG 236 for 
REACH requirements (and other regulatory frameworks) still needs to be discussed and 
agreed upon with the regulatory authorities. 
 
As per Article 1(3)(a)(i) of Directive 2010/63/EU (EU, 2010) on the protection of animals 
used for scientific purposes, live non-human vertebrate animals including independently 
feeding larval forms are covered by its scope. According to the description of OECD TG 236, 
the zebrafish embryos are used until 96 h post-fertilisation. Zebrafish is generally not 
considered as being capable of independent feeding until 5 days post-fertilisation. This is 
confirmed by the Commission Implementing Decision 2012/707/EU (EU, 2012b) on a 
common format on collection of information on the use of animals for scientific purposes in 
the EU states that "Fish should be counted from the stage of being capable of independent 
feeding onward. Zebrafish kept in optimal breeding conditions (approximately + 28°C) 
should be counted 5 days post fertilisation". Taking this into consideratoin, the zebrafish 
embryos in question should not be considered as "independently feeding larval forms" within 
the meaning of the Directive and therefore the procedure, as far as the zebrafish embryos are 
concerned, does not fall within its scope.  
 
13.4 Mechanistic understanding of the endpoint 
The mode of action (MOA) has been defined (ECETOC, 2007) as "a common set of 
physiological and behavioural signs … that characterise a type of adverse biological 
response", whereas the mechanism of action refers to a comprehensive understanding of the 
entire sequence of events that result in toxicity. The report highlights the need to utilise all 
available information on a chemical, including mammalian toxicity data, to provide insight 
into a chemical MOA which will help to target testing to the most appropriate and sensitive 
species and identify specific tests for further characterisation. In addition, genomics, 
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proteomics, and biomarkers information could be used to define mechanism of action and 
specific biological activity and to identify critical toxicity pathway.  
 
The definition of MOA has evolved over time and MOA is currently defined by the WHO 
(2009) as “A biologically plausible sequence of key events leading to an observed effect 
supported by robust experimental observations and mechanistic data. A mode of action 
describes key cytological and biochemical events – that is, those that are both measurable 
and necessary to the observed effect – in a logical framework.”  
 
Several attempts have been made to categorise chemicals based on their mechanism or mode 
of action. Based on Verhaar et al. (1992), the following classification scheme was proposed:  
 
• class 1 – non-polar narcosis or baseline toxicity; this covers inert chemicals with a 
non-specific mode of action (non-specific reaction between chemicals and 
membranes; effect depends on the hydrophobicity of the chemicals) leading in vivo to 
lethargy and narcosis;  
• class 2 – polar narcosis; this covers less inert chemicals and is similar to non-polar 
narcosis except the fish become hyperactive before the onset of narcosis; 
• class 3 – reactivity; this covers electrophilic chemicals that react in a non-specific way 
with the nucleophilic proteins in membranes or the cytosol and ultimately disrupt cell 
function and lead to death; 
• class 4 –specifically acting chemicals; in this case, the targets are specific cellular 
receptors; 
• class 5 – chemicals not assigned to class 1-4 (Enoch et al., 2008).  
 
The Verhaar classification scheme has been implemented in the freely available Toxtree 
software (http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/qsar_tools/toxtree), as 
well as the OECD QSAR Toolbox (http://www.qsartoolbox.org/. The Toxtree 
implementation has been verified by Enoch et al. (2008), who also made recommendations to 
improve the decision tree (such as the reordering of the rules and the creation of more 
specific subclasses).  
 
Russom et al. (1997) further extended the Verhaar classification scheme and distinguished 8 
modes of toxic action (base-line narcosis or narcosis I, polar narcosis or narcosis II, ester 
narcosis or narcosis III, oxidative phosphorylation uncoupling, respiratory inhibition, 
electrophile/proelectrophile reactivitiy, acetylcholinesterase inhibition, and central nervous 
system seizure). 
 
Knowledge of the different modes of action has been used to develop QSARs (see below), 
based on the principle that the mode of action and respective QSAR can be assigned to a 
chemical based on its molecular structure (McKim et al., 1987).  
 
13.5 Status of non-standard methods and Integrated Testing Strategies 
13.5.1 Quantitative Structure-Activity Relationships  
There is an extensive literature on QSARs for fish toxicity, and in particular acute fish 
toxicity, as described in a number of reviews (Pavan et al., 2005a; Pavan et al., 2005b; 
Netzeva et al., 2007; 2008; Brooke et al., 2006a; Brooke et al., 2006b) and in the recently 
published EFSA guidance on the aquatic risk assessment of plant protection products in edge-
of-field surface waters (EFSA, 2013).  
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Netzeva et al. (2007) summarised the features of several fish acute toxicity QSARs and found 
that r2 values for most narcosis QSARs were in the region of 0.9. The evidence for the 
predictive power of acute fish baseline toxicity QSARs is therefore strong. 
 
Many of these studies have focused on the development of QSARs for specific modes of 
action, including polar narcosis, non-polar narcosis, reactivity-based toxicity, and specifically 
acting mechanisms (involving non-covalent interactions with receptors or enzymes), which 
are the MOAs 1-4 in the Verhaar classification scheme (Verhaar et al., 1992). While it is 
conventional to distinguish between polar and non-polar narcosis, with the latter being 
slightly more toxic than the former, both modes of action can be modelled solely by the 
octanol-water partition coefficient, which has prompted several authors to combine the polar 
and non-polar narcosis MOAs into a general narcosis model (e.g. Pavan et al., 2006). It has 
been estimated that at least 50% of industrial chemicals act as narcotics (Pavan et al., 2005a; 
Pavan et al., 2005b), and for more toxic chemicals, a narcosis model provides a minimal 
estimate of toxicity. The so called “excess toxicity” of more toxic chemicals, i.e. the 
difference compared with the narcosis baseline, can often be related to specific mechanistic 
reaction classes (e.g. Schiff base formers, Michael acceptors, nucleophilic substitution (SN2) 
mechanisms) or to specific subgroups (e.g. acrylates and isothiocyanates). These reaction 
classes can be identified on the basis of molecular structure by using Toxtree or the OECD 
QSAR Toolbox. 
 
Other studies have focused on the modelling of specific chemical classes. Examples include 
the QSARs implemented in the freely available ECOSAR software 
(http://www.epa.gov/oppt/newchems/tools/21ecosar.htm), and QSARs developed in the 
recently completed Cadaster project (Cassani et al., 2013; http://www.cadaster.eu/). 
 
Relatively few QSARs have been developed for specifically acting chemicals, with the 
exception of some models for endocrine active chemicals (Jacobs, 2004). Another major gap 
concerns QSARs for chronic fish toxicity, although some have been implemented in 
ECOSAR (de Haas et al., 2011) and two became recently available for prediction NOEC 
values of MOAs1-2 chemicals (Claeys et al.,  2013) and MOA1 chemicals (Austin and 
Eadsforth, 2014). 
 
13.5.2 Toxicokinetic models 
Stadnicka et al. (2012) investigated whether the internal concentration of chemical in fish can 
be predicted using a physiologically based toxicokinetic (PBTK) model and two one-
compartment models. None of the models accounted for possible biotransformation and the 
only uptake route considered was via the gills. They compared the predicted internal 
concentration to the measured concentration of 39 chemicals in fish (rainbow trout, fathead 
minnow). The three models predicted the measured internal concentrations in fish within 1 
order of magnitude for at least 68% of the chemicals; whereas, the PBTK model performed 
better with respect to simulating chemical concentrations in the whole body (at least 88% of 
internal concentrations were predicted within 1 order of magnitude using the PBTK model). 
The authors conclude that the three models can be used to predict concentrations in different 
fish species without additional experiments and propose the development of further 
toxicokinetic models for polar, ionisable, and easily biotransformed compounds. Moreover, 
Stadnicka-Michalak et al. (2014) developed a toxicokinetic model to quantify the 
concentration of organic chemicals in fish cells (RTgill-W1) and perform in vitro to in vivo 
extrapolations (IVIVE). They compared internal concentration causing effects on fish cells to 
in vivo concentration in fish gills predicted with a PBTK model and demonstrated that in 
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vitro data can be used to determine fish internal concentrations causing long-term effects, 
such as as reduced fish weight and length. 
  
13.5.3 Cytotoxicity assays based on fish cell lines 
These have been developed and used as research tools, and have been proposed as 
alternatives to the acute fish toxicity test (Castaño et al., 2003; Bols et al., 2005). More 
recently, they have also been used as tools to explore toxicity pathways at the molecular and 
cellular levels (Ankley et al., 2010). More than 280 fish cell lines have been established so far 
but only about 43 are listed in the international cell repositories such as the American Type 
Culture Collection (ATCC) and the European Collection of Cell Cultures (ECACC). After 
the ovary, the second most common tissue used for cultivation is the fin due to its high 
regenerative ability (Lakra et al., 2011). Gills and liver cells are also widely used, because of 
their importance in fish biology: gills are the primary target and uptake site of aquatic 
contaminants and are involved in gas exchange, osmoregulation and other critical functions 
(Lee et al., 2009); and the liver has a high metabolic capacity and detoxification function 
(Schirmer, 2006; Fent, 2007). For aquatic toxicity assessment, fish cell lines are preferred to 
mammalian cell lines as they better reflect fish-specific features, e.g. their incubation 
temperature is similar to the species-specific water temperature. Moreover, most of the fish 
cells lines are permanent, i.e. due to the spontaneously occurring immortalisation they can 
proliferate indefinitely. In contrary to many human cell lines, they are not cancerous, thus 
avoiding questions over the relevance of cancerous vs non-cancerous cells.  
 
When using cell lines knowledge on the bioavailability of a substance in vitro is crucial: it 
can be decreased by serum components (Hestermann et al., 2000; Gülden et al., 2005) or 
influenced by the type of solvent used or the dosing procedure, especially for volatile and 
hydrophobic test chemicals (Tanneberger et al., 2010).  
 
In the recently finalised research project, CEllSens (ECO8; http://www.cefic-lri.org/projects), 
funded by CEFIC LRI and UK-Defra, the use of a rainbow trout gill cell line-based assay 
(RTgill-W1) for acute fish toxicity testing was systematically evaluated taking into account 
various scenarios which could improve the sensitivity of fish cell lines as reviewed by 
Schirmer (2006). In the CEllSens project, exposure concentrations were measured at the 
beginning (0 h) and end of the exposure (24 h) and used to calculate the effective 
concentration (Tanneberger et al., 2013). The gill cell line was chosen, since gill epithelial 
cells are the primary site of uptake of contaminants, and damage of gill epithelial cell 
membrane function or other vital cell functions may affect the whole organism and result in 
death. In order to capture possible damage in vitro, several indicators for cell viability 
(metabolic capacity, cell membrane integrity, lysosomal membrane integrity) were measured. 
Moreover, the RTgill-W1 cells can sustain exposure without any serum or in a simplified 
buffer (L15-ex) (Schirmer et al., 1997; Ackermann and Fent, 1998).  
 
In the CEllSens project, 35 organic chemicals were tested with the RTgill-W1 assay. 
Chemicals derived from a list of 60 reference chemicals (Schirmer et al., 2008) covering a 
wide range of in vivo fish toxicity, physicochemical properties and MOAs. The results 
(Tanneberger et al., 2013) showed a good agreement between the in vivo and in vitro 
effective concentrations. For up to 73% of the tested chemicals, covering chemicals acting 
via baseline toxicity and some with a specific MOA, the difference was less than 5-fold. For 
three chemicals, the fish cell assay was far less sensitive than the in vivo assay, two of them 
were neurotoxic (permethrin, lindane) and one needed metabolic activation (allyl alcohol). 
The outcome of the CEllSens project indicates that RTgill-W1 cytotoxicity assay is more 
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sensitive than other fish cell-line based assays and a promising method to reduce the use of 
fish for acute toxicity testing. However, further evaluation of its inter-laboratory 
reproducibility, predictive capacity and applicability domain (i.e. validation) is crucial prior 
to its use in a broader regulatory context.  
 
Fish cell lines are also valuable tools for studying specific effects of chemicals in vitro and 
can be used to develop AOPs, chemical categories and QSAR models, or to focus toxicity 
testing strategies. It is however important to select the appropriate cell type and cellular or 
sub-cellular endpoint (Knauer et al., 2007; Tollefsen et al., 2008; Kramer et al., 2009).  
 
13.5.4 The Adverse Outcome Pathway (AOP) concept 
The so-called Adverse Outcome Pathways (AOP) concept was proposed by Ankley et al. 
(2010) as a means of advancing ecological risk assessment (see also Chapter 1). An AOP was 
defined as “a conceptual construct that portrays existing knowledge concerning the linkage 
between a direct molecular initiating event and an adverse outcome at a biological level of 
organisation relevant to risk assessment”, e.g. survival, development, reproduction at the 
population level for ecology. This framework incorporates the above mentioned “mechanism 
of action” and “mode of action” approaches. Ankley et al. (2010) provide five examples of 
AOPs and elaborate on their practical impact on risk assessment (the Episuite narcosis 
QSAR, the photoactivated toxicity of PAHs, toxicity induced via the aryl hydrocarbon 
receptor, activation of the oestrogen receptor and impaired vitellogenesis). AOPs can be used 
to focus toxicity testing in terms of species and endpoint selection, extrapolation between 
chemicals, and support the prediction of mixture effects (Ankley et al., 2010). Moreover, 
AOPs can be used as the basis for developing integrated approaches to testing and assessment 
(IATA; see below) and chemical categories (Schultz, 2010). An OECD guidance document 
on the development and assessment of AOPs has been published recently (OECD, 2013c).  
 
In recent years, AOP-based approaches have been proposed to reduce the use of fish for long-
term fish toxicity testing (e.g. with the fish early life stage test [FELS]). Two workshops 
organised by ILSI-HESI in 2010 and 2012 tackled this issue. Based on the discussions at the 
first workshop, Volz et al. (2011) proposed AOPs for 2,3,7,8-tetrachlorodibenzeno-p-dioxin 
(TCDD)-induced cardiotoxicity, chlorpyrifos-induced neurotoxicity, and LAS (a narcotic 
surfactant)-induced gill toxicity on early life stages of fish. They also proposed a three-tier 
testing scheme for screening and prioritising of chemicals for FELS testing, starting with 
high-throughput AOP-based in vitro screening at Tier 1, applying fish embryo test at Tier 2, 
and only testing chemicals positive in Tier 1 and Tier 2 in the FELS at Tier 3.  
 
The 2nd workshop discussed which AOPs are relevant to FELS toxicity, as well as how they 
could be discovered and annotated (Villeneuve et al., 2014). The authors defined key events 
in the development of a fish embryo as development of the central nervous system, 
cardiovascular system, liver, kidney, etc. They gave examples of hypothesised AOPs related 
to impaired swim bladder inflation and reduced survival of young fish. 
 
In 2013, the CEFIC LRI-funded project (LRI-ECO20-UA) Development of an alternative 
testing strategy for the fish early life-stage test for predicting chronic toxicity started. It aims 
to map FELS-relevant AOPs, develop an in vitro toolbox for screening FELS-relevant AOPs 
(Tier 1) and zebrafish embryo based assays (Tier 2). 
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In addition, an AOP for acute aquatic toxicity initiated by weak acid respiratory uncoupling 
has been proposed (OECD, 2011), as well as an AOP for paraoxon-induced toxicity during 
zebrafish embryogenesis (Yozzo et al., 2013). 
 
The recent workshop on "Advancing Adverse Outcome Pathways for Integrated Toxicology 
and Regulatory Applications" (March 2014; Somma Lombardo Italy; co-organised by 
Environment Canada, US EPA, US ERDA, JRC, as well as academic institutes/organisation 
from USA, Switzerland, and Norway) brought together more than 50 experts from regulatory 
agencies, academia and industry to discuss the Adverse Outcome Pathway concept with a 
focus on environmental hazard and risk assessment. Reports from this workshop will become 
available during 2014-2015. 
 
13.5.5 Use of fish embryos for chronic toxicity testing 
Weil et al. (2009) evaluated 14 substances in the zebrafish embryo toxicity test (48h 
exposure) and determined their effects on lethal and sublethal effects as well as on the 
expression of potential marker genes (Gene-DarT assay). Out of seven, two marker genes 
(cyp1a, hmox1) appeared to be the most sensitive. For 10 substances, the LOEC derived with 
the Gene-DarT assay differed by a factor less than 10 from the LOECs derived from fish 
early life stage tests with zebrafish, whereas two substances were more and one substance 
less potent in the Gene-DarT. 
 
13.5.6 Extrapolating across species and from acute to chronic effects   
Regulatory aquatic risk assessment schemes require toxicity testing of chemicals on a limited 
number of laboratory species; thus, extrapolation from the obtained toxic responses to all 
species representing that trophic level in the environment is a fundamental tenet of regulatory 
ecotoxicological risk assessment. To derive the Predicted No-Effect Concentration (PNEC) 
for aquatic toxicity, safety factors are applied to the laboratory data. These factors are 
intended to account for interspecies differences in sensitivity, extrapolation from acute to 
chronic effects, and the physicochemical complexity of natural water versus laboratory test 
media. The choice of the factor (10, 100 or 1000) depends on the quality and quantity of the 
available data.  
 
Differences in species sensitivity to acute aquatic toxicity have been well described (Weyers 
et al., 2000; Hutchinson et al., 2003, Jeram et al., 2005; Hoekzema et al., 2006; Tebby et al., 
2011). The observation that fish is the most sensitive species in only 15-20% of the cases 
resulted in the development of the threshold approach (OECD GD 126; OECD, 2010), which 
reduces the number of fish needed for acute aquatic toxicity testing.  
 
To address the question whether it is possible to predict acute toxicity in fish from non-
vertebrate species, Netzeva et al. (2007) reviewed several Quantitative Activity-Activity 
Relationships (QAAR) between species, the most relevant and reliable relationship for acute 
fish toxicity being between D. magna and rainbow trout (n=360), with an r2 value of 0.67. 
More recent studies have confirmed the good correlation between acute fish and daphnia 
toxicity data, especially for organothiophosphates (0.74< r2<0.94) and (benzo)triazoles 
(r2=0.87) (Zvinavashe et al., 2009; Kar et al., 2010; Zhang et al., 2010; Cassani et al., 2013). 
The correlation depends on both the bio-uptake process and the MOA of the chemical (Zhang 
et al., 2010), as well as its physicochemical properties (Tebby et al., 2011).  
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The US EPA has developed a tool (ICE – Interspecies Correlation Estimation, implemented 
as WebICE; Raimondo et al., 2010) to predict acute toxicity to three relevant fish species 
(fathead minnow, rainbow trout, and common carp) on the basis of Daphnia magna toxicity, 
with the strongest correlation being evident between D. magna and rainbow trout. 
 
Concerning the extrapolation from acute to chronic effects for a given substance, Ahlers et al. 
(2006) found that acute to chronic ratios (ACRs) vary considerably between different 
chemicals and can be as high as 4400. They also compared ACRs for the same substances 
between daphnia and fish, and found no correlation. This means that the ACR for a given 
substance obtained in an invertebrate species cannot be used to reliably extrapolate from the 
(known) acute toxicity to the (unknown) chronic toxicity in a fish species. However, there are 
better options for predicting chronic fish toxicity, such as the use of interspecies correlations 
from effects in daphnia. 
 
13.5.7 Threshold of Toxicological Concern (TTC) approach 
The TTC approach is based on the premise that there is a general exposure limit for 
chemicals below which no significant risk to human health or the environment is expected. 
By applying the TTC concept, testing on aquatic organisms can be reduced or avoided. The 
potential application of the TTC approach in aquatic toxicity assessment has been explored 
by de Wolf et al., 2005); and for endocrine active substances in the aquatic environment by 
Gross et al. (2010). De Wolf et al. (2005) collated reliable acute and chronic aquatic toxicity 
data from several ecotoxicity databases and derived an aquatic threshold of no concern 
(ETNCaq) of 0.1 μg/L for chemicals with MOA 1-3 according to the Verhaar MOA scheme. 
For MOA 4 (specifically reacting) chemicals, the ETNC was significantly lower. Tolls et al. 
(2009) proposed using the approach for the risk assessment of poorly water soluble chemicals 
with MOA 1-2 and ETNCaq of 1.9 ug/L. They concluded that the aquatic exposure levels of 
chemicals with water solubility below this ETNCaq will not exceed the ecotoxicological no-
effect concentration and thus their risk would be negligible.  
 
13.5.8 Integrated testing strategies 
Over the last decade, various testing strategies to reduce the use of fish in aquatic toxicity 
testing have been discussed in the context of the (then upcoming) REACH legislation 
(ECETOC, 2005; ECETOC, 2007; Grindon et al., 2008) or more recently in a broader OECD 
context (OECD, 2012a). The various strategies largely agree on the approach to acute aquatic 
toxicity testing. They start with the evaluation of existing information (chemical properties, 
possible aquatic exposure, existing mammalian and environmental data derived with standard 
or non-standard methods, etc.) and decision of its suitability for CLP and CSA. If this is not 
conclusive, a step-wise approach is proposed and, after each step, a decision should be taken 
whether the new information allows a conclusion on CLP and CSA for acute aquatic toxicity. 
Several possibilities to derive relevant information are listed e.g. in silico methods, testing on 
invertebrates (OECD TG 202) and algae (OECD TG 201), and use of alternatives to acute 
fish tests (fish cells, fish embryos, use of less fish). Some of the fish alternatives are now 
described in OECD documents, e.g. the threshold approach in OECD GD 126 (OECD, 2010) 
and the fish embryo acute toxicity test in OECD TG 236 (OECD, 2013b). 
 
The strategies differ when it comes to long-term aquatic toxicity testing. ECETOC (2007) 
acknowledges that long-term testing in fish may be driven by PEC/PNEC >1 or specific 
regulatory requirements (e.g. human pharmaceuticals). However, there might be a low 
priority for fish long-term tests, if a chemical is not taken up by fish (high molecular weight 
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chemicals) or rapidly metabolised or excreted, i.e. having a low potential to bioaccumulate. 
Based on the MOA of the leading toxic effect, long-term testing would be considered and 
designed (MOA 3-4) or not required (MOA 1 or MOA 2). Grindon et al. (2008) 
recommended that long-term fish toxicity tests should only be performed if a chemical may 
bioaccumulate in fish. Information on potential bioaccumulation should preferably be derived 
by using physicochemical properties and/or in silico methods, and in case conclusive 
predictions cannot be made, a fish bioaccumulation test (OECD TG 305) should be 
conducted. The report of the OECD workshop “Fish toxicity testing framework” (OECD, 
2012a) outlines a generic testing strategy on how to best combine OECD TGs to derive the 
required information. If information on aquatic long-term toxicity is required, fish toxicity 
testing may not be necessary, if there is evidence that daphnia or algae are more sensitive. 
However, if a chemical is more acutely toxic to fish or there is a risk of bioaccumulation or 
potential endocrine activity in fish, further testing on fish would need to be considered, e.g. 
the appropriate OECD TG for assessing endocrine activity or long-term fish toxicity (e.g. 
OECD TG 210, TG 212 or TG 215 depending on the target life stage).  
 
A recently published review paper (Scholz et al., 2013) addresses possibilities to reduce the 
use of animals (birds, fish, amphibia) for environmental hazard and risk assessment of 
chemicals, plant protection products, biocides, pharmaceuticals and other products. Apart 
from reviewing currently available alternative methods, the authors discuss how animal test 
design and risk assessment schemes could be modified to become more resource efficient 
whilst providing the same level of protection. They advocate for the development of 
"formalised" ITS combining the various alternative approaches. 
 
13.6 Conclusions and recommendations on aquatic toxicity 
There are many options to reduce or waive the use of fish in acute aquatic toxicity testing. 
Some have been in use for many years, e.g. QSARs, whereas others have only recently 
gained acceptance, e.g. the threshold approach (OECD GD 126) and the fish embryo acute 
toxicity test (OECD TG 236). Both methods are mentioned in the REACH Endpoint Specific 
Guidance (Chapter 7b), for instance, the threshold approach is an integrated part of the ITS 
for CSA (where it is referred to as a limit test) and the fish embryo acute toxicity test is 
referred to as a possible alternative to OECD TG 203.  
 
Since OECD TG 236 does not indicate whether the fish embryo acute toxicity test can be 
used as an alternative to the acute fish toxicity test, it may be useful to develop guidance on 
this option within the REACH legislation. Such guidance should also address the limitations 
of the zebrafish embryo acute toxicity test. 
 
The results of the CEllSens project show that the well-developed and standardised 
cytotoxicity assay based on the rainbow trout gill cell line, RTgill-W1, is a promising method 
and as predictive as the 48 h zebrafish embryo acute toxicity test (Tanneberger et al., 2013; 
Knöbel et al., 2012). However, the RTgill-W1 cytotoxicity assay is not yet formally 
validated. A ring trial on assessment of the transferability of RTgill-W1 cytotoxicity assay is 
on-going under the coordination of K. Schirmer (EAWAG, Switzerland). 
 
QSARs provide a reliable means of predicting the acute fish toxicity of organic chemicals, 
especially those acting via a narcosis mode of action. Even for more reactive or specifically 
acting chemicals, QSARs provide estimates of the minimal (baseline) toxicity that can be 
expected, which may be adequate for the regulatory purpose. Relatively few QSARs are 
available for chronic fish toxicity, but other options can be applied; for example, the OECD 
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QSAR Toolbox provides extensive databases and functionalities to support grouping and 
read-across. The application of QSAR analysis to the modelling of fish toxicity (and aquatic 
toxicity in general) was very popular in the 80s and 90s, but has received relatively little 
attention in the 21st century. This can be attributed to the fact that the available QSARs, for 
narcosis at least, are as reliable as can be achieved using existing data sets, but it is also a 
reflection that the modelling community has shifted its efforts to other endpoints, especially 
those relevant to human health. Nevertheless, there is still an opportunity to develop more 
and improved QSARs, especially for reactive and specifically acting chemicals. Furthermore, 
there is merit in further investigating how different MOA classification schemes can be used 
in the context of TTC approaches in which specific thresholds of no environmental concern 
are associated with MOA classes. 
 
There is a need to more accurately extrapolate responses across species and to identify 
species-specific effects. In this context, Celander et al. (2011) proposed a strategy consisting 
of the identification of specific MOAs / AOPs and the homology assessment of target genes, 
to estimate how species differences in protein functions are related to differences in in vivo 
sensitivity. In addition, knowledge on absorption, distribution, metabolism and excretion, 
including species differences at various life stages, will allow a more accurate extrapolation 
of toxic effects across species.  
 
Several research groups are working on the identification and description of potential AOPs 
relevant to fish early life-stage toxicity (OECD TG 210) and CEFIC LRI launched a research 
project on this topic in early 2013. It is hoped that the definition of FELS-related AOPs will 
help to develop predictive assays using fish cell lines and fish embryos. 
 
For the assessment of chronic fish toxicity, the options for reducing or waiving fish tests are 
currently more limited. However, an analysis carried out by the JRC shows that predictions 
can be based on toxicity data on Daphnia (OECD TG 211) using interspecies correlation 
equations (QAARs).  
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Table 13.1. OECD test guidelines for fish toxicity testing  
 
OECD Guideline 203 – Fish, Acute 
Toxicity Test 
236 – Fish Embryo 
Acute Toxicity 
(FET) Test  
204 – Fish, 
Prolonged Toxicity 
Test 
 
210  - Fish, Early-life 
Stage Toxicity Test 
(revised in 2013) 
212 - Fish, Short-
term Toxicity Test 
on Embryo and Sac-
Fry Stages 
215 – Fish, Juvenile 
Growth Test 
Species zebrafish (Danio 
rerio),  
fathead minnow 
(Pimephales 
promelas),  
Japanese medaka 
(Oryzias latipes), 
rainbow trout 
(Oncorhynchus 
mykiss) 
bluegill sunfish1 
(Lepomis 
macrochirus), 
common carp1 
(Cyprinus carpio), 
guppy1 (Poecilia 
reticulate) 
zebrafish (Danio 
rerio); 
 
in development for 
fathead minnow 
See OECD TG 203 rainbow trout 
(Oncorhynchus 
mykiss) 
zebrafish (Danio 
rerio),  
fathead minnow 
(Pimephales 
promelas),  
Japanese medaka 
(Oryzias latipes) 
sheepshead minnow2 
(Cyprinodon 
varieqatus), 
silverside 2 (Menidia 
sp) 
zebrafish (Danio 
rerio),  
Japanese medaka 
(Oryzias latipes), 
rainbow trout 
(Oncorhynchus 
mykiss),  
fathead minnow 
(Pimephales 
promelas),  
common carp 
(Cyprinus carpio), 
goldfish (Carassius 
auratus) 
bluegill (Lepomis 
macrochirus) 
tidewater silverside 2 
(Menidia peninsulae) 
herring2 (Clupea 
harengus) 
cod2 (Gadus morhua) 
sheepshead minnow2 
(Cyprinodon 
variegatus) 
rainbow trout 
(Oncorhynchus 
mykiss) is 
recommended species 
 
zebrafish (Danio 
rerio),  
Japanese medaka 
(Oryzias latipes) 
Life-stages covered Juvenile or adult fertilised eggs, 
embryos until 96h 
post-fertilisation 
Juvenile or adult fertilised eggs, 
embryo, sac-fry, 
larvae 
juvenile fish 
fertilised eggs, 
embryo, sac-fry 
juvenile 
Number of animals 
(min) 
42  
(at least 7-10 per 
120  
(at least 20 fertilised 
10 per concentration  
& control  
480  
(at least 
150  
(at least 30 fertilised 
Not defined; depends 
on the test design; at 
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OECD Guideline 203 – Fish, Acute 
Toxicity Test 
236 – Fish Embryo 
Acute Toxicity 
(FET) Test  
204 – Fish, 
Prolonged Toxicity 
Test 
 
210  - Fish, Early-life 
Stage Toxicity Test 
(revised in 2013) 
212 - Fish, Short-
term Toxicity Test 
on Embryo and Sac-
Fry Stages 
215 – Fish, Juvenile 
Growth Test 
concentrations & 
control) 
eggs per concentration 
& control) 3 
80/concentration & 
control) 
eggs per concentration 
& control) 
least two replicates 
per concentration 
Concentrations At least 5  At least 5 Not stated; should 
allow calculation of 
LC50, ECx, NOEC 
At least 5 (or less 
when only NOEC 
needed; see limit test) 
At least 5 (or less with 
justification) 
At least 5 
Controls Water, and if needed 
solvent 
Water, and if needed 
solvent 
Water, and if needed 
solvent 
Water, and if needed 
solvent 
Water, and if needed 
solvent 
Water, and if needed 
solvent 
Duration 96 h 96 h 14 days 28-60 days (species 
dependant) 
Until embryos start 
feeding or onset of 
mortality due to 
starvation (for 
zebrafish TG states 8-
10 days) 
28 days 
Endpoint Lethal effects 
LC50 
Lethal effects 
LC50 
Lethal & sublethal 
effects (appearance, 
size, behaviour) 
LC50, ECx, NOEC 
At all life stages: 
hatching success, 
abnormal appearance, 
abnormal behaviour, 
survival / mortality  
At the end of the test 
wet weight, length 
NOEC, LOEC (or 
ECx) for each 
observation 
Embryo/sac-fry stage: 
hatching success, 
abnormal appearance, 
abnormal behaviour, 
survival / mortality  
At the end of the test: 
weight, length 
Growth rate as ECx; 
NOEC, LOEC 
Effects in control Max 1 control fish can 
die  
Survival rate >90% Effects  <10% Thresholds for 
hatching success, 
post-hatch survival 
(depending on the 
species) 
Thresholds for 
hatching success, 
post-hatch survival 
(depending on the 
species) 
<10% mortality; 
>50% weight gain 
Limit test Limit test at single 
concentration >100 
mg/L; control(s); 7-10 
fish 
Limit test at single 
concentration >100 
mg/L; control(s); at 
least 20 fertilised eggs 
- Limit test; 
concentrations above 
LC50 derived with 
TG 203 or >10 mg/L 
not to be tested 
Limit test; 
concentrations above 
LC50 derived with 
TG 203 or >100 mg/L 
not to be tested 
- 
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1 = warm water species; 2 = estuarine or saltwater species; 3 = Depending on regulatory national framework, may not be considered an animal test  
LC = Lethal Concentration; NOEC = No Observed Effect Concentration; ECx = x% Effect Concentration; LOEC = Lowest Observed Effect Concentration; OECD TG 204 
deleted in 2012 
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Table 13.2. Fish toxicity tests – Regulatory requirements across sectors 
Endpoint 
Regulatory framework Short-term fish toxicity Long-term fish toxicity Bioaccumulation 
REACH >10 t/year 
Not to be conducted if: 
- aquatic toxicity is unlikely to occur, e.g. 
chemical highly insoluble in water or 
unlikely to cross biological membranes 
or 
- a long-term aquatic toxicity study on 
fish is available  
In general applicants are invited to 
consider long-term aquatic toxicity 
testing:  
- as described in Annex IX  
o shall be considered if the chemical 
safety assessment according to 
Annex I indicates the need to 
investigate further effects on 
aquatic organisms. 
o if the substance is poorly water 
soluble. 
>100 t/year 
- Long-term toxicity testing shall be 
proposed by the registrant if the 
chemical safety assessment 
according to Annex I indicates the 
need to investigate further the 
effects on aquatic organisms. The 
choice of the appropriate test(s) 
depends on the results of the 
chemical safety assessment. 
- Appropriate tests: Fish early-life 
stage (FELS) toxicity test (OECD 
210); Fish short-term toxicity test on 
embryo and sac-fry stages (OECD 
212) or Fish, juvenile growth test 
(OECD 215) 
>100 t/year 
Not to be conducted if: 
- the substance has a low potential for 
bioaccumulation (for instance a log 
Kow ≤ 3) and/or a low 
- potential to cross biological 
membranes, or 
- direct and indirect exposure of the 
aquatic compartment is unlikely. 
Plant protection products (until 2013) 
(EC, 2009a) 
Active substance: 
OECD TG 203 (rainbow trout and warm 
water species) 
 
Formulations: OECD TG 203 if fish is 
the most sensitive species for the active 
substances included 
Active substance: 
OECD TG 204 or OECD TG 215 over 
28 days, LC50 <0.1 mg/L triggers TG 
210 or fish life cycle test 
 
 
Active substance 
To be conducted if  
- log Kow >3 or other indications that 
the chemical may bioaccumulate in 
fish,  
- the substance is stable in water 
 
Formulations: 
fish bioconcentration studies are 
triggered when log Pow >3 and dt90 
(w/s) >10 d or if >1 application 
Plant protection products data 
requirements (from 2014 onwards) (EU, 
2013a; 2013b) 
Active substance: 
Threshold approach or OECD TG 203 
(rainbow trout) 
 
 
 
 
Active substance: 
Fish early-life stage (FELS) toxicity test 
(OECD TG 210) 
- if exposure of surface water likely 
and the substance stable in water;  
Fish full life cycle test may be required 
 
Active substance: 
To be conducted if  
- log Kow >3 or other indications that 
the chemical may bioaccumulate in 
fish,  
- the substance is stable in water 
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Endpoint 
Regulatory framework Short-term fish toxicity Long-term fish toxicity Bioaccumulation 
Product: 
Only if the toxicity cannot be predicted 
from the active substance(s) or read-
across 
 
In case that fish data are needed: 
Threshold approach or OECD TG203 
(rainbow trout) 
Product: 
Only if the toxicity cannot be predicted 
from the active substance(s) 
 
Necessary studies should be discussed 
with competent authority. 
Biocides (EU, 2012a) Core data set: Short-term toxicity on 
fish (use of threshold approach).  
If a valid long-term fish toxicity study is 
available, the short-term fish toxicity 
study can be waived 
Additional data set: depending on the 
results of the studies on fate / behaviour 
and intended use, e.g. risk to the aquatic 
environment, and long-term exposure - 
long-term toxicity studies on fish may be 
required, one or two tests, OECD 210, 
212, 215 or fish full life cycle test; 
bioaccumulation in an appropriate 
aquatic species. 
Core data set: Experimental 
bioconcentration test can be waived if log 
Kow <3 or other evidence that the 
substance has a low potential for 
bioconcentration 
 
Additional data set: depending on the 
results of the studies on fate / behaviour 
and intended use, e.g. risk to the aquatic 
environment, bioaccumulation in an 
appropriate aquatic species may be 
required 
Veterinary Pharmaceuticals (EMA, 
2004) 
Stepwise approach with initial 
screening (Phase I) to identify 
exposure, bioaccumulation, 
persistence. If given then studies are 
performed (Phase II): 
Tier A – base set requirement OECD TG 
203 
if risk quotient (PEC/PNEC) >1 for fish, 
OECD TG 210 fish early life stage test 
Tier B – if log Kow >4 and evidence for 
bioaccumulation from other studies, 
OECD 305 to be carried out 
Human Pharmaceuticals (EMA, 2006) 
Stepwise approach with initial 
screening (Phase I) to identify 
exposure, bioaccumulation, 
persistence. If given then studies are 
performed (Phase II):  
- Tier A – base set requirement OECD TG 
210 – fish early life stage test 
Tier B – depending on information on 
fate in Tier A, bioconcentration study 
with drug substance or its metabolites 
Feed (EC, 2008; EFSA, 2008) 
Stepwise approach with initial 
determination (Phase I) whether a 
Phase IIa: OECD TG 203 Phase IIb: OECD TG 210  
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Endpoint 
Regulatory framework Short-term fish toxicity Long-term fish toxicity Bioaccumulation 
significant environmental effect of 
the additive is likely (based on 
estimated PEC). If likely, then 
studies are performed (Phase II): 
Cosmetic ingredients (EC, 2009b) See REACH See REACH See REACH 
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Chapter 13. Table of References with Notes 
 
Traditional fish tests – OECD TGs and GD 
Short-term fish toxicity  
OECD (1992a). Guidelines for Testing of Chemicals, 203, Fish, 
acute toxicity test. Paris, France. Available from: 
http://www.oecd.org 
 
The fish acute toxicity test determines the concentration of a compound which is lethal to 
50% of the fish (LC50) at 24, 48, 72, 96 h exposure. At least 5 concentrations; groups of 7-
10 fish; 7-10 control (dilution water) fish and if used also solvent control group with 7-10 
fish; LC0 and LC100 determined (latter not used in risk assessment). 
Allows limit test at a single concentration (= 100 mg/L) with 7-10 fish in the treatment group 
and 7-10 fish in the control group / solvent group. If no mortality occurs LC50 is reported as 
>100mg/L. If mortality occurs, full test is required. 
Species: zebrafish, fathead minnow, medaka, rainbow trout, bluegill sunfish (and others) 
Rufli and Springer (2011) See below Status of Non-standard methods // Reduction / refinement general 
Rufli (2012) See below Status of Non-standard methods // Reduction / refinement general 
Note: TG 204 will be deleted in April 2014 
 
OECD (1984). Guidelines for Testing of Chemicals, 204. Fish, 
Prolonged Toxicity Test: 14-day Study. OECD, Paris, France 
(deleted since 2012; deletion to be implemented in 2014) 
Determines threshold levels for lethal effects, observed (non-lethal) effects and NOEC after 
14 day exposure (option to extend by 2 weeks); 10 fish per concentration, control group, 
solvent group if necessary; number of concentrations not defined, should be chosen to allow 
determining threshold levels for the lethal and other observable effects, NOEC; not necessary 
to test beyond 100 mg/L if threshold levels not reached.  
Species: as TG 203 
OECD Fish Toxicity Testing Framework report recommends deletion of TG 204, since it is 
hardly performed and not well defined. Moreover, OECD TG 203 allows extension of 
exposure beyond 96 h, in case slow mortality occurs.  
OECD (2010). Series on Testing and Assessment No. 126; Short 
Guidance on the Threshold Approach for Acute Fish Toxicity 
Testing. OECD, Paris, France. Available from: http://www.oecd.org 
 
The threshold approach for acute fish toxicity testing is a reduction strategy and based on the 
observation that fish are not always the most sensitive of the three test species used in acute 
aquatic toxicity testing. Testing of fish is performed at a single concentration (= threshold 
concentration, TC) following the limit test as described in TG 203. The threshold 
concentration is derived from reliable invertebrate (e.g. daphnia) and algae data and 
corresponds to the lowest of the LC50/EC50 value. 
OECD (2013b). Guidelines for Testing of Chemicals, 236. Fish 
Embryo Acute Toxicity (FET) Test. OECD, Paris, France. Available 
from: http://www.oecd.org 
The fish embryo acute toxicity test determines the concentration of a compound which is 
lethal to 50% of the embryos at 48 h and 96 h exposure. At least 5 concentrations; 20 
fertilised eggs / concentration, positive control (3,4-dichloroaniline), water control, solvent 
control if required; the following observations are recorded and indicate the death of the fish 
embryo: coagulation, absence of somites (no muscular structure, embryo will not be able to 
hatch and will die), non-detachment of the tail (functional tail is needed for the hatching), 
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and absence of heartbeat. As TG 203, TG 236 allows a limit test at a single concentration (= 
100mg/L) with 20 embryos in the treatment group and 20 embryos in the respective control 
groups. If no mortality occurs, the LC50 is reported >100mg/L. If mortality occurs, full test 
is required. If a compound needs to get activated via metabolism and the metabolites or 
transformation products are believed to be more toxic than the parent compound, the test 
should also be carried out with the relevant metabolites / transformation products and the 
results be considered when concluding on the toxicity. The test might not be appropriate for 
compounds with a molecular weight ≥3kDa, a very bulky molecular or compounds 
precluding or delaying hatch, since in these cases zebrafish embryos will not be fully 
exposed to the compound and due to decreased bioavailability of the compound toxic effect 
may not develop.  
Long-term fish toxicity  
OECD (1992). Guidelines for Testing of Chemicals, 210. Fish, 
Early-life Stage Toxicity Test. (out of date) 
 
 
 
 
 
 
OECD (2013a). Guidelines for Testing of Chemicals, 210. Fish, 
Early Life Stage Test. OECD, Paris, France. Available at: 
http://www.oecd.org 
 
As stated before the revision: 
Chronic exposure. Assesses effects (lethal, sublethal) of a chemical on early life stages of 
fish (embryos, larvae, juvenile fish), endpoints are: hatching, abnormal appearance, abnormal 
behaviour, survival / mortality at embryo, larval, juvenile stage and overall; dry weight and 
length at the end of the test; NOEC and LOEC (not always possible) for each endpoint. Starts 
fertilised eggs and continues until the controls are freely feeding. At least 5 concentrations 
with at least 60 eggs / concentration divided in two replicates; control group and solvent 
control group if needed;  
Species: freshwater - zebrafish, fathead minnow, medaka, rainbow trout; saltwater sheephead 
minnow 
 
Revised guideline: main differences 
At least 80 eggs / concentration / control;  divided into at least four replicates; wet weight 
instead of dry weight; performance standards set for control fish (hatching success, post-
hatch survival); guidance on statistical analysis for NOEC determination and ECx 
determination; allows conducting a limit test or using less than five concentrations when only 
an empirical NOEC is needed. 
OECD (1998). Guidelines for Testing of Chemicals, 212. Fish, 
Short-term Toxicity Tests on Embryo and Sac-fry Stages. OECD, 
Paris, France. Available from: http://www.oecd.org 
 
Sub-chronic exposure: exposure starts with eggs and should end before the yolk-sac is 
completely absorbed or before mortality due to starvation begins. Assesses effects of a 
chemical on hatching, abnormal appearance, abnormal behaviour, survival / mortality at 
embryo and larval stages and overall; weight and length at the end of the test; NOEC and 
LOEC. May be used as range finding test for OECD TG 210. Less sensitive compared to 
OECD TG 210, in particular for highly lipophilic substances or substances with specific 
  396 
mode of action. Species: zebrafish, fathead minnow, medaka, rainbow trout, carp. 
Note: There is a major animal welfare concern associated with OECD TG 212 being also 
called the fish "starvation" assay, since no food is provided to the hatched embryos during 
the test. Many species already start feeding at the sac-fry stage, e.g. zebrafish embryo start 
feeding around 48 h after hatch. OECD Fish Toxicity Testing Framework report (OECD, 
2012) recommends its deletion due to the animal welfare concerns and its low sensitivity. 
OECD (2000). Guideline for Testing of Chemicals, 215. Fish, 
Juvenile Growth Test. OECD, Paris, France. Available from: 
http://www.oecd.org 
 
Chronic exposure: assesses effects of a chemical on the growth of juvenile fish for 28 days; 
at least five concentrations; number of fish per concentration/control not stated but should be 
based on statistical power. Effects: weight, length, mortality, abnormal appearance, abnormal 
behaviour; NOEC and LOEC for each effect 
Species: rainbow trout, zebrafish, medaka 
Note: only rarely used; does not cover all life stages 
Bioaccumulation / bioconcentration  
OECD (2012). Guidelines for Testing of Chemicals, 305, 
Bioaccumulation in Fish: Aqueous and Dietary Exposure. Paris, 
France. Available from: http://www.oecd.org 
 
OECD TG 305 has recently been revised and now includes two exposure routes: aqueous and 
dietary. The latter is recommended for strongly hydrophobic substances (log Kow > 5 and 
solubility below ~ 0.01-0.1 mg/L).  
305-I Aqueous exposure: BCF is determined by exposure of fish for (usually) 28 days 
(uptake phase) followed by the depuration phase (usually half of the duration of the uptake 
phase). Fish are samples (4 x sampling) on at least five occasions during the uptake and at 
least four occasions during the depuration phase. At least 108 fish are used, i.e. 36 per 
concentration or control. 
BCF should be normalised for lipid concentration and fish weight. Possible to use only one 
concentration for non-polar narcotics. 
305-II Minimised aqueous exposure: to be used only for non-polar organic substances; 
sampling is reduced to four; thus less fish are used, i.e. 48 for a study with two 
concentrations and water control. 
305-III: Dietary Exposure Bioaccumulation Fish Test 
Should be used for substances where the aqueous exposure methodology is not practicable 
(for example because stable, measurable water concentrations cannot be maintained, or 
adequate body burdens cannot be achieved within 60 days of exposure); the endpoint from 
this test will be a dietary biomagnification factor (BMF). The test consists of two phases: 
uptake (test substance-spiked feed) and depuration (clean, untreated feed). Depending on the 
test design and sampling scheme, at least 50-120 fish (treatment group), 50-110 control fish, 
and if needed 15 fish for lipid correction are used. 
Regulatory requirements across sectors  
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EC (2006). Regulation (EC) No 1907/2006 of the European 
Parliament and the Council of 18 December 2006 concerning the 
Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH), establishing a European Chemicals Agency, 
amending Directive 1999/45/EC and repealing Council Regulation 
(EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as 
well as Council Directive 76/769/EEC and Commission Directives 
91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. Official 
Journal of the European Union L396, 1-849. 
Chemicals: Information requirements depend on the production volume of the chemical 
concerned: 
• Annex VIII (10-100 tpa): short-term fish toxicity 
o The study does not need to be conducted  
 there are mitigating factors indicating that aquatic toxicity is 
unlikely to occur, for instance if the substance is highly insoluble in 
water or the substance is unlikely to cross biological membranes or 
 if a long-term aquatic toxicity study on fish is available  
o in general applicants are invited to consider long-term aquatic toxicity 
testing  
o long-term toxicity testing as described in Annex IX  
 shall be considered if the chemical safety assessment according to 
Annex I indicates the need to investigate further effects on aquatic 
organisms. 
  if the substance is poorly water soluble. 
• Annex IX-X (100->1000 tpa):  
o long-term toxicity testing: 
• Long-term toxicity testing shall be proposed by the registrant if the 
chemical safety assessment according to Annex I indicates the need 
to investigate further the effects on aquatic organisms. The choice of 
the appropriate test(s) depends on the results of the chemical safety 
assessment. 
• Appropriate tests: Fish early-life stage (FELS) toxicity test (OECD 
TG 210); Fish short-term toxicity test on embryo and sac-fry stages 
(OECD TG 212) or Fish, juvenile growth test (OECD TG 215) 
o Bioaccumulation in aquatic species, preferably fish 
• The study need not be conducted if: 
• the substance has a low potential for bioaccumulation (for 
instance a log Kow ≤ 3) and/or a low 
• potential to cross biological membranes, or 
• direct and indirect exposure of the aquatic compartment is 
unlikely. 
EC (2009a). Regulation (EC) No 1107/2009 of the European Plant protection products: Requirements are stated in SANCO/3268/2001 rev.4 (final) 17 
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Parliament and of the Council of 21 October 2009 concerning the 
placing of plant protection products on the market and repealing 
Council Directives 79/117/EEC and 91/414/EEC. Official Journal of 
the European Union L309: 1-47. 
 
 
 
 
 
From 2014 onwards 
EU (2013a). Commission Regulation (EU) No 283/2013 of 1 March 
2013 setting out the data requirements for active substances, in 
accordance with Regulation (EC) No 1107/2009 of the European 
Parliament and of the Council concerning the placing of plant 
protection products on the market. Official Journal of the European 
Union L93: 1-84. 
 
EU (2013b). Commission Regulation (EU) No 284/2013 of 1 March 
2013 setting out the data requirements for plant protection products, 
in accordance with Regulation (EC) No 1107/2009 of the European 
Parliament and of the Council concerning the placing of plant 
protection products on the market. Official Journal of the European 
Union L93: 85-152. 
 
October 2002, Working Document, Guidance document on Aquatic Ecotoxicology in the 
context of the Directive 91/414/EEC – (from 2014 onwards obsolete; superseded by EU 
2013a and EU2013b)) 
Active substance: Short-term fish toxicity (OECD TG 203) with rainbow trout and one warm 
water species; long-term/chronic fish toxicity: OECD TG 204 or OECD TG 215 over 28 
days, LC50 <0.1 mg/L triggers TG 210 or fish life cycle test  
Formulations: Acute fish toxicity test if fish is the most sensitive species for the active 
substances included; fish bioconcentration studies are triggered when log Pow > 3 and dt90 
(w/s) > 10 d or if > 1 application 
 
Active substance: Short-term fish toxicity (threshold approach (OECD GD126) or OECD TG 
203 with rainbow trout); long-term fish toxicity with OECD TG 210 if exposure of surface 
water likely and the substance stable in water; fish full life cycle test may be required; 
Bioconcentration (fish) studies are required if log Kow > 3 or other indications that the 
chemical may bioaccumulate in fish, if the substance is stable in water 
 
 
Products: short-term fish toxicity only if the toxicity cannot be predicted from the active 
substance(s) or read-across. In case that fish data are needed: Threshold approach or OECD 
TG203 (rainbow trout); long-term toxicity: Only if the toxicity cannot be predicted from the 
active substance(s). Necessary studies should be discussed with competent authority. 
EU (2012a). Regulation (EU) No 528/2012 of the European 
Parliament and of the Council of 22 May 2012 concerning the 
making available on the market and use of biocidal products. 
Official Journal of the European Union L167: 1-116. 
Biocides: requirements are outlined in Annex II.  
Core data set: short-term toxicity on fish (use of threshold approach; OECD GD126). If a 
valid long-term fish toxicity study is available, the short-term fish toxicity study can be 
waived. 
Experimental bioconcentration test can be waived if log Kow <3 or other evidence that the 
substance has a low potential for bioconcentration.  
Additional data set: depending on the results of the studies on fate / behaviour and intended 
use, e.g. risk to the aquatic environment, and long-term exposure - long-term toxicity studies 
on fish may be required, one or two tests, OECD TG 210, TG 212, TG 215 or fish full life 
cycle test; bioaccumulation in an appropriate aquatic species. 
EMA (2004). Guideline on environmental impact assessment for Pharmaceuticals for veterinary use: Stepwise approach with initial screening (Phase I) to 
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veterinary medicinal products Phase II, CVMP/VICH/790/03-Final 
(corresponds to VICH GL38). [based on outcome of Guideline on 
environmental impact assessment for veterinary medicinal products 
– Phase I (CVMP/VICH/592/98 // VICH GL6)] 
identify exposure, bioaccumulation, persistence. If given then studies are performed (Phase 
II): 
Tier A – base set requirement OECD TG 203 – fish acute toxicity test; Tier B – if log Kow>4 
and evidence for bioaccumulation from other studies, OECD TG 305 to be carried out; if risk 
quotient (PEC/PNEC) > 1 for fish, OECD TG 210 fish early life stage test (OECD TG 212, 
TG 215 not recommended) 
EMA (2006). Guideline on the environmental risk assessment of 
medicinal products for human use (EMEA/CHMP/SWP/4447/00). 
Pharmaceuticals for human use: Stepwise approach with initial screening (Phase I) to 
identify exposure, bioaccumulation, persistence. If given then studies are performed (Phase 
II): 
Tier A – base set requirement OECD TG 210 – fish early life stage test; Tier B – depending 
on information on fate in Tier A, bioconcentration study with drug substance or its 
metabolites  
EC 2008 Commission Regulation (EC) No 429/2008 of 25 April 
2008 on detailed rules for the implementation of Regulation (EC) 
No 1831/2003 of the European Parliament and of the Council as 
regards the preparation and the presentation of applications and the 
assessment and the authorisation of feed additives. Official Journal 
of the European Union L133: 1-65 
 
EFSA (2008). Technical Guidance for assessing the safety of feed 
additives for the environment The EFSA Journal 842: 1-28. 
 
 
 
 
 
 
Feed additives: Stepwise approach with initial determination (Phase I) whether a significant 
environmental effect of the additive is likely (based on estimated PEC). If likely, acute fish 
toxicity (OECD TG 203) would be tested in Phase IIa and chronic fish toxicity (OECD TG 
210) in Phase IIb.  
EC (2009b). Regulation (EC) No 1223/2009 of the European 
Parliament and the Council of 30 November 2009 on cosmetic 
products. Official Journal of the European Union L342: 59-209. 
Cosmetics: The environmental concerns that substances used in cosmetic products may raise 
are considered through the application of Regulation (EC) No 1907/2006 of the European 
Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) and establishing a European 
Chemicals Agency(4) OJ L 396, 30.12.2006, p. 1. (4), which enables the assessment of 
environmental safety in a cross-sectoral manner. 
EC (2008). Regulation (EC) No 1272/2008 of the European 
Parliament and of the Council of 16 December 2008 on 
classification, labelling and packaging of substances and mixtures, 
amending and repealing Directives 67/548/EEC and 1999/45/EC, 
and amending Regulation (EC) No 1907/2006. Official Journal of 
the European Union L353: 1- 1355. EC (2008).  
Art 7: Where new tests are carried out for the purposes of this Regulation, tests on animals 
within the meaning of Directive 86/609/EEC shall be undertaken only where no other 
alternatives, which provide adequate reliability and quality of data, are possible. 
Four classification categories – Acute Category 1 and Chronic Categories 1 – 3; Safety net 
classification = Chronic Category 4; considered are acute aquatic toxicity (fish, daphnia, 
algae), potential for or actual bioaccumulation, degradation, chronic aquatic toxicity (fish, 
daphnia, algae) 
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Standard methods to replace, reduce or refine the use of fish 
Threshold Approach for fish acute toxicity testing  
OECD GD126 (OECD, 2010) See above – Acute fish toxicity guidelines 
Hutchinson et al. (2003) See below REDUCTION - Step-down Approach  
Jeram et al. (2005) See below REDUCTION - Step-down Approach  
Hoeger, B., S. Jeram, M. Holt, P. Douben and M. Halder (2006). 
Reduction of animal use in acute aquatic toxicity testing: Further 
development of the threshold approach and its application to 
existing chemicals and plant protection products. Poster presentation 
at SETAC Europe 16th Annual Meeting 7-11 May 2006: abstract no 
MO1/AM/P05. 
Both, the step-down approach (see below) and the threshold approach (OECD GD126) start 
with the derivation of the (upper) threshold concentration = the lowest of EC/LC 50 of 
daphnia / algae tests. An acute fish test is carried out at this concentration using 5 test / 5 
control fish (step-down approach) or 7-10 test / 7-10 control fish as given in the limit test 
according to OECD TG 203. When mortality occurs, the threshold approach requires a full 
OECD TG 203 to be conducted; whereas in the step-down approach testing is continued at 
lower concentrations until no mortality occurs. The LC50 is then calculated based on the 
mortality rates of the individual tests. 
The ECVAM Scientific Advisory Committee only endorsed the threshold approach. 
ECVAM applied the threshold (step-down) and threshold approach to various datasets (fish, 
daphnia, algae) retrieved for plant protection products and industrial chemicals from various 
databases (IUCLID4, ECETOC, DG SANCO) databases. Depending on the database, fish 
was the most sensitive species for 17-30% chemicals/plant protection products and potential 
for reduction was between 32 % for the threshold approach and up to 60% for the threshold 
(step-down) approach. 
ECVAM (2006). ECVAM Advisory Committee Statement on the 
scientific validity of the upper treshold concentration (UTC) step-
down approach - a new testing strategy to reduce the use of fish in 
acute toxicity testing. Available on: 
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-
ecvam/publication/ESAC%20statement%20UTC%20step%20down
%20approach%2020060321.pdf 
The ECVAM Scientific Advisory Committee evaluated the threshold/step-down approach as 
proposed by Jeram et al. (2005) and other scenarios proposed in the ESAC dossier. ESAC 
approved the threshold approach. 
For further explanation see OECD GD126 and Hoeger et al., 2006 (above). 
Zebrafish embryo toxicity test  
OECD TG 236 (OECD 2013b) See above – Acute fish toxicity guidelines 
Weigt, S., N. Hübler, N. Strecker, T. Braunbeck and T. H. 
Broschard (2011). Zebrafish (Danio rerio) embryos as a model for 
testing proteratogens. Toxicology 281: 25-36. 
 
The authors tested 10 well-know proteratogens in a zebrafish embryo toxicity test (72 h 
exposure; specific malformation endpoints; proposed as teratogenicity screening test for 
human health to reduce reproductive toxicity studies) and found that 9 caused teratogenic 
effects in zebrafish embryos. They conclude from these results that zebrafish embryos can 
bioactivate the proteratogens without any addition of exogenous metabolic activation 
systems and have phase I enzyme activity (CYP) at very early stages of development.  
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Weigt, S., N. Hübler, R. Strecker, T. Braunbeck and T. H. 
Broschard (2012). Developmental effects of coumarin and the 
anticoagulant coumarin derivative warfarin on zebrafish (Danio 
rerio) embryos. Reproductive Toxicology 33: 133-141. 
The authors used a zebrafish embryo toxicity test (72 h exposure; specific malformation 
endpoints; proposed as teratogenicity screening test for human health to reduce reproductive 
toxicity studies) to study effects of coumarin and its derivative warfin. Both caused 
teratogenic effects in zebrafish which demonstrates that the enzymes necessary for 
bioactivation are present in 72 h old zebrafish embryos (CYP2A6, CYP2C9 and others). 
Incardona, J. P., T. L. Linbo and N. L. Scholz (2011). Cardiac 
toxicity of 5-ring polycyclic aromatic hydrocarbons is differentially 
dependent on the aryl hydrocarbon receptor 2 isoform during 
zebrafish development. Toxicology and Applied Pharmacology 257: 
242-249. 
The authors report on the role of the aryl hydrocarbon (AHR) / cytochrome P4501A 
(CYP1A) in the toxicity of different polycyclic aromatic hydrocarbons to very early life 
stages of zebrafish embryos (4-48 h post-fertilisation). PAHs induce CYP1A through AHR2 
binding and cause cardiotoxic effects.  
Kubota, A., J. J. Stegeman, B. R. Woodin, T. Iwanaga, R. Harano, 
R. E. Peterson, T. Hiraga and H. Teraoka (2011). Role of zebrafish 
cytochrome P450 CYP1C genes in the reduced mesencephalic vein 
blood flow caused by activation of AHR2. Toxicology and Applied 
Pharmacology 253(21): 244-252. 
The study shows that TCDD induces CYP1Cs in zebrafish embryos (used up to 50 h post-
fertilisation).  
Reports on OECD validation of the zebrafish embryo toxicity test – 
Phase 1 & Phase 2 
OECD (2011) OECD Series on Testing and Assessment No. 157: 
Validation report (Phase 1) for the zebrafish embryo toxicity test. 
Part 1 http://www.oecd.org/env/ehs/testing/48572244.pdf 
Part 2 
http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=
ENV/JM/MONO(2011)40&doclanguage=en 
 
OECD (2012b). Validation report (Phase 2) for the zebrafish 
embryo toxicity test. Series on Testing and Assessment No. 179: 
OECD, Paris, France. 
Summary 
http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=
env/jm/mono%282012%2925&doclanguage=en 
Annexes 
http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=
env/jm/mono%282012%2925/ANN&doclanguage=en 
The development of TG 236 started in 2005 when the lead country for this TG, Germany, 
had submitted a first draft of the guideline with supporting background information to the 
OECD. OECD established an expert group to review the draft TG and the validation status of 
the test. Since reliable data on the transferability and reproducibility of the proposed protocol 
were lacking, it was decided to carry out a validation study to evaluate the performance of 
the test with 20 chemicals and as major deviations from the initially proposed protocol 
extend the exposure period from 48 to 96 h (beyond hatch) and increase the number of 
embryos from 10 to 20 / concentration and controls. The study was coordinated by EURL 
ECVAM and steered by a validation management group. Each chemical was tested in three 
independent runs in at least three laboratories. The results demonstrate that the test is 
transferable and reproducible. The protocol used in the validation study formed the basis for 
the final TG 236.  
Lammer, E., G. J. Carr, K. Wendler, J. M. Rawlings, S. E. Belanger 
and T. Braunbeck (2009). Is the fish embryo toxicity test (FET) with 
Lammer et al. compared LC50 values derived with fish embryo toxicity (FET) tests to LC50 
values of acute fish toxicity (AFT) tests carried out with OECD TG 203 or other standard 
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the zebrafish (Danio rerio) a potential alternative for the fish acute 
toxicity test? Comparative Biochemistry and Physiology 149(2): 
196-209. 
 
tests. The FET database included 250 FET (mainly zebrafish, few fathead minnow, medaka 
and others) assays for 142 compounds. For 77 compounds AFT data from 2146 studies were 
available (restricted to main OECD species: rainbow trout, fathead minnow, zebrafish, 
medaka, bluegill). FET data had been retrieved from literature and AFT data from US EPA 
ECOTOX database and the ECETOC Aquatic toxicity database. Strict quality criteria had to 
be fulfilled for the FET: well-described protocol, exposure from 48-96 h, exposure via the 
water; peer-reviewed literature, in-house data from defined sources. Only AFT LC50 from 
24-96 h exposure were used with preference for 96 h. Comparison of data pairs for 77 
chemicals reveal a very good correlation of 0.90 and a slope of 1.07. They also compared 
AFT LC50s values of the five species and found correlations ranging from 0.89 to 0.96. The 
authors concluded that FET can provide equivalent information as AFT with juvenile and 
adult fish.  
Knöbel, M., F. J. M. Busser, A. Rico-Rico, N. I. Kramer, J. L. M. 
Hermens, C. Hafner, K. Tanneberger, K. Schirmer and S. Scholz 
(2012). Predicting adult fish acute lethality with the zebrafish 
embryo: Relevance of test duration, endpoints, compound 
properties, and exposure concentration analysis. Environmental 
Science and Technology 46(17): 9690-9700. 
 
This work was carried out within the framework of CEllSens project funded by CEFIC LRI 
and Defra (UK) [add reference]. It demonstrates the very good correlation of acute toxicity 
values (LC50) derived with zebrafish embryos and adult fish (fathead minnow [FHM] data 
from US EPA database) for 39 chemicals. For 12 chemicals values of other studies were 
used, whereas 27 chemicals were tested with zebrafish embryos following, in general, the 
first draft of the OECD FET guideline (OECD, 2006). Lethal and sublethal effects were 
recorded at 24h, 48h, and 120h (for at least one run/chemical). For 17 chemicals, exposure 
concentrations were measured. Comparison of nominal and measured LC50/EC50 zebrafish 
embryos and FHM revealed that measured concentrations improve the predictivity of the 
zebrafish embryo data for fish toxicity, whereas the prolongation of the exposure beyond 
hatch did not. Two chemicals were less toxic to embryos, the neurotoxic permethrin and ally 
alcohol requiring metabolic activation.  
Belanger, S. E., J. M. Rawlings and G. J. Carr (2013). Use of fish 
embryo toxicity tests for the prediction of acute toxicity to 
chemicals. Environmental Toxicology and Chemistry 32(8): 1768-
1783. 
Belanger and colleagues increased the FET database initially compiled by Lammer et al. 
(2009) by results from recent FET studies, e.g. OECD validation study, Knöbel et al. (2012), 
unpublished data from in-house studies. The database used for the FET – AFT correlation 
consisted of 985 FET studies covering 229 compounds and 1531 AFT studies on 151 
compounds. The range of log Kow was from -4.15 to 7.85, 15 different categories of 
functional use are evident with industrial organic compounds as largest category followed by 
pesticides, pharmaceuticals, surfactants and biocides. A total of 17 modes of action could be 
identified for the organic chemicals via ASTER. Compared to the Lammer et al. (2009) 
paper, the number of data pairs used for FET-AFT regression analysis doubled, i.e. from 77 
to 151 chemicals. When including all data, correlation was r = 0.90 and slope of 1.027; when 
restricting exposure to 96 h for FET and AFT (n = 72), correlation was r = 0.95 and a slope 
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of 0.989. When comparing this relationship to all possible fish to fish relationships, the FET 
performs as a fish. The authors conclude that "In the FET is regarded as an alternative to the 
AFT, the FET will provide nearly equivalent predictions of hazard while improving overall 
animal welfare." 
Henn, K. and T. Braunbeck (2011). Dechorionation as a tool to 
improve the fish embryo toxicity test (FET) with the zebrafish 
(Danio rerio). Comparative Biochemistry and Physiology 153C: 91-
98. 
Fish embryos are surrounded by the chorion, an acelluar envelope until they hatch. It is not 
fully clarified whether the chorion presents a barrier and protects the embryo from exposure 
to chemicals. Henn and Braunbeck show that zebrafish embryos can be dechorionated at 24 h 
post-fertilisation with >90% survival rate and used in the zebrafish embryo toxicity test.  
Mechanistic understanding of aquatic toxicity 
Verhaar, H. J. M., C. J. van Leeuwen and J. L. M. Hermens (1992). 
Classifying environmental pollutants. Chemosphere 25(4): 471-491. 
 
In this paper a scheme is presented that makes it possible to classify a large number of 
organic pollutants into one of four classes: 1) inert chemicals, 2) less inert chemicals, 3) 
reactive chemicals and 4) specifically acting chemicals. For chemicals that are thus classified 
as belonging to one of these four classes it is possible to calculate either an expected effect 
concentrations, from a compound's octanol/water partition coefficient (Log Kow). For 
chemicals that cannot be classified as belonging to one of these four classes no prediction can 
be made. 
This approach can be implemented to estimate aquatic effect concentrations, which can be 
used to derive preliminary environmental quality objectives, or for the prioritisation of 
chemicals for subsequent testing. Moreover, these estimates could be of great value in risk 
and hazard assessment. This paper is especially focused on identifying the limits of 
applicability of Quantitative Structure-Activity Relationships for predicting aquatic toxicity. 
Russom, C. L., S. P. Bradbury, S. J. Broderius, D. E. 
Hammermeister and R. A. Drummond (1997). Predicting modes of 
toxic action from chemical structure: Acute toxicity in the fathead 
minnow (Pimephales promelas). Environmental Toxicology and 
Chemistry 16(5): 948-967. 
 
In the field of aquatic toxicology, there has been an evolution of QSAR development and 
application from that of a chemical-class perspective to one that is more consistent with 
assumptions regarding modes of toxic action. The objective of this research was to develop 
procedures that relate modes of acute toxic action in the fathead minnow (Pimephales 
promelas) to chemical structures and properties. An empirically derived database for diverse 
chemical structures of acute toxicity and corresponding modes of toxic action was developed 
through joint toxic action studies, the establishment of toxicodynamic profiles, and 
behavioral and dose–response interpretation of 96 h LC50 tests. Using the results from these 
efforts, as well as principles in the toxicological literature, approximately 600 chemicals 
were classified as narcotics (three distinct groups), oxidative phosphorylation uncouplers, 
respiratory inhibitors, electrophiles/ proelectrophiles, acetylcholinesterase inhibitors, or 
central nervous system seizure agents. Using this data set, a computer-based expert system 
has been established whereby chemical structures are associated with likely modes of toxic 
action and, when available, corresponding QSARs. 
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McKim, J. M., S. P. Bradbury and G. J. Niemi (1987). Fish acute 
toxicity syndrome and their use in the QSAR approach to hazard 
assessment. Environmental Health Perspectives 71: 171-186. 
The authors describe the development of a "mode-of-action" database, and formulate a 
qualitative structure-activity relationship to assign the proper mode of action, and respective 
QSAR, to a given chemical structure. They define fish acute toxicity syndromes (FATS) as a 
characteristic set of whole-animal responses (clinical signs), based on various behavioural 
and physiological-biochemical measurements, and proposed that chemicals with a common 
mode of action will elicit a set of response associated with a specific FATS, thereby 
providing categories into which whole- fish response to acute toxicity can be grouped. Using 
behavioural parameters monitored in the fathead minnow during acute toxicity testing, FATS 
associated with acetylcholinesterase (AChE) inhibitors and narcotics could be reliably 
predicted. However, compounds classified as oxidative phosphorylation uncouplers or 
stimulants could not be resolved. Refinement of this approach by using respiratory-
cardiovascular responses in the rainbow trout enabled FATS associated with AChE 
inhibitors, convulsants, narcotics, respiratory blockers, respiratory membrane irritants, and 
uncouplers to be correctly predicted. 
Enoch, S. J., M. Hewitt, M. T. D. Cronin, S. Azam and J. C. 
Madden (2008). Classification of chemicals according to mechanism 
of aquatic toxicity: An evaluation of the implementation of the 
Verhaar scheme in Toxtree. Chemosphere 73(3): 243-248. 
A number of mechanisms have been identified that can lead to (acute) aquatic toxicity, with 
the majority of industrial chemicals exerting their toxic influence via two non-covalent 
mechanisms: polar narcosis and non-polar narcosis. Verhaar et al. (1992) published a series 
of structural rules which aimed to classify compounds according to mechanism of action (see 
above); The importance of this classification scheme, and its utility for regulators and risk-
assessors, has led it to be coded computationally within the Toxtree software from the 
European Chemicals Bureau website and within the OECD (Q)SAR Application Toolbox. 
The aim of this study was to assess the performance of the Verhaar classification scheme, 
using two important acute ecotoxicological databases, and to assess the strengths and 
weaknesses of this classification scheme. This study also highlights rule, and possible 
coding, errors that may lead to misclassifications.  According to the authors, the Verhaar 
scheme in its current implementation misclassifies too many chemicals to be of significant 
practical use in terms of regulatory usage. The results suggest that significant additions are 
needed in the Verhaar scheme in order to improve the mechanistic assignments. According to 
the authors, such improvements should focus on a reordering of the rules in the decision tree, 
with the identification of electrophilic and specific noncovalent excess toxic mechanisms 
first (Verhaar classes 3 and 4, respectively), and the narcosis class (Verhaar class 1) should 
be the last class to be assigned. This is the opposite of the Verhaar approach and would 
enable a significant reduction in the numbers of chemicals currently assigned to Verhaar 
class 5. In addition, significant work on improving Verhaar classes 3 and 4 is required, 
involving the creation of more specific sub-classes, which would be extremely useful to aid 
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category formation and to enable mechanistic read-across predictions. Such additional sub-
classes for both Verhaar classes 3 and 4 should reflect the number of differing mechanisms 
of action that have been identified since the original Verhaar publication and would require 
rules for the identification of metabolically and abiotically activated chemicals. It is clear 
from the analysis presented that, should these changes be implemented, the classification 
results would be significantly improved. 
ECETOC (2007) See below - Integrated testing strategies 
Ankley, G. T., R. S. Bennett, R. J. Erickson, D. J. Hoff, M. W. 
Hornung, R. D. Johnson, D. R. Mount, J. W. Nichols, C. L. Russom, 
P. K. Schmieder, J. A. Serrrano, J. E. Tietge and D. L. Villeneuve 
(2010). Adverse outcome pathways: A conceptual framework to 
support ecotoxicology research and risk assessment. Environmental 
Toxicology and Chemistry 29(3): 730-741. 
The authors discuss the use of the adverse outcome pathway (AOP) in ecotoxicology. An 
AOP is a conceptual construct that portrays existing knowledge concerning the linkage 
between a direct molecular initiating event and an adverse outcome at a biological level of 
organization relevant to risk assessment. AOP has been created to allow for an effective 
translation of this information into endpoints meaningful to ecological risk - effects on 
survival, development, and reproduction in individual organisms and, by extension, impacts 
on populations. This makes thus possible the use of mechanistic data to support chemical 
assessments, helping the ecological risk assessors to face the increasing demand to assess 
more chemicals, and to do so using fewer resources and experimental animals. The practical 
utility of AOPs for ecological risk assessment of chemicals is illustrated using five case 
examples. The examples demonstrate how the AOP concept can focus toxicity testing in 
terms of species and endpoint selection, enhance across-chemical extrapolation, and support 
prediction of mixture effects. The examples also show how AOPs facilitate use of molecular 
or biochemical endpoints for forecasting chemical impacts on individuals and populations. 
To conclude, the authors discuss how AOPs can help to guide research that supports 
chemical risk assessments and advocate for the incorporation of this approach into a broader 
systems biology framework. 
OECD (2013c). Guidance Document on developing and assessing 
Adverse Outcome Pathways. Series on Testing and Assessment No. 
184. ENV/JM/MONO(2013)6. OECD, Paris, France. Available 
from: http://www.oecd.org 
This guidance document intends to provide the framework for consistent information 
gathering and organisation and to provide an introduction to the development and assessment 
of AOPs. It also provides initial assistance on how to undertake the assessment of an AOP in 
terms of its relevance and adequacy. A template has been included allowing authors to 
develop thorough AOPs and to improve consistency in AOPs developed by different risk 
assessor and stakeholders, as well as a glossary with definitions for AOP-specific 
terminology. The document also briefly outlines the potential use for regulatory purposes of 
AOP, but detailed guidance on how to use AOPs for integrated testing strategies and risk 
assessment will be developed in the future. 
A distinction is made between qualitative and quantitative AOP: a qualitative AOP is one 
where the key events have been identified but methods for assessing these events have not 
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been identified and/or assessed in sufficient detail to allow for identification of the 
applicability domains, threshold values and/or the response relationships to other key events. 
In contrast, a quantitative AOP is one where the methods for assessing the key events have 
been identified and sufficient data generated to identify the applicability domain, threshold 
values and/or the response relationships with other key events. An AOP may also be partial 
(i.e. one where not all key events are known); such an AOP may be useful in priority setting 
for further testing and development or may be used in hazard identification, as is currently 
performed with the OECD QSAR Toolbox. At present, physiologically-based 
pharmacokinetic (PBPK) modelling and toxicokinetics information on absorption, 
distribution, metabolism, and excretion (ADME) are not addressed in the AOP concept but 
will have to be addressed to develop a quantitative AOP required for a complete risk 
assessment. 
Status of non-standard methods 
QSARs  
Pavan, M., A. Worth and T. I. Netzeva (2005a). Preliminary 
analysis of an aquatic toxicity dataset and assessment of QSAR 
models for narcosis. JRC Report EUR 21749 EN Available from:  
http://publications.jrc.ec.europa.eu/repository 
 
In this work, analyses were performed to evaluate the possibility of using QSAR predictions 
for regulatory purposes. To this end, three literature-based narcosis QSAR models for acute 
fish toxicity to Pimephales promelas were analysed with respect to their ability to predict 
OECD Screening Information Data Set (SIDS) data for 177 High Production Volume (HPV) 
chemicals. 
The first two models are QSARs recommended by the EU Technical Guidance Document on 
chemical risk assessment for the polar and non-polar narcotic mechanisms of action. The 
third model was developed by ECB to represent the narcosis mechanism of action, including 
both non-polar and polar action. SIDS substances were classified according to expected 
Mode of Action (MOA) by using three different classification schemes and by applying a 
consensus scheme for the SIDS MOA. As a result, 75 chemicals were classified as non-polar 
narcotics (NPN) and 12 as polar narcotics (PN). Their acute toxicity to fish could be 
predicted confidently by the NPN and PN models. To predict the toxicities of the remaining 
90 chemicals, which were classified as reactive, the use of MOA specific QSAR models was 
suggested. The three models were also assessed according to the extent to which they meet 
OECD principles for the validation of (Q)SARs for regulatory purposes, i.e. it should be 
associated with a defined endpoint, an unambiguous algorithm, a defined domain of 
applicability, appropriate measures of internal performance (as represented by goodness-of-
fit and robustness), predictivity (as determined by external validation), and a mechanistic 
interpretation (wherever possible). Model predictions for the 57 substances ranged from 0.1–
10 times the actual acute toxicity values, when the model was applied only to substances in 
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the model’s applicability domain. The range became much larger when the applicability 
domain constraints were ignored. Those results emphasise the importance of defining the 
model applicability domain in order to identify reliable predictions for the regulatory 
assessment of chemicals. 
Pavan, M., A. Worth and T. I. Netzeva (2005b). Comparative 
assessment of QSAR models for aquatic toxicity. JRC Scientific and 
Technical Report EUR 21750 EN Available from: 
http://publications.jrc.ec.europa.eu/repository 
 
This report describes a comparative assessment of QSAR models for aquatic toxicity, in 
order to evaluate the possibility of using QSAR predictions for regulatory purposes. Six 
literature-based QSAR models for acute fish toxicity were analysed with respect to their 
ability to predict OECD Screening Information Data Set (SIDS) data for 177 High 
Production Volume (HPV) chemicals. 
The first three models are the ones quoted above (Pavan et al., 2005a); the fourth model is 
more general than the previous ones since by including an electrophilicity descriptor it is 
supposed to describe potentially bioreactive (electrophilic) chemicals; the fifth model is 
based on hydrophobic and polar atom-type electrotopological state (E-state) indices; and the 
sixth model is a commercially available neural network software program, developed by the 
TerraBase Inc., for the computation of acute (96hr) median lethal concentrations (LC50) of 
organic substances. The SIDS substances were classified according to expected Mode of 
Action according to a consensus classification scheme based on three different schemes. The 
six models were also assessed according to the extent to which they meet OECD principles 
for the validation of (Q)SARs for regulatory purposes (see above).  For each model, a 
comparison between predictions and experimental fish toxicity was performed by calculating 
the number of chemicals with predicted effect concentrations within factors of 10, 100 and 
1000 of the corresponding SIDS test data. For each model the ratio was calculated first by 
using the entire SIDS data set and then by using only the chemicals falling with the model 
applicability domain. The results show that when the model domain was taken into account, 
the ratio was always near one and in the range from 0.1 to 10. The range became much larger 
when the applicability domain constraints were ignored. The results of this study support the 
view that the regulatory application of a QSAR model should be based on a suitable 
definition of the model applicability domain in order to identify reliable predictions. 
Netzeva, T. I., M. Pavan and A. Worth (2007). Review of data 
sources, QSARs, and integrated Testing Strategies for aquatic 
toxicity. European Commission Joint Research Centre Scientific and 
Technical Report, EUR 229443EN, Ispra, Italy. Publications Office 
of the European Union, Luxembourg. Available from: 
http://publications.jrc.ec.europa.eu/repository 
 
This review collects information on sources of aquatic toxicity data and computational tools 
for estimation of chemical toxicity to aquatic organisms, such as expert systems and 
quantitative structure-activity relationship (QSAR) models. The review also captures current 
thinking of what constitutes an integrated testing strategy (ITS) for this endpoint and put an 
emphasis on the usefulness of the models for the regulatory assessment of chemicals, 
particularly for the Registration, Evaluation, Authorisation and Restriction of Chemicals 
(REACH) legislation. Effects on organisms from three trophic levels (fish, Daphnia and 
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algae) are considered and data sources such as databases and papers publishing experimental 
data are identified. Models for narcosis, general (global) models as well as models for 
specific chemical classes and mechanisms of action are summarised. Where possible, models 
were included in a form allowing reproduction without consultation with the original paper. 
This review builds on work carried out in the framework of the REACH Implementation 
Projects, and was prepared as a contribution to the EU funded Integrated Project, OSIRIS. 
Netzeva, T. I., M. Pavan and A. P. Worth (2008). Review of 
(Quantitative) Structure–Activity Relationships for Acute Aquatic 
Toxicity. QSAR & Combinatorial Science 27(1): 77-90. 
This paper reviews different approaches described in the literature for estimating the aquatic 
toxicity of chemical substances. It is based on an extended review performed by the 
European Chemicals Bureau of the European Commission's Joint Research Centre in support 
of the development of technical guidance for the implementation of the REACH legislation. 
The paper is organised by approach for (Q)SAR development and includes a review of: (i) 
(Q)SARs for acute aquatic toxicity by chemical class, (ii) (Q)SARs for acute aquatic toxicity 
by mode of action, (iii) review of statistically derived (Q)SARs, (iv) structural alerts for 
excess aquatic toxicity and (v) expert systems that combine structural rules and multiple 
(Q)SAR models to predict aquatic toxicological endpoints. Effects on organisms from three 
trophic levels (fish, Daphnia and algae) were considered, and both traditional data sources 
such as databases and literature were identified. Models for narcosis, general (global) models 
as well as models for specific chemical classes and mechanisms of action were summarised. 
This review also captures current thinking of what constitutes an integrated testing strategy 
(ITS) for this endpoint, and put an emphasis on the usefulness of the models and for the 
regulatory assessment of chemicals. Directions and recommendations for further research are 
also provided. 
Brooke, D. and M. Crookes (2006a). Validation of (quantitative) 
structure-activity relationships for toxicological endpoints of 
regulatory importance: (Q)SARs for acute toxicity to fish - Part A. 
European Commission - Joint Research Centre - Institute for Health 
and Consumer Protection: 393 p. 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/informati
on-sources/qsar-document-area/Final_report_BRE_partA.pdf 
The objective of this project was to identify a short-list of promising QSARs for acute 
toxicity to fish, and to provide sufficient information on each short-listed QSAR to enable its 
scientific validity to be established. 
This report reviewed and summarized 578 QSARs for acute fish toxicity from 81 sources, 
and provides recommendations for a short-list of 7 promising QSARs that should be further 
validated, as well as for the aspects that should be considered during the further validation of 
QSARs and the application of QSARs. The results of this validation exercise are given in a 
separate report (Part B). All of these QSARs consider the 96h LC50 (amongst other 
endpoints).  
Based on this work, recommendations for future approaches for validation of QSARs for fish 
toxicity are also provided. This include recommendations for the factors to be considered 
when validating QSARs and consideration of the use of in vitro fish cell line tests for the 
development of high quality QSARs and/or identification of the mode of toxic action of new 
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unknown chemical 
Brooke, D. and M. Crookes (2006b). Validation of (quantitative) 
structure-activity relationships for toxicological endpoints of 
regulatory importance: (Q)SARs for acute toxicity to fish - Part B. 
European Commission - Joint Research Centre - Institute for Health 
and Consumer Protection: 138 p. 
http://ihcp.jrc.ec.europa.eu/our_labs/predictive_toxicology/informati
on-sources/qsar-document-area/Final_report_BRE_partB.pdf 
 
The following further validation work has been carried out (where possible) on the 7 short-
listed QSARs in Part A (above): 
- Verification of the algorithm and associated statistics given in the paper. 
- Cross-validation of the QSAR. 
- Validation using an independent test set. 
- Exploration of the domain of applicability of the QSAR. 
This work has shown that the confidence in the validity of QSARs for acute fish toxicity can 
be increased by carrying out relatively simple analysis of the QSARs. The score of all of the 
QSARs against the OECD principles for QSAR validity (given in Part A of this report) have 
been substantially increased. 
EFSA (2013). Scientific Opinion - Guidance on tiered risk 
assessment for plant protection products for aquatic organisms in 
edge-of-field surface waters. EFSA Panel on Plant Protection 
Products and their Residues (PPR). EFSA Journal 11(7): 3290. 
http://www.efsa.europa.eu/en/efsajournal/doc/3290.pdf 
 
Regarding the use of QSARs, this guidance states the following (executive summary): 
Guidance, largely following the European Chemicals Agency (ECHA) recommendations 
(ECHA, 2008), is provided on the use of non-testing methods in PPP RA, such as 
(Quantitative) Structure– Activity Relationship ((Q)SAR) models, expert test systems and 
analogue read-across as tools for deriving intrinsic properties of substances. Non-testing 
methods may be used to estimate endpoints for metabolites without the toxophore and for 
impurities. In addition, (Q)SARs might, together with available test data, be used to rank 
species for identifying the most likely sensitive taxonomic group to focus experimental testing 
(EFSA PPR Panel, 2012a). For a detailed description of non-testing methods see section 
10.1.  
Only suitable models (e.g. covering the right domain) with a high predictive reliability 
should be used (see section 10.1.2). This should, among others, be reflected in the level of 
statistical significance required for estimates from (Q)SAR models. Validation parameters 
should ideally indicate good fits (e.g. Q2 > 0.7, concordance correlation coefficient (CCC) > 
0.85). Estimates of toxicity should, where possible, be assisted by confidence intervals around 
the prediction. In case the standard deviation exceeds the predicted value itself, such values 
should not be accepted. Generally, the worst-case endpoint from several modelling 
approaches should be used.  
Estimates should be confirmed by using weight-of-evidence approaches where all available 
information is taken into account. This could include a combination of the different (Q)SAR 
model predictions combined with read-across and other available information like non-
standard test data and TK/TD information from mammals. 
To date, most experience is gained with (Q)SAR models that predict acute toxicity. It is noted 
that fewer valid (Q)SAR models are currently available for deriving chronic toxicity data.  
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A decision scheme for use of non-testing systems is presented below (see section 10.1). 
Decision scheme not included here. 
Pavan, M., T. I. Netzeva and A. Worth (2006). Validation of a 
QSAR model for acute toxicity. SAR and QSAR in Environmental 
Research 17: 147-171. 
In this work, a quantitative structure – activity relationship (QSAR) model has been 
developed for predicting acute toxicity to the fathead minnow (Pimephales promelas) in 
order to demonstrate how statistical validation and domain definition are both required to 
establish model validity and to provide reliable predictions. A dataset of 408 heterogeneous 
chemicals was modeled by a diverse set of theoretical molecular descriptors by using 
multivariate linear regression (MLR) and Genetic Algorithm – Variable Subset Selection 
(GA-VSS). This QSAR model was developed to generate reliable predictions of toxicity for 
organic chemicals not yet tested, so particular emphasis was given to statistical validity and 
applicability domain. External validation was performed by using OECD Screening 
Information Data Set (SIDS) data for 177 High Production Volume (HPV) chemicals, and a 
good predictivity was obtained (Q2ext  = 72.1). The model was evaluated according to the 
OECD principles for QSAR validation, and compliance with all five principles was 
established. According to the author, the model could therefore be useful for the regulatory 
assessment of chemicals, and could be used to fill data gaps within its chemical domain or 
contribute to the prioritization of chemicals for aquatic toxicity testing.  
Cassani, S., S. Kovarich, E. Papa, P. P. Roy, L. van der Wal and P. 
Gramatica (2013). Daphnia and fish toxicity of (benzo)triazoles: 
Validated QSAR models, and interspecies quantitative activity-
activity modelling. Journal of Hazardous Materials 258-259: 50-60. 
 
In the present study, QSAR models for the prediction of acute synthetic triazoles and benzo-
triazoles ((B)TAZs) toxicity in Daphnia magna and Onchorhynchus mykiss have been 
developed according to the principles for the validation of QSARs and their acceptability for 
regulatory purposes, proposed by the Organisation for Economic Co-operation and 
Development(OECD). They have been applied to predict acute toxicity for over 300 
(B)TAZs without experimental data. Additionally, on the basis of the high correlation 
coefficient found among the experimental values of pEC(LC)50 available for Daphnia 
magna and Onchorhynchus mykiss (r=0.93), a model based on Quantitative Activity-Activity 
Relationships (QAAR) has been developed, which allows for interspecies extrapolation from 
daphnids to fish. On 40 substances, only one response outlier was found (the most simple and 
least toxic compound, 1,2,4-triazole), and this QAAR model overestimate its toxicity. 
According to the authors, predictions generated by the here proposed QSAR and QAAR 
models for all the studied chemicals can be used by regulators to support the use of Weight-
of-Evidence and non testing-based approaches. The authors also highlight the importance of 
QSAR/QAAR, especially when dealing with specific chemical classes like (B)TAZs, for 
screening and prioritization of pollutants under REACH. 
Jacobs, M. N. (2004). In silico tools to aid risk assessment of 
endocrine disrupting chemicals. Toxicology 205(1–2): 43-53. 
This paper reviews in silico tools used in risk assessment of endocrine disrupting chemicals, 
including the use of: (1) nuclear receptor (NR) crystal structures and homology models to 
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examine potential modes of ligand binding by different representative compounds; (2) 
multivariate principal component analyses (PCA) techniques to select best predicted cell 
lines for endocrine disrupting chemicals (EDC) risk assessment purposes; (3) NR 
quantitative structure-activity relationships (QSARs) that can be constructed from varied 
biological data sources. The cytosolic and NR examples discussed in this work include the 
Ah receptor, (AhR), the human oestrogen receptor α (hERα) and the human pregnane X 
receptor (PXR). The varied biological data sets can be compared to give a more integrated 
dimension to receptor cross talk mechanisms, with further support from molecular modelling 
studies. According to the author, in silico or computational tools could be used more 
effectively in endocrine disruptor risk assessment for prescreening potential endocrine 
disruptors, improving experimental in vitro screening assay design and facilitating more 
thorough data analyses. 
de Haas, E. M., T. Eikelboom and T. Bouwman (2011). Internal and 
external validation of the long-term QSARs for neutral organics to 
fish from ECOSAR™. SAR and QSAR in Environmental Research 
22(5-6): 545-559. 
This study concentrates on the external validation of an existing Quantitative Structure–
Activity Relationship (QSAR) model widely used for long-term aquatic toxicity to fish. The 
predictivity of the model was evaluated in order to increase its reliability. The authors 
assessed whether the model met all of the OECD principles. The model was adapted to 
become more robust, and predictions were made with an external validation set collected 
from several databases. For the internal validation of the QSAR, the r2, Q2LOO and Q2LMO 
were used as validation criteria, and for the external validation r2, Q2ext, h and the validation 
ratio were used. A few substances were classified as outliers and therefore the applicability 
domain of the QSAR had to be adjusted. The QSAR passed all validation criteria and met all 
the OECD principles for QSAR validation. According to the authors, the long-term toxicity 
QSAR for fish can be applied with high certainty of a correct prediction within the limits of 
the inherent uncertainty of the model in cases where the substance falls within the 
applicability domain. 
Claeys, L., Iaccino, F., Janssen, C.R., Van Sprang, P., Verdonck, F. 
(2013) Development and validation of a quantitative structure-
activity relationship for chronic narcosis to fish. Environmental 
Toxicology and Chemistry 32(10): 2217-25.  
The authors describe the development of a QSAR for prediction of chronic fish toxicity of 
MOA1 and MOA2 chemicals using NOEC values derived from mortality endpoint. 
The MOA1 model is based on a training set of 49 chemicals (114 experimental data points) 
and a test set of 20 chemicals: log NOEC(mmol/L) = - 0.9402 log Kow + 0.8911. Internal 
validation provided the following values: r2 = 0.76, r2adj = 0.76, Q2LOO = 0.75. External 
validation reveals r2ext = 0.72 confirming the good predictivity of the model. 
The MOA2 model is based on a training set of 10 chemicals (42 experimental data points) 
and a test set of 3 chemicals: log NOEC(mmol/L) = -1.0117-0.61147 log Kow + 0.04177. 
Internal validation provided the following values: r2 = 0.80, r2adj = 0.79, Q2LOO = 0.78 and  
external validation gives an r2ext = 0.65.  
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Austin, T.J. and C.V. Eadsforth (2014). Development of a chronic 
fish toxicity model for predicting sub-lethal NOEC values for non-
polar narcotics. SAR QSAR Environmental Research 25(2): 147-60. 
The authors developed a QSAR using only sub-lethal no-observed-effect concentration 
(NOEC) end-point data according to best practice QSAR development. Only the lowest 
NOEC value was taken for each compound, in line with the conservative approach taken by 
the ECHA.  
Using a training set of 19 chemicals a model was created: log NOEC(mmol/L) = 0.711-0.914 
log Kow. Internal validation resulted in the following values: r2 = 0.91, r2adj = 0.9, Q2LOO = 
0.88. For external validation a set of 10 chemicals was used and the r2ext = 0.89 confirms the 
good predictivity of the model. The authors conclude that the model developed meets the 
OECD principles, has strong internal and external validation statistics, and can reliably 
predict sub-lethal chronic NOEC values for fish within its defined applicability domain, i.e. 
chemicals which act via non-polar narcosis and have a logKow between 0.46 and 5.30.   
Schultz, T. W. (2010). Chapter 14 Adverse Outcome Pathways: A 
Way of Linking Chemical Structure to In Vivo Toxicological 
Hazards. In Silico Toxicology: Principles and Applications, The 
Royal Society of Chemistry: 346-371. 
 
The concept of Adverse Outcome Pathway (AOP) and its potential to link chemical structure 
of toxicants to in vivo toxicological hazards is described. A definition of a chemical category 
in hazards assessment (a group of chemicals whose physico-chemical properties, human 
health and/or environmental toxicological properties and/or environmental fate properties are 
likely to be similar or follow a regular pattern) is given and their importance to fill data gap, 
whether by read-across or quantitative structure-activity relationship (QSAR) modelling 
explained. The authors also highlight the importance of the mode of action within a category 
of chemical, based on the fact that the compounds are grouped on the hypothesis that the 
properties of the chemicals in the category will show coherent trends in their toxicological 
effects. However, current knowledge of toxicological categories and category formation is 
limited, in part due to the depth and breadth of available database needed to support category 
formation and the complexity of the hazard endpoint being evaluated. The authors also 
present the AOP concept and give some examples of detailed AOPs, such as skin 
sensitisation, acethylcholine esterase inhibition, or receptor binding pathways for phenolic 
oestrogen mimics. They discuss advantages of the AOP approach and to conclude with the 
basic elements in developing a pathway. 
Tremolada, P., A. Finizio, S. Villa, C. Gaggi and M. Vighi (2004). 
Quantitative inter-specific chemical activity relationships of 
pesticides in the aquatic environment. Aquatic Toxicology 67: 87-
103. 
This work aims at developing quantitative inter-specific chemical activity relationship for 
aquatic organisms to verify if such an approach could be utilised for estimating toxicological 
data when no other information is available. Inter-specific toxicity relationships on fish, 
Daphnia, and algae were performed for pesticides considering more than 600 compounds. 
Good correlation were found between several fishes species and were improved by excluding 
highly specific compounds such as organophosphorous insecticides.   
de Roode, D., C. Hoekzema, S. de Vries-Buitenweg, B. van de 
Waart and J. van der Hoeven (2006). QSARs in ecotoxicological 
In this paper, four QSARs were evaluated to predict toxicity for 170 compounds from a 
broad chemical class, using them as a black-box. Predictions were obtained for 122 
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risk assessment. Regulatory Toxicology and Pharmacology 45(1): 
24-35. 
compounds, indicating an important drawback of QSARs, i.e., for 28% of the compounds 
QSARs cannot be used at all. ECOSAR, Topkat, and QSARs for non-polar and polar 
narcosis generated predictions for 120, 39, 24, and 11 compounds, respectively. Correlations 
between experimental and predicted effect concentrations were significant for Topkat and the 
QSAR for polar narcosis, but generally poor for ECOSAR and the QSAR for non-polar 
narcosis. When predicted effect concentrations for fish were allowed to deviate from 
experimental values by a factor of 5, correct predictions were generated for 77%, 54%, 68%, 
and 91% of the compounds using ECOSAR, Topkat, and the QSARs for non-polar and polar 
narcosis, respectively. It was impossible to indicate specific chemical classes for which a 
QSAR should be used or not. Those results show that currently available QSARs cannot be 
used as a black-box. 
Yan, D., X. Jiang, G. Yu, Z. Zhao, Y. Bian and F. Wang (2006). 
Quantitative structure–toxicity relationships of organophosphorous 
pesticides to fish (Cyprinus carpio). Chemosphere 63(5): 744-750. 
This study was conducted to determine the relationships between 1381 chemical and 
structural parameters of 43 organophosphorus pesticides (OPs) and their toxicity to fish, 
Cyprinus carpio. By multivariate linear regression and intervariable regression analyses, 
various equations have been derived to calculate the lethal toxicity value, LC50, for 43 OPs 
found in fish with different levels of toxicity. Results show that for all selected OPs, 
especially those of low toxic OPs (LC50 < 2.5 mM), one equation could account for 86.2% 
of the variability of the toxic effect. The steric and electronic characteristics and the 
hydrophobicity of OPs, in particular, are among the most important parameters determining 
the toxicity of OPs to fish. For the OPs with high toxicity, different structural parameters 
were introduced into two other equations. These results suggest that chemical and structural 
parameters could be useful in modelling chemical reactivity within homologous series of OP 
compounds and elucidating possible mechanisms associated with different levels of toxicity 
to fish. 
Yuan, H., Y.-Y. Wang and Y.-Y. Cheng (2007). Mode of action-
based local QSAR modeling for the prediction of acute toxicity in 
the fathead minnow. Journal of Molecular Graphics and Modelling 
26(1): 327-335. 
In this paper, the acute toxicity, 96 h LC50 (median lethal concentration) for the fathead 
minnow served as the toxicity endpoint of interest, and the mode of action (MOA) was 
employed as a criterion to compartmentalize the chemical domains. MOA-based local QSAR 
models were built by partial least squares (PLS) regression for each subset with single mode 
of action such as Narcosis I, Narcosis II or Reactive, and global model was also developed 
for the combined data set containing several subsets above. By comparing the performances 
of these two types of models, the local models were superior to the global model in that the 
relative standard error (R.S.E.) of the former was much lower for both the training set and the 
test set of any subset. In addition, the influence of the reliability of MOA determination on 
the performance of local model was also investigated and the statistical results for subsets 
with MOAs at A and B confidence level were better than those at C and D confidence level. 
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Therefore, the MOA-based local QSAR models are promising to improve the accuracy of 
toxicity prediction as long as the assessment of MOA is of high reliability. 
Colombo, A., E. Benfenati, M. Karelson and U. Maran (2008). The 
proposal of architecture for chemical splitting to optimize QSAR 
models for aquatic toxicity. Chemosphere 72(5): 772-780. 
In QSAR analysis, compounds have often been divided into distinct groups according to their 
mode of action or chemical class. In the current study, theoretical molecular descriptors were 
used to divide 568 organic substances into subsets with toxicity measured for the 96 h lethal 
median concentration for the fathead minnow (Pimephales promelas). Simple constitutional 
descriptors such as the number of aliphatic and aromatic rings and a quantum chemical 
descriptor, maximum bond order of a carbon atom divide compounds into nine subsets. For 
each subset of compounds the automatic forward selection of descriptors was applied to 
construct QSAR models. Significant correlations were achieved for each subset of chemicals 
and all models were validated with the leave-one-out internal validation procedure (r2 cv ≈ 
0.80). The results encourage considering this alternative way for the prediction of toxicity 
using QSAR subset models without direct reference to the mechanism of toxic action or the 
traditional chemical classification. 
Reuschenbach, P., M. Silvani, M. Dammann, D. Warnecke and T. 
Knacker (2008). ECOSAR model performance with a large test set 
of industrial chemicals. Chemosphere 71(10): 1986-1995. 
This work aimed at evaluating the widely used ECOSAR computer programme for QSAR 
prediction of chemical toxicity towards aquatic organisms. This was done by using large data 
sets of industrial chemicals with varying molecular structures. Experimentally derived 
toxicity data covering acute effects on fish, Daphnia and green algae growth inhibition of 
more than 1000 randomly selected substances were compared to the prediction results of the 
ECOSAR programme in order (1) to assess the capability of ECOSAR to correctly classify 
the chemicals for aquatic toxicity according to rules of EU regulation and (2) to determine 
the number of correct predictions within tolerance factors from 2 to 1000. Regarding 
ecotoxicity classification, 65% (fish), 52% (Daphnia) and 49% (algae) of the substances 
were correctly predicted into the classes ‘‘not harmful”, ‘‘harmful”, ‘‘toxic” and ‘‘very 
toxic”. At all trophic levels about 20% of the chemicals were underestimated in their toxicity. 
The class of ‘‘not harmful” substances (experimental LC/EC50 > 100 mg l-1) represents 
nearly half of the whole data set. The percentages for correct predictions of toxic effects on 
fish, Daphnia and algae growth inhibition were 69%, 64% and 60%, respectively, when a 
tolerance factor of 10 was allowed. Focussing on those experimental results which were 
verified by analytically measured concentrations, the predictability for Daphnia and algae 
toxicity was improved by approximately three percentage points, whereas for fish no 
improvement was determined. The calculated correlation coefficients demonstrated poor 
correlation when the complete data set was taken, but showed good results for some of the 
ECOSAR chemical classes. The authors also discuss the results in the context of literature 
data on the performance of ECOSAR and other QSAR models. 
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Jager, T. and S. L. M. Kooijman (2009). A biology-based approach 
for quantitative structure-activity relationships (QSARs) in 
ecotoxicity. Ecotoxicology 18(2): 187-196. 
 
The standard approach in developing QSARs for toxicity is to collect toxicity values for one 
species for a group of chemicals, and attempt to find one or a few molecular descriptors that, 
in some form of regression, provide an adequate description. Progress in this field has been 
limited to developing equations for new species, new groups of toxicants and using other 
descriptors. However, according to the authors, the use of descriptive summary statistics for 
toxicity, such as the 4-day LC50 for fish, introduces bias and ignores valuable kinetic 
information in the data. To extract all relevant information from toxicity test results requires 
biology-based methods such as DEBtox. Those methods use all of the toxicity data in time to 
derive time-independent and unbiased parameter estimates. Additionally, those parameters 
are expected to co-vary in specific ways, which offers unique opportunities for the 
development of predictive QSARs. In this paper, the authors explore the potential of biology-
based modelling in QSARs development, by applying the hazard model from DEBtox to 
analyse survival data for fathead minnows (Pimephales promelas), and they demonstrate 
how these methods can lead to a different approach towards QSARs. As a conclusion, the 
results show that different modes of action resulted in different patterns in the parameter 
estimates, and therefore, that the toxicity data by themselves reveal insight into the actual 
mechanism of toxic action. 
Sanderson, H. and M. Thomsen (2009). Comparative analysis of 
pharmaceuticals versus industrial chemicals acute aquatic toxicity 
classification according to the United Nations classification system 
for chemicals. Assessment of the (Q)SAR predictability of 
pharmaceuticals acute aquatic toxicity and their predominant acute 
toxic mode-of-action. Toxicology Letters 187(2): 84-93. 
The aim of this paper was to compile a comprehensive database based on OECD’s 
standardised measured ecotoxicological data and to evaluate if there is generally cause of 
greater concern with regard to pharmaceutical aquatic toxicological profiles compared to 
industrial chemicals. Comparisons were based upon aquatic ecotoxicity classification under 
the United Nations Global Harmonized System for classification and labeling of chemicals 
(GHS). The authors statistically explored whether the predominant mode-of-action (MOA) 
for pharmaceuticals is narcosis, and found 275 pharmaceuticals with 569 acute aquatic effect 
data and 23 pharmaceuticals with chronic data. Pharmaceuticals were found to be more 
frequent than industrial chemicals in GHS category III. Acute toxicity was predictable 
(>92%) using a generic (Q)SAR ((Quantitative) Structure Activity Relationship) suggesting a 
narcotic MOA. Analysis of model prediction error suggests that 68% of the pharmaceuticals 
have a non-specific MOA. Additionally, the acute-to-chronic ratio (ACR) for 70% of the 
analysed pharmaceuticals was below 25 further suggesting a non-specific MOA. Sub-lethal 
receptor-mediated effects may however have a more specific MOA. 
Dom, N., D. Knapen and R. Blust (2012). Assessment of aquatic 
experimental versus predicted and extrapolated chronic toxicity data 
of four structural analogues. Chemosphere 86(1): 56-64. 
The present study was developed to assess the chronic toxicity predictions and extrapolations 
for a set of chlorinated anilines (aniline (AN), 4-chloroaniline (CA), 3,5-dichloroaniline 
(DCA) and 2,3,4-trichloroaniline (TCA)). Daphnia magna 21 days chronic experimental data 
was compared to the chronic toxicity predictions made by the US EPA ECOSAR QSAR 
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tools and to acute-to-chronic extrapolations. Additionally, Species Sensitivity Distributions 
(SSDs) were constructed to assess the chronic toxicity variability among different species 
and to investigate the acute versus chronic toxicity in a multi-species context. Although 
chlorinated anilines are structural analogues with a designated polar narcotic mode of action, 
rather large interchemical and interspecies differences in toxicity were observed. Compared 
to the other three test compounds, TCA exposure had a significantly larger impact on growth 
and reproduction of D. magna. Furthermore, this study illustrated that QSARs or a fixed 
ACR are not able to account for these interchemical and interspecies differences. 
Consequently, ECOSAR was found to be inadequate to predict the chronic toxicity of the 
anilines and the use of a fixed ACR (of 10) led to under of certain species. The experimental 
ACRs determined in D. magna were substantially different among the four aromatic amines 
(ACR of 32 for AN, 16.9 for CA, 5.7 for DCA and 60.8 for TCA). Furthermore, the SSDs 
illustrated that Danio rerio was rather insensitive to AN in comparison to another fish 
species, Pimephales promelas. The authors therefore suggest that available toxicity data 
should be used in an integrative multi-species way, rather than using individual-based 
toxicity extrapolations. In this way, a relevant overview of the differences in species 
sensitivity is given, which in turn can serve as the basis for acute to chronic extrapolations. 
McCarty, L. S. (2012). Model validation in aquatic toxicity testing: 
Implications for regulatory practice. Regulatory Toxicology and 
Pharmacology 63(3): 353-362. 
In this study, the authors wanted to check the validity of models and assumptions used in 
toxicity testing. In this aims, they have done a quality control evaluation of the acute toxicity 
testing protocol using the US. EPA fathead minnow database, focusing around three key 
assumptions that ensure results represent valid toxicological metrics: 1) it must be possible to 
estimate steady-state LC50s; 2) LC50s should occur at equivalent exposure durations; 3) all 
substantive toxicity modifying factors should be adequately controlled. About 8% of the tests 
failed the first assumption and are invalid and unusable. Examination of remaining data 
indicated variance from unquantified effects of toxicity modifying factors remained in LC50s, 
thereby failing assumption three. Such flaws in toxicity data generated via recommended 
LC50 testing protocols mean that resulting data do not represent consistent, comparable 
measures of relative toxicity. Then, according to the authors, current regulations employing 
LC50 testing data are acceptable due to the use of semiquantitative, policy-driven 
development guidance that considers such data uncertainty, but quantitative applications such 
as QSARs, mixture toxicity, and regulatory chemical grouping can be compromised. These 
validation failures justify a formal quality control review of the LC50 toxicity testing 
protocol. Interim improvements in the design, execution, interpretation, and regulatory 
applications of LC50 and related protocols using exposure-based dose surrogates are 
warranted. 
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Toxicokinetic models  
Stadnicka, J., K. Schirmer and R. Ashauer (2012). Predicting 
concentrations of organic chemicals in fish by using toxicokinetic 
models. Environmental Science & Technology 46: 3273−3280. 
In aquatic toxicology, quantification of chemical toxicity is usually based on nominal or 
measured concentrations (here named external concentration) of the chemical in the water. 
However, chemical concentrations in the fish (here named internal concentration) have been 
suggested to be a more suitable parameter. To better understand the relationship between the 
external and internal concentrations of chemicals in fish, and to quantify internal 
concentrations, the authors compared three toxicokinetic (TK) models with each other and 
with literature data of measured concentrations of 39 chemicals. They used two one 
compartment models, a physiologically based toxicokinetic (PBTK) model, improved for the 
treatment of lipids, to predict concentrations of organic chemicals in two fish species: 
rainbow trout (Oncorhynchus mykiss) and fathead minnow (Pimephales promelas). The three 
models predicted the measured internal concentrations in fish within 1 order of magnitude for 
at least 68% of the chemicals. The PBTK model outperformed the one-compartment models 
with respect to simulating chemical concentrations in the whole body (at least 88% of 
internal concentrations were predicted within 1 order of magnitude using the PBTK model). 
All the models can be used to predict concentrations in different fish species without 
additional experiments. However, further development of TK models is required for polar, 
ionisable, and easily biotransformed compounds. 
Stadnicka-Michalak, J., Tanneberger, K., Schirmer, K., et al., 2014. 
Measured and modeled toxicokinetics in cultured fish cells and 
application to in vitro-in vivo toxicity extrapolation. PLoS One. 9, 
e92303. 
Effect concentrations in the toxicity assessment of chemicals with fish and fish cells are 
generally based on external exposure concentrations. External concentrations as dose 
metrics, may, however, hamper interpretation and extrapolation of toxicological effects 
because it is the internal concentration that gives rise to the biological effective dose. There 
is a need to understand the relationship between the external and internal concentrations of 
chemicals and therefore the authors investigated the following: (i) the time-course of the 
concentration of chemicals with a wide range of physicochemical properties in the 
compartments of an in vitro test system, (ii) derive a predictive model for toxicokinetics in 
the in vitro test system, (iii) test the hypothesis that internal effect concentrations in fish (in 
vivo) and fish cell lines (in vitro) correlate, and (iv) develop a quantitative in vitro to in vivo 
toxicity extrapolation method for fish acute toxicity. To achieve these goals, time-dependent 
amounts of organic chemicals were measured in medium, cells (RTgill-W1) and the plastic 
of exposure wells. Then, the relation between uptake, elimination rate constants, and log 
Kow was investigated for cells in order to develop a toxicokinetic model. This model was 
used to predict internal effect concentrations in cells, which were compared with internal 
effect concentrations in fish gills predicted by a Physiologically Based Toxicokinetic model. 
The model could predict concentrations of non-volatile organic chemicals with log Kow 
  418 
between 0.5 and 7 in cells. The correlation of the log ratio of 
internal effect concentrations in fish gills and the fish gill cell line with the log Kow was 
significant (r > 0.85, p = 0.0008, Ftest). This ratio can be predicted from the log Kow of the 
chemical (77% of variance explained), comprising a promising model to predict lethal effects 
on fish based on in vitro data. 
Reduction - Step-down Approach – basis for the above described 
threshold approach 
 
Hutchinson, T. H., S. Barret, M. Buzby, D. Constable, A. Hartmann, 
A. Hayes, D. Huggett, R. Länge, A. D. Lillicrap, J. O. Straub and R. 
S. Thompson (2003). A strategy to reduce the numbers of fish used 
in acute ecotoxicity testing of pharmaceuticals. Environmental 
Toxicology and Chemistry 22: 3031-3036. 
At the time of the publication of this paper, the draft European regulation on environmental 
safety assessment of human pharmaceuticals was discussed. The authors proposed that 
testing can be moved from fish LC50 testing (typically using 42 fish/active pharmaceutical 
ingredient [API]) to acute threshold tests using fewer fish (typically 10 fish/API). Base-set 
ecotoxicity data from regulatory studies of 91 API were collated and found that for 73 of the 
91 APIs, the algal EC50 and daphnid EC50 values were lower than or equal to the fish LC50 
data. Thus, for approximately 80% of these APIs, algal and daphnid acute EC50 data could 
have been used in the absence of fish LC50 data to derive PNECwater values. For the other 
18 APIs, use of an acute threshold test with a step-down factor of 3.2 is predicted to give 
comparable PNECwater outcomes. Based on this so-called fish acute threshold (step-down) 
approach the total number of fish used could be reduced from 3,822 to 1,025 (73%) with no 
loss of data for PNECwater estimates. 
Jeram, S., J. M. R. Sintes, M. Halder, J. B. Fentanes, B. Sokull-
Klüttgen and T. H. Hutchinson (2005). A strategy to reduce the use 
of fish in acute ecotoxicity testing of new chemical substances 
notified in the European Union. Regulatory Toxicology and 
Pharmacology 42(2): 218-224. 
The authors applied the above described threshold/step-down approach to industrial 
chemicals from the New Chemicals Database (1439 data sets). The findings of Hutchinson et 
al. (2003) were confirmed and only for 15-20% chemicals fish was the most sensitive test 
species. By applying the threshold (step-down) approach a reduction of at least 50%-70% 
would be feasible. In contrast to Hutchinson et al. (2003), the authors propose to use seven 
fish/concentration and control, which corresponds to the minimum number of fish required in 
the limit test of OECD TG 203. 
The authors report for the dataset with the most precise values, the following distribution 
regarding species sensitivity: 51% algae most sensitive, 28.6% daphnia most sensitive, 18.6 
% fish most sensitive; equal sensitivity in 1.2% of the cases;  algae and daphnia equally 
sensitive 0.8%. 
Hoekzema, C. C., A. J. Murk, B. J. v. d. Waart, J. C. M. v. d. 
Hoeven and D. F. d. Roode (2006). Alternative approaches can 
greatly reduce the number of fish used for acute toxicity testing. 
Environmental Toxicology and Chemistry 25(5): 1322-1325. 
The authors applied the acute threshold (step-down) approach to data sets for 507 
compounds, including agrochemicals, industrial chemicals, and pharmaceuticals from the 
internal NOTOX database. Theoretical applications of the acute threshold (step-down) 
approach gave similar results to those obtained with the standard fish median lethal 
concentration (LC50) test but required only 12% of the fish (3,195 instead of 27,324 fish 
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used for all compounds in the database). In 188 (90%) of the 208 cases for which a complete 
data set was available, the EC50 for algae or daphnids was lower than the LC50 for fish. 
These results show that replacement of the standard fish LC50 test by the acute threshold 
(step-down) approach would greatly reduce the number of fish needed for acute ecotoxicity 
testing without any loss of reliability. 
Reduction / Refinement - general  
Rufli, H. and T. A. Springer (2011). Can we reduce the number of 
fish in the OECD acute toxicity test? Environmental Toxicology and 
Chemistry 30(4): 1006-1011. 
 
The authors evaluated acute fish toxicity data retrieved from an industrial database and the 
U.S. EPA Office of Pesticide Programs Ecotoxicity database and simulated various scenarios 
to improve the design of acute fish toxicity tests according to OECD TG 203. They 
concluded that the number of fish/concentration could be reduced to six without loss of 
statistical power. Moreover, they proposed to use the 96 h fish embryo acute toxicity test 
(now OECD TG 236) to define the concentrations for OECD TG 203. They further propose 
to use the 96 h fish embryo acute toxicity test in the step-down approach and confirm the 
concentration where no mortality occurs with a test using juvenile fish. 
Rufli, H. (2012). Introduction of moribund category to OECD fish 
acute test and its effect on suffering and LC50 values. 
Environmental Toxicology and Chemistry 31(5): 1107-1112. 
 
The term "moribund" is used to describe a state close to death. This state involves severe 
suffering and, in the interest of animal welfare, moribund animals should be removed from 
tests and humanely killed. The author uses a combination of severe sublethal symptoms 
(swimming behaviour, loss of equilibrium, ventilation, pigmentation) to define five moribund 
categories. Retrospective analysis of more than 400 acute fish toxicity studies revealed that a 
significant percentage (10-23%) of the fish in 49-79% of the studies would fulfil the 
moribund criteria, and in consequence, applying the criterion as endpoint would have 
reduced suffering of severity grade 3 (= severe distress) by up to 92 h. On the other side, the 
LC50 would be lower (by factor 2 in most cases) in 36-52% of the studies. Rufli 
recommends further research into the topic and clear definition of the moribund stage before 
introducing it into OECD TG 203. 
Oris, J. T., S. E. Belanger and A. J. Bailer (2012). Baseline 
characteristics and statistical implications for the OECD TG 210 
fish early-life stage chronic toxicity test. Environmental Toxicology 
and Chemistry 31(2): 370-376. 
The authors systematically analysed the data and results of fish early-life stage tests (OECD 
TG 210) conducted in industry laboratories. The distribution of responses observed in control 
treatments was evaluated with the goal of understanding the implication of this variability on 
the sensitivity of OECD TG 210. The following recommendations on revised experimental 
design were given: maximise the number of replicate chambers per treatment concentration, 
increase the acceptable level of control hatching success and larval survival compared to 
current levels, using wet weight measurements rather than dry weight, and focusing test 
efforts on species that demonstrate less variability in outcome measures. From these 
analyses, the authors provide evidence of the impact of expected levels of variability on the 
sensitivity of traditional OECD TG 210 studies and the implications for defining a target for 
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future animal alternative methods for chronic toxicity testing in fish. 
Cytotoxicity assays based on fish cell lines  
Castaño, A., N. Bols, T. Braunbeck, P. Dierickx, M. Halder, B. 
Isomaa, K. Kawahara, L. Lee, C. Mothersill, P. Pärt, G. Repetto, J. 
Sintes, H. Rufli, R. Smith, C. Wood and H. Segner (2003). The use 
of fish cells in ecotoxicology. The report and recommendations of 
ECVAM Workshop 47. ATLA Alternatives to Laboratory Animals 
31(3): 317-351. 
The main objectives of this ECVAM workshop report were: - To critically review the 
potential use of fish cell to replace, reduce or refine existing regulatory tests which involve 
the use of fish for ecotoxicological purpose 
- To discuss the advantage, limitations and possible future applications of fish cells systems 
in hazard assessment, ecotoxicological research and testing and environmental surveillance 
and monitoring.  
Bols, N. C., V. R. Dayeh, L. E. J. Lee and K. Schirmer (2005). 
Chapter 2 Use of fish cell lines in the toxicology and ecotoxicology 
of fish. Piscine cell lines in environmental toxicology. Biochemistry 
and Molecular Biology of Fishes. T. P. Mommsen and T. W. Moon, 
Elsevier. Volume 6: 43-84. 
The authors review the use of fish cell lines in toxicology and ecotoxicology. Existing fish 
cell lines and their advantages, as well as comparison of fish cell lines, fish primary cultures 
and mammalian cell lines are covered. The authors report on general cellular responses 
(cytotoxicity, cell growth, genotoxicity and xenobiotic metabolism) studied on these models 
and highlight the toxicology (e.g. receptor-mediated toxicity, xenobiotic metabolism and 
cytotoxicity or mechanism of cell death) and ecotoxicology use of fish cell lines (e.g. ranking 
compounds for their potency, or assessing environmental samples, studying interactions 
between ecotoxicants and physical environment, developing and improving of biomarkers). 
Ankley et al. (2010) See above – Mechanistic understanding of the endpoint 
Lakra, W. S., T. R. Swaminathan and K. P. Joy (2011). 
Development, characterization, conservation and storage of fish cell 
lines: a review. Fish Physiology and Biochemistry 37(1): 1-20. 
This review gives an overview on teleost fish cells lines (their origins, development, 
characterization, conservation and storage) and provides a scientific update on new cell lines. 
It also discusses the importance of authentication, applications, cross-contamination and 
implications of overpassaged cell lines. 
Lee, L. E. J., V. R. Dayeh, K. Schirmer and N. Bols (2009). 
Applications and potential uses of fish gill cell lines: examples with 
RTgill-W1. In Vitro Cellular and Developmental Biology - Animal 
45(3-4): 127-134. 
This work focuses on the importance of gills in fish biology and reviews the potential uses 
and applications of the RTgill-W1 fish cell lines. Their main advantages are: they can be 
grown in regular tissue culture surfaces or in transwell membranes in direct contact with 
water on their apical surfaces and environmental samples can be directly evaluated on these 
cells; they can withstand hypo- and hyper osmotic conditions; they have an optimal growth 
capacity at room temperature. All these features make them ideal sentinel models for in vitro 
aquatic toxicology and RTgill-W1 has been used to evaluated the toxicity of industrial 
effluent, polycyclic aromatic hydrocarbons, metals, or polybrominated diphenyl ethers 
(PBDEs); moreover, they are also used to study fish gill function and gills diseases. 
Schirmer, K. (2006). Proposal to improve vertebrate cell cultures to 
establish them as substitutes for the regulatory testing of chemicals 
and effluents using fish. Toxicology 224(3): 163-183. 
This review explains how in vitro assays based on vertebrate cell cultures could be improved 
so that a replacement of acute fish tests could more likely be achieved. The author reports 
that fish cell lines compare well with fish lethality in their relative sensitivity towards the 
toxicity of chemicals, as shown by strong correlation found for cell line versus fish acute 
toxicity test, excepted for organophosphate pesticides. This illustrates the first limit of these 
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models: a single culture cell will always have a limited number of target sites in comparison 
to whole organisms. The author also shows that fish cell lines are usually from one to several 
orders of magnitude less sensitive than whole organisms, which is the second limit of these 
models. According to the author, the diversity of target sites issue would have to be tackled 
by the establishment and/or characterization of cell culture models with functions typical of 
their origin. Concerning the sensitivity issue, various ways of improvement are highlighted, 
including the selection of appropriate cell lines, culture environment, endpoint measurements 
and means to account for the in vitro bioavailability of chemicals. 
Fent, K. (2007). Permanent fish cell cultures as important tools in 
ecotoxicology. ALTEX: Alternativen zu Tierexperimenten 24 Spec 
No: 26-28. 
This paper summarises some previous work in fish cell lines and highlights the importance of 
such in vitro systems for the acute toxicity assessment of a variety of environmental 
pollutants (organotins, substituted phenols, pharmaceuticals). It reports a significant 
correlation between cytotoxicity and physical-chemicals properties of the compounds on one 
hand, and between in vitro cytotoxicity data and fish acute toxicity (organotins, substituted 
phenols) and Daphnia magna (pharmaceuticals) on the other hand. 
CEFIC LRI project - ECO 8 Development of a strategy to predict 
acute fish lethality using fish cell lines and fish embryos 
http://www.cefic-lri.org/projects/1224841821/21/ECO8-
Development-of-a-strategy-to-predict-acute-fish-lethality-using-
fish-cell-lines-and-fish-embryos/?cntnt01template=display_list_test 
The goal of this research project was to investigate if in vitro approaches based on fish cell 
lines and/or fish embryos can be improved to be widely accepted as an alternative to the 
acute fish test. With regard to the cell lines, four issues were addressed in an attempt to 
overcome the seemingly lower absolute sensitivity. Firstly, several fish cell lines possessing 
origin-specific differentiated functions were employed. Secondly, the cell culture 
environment during toxicity testing was altered to increase the sensitivity of cells. Thirdly, a 
variety of endpoints were used in order to better reflect different modes of toxic action. 
Finally, the truly bio-available fraction of each chemical, rather than the nominally added 
concentration, was taken into account for concentration-response analysis. This latter issue 
will also be addressed for the same set of chemicals in the DarT.  
Hestermann, E. V., J. J. Stegeman and M. E. Hahn (2000). Cell 
culture serum alters the uptake and relative potencies of halogenated 
aromatic hydrocarbons in PLHC-1 cells. Marine Environmental 
Research 50(1–5): 545-546. 
 
This study focuses on the effect of serum in cell culture medium on the bioavailability of 
cytochrome P450 1A (CYP1A)-inducing compounds, in PLHC-1 cells (Poeciliopsis lucida 
hepatocellular carcinoma). The presence of 10% calf serum in the medium increased the 
EC50 for induction of ethoxyresorufin O-deethylase (EROD) activity by 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) 20-fold as compared to treatment in serum-free 
medium. Measurement of [3H]TCDD uptake and Ah receptor binding indicated that the 
apparent difference in potencies was a result of decreased bioavailability in the presence of 
serum, effectively reducing the concentration of TCDD within the cells. Induction of EROD 
and CYP1A protein in response to treatment with each of three coplanar polychlorinated 
biphenyls (PCB congeners 77, 126, and 169) was similarly affected by serum, although the 
magnitude varied among inducers and assays. Relative potencies (calculated as EC50TCDD / 
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EC50PCB) for EROD induction by the three PCBs were significantly higher in the absence 
of serum. However, serum showed no significant effect on the relative potencies for CYP1A 
protein induction. These results demonstrate that measured inducing potencies, and relative 
potencies for EROD induction, by halogenated aromatic hydrocarbons are strongly 
dependent on the composition of culture medium, which can lead to artificial differences in 
comparisons among cell types. 
Gülden, M. and H. Seibert (2005). Impact of bioavailability on the 
correlation between in vitro cytotoxic and in vivo acute fish toxic 
concentrations of chemicals. Aquatic Toxicology 72(4): 327-337. 
 
The main objective of this study was to investigate whether a reduced availability of 
chemicals in vitro can account for the lower sensitivity of in vitro toxicity test systems. For 
this purpose, the bioavailable free fractions of the nominal cytotoxic concentrations (EC50) 
of chemicals determined with a cytotoxicity test system using the mammalian cell line Balb/c 
3T3 and the corresponding free cytotoxic concentrations (ECu50) were calculated. The 
algorithm applied is based on a simple equilibrium distribution model for chemicals in cell 
cultures with serum-supplemented culture media, considering the distribution of chemicals 
between water, lipids and serum albumin.  
Organic chemicals covering a wide range of cytotoxic potency and lipophilicity were 
selected, for which fish acute toxicity data (LC50-values) from at least one of the three fish 
species, medaka, rainbow trout and fathead minnow, were available. The availability of 
several chemicals was shown to be extensively reduced either by partitioning into lipids or 
by serum albumin binding or due to both mechanisms, and reduction of bioavailability 
became more important with increasing cytotoxic potency. The sensitivity of the Balb/c 3T3 
cytotoxicity assay and the correspondence between in vivo and in vitro toxic potencies were 
increased when the free cytotoxic concentrations instead of the nominal cytotoxic 
concentrations were used. The few remaining differences between cytotoxic and acute toxic 
concentrations can be explained by a more specific mechanism of acute toxic action than 
basal cytotoxicity. It is concluded that the frequently observed low sensitivity of in vitro 
cytotoxicity test systems, compared to fish acute toxicity assays, at least in part, can be 
explained by differences in the availability of chemicals in vitro and in vivo. Moreover, 
neglecting these differences systematically causes a bias of the correlation between in vivo 
and in vitro toxic potencies of chemicals, whereas taking them into account increases the 
predictivity of the in vitro assays. 
Tanneberger, K., A. Rico-Rico, N. I. Kramer, F. J. M. Busser, J. L. 
M. Hermens and K. Schirmer (2010). Effects of Solvents and 
Dosing Procedure on Chemical Toxicity in Cell-Based in Vitro 
Assays. Environmental Science & Technology 44(12): 4775-4781. 
 
The aims of this study were to quantify the exposure and associated toxicity of chemicals 
with different physicochemical properties toward a fish gill cell line when different solvents 
and procedural steps are used to introduce test chemicals to cells. Three chemicals with a 
range of hydrophobicity and volatility were selected and delivered in three different solvents 
using two common dosing procedures. Toxicity tests were coupled with chemical analysis to 
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quantify the chemical concentrations within culture wells. The results show that the impact 
of solvents and dosing procedure was greatest for the most volatile and hydrophobic test 
chemical, and that certain combinations of the test chemical, solvent, and procedural steps 
can lead to inhomogeneous distribution of the test chemical and thus differing degrees of 
bioavailability, resulting in quantitative differences in apparent toxicity. 
Tanneberger, K., M. Knöbel, F. J. M. Busser, T. L. Sinnige, J. L. M. 
Hermens and K. Schirmer (2013). Predicting fish acute toxicity 
using a fish gill cell line-based toxicity assay. Environmental 
Science & Technology 47: 1110-1119. 
 
This article summarises the outcome of the CEllSens project. The authors developed a fish 
gill cell line-based (RTgill-W1) assay, using several measures to improve sensitivity. The 
optimized assay was applied to determine the toxicity of 35 organic chemicals, having a wide 
range of toxicity to fish, mode of action and physicochemical properties. The authors found a 
very good agreement between in vivo and in vitro effective concentrations. For up to 73% of 
the tested compounds, the difference between the two approaches was less than 5-fold, 
covering baseline toxicants but as well compounds with presumed specific modes of action, 
including reactivity, inhibition of acetylcholine esterase or uncoupling of oxidative 
phosphorylation. Accounting for measured chemical concentrations eliminated two outliers 
(one hydrophobic and one volatile). Few outliers remained. The most striking were allyl 
alcohol (2700-fold), which likely needs to be metabolically activated; permethrin (190-fold), 
and lindane (63-fold), compounds acting, respectively, on sodium and chloride channels in 
the brain of fish. The authors also discuss further developments of this assay and suggest its 
use beyond predicting acute toxicity to fish, for example, as part of adverse outcome 
pathways to replace, reduce, or refine chronic fish tests. 
Schirmer, K., A. G. J. Chan, B. M. Greenberg, D. G. Dixon and N. 
C. Bols (1997). Methodology for demonstrating and measuring the 
photocytotoxicity of fluoranthene to fish cells in culture. Toxicology 
in Vitro 11(1–2): 107-119. 
 
The authors have developed a methodology for quantifying the photocytotoxicity of 
fluoranthene to a gill cell line from rainbow trout. Solubilisation in a modified culture 
medium was achieved with and without foetal bovine serum (FBS) and with and without 
dimethyl sulfoxide (DMSO). FBS caused most of the fluoranthene to remain in solution and 
blocked photocytotoxicity if present during UV irradiation. DMSO had little effect on 
fluoranthene distribution in cell cultures but caused cells to be slightly more sensitive to the 
phototoxicity of fluoranthene, which indicate that both the presence of FBS and the type of 
solvent can influence the outcome of the assay. The indicator dyes alamar blue and 5-
carboxyfluorescein diacetate acetoxymethyl ester were used to quantify cytotoxicity in two 
different ways: singly in two separate assays, and mixed together. With UV irradiation for 2 
h, both dyes indicated increasing loss of viability with increasing doses of fluoranthene. 
EC50 values ranged from 18 to 44 ng/ml (89–217 nM), with the alamar blue assay being 
slightly more sensitive. 
Ackermann, G. E. and K. Fent (1998). The adaptation of the 
permanent fish cell lines PLHC-1 and RTG-2 to FCS-free media 
The omission of foetal calf serum (FCS) from culture medium can influence the response of 
cells in assays measuring cytotoxicity, cytochrome P450 induction or estrogenic activity of 
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results in similar growth rates compared to FCS-containing 
conditions. Marine Environmental Research 46(1–5): 363-367. 
 
chemicals. The purpose of this study was to provide a selection of different FCS-free cell 
culture media in which the two established fish cell lines PLHC-1 (a hepatoma cell line 
derived from Poeciliopsis lucida) and RTG-2 (a gonadal cell line derived from 
Oncorhynchus mykiss) grow as well as in FCS-containing medium. The results shows that 
PLHC-1 and RTG-2, adapted to FCS-free conditions, show similar growth rates as when 
thriving in FCS-containing medium. Cultivation under FCS-free conditions may represent an 
improvement in the widely used cytotoxicity tests or cytochrome P450-activity assays and is 
a prerequisite of in vitro systems for detecting estrogenic compounds in fish. 
Schirmer, K., K. Tanneberger, N. I. Kramer, D. Völker, S. Scholz, 
C. Hafner, L. E. J. Lee, N. C. Bols and J. L. M. Hermens (2008). 
Developing a list of reference chemicals for testing alternatives to 
whole fish toxicity tests. Aquatic Toxicology 90(2): 128-137. 
 
This paper details the derivation of a list of 60 reference chemicals for the development of 
alternatives to animal testing in ecotoxicology with a particular focus on fish, for the 
CEllSens project. This project aims to systematically gather mechanistic information on the 
performance of alternative testing methods. Specifically, the ability of fish cell lines and 
zebrafish embryos to detect specific modes of action, and the role of dosing and exposure 
schemes in the expression of toxicity of chemicals with a wide range of physico-chemical 
properties will be investigated. These investigations called for a carefully selected list of 
reference chemicals.  
The chemicals were selected as a prerequisite to gather mechanistic information on the 
performance of alternative testing systems (vertebrate cell lines and fish embryos), in 
comparison to the fish acute lethality test. The U.S. EPA fathead minnow database was 
consulted as reference for whole organism responses. This database was compared to the 
Halle Registry of Cytotoxicity and a collation of data by the German EPA (UBA) on acute 
toxicity data derived from zebrafish embryos. Chemicals that were present in the fathead 
minnow database and in at least one of the other two databases were subject to selection. 
Criteria included the coverage of a wide range of toxicity and physico-chemical parameters 
as well as the determination of outliers of the in vivo/in vitro correlations.  
According to the authors, this reference list could also be of benefit to search for alternatives 
in ecotoxicology in general, as a reference set of chemicals whose common use could help 
accelerate the development of non-animal alternatives in toxicology and ecotoxicology. One 
example would be the use of this list to validate structure–activity prediction models, which 
in turn would benefit from a continuous extension of this list with regard to physico-chemical 
and toxicological data. 
Knauer, K., C. Lampert and J. Gonzalez-Valero (2007). Comparison 
of in vitro and in vivo acute fish toxicity in relation to toxicant mode 
of action. Chemosphere 68(8): 1435-1441. 
 
The authors investigated the acute toxicity of 18 plant protection products to the fish 
hepatoma cell line PLHC-1 and to juvenile rainbow trout, the main objective being to explore 
whether hepatoma cells could be used to predict acute toxicity in fish taking into account the 
mode of toxic action and compound properties. Acute fish toxicity was determined using the 
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OECD guideline test 203 and compared to predicted baseline LC50 of acute fish toxicity 
calculated with a quantitative structure–activity relationship (QSAR) derived for guppy fish. 
Cytotoxicity was determined through the inhibition of neutral red uptake (NR50) into 
lysosomes and compared to predicted baseline cytotoxicity derived for goldfish GFS cells. In 
general, NR50 values were higher by a factor ranging from 3 to 3000 than the corresponding 
acute LC50. A weak correlation between NR50 and LC50 values was found (log/log: r2 = 
0.62). The lipophilicity (log Kow) was not a good predictor for cytotoxicity (r2 = 0.43) and 
lethality (r2 = 0.57) of these pesticides. The neutral red assay is detecting general baseline 
toxicity only, and may be of a limited use in predicting acute fish toxicity.  
Comparing LC50 data to QSAR results, the compounds can be classified to act as narcotics 
or reactive compounds with a specific mode of toxic action in fish. According to the authors, 
a set of in vitro tests investigating effects on different endpoints in various cell culture 
models might be a suitable replacement for acute in vivo toxicity tests with fish, the 
challenge for selecting functional endpoints being to identify those that do have predictive 
value for the expression of toxicity. 
Tollefsen, K. E., C. Blikstad, S. Eikvar, E. Farmen Finne and I. 
Katharina Gregersen (2008). Cytotoxicity of alkylphenols and 
alkylated non-phenolics in a primary culture of rainbow trout 
(Onchorhynchus mykiss) hepatocytes. Ecotoxicology and 
Environmental Safety 69(1): 64-73. 
 
The aim of this study was to assess the cytotoxicity of a range of alkylphenols and alkylated 
non-phenolics in a primary culture of rainbow trout (Onchorhynchus mykiss) hepatocytes to 
construct a structure–toxicity relationship for this group of ubiquitous aquatic pollutants. The 
metabolic inhibition and loss of membrane integrity were used as cytotoxic endpoints 
through use of the cellular markers alamar blue and 5 carboxyfluorescein diacetate 
acetoxymethyl ester, respectively. The results show that cytotoxicity increased with the 
hydrophobicity of the alkylphenols for compounds with log Kow < 4.9. Normal chained 
alkylphenols, branched alkylphenols and multi-substituted alkylphenols with log Kow ≥ 4.9 
deviated clearly from this relationship. The alkylphenols displayed greater cytotoxicity than 
alkylated non-phenolics and it is proposed that most alkylated non-phenolic caused non-polar 
narcosis (baseline toxicity) whereas the alkylphenols caused polar narcosis. Observations that 
metabolic inhibition occurred at lower concentrations than loss of membrane integrity for 
most chemicals indicated that interference with cellular metabolic functions was the main 
cause of cytotoxicity. Metabolic inhibition corresponded better than loss of membrane 
integrity to reported acute toxicity to fish, although the in vivo acute toxicity of hydrophobic 
compounds (log Kow > 2-3) was clearly underestimated by both endpoints. 
Kramer, N. I., J. L. M. Hermens and K. Schirmer (2009). The 
influence of modes of action and physicochemical properties of 
chemicals on the correlation between in vitro and acute fish toxicity 
data. Toxicology in Vitro 23(7): 1372-1379. 
The objective of this study was to determine what factors influence the correlation between 
in vitro and fish toxicity data. Basal cytotoxicity (IC50) from mammalian cells and acute 
toxicity data from fathead minnow (LC50) of 82 industrial organic chemicals were obtained 
from the Halle Registry of Cytotoxicity and the US EPA Fathead Minnow Database and 
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compared. A good correlation between IC50 with LC50 data was found (r = 0.84). Yet, IC50 
data were less sensitive than LC50 data by an order of magnitude. 
Using multiple regression analysis, the octanol–water partition coefficient (log Kow) and the 
Henry’s Law Constant (H) were found to significantly explain the low absolute sensitivity. 
The mode of action (MOA) of the chemical was found to significantly explain the general 
variation in the log IC50/log LC50 regression line. These results support the notion that (a) 
the bioavailability of hydrophobic (high log Kow) and volatile (high H) chemicals is 
significantly lower in in vitro assays than in the fish bioassay and (b) multiple cell types and 
endpoints should be included to mimic the modes of action possible in the whole organism.  
Moreover, the free concentration is a better measure of exposure in in vitro assays and may 
be modelled using a compound’s log Kow and H. 
Segner, H., A. Behrens, E. M. Joyce, K. Schirmer and N. C. Bols 
(2000). Transient induction of 7-ethoxyresorufin-O-deethylase 
(EROD) activity by medium change in the rainbow trout liver cell 
line, RTL-W1. Marine Environmental Research 50(1–5): 489-493. 
Cytochrome P4501A (CYP1A) metabolises a wide array of lipophilic xenobiotics. In fish 
liver, CYP1A is constitutively expressed at low levels, and xenobiotics can strongly induce 
CYP1A expression via a receptor-mediated pathway. The authors show that in the rainbow 
trout liver cell line, RTL-W1, CYP1A-catalysed 7-ethoxyresoru®n-O-deethylase (EROD) 
activity can be induced by a change of the culture medium, in the absence of xenobiotics. 
The increase in cellular EROD levels is of transient nature, and the results obtained indicate 
that photooxidised tryptophan is the agent causing the increase of EROD activity after 
medium change. 
Fent, K. (2001). Fish cell lines as versatile tools in ecotoxicology: 
assessment of cytotoxicity, cytochrome P4501A induction potential 
and estrogenic activity of chemicals and environmental samples. 
Toxicology in Vitro 15(4–5): 477-488. 
This paper illustrates the versatility and high potential of fish cell lines in ecotoxicology. It 
presents fish cell lines and their use in cytotoxicity testing, and highlights the importance of 
aryl hydrocarbons receptor (AHR) and cytochrome P450 induction and dioxin-like activity in 
fish cell lines and in the ecotoxicology of fish. It presents the TEQ (toxic equivalency) 
concept used to estimate the toxic potential of environmental mixtures of halogenated 
aromatic hydrocarbons. It also reports the use of fish-related in vitro system for the detection 
of hormonally active compounds such as xeno-estrogens, and the development of a RTG-2 
cell-based reporter gene system, based on the transfection of a reporter gene plasmid 
consisting of an estrogen responsive element (ERE) fused to a firefly luciferase gene, which 
induces luciferase expression after binding of an estrogenic agonist to the estrogen receptor 
(ER) and transcriptional activation. The use of fish cell lines as bioassays for evaluation of 
environmental samples contaminated with CYP1A inducing compounds or estrogenic 
compounds is discussed. 
Hestermann, E. V., J. J. Stegeman and M. E. Hahn (2002). Serum 
withdrawal leads to reduced aryl hydrocarbon receptor expression 
and loss of cytochrome P4501A inducibility in PLHC-1 cells. 
The authors tested the ability of changes in serum used in cell culture medium to alter 
expression of the AHR and induction of cytochrome P4501A (CYP1A) in PLHC-1 cells. 
Culture of early-passage cells in serum-free medium for 2 days led to a loss of CYP1A 
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Biochemical Pharmacology 63(8): 1405-1414. 
 
inducibility by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), whereas culture in 10% 
delipidated calf serum increase the TCDD-induced levels of both CYP1A protein and 
enzymatic activity relative to levels in cells cultured in 10% complete calf serum. The 
kinetics of induction were unaffected.  
In cells cultured in serum-free medium for 1 and 2 days there was a progressive loss of 
CYP1A inducibility and a time-dependent decline in AHR protein. The measured reduction 
in AHR could be shown to predict the loss of CYP1A induction. Expression of AHR protein 
was unaffected by culture in 10% delipidated serum. The effects of serum-free medium and 
delipidated were unaffected by serum withdrawal. 
Comparison of early- and late-passage cells revealed a twofold greater rate of proliferation in 
the latter, suggesting that a growth advantage is coincident with loss of the serum-
dependency of AHR expression. These results provide a quantitative link between changes in 
receptor expression and a downstream response, establishing a foundation for future studies 
of receptors expression and sensitivity to toxic responses in vitro and in vivo.   
Bopp, S. K., N. Bols and K. Schirmer (2006). Development of a 
solvent-free, solid-phase in vitro bioassay using vertebrate cells. 
Environmental Toxicology and Chemistry 25(5): 1390-1398. 
 
One problem common to miniaturized systems is the loss of test chemicals because of 
sorption. In the present study, the authors used the sorption phenomenon in a positive way: as 
it was found that contaminants sorbed to the growth surface in wells of tissue-culture plates 
are available to vertebrate cells growing in direct contact with the contaminant-coated 
surface, they used Biosilon, a bead cell-culture carrier made of polystyrene, and 
contaminated with polycyclic aromatic hydrocarbons (PAHs), to support cell adherence. This 
allowed the detection of reproducible dose–response curves of an increase in cytochrome 
CYP1A enzyme activity by sorbed PAHs in the rainbow trout (Oncorhynchus mykiss) liver 
cell line, RTL-W1. The resulting bead assay provides a miniaturized, solvent-free exposure 
system. Potential future applications include the coupling to environmental sampling, in 
which the bead material is used as solid receiving phase before serving as a surface for 
vertebrate cells to attach and respond. 
Kramer, N. I., F. J. M. Busser, T. T. Oosterwijk, K. Schirmer, B. 
Escher and J. L. M. Hermens (2010). Development of a partition-
controlled dosing system for cell assays. Chemical Research in 
Toxicology 23: 1806-1814. 
 
Hydrophobic and volatile chemicals have proven to be difficult to dose in cell assays, and the 
free concentration of these chemicals in culture medium may diminish over time due to 
metabolism, evaporation, and nonspecific binding to well plate surfaces and serum 
constituents. The aim of this study was therefore to develop a partition controlled dosing 
system to maintain constant concentrations of benzo(a)pyrene, 1,2-dichlorobenzene, and 
1,2,4-trichlorobenzene in an ethoxyresorufin-O-deethylase (EROD) assay and a cytotoxicity 
assay with the rainbow trout (Oncorhynchus mykiss) cell lines RTL-W1 and RTgill-W1. 
Polydimethylsiloxane (PDMS) sheets were loaded with test chemicals in a spiked 
methanol/water solution and placed in the wells, filled with culture medium, of a 24-well 
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culture plate. Cells were grown on inserts and were subsequently added to the wells with the 
PDMS sheets. The system reached equilibrium within 24 h. The reservoir of test chemical in 
PDMS allow to compensate for the loss of >95% of the test chemical from the culture 
medium. The PDMS sheets maintained medium concentrations constant for >72 h. Nominal 
median effect concentrations (EC50) were 1.3-7.0 times lower in the partition-controlled 
dosing systems than in conventional assays spiked using dimethyl sulfoxide (DMSO) as a 
carrier solvent, thus indicating that the apparent sensitivity of the bioassay increased when 
controlled and constant exposure conditions could be assured. The EC50 values of the test 
chemicals based on free concentrations were estimated in the partition-controlled dosing 
systems using measured PDMS-bare culture medium partition coefficients. Results indicated 
that 61, 70, and 99.8% of 1,2-diclorobenzene, 1,2,4-trichlorobenzene, and benzo(a)pyrene 
were bound to serum constituents in the culture medium. 
Adverse Outcome Pathways  
Volz, D. C., S. Belanger, M. Embry, S. Padilla, H. Sanderson, K. 
Schirmer, S. Scholz and D. Villeneuve (2011). Adverse Outcome 
Pathways during Early Fish Development: A Conceptual 
Framework for Identification of Chemical Screening and 
Prioritization Strategies. Toxicological Sciences 123(2): 349-358. 
 
The fish early life-stage (FELS) test guideline (OECD TG 210) is the most frequently used 
bioassay for predicting chronic fish toxicity and supporting aquatic ecological risk 
assessments. Although valuable for predicting fish full life-cycle toxicity, this test is labor 
and resource intensive and, due to an emphasis on apical endpoints, provide little to no 
information about chemical mode of action. Therefore, the development and implementation 
of alternative testing strategies for screening and prioritizing chemicals could reduce the cost 
and number of animals required for estimating FELS toxicity and, at the same time, provides 
insights into mechanisms of toxicity. In this context, the authors proposed 3 FELS-specific 
adverse outcome pathways (AOPs) as conceptual frameworks for identifying useful chemical 
screening and prioritization strategies, using three reference chemicals: a cardiotoxic aryl 
hydrocarbon receptor agonist (2,3,7,8-tetrachlorodibenzo-p-dioxin), a neurotoxic 
acetylcholinesterase inhibitor (chlorpyrifos), and a narcotic surfactant (linear alkylbenzene 
sulfonate). Using qualitative descriptions for each chemical during early fish development, 
they developed generalized AOPs and, based on these examples, proposed a three-tiered 
testing strategy for screening and prioritizing chemicals for FELS testing.  
According to the authors, this tiered testing strategy linked with biologically based 
concentration-response models, could help reduce the reliance on long-term and costly FELS 
tests required for assessing the hazard of thousands of chemicals currently in commerce. 
Villeneuve, D., Volz, D.C., Embry, M.R., Ankley, G., Belanger, 
S.E., Léonard, M., Schirmer, K., Tanguay, R., Truong, L, and 
Wehmas, L. (in preparation) Alternatives to the Fish Early Life-
Stage Test: A Strategy for Discovering and Annotating Adverse 
This is the report of an ILSI HESI expert workshop organised in 2012. Participants discussed 
the development of efficient and cost-effective alternatives to the fish early life-stage (FELS) 
test (OECD TG 210) used to estimate chronic fish toxicity in support of ecological risk 
assessments and global chemical management programs. Identification and description of 
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Outcome Pathways for Early Fish Development. potential adverse outcome pathways (AOPs) relevant to FELS toxicity would support the 
development of such alternatives. An overall strategy for discovery and annotation of FELS 
AOPs was outlined and key events represented by major developmental landmarks were 
organised into a preliminary conceptual model of fish development. Using swim bladder 
inflation as an example, a weight-of-evidence-based approach was used to support linkage of 
key molecular initiating events to adverse phenotypic outcomes and reduced young-of-year 
survival. Based on an iterative approach, the feasibility of using key events as the foundation 
for expanding a network of plausible linkages and AOP knowledge was explored, important 
knowledge gaps identified, and key research objectives were defined. The example and 
strategy described are intended to guide collective efforts to define FELS-related AOPs and 
develop resource-efficient predictive assays that address the toxicological domain of the 
OECD TG 210 test. 
CEFIC LRI funded project (LRI-ECO20-UA) Development of an 
alternative testing strategy for the fish early life-stage test for 
predicting chronic toxicity 
http://www.cefic-lri.org/projects/35/21/LRI-ECO20-UA-
Development-of-an-alternative-testing-strategy-for-the-fish-early-
life-stage-test-for-predicting-chronic-
toxicity/?cntnt01template=display_list_test 
 
The main objective of this project is to use a mechanistic framework to develop and propose 
a high-throughput tiered-testing strategy for screening and prioritizing chemicals for FELS 
testing (OECD 210). The main objective can be divided into four parts:  
1) Establish a database of toxicologically relevant FELS-specific AOPs, identify molecular 
initiating events and subsequent intermediate responses resulting into the apical outcome of 
interest 
2) Propose Tier 1 in vitro screening toolbox to test for AOP-specific events and responses 
predictive for FELS chronic toxicity. 
3) Propose Tier 2 whole-organism ZFET assays to test for AOP-specific events and 
responses predictive for FELS chronic toxicity and assess the potential of a ZFET molecular 
screening tool to predict cellular, organ and/or organism responses giving rise to FELS 
chronic toxicity. 
4) Offering a proposal for implementation of a tiered-testing strategy in EU regulation. 
Assessment of usefulness and applicability of tiered testing strategy for global scientific and 
regulatory community 
OECD (2011). Report of the workshop on using mechanistic 
information in forming chemical categories. Series on Testing and 
Assessment n° 138. ENV/JM/MONO(2011)8; OECD, Paris, France. 
 
This document is a report of the Workshop on Using Mechanistic Information in Forming 
Chemical Categories, held on 8-10 December 2010 in Crystal City VA, USA. One of the 
aims of the OECD QSAR project is to build tools which allow the user to fill data gaps by 
using existing data for similar chemicals. Using mechanistic characteristics to group similar 
chemicals has been shown to be very successful with the OECD QSAR Toolbox for some 
endpoints such as skin sensitisation or acute aquatic toxicity. A key aspect in forming 
toxicologically meaningful categories is identifying mechanistic characteristics (i.e. key 
events and processes) which relate to the risk assessment endpoint in question and can be 
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measured or predicted. 
The purpose of this workshop was to acquire scientific input which will guide further 
development and use of the concept of the adverse outcome pathway (AOP). An AOP 
delineates the documented, plausible, and testable processes by which a chemical induces 
molecular perturbations and the associated biological responses which describe how the 
molecular perturbations cause effects at the subcellular, cellular, tissue, organ, whole animal 
and (when required ) population levels of observation. 
The aims of the workshop were to: 
- Review the extent of the knowledge on mechanism or mode of action in the context of key 
events or processes that lead to specific adverse outcomes that are used in risk assessment; 
- Propose how scientific information on mechanism or mode of action can be organised as 
key events and processes within adverse outcome pathways to aid the formation of 
categories; 
- Examine a series of case studies using adverse outcome pathways; 
- Gather input on work flow(s) for using adverse outcome pathways to form chemical 
categories, 
and to 
- Gather input on the role of (Q)SAR methods in forming categories based on key events in 
an adverse outcome pathway. 
The example of AOP presented in this document are the following: 
- Weak acid respiratory uncoupling and acute aquatic toxicity 
- ER-mediated reproductive impairment and reproductive toxicity 
- Voltage gated sodium channels and neurotoxicity 
- Haemolytic anaemia induced by anilines and nephrotoxicity induced by 4-aminophenols 
and repeated dose toxicity 
Using those AOP proposals, the authors also develop chemical categories corresponding to 
these modes of action.  
Yozzo, K. L., S. P. McGee and D. C. Volz (2013). Adverse outcome 
pathways during zebrafish embryogenesis: A case study with 
paraoxon. Aquatic Toxicology 126(0): 346-354. 
The objective of this study was to develop an adverse outcome pathway (AOP) that provided 
quantitative linkages across levels of biological organization during zebrafish 
embryogenesis, using paraoxon as a reference acetylcholinesterase (AChE) inhibitor.  
Within normal zebrafish embryos, the authors first demonstrated that ache transcripts and 
AChE activity increased in a stage-dependent manner following segmentation. They then 
showed that static exposure of embryos to paraoxon (31.2–500 nM) from 5 to 96 hpf resulted 
in significant stage- and concentration-dependent AChE inhibition, albeit these effects were 
fully reversible within 48 h following transfer to clean water. However, even in the presence 
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of significant AChE inhibition, exposure to non-teratogenic paraoxon concentrations (≤250 
nM) did not adversely impact secondary motoneuron development at 96 hpf. They also 
investigated the potential effects of paraoxon exposure on spontaneous tail contractions at 26 
hpf – an early locomotor behaviour that results from innervation of primary motoneuron 
axons to target axial muscles, and found that the frequency of spontaneous tail contractions at 
26 hpf – a developmental stage with minimal AChE expression and activity – was 
significantly higher following exposure to paraoxon concentrations as low as 31.2 nM. Those 
results suggest that (1) normal AChE activity is not required for secondary motoneuron 
development and (2) spontaneous tail contractions at 26 hpf are sensitive to paraoxon 
exposure, an effect that may be independent of AChE inhibition. Using a well-studied 
reference chemical, this study highlights the potential challenges in developing quantitative 
AOPs to support chemical screening and prioritization strategies. 
Use of fish embryos for chronic toxicity testing  
Weil, M., S. Scholz, M. Zimmer, F. Sacher and K. Duis (2009). 
Gene expression analysis in zebrafish embryos: a potential approach 
to predict effect concentrations in the fish early life stage test. 
Environmental Toxicology and Chemistry 28(9): 1970-1978. 
Based on the hypothesis that analysis of gene expression could be used to predict chronic fish 
toxicity, the authors used a 48 h zebrafish (Danio rerio) embryo test and expanded it to a 
gene expression D. rerio embryo test (Gene-DarT). The effects of 14 substances on lethal 
and sublethal endpoints of the DarT and on expression of potential marker genes were 
investigated: the aryl hydrocarbon receptor 2, cytochrome P450 1A (cyp1a), heat shock 
protein 70, fizzy-related protein 1, the transcription factors v-maf musculoaponeurotic 
fibrosarcoma oncogene family protein g (avian) 1 and NF-E2-p45-related factor, and heme 
oxygenase 1 (hmox1). After exposure of zebrafish embryos for 48 h, differential gene 
expression was evaluated using reverse transcriptase–polymerase chain reaction, gel 
electrophoresis, and densitometric analysis of the gels. All tested compounds significantly 
affected the expression of at least one potential marker gene, with cyp1a and hmox1 being 
most sensitive. Lowest observed-effect concentrations (LOECs) for gene expression were 
below concentrations resulting in 10% lethal effects in the DarT. For 10 (3,4- and 3,5-
dichloroaniline, 1,4-dichlorobenzene, 2,4-dinitrophenol, atrazine, parathion-ethyl, 
chlorotoluron, genistein, 4-nitroquinoline-1-oxide, and cadmium) out of the 14 tested 
substances, LOEC values derived with the Gene-DarT differ by a factor of less than 10 from 
LOEC values of fish early life stage tests with zebrafish. For pentachloroaniline and 
pentachlorobenzene, the Gene-DarT showed a 23- and 153-fold higher sensitivity, 
respectively, while for lindane, it showed a 13-fold lower sensitivity. For ivermectin, the 
Gene-DarT was by a factor of more than 1,000 less sensitive than the acute fish test. The 
results of the present study indicate that gene expression analysis in zebrafish embryos could 
principally be used to predict effect concentrations in the fish early life stage test. 
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Species extrapolation  
Ahlers, J., C. Riedhammer, M. Vogliano, R.-U. Ebert, R. Kühne and 
G. Schüürmann (2006). Acute to chronic ratios in aquatic toxicity - 
Variation across trophic levels and relationship with chemical 
structure. Environmental Toxicology and Chemistry 25(11): 2937-
2945. 
The authors determined acute to chronic ratios (ACRs) for fish, daphnids, and algae, 
for new and existing chemicals. They used only test results derived in compliance 
with the European Union Technical Guidance Document (TGD) and validated by 
authorities. The results show that the median ACRs of 10.5 (fish), 7.0 (daphnids), 
and 5.4 (algae) are well below the ACR safety factor of 100 as implied by the TGD; 
however individual ACRs vary considerably and go up to 4,400, which suggest that a 
safety factor of 100 is not protective for all chemicals and trophic levels. They did 
neither find correlation between ACR and baseline toxicity nor between ACR across 
trophic levels. Narcosis is associated with a preference for a low ACR; nevertheless, 
low ACRs are frequently obtained for nonnarcotics. Analysis of chemical structures 
led to the derivation of structural alerts to identify compounds with a significantly 
increased potential for a high ACR, which may prove to be useful in setting test 
priorities. Thus, according to the authors, life-cycle tests are the only way to 
conservatively predict long-term toxicity. 
Weyers, A., B. Sokull-Klüttgen, J. Baraibar-Fentanes and G. 
Vollmer (2000). Acute toxicity data: A comprehensive comparison 
of results of fish, daphnia, and algae tests with new substances 
notified in the European Union. Environmental Toxicology and 
Chemistry 19(7): 1931-1933. 
Acute aquatic toxicity data (fish, Daphnia, and algae) from the New Chemicals Database of 
the European Chemicals Bureau were compared according to their sensitivity. The algal 
growth inhibition test was the most sensitive (43.5%). For 18.5% cases, species were equally 
sensitive. In 37.9% cases, either fish or Daphnia tests were more sensitive. Correlation 
between fish and Daphnia toxicity values was better (r2=0.597) than the correlation with 
algae, which might reflect similarities in physiology between the two animals not shared by 
algae. Toxicity values among the three organisms correlated more strongly than any with log 
Pow. 
Hutchinson et al. (2003) See above REDUCTION - Step-down Approach  
Jeram et al. (2005) See above REDUCTION - Step-down Approach  
Hoekzema et al. (2006) See above REDUCTION - Step-down Approach  
Tebby, C., E. Mombelli, P. Pandard and A. R. R. Péry (2011). 
Exploring an ecotoxicity database with the OECD (Q)SAR Toolbox 
and DRAGON descriptors in order to prioritise testing on algae, 
daphnids, and fish. Science of the Total Environment 409(18): 
3334-3343. 
In this paper, the authors analysed acute toxicity data gathered by the Japanese Ministry of 
Environment for three species belonging to three different trophic levels (i.e., 
Pseudokirchneriella subcapitata 72 h EC50, Daphnia magna 48h EC50 and Oryzias latipes 
96 h LC50), and investigate the relationships between the chemical structure and both the 
toxicity of the chemicals and the cross-species differences in sensitivity. In predicting 
toxicity towards each species, simple linear regression on logP performed better than PLS 
regression of toxicity on a very large set of molecular descriptors; moreover the predictions 
based on the interspecies correlations performed better than the QSAR predictions, which, in 
terms of cross-species comparisons, encourage the use of test strategies focussing on 
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reducing the number of tests on fish. 
Netzeva et al. (2007) See above - QSAR 
Zvinavashe, E., T. Du, T. Griff, H. H. J. v. d. Berg, A. E. M. F. 
Soffers, J. Vervoort, A. J. Murk and I. M. C. M. Rietjens (2009). 
Quantitative structure-activity relationship modeling of the toxicity 
of organothiophosphate pesticides to Daphnia magna and Cyprinus 
carpio. Chemosphere 75(11): 1531-1538. 
 
The objective of this study was to develop QSAR models to describe the acute toxicity of 
organothiophosphate pesticides to aquatic organisms. Literature data sets for acute toxicity 
data of organothiophosphates to fish and one data set from experiments with 15 
organothiophosphates on Daphnia magna performed in the present study were used to 
establish QSARs. 
Additionally, the authors investigated if toxicity data for the invertebrate D. magna could be 
used to build a QSAR model to predict toxicity to fish. Suitable QSAR models (0.80 < r2 < 
0.82) were derived to predict acute toxicity of organothiophosphates to fish (Cyprinus 
carpio) and the invertebrate (D. magna). The results shows that toxicity data for D. magna 
correlated well (r2 = 0.94) with toxicity data for C. carpio, which implies that by performing 
toxicity tests with D. magna, one can use this interspecies QSAR model to predict the acute 
toxicity of organothiophosphates to fish. Finally, from the 100196 European Inventory of 
Existing Commercial Chemical Substances (EINECS), 83 compounds were identified that fit 
the selection criteria for the QSAR models. By applying the QSAR models to these 
chemicals, the authors obtained an indication of their toxicity without the need for additional 
experimental testing. 
Kar, S. and K. Roy (2010). First report on interspecies quantitative 
correlation of ecotoxicity of pharmaceuticals. Chemosphere 81(6): 
738-747. 
 
Pharmaceuticals are designed to have a specific mode of action and many of them are 
persistent in the body, which makes them of concern for potential effects on aquatic flora and 
fauna. As there is a general scarcity of publicly available ecotoxicological data concerning 
pharmaceuticals, interspecies toxicity correlations could provide a tool for estimating 
contaminant sensitivity with known levels of uncertainty for a diversity of wildlife species. 
In this context, the authors have developed interspecies toxicity correlation between Daphnia 
magna (zooplankton) and fish, assessing the ecotoxicological hazard potential of diverse 77 
pharmaceuticals. The developed models are validated and a consensus models are presented 
to predict toxicity of the individual compounds for any one species when the data for the 
other species are available (r2=0.75 and r2=0.724 for the prediction of daphnia and fish 
toxicity respectively). Informative illustrations of the contributing structural fragments which 
are responsible for the greater toxicity of the diverse pharmaceuticals are also identified by 
the developed models, and the developed models are used to predict fish toxicities of 59 
pharmaceuticals (from Daphnia toxicity data) and Daphnia toxicities of 30 pharmaceuticals 
(from fish toxicity data). 
Zhang, X. J., H. W. Qin, L. M. Su, W. C. Qin, M. Y. Zou, L. X. 
Sheng, Y. H. Zhao and M. H. Abraham (2010). Interspecies 
This article describes the link between the interspecies relationship and the differences of 
bio-uptake and toxic mechanism between species. For this purpose, the authors examined the 
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correlations of toxicity to eight aquatic organisms: Theoretical 
considerations. Science of the Total Environment 408(20): 4549-
4555. 
interspecies correlations of toxicity between species of Vibrio fischeri, river bacteria, algae, 
Daphnia magna, carp, Tetrahymena pyriformis, fathead minnow and guppy based on the 
theoretical background. The results show that there are good interspecies correlations 
between marine bacterium and fresh water bacteria or fish and fish, which suggest that 
compounds share the same bio-uptake and toxic mechanism of action between the species. 
On the other hand, poor interspecies relationships were found between toxicities to algae and 
T. pyriformis or D. magna, which suggests that compounds have different toxic mechanisms 
of action between these species.  
The authors also show that interspecies relationships can be improved by inclusion of the 
octanol/water partition coefficient or the energy of the lowest unoccupied molecular orbital, 
which reflect the difference of bio-uptake or toxic mechanism of action between species for 
organic compounds. Benzoic acids show very different toxicity contributions to the three 
species, V. fischeri, D. magna and carp, which can be explain by the fact that they can be 
easily absorbed into the unicellular bacteria, V. fischeri, whereas the skin and lipid content of 
multicellular organisms (D. magna and fish) can strongly inhibit the bio-uptake for ionisable 
compounds. Good correlation coefficients were observed between toxicities to V. fischeri and 
D. magna or fishes by inclusion of hydrophobic and ionisation parameters. Thus, according 
to the authors, V. fischeri or D. magna can serve as a surrogate of fish toxicity for the 
hydrophobic and ionisable compounds studied. The authors also discuss toxic mechanisms of 
action based on the theoretical background of the interspecies correlation. 
Cassani, S., S. Kovarich, E. Papa, P. P. Roy, L. van der Wal and P. 
Gramatica (2013). Daphnia and fish toxicity of (benzo)triazoles: 
Validated QSAR models, and interspecies quantitative activity-
activity modelling. Journal of Hazardous Materials 258-259: 50-60. 
See above - QSAR 
Raimondo, S., D. N. Vivian and M. G. Barron (2010). Web-based 
Interspecies Correlation Estimation (Web-Ice) for acute toxicity: 
User manual. Version 1.1. EPA/600/R-10/004 Gulf Breeze, F.L. 
http://www.epa.gov/ceampubl/fchain/webice/index.html 
See above - QSAR 
Weltje, L., P. Simpson, M. Gross, M. Crane and J. R. Wheeler 
(2013). Comparative acute and chronic sensitivity of fish and 
amphibians: a critical review of data. Environmental Toxicology 
and Chemistry 32(5): 984-994. 
 
The objective of this study was to compare the relative sensitivity of amphibians and fish to 
chemicals. Acute and chronic toxicity data were obtained from the U.S. Environmental 
Protection Agency (U.S. EPA) ECOTOX database and from the scientific and regulatory 
literature. The overall outcome is that fish and amphibian toxicity data are highly correlated 
and that fish are more sensitive (both acute and chronic) than amphibians. In terms of acute 
sensitivity, amphibians were between 10- and 100-fold more sensitive than fish for only four 
of 55 chemicals and more than 100-fold more sensitive for only two chemicals. Concerning 
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chronic toxicity data, amphibians were between 10- and 100-fold more sensitive than fish for 
only two substances (carbaryl and dexamethasone) and greater than 100-fold more sensitive 
for only a single chemical (sodium perchlorate). However, the comparison for carbaryl was 
subsequently determined to be unreliable and that for sodium perchlorate is a potential 
artefact of the exposure medium. Only a substance such as dexamethasone, which interferes 
with a specific aspect of amphibian metamorphosis, might not be detected using fish tests. 
However, several other compounds known to influence amphibian metamorphosis were 
included in the analysis, and these did not affect amphibians disproportionately. According to 
the authors, the results suggest that additional amphibian testing is not necessary during 
chemical risk assessment. 
Threshold of toxicological concern  
de Wolf, W., A. Siebel-Sauer, A. Lecloux, V. Koch, M. Holt, T. 
Feijtel, M. Comber and G. Boeije (2005). Mode of action and 
aquatic exposure thresholds of no concern. Environmental 
Toxicology and Chemistry 24(2): 479-485. 
 
Thresholds of toxicological concern are based on the possibility of establishing an exposure 
threshold value for chemicals below which no significant risk is to be expected. The authors 
addressed environmental thresholds of no toxicological concern for freshwater systems 
(ETNCaq) for organic chemicals. They analysed several environmental toxicological 
databases (e.g. ECETOC, EURATS, US EPA fathead minnow, University of Utrecht) for 
acute and chronic endpoints and substance hazard assessments. Lowest numbers and 95th-
percentile values were derived using data stratification based on mode of action (MOA) 
according to Verhaar (1 - inert chemicals; 2 - less inert chemicals; 3 – reactive chemicals; 4 - 
specifically acting chemicals). The ETNCaq values were derived by multiplying the lowest 
95th percentile values with appropriate application factors; ETNCaq for MOA1–3 is 
approximately 0.1 µg/L. A preliminary analysis with complete MOA stratification of the 
databases shows that in the case of MOA1 or MOA2, the ETNCaq value could be even 
higher than 0.1 µg/L. For MOA4, a significantly lower ETNCaq value was observed based 
on the long-term toxicity information in the ECETOC database. The authors propose that the 
application of the ETNCaq value in a tiered risk-assessment scheme may help chemical 
producers to set data-generation priorities and to refine or reduce animal use. Further, it may 
help to inform downstream users concerning the relative risk associated with their specific 
uses and be of value in putting environmental monitoring data into a risk-assessment 
perspective. 
Gross, M., K. Daginnus, G. Deviller, W. de Wolf, S. Dungey, C. 
Galli, A. Gourmelon, M. Jacobs, P. Matthiessen, C. Micheletti, E. 
Nestmann, M. Pavan, A. Paya-Perez, H.-T. Ratte, B. Safford, B. 
Sokull-Kluttgen, F. Stock, H.-C. Stolzenberg, J. Wheeler, M. 
Willuhn, A. Worth, J. M. Z. Comenges and M. Crane (2010). 
This paper summarises the outcome of a workshop of regulatory, industry and academic 
scientists held to discuss the use of the threshold of toxicological concern (TTC) concept in 
aquatic environmental risk assessment, and in particular for endocrine active substances 
(EAS). A case study examining the use of the TTC for an EAS with an estrogenic MOA 
formed the basis for the discussions on the feasibility and acceptability, general advantages 
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Thresholds of toxicological concern for endocrine active substances 
in the aquatic environment. Integrated environmental assessment 
and management 6(1): 2-11. 
and disadvantages, and the specific issues that need to be considered when applying the TTC 
concept for EAS in risk assessment. Issues surrounding the statistical approaches used to 
derive TTCs were also discussed. The participants concluded that the reliable use of a TTC 
in environmental risk assessment will require understanding of an untested substance’s MOA 
and potency class, plus a reliable training set of data for long-term demographic effects on 
sensitive organisms of substances with that specific MOA, and that these are significant 
limiting factors for the applicability of this concept for EAS at the present time.  
To investigate further the applicability of the TTC concept for EAS, and to help develop the 
basis for eventual guidance, they recommended several follow-up activities: 1) further 
investigation into the combined use of in vitro and structure-activity data in establishing 
MOAs; 2) establishing criteria for the type, number, and acceptability of data when deriving 
a TTC, and for its subsequent use with a ‘‘new’’ substance with a reliably identified MOA; 
3) establishing criteria for estimating reliable exposure concentrations of that substance for 
comparison with the TTC; and 4) investigation of whether an approach analogous to the use 
of toxic equivalents could be incorporated into use of the TTC for substances with a similar 
MOA to address mixture toxicity issues. 
Tolls, J., M. Muller, A. Willing and J. Steber (2009). A new concept 
for the environmental risk assessment of poorly water soluble 
compounds and its application to consumer products. Integrated 
environmental assessment and management 5(3): 374-378. 
 
The authors propose the use of the aquatic exposure threshold of no concern (ETNCaq; i.e., a 
concentration below which no adverse effects on the environment are to be expected) as 
described by de Wolf et al. (2005) for the environmental risk assessment of consumer 
products and in particular their lipophilic, poorly soluble ingredients representing large-
volume substances whose aquatic toxicity cannot be adequately determined with standard 
methods for a number of reasons. 
For this purpose, the ETNCaq value of these poorly soluble substances is compared with the 
aquatic exposure levels. Aquatic exposure levels of substances with water solubility below 
the ETNCaq will not exceed the ecotoxicological no-effect concentration; therefore, their 
risk can be assessed as being negligible. The ETNCaq value relevant for substances with a 
narcotic mode of action is 1.9 µg/L. To apply the above risk assessment strategy, the 
solubility in water needs to be known. Most frequently, this parameter is estimated by means 
of quantitative structure/activity relationships based on the log octanol–water partition 
coefficient (log Kow). The predictive value of several calculation models for water solubility 
has been investigated by this method with the use of more recent experimental solubility data 
for lipophilic compounds. A linear regression model was shown to be the most suitable for 
providing correct predictions without underestimation of real water solubility. To define a 
log Kow threshold suitable for reliably predicting a water solubility of less than 1.9 µg/L, a 
confidence limit was established by statistical comparison of the experimental solubility data 
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with their log Kow. It was found that a threshold of log Kow = 7 generally allows 
discrimination between substances with solubility greater than and less than 1.9 µg/L. 
Accordingly, organic substances with a baseline toxicity and log Kow > 7 do not require 
further testing to prove that they have low environmental risk. In applying this concept, the 
uncertainty of the prediction of water solubility can be accounted for. If the predicted 
solubility in water is to be below ETNCaq with a probability of 95%, the corresponding log 
Kow value is 8. 
Mons, M. N., M. B. Heringa, J. van Genderen, L. M. Puijker, W. 
Brand, C. J. van Leeuwen, P. Stocks, J. P. van der Hoek and D. van 
der Kooij (2013). Use of the Threshold of Toxicological Concern 
(TTC) approach for deriving target values for drinking water 
contaminants. Water Research 47: 1666-1678. 
Improving analytical techniques reveal more and more anthropogenic substances in drinking 
water and treated water. Most of the substances detected lack toxicity data to derive safe 
levels and have not yet been regulated, and although the concentrations found usually do not 
have adverse health effects, those substances are still undesired because of customer 
perception. This leads to the question how sensitive analytical methods need to become for 
water quality screening, at what levels water suppliers need to take action and how effective 
treatment methods need to be designed to remove contaminants sufficiently. In the 
Netherlands a clear and consistent approach called ’Drinking Water Quality for the 21st 
century (Q21)’ has been developed. Target values for anthropogenic drinking water 
contaminants were derived by using the recently introduced Threshold of Toxicological 
Concern (TTC) approach. The target values for individual genotoxic and steroid endocrine 
chemicals were set at 0.01 mg/L. For all other organic chemicals the target values were set at 
0.1 mg/L. The target value for the total sum of genotoxic chemicals, the total sum of steroid 
hormones and the total sum of all other organic compounds were set at 0.01, 0.01 and 1.0 
mg/L, respectively. The Dutch Q21 approach is further supplemented by the standstill-
principle and effect-directed testing. The approach is helpful in defining the goals and limits 
of future treatment process designs and of analytical methods to further improve and ensure 
the quality of drinking water, without going to unnecessary extents. 
Integrated testing strategies  
ECETOC (2005). Workshop on Alternative Testing Approaches in 
Environmental Risk Assessment. . ECETOC Workshop Report No 
5: 34 pp. 
This report summarises possibilities to reduce the number of fish in environmental risk 
assessment, i.e. acute and chronic fish toxicity testing, fish bioconcentration/bioaccumulation 
as discussed at an ECETOC workshop in 2004. The status of testing methods under 
development (fish cell lines, fish embryos, omics, reduction strategies as the threshold/step-
down approach, review of guidelines for chronic fish toxicity testing) was discussed as well 
as the use of QSARs for acute fish toxicity testing, and recommendations for further research 
(e.g. call for CEFIC LRi ECO 8 project drafted at this workshop) were given. Regarding 
bioconcentration/bioaccumulation the focus was on tiered testing strategies and improvement 
of in silico prediction models with ADME information. A lot of the recommendations had 
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been followed up with several activities and/or introduced into the regulatory frameworks. 
ECETOC (2007). Intelligent testing strategies in ecotoxicology: 
mode of action approach for specifically acting chemicals. Technical 
Report No. 102: 182 pp. 
This report provides an in-depth assessment of the current science underlining the use of 
mode of action (MOA) information for specifically acting chemicals. The MOA describes 
the understanding of selected key events that leads to toxic effects. After a review of 
different MOA classification schemes, the Verhaar et al. (1992) approach, based on acute 
effect information and comprising 4 class of chemicals according to their MOA (MOA1 to 
MOA4), was adopted as a starting point. To date, the MOA4 (specifically acting chemicals 
with selective biomolecular interactions) has not been utilized for chronic assessment. 
Considering both acute and chronic effects, the taskforce has therefore extended the MOA4 
class into 4 pharmacological sub-classes based on: (a) protein receptors, (b) enzymes, (c) 
ions channels and (d) transporters, which provide a consistent a consistent basis to review the 
MOA for both therapeutic (intended) effects and for toxicity (e.g. MOAs for neurotoxicity 
and tumour induction by some carbamates).  
Expanding upon published intelligent testing strategy (ITS) schemes the Task Force has 
developed a simple five step flow-chart which starts with data gathering on physical-
chemical data, SAR predictions, in vitro tests, and data from mammalian studies for the 
compound of interest and for related chemicals.  Evaluation of these data provides 
information on exposure to, and possible MOA of, the substance.  Data may come from 
efficacy or therapeutic data, or from read-across within chemical classes.  Concerning 
effects, valuable guidance may be obtained from molecular, biochemical or cellular toxic 
responses measured in both in vivo and in vitro studies.   
This culminates with a pragmatic, stepwise prioritisation for the assessment of chronic 
effects in regulatory aquatic test species, providing guidance on the selection from microbial, 
plant, invertebrate or vertebrates.  The application of the 'specific MOA flow-chart' is 
illustrated through five case studies: (i) Ion channel mediated effect case study and 
cypermethrin, (ii) Receptor mediated effect case study and 17a-ethinylestradiol (EE2), (iii) 
Transporter protein mediated effects case study and fluoxetine, (iv) Enzyme mediated effect 
case study and ketoconazole, (v) Microbial enzyme inhibitor case study and triclosan.   
As a conclusion, the Task Force highlight the fact that depending on the exposure conditions, 
some chemicals may induce biological effects that suggest more than one MOA (e.g. 
carbamates), thus caution is needed when using the protein target ITS approach to guide test 
protocol design.  Therefore, the Task Force recommends an ITS approach to aquatic 
ecotoxicity testing that includes the following key elements: 
- Gather MOA information on the primary pharmacological/toxicological activity for the 
chemical of interest for the target species as well as mammalian data, also considering 
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structurally-related chemicals, to be used in a weight-of-evidence type of approach;  
- Make use of non-traditional sources of biological information, especially the growing 
biomedical and 'omics' electronic databases on zebrafish, marine invertebrates and other non-
mammalian species;  
- If there is evidence for the main MOA being via a protein target, use this insight to guide 
the efficient selection of regulatory test methods;  
- Measure biomarker responses (e.g. vitellogenin) if desired for read-across purposes or 
setting test concentrations, however, focus on population relevant endpoints (survival, 
development growth and reproduction) for generating NOEC (or ECx) values or calculation 
of PNEC values for application in environmental risk assessment;  
- Be cautious of using acute interspecies sensitivity ratios (ISRs) for algae, crustaceans or 
fish, since the available data suggests they are of limited value for ITS application, 
presumably since acute high levels exposure induces different MOAs compared to chronic 
low level exposures.  
Finally, the Task Force has identified key knowledge gaps around regulatory test species 
which create major uncertainty in developing the ITS approach for many MOA4 
chemicals.  Therefore, the Task Force has also identified five research needs that will help 
reduce the scale of this problem in the ITS context.  These recommendations are: 
- To critically review data (especially chronic studies) from a wider range of chemicals in the 
context of the proposed MOA and ITS  framework, including chemicals where the 
mammalian MOA is less specific than for agrochemicals and pharmaceuticals;  
- To develop aquatic plant ADME models with special regard to understanding key 
biotransformation enzymes;  
- To strengthen the use of small invertebrate models by investing in a hierarchy of biological 
understanding (including genomics, proteomics and population responses) in the commonly 
used freshwater and marine invertebrate species (including both arthropods and non-
arthropods);  
- For animal welfare reasons, to minimise the need for in vivo fish bioconcentration testing 
by developing in vitro fish protocols for chemical metabolism and by developing a small-
scale invertebrate bioconcentration test method;  
-To support risk assessments of endocrine disrupters, develop a database of the normal 
(baseline) range for developmental and reproductive endpoints in aquatic organisms 
measured across different laboratories;  
-To capitalise on the learning from zebrafish biomedical and 'omic' research, there would be 
value in the establishment of a publicly available database on zebrafish ADME and toxicity 
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information; -To support continuing research into SAR validation by providing 'training data 
sets' based on high quality in vivo chronic tests with plants, invertebrates and fish. 
Grindon, C., R. Combes, M. T. D. Cronin, D. W. Roberts and J. F. 
Garrod (2008). Integrated decision-tree testing strategies for 
environmental toxicity with respect to the requirements of the EU 
REACH legislation. Alternatives to Laboratory Animals 36 Suppl 1: 
29-42. 
In the light of the, at that time, upcoming REACH legislation, the authors discuss 
possibilities to reduce the number of fish for environmental toxicity testing, evaluate the 
status of alternative methods and present integrated decision-tree testing strategies covering 
acute and chronic fish toxicity as well as bioconcentration/bioaccumulation. The testing 
strategy is based on the use of available information on the chemical (including mammalian 
toxicity), exposure, in silico, in vitro, fish embryos, bacterial based assays, threshold/step-
down approach for acute toxicity testing. Before carrying out a chronic fish test the authors 
recommend estimating the bioaccumulation (BCF models or fish bioconcentration test). Only 
if long-term exposure and bioaccumulation may occur, chronic fish test are recommended by 
the authors.  
OECD (2012a). Fish toxicity testing framework. Series on Testing 
and Assessment No. 171; ENV/JM/MONO(2012)16; OECD, Paris, 
France. 
 
This document presents a review of fish toxicity testing for the regulatory purpose of 
chemical safety as proposed by the USA in 2008. The main focus is on fish toxicity with an 
emphasis on endrocrine disruptors, but fish bioaccumulation is also considered where 
relevant. The document was initially elaborated by a group of experts and reviewed at an 
OECD Workshop on a Fish Toxicity Testing Framework, held on 28-30 September 2010 
(UK). A review of regulatory needs for fish tests under various jurisdictions in OECD 
countries is provided, followed by a review of statistical issues and general test 
considerations. The document examines animal welfare concerns and alternatives and 
provides a systematic review of existing and draft OECD Guidelines which use fish for 
toxicity or bioaccumulation studies. A generic framework for assessing the environmental 
hazards of chemicals using fish tests in the most efficient way. An Annex contains 
conclusions and recommendations made and agreed at the workshop in September 2010. The 
recommendations concern, among other aspects, possible improvements to existing Test 
Guidelines, development of guidance on specific issues, harmonisation of existing Test 
Guidelines for common issues, development of new Test Guidelines, and proposals for 
deletion of outdated Test Guidelines. 
Recommendations resulted in the deletion of OECD TG 204 (see above) and revision of 
OECD TG 210. 
Scholz, S., E. Sela, L. Blaha, et al. (2013). A European perspective 
on alternatives to animal testing for environmental hazard 
identification and risk assessment. Regulatory Toxicology and 
Pharmacology 67(3): 506-530. 
The authors provide an overview on current regulatory requirements for animal tests in 
environmental hazard and risk assessment of chemicals, plant protection products, 
pharmaceuticals, biocides, feed additives and effluents. They discuss replacement, reduction 
and refinement of animal tests (e.g using fish, birds, amphibian) covering acute and chronic 
toxicity (incl endocrine disruptors), and bioaccumulation. Perspectives and limitations of 
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alternative approaches are discussed. Free access to existing (proprietary) animal test data, 
availability of validated alternative methods and a practical implementation of conceptual 
approaches such as the Adverse Outcome Pathways and Integrated Testing Strategies were 
identified as major requirements towards the successful development and implementation of 
alternative approaches. Although this article focusses on European regulations, its 
considerations and conclusions are of global relevance. 
In vitro methods for fish bioaccumulation testing – improvement 
of prediction models 
This topic is not further discussed in the report, however, it is an important topic and industry 
is very much interested in in vitro biotransformation assays, e.g. use of fish hepatocytes or 
cellular subfractions as the fish S9 (see below Johanning et al., 2012). A lot of efforts have 
been put into the development of in vitro to in vivo extrapolation models and refined 
bioconcentration/bioaccumulation prediction models (see recent publication of Nichols et al., 
2013). 
Johanning, K., G. Hancock, B. Escher, A. Adekola, M. J. Bernhard, 
C. Cowan-Ellsberry, J. Domoradzki, S. Dyer, C. Eickhoff, M. 
Embry, S. Erhardt, P. Fitzsimmons, M. Halder, J. Hill, D. Holden, 
R. Johnson, S. Rutishauser, H. Segner, I. Schultz and J. Nichols 
(2012). Assessment of metabolic stability using the rainbow trout 
(Oncorhynchus mykiss) liver S9 fraction. Current Protocols in 
Toxicology Suppl. 53: Chapter: 14.10.11-14.10.28, August 2012. 
To summarise, standard protocols are given for assessing metabolic stability in rainbow trout 
using the liver S9 fraction, they address: the isolation of S9 fractions from trout livers, 
evaluation of metabolic stability using a substrate depletion approach, and expression of the 
result as in vivo intrinsic clearance. Additional guidance is provided on the care and handling 
of test animals, design and interpretation of preliminary studies, and development of 
analytical methods. Although initially developed to predict metabolism impacts on chemical 
accumulation by fish, these procedures can be used to support a broad range of scientific and 
risk assessment activities including evaluation of emerging chemical contaminants and 
improved interpretation of toxicity testing results. These protocols have been designed for 
rainbow trout and can be adapted to other species as long as species-specific considerations 
are modified accordingly (e.g., fish maintenance and incubation mixture temperature). 
Rainbow trout is a cold-water species. Protocols for other species (e.g., carp, a warm-water 
species) can be developed based on these procedures as long as the specific considerations 
are taken into account.  
The detailed protocols (including the calculation tool) are available from: 
http://onlinelibrary.wiley.com/doi/10.1002/0471140856.tx1410s53/full 
Nichols J.W., Huggett D.B., Arnot J.A., Fitzsimmons P.N., Cowan-
Ellsberry C.E. (2013). Toward improved models for predicting 
bioconcentration of well-metabolized compounds by rainbow trout 
using measured rates of in vitro intrinsic clearance. Environ Toxicol 
Chem. 32(7):1611-22. 
The authors developed to predict the bioconcentration of well-metabolized chemicals by 
rainbow trout. The models employ intrinsic clearance data from in vitro studies with liver S9 
fractions or isolated hepatocytes to estimate a liver clearance rate, which is extrapolated to a 
whole-body biotransformation rate constant (kMET). Estimated kMET values are then used 
as inputs to a mass-balance bioconcentration prediction model. An updated algorithm based 
on measured binding values in trout is used to predict unbound chemical fractions in blood, 
while other model parameters are designed to be representative of small fish typically used in 
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whole-animal bioconcentration testing efforts. Overall model behaviour was shown to be 
strongly dependent on the relative hydrophobicity of the test compound and assumed rate of 
in vitro activity. The results of a restricted sensitivity analysis highlight critical research 
needs and provide guidance on the use of in vitro biotransformation data in a tiered approach 
to bioaccumulation assessment. 
The authors provide supplemental data on estimation of S9 protein content and scaling of 
specific metabolic rates among fish of different sizes. 
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Appendix 1 Weblinks to general information on non-standard methods 
This compilation is not intended to be complete but it may serve as a starting point for further information in the field of alternatives to animal 
testing. 
 
Web address Brief description 
  
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam EURL ECVAM website 
http://ecvam-dbalm.jrc.ec.europa.eu 
 
EURL ECVAM DataBase service on ALTernative Methods to animal 
experimentation (DB-ALM) 
http://bookshop.europa.eu/en/the-eurl-ecvam-search-guide-pbLBN124391 The DB-ALM search guide 
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/laboratories-research/predictive_toxicology JRC Predictive Toxicology 
http://www.oecd.org/env/testguidelines OECD Test Guidelines Programme 
http://ec.europa.eu/dgs/health_consumer/index_en.htm DG SANCO 
http://ec.europa.eu/dgs/environment/index_en.htm  DG ENV 
http://ec.europa.eu/enterprise/index_en.htm DG ENTR 
http://echa.europa.eu ECHA 
http://www.efsa.europa.eu EFSA 
http://www.jacvam.jp/en/index.html Japanese Center for the Validation of Alternative Methods (JaCVAM) 
http://iccvam.niehs.nih.gov 
 
The Interagency Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM) (USA) 
http://www.niehs.nih.gov/research/atniehs/dntp/assoc/niceatm 
 
NTP Interagency Center for the Evaluation of Alternative Toxicological 
Methods (NICEATM) 
http://www.seurat-1.eu  Seurat-1 
http://www.cosmostox.eu/home/welcome  COSMOS 
http://www.detect-iv-e.eu  DETECTIVE 
http://www.alttox.org  ALTTOX 
http://www.journals.elsevier.com/toxicology-in-vitro  Toxicology in Vitro  
http://altweb.jhsph.edu/pubs/journals/atla/issue.html  ATLA: Alternatives to Lab Animals 
http://www.altex.ch/Home.12.html  ALTEX: Alternatives to Animal Experimentation 
http://www.estiv.org  The European Society of Toxicology In Vitro 
http://www.icare-worldwide.org  International Centre for Alternatives in Research and Education 
https://www.cosmeticseurope.eu/index.php  Cosmetics Europe (CE) 
http://ec.europa.eu/enterprise/epaa  The European Partnership for Alternative Approaches to Animal Testing 
(EPAA) 
http://www.bfr.bund.de/en/zebet-58194.html  BfR, ZEBET 
http://www.nc3rs.org.uk  National Centre for the Replacement, Refinement and Reduction of Animals 
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Web address Brief description 
in Research 
http://www.forschung3r.ch  3R Research Foundation Switzerland 
http://toxnet.nlm.nih.gov/altbib.html  Resources for Alternatives to the Use of Live Vertebrates in Biomedical 
Research and Testing 
http://www.gopubmed.org/web/go3r  Transinsight GmbH 
http://www.epa.gov/ncct/Tox21 Tox21 
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Appendix 2 Status of test method submissions to EURL ECVAM  
 
Table updated as of 31/07/2014 
 
TM no Health  effect 
or  
environmental 
effect or other 
TM description Assessment 
of pre-
submission 
Outcome of pre-
submission 
assessment 
Assessment 
status of full 
submission 
Outcome of full 
submission 
assessment* 
Validation and 
acceptance 
status  
TM2014-03 Respiratory 
permeability/penet
ration, 
toxicokinetics 
In vitro 3D 
reconstructed human 
airway epithelial model 
for evaluation of 
substances through the 
respiratory track 
Ongoing     
TM2014-02 Genotoxicity gHistone 2AX coupled 
with in cell western 
technique, as 
biomarker of 
genotoxicity 
On hold Request of 
additional 
information 
   
TM2014-01 Fish acute toxicity Fish cell line acute 
toxicity test using 
Rainbow Trout (RT) gill 
cell line and using a 
combination of 
fluorescent dyes in 
order to measure cell 
viability and establish 
EC50 value 
Finalised Invitation to send 
a full submission 
   
TM2013-03 Skin sensitisation Test method for the 
assessment of the skin 
sensitization potential 
of chemicals based on 
transcriptomics and 
intracellular signal 
transduction analysis in 
a mouse dendritic cell-
like cell line 
Finalised Not considered for 
follow-up 
   
TM2013-02 Skin sensitisation Updated Myeloid U937 
Skin Sensitisation Test 
Finalised Invitation to send a 
full submission 
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TM2013-01 Intestinal 
permeability/penet
ration, 
toxicokinetics 
In vitro assay to 
measure the 
permeability of 
compounds (expressed 
as apparent 
permeability- Papp 
value) through the 
human intestinal 
Caco˗2 cell line 
Finalised Not considered for 
follow-up 
   
TM2012-06 Carcinogenicity CTA test method using 
Bhas 42 cell line for 
carcinogenicity 
assessment, based on 
a two-component 
protocol: (i) initiation 
assay at low cell 
density; (ii) promotion 
assay at higher cell 
density. 
n.a.  n.a.  Validation finalised, 
ECVAM 
Recommendation 
published 
TM2012-05 Skin sensitisation Method for assessing 
the skin sensitization 
potential and potency of 
chemicals based on IL-
18 release and 
cytotoxicity 
measurements in 
reconstituted human 
epidermis (RHE) 
Finalised Invitation to send a 
full submission 
   
TM2012-04 Reproductive 
toxicity - 
Embryotoxicity 
Stem cell Test method 
for the identification of 
embryotoxic hazards 
for humans on the 
basis of the analysis of 
molecular end-points in 
D3 mouse embryonic 
stem cells under 
differentiation 
Finalised Not considered for 
follow-up 
   
TM2012-03 Skin sensitisation Test method for the 
assessment of the skin 
sensitization potential 
of substances based on 
the assessment of 
histological damage in 
Finalised Not considered for 
follow-up 
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human skin explants 
TM2012-02 Skin 
permeability/penet
ration, 
toxicokinetics 
In vitro permeability 
method employing an 
artificial skin-mimetic 
membrane to predict 
skin penetration of 
active pharmaceutical 
ingredient solutions or 
test formulations 
On hold Context of test 
method to be 
clarified 
   
TM2012-01 Quality control of 
vaccines 
Combined assay for 
detection of tetanus 
toxicity in tetanus 
vaccines 
Finalised Invitation to send a 
full submission 
   
TM2011-14 Sensitisation In vitro testing strategy 
based on the 
combination of 
information on peptide 
reactivity, responses in 
keratinocytes and 
activation of Dendritic 
cells for the 
identification of skin 
sensitisation hazard 
Finalised Not considered for 
follow-up, skin 
sensitisation IATAs 
will be addressed in 
the OECD Task 
Force on Hazard 
Assessment 
   
TM2011-13 Eye irritation Extracellular 
acidification test for 
water-soluble severe or 
non-classified eye 
irritants 
On hold Request of 
additional 
information 
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TM2011-12 Sensitisation Two-tiered approach to 
determine the skin 
sensitising capacity and 
potency of chemicals 
Finalised Not considered for 
follow-up because 
an improved version 
of the test method 
has been submitted 
under TM2012-05 
   
TM2011-11 Skin sensitisation In vitro method based 
on gene expression in 
3D reconstructed 
epidermis for identifying 
skin sensitisers 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Under external 
validation 
TM2011-10 Skin sensitisation In vitro test measuring 
luciferase induction in a 
human cell line for the 
testing of skin 
sensitisers 
Finalised Invitation to send a 
full submission 
   
TM2011-09 Sensitisation In vitro test for the 
detection of sensitisers 
based on the analysis 
of the relative 
expression levels of a 
biomarker signature of 
200 genes using 
microarrays 
Finalised Invitation to send a 
full submission 
Finalised Does not qualify for 
entering validation 
 
TM2011-08 Sensitisation In vitro test for the 
detection of sensitisers 
based on the 
quantification of protein 
biomarkers in Dendritic 
Cells models using  
mass spectrometric 
assays 
On hold Request of 
additional 
information 
   
TM2011-07 Sensitisation In vitro method for the 
identification of 
sensitisers based on 
the evaluation of 
Denditric Cells 
migration in a two-
Finalised Not considered for 
follow-up 
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compartment system 
TM2011-06 Eye irritation In vitro prediction of 
acute ocular irritation 
Finalised Invitation to send a 
full submission 
   
TM2011-05 Skin irritation In vitro Skin Irritation 
Test with an open 
source reconstructed 
epidermis 
Finalised Invitation to send a 
full submission 
Ongoing for a 
revised full 
submission 
  
TM2011-04 (Not specified) Bioaccessibility testing 
from powder and 
massive samples of 
metals and alloys 
Finalised Not considered for 
follow-up (no 
regulatory 
relevance with 
regard to impact on 
the 3Rs) 
   
TM2011-03 Reproductive 
toxicity - 
Endocrine 
disruption 
Yeast Estrogen 
Screening Assay (YES) 
and Yeast Androgen 
Screening Assay (YAS) 
Finalised Invitation to send a 
full submission 
Finalised for YAS Request of 
additional 
information 
 
TM2011-02 Skin sensitisation In vitro Method for 
Identifying Skin 
Sensitisers Combining 
Peptide Binding with 
ARE/EpRE Mediated 
Gene Expression in 
Human Skin Cells 
Finalised Invitation to send a 
full submission 
   
TM2011-01 Acute toxicity, 
chronic toxicity, 
genotoxicity 
Dequenching after 
photobleaching 
cytotoxicity test 
On hold Request of 
additional 
information 
   
TM2010-08 Genotoxicity Transcriptomics-based 
Genomics-Genotox 
assay - Gene 
expression profiling in 
HepG2 cells for in vivo 
genotoxicity prediction 
Finalised Invitation to send a 
full submission 
Finalised Does not qualify for 
entering validation 
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TM2010-07 Reproductive 
Toxicity - 
Endocrine 
disruption 
Transcriptional 
activation assay for 
detection of (anti-
)androgenic activity of 
chemicals 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Under validation 
TM2010-06 Neurotoxicity Embryonic Rat Dorsal 
Root Ganglia 
Organotypic Culture 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Not prioritised for 
validation by 
ECVAM 
TM2010-05 Reproductive 
toxicity - Meiosis 
Bovine Oocyte 
Maturation Assay 
Finalised Invitation to send a 
full submission 
   
TM2010-04 Eye irritation In vitro method to 
detect changes in the 
metabolic rate of cells 
On hold Request of 
additional 
information 
   
TM2010-03 Skin sensitisation In vitro test measuring 
luciferase induction in a 
human cell line for the 
testing of skin 
sensitisers 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering peer 
review 
Validation finalised, 
ECVAM 
Recommendation 
published 
TM2010-02 Reproductive 
toxicity - 
Endocrine 
disruption 
Transactivation assay 
for detection of 
compounds with 
(anti)androgenic 
potential using PALM 
cells 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Not prioritised for 
validation by 
ECVAM due to 
issues regarding the 
material transfer 
agreement 
TM2010-01 Reproductive 
toxicity - 
Endocrine 
disruption 
Rat recombinant 
androgen receptor 
binding assay for the 
dectection of 
compounds with 
(anti)androgenic 
potential 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Not prioritised for 
validation by 
ECVAM 
TM2009-12 Neurotoxicity In vitro aproach for 
organophosphorous 
compounds-induced 
neurotoxicity 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Not prioritised for 
validation by 
ECVAM 
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TM2009-11 Reproductive 
toxicity - 
Endocrine 
disruption 
Transcriptional 
activation assay for 
detection of (anti-
)estrogenic activity of 
chemicals 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering 
performance 
standards based 
validation 
Not prioritised for 
validation by 
ECVAM 
TM2009-10 Skin irritation Reconstructed human 
Epidermis test method 
for In vitro skin irritation 
testing 
Finalised Invitation to send a 
full submission 
   
TM2009-09 Skin irritation Epidermal skin irritation 
test 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering peer 
review 
 
TM2009-08 Genotoxicity Human lymphoblastoid 
TK6 cells transfected 
with the GADD45a-
green fluorescent 
protein for detecting 
genome damage and 
genotoxic stress 
Finalised Invitation to send a 
full submission 
Finalised Consultation 
ongoing with the 
Preliminary 
Assessment of 
Regulatory 
Relevance 
(PARERE) network 
 
TM2009-07 Cardiotoxicity Automated screening 
test to detect 
cardiotoxicity in 
zebrafish 
On hold Request of 
additional 
information 
   
TM2009-06 Skin sensitisation Direct Peptide 
Reactivity Assay for 
Screening the Skin 
Sensitisation Potential 
of Chemicals 
n.a.  Finalised Qualifies for 
entering validation 
Validation finalised, 
ECVAM 
Recommendation 
published 
TM2009-05 Skin sensitisation Myeloid U937 Skin 
Sensitisation Test 
n.a.  Finalised Qualifies for 
entering validation 
Validation stopped 
TM2009-04 Eye irritation Chemical reactivity 
measurement using the 
gluthatione (GSH and 
GSSG) peptide binding 
HPLC assay 
n.a.  Finalised Qualifies for 
entering validation 
Not prioritised for 
validation by 
ECVAM 
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TM2009-03 Eye irritation Chemical reactivity 
measurement using the 
cysteine or lysine 
peptide binding HPLC 
assay 
n.a.  Finalised Qualifies for 
entering validation 
Validation stopped 
TM2009-02 Reproductive 
toxicity - 
Endocrine 
disruption 
Transactivation assay 
for detection of 
compounds with 
(anti)estrogenic 
potential using MELN 
cells 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Under validation 
TM2009-01 Eye irritation In vitro assay to predict 
the ocular irritation 
potential by measuring 
protein denaturation 
Finalised Invitation to send a 
full submission 
Ongoing   
TM2008-13 Skin 
absorption/penetr
ation 
In vitro diffusion method 
for measuring skin 
absorption 
Finalised Invitation to send a 
full submission 
   
TM2008-12 Acute and chronic 
toxicity 
Quantitative live cell 
cytotoxicity assay 
based on 
measurements of DNA 
alterations (later 
resubmitted as DAP) 
On hold Request of 
additional 
information 
   
TM2008-11 Skin sensitisation Test method for 
assessing the 
sensitization potential 
of proteins associated 
with type I (IgE 
mediated) 
hypersensitivity 
reactions 
Finalised Not considered for 
follow-up 
   
TM2008-10 Eye irritation Test method based on 
recontsructed human 
tissue model 
n.a.  Finalised Qualifies for 
entering validation 
Validation finalised, 
under ESAC peer 
review 
TM2008-09 Eye irritation Test method based on 
human corneal 
epithelium 
n.a.  Finalised Qualifies for 
entering validation 
Validation stopped 
TM2008-08 Genotoxicity Assay for the 
assessment of DNA-
modifying agents 
Finalised Not considered for 
follow-up 
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TM2008-07 Reproductive 
toxicity - 
Endocrine 
disruption 
Test for edoncrine 
disruptor identification 
Finalised Invitation to send a 
full submission 
   
TM2008-06 Eye irritation Chorioallantoic 
membrane vascular 
assay 
Finalised Invitation to send a 
full submission 
  Under external 
validation 
TM2008-05 Skin sensitisation Human Cell Line 
Activation Test 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Validation finalised, 
ESAC peer review 
finalised 
Draft EURL ECVAM 
recommendation 
under restricted 
commenting 
TM2008-04 Skin sensitisation Test method based on 
gene-expression 
analysis in human 
Dendritic Cells for 
discriminating 
sensitisers from non 
sensitisers 
Finalised Invitation to send a 
full submission 
Finalised Qualifies for 
entering validation 
Under external pre-
validation 
TM2008-03 Eye irritation Porcine corneal opacity 
reversibility assay 
Finalised Invitation to send a 
full submission 
   
TM2008-02 Skin irritation Test method based on 
reconstructed human 
epidermis 
n.a.  Finalised Qualifies for 
entering validation 
Validation finalised, 
OECD Test 
Guideline / EU Test 
Method available 
TM2008-01 Skin irritation  n.a.  Finalised Qualifies for 
entering validation 
Validation finalised, 
OECD Test 
Guideline / EU Test 
Method available 
 
*Outcome of full submission assessment: 
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"Qualifies for entering validation" or "Qualifies for entering performance standards-based validation" or "Qualifies for entering peer review" means that the 
test method is ready to enter a (performance standards-based) validation or peer review process. It does, however, not mean that a test method, which qualifies 
for entering validation, will automatically be validated by EURL ECVAM. 
 
EURL ECVAM regularly prioritises all test methods which have been submitted and found to qualify for entering validation, against pre-defined criteria, and 
decides which test methods/approaches will finally enter validation by EURL ECVAM in the light of available capacities. It is foreseeable that not all 
submitted test methods can be validated. 
 
In some cases, the test methods listed in this table may already undergo a validation study (by ECVAM or other organisations).  
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Appendix 3 Status of computational models in the JRC QSAR database 
 
Documenting the validity of QSAR models 
Although thousands of QSAR models have been developed and published in the scientific 
literature, and some models have been used in regulatory assessment of chemicals in some 
countries for many years, a transparent validation process and objective determination of the 
reliability of QSAR models are crucial to further enhance their regulatory acceptance. 
 
In November 2004, the OECD Member Countries agreed on the principles for validating 
QSAR models for their use in the regulatory assessment of chemical safety. The 
internationally agreed principles provide Member Countries with a consistent and 
scientifically motivated framework for evaluating the regulatory applicability of QSAR 
models. 
 
In February 2007, the OECD published a "Guidance Document on the Validation of (Q)SAR 
Models" with the aim of providing guidance on how specific QSAR models can be evaluated 
with respect to the OECD principles. A check list for the validation, a reporting format for the 
validation, and case studies are attached as annexes: 
 
The OECD Principles for QSAR Model Validation, which are intended to be read in 
conjunction with the guidance document, are as follows: 
 
"To facilitate the consideration of a (Q)SAR model for regulatory purposes, it should be 
associated with the following information: 
 
1) a defined endpoint 
2) an unambiguous algorithm 
3) a defined domain of applicability 
4) appropriate measures of goodness-of-fit, robustness and predictivity 
5) a mechanistic interpretation, if possible" 
 
The QSAR Model Reporting Format (QMRF) was developed by the JRC and EU Member 
State authorities as a harmonised template for summarising and reporting key information on 
QSAR models, including the results of any validation studies. The information is structured 
according to the OECD validation principles. 
 
 
Introduction to the JRC QSAR Model Database 
The JRC QSAR Model Database (http://qsardb.jrc.ec.europa.eu/qmrf) is a freely accessible 
web application that enables users to submit, publish, and search QMRF reports. Developers 
and users of QSAR models can submit to the dedicated mailbox information on QSARs by 
using the QMRF. A downloadable QMRF editor 
(http://sourceforge.net/projects/qmrf/files/QMRF%20Editor/2.0.0) is used for this purpose. 
The JRC then performs a quality control (i.e. adequacy and completeness of the 
documentation) of the QMRF submitted. Properly documented QMRFs are included in the 
JRC QSAR Model Database. Inclusion of the model does not imply acceptance or 
endorsement by the JRC or the European Commission, and responsibility for use of the 
models lies with the end-users.  
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Status of QMRFs in the JRC QSAR Model Database 
At the time of writing (December 2013), the JRC QSAR Model Database contains 70 
QMRFs (Figure 1). A number of additional QMRFs will also be uploaded in a new version of 
the database that will be available soon from the same webpage. 
 
 
 
 
 
 
Figure 1. Status of QMRFs in the JRC QSAR Model Database 
 
 
Reference 
 
OECD (2007). Guidance Document No. 69 on the Validation of (Quantitative) Structure-Activity 
Relationship [(Q)SAR] Models. ENV/JM/MONO(2007)2. Available from: 
http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono%282007%292&do
clanguage=en 
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Appendix 4 Status of alternative methods in DB-ALM 
Annett Janusch Roi 
 
1. DB-ALM  
Ready access to comprehensively and adequately described alternative methods is a 
prerequisite for their use within decision making processes by regulators and scientists or any 
end-user in the life sciences. The JRC has established and is managing the EU EURL 
ECVAM DataBase service on ALternative Methods to animal experimentation (DB-ALM), 
which provides standardised method descriptions and related information to enhance the 
knowledge about and the uptake of alternative and advanced methods at all stages of 
development and regulatory acceptance in the different policy areas and for different 
purposes.  
 
DB-ALM originated from the Communication of the Commission to Council and European 
Parliament SEC (91)1794 and has further been reinforced by Directive 2010/63/EU. 
 
1.1 Key Features 
The DB-ALM is a freely accessible Internet based database service covering various aspects 
of alternative (principally, but not only, in vitro) methods, with focus on toxicity assessments 
of chemicals and/or formulations. The DB-ALM is accessible at:  
http://ecvam-dbalm.jrc.ec.europa.eu 
 
The key feature of the DB-ALM is to provide user-oriented documentation in the form of 
quality controlled descriptions of alternative approaches, prepared by experts and are 
consequently ready for immediate use (factual and evaluated information). The descriptions 
represent an outcome of extensive bibliographic reviews and/or direct contacts with the 
method developer/user.  
 
The methods are described at various levels of detail and according to pre-determined criteria 
for data content to ensure consistent and adequately descriptions of methods. The respective 
reporting formats have evolved significantly since the first establishment of the DB-ALM in 
the early 2000’s so as to capture all information elements necessary to allow judgments of its 
usefulness, that now cover information on the potential of a method including its intended 
objective and applications, its rationale and scientific principle, its relevance, a summary 
description of study results obtained so far including performance and reliability evaluations 
as available and appropriate, discussions on strengths and eventual limitations completed 
with their status of development, validation or regulatory acceptance.  
 
These review documents are complemented with detailed step-by-step descriptions in the 
form of protocols, where available, to also allow the transfer of a technique to another 
laboratory.  
 
1.2 Status  
In terms of content, the DB-ALM currently provides the information summarised in Table 1: 
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Table 1. Information provided by DB-ALM 
 
Information Sector Data Sheet Number 
Topic Summaries 5 
Method Summaries 159 
Protocols 150 
Evaluation Studies 61 
EU Integrated Project 2 
Validation studies 19 
Test Results 
(individual investigations) 9240 
Persons & Institutions 
active in the field of 
alternative methods 
242 
Bibliographic References 6958 
June 2014 
In total, five topic areas in the form of thematic reviews are covered providing method 
summary descriptions, while individual protocols are made available for 26 topic areas 
addressing human health and eco-toxicological effects of chemical substances, mechanistic 
information, quality control of biological products, and biocompatibility and safety testing of 
medical devices (Table 2). 
 
Over 150 biological endpoints are addressed referring to biological processes, responses or 
effects that can be measured at various levels of biological organisation. 
 
The biological endpoints are both cytological and tissue-specific, including: a) interactions on 
the molecular level (including biochemistry and bio-kinetics); b) basal cytotoxicity testing; 
and c) functional parameters of organs and tissues. 
 
1.3 Usage 
Recent years have shown the consolidation of the DB-ALM where the online information 
content has been enhanced and/or revised by 33 % over the past four years leading to a 
constant average annual increase in new registrations to the service (Figure 1).   
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Figure 1. Usage of DB-ALM since 2006 
 
In 2013 there was a doubling in the number of new registrations compared to the same period 
of the year before and there was a download of medially over  
300 documents/months, representing an increase by 75% compared to the same period of 
2012. In total, the DB-ALM can refer to over 4000 registered users from 82 countries 
covering representatives from academia (45%), industry (33%) and regulators (13%), the 
animal welfare movement and others (9 %).  
 
In 2011, the AXLR8 coordination and support action (funded by DG Research & Innovation) 
that aims to accelerate the transition period versus a more sophisticated approach to chemical 
and product safety assessment, whilst reducing the animal use, indicated the DB-ALM as the 
platform where to store and disseminate their FP6 & FP7 research projects results regarding 
non-animal approaches. 
 
In 2013 the OECD Advisory Group on Molecular Screening and Toxicogenomics has set up 
a drafting group to develop guidance for characterising non-guideline in vitro methods used 
for regulatory purposes as a supplement to the existing guidance for development and 
assessment of Adverse Outcome Pathways. The DB-ALM was considered as a potential 
resource for storing those methods in a standardised manner. 
 
 
2. EURL ECVAM Search Guide 
The EURL ECVAM Search Guide (SG) was developed to inform and support untrained 
database users to find high quality information on relevant alternative methods and strategies 
in the large amount of available information resources in an easy, yet systematic, and 
efficient way. This is most relevant where regulatory requirements mandate the application of 
the 3Rs, particularly, during the project preparations in biomedical sciences and toxicology. 
The SG is downloadable from: http://bookshop.europa.eu. 
 
The SG provides search procedures, suggested search terms and user guidance to facilitate 
the location of the desired information on 3Rs animal alternatives in addition to an inventory 
of relevant information resources.  
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The SG was first published as a handbook in 2012 by the EU Bookshop where it was 
included at a certain point at 4th position in the Top 10 of the most downloaded publications 
of the EU Bookshop. Encouraged by this success, the JRC has re-published a second entirely 
updated version, publicly available since August 2013. 
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Table 2. DB-ALM Information Coverage – Method Summaries and Protococols5 
 
No. of Datasheets Topic (field of application) 
Method Summary Protocol 
Acute Systemic Toxicity  6 
Basal Cytotoxicity  17 
Biocompatibility & Safety of Medical Devices  3 
Biokinetics (Percutaneous Absorption) 11 3 
Cancer Research (Drug Discovery and Activity Testing) 5 1 
Carcinogenicity (Cell transformation and Tumour promotion)  5 
Cardiotoxicity  2 
Culture Methods  4 
Digestive System Toxicity  1 
Effects on Reproduction  38 14 
Developmental toxicity 21 8 
Effects on Female fertility 8 3 
Effects on Male fertility 9 3 
Endocrine Organs Toxicity  1 
Environmental Toxicity(Aquatic Short-Term toxicity)  5 
Genotoxicity/Mutagenicity  7 
Haematotoxicity  1 
Hepatotoxicity / Metabolism-mediated Toxicity 23 8 
Immunotoxicity  1 
Local Toxicity 71 53 
Eye Irritation 70 32 
Phototoxicity  9 
Skin Irritation and Corrosivity 1 12 
Myotoxicity  1 
Nephrotoxicity  4 
Neurotoxicity 7 1 
Pyrogenicity testing  2 
Respiratory Tract Toxicity)  1 
Sensitisation and Allergy (Photoallergenicity, Skin sensitisation 
and allergic contact dermatitis  3 
Total 155 143 
 
                                                 
5 One or more protocols can belong to a method summary 
  
 
 
Europe Direct is a service to help you find answers to your questions about the European Union 
Freephone number (*): 00 800 6 7 8 9 10 11 
(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. 
 
A great deal of additional information on the European Union is available on the Internet. 
It can be accessed through the Europa server http://europa.eu. 
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